447482	Androgens	Kaighn ME	Establishment and characterization of a human prostatic carcinoma cell line (PC-3).	Investigative urology	1979	316
1458483	Androgens	McDonnell TJ	Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.	Cancer research	1992	151
9214605	Androgens	Bello D	Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18.	Carcinogenesis	1997	129
9839517	Androgens	Risch HA	Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone.	Journal of the National Cancer Institute	1998	141
9916127	Androgens	Benjamin LE	Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.	The Journal of clinical investigation	1999	230
10086382	Androgens	Craft N	A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.	Nature medicine	1999	181
10550143	Androgens	Bubley GJ	Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.	Journal of clinical oncology 	1999	178
10835690	Androgens	Zhao XY	Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor.	Nature medicine	2000	98
10987273	Androgens	Truica CI	Beta-catenin affects androgen receptor transcriptional activity and ligand specificity.	Cancer research	2000	104
11032808	Androgens	Migliaccio A	Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation.	The EMBO journal	2000	157
11306464	Androgens	Gregory CW	Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.	Cancer research	2001	146
11404460	Androgens	Lin HK	Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor.	Proceedings of the National Academy of Sciences of the United States of America	2001	102
11717329	Androgens	Grossmann ME	Androgen receptor signaling in androgen-refractory prostate cancer.	Journal of the National Cancer Institute	2001	112
11792709	Androgens	Yang F	Linking beta-catenin to androgen-signaling pathway.	The Journal of biological chemistry	2002	101
11861374	Androgens	Zegarra-Moro OL	Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells.	Cancer research	2002	119
11943742	Androgens	Heinlein CA	Androgen receptor (AR) coregulators: an overview.	Endocrine reviews	2002	189
12351684	Androgens	Heinlein CA	The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions.	Molecular endocrinology	2002	97
12429632	Androgens	Di Lorenzo G	Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.	Clinical cancer research 	2002	93
12438256	Androgens	Tepper CG	Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line.	Cancer research	2002	86
12788802	Androgens	Liu PY	Androgens and cardiovascular disease.	Endocrine reviews	2003	120
14755679	Androgens	Taplin ME	Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.	Journal of cellular biochemistry	2004	96
14760063	Androgens	Mohler JL	The androgen axis in recurrent prostate cancer.	Clinical cancer research 	2004	217
15042618	Androgens	Halkidou K	Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.	The Prostate	2004	128
15050917	Androgens	Graner E	The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer.	Cancer cell	2004	78
15126525	Androgens	Wang C	Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.	The Journal of clinical endocrinology and metabolism	2004	86
15316903	Androgens	Chen G	Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.	Cancer	2004	77
15369448	Androgens	Scher HI	Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer.	Endocrine-related cancer	2004	72
15389811	Androgens	Miyamoto H	Androgen deprivation therapy for prostate cancer: current status and future prospects.	The Prostate	2004	77
15601642	Androgens	Missmer SA	Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.	Journal of the National Cancer Institute	2004	142
15668482	Androgens	Lukanova A	Endogenous hormones and ovarian cancer: epidemiology and current hypotheses.	Cancer epidemiology, biomarkers & prevention 	2005	74
15930347	Androgens	Murphy C	Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer.	Clinical cancer research 	2005	67
16079795	Androgens	Metzger E	LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription.	Nature	2005	471
16137620	Androgens	Wang Q	Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking.	Molecular cell	2005	188
16140968	Androgens	Agoulnik IU	Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression.	Cancer research	2005	67
16254181	Androgens	Tomlins SA	Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.	Science	2005	1164
16278481	Androgens	Scher HI	Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.	Journal of clinical oncology 	2005	313
16322344	Androgens	Kaaks R	Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition.	Endocrine-related cancer	2005	128
16491124	Androgens	Doane AS	An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen.	Oncogene	2006	154
16505103	Androgens	Mantena SK	Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells.	Molecular cancer therapeutics	2006	71
16510604	Androgens	Stanbrough M	Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.	Cancer research	2006	325
16518832	Androgens	Dehm SM	Molecular regulation of androgen action in prostate cancer.	Journal of cellular biochemistry	2006	74
16702379	Androgens	Missmer SA	Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period.	Cancer epidemiology, biomarkers & prevention 	2006	69
17030978	Androgens	McTiernan A	Relation of BMI and physical activity to sex hormones in postmenopausal women.	Obesity	2006	66
17045208	Androgens	Guo Z	Regulation of androgen receptor activity by tyrosine phosphorylation.	Cancer cell	2006	149
17079484	Androgens	Agoulnik IU	Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.	Cancer research	2006	71
17185378	Androgens	Srinivasan S	Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells.	Cancer research	2007	67
17229978	Androgens	Guzik TJ	Adipocytokines - novel link between inflammation and vascular function?	Journal of physiology and pharmacology 	2006	87
17494760	Androgens	Mahajan NP	Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.	Proceedings of the National Academy of Sciences of the United States of America	2007	93
17636035	Androgens	Dehm SM	Androgen receptor structural and functional elements: role and regulation in prostate cancer.	Molecular endocrinology	2007	79
17638896	Androgens	Araki S	Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer.	Cancer research	2007	87
17699749	Androgens	Bolton EC	Cell- and gene-specific regulation of primary target genes by the androgen receptor.	Genes & development	2007	133
17940184	Androgens	Heemers HV	Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex.	Endocrine reviews	2007	187
18056640	Androgens	Shi XB	An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2007	161
18066052	Androgens	Metzger E	Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation.	Nature cell biology	2008	62
18174313	Androgens	Lin SL	Loss of mir-146a function in hormone-refractory prostate cancer.	RNA	2008	122
18483239	Androgens	Mehra R	Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.	Cancer research	2008	80
18519708	Androgens	Montgomery RB	Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.	Cancer research	2008	377
18573234	Androgens	Kojima K	A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells.	Biochemical and biophysical research communications	2008	53
18667687	Androgens	Zhu ML	Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.	Endocrine-related cancer	2008	68
18676866	Androgens	Locke JA	Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.	Cancer research	2008	226
18701501	Androgens	Jin RJ	The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.	Cancer research	2008	65
18723679	Androgens	Niu Y	Androgen receptor is a tumor suppressor and proliferator in prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2008	104
18782595	Androgens	Dillard PR	Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol.	Molecular and cellular endocrinology	2008	58
18794152	Androgens	Han B	A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.	Cancer research	2008	54
18794802	Androgens	Schaeffer EM	Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer.	Oncogene	2008	66
18821585	Androgens	Cirillo D	Leptin signaling in breast cancer: an overview.	Journal of cellular biochemistry	2008	65
19111796	Androgens	Yuan X	Mechanisms mediating androgen receptor reactivation after castration.	Urologic oncology	2009	87
19124476	Androgens	Neilson HK	Physical activity and postmenopausal breast cancer: proposed biologic mechanisms and areas for future research.	Cancer epidemiology, biomarkers & prevention 	2009	52
19153072	Androgens	Chang BL	Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk.	Human molecular genetics	2009	47
19198621	Androgens	Harris WP	Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.	Nature clinical practice. Urology	2009	142
19212411	Androgens	Sreekumar A	Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.	Nature	2009	522
19244107	Androgens	Guo Z	A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.	Cancer research	2009	275
19289629	Androgens	Mendiratta P	Genomic strategy for targeting therapy in castration-resistant prostate cancer.	Journal of clinical oncology 	2009	44
19345326	Androgens	Xu K	Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination.	Cancer cell	2009	76
19351832	Androgens	Sun T	The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines.	Cancer research	2009	77
19552894	Androgens	Gannon PO	Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.	Journal of immunological methods	2009	53
19584279	Androgens	Cai C	Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.	Cancer research	2009	59
19620249	Androgens	Vigneri P	Diabetes and cancer.	Endocrine-related cancer	2009	199
19632176	Androgens	Wang Q	Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.	Cell	2009	337
19638458	Androgens	Knudsen KE	Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.	Clinical cancer research 	2009	120
19738047	Androgens	Ribas J	miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth.	Cancer research	2009	133
19752089	Androgens	Cao Q	A role for the clock gene per1 in prostate cancer.	Cancer research	2009	49
19796750	Androgens	Chen Y	Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target.	The Lancet. Oncology	2009	84
19917249	Androgens	Norris JD	The homeodomain protein HOXB13 regulates the cellular response to androgens.	Molecular cell	2009	68
20086173	Androgens	Hofland J	Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.	Cancer research	2010	58
20103546	Androgens	Lawrence MG	Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus.	Endocrine reviews	2010	50
20133657	Androgens	McPherson SJ	Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated.	Proceedings of the National Academy of Sciences of the United States of America	2010	51
20138542	Androgens	Knudsen KE	Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer.	Trends in endocrinology and metabolism	2010	107
20220849	Androgens	Ammirante M	B-cell-derived lymphotoxin promotes castration-resistant prostate cancer.	Nature	2010	148
20228790	Androgens	Metzger E	Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4.	Nature	2010	96
20440270	Androgens	Niu Y	Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.	Oncogene	2010	46
20525905	Androgens	Bhasin S	Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.	The Journal of clinical endocrinology and metabolism	2010	274
20577262	Androgens	Lian J	A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum.	Cell death and differentiation	2011	45
20601956	Androgens	Haffner MC	Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.	Nature genetics	2010	157
20616601	Androgens	Yeh SH	Gender disparity of hepatocellular carcinoma: the roles of sex hormones.	Oncology	2010	53
20823238	Androgens	Watson PA	Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.	Proceedings of the National Academy of Sciences of the United States of America	2010	219
20921964	Androgens	Harvie MN	The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women.	International journal of obesity	2011	91
20945501	Androgens	Waltering KK	Androgen regulation of micro-RNAs in prostate cancer.	The Prostate	2011	47
21098087	Androgens	Frigo DE	CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells.	Cancer research	2011	39
21224358	Androgens	Hodgson MC	Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer.	Cancer research	2011	37
21266523	Androgens	Wright JL	Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.	Cancer epidemiology, biomarkers & prevention 	2011	39
21303972	Androgens	Mohler JL	Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.	Cancer research	2011	47
21372223	Androgens	Attard G	New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.	Clinical cancer research 	2011	49
21400613	Androgens	Kauffman EC	Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.	Molecular carcinogenesis	2011	47
21436259	Androgens	Lamont KR	Minireview: Alternative activation pathways for the androgen receptor in prostate cancer.	Molecular endocrinology	2011	52
21499299	Androgens	Jeter CR	NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation.	Oncogene	2011	110
21606417	Androgens	Yang M	SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.	Journal of clinical oncology 	2011	47
21709130	Androgens	Santer FR	Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.	Molecular cancer therapeutics	2011	55
21741601	Androgens	Ni M	Targeting androgen receptor in estrogen receptor-negative breast cancer.	Cancer cell	2011	100
21859989	Androgens	Ryan CJ	Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically.	Journal of clinical oncology 	2011	81
21878636	Androgens	Yang X	Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells.	The Journal of biological chemistry	2011	39
21909140	Androgens	Urbanucci A	Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer.	Oncogene	2012	33
21915096	Androgens	Sahu B	Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.	The EMBO journal	2011	103
21926054	Androgens	Dewailly D	Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries.	Human reproduction	2011	43
21969603	Androgens	Andreu-Vieyra C	Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells.	Molecular and cellular biology	2011	38
22014572	Androgens	Cai C	Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.	Cancer cell	2011	131
22083957	Androgens	Tan PY	Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.	Molecular and cellular biology	2012	57
22108827	Androgens	Sun Y	Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.	Cancer research	2012	94
22114732	Androgens	Zhang X	Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.	PloS one	2011	101
22265403	Androgens	Li Z	Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer.	Cell	2012	92
22266859	Androgens	Jalava SE	Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer.	Oncogene	2012	65
22275373	Androgens	Chen S	Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation.	The Journal of biological chemistry	2012	32
22438320	Androgens	Germann M	Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer.	Stem cells	2012	35
22447389	Androgens	Willmann D	Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.	International journal of cancer	2012	38
22453214	Androgens	Green SM	Androgen action and metabolism in prostate cancer.	Molecular and cellular endocrinology	2012	40
22479342	Androgens	Nadiminty N	MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth.	PloS one	2012	42
22505583	Androgens	Fletcher CE	Androgen-regulated processing of the oncomir miR-27a, which targets Prohibitin in prostate cancer.	Human molecular genetics	2012	32
22531786	Androgens	Chng KR	A transcriptional repressor co-regulatory network governing androgen response in prostate cancers.	The EMBO journal	2012	50
22614972	Androgens	Campbell KL	Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: randomized controlled trial.	Journal of clinical oncology 	2012	41
22745190	Androgens	Hickey TE	Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?	Molecular endocrinology	2012	46
22831834	Androgens	Lee SO	New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.	Journal of molecular cell biology	2013	33
22971343	Androgens	Mitsiades N	Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.	Cancer research	2012	57
23019221	Androgens	Decker KF	Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions.	Nucleic acids research	2012	35
23065822	Androgens	Diamanti-Kandarakis E	Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.	Endocrine reviews	2012	128
23157556	Androgens	Matsumoto T	The androgen receptor in health and disease.	Annual review of physiology	2013	45
23300485	Androgens	Francis JC	β-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma.	PLoS genetics	2013	28
23426182	Androgens	Cai C	ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.	The Journal of clinical investigation	2013	44
23435229	Androgens	Coffey K	The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover.	Nucleic acids research	2013	26
23451058	Androgens	Mo W	Identification of novel AR-targeted microRNAs mediating androgen signalling through critical pathways to regulate cell viability in prostate cancer.	PloS one	2013	35
23503464	Androgens	Sun D	Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells.	Oncogene	2014	25
23512661	Androgens	Baena E	ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients.	Genes & development	2013	38
23517348	Androgens	Schiaffino S	Mechanisms regulating skeletal muscle growth and atrophy.	The FEBS journal	2013	163
23720054	Androgens	Itkonen HM	O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells.	Cancer research	2013	53
23727860	Androgens	Lunardi A	A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.	Nature genetics	2013	43
23729330	Androgens	Ayala G	Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression.	The Journal of pathology	2013	28
23752196	Androgens	Yuan X	Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.	Oncogene	2014	77
23770851	Androgens	Sun T	MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A.	Oncogene	2014	31
23806491	Androgens	Schrecengost R	Molecular pathogenesis and progression of prostate cancer.	Seminars in oncology	2013	26
23851510	Androgens	Liu LL	Mechanisms of the androgen receptor splicing in prostate cancer cells.	Oncogene	2014	61
23859952	Androgens	Shafi AA	Androgen receptors in hormone-dependent and castration-resistant prostate cancer.	Pharmacology & therapeutics	2013	53
23993097	Androgens	Chang KH	A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer.	Cell	2013	80
23993415	Androgens	Wen S	Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death.	Cancer treatment reviews	2014	25
23995860	Androgens	Yepuru M	Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.	Clinical cancer research 	2013	27
24054868	Androgens	Chen R	Cav1.3 channel α1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers.	Urologic oncology	2014	22
24186207	Androgens	Tennakoon JB	Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch.	Oncogene	2014	45
24423344	Androgens	O'Reilly MW	Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione.	The Journal of clinical endocrinology and metabolism	2014	25
24508459	Androgens	An J	Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.	Cell reports	2014	52
24706793	Androgens	McAllister JM	Overexpression of a DENND1A isoform produces a polycystic ovary syndrome theca phenotype.	Proceedings of the National Academy of Sciences of the United States of America	2014	26
24909511	Androgens	Tan MH	Androgen receptor: structure, role in prostate cancer and drug discovery.	Acta pharmacologica Sinica	2015	41
24951107	Androgens	McNamara KM	Complexities of androgen receptor signalling in breast cancer.	Endocrine-related cancer	2014	20
25065599	Androgens	Kroiss A	Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2.	Oncogene	2015	26
25220414	Androgens	Jin R	Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression.	Oncogene	2015	16
25267627	Androgens	Ammirante M	Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts.	Proceedings of the National Academy of Sciences of the United States of America	2014	25
25274033	Androgens	Geng C	Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.	Cancer research	2014	28
25351819	Androgens	Zhou Y	Androgens and androgen receptor signaling in prostate tumorigenesis.	Journal of molecular endocrinology	2015	20
25535248	Androgens	Chen Z	Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer.	The EMBO journal	2015	17
25568070	Androgens	Schweizer MT	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.	Science translational medicine	2015	40
25591066	Androgens	Njar VC	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.	Journal of medicinal chemistry	2015	26
25645929	Androgens	Zhang L	The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells.	Molecular and cellular biology	2015	23
25830880	Androgens	Gundem G	The evolutionary history of lethal metastatic prostate cancer.	Nature	2015	136
26060018	Androgens	Xu D	Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes.	Cancer research	2015	33
26342199	Androgens	Kawahara T	ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.	Oncotarget	2015	18
26411689	Androgens	Zhang A	LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer.	Cell reports	2015	28
27049719	Androgens	Liu C	Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.	Oncotarget	2016	15
27052658	Androgens	Bonnefoi H	A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).	Annals of oncology 	2016	12
27184811	Androgens	Antonarakis ES	Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.	Prostate cancer and prostatic diseases	2016	14
27459230	Androgens	Rosenfield RL	The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.	Endocrine reviews	2016	16
27487144	Androgens	Wadosky KM	Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.	Oncotarget	2016	18
27528625	Androgens	Pietri E	Androgen receptor signaling pathways as a target for breast cancer treatment.	Endocrine-related cancer	2016	12
27801901	Androgens	Benzon B	Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.	Prostate cancer and prostatic diseases	2017	6
28578607	Androgens	Fizazi K	Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.	The New England journal of medicine	2017	28
2328727	Estrogens	Kastner P	Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B.	The EMBO journal	1990	265
7658481	Estrogens	Hankinson SE	Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women.	Journal of the National Cancer Institute	1995	147
8168078	Estrogens	Ottaviano YL	Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells.	Cancer research	1994	122
8405201	Estrogens	Pike MC	Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk.	Epidemiologic reviews	1993	171
9039267	Estrogens	Zwijsen RM	CDK-independent activation of estrogen receptor by cyclin D1.	Cell	1997	170
9252329	Estrogens	Anzick SL	AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.	Science	1997	373
9338076	Estrogens	Baylin SB	Alterations in DNA methylation: a fundamental aspect of neoplasia.	Advances in cancer research	1998	332
9367686	Estrogens	Carmeci C	Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer.	Genomics	1997	125
9504686	Estrogens	Allred DC	Prognostic and predictive factors in breast cancer by immunohistochemical analysis.	Modern pathology 	1998	420
9524123	Estrogens	Migliaccio A	Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor.	The EMBO journal	1998	125
9662379	Estrogens	Kononen J	Tissue microarrays for high-throughput molecular profiling of tumor specimens.	Nature medicine	1998	777
10334533	Estrogens	Harvey JM	Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.	Journal of clinical oncology 	1999	417
10334989	Estrogens	Fan S	BRCA1 inhibition of estrogen receptor signaling in transfected cells.	Science	1999	103
10454584	Estrogens	Vigo E	CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase.	Molecular and cellular biology	1999	98
10579320	Estrogens	Hall JM	The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens.	Endocrinology	1999	193
10713699	Estrogens	Cogswell PC	Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3.	Oncogene	2000	126
11016622	Estrogens	Eads CA	Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.	Cancer research	2000	102
11140706	Estrogens	Camp RL	Validation of tissue microarray technology in breast carcinoma.	Laboratory investigation; a journal of technical methods and pathology	2000	121
11171938	Estrogens	Clarke R	Cellular and molecular pharmacology of antiestrogen action and resistance.	Pharmacological reviews	2001	93
11181778	Estrogens	Bos R	Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.	Journal of the National Cancer Institute	2001	143
11257103	Estrogens	Welcsh PL	BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.	Human molecular genetics	2001	122
11289127	Estrogens	Roger P	Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.	Cancer research	2001	92
11438457	Estrogens	Leav I	Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma.	The American journal of pathology	2001	97
11473106	Estrogens	Wijayaratne AL	The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators.	The Journal of biological chemistry	2001	107
11504747	Estrogens	Chia SK	Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.	Journal of clinical oncology 	2001	94
11517191	Estrogens	Lazennec G	ER beta inhibits proliferation and invasion of breast cancer cells.	Endocrinology	2001	101
11553815	Estrogens	Sørlie T	Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.	Proceedings of the National Academy of Sciences of the United States of America	2001	2677
11733374	Estrogens	Torhorst J	Tissue microarrays for rapid linking of molecular changes to clinical endpoints.	The American journal of pathology	2001	88
11751417	Estrogens	Xie D	Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features.	Cancer research	2001	90
11826265	Estrogens	Simpson ER	Aromatase--a brief overview.	Annual review of physiology	2002	123
11897506	Estrogens	Filardo EJ	Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer.	The Journal of steroid biochemistry and molecular biology	2002	94
11940574	Estrogens	Leung JY	Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling.	The Journal of biological chemistry	2002	125
11981002	Estrogens	Lakhani SR	The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.	Journal of clinical oncology 	2002	177
12040178	Estrogens	McDonnell DP	Connections and regulation of the human estrogen receptor.	Science	2002	129
12060624	Estrogens	Schindl M	Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.	Clinical cancer research 	2002	102
12400004	Estrogens	Real PJ	Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells.	Oncogene	2002	88
12408373	Estrogens	Anderson WF	Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.	Breast cancer research and treatment	2002	107
12415108	Estrogens	Wong CW	Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade.	Proceedings of the National Academy of Sciences of the United States of America	2002	84
12498683	Estrogens	Daujat S	Crosstalk between CARM1 methylation and CBP acetylation on histone H3.	Current biology 	2002	85
12529347	Estrogens	Konecny G	Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.	Journal of the National Cancer Institute	2003	91
12627523	Estrogens	Bos R	Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.	Cancer	2003	141
12657462	Estrogens	Wu C	The function of the protein tyrosine phosphatase SHP-1 in cancer.	Gene	2003	76
12705869	Estrogens	Fujita N	MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer.	Cell	2003	149
12743151	Estrogens	Bardou VJ	Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.	Journal of clinical oncology 	2003	122
12824206	Estrogens	Li CI	Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.	JAMA	2003	77
12858169	Estrogens	Johnson MD	Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland.	Nature medicine	2003	89
12917485	Estrogens	Sotiriou C	Breast cancer classification and prognosis based on gene expression profiles from a population-based study.	Proceedings of the National Academy of Sciences of the United States of America	2003	486
12960427	Estrogens	Schaner ME	Gene expression patterns in ovarian carcinomas.	Molecular biology of the cell	2003	80
14576841	Estrogens	Clarke R	Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.	Oncogene	2003	132
14578209	Estrogens	Lin EY	Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.	The American journal of pathology	2003	356
14623515	Estrogens	Simpson ER	Sources of estrogen and their importance.	The Journal of steroid biochemistry and molecular biology	2003	126
14695316	Estrogens	Cronin M	Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay.	The American journal of pathology	2004	134
14734488	Estrogens	Schiff R	Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.	Clinical cancer research 	2004	87
14759989	Estrogens	Colditz GA	Risk factors for breast cancer according to estrogen and progesterone receptor status.	Journal of the National Cancer Institute	2004	152
14871808	Estrogens	Foulkes WD	The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer.	Cancer research	2004	73
15001666	Estrogens	Bourdeau V	Genome-wide identification of high-affinity estrogen response elements in human and mouse.	Molecular endocrinology	2004	102
15041722	Estrogens	Foulkes WD	Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.	Clinical cancer research 	2004	77
15084238	Estrogens	Arpino G	Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.	Breast cancer research 	2004	115
15169792	Estrogens	Nevalainen MT	Signal transducer and activator of transcription-5 activation and breast cancer prognosis.	Journal of clinical oncology 	2004	71
15181027	Estrogens	Bray GA	Medical consequences of obesity.	The Journal of clinical endocrinology and metabolism	2004	228
15207254	Estrogens	Platet N	Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion.	Critical reviews in oncology/hematology	2004	94
15220474	Estrogens	Biswas DK	NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis.	Proceedings of the National Academy of Sciences of the United States of America	2004	115
15221988	Estrogens	Giordano SH	Breast carcinoma in men: a population-based study.	Cancer	2004	114
15223047	Estrogens	Dontu G	Breast cancer, stem/progenitor cells and the estrogen receptor.	Trends in endocrinology and metabolism	2004	95
15328174	Estrogens	Nielsen TO	Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.	Clinical cancer research 	2004	631
15342389	Estrogens	Kubo M	Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer.	Cancer research	2004	110
15345050	Estrogens	Lin CY	Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells.	Genome biology	2004	103
15361840	Estrogens	Usary J	Mutation of GATA3 in human breast tumors.	Oncogene	2004	80
15369453	Estrogens	Bardin A	Loss of ERbeta expression as a common step in estrogen-dependent tumor progression.	Endocrine-related cancer	2004	80
15380517	Estrogens	Torres-Arzayus MI	High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene.	Cancer cell	2004	148
15455388	Estrogens	Lengyel E	C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.	International journal of cancer	2005	88
15475452	Estrogens	Colleoni M	Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.	Clinical cancer research 	2004	73
15520168	Estrogens	Campbell IG	Mutation of the PIK3CA gene in ovarian and breast cancer.	Cancer research	2004	226
15534099	Estrogens	Camp RL	X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.	Clinical cancer research 	2004	337
15539556	Estrogens	Thomas P	Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells.	Endocrinology	2005	359
15574759	Estrogens	Al-Kuraya K	Prognostic relevance of gene amplifications and coamplifications in breast cancer.	Cancer research	2004	82
15574760	Estrogens	Loo LW	Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes.	Cancer research	2004	70
15583021	Estrogens	Herynk MH	Estrogen receptor mutations in human disease.	Endocrine reviews	2004	83
15617686	Estrogens	Clarke RB	A putative human breast stem cell population is enriched for steroid receptor-positive cells.	Developmental biology	2005	89
15701879	Estrogens	Osborne CK	Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.	Clinical cancer research 	2005	93
15734144	Estrogens	Kalaitzidis D	Transcription factor cross-talk: the estrogen receptor and NF-kappaB.	Trends in endocrinology and metabolism	2005	84
15746036	Estrogens	Takahashi Y	Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.	Clinical cancer research 	2005	89
15755967	Estrogens	Osborne CK	Estrogen-receptor biology: continuing progress and therapeutic implications.	Journal of clinical oncology 	2005	81
15762276	Estrogens	Nadji M	Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers.	American journal of clinical pathology	2005	70
15808510	Estrogens	Park KJ	Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation.	Molecular cell	2005	65
15814851	Estrogens	Brueggemeier RW	Aromatase inhibitors in the treatment of breast cancer.	Endocrine reviews	2005	65
15857973	Estrogens	Koehler KF	Reflections on the discovery and significance of estrogen receptor beta.	Endocrine reviews	2005	68
15899795	Estrogens	Dai H	A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients.	Cancer research	2005	91
16009131	Estrogens	Carroll JS	Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1.	Cell	2005	521
16012726	Estrogens	Tsutsui S	Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density.	Oncology reports	2005	92
16019138	Estrogens	Chen DC	Serum adiponectin and leptin levels in Taiwanese breast cancer patients.	Cancer letters	2006	86
16103053	Estrogens	Iorio MV	MicroRNA gene expression deregulation in human breast cancer.	Cancer research	2005	1201
16112414	Estrogens	Tsuchiya Y	Cytochrome P450-mediated metabolism of estrogens and its regulation in human.	Cancer letters	2005	99
16165085	Estrogens	Wang Z	Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66.	Biochemical and biophysical research communications	2005	103
16172792	Estrogens	Zhang Z	Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.	Breast cancer research and treatment	2005	71
16234531	Estrogens	Cui X	Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.	Journal of clinical oncology 	2005	118
16299229	Estrogens	Willipinski-Stapelfeldt B	Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells.	Clinical cancer research 	2005	81
16317585	Estrogens	Li SY	PIK3CA mutations in breast cancer are associated with poor outcome.	Breast cancer research and treatment	2006	60
16322319	Estrogens	Normanno N	Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.	Endocrine-related cancer	2005	75
16341146	Estrogens	Livasy CA	Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.	Modern pathology 	2006	250
16357129	Estrogens	Mehra R	Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.	Cancer research	2005	84
16368942	Estrogens	McCabe A	Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis.	Journal of the National Cancer Institute	2005	81
16394250	Estrogens	Hall JM	Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting.	Molecular interventions	2005	75
16396959	Estrogens	Carroll JS	Estrogen receptor target gene: an evolving concept.	Molecular endocrinology	2006	90
16455494	Estrogens	Cheng AS	Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters.	Molecular cell	2006	72
16469706	Estrogens	Zhu P	Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway.	Cell	2006	94
16478745	Estrogens	Sotiriou C	Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.	Journal of the National Cancer Institute	2006	549
16511588	Estrogens	Deroo BJ	Estrogen receptors and human disease.	The Journal of clinical investigation	2006	283
16533778	Estrogens	Rodríguez-Pinilla SM	Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.	Clinical cancer research 	2006	73
16585219	Estrogens	Creighton CJ	Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.	Cancer research	2006	86
16603601	Estrogens	Pestalozzi BC	Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).	Annals of oncology 	2006	76
16611412	Estrogens	Ghebeh H	The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.	Neoplasia	2006	142
16626501	Estrogens	Perreard L	Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay.	Breast cancer research 	2006	62
16636149	Estrogens	Sukocheva O	Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1.	The Journal of cell biology	2006	63
16648502	Estrogens	Wapnir IL	Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.	Journal of clinical oncology 	2006	71
16651450	Estrogens	Dreijerink KM	Menin links estrogen receptor activation to histone H3K4 trimethylation.	Cancer research	2006	67
16707433	Estrogens	Bond GL	MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.	Cancer research	2006	111
16729877	Estrogens	Sørlie T	Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.	BMC genomics	2006	110
16757721	Estrogens	Carey LA	Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.	JAMA	2006	1027
16846527	Estrogens	Birgisdottir V	Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.	Breast cancer research 	2006	75
16849684	Estrogens	Asselin-Labat ML	Steroid hormone receptor status of mouse mammary stem cells.	Journal of the National Cancer Institute	2006	98
16885386	Estrogens	Wolf I	15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.	Cancer research	2006	63
16897746	Estrogens	Bergamaschi A	Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.	Genes, chromosomes & cancer	2006	162
16899776	Estrogens	Fan C	Concordance among gene-expression-based predictors for breast cancer.	The New England journal of medicine	2006	352
16901744	Estrogens	Ilan N	Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.	The international journal of biochemistry & cell biology	2006	159
16904320	Estrogens	Singh PK	Cell surface-associated mucins in signal transduction.	Trends in cell biology	2006	122
16931954	Estrogens	Hicks DG	Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.	The American journal of surgical pathology	2006	71
16938528	Estrogens	Kim MJ	Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.	Human pathology	2006	84
16940181	Estrogens	Hossain A	Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA.	Molecular and cellular biology	2006	171
16951137	Estrogens	Amend K	Breast cancer in African-American women: differences in tumor biology from European-American women.	Cancer research	2006	67
16954471	Estrogens	Buyse M	Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.	Journal of the National Cancer Institute	2006	257
17028294	Estrogens	Hecht JL	Molecular and pathologic aspects of endometrial carcinogenesis.	Journal of clinical oncology 	2006	94
17085646	Estrogens	Filardo EJ	Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression.	Clinical cancer research 	2006	101
17113977	Estrogens	Russo J	The role of estrogen in the initiation of breast cancer.	The Journal of steroid biochemistry and molecular biology	2006	82
17116942	Estrogens	Haffty BG	Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.	Journal of clinical oncology 	2006	226
17123779	Estrogens	Prins GS	Developmental estrogen exposures predispose to prostate carcinogenesis with aging.	Reproductive toxicology	2007	69
17135638	Estrogens	Bates GJ	Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.	Journal of clinical oncology 	2006	234
17146782	Estrogens	Rakha EA	Prognostic markers in triple-negative breast cancer.	Cancer	2007	285
17169390	Estrogens	Jordan VC	Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.	Steroids	2007	78
17234468	Estrogens	Livasy CA	Identification of a basal-like subtype of breast ductal carcinoma in situ.	Human pathology	2007	60
17239243	Estrogens	Dunnwald LK	Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.	Breast cancer research 	2007	158
17312270	Estrogens	Adams BD	The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines.	Molecular endocrinology	2007	152
17325027	Estrogens	Haiman CA	Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women.	Cancer research	2007	66
17332353	Estrogens	Huang F	Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.	Cancer research	2007	105
17334996	Estrogens	Jönsson G	High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.	Genes, chromosomes & cancer	2007	66
17360330	Estrogens	Kwon YS	Sensitive ChIP-DSL technology reveals an extensive estrogen receptor alpha-binding program on human gene promoters.	Proceedings of the National Academy of Sciences of the United States of America	2007	59
17372238	Estrogens	Yang XR	Differences in risk factors for breast cancer molecular subtypes in a population-based study.	Cancer epidemiology, biomarkers & prevention 	2007	161
17387718	Estrogens	Bauer KR	Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.	Cancer	2007	481
17403429	Estrogens	Smith HO	GPR30: a novel indicator of poor survival for endometrial carcinoma.	American journal of obstetrics and gynecology	2007	77
17409397	Estrogens	Pick E	High HSP90 expression is associated with decreased survival in breast cancer.	Cancer research	2007	78
17417639	Estrogens	Holst F	Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.	Nature genetics	2007	77
17440086	Estrogens	Fu Y	GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis.	Cancer research	2007	92
17456570	Estrogens	Rohrmann S	Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans.	The Journal of clinical endocrinology and metabolism	2007	57
17493263	Estrogens	Herschkowitz JI	Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.	Genome biology	2007	443
17502350	Estrogens	Shi B	Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells.	Molecular and cellular biology	2007	107
17529974	Estrogens	Stacey SN	Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer.	Nature genetics	2007	320
17554627	Estrogens	Bauer M	Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer.	Breast cancer research and treatment	2008	58
17575221	Estrogens	Pérez-Tenorio G	PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.	Clinical cancer research 	2007	96
17578664	Estrogens	Millikan RC	Epidemiology of basal-like breast cancer.	Breast cancer research and treatment	2008	306
17586727	Estrogens	Sasser AK	Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer.	FASEB journal 	2007	70
17592774	Estrogens	Levin ER	Estrogen receptors outside the nucleus in breast cancer.	Breast cancer research and treatment	2008	50
17615392	Estrogens	Heldring N	Estrogen receptors: how do they signal and what are their targets.	Physiological reviews	2007	360
17626182	Estrogens	Liu X	Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	115
17639037	Estrogens	Vona-Davis L	Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression.	Endocrine-related cancer	2007	137
17652280	Estrogens	Glass AG	Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.	Journal of the National Cancer Institute	2007	99
17660348	Estrogens	Gomez BP	Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines.	FASEB journal 	2007	67
17663798	Estrogens	Hoadley KA	EGFR associated expression profiles vary with breast tumor subtype.	BMC genomics	2007	104
17671124	Estrogens	Badve S	FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.	Clinical cancer research 	2007	69
17671126	Estrogens	Dent R	Triple-negative breast cancer: clinical features and patterns of recurrence.	Clinical cancer research 	2007	767
17683518	Estrogens	Teschendorff AE	An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.	Genome biology	2007	176
17700529	Estrogens	Williams C	A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells.	Oncogene	2008	70
17761946	Estrogens	Dhasarathy A	The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha.	Molecular endocrinology	2007	79
17910759	Estrogens	Kreike B	Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.	Breast cancer research 	2007	171
17925008	Estrogens	Chin SF	High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer.	Genome biology	2007	116
17954709	Estrogens	Harris L	American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.	Journal of clinical oncology 	2007	496
17981890	Estrogens	Rose DP	Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women.	Endocrine reviews	2007	71
18006846	Estrogens	Mertens-Talcott SU	The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells.	Cancer research	2007	152
18037158	Estrogens	Tomsová M	Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.	Gynecologic oncology	2008	64
18048329	Estrogens	Gupta GP	ID genes mediate tumor reinitiation during breast cancer lung metastasis.	Proceedings of the National Academy of Sciences of the United States of America	2007	91
18089790	Estrogens	Sempere LF	Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer.	Cancer research	2007	212
18093629	Estrogens	Prins GS	The role of estrogens and estrogen receptors in normal prostate growth and disease.	Steroids	2008	57
18216219	Estrogens	Arpino G	Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.	Endocrine reviews	2008	143
18219273	Estrogens	Krum SA	Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival.	The EMBO journal	2008	81
18230721	Estrogens	Liu S	BRCA1 regulates human mammary stem/progenitor cell fate.	Proceedings of the National Academy of Sciences of the United States of America	2008	157
18240539	Estrogens	Mundy GR	Osteoporosis and inflammation.	Nutrition reviews	2007	102
18242510	Estrogens	Iorns E	Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.	Cancer cell	2008	53
18250347	Estrogens	Liedtke C	Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.	Journal of clinical oncology 	2008	473
18271749	Estrogens	Prossnitz ER	Estrogen signaling through the transmembrane G protein-coupled receptor GPR30.	Annual review of physiology	2008	172
18285604	Estrogens	Kyndi M	Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.	Journal of clinical oncology 	2008	89
18294387	Estrogens	Ghebeh H	FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.	BMC cancer	2008	52
18297396	Estrogens	Lu X	Predicting features of breast cancer with gene expression patterns.	Breast cancer research and treatment	2008	90
18316557	Estrogens	Cheang MC	Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.	Clinical cancer research 	2008	318
18317227	Estrogens	Soslow RA	Histologic subtypes of ovarian carcinoma: an overview.	International journal of gynecological pathology 	2008	63
18324472	Estrogens	Lund MJ	Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.	Breast cancer research and treatment	2009	114
18334610	Estrogens	Gao Q	Cross-talk between estrogen and leptin signaling in the hypothalamus.	American journal of physiology. Endocrinology and metabolism	2008	56
18339859	Estrogens	Cheng AS	Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome.	Cancer research	2008	54
18375767	Estrogens	Tan-Wong SM	Dynamic interactions between the promoter and terminator regions of the mammalian BRCA1 gene.	Proceedings of the National Academy of Sciences of the United States of America	2008	62
18381931	Estrogens	Wu JM	Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases.	Clinical cancer research 	2008	68
18391223	Estrogens	Horwitz KB	Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.	Proceedings of the National Academy of Sciences of the United States of America	2008	62
18413639	Estrogens	Nguyen PL	Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.	Journal of clinical oncology 	2008	162
18414489	Estrogens	Hua S	Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression.	Molecular systems biology	2008	66
18437174	Estrogens	Gown AM	Current issues in ER and HER2 testing by IHC in breast cancer.	Modern pathology 	2008	66
18438407	Estrogens	Stacey SN	Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer.	Nature genetics	2008	219
18443585	Estrogens	Ben-Porath I	An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.	Nature genetics	2008	811
18451146	Estrogens	Yang XH	CD151 accelerates breast cancer by regulating alpha 6 integrin function, signaling, and molecular organization.	Cancer research	2008	63
18451221	Estrogens	Ignatiadis M	Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.	Clinical cancer research 	2008	52
18451222	Estrogens	Ma XJ	A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer.	Clinical cancer research 	2008	66
18458044	Estrogens	Pestalozzi BC	Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.	Journal of clinical oncology 	2008	54
18471979	Estrogens	Subramanian K	Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase.	Molecular cell	2008	92
18487567	Estrogens	Badve SS	Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.	Journal of clinical oncology 	2008	60
18505969	Estrogens	Setlur SR	Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.	Journal of the National Cancer Institute	2008	110
18506688	Estrogens	Shabo I	Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival.	International journal of cancer	2008	52
18515733	Estrogens	Ross JS	Commercialized multigene predictors of clinical outcome for breast cancer.	The oncologist	2008	55
18543098	Estrogens	Dent R	Pattern of metastatic spread in triple-negative breast cancer.	Breast cancer research and treatment	2009	88
18559090	Estrogens	Honeth G	The CD44+/CD24- phenotype is enriched in basal-like breast tumors.	Breast cancer research 	2008	186
18593897	Estrogens	Kondo N	miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.	Cancer research	2008	106
18612148	Estrogens	Anders CK	Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.	Journal of clinical oncology 	2008	159
18657504	Estrogens	Le Romancer M	Regulation of estrogen rapid signaling through arginine methylation by PRMT1.	Molecular cell	2008	76
18662380	Estrogens	Wirapati P	Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.	Breast cancer research 	2008	249
18679793	Estrogens	Tewes M	Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies.	Breast cancer research and treatment	2009	52
18687985	Estrogens	Pinzone JJ	The role of Dickkopf-1 in bone development, homeostasis, and disease.	Blood	2009	85
18698033	Estrogens	Desmedt C	Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.	Clinical cancer research 	2008	235
18698041	Estrogens	Shaaban AM	Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients.	Clinical cancer research 	2008	63
18714348	Estrogens	Martin KJ	Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets.	PloS one	2008	90
18722177	Estrogens	Kim JH	CCAR1, a key regulator of mediator complex recruitment to nuclear receptor transcription complexes.	Molecular cell	2008	55
18726992	Estrogens	Phipps AI	Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer.	Cancer	2008	54
18755890	Estrogens	Foekens JA	Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2008	132
18757322	Estrogens	Creighton CJ	Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis.	Journal of clinical oncology 	2008	102
18779615	Estrogens	Atchley DP	Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.	Journal of clinical oncology 	2008	113
18806226	Estrogens	Dumont N	Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers.	Proceedings of the National Academy of Sciences of the United States of America	2008	81
18841463	Estrogens	Tan AR	Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?	Breast cancer research and treatment	2009	48
18974155	Estrogens	Studebaker AW	Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner.	Cancer research	2008	70
18988226	Estrogens	Suzuki R	Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis.	International journal of cancer	2009	72
18996136	Estrogens	Fox EM	Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways.	Steroids	2009	47
19001334	Estrogens	Chia S	Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.	Journal of clinical oncology 	2008	57
19027010	Estrogens	Liu WH	MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells.	Gastroenterology	2009	65
19028704	Estrogens	Rebbeck TR	Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women.	Carcinogenesis	2009	46
19042984	Estrogens	Sturgeon CM	National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.	Clinical chemistry	2008	97
19052240	Estrogens	Hu Q	Enhancing nuclear receptor-induced transcription requires nuclear motor and LSD1-dependent gene networking in interchromatin granules.	Proceedings of the National Academy of Sciences of the United States of America	2008	111
19079346	Estrogens	Gonzalez ME	Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.	Oncogene	2009	75
19088018	Estrogens	Dowsett M	Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.	Clinical cancer research 	2008	64
19112174	Estrogens	Yamnik RL	S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation.	The Journal of biological chemistry	2009	62
19116762	Estrogens	Toh Y	The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications.	Clinical & experimental metastasis	2009	67
19139166	Estrogens	Pauklin S	Estrogen directly activates AID transcription and function.	The Journal of experimental medicine	2009	57
19147748	Estrogens	Andre F	Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.	Clinical cancer research 	2009	97
19188147	Estrogens	Beck AH	The macrophage colony-stimulating factor 1 response signature in breast carcinoma.	Clinical cancer research 	2009	59
19204204	Estrogens	Parker JS	Supervised risk predictor of breast cancer based on intrinsic subtypes.	Journal of clinical oncology 	2009	954
19219042	Estrogens	Zheng W	Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1.	Nature genetics	2009	252
19237579	Estrogens	Yang J	Lipocalin 2 promotes breast cancer progression.	Proceedings of the National Academy of Sciences of the United States of America	2009	85
19272155	Estrogens	Rody A	T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.	Breast cancer research 	2009	94
19276248	Estrogens	Gonzalez-Angulo AM	Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.	Clinical cancer research 	2009	72
19298662	Estrogens	Young SR	The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.	BMC cancer	2009	55
19299408	Estrogens	Simmons C	Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?	Annals of oncology 	2009	62
19317994	Estrogens	Gnerlich JL	Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease.	Journal of the American College of Surgeons	2009	69
19318616	Estrogens	Setiawan VW	Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study.	American journal of epidemiology	2009	76
19330030	Estrogens	Thomas G	A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1).	Nature genetics	2009	273
19343511	Estrogens	Trivers KF	The epidemiology of triple-negative breast cancer, including race.	Cancer causes & control 	2009	82
19349544	Estrogens	Anderson SJ	Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.	Journal of clinical oncology 	2009	63
19351835	Estrogens	Alli E	Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.	Cancer research	2009	52
19372580	Estrogens	Hu X	Genetic alterations and oncogenic pathways associated with breast cancer subtypes.	Molecular cancer research 	2009	80
19385968	Estrogens	Morimoto K	Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.	Cancer science	2009	59
19414598	Estrogens	Pandey DP	miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA.	Molecular and cellular biology	2009	71
19421758	Estrogens	Fang YJ	Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer.	International journal of colorectal disease	2009	47
19436038	Estrogens	Cheang MC	Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.	Journal of the National Cancer Institute	2009	447
19451693	Estrogens	Bierie B	Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer.	The Journal of clinical investigation	2009	46
19463150	Estrogens	Kwan ML	Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors.	Breast cancer research 	2009	95
19464786	Estrogens	Prossnitz ER	Mechanisms of estrogen signaling and gene expression via GPR30.	Molecular and cellular endocrinology	2009	81
19473525	Estrogens	Luo W	GAGE: generally applicable gene set enrichment for pathway analysis.	BMC bioinformatics	2009	219
19498003	Estrogens	Paulsson J	Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer.	The American journal of pathology	2009	59
19514831	Estrogens	Vona-Davis L	The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review.	Journal of women's health	2009	69
19535820	Estrogens	Goldhirsch A	Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.	Annals of oncology 	2009	262
19549922	Estrogens	Lin BC	Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation.	Cancer research	2009	47
19563758	Estrogens	Hua S	Genomic antagonism between retinoic acid and estrogen signaling in breast cancer.	Cell	2009	112
19567422	Estrogens	Milne RL	Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042.	Journal of the National Cancer Institute	2009	52
19574486	Estrogens	Onitilo AA	Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.	Clinical medicine & research	2009	165
19581928	Estrogens	Sullivan NJ	Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells.	Oncogene	2009	186
19582160	Estrogens	Kao J	Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.	PloS one	2009	264
19584327	Estrogens	Menashe I	Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis.	Journal of the National Cancer Institute	2009	54
19596702	Estrogens	Liedtke C	Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.	Annals of oncology 	2009	71
19602591	Estrogens	Hartman J	Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells.	Cancer research	2009	52
19622763	Estrogens	Deblois G	Genome-wide identification of direct target genes implicates estrogen-related receptor alpha as a determinant of breast cancer heterogeneity.	Cancer research	2009	58
19628648	Estrogens	Welboren WJ	Genomic actions of estrogen receptor alpha: what are the targets and how are they regulated?	Endocrine-related cancer	2009	46
19653045	Estrogens	Arrington AK	Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer.	Annals of surgical oncology	2009	49
19664291	Estrogens	Fehm T	Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.	Breast cancer research 	2009	61
19684618	Estrogens	Leivonen SK	Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines.	Oncogene	2009	75
19704069	Estrogens	Huo D	Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.	Journal of clinical oncology 	2009	109
19706389	Estrogens	Castellano L	The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response.	Proceedings of the National Academy of Sciences of the United States of America	2009	120
19720911	Estrogens	Millar EK	Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.	Journal of clinical oncology 	2009	69
19730444	Estrogens	Spizzo R	miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells.	Cell death and differentiation	2010	85
19764994	Estrogens	Parise CA	Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.	The breast journal	2009	73
19767412	Estrogens	Maggiolini M	The unfolding stories of GPR30, a new membrane-bound estrogen receptor.	The Journal of endocrinology	2010	95
19826037	Estrogens	Maillot G	Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth.	Cancer research	2009	92
19838210	Estrogens	Hao L	Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells.	Oncogene	2010	43
19858088	Estrogens	Aitken SJ	Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.	Annals of oncology 	2010	43
19887463	Estrogens	Park S	Expression of androgen receptors in primary breast cancer.	Annals of oncology 	2010	71
19887647	Estrogens	Ma Y	BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha.	Molecular endocrinology	2010	55
19898421	Estrogens	Niemeier LA	Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.	Modern pathology 	2010	81
19901010	Estrogens	Gluz O	Triple-negative breast cancer--current status and future directions.	Annals of oncology 	2009	125
19911270	Estrogens	Resetkova E	Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.	Breast cancer research and treatment	2010	60
19925796	Estrogens	Yamnik RL	mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation.	FEBS letters	2010	43
19994911	Estrogens	Giskeødegård GF	Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics.	Journal of proteome research	2010	43
20020197	Estrogens	Györffy B	An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.	Breast cancer research and treatment	2010	524
20042638	Estrogens	Lim S	Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology.	Carcinogenesis	2010	129
20080637	Estrogens	Lovén J	MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.	Proceedings of the National Academy of Sciences of the United States of America	2010	48
20080953	Estrogens	Ross-Innes CS	Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer.	Genes & development	2010	87
20082448	Estrogens	Rimawi MF	Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.	Cancer	2010	52
20124474	Estrogens	Hoffman AE	CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses.	Cancer research	2010	49
20127405	Estrogens	Castellano I	Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.	Breast cancer research and treatment	2010	49
20134314	Estrogens	Heneghan HM	Circulating microRNAs as novel minimally invasive biomarkers for breast cancer.	Annals of surgery	2010	189
20144946	Estrogens	Reverter A	Regulatory impact factors: unraveling the transcriptional regulation of complex traits from expression data.	Bioinformatics	2010	42
20180843	Estrogens	Xiong J	An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples.	The FEBS journal	2010	48
20194857	Estrogens	Voduc KD	Breast cancer subtypes and the risk of local and regional relapse.	Journal of clinical oncology 	2010	247
20208560	Estrogens	Millour J	FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.	Oncogene	2010	44
20219941	Estrogens	Schmidt D	A CTCF-independent role for cohesin in tissue-specific transcription.	Genome research	2010	159
20231686	Estrogens	Staaf J	Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.	Journal of clinical oncology 	2010	58
20332136	Estrogens	Cancello G	Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer.	Annals of oncology 	2010	41
20332324	Estrogens	Johnston SR	New strategies in estrogen receptor-positive breast cancer.	Clinical cancer research 	2010	66
20395295	Estrogens	Motiani RK	A novel native store-operated calcium channel encoded by Orai3: selective requirement of Orai3 versus Orai1 in estrogen receptor-positive versus estrogen receptor-negative breast cancer cells.	The Journal of biological chemistry	2010	75
20404251	Estrogens	Hammond ME	American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.	Journal of clinical oncology 	2010	560
20411366	Estrogens	Ibrahim EM	Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies.	Medical oncology	2011	94
20427430	Estrogens	Kerlikowske K	Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.	Journal of the National Cancer Institute	2010	84
20442245	Estrogens	Hsu PY	Estrogen-mediated epigenetic repression of large chromosomal regions through DNA looping.	Genome research	2010	41
20459607	Estrogens	Staaf J	High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.	Breast cancer research 	2010	52
20501593	Estrogens	Bernardo GM	FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis.	Development	2010	71
20501637	Estrogens	Leung YK	Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion.	Endocrine-related cancer	2010	43
20509143	Estrogens	Storci G	TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype.	Journal of cellular physiology	2010	41
20524868	Estrogens	Hammond ME	American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.	Archives of pathology & laboratory medicine	2010	84
20535543	Estrogens	Zhao Y	Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer.	Breast cancer research and treatment	2011	41
20537966	Estrogens	Podo F	Triple-negative breast cancer: present challenges and new perspectives.	Molecular oncology	2010	70
20547749	Estrogens	Stender JD	Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation.	Molecular and cellular biology	2010	67
20586616	Estrogens	Hammond ME	American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).	Archives of pathology & laboratory medicine	2010	150
20629078	Estrogens	Stark A	African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study.	Cancer	2010	54
20647302	Estrogens	Weigel MT	Current and emerging biomarkers in breast cancer: prognosis and prediction.	Endocrine-related cancer	2010	99
20661439	Estrogens	Stacey SN	Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus.	PLoS genetics	2010	45
20663194	Estrogens	Tuominen VJ	ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67.	Breast cancer research 	2010	142
20664043	Estrogens	Reeves GK	Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci.	JAMA	2010	51
20664514	Estrogens	Ismail-Khan R	A review of triple-negative breast cancer.	Cancer control 	2010	42
20664598	Estrogens	Dawson SJ	BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received.	British journal of cancer	2010	58
20679727	Estrogens	Jiang Z	Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.	The Journal of clinical investigation	2010	58
20699374	Estrogens	Long J	Evaluation of breast cancer susceptibility loci in Chinese women.	Cancer epidemiology, biomarkers & prevention 	2010	46
20813970	Estrogens	Esteva FJ	PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.	The American journal of pathology	2010	100
20821253	Estrogens	Grossmann ME	Obesity and breast cancer: status of leptin and adiponectin in pathological processes.	Cancer metastasis reviews	2010	52
20852631	Estrogens	Antoniou AC	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.	Nature genetics	2010	160
20858276	Estrogens	Lowery AJ	Dysregulated miR-183 inhibits migration in breast cancer cells.	BMC cancer	2010	45
20861225	Estrogens	Toft DJ	Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies.	Molecular endocrinology	2011	40
20863372	Estrogens	Hoefnagel LD	Receptor conversion in distant breast cancer metastases.	Breast cancer research 	2010	52
20876186	Estrogens	Suzuki HI	Emerging complexity of microRNA generation cascades.	Journal of biochemistry	2011	38
20880178	Estrogens	Pu XX	Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression.	Journal of gastroenterology and hepatology	2010	97
20887199	Estrogens	Osborne CK	Mechanisms of endocrine resistance in breast cancer.	Annual review of medicine	2011	237
20889718	Estrogens	Lupien M	Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance.	Genes & development	2010	59
20932292	Estrogens	Sircoulomb F	Genome profiling of ERBB2-amplified breast cancers.	BMC cancer	2010	54
20935677	Estrogens	Zhang XT	A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells.	Oncogene	2011	41
20946665	Estrogens	Yau C	A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.	Breast cancer research 	2010	52
20956553	Estrogens	Madak-Erdogan Z	Genomic collaboration of estrogen receptor alpha and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs.	Molecular and cellular biology	2011	48
20956939	Estrogens	Sachdeva M	MicroRNA-101-mediated Akt activation and estrogen-independent growth.	Oncogene	2011	37
20975711	Estrogens	Li J	Identification of high-quality cancer prognostic markers and metastasis network modules.	Nature communications	2010	136
20978187	Estrogens	de Souza Rocha Simonini P	Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells.	Cancer research	2010	78
21057539	Estrogens	Patel JB	Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22.	Oncogene	2011	39
21059212	Estrogens	Thompson AM	Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).	Breast cancer research 	2010	63
21067385	Estrogens	Foulkes WD	Triple-negative breast cancer.	The New England journal of medicine	2010	625
21084273	Estrogens	Wynendaele J	An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.	Cancer research	2010	51
21092082	Estrogens	Kurian AW	Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups.	Breast cancer research 	2010	45
21098263	Estrogens	Fillmore CM	Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling.	Proceedings of the National Academy of Sciences of the United States of America	2010	94
21124311	Estrogens	Nilsson S	Estrogen receptors: therapies targeted to receptor subtypes.	Clinical pharmacology and therapeutics	2011	76
21127264	Estrogens	Fedele CG	Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.	Proceedings of the National Academy of Sciences of the United States of America	2010	77
21149515	Estrogens	Murphy LC	Clinical significance of estrogen receptor phosphorylation.	Endocrine-related cancer	2011	47
21149639	Estrogens	Sandén C	G protein-coupled estrogen receptor 1/G protein-coupled receptor 30 localizes in the plasma membrane and traffics intracellularly on cytokeratin intermediate filaments.	Molecular pharmacology	2011	41
21164480	Estrogens	Tsai WW	TRIM24 links a non-canonical histone signature to breast cancer.	Nature	2010	123
21169259	Estrogens	O'Brien KM	Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.	Clinical cancer research 	2010	103
21172665	Estrogens	Yang Y	TDRD3 is an effector molecule for arginine-methylated histone marks.	Molecular cell	2010	71
21191116	Estrogens	Iwamoto T	Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.	Journal of the National Cancer Institute	2011	69
21191117	Estrogens	Yang XR	Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.	Journal of the National Cancer Institute	2011	223
21193018	Estrogens	Guo S	Role of Notch and its oncogenic signaling crosstalk in breast cancer.	Biochimica et biophysica acta	2011	73
21212030	Estrogens	Rønneberg JA	Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer.	Molecular oncology	2011	52
21220595	Estrogens	Loo CE	Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype.	Journal of clinical oncology 	2011	42
21235772	Estrogens	Grober OM	Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation.	BMC genomics	2011	49
21263130	Estrogens	Fletcher O	Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study.	Journal of the National Cancer Institute	2011	120
21292829	Estrogens	Becker MA	The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells.	Molecular endocrinology	2011	41
21310761	Estrogens	Park S	Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.	Annals of oncology 	2011	43
21324165	Estrogens	Soini Y	Transcription factors zeb1, twist and snai1 in breast carcinoma.	BMC cancer	2011	37
21325075	Estrogens	Hu R	Androgen receptor expression and breast cancer survival in postmenopausal women.	Clinical cancer research 	2011	87
21335088	Estrogens	Chumsri S	Aromatase, aromatase inhibitors, and breast cancer.	The Journal of steroid biochemistry and molecular biology	2011	48
21356373	Estrogens	Conklin MW	Aligned collagen is a prognostic signature for survival in human breast carcinoma.	The American journal of pathology	2011	217
21363912	Estrogens	Hill VK	Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity.	Cancer research	2011	47
21364029	Estrogens	Phipps AI	Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer.	Cancer epidemiology, biomarkers & prevention 	2011	58
21369698	Estrogens	Catchpole S	PLU-1/JARID1B/KDM5B is required for embryonic survival and contributes to cell proliferation in the mammary gland and in ER+ breast cancer cells.	International journal of oncology	2011	45
21375733	Estrogens	Hannafon BN	Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer.	Breast cancer research 	2011	57
21387260	Estrogens	Lara-Medina F	Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity.	Cancer	2011	47
21472708	Estrogens	Anders CK	The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.	Cancer	2011	35
21482677	Estrogens	Meyer DS	Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.	Cancer research	2011	43
21482760	Estrogens	Nicolau M	Topology based data analysis identifies a subgroup of breast cancers with a unique mutational profile and excellent survival.	Proceedings of the National Academy of Sciences of the United States of America	2011	38
21483002	Estrogens	Mahmoud SM	Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.	Journal of clinical oncology 	2011	287
21490305	Estrogens	Gonzalez-Angulo AM	PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.	Molecular cancer therapeutics	2011	76
21502505	Estrogens	Shi L	Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2011	71
21505063	Estrogens	Sieuwerts AM	mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients.	Clinical cancer research 	2011	65
21552212	Estrogens	Collins LC	Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.	Modern pathology 	2011	49
21553120	Estrogens	Guttilla IK	Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs.	Breast cancer research and treatment	2012	38
21605893	Estrogens	Aktas B	Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.	Gynecologic oncology	2011	37
21622563	Estrogens	Zhou H	Novel mechanism of anti-apoptotic function of 78-kDa glucose-regulated protein (GRP78): endocrine resistance factor in breast cancer, through release of B-cell lymphoma 2 (BCL-2) from BCL-2-interacting killer (BIK).	The Journal of biological chemistry	2011	39
21667121	Estrogens	Gaudet MM	Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger.	Breast cancer research and treatment	2011	56
21670451	Estrogens	Abdulkarim BS	Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.	Journal of clinical oncology 	2011	57
21677874	Estrogens	Davison Z	Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy.	Neoplasia	2011	50
21689398	Estrogens	Patnaik JL	Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study.	Breast cancer research 	2011	87
21690342	Estrogens	Jin K	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway.	Proceedings of the National Academy of Sciences of the United States of America	2012	31
21701558	Estrogens	Robinson JL	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1.	The EMBO journal	2011	73
21713035	Estrogens	Al Saleh S	Estrogen receptor silencing induces epithelial to mesenchymal transition in human breast cancer cells.	PloS one	2011	39
21737487	Estrogens	Buffa FM	microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer.	Cancer research	2011	115
21753181	Estrogens	Anderson WF	Incidence of breast cancer in the United States: current and future trends.	Journal of the National Cancer Institute	2011	52
21775990	Estrogens	Matson CK	DMRT1 prevents female reprogramming in the postnatal mammalian testis.	Nature	2011	92
21779467	Estrogens	Ossovskaya V	Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.	Genes & cancer	2010	49
21795664	Estrogens	Yaghjyan L	Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics.	Journal of the National Cancer Institute	2011	50
21796367	Estrogens	van Nes JG	Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients.	Breast cancer research and treatment	2012	30
21807638	Estrogens	Filipits M	A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.	Clinical cancer research 	2011	96
21825015	Estrogens	Fackler MJ	Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence.	Cancer research	2011	72
21830014	Estrogens	Tamimi RM	Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer.	Breast cancer research and treatment	2012	59
21844186	Estrogens	Stevens KN	Common breast cancer susceptibility loci are associated with triple-negative breast cancer.	Cancer research	2011	53
21846820	Estrogens	Palmer JR	Parity and lactation in relation to estrogen receptor negative breast cancer in African American women.	Cancer epidemiology, biomarkers & prevention 	2011	57
21852249	Estrogens	Figueroa JD	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium.	Human molecular genetics	2011	41
21859480	Estrogens	Li J	A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China.	BMC cancer	2011	50
21868756	Estrogens	Pan D	Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer.	Cancer research	2011	49
21868760	Estrogens	Qian P	Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis.	Cancer research	2011	51
21870331	Estrogens	Pinheiro C	GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression.	Histology and histopathology	2011	52
21878914	Estrogens	Kong SL	Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.	Molecular systems biology	2011	57
21893191	Estrogens	Wertheimer E	Rac signaling in breast cancer: a tale of GEFs and GAPs.	Cellular signalling	2012	66
21900114	Estrogens	Arvold ND	Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy.	Journal of clinical oncology 	2011	67
21908496	Estrogens	Rojo F	Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.	Annals of oncology 	2012	42
21914172	Estrogens	Sihto H	Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.	Breast cancer research 	2011	50
21920899	Estrogens	Elangovan S	SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancer.	Cancer research	2011	37
21940501	Estrogens	Keller PJ	Defining the cellular precursors to human breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2012	84
21969591	Estrogens	Haughian JM	Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch.	Proceedings of the National Academy of Sciences of the United States of America	2012	42
21983130	Estrogens	Chen X	Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ERα-positive endometrioid adenocarcinoma.	Cancer letters	2012	31
21984977	Estrogens	Brough R	Functional viability profiles of breast cancer.	Cancer discovery	2011	49
21996731	Estrogens	Fanale D	Breast cancer genome-wide association studies: there is strength in numbers.	Oncogene	2012	34
22028449	Estrogens	Hammes SR	Minireview: Recent advances in extranuclear steroid receptor actions.	Endocrinology	2011	50
22037553	Estrogens	Haiman CA	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer.	Nature genetics	2011	145
22042860	Estrogens	Santagata S	High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2011	89
22049316	Estrogens	Miller TW	ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.	Cancer discovery	2011	71
22081016	Estrogens	Jeong KW	Recognition of enhancer element-specific histone methylation by TIP60 in transcriptional activation.	Nature structural & molecular biology	2011	39
22081974	Estrogens	Fasching PA	Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.	BMC cancer	2011	62
22083089	Estrogens	Andò S	The multifactorial role of leptin in driving the breast cancer microenvironment.	Nature reviews. Endocrinology	2011	40
22114931	Estrogens	Miller TW	Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.	Breast cancer research 	2011	97
22115959	Estrogens	Wetendorf M	The progesterone receptor regulates implantation, decidualization, and glandular development via a complex paracrine signaling network.	Molecular and cellular endocrinology	2012	48
22124102	Estrogens	Amir E	Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer.	Journal of clinical oncology 	2012	88
22125492	Estrogens	Magnani L	PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer.	PLoS genetics	2011	50
22138582	Estrogens	Gerhardt J	FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer.	The American journal of pathology	2012	32
22144499	Estrogens	Mavaddat N	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).	Cancer epidemiology, biomarkers & prevention 	2012	80
22147079	Estrogens	Lowery AJ	Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype.	Breast cancer research and treatment	2012	61
22151997	Estrogens	Chimge NO	Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2.	Breast cancer research 	2011	38
22158050	Estrogens	Keklikoglou I	MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways.	Oncogene	2012	70
22158945	Estrogens	Nasser MW	S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways.	Cancer research	2012	38
22177311	Estrogens	Dittrich R	Live birth after ovarian tissue autotransplantation following overnight transportation before cryopreservation.	Fertility and sterility	2012	37
22178455	Estrogens	Eroles P	Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.	Cancer treatment reviews	2012	103
22178456	Estrogens	Amir E	Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies.	Cancer treatment reviews	2012	35
22217398	Estrogens	Tran B	Luminal-B breast cancer and novel therapeutic targets.	Breast cancer research 	2011	50
22217937	Estrogens	Ross-Innes CS	Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.	Nature	2012	270
22223266	Estrogens	Markowski DN	MED12 mutations in uterine fibroids--their relationship to cytogenetic subgroups.	International journal of cancer	2012	38
22231848	Estrogens	Visser JA	Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency.	Nature reviews. Endocrinology	2012	39
22240241	Estrogens	Jamieson S	Molecular pathogenesis of granulosa cell tumors of the ovary.	Endocrine reviews	2012	31
22244658	Estrogens	Cramer DW	The epidemiology of endometrial and ovarian cancer.	Hematology/oncology clinics of North America	2012	40
22252842	Estrogens	Sharma A	HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.	Cancer	2012	33
22257677	Estrogens	Guttilla IK	ERα, microRNAs, and the epithelial-mesenchymal transition in breast cancer.	Trends in endocrinology and metabolism	2012	31
22261811	Estrogens	Azim HA Jr	Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling.	Clinical cancer research 	2012	57
22262870	Estrogens	Haibe-Kains B	A three-gene model to robustly identify breast cancer molecular subtypes.	Journal of the National Cancer Institute	2012	86
22264274	Estrogens	Chan SR	STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.	Breast cancer research 	2012	56
22267197	Estrogens	Ghoussaini M	Genome-wide association analysis identifies three new breast cancer susceptibility loci.	Nature genetics	2012	114
22270867	Estrogens	Krzeslak A	Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers.	Pathology oncology research 	2012	39
22282662	Estrogens	Barone I	Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells.	Cancer research	2012	30
22291085	Estrogens	Iwamoto T	Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.	Journal of clinical oncology 	2012	38
22301780	Estrogens	Baumgarten SC	Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers.	Molecular endocrinology	2012	46
22330809	Estrogens	Cizkova M	PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.	Breast cancer research 	2012	44
22331459	Estrogens	Stevens KN	19p13.1 is a triple-negative-specific breast cancer susceptibility locus.	Cancer research	2012	50
22348646	Estrogens	Antoniou AC	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.	Breast cancer research 	2012	33
22391567	Estrogens	Bernardo GM	FOXA1 represses the molecular phenotype of basal breast cancer cells.	Oncogene	2013	41
22408746	Estrogens	Novitskiy SV	TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms.	Cancer discovery	2011	38
22420471	Estrogens	Liu S	CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer.	Breast cancer research 	2012	82
22422990	Estrogens	Julin B	Dietary cadmium exposure and risk of postmenopausal breast cancer: a population-based prospective cohort study.	Cancer research	2012	42
22430211	Estrogens	Yeramian A	Endometrial carcinoma: molecular alterations involved in tumor development and progression.	Oncogene	2013	26
22430216	Estrogens	De Marco P	Insulin-like growth factor-I regulates GPER expression and function in cancer cells.	Oncogene	2013	29
22430491	Estrogens	Horiuchi D	MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.	The Journal of experimental medicine	2012	79
22452927	Estrogens	Keegan TH	Occurrence of breast cancer subtypes in adolescent and young adult women.	Breast cancer research 	2012	34
22495674	Estrogens	Filardo EJ	Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology.	Endocrinology	2012	73
22496456	Estrogens	Asmann YW	Detection of redundant fusion transcripts as biomarkers or disease-specific therapeutic targets in breast cancer.	Cancer research	2012	38
22496457	Estrogens	Palafox M	RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.	Cancer research	2012	44
22503553	Estrogens	Klinge CM	miRNAs and estrogen action.	Trends in endocrinology and metabolism	2012	49
22508765	Estrogens	He HH	Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics.	Genome research	2012	84
22508827	Estrogens	Ignatiadis M	Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.	Journal of clinical oncology 	2012	62
22517820	Estrogens	Gelmon K	Targeting triple-negative breast cancer: optimising therapeutic outcomes.	Annals of oncology 	2012	45
22532573	Estrogens	Fasching PA	The role of genetic breast cancer susceptibility variants as prognostic factors.	Human molecular genetics	2012	40
22538770	Estrogens	Santarpia L	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.	Breast cancer research and treatment	2012	37
22544643	Estrogens	Lin NU	Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.	Cancer	2012	64
22562122	Estrogens	Niraula S	Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis.	Breast cancer research and treatment	2012	36
22566377	Estrogens	Mohan HM	Molecular pathways: the role of NR4A orphan nuclear receptors in cancer.	Clinical cancer research 	2012	42
22583394	Estrogens	Ritte R	Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.	Breast cancer research 	2012	33
22632819	Estrogens	Zhi X	YAP promotes breast cell proliferation and survival partially through stabilizing the KLF5 transcription factor.	The American journal of pathology	2012	33
22648069	Estrogens	Burns KA	Estrogen receptors and human disease: an update.	Archives of toxicology	2012	44
22692575	Estrogens	Leth-Larsen R	Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis.	Molecular medicine	2012	36
22711854	Estrogens	Lindström LS	Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.	Journal of clinical oncology 	2012	89
22723937	Estrogens	Zhao Y	MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells.	PloS one	2012	32
22770227	Estrogens	Kim J	Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer.	Breast cancer research 	2012	31
22773826	Estrogens	Clarke CA	Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.	Journal of the National Cancer Institute	2012	61
22821401	Estrogens	Kabos P	Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.	Breast cancer research and treatment	2012	40
22824040	Estrogens	Medrek C	The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients.	BMC cancer	2012	113
22847191	Estrogens	Liu Y	MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis.	Medical science monitor 	2012	35
22933934	Estrogens	Ovcaricek T	Triple negative breast cancer - prognostic factors and survival.	Radiology and oncology	2011	40
22936542	Estrogens	Rose DP	The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression.	Endocrine-related cancer	2012	33
22956860	Estrogens	Creighton CJ	The molecular profile of luminal B breast cancer.	Biologics 	2012	54
22993197	Estrogens	Motiani RK	Orai3 is an estrogen receptor α-regulated Ca²⁺ channel that promotes tumorigenesis.	FASEB journal 	2013	45
23035151	Estrogens	Dubsky P	EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.	Annals of oncology 	2013	35
23035882	Estrogens	Bastien RR	PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.	BMC medical genomics	2012	75
23045283	Estrogens	Chimge NO	The RUNX family in breast cancer: relationships with estrogen signaling.	Oncogene	2013	43
23060440	Estrogens	Zhang Y	Estrogen receptor α signaling regulates breast tumor-initiating cells by down-regulating miR-140 which targets the transcription factor SOX2.	The Journal of biological chemistry	2012	34
23088371	Estrogens	Shehata M	Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland.	Breast cancer research 	2012	88
23112837	Estrogens	Castilla MÁ	MicroRNA-200 family modulation in distinct breast cancer phenotypes.	PloS one	2012	34
23128390	Estrogens	Rao X	CpG island shore methylation regulates caveolin-1 expression in breast cancer.	Oncogene	2013	33
23136140	Estrogens	Palmer JR	Genetic susceptibility loci for subtypes of breast cancer in an African American population.	Cancer epidemiology, biomarkers & prevention 	2013	29
23136233	Estrogens	Eiermann W	The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.	Annals of oncology 	2013	36
23139210	Estrogens	McCleland ML	An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer.	Cancer research	2012	33
23169515	Estrogens	Azim HA Jr	Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.	Journal of clinical oncology 	2013	29
23171949	Estrogens	Craig DW	Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.	Molecular cancer therapeutics	2013	56
23172872	Estrogens	Theodorou V	GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility.	Genome research	2013	86
23208510	Estrogens	Deblois G	The PGC-1/ERR signaling axis in cancer.	Oncogene	2013	30
23224237	Estrogens	Li CI	Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age.	Breast cancer research and treatment	2013	38
23251644	Estrogens	Budczies J	Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization.	PloS one	2012	159
23274845	Estrogens	Wu Y	Physical activity and risk of breast cancer: a meta-analysis of prospective studies.	Breast cancer research and treatment	2013	68
23319610	Estrogens	Ferraro DA	Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.	Proceedings of the National Academy of Sciences of the United States of America	2013	33
23319822	Estrogens	Wik E	Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.	Clinical cancer research 	2013	38
23321033	Estrogens	Turner N	Targeting triple negative breast cancer: is p53 the answer?	Cancer treatment reviews	2013	39
23334326	Estrogens	D'Assoro AB	The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.	Oncogene	2014	38
23344024	Estrogens	García-Becerra R	Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.	International journal of molecular sciences	2012	59
23347430	Estrogens	Sanders DA	Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells.	Genome biology	2013	46
23358903	Estrogens	Bayraktar S	Molecularly targeted therapies for metastatic triple-negative breast cancer.	Breast cancer research and treatment	2013	35
23364277	Estrogens	Hervouet E	Epigenetic regulation of estrogen signaling in breast cancer.	Epigenetics	2013	26
23403292	Estrogens	Mohammed H	Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor.	Cell reports	2013	78
23425944	Estrogens	Ruddy KJ	Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship.	Annals of oncology 	2013	29
23436342	Estrogens	De Los Santos JF	Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.	Cancer	2013	27
23442322	Estrogens	Ithimakin S	HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.	Cancer research	2013	62
23451089	Estrogens	Taher C	High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes.	PloS one	2013	30
23480168	Estrogens	Kim GH	The role of redox signaling in epigenetics and cardiovascular disease.	Antioxidants & redox signaling	2013	34
23505378	Estrogens	Di Leva G	Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status.	PLoS genetics	2013	45
23532539	Estrogens	Dethlefsen C	The role of intratumoral and systemic IL-6 in breast cancer.	Breast cancer research and treatment	2013	67
23535731	Estrogens	Bojesen SE	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.	Nature genetics	2013	199
23535733	Estrogens	Garcia-Closas M	Genome-wide association studies identify four ER negative-specific breast cancer risk loci.	Nature genetics	2013	173
23535825	Estrogens	Zheng W	Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls.	Human molecular genetics	2013	35
23536562	Estrogens	Stevens KN	Genetic susceptibility to triple-negative breast cancer.	Cancer research	2013	45
23540573	Estrogens	French JD	Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers.	American journal of human genetics	2013	76
23542418	Estrogens	Nagpal N	MicroRNA-191, an estrogen-responsive microRNA, functions as an oncogenic regulator in human breast cancer.	Carcinogenesis	2013	29
23550157	Estrogens	Redfern AD	RNA-induced silencing complex (RISC) Proteins PACT, TRBP, and Dicer are SRA binding nuclear receptor coregulators.	Proceedings of the National Academy of Sciences of the United States of America	2013	26
23607871	Estrogens	Falk RT	Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study.	Breast cancer research 	2013	32
23629941	Estrogens	Pellatt AJ	Telomere length, telomere-related genes, and breast cancer risk: the breast cancer health disparities study.	Genes, chromosomes & cancer	2013	33
23634195	Estrogens	Stagg J	Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects.	Therapeutic advances in medical oncology	2013	30
23644528	Estrogens	Berry WL	KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells.	Cancer research	2013	74
23645624	Estrogens	Rosner B	Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers.	American journal of epidemiology	2013	33
23711559	Estrogens	Feng S	Role of aryl hydrocarbon receptor in cancer.	Biochimica et biophysica acta	2013	35
23715497	Estrogens	Xuan D	APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry.	Carcinogenesis	2013	32
23739063	Estrogens	Loi S	Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.	Journal of the National Cancer Institute	2013	37
23748853	Estrogens	Eichelser C	Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression.	Clinical chemistry	2013	41
23774759	Estrogens	Madak-Erdogan Z	Integrative genomics of gene and metabolic regulation by estrogen receptors α and β, and their coregulators.	Molecular systems biology	2013	27
23791814	Estrogens	Jiang X	The immune system and inflammation in breast cancer.	Molecular and cellular endocrinology	2014	28
23850489	Estrogens	Foulds CE	Proteomic analysis of coregulators bound to ERα on DNA and nucleosomes reveals coregulator dynamics.	Molecular cell	2013	38
23861811	Estrogens	Lamb R	Wnt pathway activity in breast cancer sub-types and stem-like cells.	PloS one	2013	41
23890118	Estrogens	Hoth M	The neglected CRAC proteins: Orai2, Orai3, and STIM2.	Current topics in membranes	2013	30
23917289	Estrogens	Silber JH	Characteristics associated with differences in survival among black and white women with breast cancer.	JAMA	2013	68
23920327	Estrogens	Engebraaten O	Triple-negative breast cancer and the need for new therapeutic targets.	The American journal of pathology	2013	34
23939688	Estrogens	Piva R	From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review).	International journal of oncology	2013	31
23948299	Estrogens	Hsu PY	Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer.	Cancer cell	2013	26
23954741	Estrogens	Haldosén LA	Estrogen receptor beta in breast cancer.	Molecular and cellular endocrinology	2014	26
23958744	Estrogens	Howe LR	Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer.	Clinical cancer research 	2013	78
23965904	Estrogens	Barzi A	Molecular pathways: Estrogen pathway in colorectal cancer.	Clinical cancer research 	2013	33
23985562	Estrogens	-	Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.	Menopause	2013	55
23988612	Estrogens	Mohamed A	Targeted therapy for breast cancer.	The American journal of pathology	2013	28
23993780	Estrogens	Rivenbark AG	Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine.	The American journal of pathology	2013	31
24013225	Estrogens	Zhou ZN	Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo.	Oncogene	2014	26
24028341	Estrogens	Zhang Z	Folate receptor α associated with triple-negative breast cancer and poor prognosis.	Archives of pathology & laboratory medicine	2014	21
24029245	Estrogens	Sestak I	Factors predicting late recurrence for estrogen receptor-positive breast cancer.	Journal of the National Cancer Institute	2013	41
24031087	Estrogens	Dey P	Insight into the mechanisms of action of estrogen receptor β in the breast, prostate, colon, and CNS.	Journal of molecular endocrinology	2013	26
24055055	Estrogens	Li S	Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.	Cell reports	2013	146
24058649	Estrogens	Babayan A	Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients.	PloS one	2013	29
24077289	Estrogens	Dey P	Estrogen receptor β upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer.	Oncogene	2014	29
24101509	Estrogens	Zhang X	Regulation of estrogen receptor α by histone methyltransferase SMYD2-mediated protein methylation.	Proceedings of the National Academy of Sciences of the United States of America	2013	33
24114568	Estrogens	DeSantis C	Breast cancer statistics, 2013.	CA	2014	417
24185510	Estrogens	Robinson DR	Activating ESR1 mutations in hormone-resistant metastatic breast cancer.	Nature genetics	2013	197
24185512	Estrogens	Toy W	ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.	Nature genetics	2013	185
24188089	Estrogens	Bertrand KA	Mammographic density and risk of breast cancer by age and tumor characteristics.	Breast cancer research 	2013	34
24188694	Estrogens	Bilir B	Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.	Journal of translational medicine	2013	29
24258260	Estrogens	Sørensen KP	Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer.	Breast cancer research and treatment	2013	66
24273215	Estrogens	Vera-Badillo FE	Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.	Journal of the National Cancer Institute	2014	56
24290378	Estrogens	Meyer KB	Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1.	American journal of human genetics	2013	42
24298069	Estrogens	Zhang XH	Metastasis dormancy in estrogen receptor-positive breast cancer.	Clinical cancer research 	2013	32
24322788	Estrogens	Cadoo KA	Biological subtypes of breast cancer: current concepts and implications for recurrence patterns.	The quarterly journal of nuclear medicine and molecular imaging 	2013	28
24337597	Estrogens	Auvinen P	Hyaluronan synthases (HAS1-3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival.	Breast cancer research and treatment	2014	24
24343304	Estrogens	Palmer JR	A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium.	Cancer causes & control 	2014	33
24353241	Estrogens	Park SH	Correlations between apparent diffusion coefficient values of invasive ductal carcinoma and pathologic factors on diffusion-weighted MRI at 3.0 Tesla.	Journal of magnetic resonance imaging 	2015	17
24375928	Estrogens	Munsell MF	Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status.	Epidemiologic reviews	2014	40
24398047	Estrogens	Jeselsohn R	Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.	Clinical cancer research 	2014	102
24412361	Estrogens	Klein BJ	The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers.	Cell reports	2014	30
24431073	Estrogens	Cheng Y	XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer.	Molecular cancer therapeutics	2014	31
24449868	Estrogens	Huang B	Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	24
24463450	Estrogens	Santagata S	Taxonomy of breast cancer based on normal cell phenotype predicts outcome.	The Journal of clinical investigation	2014	60
24469049	Estrogens	Cyr AR	TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis.	Oncogene	2015	22
24477977	Estrogens	Anderson KN	Reproductive risk factors and breast cancer subtypes: a review of the literature.	Breast cancer research and treatment	2014	57
24521995	Estrogens	Sweeney C	Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.	Cancer epidemiology, biomarkers & prevention 	2014	30
24523301	Estrogens	Gross MI	Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.	Molecular cancer therapeutics	2014	113
24722644	Estrogens	Soussan M	Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer.	PloS one	2014	33
24735615	Estrogens	Tan S	Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2.	Breast cancer research 	2014	26
24774538	Estrogens	Ciruelos Gil EM	Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.	Cancer treatment reviews	2014	41
24777111	Estrogens	Howlader N	US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.	Journal of the National Cancer Institute	2014	107
24803582	Estrogens	Silwal-Pandit L	TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.	Clinical cancer research 	2014	41
24876105	Estrogens	Dinami R	miR-155 drives telomere fragility in human breast cancer by targeting TRF1.	Cancer research	2014	23
24889938	Estrogens	Sun Y	Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation.	Molecular cancer	2014	35
24895374	Estrogens	Rohan TE	Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.	Journal of the National Cancer Institute	2014	40
24915873	Estrogens	Ali HR	Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.	Annals of oncology 	2014	60
24929677	Estrogens	Varley KE	Recurrent read-through fusion transcripts in breast cancer.	Breast cancer research and treatment	2014	32
24935269	Estrogens	Chung L	Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer.	Breast cancer research 	2014	21
24951027	Estrogens	Maisonneuve P	Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes.	Breast cancer research 	2014	25
24971815	Estrogens	Paterni I	Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential.	Steroids	2014	34
24975878	Estrogens	Li CL	Elevated p53 promotes the processing of miR-18a to decrease estrogen receptor-α in female hepatocellular carcinoma.	International journal of cancer	2015	15
25006803	Estrogens	Askarian-Amiri ME	Emerging role of long non-coding RNA SOX2OT in SOX2 regulation in breast cancer.	PloS one	2014	31
25009010	Estrogens	De Mattos-Arruda L	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.	Annals of oncology 	2014	63
25013076	Estrogens	Yu M	Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.	Science	2014	167
25038752	Estrogens	Lim WK	Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma.	Nature genetics	2014	37
25052473	Estrogens	Derwahl M	Estrogen and its role in thyroid cancer.	Endocrine-related cancer	2014	23
25168343	Estrogens	Santen RJ	Estrogen metabolites and breast cancer.	Steroids	2015	25
25185096	Estrogens	Partridge AH	Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.	Journal of clinical oncology 	2014	43
25193543	Estrogens	Liu S	Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration.	Breast cancer research 	2014	25
25206307	Estrogens	Hosford SR	Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.	Pharmacogenomics and personalized medicine	2014	27
25208879	Estrogens	Burstein MD	Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.	Clinical cancer research 	2015	92
25224496	Estrogens	Palmer JR	Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium.	Journal of the National Cancer Institute	2014	43
25236687	Estrogens	Villarreal-Garza C	Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.	Cancer	2015	17
25277734	Estrogens	Sabatier R	Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization.	Molecular cancer	2014	20
25296969	Estrogens	Su X	Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes.	Oncotarget	2014	52
25307233	Estrogens	Zhao W	Comprehensive characterization of cancer subtype associated long non-coding RNAs and their clinical implications.	Scientific reports	2014	26
25313140	Estrogens	Hashim A	RNA sequencing identifies specific PIWI-interacting small non-coding RNA expression patterns in breast cancer.	Oncotarget	2014	28
25327703	Estrogens	Fejerman L	Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25.	Nature communications	2014	31
25347744	Estrogens	Mahajan K	ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers.	Oncogene	2015	21
25361981	Estrogens	Tobin NP	Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.	Annals of oncology 	2015	17
25381338	Estrogens	Paoletti C	Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.	Clinical cancer research 	2015	20
25388283	Estrogens	Bailey ST	Loss of estrogen-regulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer.	Cancer research	2015	17
25433206	Estrogens	Huang B	Estrogen receptors in breast carcinogenesis and endocrine therapy.	Molecular and cellular endocrinology	2015	29
25488809	Estrogens	Wade MA	The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer.	Nucleic acids research	2015	18
25489079	Estrogens	Whitesell L	HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.	Proceedings of the National Academy of Sciences of the United States of America	2014	23
25501357	Estrogens	Mao Y	The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.	PloS one	2014	24
25529635	Estrogens	Glubb DM	Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.	American journal of human genetics	2015	23
25537515	Estrogens	Bihani T	Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.	Oncotarget	2015	18
25538079	Estrogens	Martz CA	Systematic identification of signaling pathways with potential to confer anticancer drug resistance.	Science signaling	2014	47
25713166	Estrogens	Ng CK	Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.	Journal of the National Cancer Institute	2015	21
25728767	Estrogens	Yi P	Structure of a biologically active estrogen receptor-coactivator complex on DNA.	Molecular cell	2015	23
25759599	Estrogens	Graveel CR	Critical analysis of the potential for microRNA biomarkers in breast cancer management.	Breast cancer	2015	17
25816016	Estrogens	Necela BM	Folate receptor-α (FOLR1) expression and function in triple negative tumors.	PloS one	2015	15
25825707	Estrogens	Tang H	Decreased BECN1 mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis.	EBioMedicine	2015	22
25848861	Estrogens	Győrffy B	Multigene prognostic tests in breast cancer: past, present, future.	Breast cancer research 	2015	37
25855707	Estrogens	Mavaddat N	Prediction of breast cancer risk based on profiling with common genetic variants.	Journal of the National Cancer Institute	2015	85
25868410	Estrogens	Killelea BK	Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database.	Journal of the American College of Surgeons	2015	15
25888956	Estrogens	Chang YY	Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.	Molecular cancer	2015	26
25893606	Estrogens	Zhou X	Estrogen regulates Hippo signaling via GPER in breast cancer.	The Journal of clinical investigation	2015	29
25902832	Estrogens	Toss A	Molecular characterization and targeted therapeutic approaches in breast cancer.	Breast cancer research 	2015	23
25964252	Estrogens	Warner ET	Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.	Journal of clinical oncology 	2015	25
25969506	Estrogens	Tao L	Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study.	Cancer epidemiology, biomarkers & prevention 	2015	15
25979954	Estrogens	Guttery DS	Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.	Clinical chemistry	2015	27
25995301	Estrogens	Dieci MV	Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.	Annals of oncology 	2015	23
26023144	Estrogens	Prossnitz ER	International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators.	Pharmacological reviews	2015	27
26033453	Estrogens	Stückrath I	Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.	Oncotarget	2015	16
26056290	Estrogens	den Boon JA	Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling.	Proceedings of the National Academy of Sciences of the United States of America	2015	30
26059247	Estrogens	Yamamoto-Ibusuki M	Targeted therapies for ER+/HER2- metastatic breast cancer.	BMC medicine	2015	15
26085483	Estrogens	Ambrosone CB	Important Role of Menarche in Development of Estrogen Receptor-Negative Breast Cancer in African American Women.	Journal of the National Cancer Institute	2015	20
26166704	Estrogens	Li W	Condensin I and II Complexes License Full Estrogen Receptor α-Dependent Enhancer Activation.	Molecular cell	2015	18
26181262	Estrogens	Santa-Maria CA	Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned.	JAMA oncology	2015	17
26182172	Estrogens	Neuhouser ML	Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials.	JAMA oncology	2015	32
26195705	Estrogens	Van Poznak C	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.	Journal of clinical oncology 	2015	37
26201402	Estrogens	Barton VN	Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.	Hormones & cancer	2015	17
26257067	Estrogens	Merino D	Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.	Oncogene	2016	14
26261103	Estrogens	Chu D	ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.	Clinical cancer research 	2016	32
26286584	Estrogens	Strong AL	Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers.	Breast cancer research 	2015	20
26303083	Estrogens	Jia M	Estrogen receptor alpha and beta in health and disease.	Best practice & research. Clinical endocrinology & metabolism	2015	31
26341644	Estrogens	Kumar P	An overview of triple-negative breast cancer.	Archives of gynecology and obstetrics	2016	19
26364613	Estrogens	Xue X	LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer.	Oncogene	2016	40
26541326	Estrogens	Baptista MZ	Prognostic significance of PD-L1 and PD-L2 in breast cancer.	Human pathology	2016	27
26573797	Estrogens	Wang X	p53: Protection against Tumor Growth beyond Effects on Cell Cycle and Apoptosis.	Cancer research	2015	25
26586665	Estrogens	Meeks HD	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.	Journal of the National Cancer Institute	2016	14
26598746	Estrogens	Levine MN	Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.	Journal of clinical oncology 	2016	17
26618344	Estrogens	Castro MA	Regulators of genetic risk of breast cancer identified by integrative network analysis.	Nature genetics	2016	12
26621851	Estrogens	Miano V	Luminal long non-coding RNAs regulated by estrogen receptor alpha in a ligand-independent manner show functional roles in breast cancer.	Oncotarget	2016	16
26683709	Estrogens	Jiang T	Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis.	Oncotarget	2016	14
26732355	Estrogens	Cox TR	Lysyl Oxidase, a Targetable Secreted Molecule Involved in Cancer Metastasis.	Cancer research	2016	16
26769139	Estrogens	Thompson E	The immune microenvironment of breast ductal carcinoma in situ.	Modern pathology 	2016	13
26772397	Estrogens	Asch-Kendrick R	The role of GATA3 in breast carcinomas: a review.	Human pathology	2016	12
26786933	Estrogens	Colleoni M	Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.	Journal of clinical oncology 	2016	13
26855592	Estrogens	Xu H	Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis.	OncoTargets and therapy	2016	15
26858339	Estrogens	Harris LN	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.	Journal of clinical oncology 	2016	73
26867935	Estrogens	Pusztai L	New Strategies in Breast Cancer: Immunotherapy.	Clinical cancer research 	2016	16
26899533	Estrogens	Masuda T	Clinical and biological significance of circulating tumor cells in cancer.	Molecular oncology	2016	14
26909695	Estrogens	Rostami R	Brain metastasis in breast cancer: a comprehensive literature review.	Journal of neuro-oncology	2016	13
26921331	Estrogens	den Hollander P	Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival.	Cancer research	2016	13
26926676	Estrogens	Gluz O	West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.	Journal of clinical oncology 	2016	21
26928228	Estrogens	Dunning AM	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.	Nature genetics	2016	18
26947176	Estrogens	Sflomos G	A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response.	Cancer cell	2016	22
26960396	Estrogens	Piscuoglio S	The Genomic Landscape of Male Breast Cancers.	Clinical cancer research 	2016	16
26987290	Estrogens	Sun X	Let-7c blocks estrogen-activated Wnt signaling in induction of self-renewal of breast cancer stem cells.	Cancer gene therapy	2016	10
27020857	Estrogens	Herrera-Abreu MT	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.	Cancer research	2016	23
27020862	Estrogens	Weir HM	AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.	Cancer research	2016	17
27029038	Estrogens	Micucci C	Current perspectives between metabolic syndrome and cancer.	Oncotarget	2016	13
27073890	Estrogens	Mao Y	The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis.	PloS one	2016	16
27107051	Estrogens	Kwa M	The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer.	Journal of the National Cancer Institute	2016	11
27144536	Estrogens	Li H	MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.	Radiology	2016	20
27160528	Estrogens	Mamtani A	How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.	Annals of surgical oncology	2016	13
27191888	Estrogens	Huang NS	Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer.	Oncotarget	2016	17
27225691	Estrogens	Speers C	Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer.	Clinical cancer research 	2016	13
27226503	Estrogens	Gradishar W	NCCN Guidelines Update: Breast Cancer.	Journal of the National Comprehensive Cancer Network 	2016	10
27233379	Estrogens	De Marchi T	Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer.	Drug discovery today	2016	10
27277684	Estrogens	Singh R	Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis.	Cell death & disease	2016	12
27348297	Estrogens	Gibson WJ	The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.	Nature genetics	2016	23
27388585	Estrogens	Millis SZ	Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.	JAMA oncology	2016	15
27390604	Estrogens	Dai X	Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.	Journal of Cancer	2016	15
27407093	Estrogens	Friedenreich CM	Physical Activity and Cancer Outcomes: A Precision Medicine Approach.	Clinical cancer research 	2016	16
27474173	Estrogens	Massihnia D	Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.	Oncotarget	2016	11
27513155	Estrogens	Giuliano AE	Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.	Annals of surgery	2016	30
27540977	Estrogens	Zhang K	Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer.	Cancer biomarkers 	2016	15
27557300	Estrogens	Cardoso F	70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.	The New England journal of medicine	2016	91
27694385	Estrogens	Svoronos N	Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells.	Cancer discovery	2017	12
27721408	Estrogens	Yu T	Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance.	Oncogene	2017	5
27725895	Estrogens	Hon JD	Breast cancer molecular subtypes: from TNBC to QNBC.	American journal of cancer research	2016	11
27748765	Estrogens	Harrod A	Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.	Oncogene	2017	8
27775705	Estrogens	Horiuchi D	PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.	Nature medicine	2016	12
27886589	Estrogens	Angus L	ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients.	Cancer treatment reviews	2017	5
27893717	Estrogens	Feng J	Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms.	Oncogene	2017	6
27903149	Estrogens	Jiralerspong S	Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities.	Journal of clinical oncology 	2016	14
27914795	Estrogens	Wintrob ZA	Insulin use, adipokine profiles and breast cancer prognosis.	Cytokine	2017	11
27926948	Estrogens	Priedigkeit N	Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.	JAMA oncology	2017	9
27935867	Estrogens	Vázquez R	The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.	Oncotarget	2017	5
27939373	Estrogens	Nault JC	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.	Gastroenterology	2017	7
27940449	Estrogens	Page K	Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.	Clinical chemistry	2017	6
27966906	Estrogens	Zhang Y	Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing Using Multifunctional pRNA Nanoparticles.	ACS nano	2017	9
28030809	Estrogens	McDaniel JM	Genomic regulation of invasion by STAT3 in triple negative breast cancer.	Oncotarget	2017	6
28052940	Estrogens	Busch EL	Endometrial Cancer Risk Factors, Hormone Receptors, and Mortality Prediction.	Cancer epidemiology, biomarkers & prevention 	2017	6
28057046	Estrogens	Ethier JL	Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis.	Breast cancer research 	2017	9
28108967	Estrogens	Inoue M	Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.	Breast cancer	2017	5
28216025	Estrogens	Dey N	PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.	Pharmacology & therapeutics	2017	13
28249905	Estrogens	Cejalvo JM	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.	Cancer research	2017	9
28259011	Estrogens	Duffy MJ	Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).	European journal of cancer	2017	12
28270386	Estrogens	Iyengar NM	Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index.	Cancer prevention research	2017	8
28356971	Estrogens	Luo Y	Elevated microRNA-125b levels predict a worse prognosis in HER2-positive breast cancer patients.	Oncology letters	2017	5
2993906	Peptides	Cuttitta F	Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer.	Nature	1985	169
3861940	Peptides	Derynck R	Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells.	Nature	1985	259
6294080	Peptides	Etchison D	Inhibition of HeLa cell protein synthesis following poliovirus infection correlates with the proteolysis of a 220,000-dalton polypeptide associated with eucaryotic initiation factor 3 and a cap binding protein complex.	The Journal of biological chemistry	1982	213
7812975	Peptides	Biswas C	The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily.	Cancer research	1995	127
8387282	Peptides	Kitamura K	Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma.	Biochemical and biophysical research communications	1993	185
9432985	Peptides	Jäger E	Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.	The Journal of experimental medicine	1998	138
9500607	Peptides	Nestle FO	Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.	Nature medicine	1998	322
9560253	Peptides	Lee N	HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A.	Proceedings of the National Academy of Sciences of the United States of America	1998	156
10694578	Peptides	Migueles SA	HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.	Proceedings of the National Academy of Sciences of the United States of America	2000	384
10860979	Peptides	Wang JL	Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells.	Proceedings of the National Academy of Sciences of the United States of America	2000	142
11290339	Peptides	Basu S	CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin.	Immunity	2001	206
11385580	Peptides	Ohtaki T	Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor.	Nature	2001	229
11386265	Peptides	Gao X	Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.	The New England journal of medicine	2001	144
11579100	Peptides	Turkson J	Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation.	The Journal of biological chemistry	2001	118
11861608	Peptides	Srivastava P	Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses.	Annual review of immunology	2002	158
12118245	Peptides	Fulda S	Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.	Nature medicine	2002	133
12509463	Peptides	Weng AP	Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling.	Molecular and cellular biology	2003	145
12820959	Peptides	Wu G	Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase.	Molecular cell	2003	219
12826605	Peptides	Phan GQ	Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.	Proceedings of the National Academy of Sciences of the United States of America	2003	339
12904296	Peptides	Endo K	Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration.	The Journal of biological chemistry	2003	88
14743220	Peptides	Papa S	Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2.	Nature cell biology	2004	114
15125843	Peptides	Shiozaki EN	Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling.	Molecular cell	2004	75
15133506	Peptides	Kolonin MG	Reversal of obesity by targeted ablation of adipose tissue.	Nature medicine	2004	131
15205345	Peptides	Liang Z	Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4.	Cancer research	2004	91
15207811	Peptides	Fredriksson L	The PDGF family: four gene products form five dimeric isoforms.	Cytokine & growth factor reviews	2004	143
15353804	Peptides	Walensky LD	Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix.	Science	2004	295
15355971	Peptides	Williams TM	Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion.	The Journal of biological chemistry	2004	89
15380518	Peptides	Arap MA	Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands.	Cancer cell	2004	116
15531890	Peptides	Polo JM	Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.	Nature medicine	2004	91
15821740	Peptides	Hahn M	Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor.	Nature immunology	2005	92
15837811	Peptides	Chen JL	Structural and kinetic basis for heightened immunogenicity of T cell vaccines.	The Journal of experimental medicine	2005	80
15958392	Peptides	Ishihama Y	Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein.	Molecular & cellular proteomics 	2005	513
16061848	Peptides	Arumugam T	S100P promotes pancreatic cancer growth, survival, and invasion.	Clinical cancer research 	2005	65
16061868	Peptides	Liau LM	Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.	Clinical cancer research 	2005	144
16177248	Peptides	Wang X	Autoantibody signatures in prostate cancer.	The New England journal of medicine	2005	155
16319141	Peptides	Li Z	Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics.	FASEB journal 	2005	71
16474402	Peptides	Sheng Y	Molecular recognition of p53 and MDM2 by USP7/HAUSP.	Nature structural & molecular biology	2006	70
16971810	Peptides	Palucka AK	Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.	Journal of immunotherapy	2006	74
17052454	Peptides	Walensky LD	A stapled BID BH3 helix directly binds and activates BAX.	Molecular cell	2006	132
17081989	Peptides	Gold MG	Molecular basis of AKAP specificity for PKA regulatory subunits.	Molecular cell	2006	111
17290220	Peptides	Stevenson LF	The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2.	The EMBO journal	2007	88
17299050	Peptides	Derse D	Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid.	Proceedings of the National Academy of Sciences of the United States of America	2007	64
17620360	Peptides	Hislop AD	A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates.	The Journal of experimental medicine	2007	65
17721783	Peptides	Britten CM	The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays.	Cancer immunology, immunotherapy 	2008	51
18172268	Peptides	Kenter GG	Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.	Clinical cancer research 	2008	77
18172269	Peptides	Welters MJ	Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.	Clinical cancer research 	2008	104
18366636	Peptides	Lin HH	Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research.	BMC immunology	2008	84
18499657	Peptides	Shan B	Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition.	The Journal of biological chemistry	2008	52
18619467	Peptides	He Z	Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.	Journal of molecular biology	2008	73
18757748	Peptides	Hansson Petersen CA	The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae.	Proceedings of the National Academy of Sciences of the United States of America	2008	159
19089837	Peptides	Veiseh O	Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles.	Small	2009	51
19091022	Peptides	Lin HH	Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research.	BMC bioinformatics	2008	75
19142965	Peptides	Rowlands MA	Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis.	International journal of cancer	2009	65
19187761	Peptides	Southall SM	Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks.	Molecular cell	2009	85
19255147	Peptides	Beauvais DM	Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor.	The Journal of experimental medicine	2009	81
19720923	Peptides	Disis ML	Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.	Journal of clinical oncology 	2009	85
19805273	Peptides	Teesalu T	C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.	Proceedings of the National Academy of Sciences of the United States of America	2009	116
19903780	Peptides	Slingluff CL Jr	Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.	Clinical cancer research 	2009	66
19949402	Peptides	Wulff H	Voltage-gated potassium channels as therapeutic targets.	Nature reviews. Drug discovery	2009	168
20103780	Peptides	Moosmann A	Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells.	Blood	2010	51
20190765	Peptides	Li J	A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.	Nature chemical biology	2010	95
20354185	Peptides	Standley SM	Induction of cancer cell death by self-assembling nanostructures incorporating a cytotoxic peptide.	Cancer research	2010	44
20516121	Peptides	Nam JM	Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin.	Cancer research	2010	53
20544025	Peptides	Jin G	An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis.	PloS one	2010	43
20698693	Peptides	Levi J	Design, synthesis, and imaging of an activatable photoacoustic probe.	Journal of the American Chemical Society	2010	46
21092157	Peptides	Wang P	Peptide binding predictions for HLA DR, DP and DQ molecules.	BMC bioinformatics	2010	123
21114420	Peptides	Page BD	Signal transducer and activator of transcription 3 inhibitors: a patent review.	Expert opinion on therapeutic patents	2011	37
21199956	Peptides	Sethi DK	A highly tilted binding mode by a self-reactive T cell receptor results in altered engagement of peptide and MHC.	The Journal of experimental medicine	2011	44
21224349	Peptides	Rérole AL	Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy.	Cancer research	2011	45
21233403	Peptides	Huang H	Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.	Clinical cancer research 	2011	43
21245041	Peptides	Bubeck D	PCNA directs type 2 RNase H activity on DNA replication and repair substrates.	Nucleic acids research	2011	40
21297667	Peptides	Switzer CH	Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy.	Oncogene	2011	42
21334333	Peptides	Elashoff M	Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.	Gastroenterology	2011	136
21389263	Peptides	Lande R	Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus.	Science translational medicine	2011	261
21470139	Peptides	Rosca EV	Anti-angiogenic peptides for cancer therapeutics.	Current pharmaceutical biotechnology	2011	39
21653320	Peptides	Wang X	A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.	Blood	2011	111
21795678	Peptides	Zarrabi K	Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration.	The Journal of biological chemistry	2011	49
21857646	Peptides	Schraivogel D	CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells.	The EMBO journal	2011	48
21886175	Peptides	Ratajczak MZ	A novel perspective on stem cell homing and mobilization: review on bioactive lipids as potent chemoattractants and cationic peptides as underappreciated modulators of responsiveness to SDF-1 gradients.	Leukemia	2012	45
21908576	Peptides	Iyer JG	Merkel cell polyomavirus-specific CD8⁺ and CD4⁺ T-cell responses identified in Merkel cell carcinomas and blood.	Clinical cancer research 	2011	42
22017869	Peptides	Kang H	Peptide switch is essential for Sirt1 deacetylase activity.	Molecular cell	2011	38
22044041	Peptides	Bridgeman JS	Structural and biophysical determinants of αβ T-cell antigen recognition.	Immunology	2012	44
22182510	Peptides	King TD	Frizzled7 as an emerging target for cancer therapy.	Cellular signalling	2012	35
22388624	Peptides	Fani M	Radiopharmaceutical development of radiolabelled peptides.	European journal of nuclear medicine and molecular imaging	2012	31
22399294	Peptides	Peng RQ	MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7.	The Journal of biological chemistry	2012	48
22418738	Peptides	Dutoit V	Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy.	Brain 	2012	39
22622039	Peptides	LaBelle JL	A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers.	The Journal of clinical investigation	2012	62
22776426	Peptides	Kono K	Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.	Journal of translational medicine	2012	39
22872572	Peptides	Crane CA	Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein.	Clinical cancer research 	2013	43
22999885	Peptides	Cohen NA	A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival.	Chemistry & biology	2012	43
23023596	Peptides	O'Donoghue AJ	Global identification of peptidase specificity by multiplex substrate profiling.	Nature methods	2012	37
23046125	Peptides	Wang JH	The structural basis of αβ T-lineage immune recognition: TCR docking topologies, mechanotransduction, and co-receptor function.	Immunological reviews	2012	32
23213206	Peptides	Mazor R	Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A.	Proceedings of the National Academy of Sciences of the United States of America	2012	34
23264595	Peptides	Li Z	PBX3 is an important cofactor of HOXA9 in leukemogenesis.	Blood	2013	33
23297075	Peptides	Wu Z	Development and evaluation of 18F-TTCO-Cys40-Exendin-4: a PET probe for imaging transplanted islets.	Journal of nuclear medicine 	2013	32
23298779	Peptides	Hu QL	Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model.	Biomaterials	2013	26
23375101	Peptides	Rapraeger AC	Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis.	The FEBS journal	2013	26
23440284	Peptides	Singh S	Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.	JAMA internal medicine	2013	66
23714121	Peptides	Shi P	Elastin-based protein polymer nanoparticles carrying drug at both corona and core suppress tumor growth in vivo.	Journal of controlled release 	2013	26
23733883	Peptides	Reeves E	Naturally occurring ERAP1 haplotypes encode functionally distinct alleles with fine substrate specificity.	Journal of immunology	2013	26
23770775	Peptides	Linette GP	Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.	Blood	2013	195
23852952	Peptides	Leone P	MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells.	Journal of the National Cancer Institute	2013	54
23926201	Peptides	Cameron BJ	Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.	Science translational medicine	2013	124
23974116	Peptides	Kim W	Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.	Nature chemical biology	2013	83
24374310	Peptides	Chen C	Identification of a major determinant for serine-threonine kinase phosphoacceptor specificity.	Molecular cell	2014	22
24491438	Peptides	Yang Y	Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms.	Cancer discovery	2014	33
24550723	Peptides	Pierce BG	Computational design of the affinity and specificity of a therapeutic T cell receptor.	PLoS computational biology	2014	22
24782567	Peptides	Tammsalu T	Proteome-wide identification of SUMO2 modification sites.	Science signaling	2014	59
24855945	Peptides	Birnbaum ME	Deconstructing the peptide-MHC specificity of T cell recognition.	Cell	2014	86
25092142	Peptides	Berlin C	Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.	Leukemia	2015	21
25277522	Peptides	Pang HB	An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability.	Nature communications	2014	21
25384421	Peptides	Zhou Z	Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.	FASEB journal 	2015	17
25391492	Peptides	Lamoliatte F	Large-scale analysis of lysine SUMOylation by SUMO remnant immunoaffinity profiling.	Nature communications	2014	30
25496365	Peptides	Tan MP	T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells.	Clinical and experimental immunology	2015	22
25624485	Peptides	Leshchiner ES	Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices.	Proceedings of the National Academy of Sciences of the United States of America	2015	24
25720354	Peptides	Roche PA	The ins and outs of MHC class II-mediated antigen processing and presentation.	Nature reviews. Immunology	2015	75
25818419	Peptides	Jiang L	Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.	Biomaterials	2015	20
25819065	Peptides	Plotnikov A	The nuclear translocation of ERK1/2 as an anticancer target.	Nature communications	2015	16
25825497	Peptides	Nguyen H	LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.	The Journal of biological chemistry	2015	18
26278051	Peptides	Jedrychowski MP	Detection and Quantitation of Circulating Human Irisin by Tandem Mass Spectrometry.	Cell metabolism	2015	58
26523866	Peptides	Adams JJ	Structural interplay between germline interactions and adaptive recognition determines the bandwidth of TCR-peptide-MHC cross-reactivity.	Nature immunology	2016	27
26621454	Peptides	Arakawa A	Melanocyte antigen triggers autoimmunity in human psoriasis.	The Journal of experimental medicine	2015	27
26810224	Peptides	Jing L	Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses.	Journal of immunology	2016	11
26828202	Peptides	Davis ZB	A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells.	PLoS pathogens	2016	21
27571370	Peptides	Bentzen AK	Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes.	Nature biotechnology	2016	23
27621419	Peptides	Tagawa T	Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing.	The Journal of experimental medicine	2016	16
27846572	Peptides	Liepe J	A large fraction of HLA class I ligands are proteasome-generated spliced peptides.	Science	2016	26
28025143	Peptides	Chatterjee S	Rapid PD-L1 detection in tumors with PET using a highly specific peptide.	Biochemical and biophysical research communications	2017	7
1652369	Zinc	de Thé H	The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR.	Cell	1991	261
2154335	Zinc	Call KM	Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus.	Cell	1990	273
2154702	Zinc	Gessler M	Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping.	Nature	1990	187
7545954	Zinc	Miki Y	A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.	Science	1994	880
8023157	Zinc	Cho Y	Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.	Science	1994	499
8235596	Zinc	Ye BH	Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma.	Science	1993	126
8649389	Zinc	Filippova GN	An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes.	Molecular and cellular biology	1996	188
8782817	Zinc	Borrow J	The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein.	Nature genetics	1996	143
8917507	Zinc	Yang WM	Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3.	Proceedings of the National Academy of Sciences of the United States of America	1996	152
9486654	Zinc	Lin RJ	Role of the histone deacetylase complex in acute promyelocytic leukaemia.	Nature	1998	210
9724795	Zinc	Wang J	ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.	Proceedings of the National Academy of Sciences of the United States of America	1998	133
9819405	Zinc	Gelmetti V	Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.	Molecular and cellular biology	1998	123
10207085	Zinc	Daniel JM	The catenin p120(ctn) interacts with Kaiso, a novel BTB/POZ domain zinc finger transcription factor.	Molecular and cellular biology	1999	132
10228159	Zinc	Brehm A	The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth.	The EMBO journal	1999	97
10357558	Zinc	Kleiner DE	Matrix metalloproteinases and metastasis.	Cancer chemotherapy and pharmacology	1999	107
10500182	Zinc	Lorick KL	RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination.	Proceedings of the National Academy of Sciences of the United States of America	1999	300
10660690	Zinc	Beerli RR	Positive and negative regulation of endogenous genes by designed transcription factors.	Proceedings of the National Academy of Sciences of the United States of America	2000	102
10725363	Zinc	Nilsson M	Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1.	Proceedings of the National Academy of Sciences of the United States of America	2000	99
11103818	Zinc	Foster KW	Increase of GKLF messenger RNA and protein expression during progression of breast cancer.	Cancer research	2000	97
11283614	Zinc	Seoane J	TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b.	Nature cell biology	2001	143
11486036	Zinc	Yao YL	Regulation of transcription factor YY1 by acetylation and deacetylation.	Molecular and cellular biology	2001	125
11525835	Zinc	Ohlsson R	CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease.	Trends in genetics 	2001	216
11719506	Zinc	Yoon JW	Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation.	The Journal of biological chemistry	2002	102
11752579	Zinc	Narla G	KLF6, a candidate tumor suppressor gene mutated in prostate cancer.	Science	2001	126
11912130	Zinc	Hajra KM	The SLUG zinc-finger protein represses E-cadherin in breast cancer.	Cancer research	2002	293
12011441	Zinc	Loukinov DI	BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma.	Proceedings of the National Academy of Sciences of the United States of America	2002	95
12032775	Zinc	Cantor AB	Transcriptional regulation of erythropoiesis: an affair involving multiple partners.	Oncogene	2002	193
12082640	Zinc	Blanco MJ	Correlation of Snail expression with histological grade and lymph node status in breast carcinomas.	Oncogene	2002	163
12191639	Zinc	Klenova EM	The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer.	Seminars in cancer biology	2002	85
12402037	Zinc	Bereshchenko OR	Acetylation inactivates the transcriptional repressor BCL6.	Nature genetics	2002	97
12576332	Zinc	Elagib KE	RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation.	Blood	2003	92
12798299	Zinc	Moss EG	Conservation of the heterochronic regulator Lin-28, its developmental expression and microRNA complementary sites.	Developmental biology	2003	102
14641026	Zinc	Fischer OM	EGFR signal transactivation in cancer cells.	Biochemical Society transactions	2003	98
14713952	Zinc	Habelhah H	Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB.	The EMBO journal	2004	84
15000152	Zinc	Zucker S	Role of matrix metalloproteinases (MMPs) in colorectal cancer.	Cancer metastasis reviews	2004	104
15448698	Zinc	Zhou BP	Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition.	Nature cell biology	2004	462
15577913	Zinc	Phan RT	The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.	Nature	2004	187
15647282	Zinc	Yook JI	Wnt-dependent regulation of the E-cadherin repressor snail.	The Journal of biological chemistry	2005	133
15653317	Zinc	Heyninck K	A20 inhibits NF-kappaB activation by dual ubiquitin-editing functions.	Trends in biochemical sciences	2005	67
15740636	Zinc	Ghaleb AM	Krüppel-like factors 4 and 5: the yin and yang regulators of cellular proliferation.	Cell research	2005	119
15750595	Zinc	Sun G	The zinc finger protein cKrox directs CD4 lineage differentiation during intrathymic T cell positive selection.	Nature immunology	2005	106
15825076	Zinc	Katz JP	Loss of Klf4 in mice causes altered proliferation and differentiation and precancerous changes in the adult stomach.	Gastroenterology	2005	98
15833848	Zinc	Yang Z	Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions.	Cancer research	2005	87
15983400	Zinc	Barrallo-Gimeno A	The Snail genes as inducers of cell movement and survival: implications in development and cancer.	Development	2005	371
16153295	Zinc	Franklin RB	hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer.	Molecular cancer	2005	73
16269333	Zinc	Adhikary S	The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation.	Cell	2005	108
16406505	Zinc	Kasper M	GLI transcription factors: mediators of oncogenic Hedgehog signalling.	European journal of cancer	2006	122
16492805	Zinc	Pasqualucci L	Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma.	The Journal of experimental medicine	2006	89
16636053	Zinc	Mehle A	A zinc-binding region in Vif binds Cul5 and determines cullin selection.	The Journal of biological chemistry	2006	94
16652230	Zinc	Ram M	Matrix metalloproteinase-9 and autoimmune diseases.	Journal of clinical immunology	2006	60
16700911	Zinc	Costello LC	The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots.	Molecular cancer	2006	92
16763212	Zinc	Ma Y	SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice.	Blood	2006	73
16831886	Zinc	Thuault S	Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition.	The Journal of cell biology	2006	148
16952552	Zinc	Spaderna S	A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer.	Gastroenterology	2006	113
16971064	Zinc	Guo Y	Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma.	Gene	2006	104
17072303	Zinc	Yook JI	A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells.	Nature cell biology	2006	212
17116689	Zinc	Lindström MS	Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.	Molecular and cellular biology	2007	63
17275314	Zinc	Verma RP	Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.	Bioorganic & medicinal chemistry	2007	76
17508399	Zinc	McConnell BB	The diverse functions of Krüppel-like factors 4 and 5 in epithelial biology and pathobiology.	BioEssays 	2007	111
17542650	Zinc	O'Geen H	Genome-wide analysis of KAP1 binding suggests autoregulation of KRAB-ZNFs.	PLoS genetics	2007	87
17587811	Zinc	Doble BW	Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions.	Cells, tissues, organs	2007	60
17673939	Zinc	Taylor KM	The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer.	Molecular medicine	2007	60
17952120	Zinc	Beach S	Snail is a repressor of RKIP transcription in metastatic prostate cancer cells.	Oncogene	2008	52
18003899	Zinc	Li M	Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression.	Proceedings of the National Academy of Sciences of the United States of America	2007	71
18054006	Zinc	Nandan MO	Krüppel-like factor 5 mediates cellular transformation during oncogenic KRAS-induced intestinal tumorigenesis.	Gastroenterology	2008	57
18055453	Zinc	Langelier MF	A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activation.	The Journal of biological chemistry	2008	56
18285338	Zinc	Schuetz A	Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity.	The Journal of biological chemistry	2008	73
18313383	Zinc	Komander D	The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module.	Molecular cell	2008	77
18385818	Zinc	Prasad AS	Zinc in human health: effect of zinc on immune cells.	Molecular medicine	2008	68
18417445	Zinc	Felicetti F	The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms.	Cancer research	2008	121
18434311	Zinc	Najy AJ	The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation.	The Journal of biological chemistry	2008	63
18483486	Zinc	Burk U	A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells.	EMBO reports	2008	570
18583420	Zinc	Taylor KM	ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer Cells.	Endocrinology	2008	52
18587387	Zinc	Perez EE	Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases.	Nature biotechnology	2008	358
18604447	Zinc	Evans PM	Roles of Krüpel-like factor 4 in normal homeostasis, cancer and stem cells.	Acta biochimica et biophysica Sinica	2008	68
18657511	Zinc	Maeder ML	Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification.	Molecular cell	2008	234
18832382	Zinc	Thuault S	HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition.	The Journal of biological chemistry	2008	99
19011757	Zinc	Vandewalle C	The role of the ZEB family of transcription factors in development and disease.	Cellular and molecular life sciences 	2009	132
19208838	Zinc	Devy L	Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis.	Cancer research	2009	92
19246244	Zinc	Hogstrand C	Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase activation.	Trends in molecular medicine	2009	55
19400752	Zinc	Lichten LA	Mammalian zinc transporters: nutritional and physiologic regulation.	Annual review of nutrition	2009	170
19544444	Zinc	Kong D	miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells.	Stem cells	2009	123
19549848	Zinc	Brunet E	Chromosomal translocations induced at specified loci in human stem cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	73
19696312	Zinc	Pan F	Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells.	Science	2009	93
19701203	Zinc	Han YG	Dual and opposing roles of primary cilia in medulloblastoma development.	Nature medicine	2009	134
19706168	Zinc	ten Haaf A	Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavourable overall survival.	BMC cancer	2009	50
19734141	Zinc	Apte SS	A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms.	The Journal of biological chemistry	2009	122
19797115	Zinc	Dennler S	Cloning of the human GLI2 Promoter: transcriptional activation by transforming growth factor-beta via SMAD3/beta-catenin cooperation.	The Journal of biological chemistry	2009	48
19915148	Zinc	Ota I	Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1.	Proceedings of the National Academy of Sciences of the United States of America	2009	72
19956766	Zinc	Nativio R	Cohesin is required for higher-order chromatin conformation at the imprinted IGF2-H19 locus.	PLoS genetics	2009	145
20103620	Zinc	Ransburgh DJ	Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination.	Cancer research	2010	40
20424117	Zinc	Ohashi S	Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors.	Cancer research	2010	57
20599425	Zinc	Verstrepen L	Expression, biological activities and mechanisms of action of A20 (TNFAIP3).	Biochemical pharmacology	2010	47
20666778	Zinc	Sun Q	Hsa-mir-27a genetic variant contributes to gastric cancer susceptibility through affecting miR-27a and target gene expression.	Cancer science	2010	49
20706219	Zinc	Brabletz S	The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer?	EMBO reports	2010	247
21343339	Zinc	Iyengar S	Functional analysis of KAP1 genomic recruitment.	Molecular and cellular biology	2011	48
21526191	Zinc	Hahn MA	Relationship between gene body DNA methylation and intragenic H3K9me3 and H3K36me3 chromatin marks.	PloS one	2011	44
21531982	Zinc	Klampfl T	Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression.	Blood	2011	37
21599891	Zinc	Thirumoorthy N	A review of metallothionein isoforms and their role in pathophysiology.	World journal of surgical oncology	2011	39
21665887	Zinc	Shih JY	The EMT regulator slug and lung carcinogenesis.	Carcinogenesis	2011	80
21673316	Zinc	Stinson S	TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer.	Science signaling	2011	73
21725353	Zinc	Spiegel S	Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.	Oncogene	2012	39
21765466	Zinc	Kim K	Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer.	Oncogene	2012	57
21770894	Zinc	Liu X	MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines.	The Biochemical journal	2011	64
21779441	Zinc	Zheng R	GATA Transcription Factors and Cancer.	Genes & cancer	2010	66
21801010	Zinc	Hui CC	Gli proteins in development and disease.	Annual review of cell and developmental biology	2011	184
21878201	Zinc	Singh AB	Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells.	Gastroenterology	2011	44
21878675	Zinc	Gutierrez A	The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia.	Blood	2011	52
21890822	Zinc	Ohashi S	A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors.	Cancer research	2011	47
21892162	Zinc	Hahn CN	Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.	Nature genetics	2011	124
21908515	Zinc	Cai Q	Genome-wide association study identifies breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium.	Human molecular genetics	2011	46
22024162	Zinc	Kim NH	A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition.	The Journal of cell biology	2011	130
22045813	Zinc	Mihelich BL	miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells.	The Journal of biological chemistry	2011	48
22099304	Zinc	Skaug B	Direct, noncatalytic mechanism of IKK inhibition by A20.	Molecular cell	2011	66
22241470	Zinc	Tan EJ	Regulation of transcription factor Twist expression by the DNA architectural protein high mobility group A2 during epithelial-to-mesenchymal transition.	The Journal of biological chemistry	2012	31
22266823	Zinc	Kim H	Regulation of Rev1 by the Fanconi anemia core complex.	Nature structural & molecular biology	2012	73
22311119	Zinc	Kurashige J	MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma.	Annals of surgical oncology	2012	45
22317921	Zinc	Taylor KM	Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7.	Science signaling	2012	52
22332039	Zinc	Kelleher SL	Zinc in specialized secretory tissues: roles in the pancreas, prostate, and mammary gland.	Advances in nutrition	2011	53
22343915	Zinc	Ali AM	FAAP20: a novel ubiquitin-binding FA nuclear core-complex protein required for functional integrity of the FA-BRCA DNA repair pathway.	Blood	2012	42
22386240	Zinc	Wang G	Expression of microRNAs in the urine of patients with bladder cancer.	Clinical genitourinary cancer	2012	49
22388088	Zinc	Aceto N	Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.	Nature medicine	2012	71
22396592	Zinc	Leung JW	Fanconi anemia (FA) binding protein FAAP20 stabilizes FA complementation group A (FANCA) and participates in interstrand cross-link repair.	Proceedings of the National Academy of Sciences of the United States of America	2012	41
22575959	Zinc	Hao HX	ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner.	Nature	2012	161
22689922	Zinc	Alder H	Dysregulation of miR-31 and miR-21 induced by zinc deficiency promotes esophageal cancer.	Carcinogenesis	2012	34
22751931	Zinc	Morita M	A novel 4EHP-GIGYF2 translational repressor complex is essential for mammalian development.	Molecular and cellular biology	2012	33
22797073	Zinc	Neilsen PM	Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.	Oncogene	2013	46
22898984	Zinc	Thornton JE	Lin28-mediated control of let-7 microRNA expression by alternative TUTases Zcchc11 (TUT4) and Zcchc6 (TUT7).	RNA	2012	67
22937066	Zinc	Lin ZS	Krüppel-like factor 4, a tumor suppressor in hepatocellular carcinoma cells reverts epithelial mesenchymal transition by suppressing slug expression.	PloS one	2012	39
23032187	Zinc	Tokunaga F	Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-κB regulation.	The EMBO journal	2012	54
23123196	Zinc	Yang W	EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.	Molecular cell	2012	61
23431171	Zinc	Rokudai S	MOZ increases p53 acetylation and premature senescence through its complex formation with PML.	Proceedings of the National Academy of Sciences of the United States of America	2013	32
23434374	Zinc	Chauhan S	ZKSCAN3 is a master transcriptional repressor of autophagy.	Molecular cell	2013	48
23559371	Zinc	Geng C	Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.	Proceedings of the National Academy of Sciences of the United States of America	2013	53
23568838	Zinc	Piganeau M	Cancer translocations in human cells induced by zinc finger and TALE nucleases.	Genome research	2013	45
23584475	Zinc	Rajabi H	MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition.	Oncogene	2014	38
23741009	Zinc	Torikai H	Toward eliminating HLA class I expression to generate universal cells from allogeneic donors.	Blood	2013	43
23851495	Zinc	Kao SH	GSK3β controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug.	Oncogene	2014	27
23893241	Zinc	Shang Y	miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1.	Oncogene	2014	43
24168186	Zinc	Wang Y	The Role of Snail in EMT and Tumorigenesis.	Current cancer drug targets	2013	85
24294107	Zinc	Lupo A	KRAB-Zinc Finger Proteins: A Repressor Family Displaying Multiple Biological Functions.	Current genomics	2013	40
24315485	Zinc	Hu L	Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.	Cell	2013	71
24332369	Zinc	Stankic M	TGF-β-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition.	Cell reports	2013	54
24434208	Zinc	Wang L	CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis.	Cancer cell	2014	48
24518294	Zinc	Truong HH	β1 integrin inhibition elicits a prometastatic switch through the TGFβ-miR-200-ZEB network in E-cadherin-positive triple-negative breast cancer.	Science signaling	2014	23
24556840	Zinc	Lamouille S	Molecular mechanisms of epithelial-mesenchymal transition.	Nature reviews. Molecular cell biology	2014	974
24623306	Zinc	Serra RW	A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype.	eLife	2014	32
24626089	Zinc	Nakaya T	KLF5 regulates the integrity and oncogenicity of intestinal stem cells.	Cancer research	2014	24
24710731	Zinc	Kambe T	Current understanding of ZIP and ZnT zinc transporters in human health and diseases.	Cellular and molecular life sciences 	2014	30
24769727	Zinc	Denecker G	Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression.	Cell death and differentiation	2014	27
24952462	Zinc	Whissell G	The transcription factor GATA6 enables self-renewal of colon adenoma stem cells by repressing BMP gene expression.	Nature cell biology	2014	25
24978435	Zinc	Gong Y	Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression.	Cancers	2014	22
25084828	Zinc	Kaufhold S	Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention.	Journal of experimental & clinical cancer research 	2014	54
25086746	Zinc	Zhang P	ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1.	Nature cell biology	2014	56
25150861	Zinc	Conomos D	NuRD-ZNF827 recruitment to telomeres creates a molecular scaffold for homologous recombination.	Nature structural & molecular biology	2014	22
25267526	Zinc	Ilagan JO	U2AF1 mutations alter splice site recognition in hematological malignancies.	Genome research	2015	40
25296715	Zinc	Ren D	Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells.	Cell and tissue research	2014	33
25421577	Zinc	Addison JB	KAP1 promotes proliferation and metastatic progression of breast cancer cells.	Cancer research	2015	16
25476932	Zinc	Zhang P	miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13.	Nature communications	2014	29
25531323	Zinc	Weber CE	Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer.	Oncogene	2015	30
25547151	Zinc	Deng X	MiR-146b-5p promotes metastasis and induces epithelial-mesenchymal transition in thyroid cancer by targeting ZNRF3.	Cellular physiology and biochemistry 	2015	22
25576492	Zinc	Lafrance-Vanasse J	Envisioning the dynamics and flexibility of Mre11-Rad50-Nbs1 complex to decipher its roles in DNA replication and repair.	Progress in biophysics and molecular biology	2015	25
25607528	Zinc	Zhang P	ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance.	Cell cycle	2015	65
25645053	Zinc	Bailey SD	ZNF143 provides sequence specificity to secure chromatin interactions at gene promoters.	Nature communications	2015	38
25687470	Zinc	Seidel C	Histone deacetylase 6 in health and disease.	Epigenomics	2015	18
25945841	Zinc	Huang N	MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling.	Oncotarget	2015	27
26023187	Zinc	Koo BK	Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3-mutant neoplasia.	Proceedings of the National Academy of Sciences of the United States of America	2015	16
26025392	Zinc	Kelwick R	The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family.	Genome biology	2015	49
26207617	Zinc	Liu H	Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer.	Molecular carcinogenesis	2016	11
26527725	Zinc	Wang J	Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery.	Nucleic acids research	2016	17
26544536	Zinc	Xue M	Long non-coding RNA urothelial cancer-associated 1 promotes bladder cancer cell migration and invasion by way of the hsa-miR-145-ZEB1/2-FSCN1 pathway.	Cancer science	2016	29
26626149	Zinc	Klein BJ	Bivalent interaction of the PZP domain of BRPF1 with the nucleosome impacts chromatin dynamics and acetylation.	Nucleic acids research	2016	13
26645689	Zinc	Horton JR	Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.	The Journal of biological chemistry	2016	10
26684803	Zinc	Kulemann B	KRAS mutations in pancreatic circulating tumor cells: a pilot study.	Tumour biology 	2016	11
26929370	Zinc	Satou Y	The retrovirus HTLV-1 inserts an ectopic CTCF-binding site into the human genome.	Proceedings of the National Academy of Sciences of the United States of America	2016	13
26943042	Zinc	Olivieri M	Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis.	Oncotarget	2016	14
27139641	Zinc	Shaban NM	1.92 Angstrom Zinc-Free APOBEC3F Catalytic Domain Crystal Structure.	Journal of molecular biology	2016	12
27162353	Zinc	Madan B	USP6 oncogene promotes Wnt signaling by deubiquitylating Frizzleds.	Proceedings of the National Academy of Sciences of the United States of America	2016	14
27274087	Zinc	Taylor KM	Zinc transporter ZIP10 forms a heteromer with ZIP6 which regulates embryonic development and cell migration.	The Biochemical journal	2016	13
27389056	Zinc	Ping N	Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia.	Leukemia	2017	6
27610572	Zinc	Singer M	A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells.	Cell	2016	32
27862275	Zinc	Fang C	Long non-coding ribonucleic acid zinc finger antisense 1 promotes the progression of colonic cancer by modulating ZEB1 expression.	Journal of gastroenterology and hepatology	2017	9
28092692	Zinc	Isakova A	SMiLE-seq identifies binding motifs of single and dimeric transcription factors.	Nature methods	2017	10
28211215	Zinc	Yao Z	ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathways.	Molecular oncology	2017	22
28242625	Zinc	Leung JW	ZMYM3 regulates BRCA1 localization at damaged chromatin to promote DNA repair.	Genes & development	2017	9
28349823	Zinc	Lv QL	Upregulation of long noncoding RNA zinc finger antisense 1 enhances epithelial-mesenchymal transition in vitro and predicts poor prognosis in glioma.	Tumour biology 	2017	6
2175676	Adenosine Triphosphate	Scheffner M	The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.	Cell	1990	935
7630397	Adenosine Triphosphate	Jeffrey PD	Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex.	Nature	1995	336
7988572	Adenosine Triphosphate	Benson FE	Purification and characterization of the human Rad51 protein, an analogue of E. coli RecA.	The EMBO journal	1994	151
8465201	Adenosine Triphosphate	Schaeffer L	DNA repair helicase: a component of BTF2 (TFIIH) basic transcription factor.	Science	1993	207
8684460	Adenosine Triphosphate	Russo AA	Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.	Nature	1996	238
8929543	Adenosine Triphosphate	Baumann P	Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro.	Cell	1996	207
9009268	Adenosine Triphosphate	Hu J	Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids.	The EMBO journal	1997	112
9054934	Adenosine Triphosphate	Allikmets R	A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy.	Nature genetics	1997	296
9157970	Adenosine Triphosphate	Eguchi Y	Intracellular ATP levels determine cell death fate by apoptosis or necrosis.	Cancer research	1997	166
9351836	Adenosine Triphosphate	Evans E	Mechanism of open complex and dual incision formation by human nucleotide excision repair factors.	The EMBO journal	1997	145
9450758	Adenosine Triphosphate	Benson FE	Synergistic actions of Rad51 and Rad52 in recombination and DNA repair.	Nature	1998	128
9790534	Adenosine Triphosphate	Zhang Y	The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities.	Cell	1998	247
9817203	Adenosine Triphosphate	Yin MJ	The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta.	Nature	1998	270
9850061	Adenosine Triphosphate	Allikmets R	A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.	Cancer research	1998	122
9861027	Adenosine Triphosphate	Doyle LA	A multidrug resistance transporter from human MCF-7 breast cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	1998	376
10078208	Adenosine Triphosphate	Gradia S	hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched DNA.	Molecular cell	1999	110
10233156	Adenosine Triphosphate	Andrei C	The secretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysosome-related vesicles.	Molecular biology of the cell	1999	118
10395545	Adenosine Triphosphate	Riballo E	Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient.	Current biology 	1999	96
10825162	Adenosine Triphosphate	Brosh RM Jr	Replication protein A physically interacts with the Bloom's syndrome protein and stimulates its helicase activity.	The Journal of biological chemistry	2000	118
10934467	Adenosine Triphosphate	Saleh A	Negative regulation of the Apaf-1 apoptosome by Hsp70.	Nature cell biology	2000	147
11030347	Adenosine Triphosphate	Rathmell JC	In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability.	Molecular cell	2000	132
11274139	Adenosine Triphosphate	Kamradt MC	The small heat shock protein alpha B-crystallin negatively regulates cytochrome c- and caspase-8-dependent activation of caspase-3 by inhibiting its autoproteolytic maturation.	The Journal of biological chemistry	2001	89
11583616	Adenosine Triphosphate	Xiao H	Dual functions of largest NURF subunit NURF301 in nucleosome sliding and transcription factor interactions.	Molecular cell	2001	91
11694888	Adenosine Triphosphate	Favelyukis S	Structure and autoregulation of the insulin-like growth factor 1 receptor kinase.	Nature structural biology	2001	97
11739410	Adenosine Triphosphate	Madesh M	VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release.	The Journal of cell biology	2001	114
12176997	Adenosine Triphosphate	Basso AD	Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function.	The Journal of biological chemistry	2002	163
12429862	Adenosine Triphosphate	Jonker JW	The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria.	Proceedings of the National Academy of Sciences of the United States of America	2002	127
12438266	Adenosine Triphosphate	Cuezva JM	The bioenergetic signature of cancer: a marker of tumor progression.	Cancer research	2002	96
12535572	Adenosine Triphosphate	Schinkel AH	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.	Advanced drug delivery reviews	2003	207
12578958	Adenosine Triphosphate	Bermudez VP	Loading of the human 9-1-1 checkpoint complex onto DNA by the checkpoint clamp loader hRad17-replication factor C complex in vitro.	Proceedings of the National Academy of Sciences of the United States of America	2003	121
12623848	Adenosine Triphosphate	Branford S	Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.	Blood	2003	115
12665508	Adenosine Triphosphate	Reddy RK	Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation.	The Journal of biological chemistry	2003	193
12835412	Adenosine Triphosphate	Reid G	The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.	Proceedings of the National Academy of Sciences of the United States of America	2003	92
12953102	Adenosine Triphosphate	Xue Y	The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies.	Proceedings of the National Academy of Sciences of the United States of America	2003	129
14530494	Adenosine Triphosphate	Leonard GD	The role of ABC transporters in clinical practice.	The oncologist	2003	147
14576852	Adenosine Triphosphate	Ambudkar SV	P-glycoprotein: from genomics to mechanism.	Oncogene	2003	169
14713298	Adenosine Triphosphate	Bijur GN	Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3-kinase activation.	Journal of neurochemistry	2003	94
14740253	Adenosine Triphosphate	Wegele H	Hsp70 and Hsp90--a relay team for protein folding.	Reviews of physiology, biochemistry and pharmacology	2004	142
15031492	Adenosine Triphosphate	Noble ME	Protein kinase inhibitors: insights into drug design from structure.	Science	2004	212
15099516	Adenosine Triphosphate	Nagaich AK	Rapid periodic binding and displacement of the glucocorticoid receptor during chromatin remodeling.	Molecular cell	2004	75
15192144	Adenosine Triphosphate	Andrei C	Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes.	Proceedings of the National Academy of Sciences of the United States of America	2004	105
15236194	Adenosine Triphosphate	Tamborini E	A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.	Gastroenterology	2004	70
15456405	Adenosine Triphosphate	Barnett SF	Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors.	The Biochemical journal	2005	132
15485900	Adenosine Triphosphate	Stark JM	Genetic steps of mammalian homologous repair with distinct mutagenic consequences.	Molecular and cellular biology	2004	172
15543203	Adenosine Triphosphate	de Kok JB	Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes.	Laboratory investigation; a journal of technical methods and pathology	2005	148
15559249	Adenosine Triphosphate	Meijer L	Pharmacological inhibitors of glycogen synthase kinase 3.	Trends in pharmacological sciences	2004	136
15695406	Adenosine Triphosphate	Xu RH	Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia.	Cancer research	2005	181
15717060	Adenosine Triphosphate	Löscher W	Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.	NeuroRx 	2005	111
15753456	Adenosine Triphosphate	Baselga J	Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.	Journal of clinical oncology 	2005	130
15766665	Adenosine Triphosphate	Gumireddy K	ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.	Cancer cell	2005	84
15845415	Adenosine Triphosphate	Leslie EM	Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense.	Toxicology and applied pharmacology	2005	197
15894266	Adenosine Triphosphate	Plescia J	Rational design of shepherdin, a novel anticancer agent.	Cancer cell	2005	67
15899892	Adenosine Triphosphate	Sharma S	Biochemical analysis of the DNA unwinding and strand annealing activities catalyzed by human RECQ1.	The Journal of biological chemistry	2005	83
15937217	Adenosine Triphosphate	Losada A	Dynamic molecular linkers of the genome: the first decade of SMC proteins.	Genes & development	2005	123
15998811	Adenosine Triphosphate	Dannenberg JH	mSin3A corepressor regulates diverse transcriptional networks governing normal and neoplastic growth and survival.	Genes & development	2005	86
16098463	Adenosine Triphosphate	Moeller BJ	Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity.	Cancer cell	2005	111
16124856	Adenosine Triphosphate	Dean M	Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates.	Annual review of genomics and human genetics	2005	132
16214424	Adenosine Triphosphate	Macris MA	Biochemical characterization of the RECQ4 protein, mutated in Rothmund-Thomson syndrome.	DNA repair	2006	63
16251956	Adenosine Triphosphate	Myong S	Repetitive shuttling of a motor protein on DNA.	Nature	2005	110
16305368	Adenosine Triphosphate	Glavinas H	The role of ABC transporters in drug resistance, metabolism and toxicity.	Current drug delivery	2004	91
16397263	Adenosine Triphosphate	Schittenhelm MM	Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.	Cancer research	2006	95
16402910	Adenosine Triphosphate	Krishnamurthy P	Role of ABCG2/BCRP in biology and medicine.	Annual review of pharmacology and toxicology	2006	82
16415863	Adenosine Triphosphate	Adrián FJ	Allosteric inhibitors of Bcr-abl-dependent cell proliferation.	Nature chemical biology	2006	76
16518375	Adenosine Triphosphate	Szakács G	Targeting multidrug resistance in cancer.	Nature reviews. Drug discovery	2006	621
16520385	Adenosine Triphosphate	Kruhlak MJ	Changes in chromatin structure and mobility in living cells at sites of DNA double-strand breaks.	The Journal of cell biology	2006	166
16728978	Adenosine Triphosphate	Li H	Molecular basis for site-specific read-out of histone H3K4me3 by the BPTF PHD finger of NURF.	Nature	2006	266
16756493	Adenosine Triphosphate	Pearl LH	Structure and mechanism of the Hsp90 molecular chaperone machinery.	Annual review of biochemistry	2006	299
16787253	Adenosine Triphosphate	Shoshan-Barmatz V	The voltage-dependent anion channel (VDAC): function in intracellular signalling, cell life and cell death.	Current pharmaceutical design	2006	80
16816140	Adenosine Triphosphate	Deeley RG	Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.	Physiological reviews	2006	164
16873062	Adenosine Triphosphate	Kadyrov FA	Endonucleolytic function of MutLalpha in human mismatch repair.	Cell	2006	220
16880519	Adenosine Triphosphate	Griswold IJ	Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.	Molecular and cellular biology	2006	62
16892079	Adenosine Triphosphate	Brandon M	Mitochondrial mutations in cancer.	Oncogene	2006	206
16935882	Adenosine Triphosphate	Fuller-Pace FV	DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation.	Nucleic acids research	2006	127
17015488	Adenosine Triphosphate	Sarkadi B	Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system.	Physiological reviews	2006	142
17095747	Adenosine Triphosphate	Fernando SL	A polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis.	American journal of respiratory and critical care medicine	2007	60
17114456	Adenosine Triphosphate	Mambula SS	Heat shock protein 70 is secreted from tumor cells by a nonclassical pathway involving lysosomal endosomes.	Journal of immunology	2006	97
17158952	Adenosine Triphosphate	Pelicano H	Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism.	The Journal of cell biology	2006	126
17244528	Adenosine Triphosphate	Høyer-Hansen M	Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2.	Molecular cell	2007	314
17322922	Adenosine Triphosphate	Lou H	Targeted therapy for cancer stem cells: the patched pathway and ABC transporters.	Oncogene	2007	62
17353904	Adenosine Triphosphate	Sims-Mourtada J	Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport.	Oncogene	2007	76
17386261	Adenosine Triphosphate	Larochelle S	Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells.	Molecular cell	2007	77
17572300	Adenosine Triphosphate	Gillet JP	Chemotherapy-induced resistance by ATP-binding cassette transporter genes.	Biochimica et biophysica acta	2007	61
17573453	Adenosine Triphosphate	Ryan JL	Mechanisms of cancer-related fatigue.	The oncologist	2007	88
17588518	Adenosine Triphosphate	Li X	Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway.	Molecular cell	2007	96
17713585	Adenosine Triphosphate	Williams RS	Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template.	Biochemistry and cell biology = Biochimie et biologie cellulaire	2007	155
17911267	Adenosine Triphosphate	Zhou J	Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance.	Proceedings of the National Academy of Sciences of the United States of America	2007	193
17952660	Adenosine Triphosphate	Wirkner K	P2X3 receptor involvement in pain states.	Molecular neurobiology	2007	59
18003859	Adenosine Triphosphate	Hu Y	RECQL5/Recql5 helicase regulates homologous recombination and suppresses tumor formation via disruption of Rad51 presynaptic filaments.	Genes & development	2007	144
18154452	Adenosine Triphosphate	Sharom FJ	ABC multidrug transporters: structure, function and role in chemoresistance.	Pharmacogenomics	2008	173
18212047	Adenosine Triphosphate	Auger A	Eaf1 is the platform for NuA4 molecular assembly that evolutionarily links chromatin acetylation to ATP-dependent exchange of histone H2A variants.	Molecular and cellular biology	2008	55
18230700	Adenosine Triphosphate	Ye J	Nuclear myosin I acts in concert with polymeric actin to drive RNA polymerase I transcription.	Genes & development	2008	52
18290764	Adenosine Triphosphate	Pearl LH	The Hsp90 molecular chaperone: an open and shut case for treatment.	The Biochemical journal	2008	144
18393293	Adenosine Triphosphate	Komuta M	Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin.	Hepatology	2008	74
18439900	Adenosine Triphosphate	Gwinn DM	AMPK phosphorylation of raptor mediates a metabolic checkpoint.	Molecular cell	2008	938
18454141	Adenosine Triphosphate	Tasdemir E	Regulation of autophagy by cytoplasmic p53.	Nature cell biology	2008	333
18468555	Adenosine Triphosphate	Szakács G	The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox).	Drug discovery today	2008	79
18523012	Adenosine Triphosphate	Piccini A	ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1beta and IL-18 secretion in an autocrine way.	Proceedings of the National Academy of Sciences of the United States of America	2008	128
18560012	Adenosine Triphosphate	Miller DS	Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy.	Pharmacological reviews	2008	79
18568041	Adenosine Triphosphate	Ow YP	Cytochrome c: functions beyond respiration.	Nature reviews. Molecular cell biology	2008	155
18691045	Adenosine Triphosphate	Guerra B	Protein kinase CK2 in human diseases.	Current medicinal chemistry	2008	55
18957201	Adenosine Triphosphate	Barber LJ	RTEL1 maintains genomic stability by suppressing homologous recombination.	Cell	2008	137
18991631	Adenosine Triphosphate	Donnelly A	Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.	Current medicinal chemistry	2008	74
19050078	Adenosine Triphosphate	Wang X	Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins.	Proceedings of the National Academy of Sciences of the United States of America	2008	232
19079736	Adenosine Triphosphate	Wu CP	Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.	Current molecular pharmacology	2008	55
19118021	Adenosine Triphosphate	Chiche J	Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH.	Cancer research	2009	121
19118027	Adenosine Triphosphate	Banerji U	Heat shock protein 90 as a drug target: some like it hot.	Clinical cancer research 	2009	73
19177149	Adenosine Triphosphate	Xu X	Dual DNA unwinding activities of the Rothmund-Thomson syndrome protein, RECQ4.	The EMBO journal	2009	55
19219026	Adenosine Triphosphate	Gao P	c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism.	Nature	2009	572
19234488	Adenosine Triphosphate	Reisman D	The SWI/SNF complex and cancer.	Oncogene	2009	188
19236062	Adenosine Triphosphate	AshaRani PV	Cytotoxicity and genotoxicity of silver nanoparticles in human cells.	ACS nano	2009	293
19251738	Adenosine Triphosphate	Schnetz MP	Genomic distribution of CHD7 on chromatin tracks H3K4 methylation patterns.	Genome research	2009	87
19258498	Adenosine Triphosphate	Samudio I	Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism.	Cancer research	2009	73
19270741	Adenosine Triphosphate	Gegg ME	Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells.	PloS one	2009	60
19292913	Adenosine Triphosphate	Sparvero LJ	RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.	Journal of translational medicine	2009	133
19303847	Adenosine Triphosphate	Carreira A	The BRC repeats of BRCA2 modulate the DNA-binding selectivity of RAD51.	Cell	2009	92
19383919	Adenosine Triphosphate	Dong X	Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.	Cancer research	2009	56
19417105	Adenosine Triphosphate	Cheng Z	Structural insights into eRF3 and stop codon recognition by eRF1.	Genes & development	2009	50
19525936	Adenosine Triphosphate	Peng G	BRIT1/MCPH1 links chromatin remodelling to DNA damage response.	Nature cell biology	2009	74
19584280	Adenosine Triphosphate	Yu K	Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.	Cancer research	2009	119
19593530	Adenosine Triphosphate	Kostenko S	Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology.	Cellular and molecular life sciences 	2009	89
19666485	Adenosine Triphosphate	Gottschalk AJ	Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler.	Proceedings of the National Academy of Sciences of the United States of America	2009	126
19689244	Adenosine Triphosphate	Hartmann JT	Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.	Current drug metabolism	2009	63
19693011	Adenosine Triphosphate	Schafer ZT	Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment.	Nature	2009	234
19697319	Adenosine Triphosphate	Zuehlke A	Hsp90 and co-chaperones twist the functions of diverse client proteins.	Biopolymers	2010	61
19711346	Adenosine Triphosphate	Zhu Z	Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma.	International journal of cancer	2010	106
19717510	Adenosine Triphosphate	Muñoz-Planillo R	A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome.	Journal of immunology	2009	111
19753307	Adenosine Triphosphate	Chen Y	Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect.	PloS one	2009	55
19778642	Adenosine Triphosphate	Fogarty S	Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer.	Biochimica et biophysica acta	2010	100
19788499	Adenosine Triphosphate	Vähäkangas K	Drug transporters in the human blood-placental barrier.	British journal of pharmacology	2009	51
19789351	Adenosine Triphosphate	Wang X	Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex.	Cancer research	2009	53
19815529	Adenosine Triphosphate	Hoppe S	AMP-activated protein kinase adapts rRNA synthesis to cellular energy supply.	Proceedings of the National Academy of Sciences of the United States of America	2009	56
19825957	Adenosine Triphosphate	Mandapathil M	Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer.	Clinical cancer research 	2009	56
19840943	Adenosine Triphosphate	Demory ML	Epidermal growth factor receptor translocation to the mitochondria: regulation and effect.	The Journal of biological chemistry	2009	51
19939921	Adenosine Triphosphate	Chambers JW	Glutamine metabolism is essential for human cytomegalovirus infection.	Journal of virology	2010	59
20038799	Adenosine Triphosphate	Samudio I	Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction.	The Journal of clinical investigation	2010	138
20081827	Adenosine Triphosphate	Berndt A	The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.	Nature chemical biology	2010	44
20086177	Adenosine Triphosphate	Aymeric L	Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity.	Cancer research	2010	79
20087650	Adenosine Triphosphate	Martin FT	Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT).	Breast cancer research and treatment	2010	59
20130576	Adenosine Triphosphate	Hatzivassiliou G	RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.	Nature	2010	402
20159023	Adenosine Triphosphate	Ding XW	ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy.	Life sciences	2010	80
20179705	Adenosine Triphosphate	Poulikakos PI	RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.	Nature	2010	469
20215500	Adenosine Triphosphate	Ben Sahra I	Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.	Cancer research	2010	133
20347038	Adenosine Triphosphate	Qian W	Alterations in bioenergetics due to changes in mitochondrial DNA copy number.	Methods	2010	47
20360943	Adenosine Triphosphate	Gandhirajan RK	Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.	Neoplasia	2010	45
20399660	Adenosine Triphosphate	Feng Z	The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein.	Trends in cell biology	2010	114
20409745	Adenosine Triphosphate	Porter JR	Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.	Current opinion in chemical biology	2010	49
20442200	Adenosine Triphosphate	Yang XR	High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma.	Gut	2010	73
20453110	Adenosine Triphosphate	Adinolfi E	Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor.	FASEB journal 	2010	42
20562527	Adenosine Triphosphate	Migneco G	Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling.	Cell cycle	2010	58
20593179	Adenosine Triphosphate	Xi H	2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion.	Cancer chemotherapy and pharmacology	2011	46
20622997	Adenosine Triphosphate	Liu Q	mTOR Mediated Anti-Cancer Drug Discovery.	Drug discovery today. Therapeutic strategies	2009	47
20644254	Adenosine Triphosphate	Imtiyaz HZ	Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation.	The Journal of clinical investigation	2010	98
20682644	Adenosine Triphosphate	Singh A	Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype.	Molecular cancer therapeutics	2010	43
20683952	Adenosine Triphosphate	Wang XQ	Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway.	Hepatology	2010	56
20729832	Adenosine Triphosphate	Jensen RB	Purified human BRCA2 stimulates RAD51-mediated recombination.	Nature	2010	201
20805324	Adenosine Triphosphate	Larsen DH	The chromatin-remodeling factor CHD4 coordinates signaling and repair after DNA damage.	The Journal of cell biology	2010	88
20819940	Adenosine Triphosphate	Tang D	Endogenous HMGB1 regulates autophagy.	The Journal of cell biology	2010	236
20847263	Adenosine Triphosphate	Vander Heiden MG	Evidence for an alternative glycolytic pathway in rapidly proliferating cells.	Science	2010	207
20971042	Adenosine Triphosphate	Holthausen JT	Regulation of DNA strand exchange in homologous recombination.	DNA repair	2010	60
21039338	Adenosine Triphosphate	Shukla S	Improving cancer chemotherapy with modulators of ABC drug transporters.	Current drug targets	2011	42
21132003	Adenosine Triphosphate	Morris MR	Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma.	Oncogene	2011	56
21172662	Adenosine Triphosphate	Lan L	The ACF1 complex is required for DNA double-strand break repair in human cells.	Molecular cell	2010	74
21212411	Adenosine Triphosphate	Frank NY	VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth.	Cancer research	2011	51
21242969	Adenosine Triphosphate	Jelassi B	P2X(7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness.	Oncogene	2011	50
21249425	Adenosine Triphosphate	Kepp O	Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy.	Cancer metastasis reviews	2011	70
21265739	Adenosine Triphosphate	Hardie DG	AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer.	Biochemical Society transactions	2011	41
21278237	Adenosine Triphosphate	Kim TH	NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α.	Cancer research	2011	65
21283107	Adenosine Triphosphate	Quintás-Cardama A	Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.	Nature reviews. Drug discovery	2011	80
21284981	Adenosine Triphosphate	Tennessen JM	The Drosophila estrogen-related receptor directs a metabolic switch that supports developmental growth.	Cell metabolism	2011	60
21358755	Adenosine Triphosphate	Hargreaves DC	ATP-dependent chromatin remodeling: genetics, genomics and mechanisms.	Cell research	2011	239
21390132	Adenosine Triphosphate	Simsek D	Crucial role for DNA ligase III in mitochondria but not in Xrcc1-dependent repair.	Nature	2011	77
21396365	Adenosine Triphosphate	Alexander A	The role of LKB1 and AMPK in cellular responses to stress and damage.	FEBS letters	2011	46
21441910	Adenosine Triphosphate	Brennan DF	A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK.	Nature	2011	73
21480217	Adenosine Triphosphate	Kryczek I	Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells.	International journal of cancer	2012	78
21531766	Adenosine Triphosphate	Jeon HM	ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2.	Cancer research	2011	54
21571596	Adenosine Triphosphate	Fuss JO	XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase.	DNA repair	2011	60
21576264	Adenosine Triphosphate	Zaugg K	Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress.	Genes & development	2011	123
21592869	Adenosine Triphosphate	Egly JM	A history of TFIIH: two decades of molecular biology on a pivotal transcription/repair factor.	DNA repair	2011	61
21620960	Adenosine Triphosphate	Hers I	Akt signalling in health and disease.	Cellular signalling	2011	223
21622723	Adenosine Triphosphate	Maugeri-Saccà M	Cancer stem cells and chemosensitivity.	Clinical cancer research 	2011	45
21692052	Adenosine Triphosphate	Sandulache VC	Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells.	Cancer	2011	40
21698063	Adenosine Triphosphate	Varum S	Energy metabolism in human pluripotent stem cells and their differentiated counterparts.	PloS one	2011	166
21709020	Adenosine Triphosphate	Avivar-Valderas A	PERK integrates autophagy and oxidative stress responses to promote survival during extracellular matrix detachment.	Molecular and cellular biology	2011	71
21734725	Adenosine Triphosphate	Saxena M	Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters.	Cell death & disease	2011	56
21740521	Adenosine Triphosphate	Chen ZS	Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases.	The FEBS journal	2011	52
21813754	Adenosine Triphosphate	Chan DA	Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality.	Science translational medicine	2011	92
21822277	Adenosine Triphosphate	Kashatus DF	RALA and RALBP1 regulate mitochondrial fission at mitosis.	Nature cell biology	2011	99
21873242	Adenosine Triphosphate	Aung T	Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3.	Proceedings of the National Academy of Sciences of the United States of America	2011	41
21892209	Adenosine Triphosphate	Mamo A	An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer.	Oncogene	2012	44
21900104	Adenosine Triphosphate	Visscher H	Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.	Journal of clinical oncology 	2012	57
21900605	Adenosine Triphosphate	Vlashi E	Metabolic state of glioma stem cells and nontumorigenic cells.	Proceedings of the National Academy of Sciences of the United States of America	2011	113
21932399	Adenosine Triphosphate	Borel F	Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs.	Hepatology	2012	44
21947008	Adenosine Triphosphate	Jiang F	Structural basis of RNA recognition and activation by innate immune receptor RIG-I.	Nature	2011	136
21967057	Adenosine Triphosphate	Sharom FJ	The P-glycoprotein multidrug transporter.	Essays in biochemistry	2011	73
21967058	Adenosine Triphosphate	Slot AJ	Mammalian multidrug-resistance proteins (MRPs).	Essays in biochemistry	2011	37
21975038	Adenosine Triphosphate	Karkhanis V	Versatility of PRMT5-induced methylation in growth control and development.	Trends in biochemical sciences	2011	48
22062686	Adenosine Triphosphate	Jhaveri K	Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers.	Biochimica et biophysica acta	2012	118
22077634	Adenosine Triphosphate	Sheng B	Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease.	Journal of neurochemistry	2012	66
22084398	Adenosine Triphosphate	Zhou Y	Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells.	Cancer research	2012	59
22098950	Adenosine Triphosphate	Nakanishi T	Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.	Chinese journal of cancer	2012	49
22123234	Adenosine Triphosphate	Bayley JP	The Warburg effect in 2012.	Current opinion in oncology	2012	64
22194014	Adenosine Triphosphate	Wu JI	Diverse functions of ATP-dependent chromatin remodeling complexes in development and cancer.	Acta biochimica et biophysica Sinica	2012	35
22198378	Adenosine Triphosphate	Gusdon AM	ATP13A2 regulates mitochondrial bioenergetics through macroautophagy.	Neurobiology of disease	2012	39
22223645	Adenosine Triphosphate	Liu Q	Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics.	The Journal of biological chemistry	2012	36
22252128	Adenosine Triphosphate	Garg AD	A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death.	The EMBO journal	2012	123
22262166	Adenosine Triphosphate	Zhang Y	mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.	Cell cycle	2012	36
22266115	Adenosine Triphosphate	Zaytseva YY	Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer.	Cancer research	2012	35
22294766	Adenosine Triphosphate	Hlavata I	The role of ABC transporters in progression and clinical outcome of colorectal cancer.	Mutagenesis	2012	42
22323447	Adenosine Triphosphate	Bernstein SH	The mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivatives.	Blood	2012	32
22396493	Adenosine Triphosphate	Diaconu I	Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.	Cancer research	2012	52
22449631	Adenosine Triphosphate	Garrido C	The small heat shock proteins family: the long forgotten chaperones.	The international journal of biochemistry & cell biology	2012	48
22460906	Adenosine Triphosphate	Liu L	Deregulated MYC expression induces dependence upon AMPK-related kinase 5.	Nature	2012	83
22461509	Adenosine Triphosphate	Miyamoto S	Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma.	Cancer research	2012	45
22469988	Adenosine Triphosphate	Peschiaroli A	miR-143 regulates hexokinase 2 expression in cancer cells.	Oncogene	2013	40
22474384	Adenosine Triphosphate	Kang YH	Properties of the human Cdc45/Mcm2-7/GINS helicase complex and its action with DNA polymerase epsilon in rolling circle DNA synthesis.	Proceedings of the National Academy of Sciences of the United States of America	2012	53
22509477	Adenosine Triphosphate	Mo W	Human ABCG2: structure, function, and its role in multidrug resistance.	International journal of biochemistry and molecular biology	2012	37
22525272	Adenosine Triphosphate	Galavotti S	The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells.	Oncogene	2013	55
22544066	Adenosine Triphosphate	Perciavalle RM	Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration.	Nature cell biology	2012	110
22544529	Adenosine Triphosphate	Franke H	Pathophysiology of astroglial purinergic signalling.	Purinergic signalling	2012	34
22552292	Adenosine Triphosphate	Xu L	Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.	Cancer research	2012	41
22561706	Adenosine Triphosphate	Dhar SK	Manganese superoxide dismutase regulation and cancer.	Free radical biology & medicine	2012	51
22564882	Adenosine Triphosphate	Martelli AM	Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.	Oncotarget	2012	50
22588883	Adenosine Triphosphate	Vivanco I	Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.	Cancer discovery	2012	91
22626470	Adenosine Triphosphate	Johnson RF	Nuclear factor-κB, p53, and mitochondria: regulation of cellular metabolism and the Warburg effect.	Trends in biochemical sciences	2012	35
22698286	Adenosine Triphosphate	Suijkerbuijk SJ	The vertebrate mitotic checkpoint protein BUBR1 is an unusual pseudokinase.	Developmental cell	2012	42
22705370	Adenosine Triphosphate	Yuan J	The HARP-like domain-containing protein AH2/ZRANB3 binds to PCNA and participates in cellular response to replication stress.	Molecular cell	2012	32
22722202	Adenosine Triphosphate	Banerji S	Sequence analysis of mutations and translocations across breast cancer subtypes.	Nature	2012	352
22820988	Adenosine Triphosphate	Bandaranayake RM	Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F.	Nature structural & molecular biology	2012	42
22869150	Adenosine Triphosphate	Kilbride SM	Central roles of apoptotic proteins in mitochondrial function.	Oncogene	2013	27
22892846	Adenosine Triphosphate	van den Heuvel AP	Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth.	Cancer biology & therapy	2012	55
22913968	Adenosine Triphosphate	Adekola K	Glucose transporters in cancer metabolism.	Current opinion in oncology	2012	40
22948162	Adenosine Triphosphate	Juliana C	Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation.	The Journal of biological chemistry	2012	116
22963440	Adenosine Triphosphate	Volonté C	P2X7 receptors: channels, pores and more.	CNS & neurological disorders drug targets	2012	48
22990239	Adenosine Triphosphate	Rampelt H	Metazoan Hsp70 machines use Hsp110 to power protein disaggregation.	The EMBO journal	2012	88
23000902	Adenosine Triphosphate	Jin MS	Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans.	Nature	2012	117
23128392	Adenosine Triphosphate	Zhao J	Mitochondrial dynamics regulates migration and invasion of breast cancer cells.	Oncogene	2013	102
23142078	Adenosine Triphosphate	Kim SG	Metabolic stress controls mTORC1 lysosomal localization and dimerization by regulating the TTT-RUVBL1/2 complex.	Molecular cell	2013	50
23151605	Adenosine Triphosphate	Krysko DV	Immunogenic cell death and DAMPs in cancer therapy.	Nature reviews. Cancer	2012	210
23175232	Adenosine Triphosphate	Oikawa T	Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers.	Hepatology	2013	51
23218009	Adenosine Triphosphate	Thadani R	Condensin, chromatin crossbarring and chromosome condensation.	Current biology 	2012	37
23318458	Adenosine Triphosphate	Kang R	The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics.	Oncogene	2014	62
23355908	Adenosine Triphosphate	Shain AH	The spectrum of SWI/SNF mutations, ubiquitous in human cancers.	PloS one	2013	101
23376776	Adenosine Triphosphate	Wu CA	Nutrient deprivation induces the Warburg effect through ROS/AMPK-dependent activation of pyruvate dehydrogenase kinase.	Biochimica et biophysica acta	2013	27
23403946	Adenosine Triphosphate	Balasubramanian MN	Asparagine synthetase: regulation by cell stress and involvement in tumor biology.	American journal of physiology. Endocrinology and metabolism	2013	45
23432475	Adenosine Triphosphate	Cheng Z	Mitochondria and metabolic homeostasis.	Antioxidants & redox signaling	2013	34
23449803	Adenosine Triphosphate	Shirasaki T	MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells.	Journal of virology	2013	55
23460667	Adenosine Triphosphate	Golebiewska A	Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells.	Brain 	2013	28
23498975	Adenosine Triphosphate	Bartolome F	Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels.	Neuron	2013	38
23542178	Adenosine Triphosphate	Ducker GS	Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.	Oncogene	2014	31
23564345	Adenosine Triphosphate	Yoshida S	Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis.	Proceedings of the National Academy of Sciences of the United States of America	2013	47
23603840	Adenosine Triphosphate	Hall A	Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene.	Oncotarget	2013	43
23636326	Adenosine Triphosphate	Yang H	mTOR kinase structure, mechanism and regulation.	Nature	2013	155
23647843	Adenosine Triphosphate	Gao P	Cyclic G(2',5')pA(3',5')p is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase.	Cell	2013	147
23651857	Adenosine Triphosphate	Hubert CG	Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A.	Genes & development	2013	36
23680146	Adenosine Triphosphate	Holderfield M	RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.	Cancer cell	2013	32
23681226	Adenosine Triphosphate	Krysko O	Many faces of DAMPs in cancer therapy.	Cell death & disease	2013	41
23685672	Adenosine Triphosphate	Lavoie H	Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization.	Nature chemical biology	2013	26
23688078	Adenosine Triphosphate	Choi YH	ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.	Current pharmaceutical design	2014	42
23698369	Adenosine Triphosphate	Dykhuizen EC	BAF complexes facilitate decatenation of DNA by topoisomerase IIα.	Nature	2013	63
23792284	Adenosine Triphosphate	Ji RR	Glia and pain: is chronic pain a gliopathy?	Pain	2013	154
23806880	Adenosine Triphosphate	Li J	Structure, function and regulation of the hsp90 machinery.	Biomedical journal	2013	83
23832118	Adenosine Triphosphate	Inoue H	Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments.	Cell death and differentiation	2014	52
23852373	Adenosine Triphosphate	Martins I	Molecular mechanisms of ATP secretion during immunogenic cell death.	Cell death and differentiation	2014	71
23852728	Adenosine Triphosphate	Betz C	Feature Article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology.	Proceedings of the National Academy of Sciences of the United States of America	2013	77
23886165	Adenosine Triphosphate	Jin J	miRNA-218 inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9.	Asian Pacific journal of cancer prevention 	2013	27
23886445	Adenosine Triphosphate	Tao R	Regulation of MnSOD enzymatic activity by Sirt3 connects the mitochondrial acetylome signaling networks to aging and carcinogenesis.	Antioxidants & redox signaling	2014	34
23911327	Adenosine Triphosphate	De Bock K	Role of PFKFB3-driven glycolysis in vessel sprouting.	Cell	2013	149
23954449	Adenosine Triphosphate	Stanley FK	CHD chromatin remodelling enzymes and the DNA damage response.	Mutation research	2013	29
24037090	Adenosine Triphosphate	Ko A	Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling.	Cell death and differentiation	2014	54
24117156	Adenosine Triphosphate	Bubici C	JNK signalling in cancer: in need of new, smarter therapeutic targets.	British journal of pharmacology	2014	32
24120954	Adenosine Triphosphate	Kunjachan S	Multidrug resistance: Physiological principles and nanomedical solutions.	Advanced drug delivery reviews	2013	40
24122795	Adenosine Triphosphate	Wang X	Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights.	Clinical cancer research 	2014	22
24206664	Adenosine Triphosphate	Morita M	mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation.	Cell metabolism	2013	119
24211491	Adenosine Triphosphate	Tahara T	Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators.	Gastroenterology	2014	23
24236104	Adenosine Triphosphate	Bhattacharyya S	Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance.	PloS one	2013	37
24265069	Adenosine Triphosphate	Burnstock G	Purinergic signalling in the urinary tract in health and disease.	Purinergic signalling	2014	29
24332968	Adenosine Triphosphate	Tornovsky-Babeay S	Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in β cells.	Cell metabolism	2014	32
24338270	Adenosine Triphosphate	Singh P	Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.	Medical oncology	2014	45
24363178	Adenosine Triphosphate	Gray LR	Regulation of pyruvate metabolism and human disease.	Cellular and molecular life sciences 	2014	42
24459177	Adenosine Triphosphate	Keppler D	The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia.	Drug metabolism and disposition	2014	23
24462205	Adenosine Triphosphate	Mollapour M	Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors.	Molecular cell	2014	31
24474669	Adenosine Triphosphate	Garcia PD	Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.	Clinical cancer research 	2014	27
24480782	Adenosine Triphosphate	Gameiro SR	Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing.	Oncotarget	2014	68
24492893	Adenosine Triphosphate	Callaghan R	Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?	Drug metabolism and disposition	2014	29
24500981	Adenosine Triphosphate	Fucikova J	High hydrostatic pressure induces immunogenic cell death in human tumor cells.	International journal of cancer	2014	24
24513530	Adenosine Triphosphate	Moreno-Sánchez R	Who controls the ATP supply in cancer cells? Biochemistry lessons to understand cancer energy metabolism.	The international journal of biochemistry & cell biology	2014	31
24550282	Adenosine Triphosphate	Faubert B	Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α.	Proceedings of the National Academy of Sciences of the United States of America	2014	49
24585446	Adenosine Triphosphate	Zhu B	Genetic variants in the SWI/SNF complex and smoking collaborate to modify the risk of pancreatic cancer in a Chinese population.	Molecular carcinogenesis	2015	18
24713656	Adenosine Triphosphate	Amato KR	Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC.	The Journal of clinical investigation	2014	21
24727893	Adenosine Triphosphate	Bonora M	Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition.	Oncogene	2015	39
24732580	Adenosine Triphosphate	Cosentino K	Mitochondrial alterations in apoptosis.	Chemistry and physics of lipids	2014	37
24746669	Adenosine Triphosphate	Wang Z	Cyclin B1/Cdk1 coordinates mitochondrial respiration for cell-cycle G2/M progression.	Developmental cell	2014	37
24768297	Adenosine Triphosphate	Liang H	PTENα, a PTEN isoform translated through alternative initiation, regulates mitochondrial function and energy metabolism.	Cell metabolism	2014	45
24777293	Adenosine Triphosphate	Shi L	miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2.	Neuromolecular medicine	2014	24
24781191	Adenosine Triphosphate	Arif T	Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo.	Molecular therapy. Nucleic acids	2014	23
24840079	Adenosine Triphosphate	Zhao Y	The clinical development of MEK inhibitors.	Nature reviews. Clinical oncology	2014	65
24875192	Adenosine Triphosphate	Pearce D	Collecting duct principal cell transport processes and their regulation.	Clinical journal of the American Society of Nephrology 	2015	36
24878061	Adenosine Triphosphate	Chou TF	Specific inhibition of p97/VCP ATPase and kinetic analysis demonstrate interaction between D1 and D2 ATPase domains.	Journal of molecular biology	2014	30
25017063	Adenosine Triphosphate	Quirós PM	ATP-dependent Lon protease controls tumor bioenergetics by reprogramming mitochondrial activity.	Cell reports	2014	31
25043816	Adenosine Triphosphate	Petruzzelli M	A switch from white to brown fat increases energy expenditure in cancer-associated cachexia.	Cell metabolism	2014	83
25057888	Adenosine Triphosphate	Babon JJ	The molecular regulation of Janus kinase (JAK) activation.	The Biochemical journal	2014	27
25092294	Adenosine Triphosphate	Eytan E	Disassembly of mitotic checkpoint complexes by the joint action of the AAA-ATPase TRIP13 and p31(comet).	Proceedings of the National Academy of Sciences of the United States of America	2014	33
25119037	Adenosine Triphosphate	Van Nostrand JL	Inappropriate p53 activation during development induces features of CHARGE syndrome.	Nature	2014	33
25220464	Adenosine Triphosphate	Fouquerel E	ARTD1/PARP1 negatively regulates glycolysis by inhibiting hexokinase 1 independent of NAD+ depletion.	Cell reports	2014	32
25241037	Adenosine Triphosphate	LeBleu VS	PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis.	Nature cell biology	2014	167
25262208	Adenosine Triphosphate	Miranda-Lorenzo I	Intracellular autofluorescence: a biomarker for epithelial cancer stem cells.	Nature methods	2014	36
25277190	Adenosine Triphosphate	Bonuccelli G	Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells.	Oncotarget	2014	23
25281745	Adenosine Triphosphate	Cole SP	Multidrug resistance protein 1 (MRP1, ABCC1), a "multitasking" ATP-binding cassette (ABC) transporter.	The Journal of biological chemistry	2014	24
25326666	Adenosine Triphosphate	Ronan B	A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy.	Nature chemical biology	2014	56
25435018	Adenosine Triphosphate	Silva R	Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy.	Pharmacology & therapeutics	2015	27
25482473	Adenosine Triphosphate	Parihar P	Mitochondrial sirtuins: emerging roles in metabolic regulations, energy homeostasis and diseases.	Experimental gerontology	2015	16
25556000	Adenosine Triphosphate	Bakthisaran R	Small heat shock proteins: Role in cellular functions and pathology.	Biochimica et biophysica acta	2015	44
25709099	Adenosine Triphosphate	Sampath D	Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.	Pharmacology & therapeutics	2015	26
25715710	Adenosine Triphosphate	Kaushik N	Responses of solid tumor cells in DMEM to reactive oxygen species generated by non-thermal plasma and chemically induced ROS systems.	Scientific reports	2015	17
25796366	Adenosine Triphosphate	Torchy MP	Structure and function insights into the NuRD chromatin remodeling complex.	Cellular and molecular life sciences 	2015	26
25801706	Adenosine Triphosphate	Israelson A	Macrophage migration inhibitory factor as a chaperone inhibiting accumulation of misfolded SOD1.	Neuron	2015	19
25807077	Adenosine Triphosphate	Lu CL	Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition--a Warburg-reversing effect.	PloS one	2015	23
25840885	Adenosine Triphosphate	Zhang YK	Multidrug Resistance Proteins (MRPs) and Cancer Therapy.	The AAPS journal	2015	24
25840982	Adenosine Triphosphate	Sadok A	Rho kinase inhibitors block melanoma cell migration and inhibit metastasis.	Cancer research	2015	19
25890351	Adenosine Triphosphate	Yang Z	T-cell metabolism in autoimmune disease.	Arthritis research & therapy	2015	22
25941621	Adenosine Triphosphate	Kepp O	Consensus guidelines for the detection of immunogenic cell death.	Oncoimmunology	2014	114
25982279	Adenosine Triphosphate	Buchert M	Targeting JAK kinase in solid tumors: emerging opportunities and challenges.	Oncogene	2016	32
26002551	Adenosine Triphosphate	Loubière C	Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells.	Oncotarget	2015	15
26062441	Adenosine Triphosphate	Wang J	Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer.	Oncotarget	2015	24
26097841	Adenosine Triphosphate	Finka A	Multi-layered molecular mechanisms of polypeptide holding, unfolding and disaggregation by HSP70/HSP110 chaperones.	Frontiers in molecular biosciences	2015	21
26098574	Adenosine Triphosphate	Furlow PW	Mechanosensitive pannexin-1 channels mediate microvascular metastatic cell survival.	Nature cell biology	2015	18
26100653	Adenosine Triphosphate	Ween MP	The role of ABC transporters in ovarian cancer progression and chemoresistance.	Critical reviews in oncology/hematology	2015	16
26232225	Adenosine Triphosphate	Sullivan LB	Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells.	Cell	2015	105
26300261	Adenosine Triphosphate	Hosios AM	Lack of Evidence for PKM2 Protein Kinase Activity.	Molecular cell	2015	21
26300264	Adenosine Triphosphate	Gao X	Human Hsp70 Disaggregase Reverses Parkinson's-Linked α-Synuclein Amyloid Fibrils.	Molecular cell	2015	43
26311743	Adenosine Triphosphate	Heerma van Voss MR	Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer.	Oncotarget	2015	18
26322680	Adenosine Triphosphate	Doménech E	AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest.	Nature cell biology	2015	29
26327810	Adenosine Triphosphate	Zhang W	Insights into Chemoresistance of Prostate Cancer.	International journal of biological sciences	2015	16
26436840	Adenosine Triphosphate	Poepsel S	Determinants of amyloid fibril degradation by the PDZ protease HTRA1.	Nature chemical biology	2015	19
26499806	Adenosine Triphosphate	Chen Z	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade.	Cancer letters	2016	53
26519060	Adenosine Triphosphate	Zhai L	Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.	Clinical cancer research 	2015	24
26649310	Adenosine Triphosphate	Moitra K	Overcoming Multidrug Resistance in Cancer Stem Cells.	BioMed research international	2015	16
26669263	Adenosine Triphosphate	Pradhan SK	EP400 Deposits H3.3 into Promoters and Enhancers during Gene Activation.	Molecular cell	2016	12
26698230	Adenosine Triphosphate	Nitulescu GM	Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review).	International journal of oncology	2016	27
26744319	Adenosine Triphosphate	Wang MD	HBx regulates fatty acid oxidation to promote hepatocellular carcinoma survival during metabolic stress.	Oncotarget	2016	11
26818947	Adenosine Triphosphate	Imamura M	Genome-wide association studies in the Japanese population identify seven novel loci for type 2 diabetes.	Nature communications	2016	13
26830313	Adenosine Triphosphate	Zhitomirsky B	Lysosomes as mediators of drug resistance in cancer.	Drug resistance updates 	2016	16
26836503	Adenosine Triphosphate	Kadoch C	PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease.	Biochemistry	2016	10
26888060	Adenosine Triphosphate	Abid Ali F	Cryo-EM structures of the eukaryotic replicative helicase bound to a translocation substrate.	Nature communications	2016	36
26895424	Adenosine Triphosphate	Luijsterburg MS	PARP1 Links CHD2-Mediated Chromatin Expansion and H3.3 Deposition to DNA Repair by Non-homologous End-Joining.	Molecular cell	2016	31
26916001	Adenosine Triphosphate	Garg G	Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.	Advances in cancer research	2016	11
26947070	Adenosine Triphosphate	Cárdenas C	Selective Vulnerability of Cancer Cells by Inhibition of Ca(2+) Transfer from Endoplasmic Reticulum to Mitochondria.	Cell reports	2016	22
27180306	Adenosine Triphosphate	Fletcher JI	ABC transporters as mediators of drug resistance and contributors to cancer cell biology.	Drug resistance updates 	2016	13
27335445	Adenosine Triphosphate	Stransky L	The Function of V-ATPases in Cancer.	Physiological reviews	2016	12
27413115	Adenosine Triphosphate	Hodges C	The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer.	Cold Spring Harbor perspectives in medicine	2016	16
27872130	Adenosine Triphosphate	Saura C	A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.	Cancer discovery	2017	9
27941796	Adenosine Triphosphate	Kadoch C	Dynamics of BAF-Polycomb complex opposition on heterochromatin in normal and oncogenic states.	Nature genetics	2017	16
28060726	Adenosine Triphosphate	Ogawa M	Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity.	Oncotarget	2017	11
28157507	Adenosine Triphosphate	Alekseev S	Transcription without XPB Establishes a Unified Helicase-Independent Mechanism of Promoter Opening in Eukaryotic Gene Expression.	Molecular cell	2017	6
28192788	Adenosine Triphosphate	Chan LN	Metabolic gatekeeper function of B-lymphoid transcription factors.	Nature	2017	10
28234357	Adenosine Triphosphate	Garg AD	Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing.	Cell death and differentiation	2017	11
28512218	Adenosine Triphosphate	Blythe EE	Ubiquitin- and ATP-dependent unfoldase activity of P97/VCP•NPLOC4•UFD1L is enhanced by a mutation that causes multisystem proteinopathy.	Proceedings of the National Academy of Sciences of the United States of America	2017	8
28723547	Adenosine Triphosphate	Di Virgilio F	The P2X7 Receptor in Infection and Inflammation.	Immunity	2017	17
1423625	Cysteine	Gu Y	The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene.	Cell	1992	157
1557402	Cysteine	Wong AJ	Structural alterations of the epidermal growth factor receptor gene in human gliomas.	Proceedings of the National Academy of Sciences of the United States of America	1992	196
1849459	Cysteine	Klein R	The trk proto-oncogene encodes a receptor for nerve growth factor.	Cell	1991	188
2158863	Cysteine	Schall TJ	Molecular cloning and expression of a receptor for human tumor necrosis factor.	Cell	1990	150
7523245	Cysteine	Eckner R	Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor.	Genes & development	1994	321
7652577	Cysteine	Wölfel T	A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.	Science	1995	187
7958843	Cysteine	Kumar S	Induction of apoptosis by the mouse Nedd2 gene, which encodes a protein similar to the product of the Caenorhabditis elegans cell death gene ced-3 and the mammalian IL-1 beta-converting enzyme.	Genes & development	1994	120
8099202	Cysteine	Mulligan LM	Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.	Nature	1993	188
8617204	Cysteine	Joukov V	A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.	The EMBO journal	1996	212
8681377	Cysteine	Muzio M	FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex.	Cell	1996	479
8944023	Cysteine	Wu LC	Identification of a RING protein that can interact in vivo with the BRCA1 gene product.	Nature genetics	1996	164
9217161	Cysteine	Irmler M	Inhibition of death receptor signals by cellular FLIP.	Nature	1997	435
9600969	Cysteine	Babic AM	CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth.	Proceedings of the National Academy of Sciences of the United States of America	1998	113
10213689	Cysteine	Mannick JB	Fas-induced caspase denitrosylation.	Science	1999	128
10458605	Cysteine	Bromberg JF	Stat3 as an oncogene.	Cell	1999	799
11090634	Cysteine	Uren AG	Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma.	Molecular cell	2000	195
11104820	Cysteine	Chang HY	Proteases for cell suicide: functions and regulation of caspases.	Microbiology and molecular biology reviews 	2000	99
11441809	Cysteine	Powis G	Properties and biological activities of thioredoxins.	Annual review of biophysics and biomolecular structure	2001	87
11714645	Cysteine	Rabkin E	Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves.	Circulation	2001	148
12223280	Cysteine	East L	The mannose receptor family.	Biochimica et biophysica acta	2002	110
12904165	Cysteine	Brigstock DR	The CCN family: a new stimulus package.	The Journal of endocrinology	2003	151
14871816	Cysteine	Caldwell GM	The Wnt antagonist sFRP1 in colorectal tumorigenesis.	Cancer research	2004	75
14988435	Cysteine	Wu G	Glutathione metabolism and its implications for health.	The Journal of nutrition	2004	361
15094120	Cysteine	Bellail AC	Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion.	The international journal of biochemistry & cell biology	2004	124
15189137	Cysteine	Jiang X	Cytochrome C-mediated apoptosis.	Annual review of biochemistry	2004	282
15314073	Cysteine	Nylandsted J	Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization.	The Journal of experimental medicine	2004	130
15520811	Cysteine	Kadrmas JL	The LIM domain: from the cytoskeleton to the nucleus.	Nature reviews. Molecular cell biology	2004	217
15607806	Cysteine	Smyth MJ	Activation of NK cell cytotoxicity.	Molecular immunology	2005	94
16046058	Cysteine	Liaudet-Coopman E	Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis.	Cancer letters	2006	73
16223732	Cysteine	Lu H	Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1.	The Journal of biological chemistry	2005	98
16278491	Cysteine	Basso AD	Lipid posttranslational modifications. Farnesyl transferase inhibitors.	Journal of lipid research	2006	77
16389449	Cysteine	Johannessen M	The multifunctional roles of the four-and-a-half-LIM only protein FHL2.	Cellular and molecular life sciences 	2006	74
16481467	Cysteine	Gocheva V	Distinct roles for cysteine cathepsin genes in multistage tumorigenesis.	Genes & development	2006	129
16550164	Cysteine	McIlwain CC	Glutathione S-transferase polymorphisms: cancer incidence and therapy.	Oncogene	2006	83
16990798	Cysteine	Allen MD	Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase.	The EMBO journal	2006	61
17084981	Cysteine	Hehlgans S	Signalling via integrins: implications for cell survival and anticancer strategies.	Biochimica et biophysica acta	2007	105
17235047	Cysteine	Infante JR	Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.	Journal of clinical oncology 	2007	118
17245112	Cysteine	Gocheva V	Cysteine cathepsins and the cutting edge of cancer invasion.	Cell cycle	2007	96
17440104	Cysteine	Cohen CJ	Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.	Cancer research	2007	83
17545618	Cysteine	DeAlmeida VI	The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo.	Cancer research	2007	62
17893322	Cysteine	Atcha FA	A unique DNA binding domain converts T-cell factors into strong Wnt effectors.	Molecular and cellular biology	2007	57
18193050	Cysteine	Cai G	CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.	Nature immunology	2008	94
18614539	Cysteine	Roberts PJ	Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification.	The Journal of biological chemistry	2008	97
18669893	Cysteine	Walne AJ	TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes.	Blood	2008	99
18711745	Cysteine	Junn E	Mitochondrial localization of DJ-1 leads to enhanced neuroprotection.	Journal of neuroscience research	2009	80
18824526	Cysteine	Gibbs GM	The CAP superfamily: cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins--roles in reproduction, cancer, and immune defense.	Endocrine reviews	2008	115
19381019	Cysteine	Qing J	Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.	The Journal of clinical investigation	2009	66
19426226	Cysteine	Cai G	The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.	Immunological reviews	2009	66
19567589	Cysteine	Lucio-Eterovic AK	Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.	Clinical cancer research 	2009	75
19648934	Cysteine	Dansen TB	Redox-sensitive cysteines bridge p300/CBP-mediated acetylation and FoxO4 activity.	Nature chemical biology	2009	61
19788417	Cysteine	Allan LA	Apoptosis and autophagy: Regulation of caspase-9 by phosphorylation.	The FEBS journal	2009	55
20061377	Cysteine	Fourquet S	Activation of NRF2 by nitrosative agents and H2O2 involves KEAP1 disulfide formation.	The Journal of biological chemistry	2010	81
20170166	Cysteine	Rauser S	Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry.	Journal of proteome research	2010	48
20213804	Cysteine	Sonnylal S	Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis.	Arthritis and rheumatism	2010	57
20385560	Cysteine	Doyle K	Redox signaling, alkylation (carbonylation) of conserved cysteines inactivates class I histone deacetylases 1, 2, and 3 and antagonizes their transcriptional repressor function.	The Journal of biological chemistry	2010	43
20414655	Cysteine	Ostrand-Rosenberg S	Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity.	Cancer immunology, immunotherapy 	2010	159
20421418	Cysteine	Lau A	A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62.	Molecular and cellular biology	2010	177
20480266	Cysteine	Ziyan W	MicroRNA-21 is involved in osteosarcoma cell invasion and migration.	Medical oncology	2011	48
20805300	Cysteine	Junutula JR	Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.	Clinical cancer research 	2010	50
20812780	Cysteine	Wilson MA	The role of cysteine oxidation in DJ-1 function and dysfunction.	Antioxidants & redox signaling	2011	65
21124317	Cysteine	Wang K	Integrative genomics identifies LMO1 as a neuroblastoma oncogene.	Nature	2011	95
21251164	Cysteine	Taguchi K	Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.	Genes to cells 	2011	237
21308479	Cysteine	Arvatz G	The heparanase system and tumor metastasis: is heparanase the seed and soil?	Cancer metastasis reviews	2011	39
21406728	Cysteine	Miliani de Marval PL	The RP-Mdm2-p53 pathway and tumorigenesis.	Oncotarget	2011	40
21536738	Cysteine	Shochat C	Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias.	The Journal of experimental medicine	2011	98
21856739	Cysteine	Ostman A	Regulation of protein tyrosine phosphatases by reversible oxidation.	Journal of biochemistry	2011	70
21892159	Cysteine	Zenatti PP	Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.	Nature genetics	2011	98
21931545	Cysteine	Qu L	Disruption of TLR3 signaling due to cleavage of TRIF by the hepatitis A virus protease-polymerase processing intermediate, 3CD.	PLoS pathogens	2011	41
22045338	Cysteine	Lynes EM	Palmitoylated TMX and calnexin target to the mitochondria-associated membrane.	The EMBO journal	2012	50
22056874	Cysteine	Harris LG	Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61.	Oncogene	2012	35
22200620	Cysteine	Raina D	Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells.	International journal of oncology	2012	33
22464443	Cysteine	Rafn B	ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression.	Molecular cell	2012	36
22632748	Cysteine	Vendramini-Costa DB	Molecular link mechanisms between inflammation and cancer.	Current pharmaceutical design	2012	101
22710668	Cysteine	Kypta RM	Wnt/β-catenin signalling in prostate cancer.	Nature reviews. Urology	2012	63
22988081	Cysteine	Axup JY	Synthesis of site-specific antibody-drug conjugates using unnatural amino acids.	Proceedings of the National Academy of Sciences of the United States of America	2012	89
23016862	Cysteine	Voronkov A	Wnt/beta-catenin signaling and small molecule inhibitors.	Current pharmaceutical design	2013	55
23174564	Cysteine	Goldsmith EC	Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression.	American journal of physiology. Cell physiology	2013	35
23219527	Cysteine	Bryan HK	The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation.	Biochemical pharmacology	2013	159
23333463	Cysteine	Wei Z	STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells.	Cellular signalling	2013	29
23386904	Cysteine	Magister S	Cystatins in immune system.	Journal of Cancer	2013	30
23407552	Cysteine	Meissner B	The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.	Blood	2013	28
23463012	Cysteine	Kulathu Y	Regulation of A20 and other OTU deubiquitinases by reversible oxidation.	Nature communications	2013	35
23770776	Cysteine	Kung Sutherland MS	SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.	Blood	2013	65
23881612	Cysteine	Hong KJ	RECK inhibits stemness gene expression and tumorigenicity of gastric cancer cells by suppressing ADAM-mediated Notch1 activation.	Journal of cellular physiology	2014	24
23902689	Cysteine	Brisson L	NaV1.5 Na⁺ channels allosterically regulate the NHE-1 exchanger and promote the activity of breast cancer cell invadopodia.	Journal of cell science	2013	28
23982174	Cysteine	Pidala J	Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality.	Blood	2013	26
24078004	Cysteine	Zhao H	MiR-25 promotes gastric cancer cells growth and motility by targeting RECK.	Molecular and cellular biochemistry	2014	27
24080158	Cysteine	Xavier CP	Secreted Frizzled-related protein potentiation versus inhibition of Wnt3a/β-catenin signaling.	Cellular signalling	2014	21
24256730	Cysteine	Ostrem JM	K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.	Nature	2013	221
24291792	Cysteine	Manolaridis I	Mechanism of farnesylated CAAX protein processing by the intramembrane protease Rce1.	Nature	2013	29
24469331	Cysteine	Smit JJ	RBR E3-ligases at work.	EMBO reports	2014	21
24675529	Cysteine	Nagaraju GP	Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis.	Carcinogenesis	2014	26
24677670	Cysteine	Aggarwal N	Cathepsin B: multiple roles in cancer.	Proteomics. Clinical applications	2014	25
24680817	Cysteine	Fonović M	Cysteine cathepsins and extracellular matrix degradation.	Biochimica et biophysica acta	2014	44
25002527	Cysteine	Ye P	Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.	Molecular and cellular biology	2014	24
25030448	Cysteine	van den Boomen DJ	TMEM129 is a Derlin-1 associated ERAD E3 ligase essential for virus-induced degradation of MHC-I.	Proceedings of the National Academy of Sciences of the United States of America	2014	22
25043025	Cysteine	Kwiatkowski N	Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.	Nature	2014	101
25087232	Cysteine	Yoshie O	CCR4 and its ligands: from bench to bedside.	International immunology	2015	30
25159986	Cysteine	Heyninck K	Withaferin A inhibits NF-kappaB activation by targeting cysteine 179 in IKKβ.	Biochemical pharmacology	2014	24
25172549	Cysteine	Le PN	Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28.	Pharmacology & therapeutics	2015	34
25175731	Cysteine	Yang J	Site-specific mapping and quantification of protein S-sulphenylation in cells.	Nature communications	2014	42
25228770	Cysteine	Westphal D	Apoptotic pore formation is associated with in-plane insertion of Bak or Bax central helices into the mitochondrial outer membrane.	Proceedings of the National Academy of Sciences of the United States of America	2014	26
25460271	Cysteine	Malinauskas T	Extracellular modulators of Wnt signalling.	Current opinion in structural biology	2014	21
25597503	Cysteine	Parent A	Mammalian frataxin directly enhances sulfur transfer of NFS1 persulfide to both ISCU and free thiols.	Nature communications	2015	21
25639489	Cysteine	Vanaja SK	Mechanisms of inflammasome activation: recent advances and novel insights.	Trends in cell biology	2015	60
25823923	Cysteine	Qin L	WNT5A promotes stemness characteristics in nasopharyngeal carcinoma cells leading to metastasis and tumorigenesis.	Oncotarget	2015	23
26117331	Cysteine	Suzuki T	Molecular basis of the Keap1-Nrf2 system.	Free radical biology & medicine	2015	81
26267657	Cysteine	Raina D	Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target.	PloS one	2015	17
26668317	Cysteine	Noy PJ	TspanC8 Tetraspanins and A Disintegrin and Metalloprotease 10 (ADAM10) Interact via Their Extracellular Regions: EVIDENCE FOR DISTINCT BINDING MECHANISMS FOR DIFFERENT TspanC8 PROTEINS.	The Journal of biological chemistry	2016	13
26722841	Cysteine	Heppner DE	Redox-dependent regulation of epidermal growth factor receptor signaling.	Redox biology	2016	12
26791894	Cysteine	Zhang C	Π-Clamp-mediated cysteine conjugation.	Nature chemistry	2016	19
26805760	Cysteine	Zhang L	Unraveling the roles of Atg4 proteases from autophagy modulation to targeted cancer therapy.	Cancer letters	2016	10
27027295	Cysteine	Chouchani ET	Mitochondrial ROS regulate thermogenic energy expenditure and sulfenylation of UCP1.	Nature	2016	36
27312108	Cysteine	Dove KK	Molecular insights into RBR E3 ligase ubiquitin transfer mechanisms.	EMBO reports	2016	16
27368101	Cysteine	Briggs KJ	Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine.	Cell	2016	20
27497696	Cysteine	Dinkova-Kostova AT	Keap1, the cysteine-based mammalian intracellular sensor for electrophiles and oxidants.	Archives of biochemistry and biophysics	2017	6
27571479	Cysteine	Zhang T	Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.	Nature chemical biology	2016	17
27626662	Cysteine	Yan D	STAT3 and STAT6 Signaling Pathways Synergize to Promote Cathepsin Secretion from Macrophages via IRE1α Activation.	Cell reports	2016	11
28336545	Cysteine	Karl JP	Changes in intestinal microbiota composition and metabolism coincide with increased intestinal permeability in young adults under prolonged physiological stress.	American journal of physiology. Gastrointestinal and liver physiology	2017	11
10815900	Cytarabine	Tamm I	Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.	Clinical cancer research 	2000	129
12200686	Cytarabine	Konopleva M	Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins.	Leukemia	2002	102
12393388	Cytarabine	Fröhling S	Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.	Blood	2002	139
12702506	Cytarabine	Xu Q	Survival of acute myeloid leukemia cells requires PI3 kinase activation.	Blood	2003	111
12897778	Cytarabine	Matsunaga T	Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia.	Nature medicine	2003	143
14534335	Cytarabine	Hughes TP	Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.	The New England journal of medicine	2003	177
15870183	Cytarabine	Tallman MS	Drug therapy for acute myeloid leukemia.	Blood	2005	146
16051734	Cytarabine	Döhner K	Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.	Blood	2005	147
16921041	Cytarabine	Paschka P	Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.	Journal of clinical oncology 	2006	111
17151364	Cytarabine	Druker BJ	Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.	The New England journal of medicine	2006	759
17658395	Cytarabine	Pieters R	A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.	Lancet	2007	89
19047294	Cytarabine	Büchner T	Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.	Journal of clinical oncology 	2009	53
20016527	Cytarabine	Salzer WL	Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group.	Leukemia	2010	48
20644121	Cytarabine	Lo-Coco F	Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.	Blood	2010	60
20660832	Cytarabine	Gisselbrecht C	Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.	Journal of clinical oncology 	2010	159
20841507	Cytarabine	Schwind S	BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.	Blood	2010	41
21131036	Cytarabine	Krug U	Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.	Lancet	2010	50
21175313	Cytarabine	Preudhomme C	Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.	The New England journal of medicine	2010	61
21220605	Cytarabine	Burnett A	Therapeutic advances in acute myeloid leukemia.	Journal of clinical oncology 	2011	142
21680954	Cytarabine	Altman JK	Targeting mTOR for the treatment of AML. New agents and new directions.	Oncotarget	2011	47
21937694	Cytarabine	Wey S	Inducible knockout of GRP78/BiP in the hematopoietic system suppresses Pten-null leukemogenesis and AKT oncogenic signaling.	Blood	2012	31
22180162	Cytarabine	Estey EH	Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.	American journal of hematology	2012	42
22718839	Cytarabine	Delarue R	CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.	Blood	2013	41
22753902	Cytarabine	Mendler JH	RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.	Journal of clinical oncology 	2012	51
23129738	Cytarabine	Attar EC	Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.	Journal of clinical oncology 	2013	30
23249862	Cytarabine	Herrmann H	Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.	Oncotarget	2012	45
23321257	Cytarabine	Jourdan E	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.	Blood	2013	39
23676502	Cytarabine	Chen Y	CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.	The Journal of clinical investigation	2013	49
24184825	Cytarabine	Chromik J	Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis.	Cancer letters	2014	20
24708856	Cytarabine	Palma CA	MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia.	Molecular cancer	2014	27
24870236	Cytarabine	Zahreddine HA	The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.	Nature	2014	43
25710880	Cytarabine	Mussai F	Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.	Blood	2015	17
25833957	Cytarabine	Burnett AK	A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.	Blood	2015	21
27367478	Cytarabine	De Kouchkovsky I	'Acute myeloid leukemia: a comprehensive review and 2016 update'.	Blood cancer journal	2016	24
27941792	Cytarabine	Göllner S	Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.	Nature medicine	2017	11
27991919	Cytarabine	Schneider C	SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.	Nature medicine	2017	8
28416471	Cytarabine	Farge T	Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.	Cancer discovery	2017	7
3264384	Cyclophosphamide	Rosenberg SA	Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.	The New England journal of medicine	1988	261
8028037	Cyclophosphamide	Rosenberg SA	Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.	Journal of the National Cancer Institute	1994	168
10653870	Cyclophosphamide	Kantarjian HM	Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.	Journal of clinical oncology 	2000	103
11181660	Cyclophosphamide	Ravdin PM	Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.	Journal of clinical oncology 	2001	169
11248153	Cyclophosphamide	Slamon DJ	Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.	The New England journal of medicine	2001	1772
11786909	Cyclophosphamide	Shipp MA	Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.	Nature medicine	2002	353
11807147	Cyclophosphamide	Coiffier B	CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.	The New England journal of medicine	2002	666
15016643	Cyclophosphamide	Pfreundschuh M	Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.	Blood	2004	72
15136595	Cyclophosphamide	Ayers M	Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.	Journal of clinical oncology 	2004	76
15494430	Cyclophosphamide	Marcus R	CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.	Blood	2005	108
15591112	Cyclophosphamide	Dreyling M	Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.	Blood	2005	75
15668467	Cyclophosphamide	Lenz G	Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).	Journal of clinical oncology 	2005	89
15738535	Cyclophosphamide	Buzdar AU	Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.	Journal of clinical oncology 	2005	185
15867204	Cyclophosphamide	Feugier P	Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.	Journal of clinical oncology 	2005	222
15897552	Cyclophosphamide	Mamounas EP	Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.	Journal of clinical oncology 	2005	110
15955905	Cyclophosphamide	Sehn LH	Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.	Journal of clinical oncology 	2005	144
16123223	Cyclophosphamide	Hiddemann W	Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.	Blood	2005	174
16129365	Cyclophosphamide	Berthold F	Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.	The Lancet. Oncology	2005	70
16230674	Cyclophosphamide	Fisher RI	New treatment options have changed the survival of patients with follicular lymphoma.	Journal of clinical oncology 	2005	69
16236738	Cyclophosphamide	Romond EH	Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.	The New England journal of medicine	2005	1023
16258083	Cyclophosphamide	Tan-Chiu E	Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.	Journal of clinical oncology 	2005	130
16502413	Cyclophosphamide	Thomas DA	Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.	Cancer	2006	84
16550168	Cyclophosphamide	Rodriguez-Antona C	Cytochrome P450 pharmacogenetics and cancer.	Oncogene	2006	95
16648042	Cyclophosphamide	Pfreundschuh M	CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.	The Lancet. Oncology	2006	285
16707747	Cyclophosphamide	Pritchard KI	HER2 and responsiveness of breast cancer to adjuvant chemotherapy.	The New England journal of medicine	2006	103
16720851	Cyclophosphamide	Bernstein M	Ewing's sarcoma family of tumors: current management.	The oncologist	2006	82
16754935	Cyclophosphamide	Habermann TM	Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.	Journal of clinical oncology 	2006	235
16796719	Cyclophosphamide	Fudaba Y	Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses.	American journal of transplantation 	2006	72
16809727	Cyclophosphamide	Perez EA	HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.	Journal of clinical oncology 	2006	87
16820385	Cyclophosphamide	Anderson RA	The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer.	Human reproduction	2006	61
16873669	Cyclophosphamide	van Oers MH	Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.	Blood	2006	85
16899602	Cyclophosphamide	Generali D	Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.	Clinical cancer research 	2006	78
16960692	Cyclophosphamide	Ghiringhelli F	Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.	Cancer immunology, immunotherapy 	2007	277
17008537	Cyclophosphamide	Kay NE	Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.	Blood	2007	78
17066459	Cyclophosphamide	Houghton PJ	The pediatric preclinical testing program: description of models and early testing results.	Pediatric blood & cancer	2007	188
17116940	Cyclophosphamide	Yakoub-Agha I	Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy.	Journal of clinical oncology 	2006	62
17132719	Cyclophosphamide	Patte C	Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.	Blood	2007	64
17138821	Cyclophosphamide	Cairo MS	Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.	Blood	2007	58
17200359	Cyclophosphamide	Buzdar AU	Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.	Clinical cancer research 	2007	94
17234791	Cyclophosphamide	Hou DY	Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.	Cancer research	2007	146
17284714	Cyclophosphamide	Hershman D	Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.	Journal of the National Cancer Institute	2007	72
17388661	Cyclophosphamide	Bertheau P	Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.	PLoS medicine	2007	55
17438091	Cyclophosphamide	Carey LA	The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.	Clinical cancer research 	2007	472
17928597	Cyclophosphamide	Hayes DF	HER2 and response to paclitaxel in node-positive breast cancer.	The New England journal of medicine	2007	139
18165643	Cyclophosphamide	Garcia AA	Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.	Journal of clinical oncology 	2008	135
18226581	Cyclophosphamide	Pfreundschuh M	Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).	The Lancet. Oncology	2008	154
18250349	Cyclophosphamide	Perez EA	Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.	Journal of clinical oncology 	2008	105
18281474	Cyclophosphamide	Furuta E	Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1.	Cancer research	2008	91
18316569	Cyclophosphamide	Laheru D	Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.	Clinical cancer research 	2008	106
18378569	Cyclophosphamide	Wilson WH	Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.	Journal of clinical oncology 	2008	58
18446337	Cyclophosphamide	Diaz-Montero CM	Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.	Cancer immunology, immunotherapy 	2009	342
18505968	Cyclophosphamide	Martín M	Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.	Journal of the National Cancer Institute	2008	51
18662969	Cyclophosphamide	Marcus R	Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.	Journal of clinical oncology 	2008	91
18756521	Cyclophosphamide	Castillo J	HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases.	American journal of hematology	2008	51
19038878	Cyclophosphamide	Lenz G	Stromal gene signatures in large-B-cell lymphomas.	The New England journal of medicine	2008	349
19075267	Cyclophosphamide	Yeo W	Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.	Journal of clinical oncology 	2009	99
19085934	Cyclophosphamide	Slominski A	Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells.	International journal of cancer	2009	54
19225538	Cyclophosphamide	Reeder CB	Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.	Leukemia	2009	51
19318486	Cyclophosphamide	Munster P	Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.	Clinical cancer research 	2009	47
19704118	Cyclophosphamide	Savage KJ	MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.	Blood	2009	112
19706817	Cyclophosphamide	Choi WW	A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.	Clinical cancer research 	2009	115
19770373	Cyclophosphamide	Arndt CA	Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.	Journal of clinical oncology 	2009	56
19805669	Cyclophosphamide	Emens LA	Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.	Journal of clinical oncology 	2009	74
19925877	Cyclophosphamide	Kasamon YL	Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.	Biology of blood and marrow transplantation 	2010	60
19961944	Cyclophosphamide	Symons HJ	Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.	Biology of blood and marrow transplantation 	2010	41
20113825	Cyclophosphamide	Gianni L	Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.	Lancet	2010	184
20152770	Cyclophosphamide	Balamuth NJ	Ewing's sarcoma.	The Lancet. Oncology	2010	108
20385988	Cyclophosphamide	Ziepert M	Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.	Journal of clinical oncology 	2010	81
20439641	Cyclophosphamide	van Oers MH	Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.	Journal of clinical oncology 	2010	48
20498406	Cyclophosphamide	Barrans S	Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.	Journal of clinical oncology 	2010	77
20528872	Cyclophosphamide	Romaguera JE	Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.	British journal of haematology	2010	46
20548096	Cyclophosphamide	Coiffier B	Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.	Blood	2010	169
20631380	Cyclophosphamide	Campbell KJ	Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.	Blood	2010	44
20660290	Cyclophosphamide	Schmitz N	Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.	Blood	2010	55
20660823	Cyclophosphamide	Thomas DA	Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.	Journal of clinical oncology 	2010	53
20664527	Cyclophosphamide	Koski A	Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.	Molecular therapy 	2010	72
20697084	Cyclophosphamide	Perez EA	HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.	Journal of clinical oncology 	2010	53
20829329	Cyclophosphamide	Tabchy A	Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.	Clinical cancer research 	2010	56
21030533	Cyclophosphamide	Flowers CR	Improving outcomes for patients with diffuse large B-cell lymphoma.	CA	2010	55
21109570	Cyclophosphamide	Tamura K	FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.	Annals of oncology 	2011	47
21135273	Cyclophosphamide	Meyer PN	Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.	Journal of clinical oncology 	2011	78
21148486	Cyclophosphamide	Viaud S	Cyclophosphamide induces differentiation of Th17 cells in cancer patients.	Cancer research	2011	40
21189393	Cyclophosphamide	Ruan J	Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.	Journal of clinical oncology 	2011	56
21189395	Cyclophosphamide	Press MF	Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.	Journal of clinical oncology 	2011	51
21482186	Cyclophosphamide	Peyrade F	Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.	The Lancet. Oncology	2011	42
21512138	Cyclophosphamide	Ling S	An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer.	Cancer research	2011	37
21611872	Cyclophosphamide	Sistigu A	Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.	Seminars in immunopathology	2011	65
21690475	Cyclophosphamide	Slingluff CL Jr	Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.	Journal of clinical oncology 	2011	40
21768458	Cyclophosphamide	Perez EA	Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.	Journal of clinical oncology 	2011	155
21788566	Cyclophosphamide	Untch M	Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.	Journal of clinical oncology 	2011	77
21849486	Cyclophosphamide	Brentjens RJ	Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.	Blood	2011	308
21917518	Cyclophosphamide	Di Leo A	HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.	The Lancet. Oncology	2011	36
21933893	Cyclophosphamide	Iqbal J	BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.	Clinical cancer research 	2011	37
22151962	Cyclophosphamide	West NR	Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.	Breast cancer research 	2011	92
22172323	Cyclophosphamide	Jensen JD	PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.	Annals of oncology 	2012	37
22231041	Cyclophosphamide	Munster PN	Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.	Journal of clinical oncology 	2012	33
22276820	Cyclophosphamide	von Minckwitz G	Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.	The New England journal of medicine	2012	104
22308288	Cyclophosphamide	Till BG	CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.	Blood	2012	107
22337718	Cyclophosphamide	Müller C	The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.	Blood	2012	37
22351696	Cyclophosphamide	Cheang MC	Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.	Clinical cancer research 	2012	37
22393002	Cyclophosphamide	Chapuis AG	Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.	Proceedings of the National Academy of Sciences of the United States of America	2012	54
22451162	Cyclophosphamide	Quek AM	Autoimmune epilepsy: clinical characteristics and response to immunotherapy.	Archives of neurology	2012	47
22665537	Cyclophosphamide	Green TM	Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.	Journal of clinical oncology 	2012	91
22721387	Cyclophosphamide	Tang Z	The role of mesothelin in tumor progression and targeted therapy.	Anti-cancer agents in medicinal chemistry	2013	27
22842478	Cyclophosphamide	Walter S	Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.	Nature medicine	2012	236
22851556	Cyclophosphamide	d'Amore F	Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.	Journal of clinical oncology 	2012	55
22851565	Cyclophosphamide	Johnson NA	Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.	Journal of clinical oncology 	2012	110
22884505	Cyclophosphamide	Ismael G	Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.	The Lancet. Oncology	2012	43
22911837	Cyclophosphamide	Li ZM	Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.	PloS one	2012	36
22926690	Cyclophosphamide	Sparano JA	Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer.	Cancer	2012	49
22955915	Cyclophosphamide	Xu-Monette ZY	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.	Blood	2012	51
22987084	Cyclophosphamide	Romond EH	Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2012	72
23057966	Cyclophosphamide	Cang S	Novel CD20 monoclonal antibodies for lymphoma therapy.	Journal of hematology & oncology	2012	36
23233710	Cyclophosphamide	Press OW	Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.	Journal of clinical oncology 	2013	34
23255238	Cyclophosphamide	Gorlick R	Children's Oncology Group's 2013 blueprint for research: bone tumors.	Pediatric blood & cancer	2013	34
23335369	Cyclophosphamide	Horn H	MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.	Blood	2013	79
23449635	Cyclophosphamide	Hu S	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.	Blood	2013	85
23490655	Cyclophosphamide	Harbeck N	Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.	European journal of cancer	2013	28
23578722	Cyclophosphamide	Delarue R	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.	The Lancet. Oncology	2013	31
23615461	Cyclophosphamide	Cunningham D	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.	Lancet	2013	38
24136883	Cyclophosphamide	Gerber B	Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).	Annals of oncology 	2013	26
24171516	Cyclophosphamide	Stiff PJ	Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.	The New England journal of medicine	2013	34
24220563	Cyclophosphamide	Huang X	Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP.	Journal of clinical oncology 	2013	35
24225944	Cyclophosphamide	Kanakry CG	Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide.	Science translational medicine	2013	55
24331154	Cyclophosphamide	Butts C	Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.	The Lancet. Oncology	2014	77
24336156	Cyclophosphamide	Tzankov A	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.	Modern pathology 	2014	27
24443618	Cyclophosphamide	Prat A	Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.	Clinical cancer research 	2014	33
24485462	Cyclophosphamide	Pallasch CP	Sensitizing protective tumor microenvironments to antibody-mediated therapy.	Cell	2014	27
24506200	Cyclophosphamide	Perry AM	MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.	British journal of haematology	2014	32
24591201	Cyclophosphamide	Flinn IW	Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.	Blood	2014	50
24652989	Cyclophosphamide	Stilgenbauer S	Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.	Blood	2014	60
24669015	Cyclophosphamide	Gonzalez-Angulo AM	Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.	Annals of oncology 	2014	22
24942756	Cyclophosphamide	Lutz ER	Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.	Cancer immunology research	2014	70
24943107	Cyclophosphamide	Oki Y	Double hit lymphoma: the MD Anderson Cancer Center clinical experience.	British journal of haematology	2014	31
25006130	Cyclophosphamide	Ellin F	Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.	Blood	2014	22
25239573	Cyclophosphamide	Green DM	Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study.	The Lancet. Oncology	2014	20
25332249	Cyclophosphamide	Perez EA	Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.	Journal of clinical oncology 	2014	88
25415283	Cyclophosphamide	Soares KC	PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.	Journal of immunotherapy	2015	66
25499448	Cyclophosphamide	Sehn LH	Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.	Blood	2015	50
25584002	Cyclophosphamide	Le DT	Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.	Journal of clinical oncology 	2015	101
25687405	Cyclophosphamide	Acharya MM	Stem cell transplantation reverses chemotherapy-induced cognitive dysfunction.	Cancer research	2015	16
25738670	Cyclophosphamide	Robak T	Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.	The New England journal of medicine	2015	37
26039205	Cyclophosphamide	Bacigalupo A	Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update.	Bone marrow transplantation	2015	17
26124482	Cyclophosphamide	Casulo C	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.	Journal of clinical oncology 	2015	36
26130705	Cyclophosphamide	Ciurea SO	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.	Blood	2015	62
26240231	Cyclophosphamide	Scott DW	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.	Journal of clinical oncology 	2015	26
26256760	Cyclophosphamide	Pastore A	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.	The Lancet. Oncology	2015	40
26304893	Cyclophosphamide	Gaspar N	Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.	Journal of clinical oncology 	2015	46
26341397	Cyclophosphamide	Blaise D	Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor.	Biology of blood and marrow transplantation 	2016	14
26359881	Cyclophosphamide	Bashey A	Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index.	Biology of blood and marrow transplantation 	2016	20
26469139	Cyclophosphamide	Perez EA	Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.	JAMA oncology	2016	16
26578779	Cyclophosphamide	Tolaney SM	Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.	Proceedings of the National Academy of Sciences of the United States of America	2015	32
26738796	Cyclophosphamide	Singh N	Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies.	Science translational medicine	2016	18
26860465	Cyclophosphamide	Naipal KA	Tumor slice culture system to assess drug response of primary breast cancer.	BMC cancer	2016	11
27270177	Cyclophosphamide	Ramos CA	Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.	The Journal of clinical investigation	2016	23
27325862	Cyclophosphamide	Colleoni M	Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.	Journal of clinical oncology 	2016	13
27605551	Cyclophosphamide	Turtle CJ	Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.	Science translational medicine	2016	48
28135148	Cyclophosphamide	Symmans WF	Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.	Journal of clinical oncology 	2017	11
28298546	Cyclophosphamide	Lee H	64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.	Clinical cancer research 	2017	10
28679654	Cyclophosphamide	Karagiannis GS	Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism.	Science translational medicine	2017	7
1360704	Doxorubicin	Cole SP	Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line.	Science	1992	351
8673929	Doxorubicin	Aas T	Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.	Nature medicine	1996	143
9661897	Doxorubicin	Baselga J	Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.	Cancer research	1998	130
9799222	Doxorubicin	Jäättelä M	Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases.	The EMBO journal	1998	127
9831867	Doxorubicin	Ross JS	The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.	Stem cells	1998	110
10029595	Doxorubicin	Damiano JS	Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.	Blood	1999	166
10080586	Doxorubicin	Kuerer HM	Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.	Journal of clinical oncology 	1999	225
10458228	Doxorubicin	Van Glabbeke M	Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.	Journal of clinical oncology 	1999	96
10802708	Doxorubicin	Teitz T	Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN.	Nature medicine	2000	154
11948130	Doxorubicin	Park JW	Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.	Clinical cancer research 	2002	106
12203114	Doxorubicin	Budanov AV	Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability.	Oncogene	2002	90
15054096	Doxorubicin	Wang S	Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways.	The Journal of biological chemistry	2004	97
15756033	Doxorubicin	Cohen BD	Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.	Clinical cancer research 	2005	86
15784621	Doxorubicin	Misra S	Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2.	The Journal of biological chemistry	2005	67
15899824	Doxorubicin	Frank NY	ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma.	Cancer research	2005	139
16115903	Doxorubicin	Rouzier R	Breast cancer molecular subtypes respond differently to preoperative chemotherapy.	Clinical cancer research 	2005	370
16170171	Doxorubicin	Hershman D	Racial disparities in treatment and survival among women with early-stage breast cancer.	Journal of clinical oncology 	2005	93
16258084	Doxorubicin	Ewer MS	Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.	Journal of clinical oncology 	2005	106
16569192	Doxorubicin	Fu X	Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1.	DNA and cell biology	2006	70
16854453	Doxorubicin	McCubrey JA	Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.	Advances in enzyme regulation	2006	168
16912156	Doxorubicin	Lee E	GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer.	Cancer research	2006	75
17135249	Doxorubicin	Sylvestre Y	An E2F/miR-20a autoregulatory feedback loop.	The Journal of biological chemistry	2007	215
17239480	Doxorubicin	Varela M	Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.	Journal of hepatology	2007	155
17415413	Doxorubicin	Biswas S	Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.	The Journal of clinical investigation	2007	100
17692808	Doxorubicin	Deng J	BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.	Cancer cell	2007	183
17823410	Doxorubicin	Corney DC	MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.	Cancer research	2007	223
17875789	Doxorubicin	Stein R	CD74: a new candidate target for the immunotherapy of B-cell neoplasms.	Clinical cancer research 	2007	56
17875987	Doxorubicin	Tazawa H	Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2007	294
17965883	Doxorubicin	Clark JC	A review of clinical and molecular prognostic factors in osteosarcoma.	Journal of cancer research and clinical oncology	2008	62
17974990	Doxorubicin	Sankala HM	Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin.	Cancer research	2007	60
18039953	Doxorubicin	Nefedova Y	Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy.	Blood	2008	54
18258979	Doxorubicin	Sparano JA	Development of the 21-gene assay and its application in clinical practice and clinical trials.	Journal of clinical oncology 	2008	127
18332865	Doxorubicin	Steelman LS	Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.	Oncogene	2008	51
18574145	Doxorubicin	Burgess DJ	Topoisomerase levels determine chemotherapy response in vitro and in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2008	87
18582981	Doxorubicin	Kratz F	Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.	Journal of controlled release 	2008	196
18619946	Doxorubicin	Zhu H	Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells.	Biochemical pharmacology	2008	113
18645006	Doxorubicin	Sullivan R	Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity.	Molecular cancer therapeutics	2008	53
18645025	Doxorubicin	Kovalchuk O	Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.	Molecular cancer therapeutics	2008	147
18758960	Doxorubicin	Tsang WP	Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3.	Apoptosis 	2008	65
18818206	Doxorubicin	Nasser MW	Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1.	The Journal of biological chemistry	2008	137
19025451	Doxorubicin	Saad M	Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.	Nanomedicine	2008	63
19156211	Doxorubicin	Mahller YY	Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus.	PloS one	2009	52
19188143	Doxorubicin	Yang JY	A new fork for clinical application: targeting forkhead transcription factors in cancer.	Clinical cancer research 	2009	83
19276287	Doxorubicin	Magnifico A	Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab.	Clinical cancer research 	2009	81
19336515	Doxorubicin	Li QQ	Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells.	Clinical cancer research 	2009	91
19380866	Doxorubicin	Dunleavy K	Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.	Blood	2009	111
19584283	Doxorubicin	Fornari F	MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.	Cancer research	2009	117
19780069	Doxorubicin	Chen AM	Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells.	Small	2009	89
19839049	Doxorubicin	Tryndyak VP	E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells.	International journal of cancer	2010	62
19840887	Doxorubicin	Fleming GF	Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.	Gynecologic oncology	2010	43
19883630	Doxorubicin	Liang Z	Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1.	Biochemical pharmacology	2010	82
20038740	Doxorubicin	De Angelis A	Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function.	Circulation	2010	70
20098429	Doxorubicin	Li Y	Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer.	Nature medicine	2010	94
20181615	Doxorubicin	Chen WC	In vivo targeting of B-cell lymphoma with glycan ligands of CD22.	Blood	2010	51
20224986	Doxorubicin	Liu T	Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.	Molecular and cellular biochemistry	2010	43
20388796	Doxorubicin	Yoo BK	Molecular mechanism of chemoresistance by astrocyte elevated gene-1.	Cancer research	2010	46
20434400	Doxorubicin	Issels RD	Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.	The Lancet. Oncology	2010	77
20442777	Doxorubicin	Bandyopadhyay A	Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models.	PloS one	2010	50
20460382	Doxorubicin	Chen Y	Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.	The Journal of biological chemistry	2010	43
20460510	Doxorubicin	Adhikari AS	CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance.	Cancer research	2010	80
20501828	Doxorubicin	Fornari F	MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.	Cancer research	2010	129
20668064	Doxorubicin	Zhang X	Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway.	Cancer research	2010	48
20682318	Doxorubicin	Cheung ST	Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance.	Gastroenterology	2011	40
20689555	Doxorubicin	Aoubala M	p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage.	Cell death and differentiation	2011	36
20706768	Doxorubicin	Slack JL	Protein arginine deiminase 4: a target for an epigenetic cancer therapy.	Cellular and molecular life sciences 	2011	36
20731437	Doxorubicin	Meng H	Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line.	ACS nano	2010	106
20798686	Doxorubicin	Li QQ	Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells.	Cell death and differentiation	2011	45
20935265	Doxorubicin	Calcagno AM	Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.	Journal of the National Cancer Institute	2010	76
21055388	Doxorubicin	Henry JC	miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines.	Biochemical and biophysical research communications	2010	48
21070600	Doxorubicin	Feng DD	Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia.	Journal of cellular and molecular medicine	2011	38
21342659	Doxorubicin	Savla R	Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer.	Journal of controlled release 	2011	47
21527554	Doxorubicin	Chen J	Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth.	Cancer research	2011	42
21562218	Doxorubicin	Buti L	Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host.	Proceedings of the National Academy of Sciences of the United States of America	2011	38
21565979	Doxorubicin	Tsuchiya N	Tumor suppressor miR-22 determines p53-dependent cellular fate through post-transcriptional regulation of p21.	Cancer research	2011	41
21591812	Doxorubicin	Agarwal A	Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods.	ACS nano	2011	38
21627074	Doxorubicin	Xiong XB	Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin.	ACS nano	2011	55
21642992	Doxorubicin	Hung T	Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters.	Nature genetics	2011	323
21646474	Doxorubicin	Mattarollo SR	Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors.	Cancer research	2011	73
21953503	Doxorubicin	Zhu Y	Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5.	Clinical cancer research 	2011	54
21996747	Doxorubicin	Lo PK	CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.	Oncogene	2012	53
22101791	Doxorubicin	Chen J	Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer.	Medical oncology	2012	30
22217342	Doxorubicin	Doublier S	HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast.	BMC cancer	2012	32
22281424	Doxorubicin	Xiao Y	Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging.	Biomaterials	2012	42
22308459	Doxorubicin	Meirelles K	Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.	Proceedings of the National Academy of Sciences of the United States of America	2012	39
22349704	Doxorubicin	Hagenbuchner J	FOXO3-induced reactive oxygen species are regulated by BCL2L11 (Bim) and SESN3.	Journal of cell science	2012	44
22461640	Doxorubicin	Munson JM	Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma.	Science translational medicine	2012	37
22521303	Doxorubicin	Bao L	Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298.	The American journal of pathology	2012	42
22673234	Doxorubicin	Shatz M	The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells.	Cancer research	2012	35
22698404	Doxorubicin	Jackson JG	p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.	Cancer cell	2012	72
22773548	Doxorubicin	Chen HP	Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies.	Gut	2013	68
22817844	Doxorubicin	Liu Z	Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro.	Journal of translational medicine	2012	30
22952218	Doxorubicin	Manzoor AA	Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors.	Cancer research	2012	61
23277563	Doxorubicin	Hirsch HA	Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth.	Proceedings of the National Academy of Sciences of the United States of America	2013	106
23278683	Doxorubicin	Tacar O	Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems.	The Journal of pharmacy and pharmacology	2013	184
23289892	Doxorubicin	Meng H	Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.	ACS nano	2013	68
23411815	Doxorubicin	Piegari E	Doxorubicin induces senescence and impairs function of human cardiac progenitor cells.	Basic research in cardiology	2013	30
23509280	Doxorubicin	Wang D	Methylation of SUV39H1 by SET7/9 results in heterochromatin relaxation and genome instability.	Proceedings of the National Academy of Sciences of the United States of America	2013	32
23526568	Doxorubicin	Qu J	MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA.	Journal of cellular physiology	2015	16
23563091	Doxorubicin	Gao AM	Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway.	Carcinogenesis	2013	26
23648833	Doxorubicin	Taratula O	Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA.	Journal of controlled release 	2013	35
23715267	Doxorubicin	Pang B	Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin.	Nature communications	2013	46
23760062	Doxorubicin	Yang G	Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1.	Oncology reports	2013	25
23776241	Doxorubicin	Loi S	CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	61
23801752	Doxorubicin	Oehme I	Histone deacetylase 10 promotes autophagy-mediated cell survival.	Proceedings of the National Academy of Sciences of the United States of America	2013	35
24078252	Doxorubicin	Akdemir KC	Genome-wide profiling reveals stimulus-specific functions of p53 during differentiation and DNA damage of human embryonic stem cells.	Nucleic acids research	2014	30
24211739	Doxorubicin	Xu L	MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.	Journal of hepatology	2014	35
24291281	Doxorubicin	Ky B	Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.	Journal of the American College of Cardiology	2014	52
24565101	Doxorubicin	Zhao N	MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3.	Molecular cancer	2014	32
24565525	Doxorubicin	Deng X	Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.	Biomaterials	2014	41
24637463	Doxorubicin	Kratz F	A clinical update of using albumin as a drug vehicle - a commentary.	Journal of controlled release 	2014	23
24733904	Doxorubicin	Ma X	Essential role for TrpC5-containing extracellular vesicles in breast cancer with chemotherapeutic resistance.	Proceedings of the National Academy of Sciences of the United States of America	2014	22
24786471	Doxorubicin	Jiang L	MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway.	FEBS letters	2014	24
24788655	Doxorubicin	Ouyang M	MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.	PloS one	2014	38
24913980	Doxorubicin	Soriani A	Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1.	Journal of immunology	2014	23
24937669	Doxorubicin	Golfieri R	Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma.	British journal of cancer	2014	40
24958102	Doxorubicin	Wang Y	Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines.	Molecular and cellular biology	2014	29
24991836	Doxorubicin	Barnard RA	Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma.	Autophagy	2014	41
25079333	Doxorubicin	Tavora B	Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy.	Nature	2014	21
25215490	Doxorubicin	Wang G	P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage.	Cell	2014	35
25292190	Doxorubicin	Xu M	miR-382 inhibits osteosarcoma metastasis and relapse by targeting Y box-binding protein 1.	Molecular therapy 	2015	18
25330770	Doxorubicin	Liu JC	Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.	EMBO molecular medicine	2014	25
25368020	Doxorubicin	Park EY	Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance.	Cancer research	2014	38
25407491	Doxorubicin	Zhang Y	miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.	Tumour biology 	2015	17
25504623	Doxorubicin	Jiang T	Furin-mediated sequential delivery of anticancer cytokine and small-molecule drug shuttled by graphene.	Advanced materials	2015	21
25512109	Doxorubicin	Amornsupak K	Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells.	BMC cancer	2014	26
25605897	Doxorubicin	Poruchynsky MS	Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins.	Proceedings of the National Academy of Sciences of the United States of America	2015	25
25675296	Doxorubicin	Moriwaki K	Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death.	Cell death & disease	2015	18
25714029	Doxorubicin	Zhang H	miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression.	Oncotarget	2015	16
25726524	Doxorubicin	Rincón R	PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.	Oncotarget	2015	18
25727016	Doxorubicin	Zhang Y	MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1.	Biochemical and biophysical research communications	2015	19
25789975	Doxorubicin	Hall JR	Long noncoding RNA lincRNA-p21 is the major mediator of UVB-induced and p53-dependent apoptosis in keratinocytes.	Cell death & disease	2015	16
25823028	Doxorubicin	Xi G	CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro.	Oncogene	2016	15
25895646	Doxorubicin	Rochette L	Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms.	Trends in pharmacological sciences	2015	15
25909227	Doxorubicin	Go H	MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.	Oncotarget	2015	20
25950484	Doxorubicin	Roca-Alonso L	Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in β-adrenergic signaling and enhances apoptosis.	Cell death & disease	2015	21
26004286	Doxorubicin	Rao W	Chitosan-Decorated Doxorubicin-Encapsulated Nanoparticle Targets and Eliminates Tumor Reinitiating Cancer Stem-like Cells.	ACS nano	2015	22
26028030	Doxorubicin	Niu J	Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer.	Oncogene	2016	19
26041409	Doxorubicin	Tan Q	Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy.	Cancer science	2015	19
26447779	Doxorubicin	Abegglen LM	Potential Mechanisms for Cancer Resistance in Elephants and Comparative Cellular Response to DNA Damage in Humans.	JAMA	2015	41
26552700	Doxorubicin	Picaud S	Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.	Cancer research	2015	36
26572075	Doxorubicin	Zheng Y	MiR-181b promotes chemoresistance in breast cancer by regulating Bim expression.	Oncology reports	2016	11
26781446	Doxorubicin	Shang C	Long noncoding RNA HOTAIR is a prognostic biomarker and inhibits chemosensitivity to doxorubicin in bladder transitional cell carcinoma.	Cancer chemotherapy and pharmacology	2016	13
26876203	Doxorubicin	Zhang ZM	Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt/β-catenin pathway.	Oncogene	2016	11
27056384	Doxorubicin	Shang C	Silence of long noncoding RNA UCA1 inhibits malignant proliferation and chemotherapy resistance to adriamycin in gastric cancer.	Cancer chemotherapy and pharmacology	2016	21
27279912	Doxorubicin	Wang C	Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.	Theranostics	2016	15
27286459	Doxorubicin	Murakami T	Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.	Oncotarget	2016	23
27694794	Doxorubicin	Fang Q	Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b.	Medical science monitor 	2016	11
27746366	Doxorubicin	Shen H	MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.	Gene	2017	7
28079894	Doxorubicin	Jin F	MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy.	Cell death & disease	2017	16
28126034	Doxorubicin	Xu J	Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer.	Journal of experimental & clinical cancer research 	2017	9
28323030	Doxorubicin	Zhang CL	Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2.	Cancer letters	2017	11
7972132	Cytidine	Lee WH	Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis.	Proceedings of the National Academy of Sciences of the United States of America	1994	134
12732658	Cytidine	Okazaki IM	Constitutive expression of AID leads to tumorigenesis.	The Journal of experimental medicine	2003	132
15019779	Cytidine	Beale RC	Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo.	Journal of molecular biology	2004	142
15911774	Cytidine	Löchelt M	The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein.	Proceedings of the National Academy of Sciences of the United States of America	2005	87
16729314	Cytidine	Bonvin M	Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication.	Hepatology	2006	87
17126871	Cytidine	Xu H	Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions.	Virology	2007	59
17353367	Cytidine	Lenz G	Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma.	The Journal of experimental medicine	2007	58
17560275	Cytidine	Chaudhuri J	Evolution of the immunoglobulin heavy chain class switch recombination mechanism.	Advances in immunology	2007	123
18066064	Cytidine	Pasqualucci L	AID is required for germinal center-derived lymphomagenesis.	Nature genetics	2008	135
18403710	Cytidine	Vartanian JP	Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions.	Science	2008	102
18598372	Cytidine	Conticello SG	The AID/APOBEC family of nucleic acid mutators.	Genome biology	2008	167
18678733	Cytidine	Takizawa M	AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development.	The Journal of experimental medicine	2008	71
18762567	Cytidine	de Yébenes VG	miR-181b negatively regulates activation-induced cytidine deaminase in B cells.	The Journal of experimental medicine	2008	81
19070574	Cytidine	Robbiani DF	AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations.	Cell	2008	156
19109396	Cytidine	Pery E	Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif.	Journal of virology	2009	54
19364882	Cytidine	Robert I	Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination.	The Journal of experimental medicine	2009	61
19941823	Cytidine	Robbiani DF	AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations.	Molecular cell	2009	100
19962179	Cytidine	Lin C	Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer.	Cell	2009	230
20219927	Cytidine	Mbisa JL	APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms.	Journal of virology	2010	63
20308164	Cytidine	Refsland EW	Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction.	Nucleic acids research	2010	154
21368204	Cytidine	Suspène R	Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism.	Proceedings of the National Academy of Sciences of the United States of America	2011	67
21762814	Cytidine	Pavri R	AID targeting in antibody diversity.	Advances in immunology	2011	57
21962510	Cytidine	Klein IA	Translocation-capture sequencing reveals the extent and nature of chromosomal rearrangements in B lymphocytes.	Cell	2011	133
21962511	Cytidine	Chiarle R	Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells.	Cell	2011	147
22260300	Cytidine	Magrath I	Epidemiology: clues to the pathogenesis of Burkitt lymphoma.	British journal of haematology	2012	31
22343534	Cytidine	Lohr JG	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.	Proceedings of the National Academy of Sciences of the United States of America	2012	260
22796521	Cytidine	Chiba T	Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation.	Gastroenterology	2012	79
23181381	Cytidine	Zan H	Regulation of Aicda expression and AID activity.	Autoimmunity	2013	28
23352430	Cytidine	Barlow JH	Identification of early replicating fragile sites that contribute to genome instability.	Cell	2013	94
23852168	Cytidine	Burns MB	Evidence for APOBEC3B mutagenesis in multiple human cancers.	Nature genetics	2013	179
23852170	Cytidine	Roberts SA	An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.	Nature genetics	2013	237
24507154	Cytidine	Matthews AJ	Regulation of immunoglobulin class-switch recombination: choreography of noncoding transcription, targeted DNA deamination, and long-range DNA repair.	Advances in immunology	2014	32
24670820	Cytidine	Olivier M	Modelling mutational landscapes of human cancers in vitro.	Scientific reports	2014	20
24728294	Cytidine	Nik-Zainal S	Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.	Nature genetics	2014	70
24858917	Cytidine	Ohba K	In vivo and in vitro studies suggest a possible involvement of HPV infection in the early stage of breast carcinogenesis via APOBEC3B induction.	PloS one	2014	26
25298230	Cytidine	Caval V	A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage.	Nature communications	2014	33
25355878	Cytidine	Warren CJ	APOBEC3A functions as a restriction factor of human papillomavirus.	Journal of virology	2015	38
25483776	Cytidine	Meng FL	Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability.	Cell	2014	54
25483777	Cytidine	Qian J	B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity.	Cell	2014	71
25730878	Cytidine	Cescon DW	APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation.	Proceedings of the National Academy of Sciences of the United States of America	2015	38
26258849	Cytidine	Chan K	An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.	Nature genetics	2015	49
26476745	Cytidine	Tsuboi M	APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.	Breast cancer	2016	10
26608778	Cytidine	Knisbacher BA	DNA Editing by APOBECs: A Genomic Preserver and Transformer.	Trends in genetics 	2016	15
26638776	Cytidine	Kasar S	Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution.	Nature communications	2015	22
26832400	Cytidine	Hoopes JI	APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication.	Cell reports	2016	24
26898111	Cytidine	Casellas R	Mutations, kataegis and translocations in B cells: understanding AID promiscuous activity.	Nature reviews. Immunology	2016	23
27149507	Cytidine	Sharma S	Transient overexpression of exogenous APOBEC3A causes C-to-U RNA editing of thousands of genes.	RNA biology	2017	7
27798611	Cytidine	Hess GT	Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells.	Nature methods	2016	27
9761805	Androgen Antagonists	Eisenberger MA	Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.	The New England journal of medicine	1998	131
14702632	Androgen Antagonists	Chen CD	Molecular determinants of resistance to antiandrogen therapy.	Nature medicine	2004	675
15082523	Androgen Antagonists	Heinlein CA	Androgen receptor in prostate cancer.	Endocrine reviews	2004	410
17404365	Androgen Antagonists	Loblaw DA	Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.	Journal of clinical oncology 	2007	105
18674639	Androgen Antagonists	Chen Y	Targeting the androgen receptor pathway in prostate cancer.	Current opinion in pharmacology	2008	143
19447877	Androgen Antagonists	Attar RM	Castration-resistant prostate cancer: locking up the molecular escape routes.	Clinical cancer research 	2009	65
19996060	Androgen Antagonists	Keating NL	Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.	Journal of the National Cancer Institute	2010	109
21871711	Androgen Antagonists	Pagliarulo V	Contemporary role of androgen deprivation therapy for prostate cancer.	European urology	2012	34
23580326	Androgen Antagonists	Balbas MD	Overcoming mutation-based resistance to antiandrogens with rational drug design.	eLife	2013	92
24027196	Androgen Antagonists	Polkinghorn WR	Androgen receptor signaling regulates DNA repair in prostate cancers.	Cancer discovery	2013	69
25484142	Androgen Antagonists	Bosco C	Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.	European urology	2015	16
26383955	Androgen Antagonists	Miyamoto DT	RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.	Science	2015	104
26509855	Androgen Antagonists	Goodman NF	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.	Endocrine practice 	2015	18
28059767	Androgen Antagonists	Ku SY	Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.	Science	2017	36
8358726	Antineoplastic Agents	Kaufmann SH	Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis.	Cancer research	1993	281
8649519	Antineoplastic Agents	Waldman T	Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21.	Nature	1996	134
9841917	Antineoplastic Agents	Müller M	p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs.	The Journal of experimental medicine	1998	123
10446993	Antineoplastic Agents	Chang BD	A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents.	Cancer research	1999	119
12639809	Antineoplastic Agents	Maeda H	Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications.	International immunopharmacology	2003	83
12676586	Antineoplastic Agents	Dolma S	Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells.	Cancer cell	2003	103
14561896	Antineoplastic Agents	Bocci G	Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.	Proceedings of the National Academy of Sciences of the United States of America	2003	88
14998492	Antineoplastic Agents	Ren J	Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents.	Cancer cell	2004	114
15141023	Antineoplastic Agents	Powis G	Hypoxia inducible factor-1alpha as a cancer drug target.	Molecular cancer therapeutics	2004	75
15231248	Antineoplastic Agents	Grommes C	Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists.	The Lancet. Oncology	2004	101
15477595	Antineoplastic Agents	Vannini A	Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.	Proceedings of the National Academy of Sciences of the United States of America	2004	136
15523088	Antineoplastic Agents	Studeny M	Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.	Journal of the National Cancer Institute	2004	237
16146333	Antineoplastic Agents	Mao Q	Role of the breast cancer resistance protein (ABCG2) in drug transport.	The AAPS journal	2005	86
16243973	Antineoplastic Agents	Zhao Y	Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.	Proceedings of the National Academy of Sciences of the United States of America	2005	81
16475973	Antineoplastic Agents	Fritz G	Rho GTPases: promising cellular targets for novel anticancer drugs.	Current cancer drug targets	2006	64
16618762	Antineoplastic Agents	Heltweg B	Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes.	Cancer research	2006	120
16705125	Antineoplastic Agents	Bohlius J	Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.	Journal of the National Cancer Institute	2006	61
16850162	Antineoplastic Agents	Hail N Jr	Mechanisms of fenretinide-induced apoptosis.	Apoptosis 	2006	61
16868082	Antineoplastic Agents	Kinoshita M	Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption.	Proceedings of the National Academy of Sciences of the United States of America	2006	151
16883305	Antineoplastic Agents	Faivre S	Current development of mTOR inhibitors as anticancer agents.	Nature reviews. Drug discovery	2006	239
16890600	Antineoplastic Agents	Takayasu K	Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.	Gastroenterology	2006	144
16890796	Antineoplastic Agents	Faivre S	New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.	Seminars in oncology	2006	61
17318448	Antineoplastic Agents	Kuo MT	The roles of copper transporters in cisplatin resistance.	Cancer metastasis reviews	2007	67
17327609	Antineoplastic Agents	Vonderheide RH	Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.	Journal of clinical oncology 	2007	126
17545512	Antineoplastic Agents	Abraham RT	The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.	Clinical cancer research 	2007	62
17694093	Antineoplastic Agents	Xu WS	Histone deacetylase inhibitors: molecular mechanisms of action.	Oncogene	2007	384
17699845	Antineoplastic Agents	Del Vecchio M	Interleukin-12: biological properties and clinical application.	Clinical cancer research 	2007	143
17854227	Antineoplastic Agents	Bagalkot V	Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer.	Nano letters	2007	126
17908954	Antineoplastic Agents	Germain D	Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy.	Clinical cancer research 	2007	69
17979839	Antineoplastic Agents	Apetoh L	The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.	Immunological reviews	2007	144
18176597	Antineoplastic Agents	Krieg AM	Toll-like receptor 9 (TLR9) agonists in the treatment of cancer.	Oncogene	2008	72
18187804	Antineoplastic Agents	Blower PE	MicroRNAs modulate the chemosensitivity of tumor cells.	Molecular cancer therapeutics	2008	97
18212742	Antineoplastic Agents	Ben Sahra I	The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.	Oncogene	2008	260
18213449	Antineoplastic Agents	Perrotti D	Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias.	Cancer metastasis reviews	2008	53
18227858	Antineoplastic Agents	Al Zaid Siddiquee K	STAT3 as a target for inducing apoptosis in solid and hematological tumors.	Cell research	2008	94
18305219	Antineoplastic Agents	Chen Q	Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.	Blood	2008	77
18347165	Antineoplastic Agents	Gautschi O	Aurora kinases as anticancer drug targets.	Clinical cancer research 	2008	110
18369371	Antineoplastic Agents	Labi V	Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?	Cell death and differentiation	2008	56
18381444	Antineoplastic Agents	Rhodes N	Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.	Cancer research	2008	83
18462867	Antineoplastic Agents	Carew JS	Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.	Cancer letters	2008	99
18648350	Antineoplastic Agents	Otsuki A	Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses.	Molecular therapy 	2008	66
18691054	Antineoplastic Agents	Zhou SF	Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development.	Current medicinal chemistry	2008	75
19176385	Antineoplastic Agents	Beevers CS	Curcumin disrupts the Mammalian target of rapamycin-raptor complex.	Cancer research	2009	54
19278961	Antineoplastic Agents	Ma WW	Novel agents on the horizon for cancer therapy.	CA	2009	80
19335068	Antineoplastic Agents	Whitesell L	Inhibiting the transcription factor HSF1 as an anticancer strategy.	Expert opinion on therapeutic targets	2009	77
19401686	Antineoplastic Agents	Mahalingam D	Targeting HSP90 for cancer therapy.	British journal of cancer	2009	56
19454274	Antineoplastic Agents	Yalcin A	Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer.	Experimental and molecular pathology	2009	81
19581909	Antineoplastic Agents	Chen HX	Adverse effects of anticancer agents that target the VEGF pathway.	Nature reviews. Clinical oncology	2009	96
19716393	Antineoplastic Agents	Pathania D	Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism.	Advanced drug delivery reviews	2009	47
19860903	Antineoplastic Agents	Yuan R	Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.	Journal of hematology & oncology	2009	61
20124458	Antineoplastic Agents	Park ES	Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set.	Molecular cancer therapeutics	2010	43
20124483	Antineoplastic Agents	Li Y	miR-146a suppresses invasion of pancreatic cancer cells.	Cancer research	2010	149
20200537	Antineoplastic Agents	Rouleau M	PARP inhibition: PARP1 and beyond.	Nature reviews. Cancer	2010	360
20215516	Antineoplastic Agents	Jin Y	Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.	Cancer research	2010	92
20215559	Antineoplastic Agents	Gonzalez-Angulo AM	Metformin: a therapeutic opportunity in breast cancer.	Clinical cancer research 	2010	58
20229590	Antineoplastic Agents	Johnston PB	A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.	American journal of hematology	2010	51
20384580	Antineoplastic Agents	Ciuffreda L	The mTOR pathway: a new target in cancer therapy.	Current cancer drug targets	2010	54
20397686	Antineoplastic Agents	Maeda H	Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects.	Bioconjugate chemistry	2010	140
20540746	Antineoplastic Agents	Liu YY	Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.	Molecular cancer	2010	40
20568732	Antineoplastic Agents	Mimasu S	Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .	Biochemistry	2010	43
20812900	Antineoplastic Agents	Zhou H	Updates of mTOR inhibitors.	Anti-cancer agents in medicinal chemistry	2010	48
20980833	Antineoplastic Agents	Vucicevic L	Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway.	Autophagy	2011	44
21247385	Antineoplastic Agents	Jia L	SCF E3 ubiquitin ligases as anticancer targets.	Current cancer drug targets	2011	48
21297102	Antineoplastic Agents	Li Q	3D models of epithelial-mesenchymal transition in breast cancer metastasis: high-throughput screening assay development, validation, and pilot screen.	Journal of biomolecular screening	2011	36
21303969	Antineoplastic Agents	Ramalingam SS	Lung cancer: New biological insights and recent therapeutic advances.	CA	2011	99
21333749	Antineoplastic Agents	Zhang YJ	Targeting the mTOR kinase domain: the second generation of mTOR inhibitors.	Drug discovery today	2011	47
21364523	Antineoplastic Agents	Blagden SP	The biological and therapeutic relevance of mRNA translation in cancer.	Nature reviews. Clinical oncology	2011	46
21374643	Antineoplastic Agents	Nobili S	Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression.	Medicinal research reviews	2012	30
21441464	Antineoplastic Agents	Shaheen M	Synthetic lethality: exploiting the addiction of cancer to DNA repair.	Blood	2011	47
21470407	Antineoplastic Agents	Dowling RJ	Understanding the benefit of metformin use in cancer treatment.	BMC medicine	2011	100
21566064	Antineoplastic Agents	Shrivastava A	Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy.	Molecular cancer therapeutics	2011	51
21630130	Antineoplastic Agents	Lacouture ME	Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.	Supportive care in cancer 	2011	44
22102692	Antineoplastic Agents	Huang J	HMGB1 promotes drug resistance in osteosarcoma.	Cancer research	2012	84
22234808	Antineoplastic Agents	Hellwig CT	TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies.	Molecular cancer therapeutics	2012	50
22239440	Antineoplastic Agents	Santarpia L	Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.	Expert opinion on therapeutic targets	2012	127
22264850	Antineoplastic Agents	Gaya A	A preclinical and clinical review of aflibercept for the management of cancer.	Cancer treatment reviews	2012	30
22301993	Antineoplastic Agents	Huang J	Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma.	Autophagy	2012	33
22305612	Antineoplastic Agents	Xia Y	Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.	European journal of medicinal chemistry	2012	61
22310279	Antineoplastic Agents	Clendening JW	Targeting tumor cell metabolism with statins.	Oncogene	2012	50
22454417	Antineoplastic Agents	Metzger-Filho O	Dissecting the heterogeneity of triple-negative breast cancer.	Journal of clinical oncology 	2012	121
22460905	Antineoplastic Agents	Barretina J	The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.	Nature	2012	1427
22529099	Antineoplastic Agents	Thurnher M	Novel aspects of mevalonate pathway inhibitors as antitumor agents.	Clinical cancer research 	2012	47
22532596	Antineoplastic Agents	Vinay DS	Immunotherapy of cancer with 4-1BB.	Molecular cancer therapeutics	2012	38
22588880	Antineoplastic Agents	Ni J	Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.	Cancer discovery	2012	56
22689530	Antineoplastic Agents	Liu Y	A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo.	Molecular cancer therapeutics	2012	78
22778315	Antineoplastic Agents	Busaidy NL	Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.	Journal of clinical oncology 	2012	41
22810206	Antineoplastic Agents	Enoiu M	Repair of cisplatin-induced DNA interstrand crosslinks by a replication-independent pathway involving transcription-coupled repair and translesion synthesis.	Nucleic acids research	2012	35
22889873	Antineoplastic Agents	Aurisicchio L	The promise of anti-ErbB3 monoclonals as new cancer therapeutics.	Oncotarget	2012	36
22926251	Antineoplastic Agents	Pollak MN	Investigating metformin for cancer prevention and treatment: the end of the beginning.	Cancer discovery	2012	131
23070002	Antineoplastic Agents	Safa AR	c-FLIP, a master anti-apoptotic regulator.	Experimental oncology	2012	58
23073759	Antineoplastic Agents	Masuda H	Role of epidermal growth factor receptor in breast cancer.	Breast cancer research and treatment	2012	98
23079083	Antineoplastic Agents	Selimovic D	Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells.	Cellular signalling	2013	35
23159620	Antineoplastic Agents	Sinnett-Smith J	Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK.	Biochemical and biophysical research communications	2013	39
23199899	Antineoplastic Agents	Hong DS	Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.	Cancer treatment reviews	2013	57
23349734	Antineoplastic Agents	Godugu C	AlgiMatrix™ based 3D cell culture system as an in-vitro tumor model for anticancer studies.	PloS one	2013	33
23396364	Antineoplastic Agents	Patel RA	Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities.	Oncogene	2014	20
23651636	Antineoplastic Agents	Reuveni H	Therapeutic destruction of insulin receptor substrates for cancer treatment.	Cancer research	2013	28
23674815	Antineoplastic Agents	Clem BF	Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.	Molecular cancer therapeutics	2013	45
23811941	Antineoplastic Agents	Shi Z	AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression.	Cancer research	2013	40
23856246	Antineoplastic Agents	Abaan OD	The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.	Cancer research	2013	87
23870513	Antineoplastic Agents	Wierstra I	FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy.	Advances in cancer research	2013	35
23896275	Antineoplastic Agents	Garcia-Carbonero R	Inhibition of HSP90 molecular chaperones: moving into the clinic.	The Lancet. Oncology	2013	74
24020520	Antineoplastic Agents	Bartlett DL	Oncolytic viruses as therapeutic cancer vaccines.	Molecular cancer	2013	71
24037533	Antineoplastic Agents	Michels J	Predictive biomarkers for cancer therapy with PARP inhibitors.	Oncogene	2014	24
24130167	Antineoplastic Agents	Akinyeke T	Metformin targets c-MYC oncogene to prevent prostate cancer.	Carcinogenesis	2013	36
24361892	Antineoplastic Agents	Cheng P	Ethyl pyruvate inhibits proliferation and induces apoptosis of hepatocellular carcinoma via regulation of the HMGB1-RAGE and AKT pathways.	Biochemical and biophysical research communications	2014	20
24481312	Antineoplastic Agents	Fruman DA	PI3K and cancer: lessons, challenges and opportunities.	Nature reviews. Drug discovery	2014	313
24536047	Antineoplastic Agents	Lal S	HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.	Cancer research	2014	28
24577086	Antineoplastic Agents	Feng Y	Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling.	Cell death & disease	2014	56
24732808	Antineoplastic Agents	Li Y	Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.	Cancer letters	2014	36
24856239	Antineoplastic Agents	Pommier Y	Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2).	DNA repair	2014	49
24874432	Antineoplastic Agents	Takahashi K	Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy.	Molecular cancer research 	2014	29
25028336	Antineoplastic Agents	Yallapu MM	Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer.	Biomaterials	2014	25
25043604	Antineoplastic Agents	Mason JM	Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.	Cancer cell	2014	27
25143389	Antineoplastic Agents	Nair V	Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors.	The Journal of biological chemistry	2014	30
25173780	Antineoplastic Agents	van Waarde A	Potential applications for sigma receptor ligands in cancer diagnosis and therapy.	Biochimica et biophysica acta	2015	16
25204288	Antineoplastic Agents	Gandhi NS	Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.	Journal of controlled release 	2014	52
25316614	Antineoplastic Agents	Parikh K	Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.	Journal of hematology & oncology	2014	30
25593033	Antineoplastic Agents	Pelletier J	Targeting the eIF4F translation initiation complex: a critical nexus for cancer development.	Cancer research	2015	53
25623213	Antineoplastic Agents	Boi M	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.	Clinical cancer research 	2015	37
25630663	Antineoplastic Agents	Shrivastava A	Recent developments in L-asparaginase discovery and its potential as anticancer agent.	Critical reviews in oncology/hematology	2016	13
25712124	Antineoplastic Agents	Prabhu VV	Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.	Cancer research	2015	30
25897862	Antineoplastic Agents	Fasano E	Long-chain n-3 PUFA against breast and prostate cancer: Which are the appropriate doses for intervention studies in animals and humans?	Critical reviews in food science and nutrition	2017	7
26604648	Antineoplastic Agents	Song A	Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.	World journal of gastroenterology	2015	17
26625127	Antineoplastic Agents	Griss T	Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis.	PLoS biology	2015	32
26625211	Antineoplastic Agents	Nogales V	Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.	Oncotarget	2016	13
26807863	Antineoplastic Agents	Asati V	PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.	European journal of medicinal chemistry	2016	28
26976114	Antineoplastic Agents	Stathis A	Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.	Cancer discovery	2016	32
27239721	Antineoplastic Agents	Manal M	Inhibitors of histone deacetylase as antitumor agents: A critical review.	Bioorganic chemistry	2016	14
27323951	Antineoplastic Agents	Jafri MA	Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies.	Genome medicine	2016	21
27555605	Antineoplastic Agents	Kurmasheva RT	Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.	Pediatric blood & cancer	2017	7
27635045	Antineoplastic Agents	Wallace EM	A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma.	Cancer research	2016	17
27694602	Antineoplastic Agents	Croce CM	Finally, An Apoptosis-Targeting Therapeutic for Cancer.	Cancer research	2016	14
28125906	Antineoplastic Agents	Alexiou GA	Difluoromethylornithine in cancer: new advances.	Future oncology	2017	6
10224280	Fluorouracil	Li S	The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.	The Journal of experimental medicine	1999	131
10411544	Fluorouracil	Ashkenazi A	Safety and antitumor activity of recombinant soluble Apo2 ligand.	The Journal of clinical investigation	1999	416
10430607	Fluorouracil	Bunz F	Disruption of p53 in human cancer cells alters the responses to therapeutic agents.	The Journal of clinical investigation	1999	255
10700175	Fluorouracil	Scherf U	A gene expression database for the molecular pharmacology of cancer.	Nature genetics	2000	247
10778957	Fluorouracil	Salonga D	Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.	Clinical cancer research 	2000	124
11309634	Fluorouracil	Watanabe T	Molecular predictors of survival after adjuvant chemotherapy for colon cancer.	The New England journal of medicine	2001	177
11590433	Fluorouracil	Hwang PM	Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells.	Nature medicine	2001	91
12912934	Fluorouracil	Van Rijnsoever M	CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.	Clinical cancer research 	2003	75
15763604	Fluorouracil	Walko CM	Capecitabine: a review.	Clinical therapeutics	2005	77
15774776	Fluorouracil	Ghadimi BM	Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.	Journal of clinical oncology 	2005	67
16246976	Fluorouracil	Rödel C	Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.	Journal of clinical oncology 	2005	191
16322293	Fluorouracil	Benatti P	Microsatellite instability and colorectal cancer prognosis.	Clinical cancer research 	2005	74
16434701	Fluorouracil	Saramäki A	Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor.	Nucleic acids research	2006	80
17228023	Fluorouracil	Kim GP	Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.	Journal of clinical oncology 	2007	87
17906203	Fluorouracil	Collette L	Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group.	Journal of clinical oncology 	2007	71
18692501	Fluorouracil	Shibata T	Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.	Gastroenterology	2008	124
19074875	Fluorouracil	Braun CJ	p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest.	Cancer research	2008	165
19244128	Fluorouracil	Dallas NA	Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition.	Cancer research	2009	149
19276252	Fluorouracil	Sakamoto K	Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth.	Clinical cancer research 	2009	62
19402749	Fluorouracil	Kunz C	Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil.	PLoS biology	2009	53
19417905	Fluorouracil	Sung JH	A micro cell culture analog (microCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs.	Lab on a chip	2009	64
19439999	Fluorouracil	Takagi T	Decreased expression of microRNA-143 and -145 in human gastric cancers.	Oncology	2009	94
19470921	Fluorouracil	Willett CG	Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.	Journal of clinical oncology 	2009	155
19603024	Fluorouracil	Souglakos J	Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.	British journal of cancer	2009	80
19622726	Fluorouracil	Yoo BK	Identification of genes conferring resistance to 5-fluorouracil.	Proceedings of the National Academy of Sciences of the United States of America	2009	57
19734943	Fluorouracil	Song B	Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells.	Oncogene	2009	125
19843160	Fluorouracil	Borralho PM	MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells.	The FEBS journal	2009	64
20081809	Fluorouracil	Ong CW	CD133 expression predicts for non-response to chemotherapy in colorectal cancer.	Modern pathology 	2010	44
20498393	Fluorouracil	Sargent DJ	Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.	Journal of clinical oncology 	2010	237
20501503	Fluorouracil	Fariña-Sarasqueta A	The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.	Annals of oncology 	2010	77
20516444	Fluorouracil	de la Chapelle A	Clinical relevance of microsatellite instability in colorectal cancer.	Journal of clinical oncology 	2010	49
20647341	Fluorouracil	Boni V	miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation.	Molecular cancer therapeutics	2010	48
20697159	Fluorouracil	Haraguchi N	CD13 is a therapeutic target in human liver cancer stem cells.	The Journal of clinical investigation	2010	135
20737575	Fluorouracil	Zhang J	Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene.	Cancer	2011	41
20978511	Fluorouracil	Tomimaru Y	MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells.	British journal of cancer	2010	57
21048039	Fluorouracil	Licitra L	Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.	Annals of oncology 	2011	58
21067862	Fluorouracil	Akao Y	Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells.	Cancer letters	2011	54
21078976	Fluorouracil	Valeri N	MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2).	Proceedings of the National Academy of Sciences of the United States of America	2010	106
21185836	Fluorouracil	Jover R	5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.	Gastroenterology	2011	60
21245094	Fluorouracil	Papageorgis P	Smad4 inactivation promotes malignancy and drug resistance of colon cancer.	Cancer research	2011	38
21841826	Fluorouracil	de la Cruz-Morcillo MA	P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance.	Oncogene	2012	32
21969819	Fluorouracil	Shibata T	NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer.	Neoplasia	2011	40
22072615	Fluorouracil	Nie J	microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2.	Carcinogenesis	2012	57
22205702	Fluorouracil	Xiong H	Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition.	The Journal of biological chemistry	2012	72
22248601	Fluorouracil	Hecht JR	EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study.	Gastrointestinal endoscopy	2012	31
22260991	Fluorouracil	Funkhouser WK Jr	Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology.	The Journal of molecular diagnostics 	2012	30
22302899	Fluorouracil	Sinicrope FA	Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications.	Clinical cancer research 	2012	53
22322955	Fluorouracil	Nishida N	MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells.	Annals of surgical oncology	2012	42
22382630	Fluorouracil	Kurokawa K	Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.	Journal of gastroenterology	2012	31
22623155	Fluorouracil	Li L	MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1.	Clinical and experimental medicine	2013	62
22790872	Fluorouracil	Nikulenkov F	Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis.	Cell death and differentiation	2012	86
22993328	Fluorouracil	Izumiya M	Chemoresistance is associated with cancer stem cell-like properties and epithelial-to-mesenchymal transition in pancreatic cancer cells.	Anticancer research	2012	33
23167930	Fluorouracil	Svoboda M	MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.	Radiation oncology	2012	32
23441212	Fluorouracil	Pan X	Autophagy inhibition promotes 5-fluorouraci-induced apoptosis by stimulating ROS formation in human non-small cell lung cancer A549 cells.	PloS one	2013	36
23684942	Fluorouracil	Lei Z	Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.	Gastroenterology	2013	62
23744359	Fluorouracil	Karaayvaz M	miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer.	Cell death & disease	2013	37
23934972	Fluorouracil	Spitzner M	STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo.	International journal of cancer	2014	21
24009080	Fluorouracil	Siemens H	Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness.	Oncotarget	2013	51
24018051	Fluorouracil	Chen Z	MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells.	Cellular signalling	2013	26
24077681	Fluorouracil	Redis RS	CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations.	Oncotarget	2013	55
24170546	Fluorouracil	Dunne PD	AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.	Clinical cancer research 	2014	29
24275137	Fluorouracil	Deng J	Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro.	Biochemical and biophysical research communications	2014	26
24323901	Fluorouracil	Touil Y	Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.	Clinical cancer research 	2014	40
24345883	Fluorouracil	Li Z	The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer.	Oncotarget	2013	26
24446491	Fluorouracil	Shin JY	High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias.	The Journal of experimental medicine	2014	38
24590654	Fluorouracil	Rosmarin D	Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.	Journal of clinical oncology 	2014	33
24658854	Fluorouracil	Xie L	MicroRNA-124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer.	Molecular and cellular biochemistry	2014	25
24743738	Fluorouracil	Kang KA	Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation.	Cell death & disease	2014	22
24859412	Fluorouracil	Honjo S	Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer.	International journal of oncology	2014	24
24885567	Fluorouracil	Du T	Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway.	Molecular cancer	2014	21
25406793	Fluorouracil	Kim IY	Neutrophil-lymphocyte ratio predicts pathologic tumor response and survival after preoperative chemoradiation for rectal cancer.	BMC surgery	2014	24
25449431	Fluorouracil	Zhang H	MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells.	Cancer letters	2015	26
25733851	Fluorouracil	Conde J	Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance.	Proceedings of the National Academy of Sciences of the United States of America	2015	16
25739674	Fluorouracil	Song S	The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer.	Clinical cancer research 	2015	38
25820415	Fluorouracil	Kawai T	Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma.	Clinical cancer research 	2015	23
26031544	Fluorouracil	Kawakami H	Microsatellite instability testing and its role in the management of colorectal cancer.	Current treatment options in oncology	2015	24
26351341	Fluorouracil	Sacco AG	Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.	Journal of clinical oncology 	2015	33
26494468	Fluorouracil	Alam SK	DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53.	Cell death and differentiation	2016	11
26603945	Fluorouracil	Meulendijks D	Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.	The Lancet. Oncology	2015	18
26673620	Fluorouracil	Wang L	MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1.	Oncotarget	2016	15
26864640	Fluorouracil	Wei X	MicroRNA-21 induces 5-fluorouracil resistance in human pancreatic cancer cells by regulating PTEN and PDCD4.	Cancer medicine	2016	17
27046651	Fluorouracil	Bian Z	LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p.	Scientific reports	2016	49
27119506	Fluorouracil	Vishnubalaji R	MicroRNA-320 suppresses colorectal cancer by targeting SOX4, FOXM1, and FOXQ1.	Oncotarget	2016	14
27145382	Fluorouracil	Otvos B	Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion.	Stem cells	2016	18
27840990	Fluorouracil	Liu N	MicroRNA-302a enhances 5-fluorouracil-induced cell death in human colon cancer cells.	Oncology reports	2017	6
28114937	Fluorouracil	Zhang JX	Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway.	Molecular cancer	2017	9
1348364	Cisplatin	Godwin AK	High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.	Proceedings of the National Academy of Sciences of the United States of America	1992	151
8194005	Cisplatin	Mandard AM	Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations.	Cancer	1994	246
8895738	Cisplatin	Fink D	The role of DNA mismatch repair in platinum drug resistance.	Cancer research	1996	115
9176490	Cisplatin	Heise C	ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.	Nature medicine	1997	133
9270026	Cisplatin	Kool M	Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines.	Cancer research	1997	114
9427750	Cisplatin	Cliby WA	Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints.	The EMBO journal	1998	163
9704716	Cisplatin	Pegram MD	Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.	Journal of clinical oncology 	1998	115
9927204	Cisplatin	Blandino G	Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy.	Oncogene	1999	97
10446958	Cisplatin	Yuan SS	BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.	Cancer research	1999	142
10673506	Cisplatin	Araújo SJ	Nucleotide excision repair of DNA with recombinant human proteins: definition of the minimal set of factors, active forms of TFIIH, and modulation by CAK.	Genes & development	2000	93
11280739	Cisplatin	Asselin E	XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.	Cancer research	2001	87
12524540	Cisplatin	Bergamaschi D	iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human.	Nature genetics	2003	96
12637505	Cisplatin	Mansouri A	Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells.	The Journal of biological chemistry	2003	85
12686563	Cisplatin	Lai J	Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer.	The Journal of biological chemistry	2003	90
12692539	Cisplatin	Taniguchi T	Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.	Nature medicine	2003	141
12698198	Cisplatin	Tassone P	BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.	British journal of cancer	2003	85
12860938	Cisplatin	Vogelzang NJ	Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.	Journal of clinical oncology 	2003	413
12944571	Cisplatin	Grossman HB	Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.	The New England journal of medicine	2003	277
14534679	Cisplatin	Boulikas T	Cisplatin and platinum drugs at the molecular level. (Review).	Oncology reports	2003	95
14576837	Cisplatin	Siddik ZH	Cisplatin: mode of cytotoxic action and molecular basis of resistance.	Oncogene	2003	574
14645242	Cisplatin	Dan HC	Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP).	The Journal of biological chemistry	2004	122
14673047	Cisplatin	Ando N	Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.	Journal of clinical oncology 	2003	88
14702041	Cisplatin	Katayama H	Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53.	Nature genetics	2004	159
15024021	Cisplatin	Ando K	Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation.	The Journal of biological chemistry	2004	74
15279797	Cisplatin	Stojic L	Mismatch repair and DNA damage signalling.	DNA repair	2004	106
15469940	Cisplatin	Liu Q	Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215.	The Journal of biological chemistry	2004	85
15797377	Cisplatin	Beuvink I	The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.	Cell	2005	142
15811630	Cisplatin	Albertella MR	The overexpression of specialized DNA polymerases in cancer.	DNA repair	2005	75
16116421	Cisplatin	Bridge WL	The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair.	Nature genetics	2005	79
16227410	Cisplatin	Safaei R	Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells.	Molecular cancer therapeutics	2005	98
16234567	Cisplatin	Yeo W	A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.	Journal of the National Cancer Institute	2005	120
16314626	Cisplatin	Burtness B	Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.	Journal of clinical oncology 	2005	171
16357177	Cisplatin	Nawrocki ST	Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.	Cancer research	2005	95
16493006	Cisplatin	Taniguchi T	Molecular pathogenesis of Fanconi anemia: recent progress.	Blood	2006	124
16540663	Cisplatin	Yang X	Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.	Cancer research	2006	83
16932740	Cisplatin	Zwang Y	p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy.	The EMBO journal	2006	75
16951202	Cisplatin	Zhang S	Organic cation transporters are determinants of oxaliplatin cytotoxicity.	Cancer research	2006	77
16951222	Cisplatin	Sok JC	Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.	Clinical cancer research 	2006	141
16957145	Cisplatin	Olaussen KA	DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.	The New England journal of medicine	2006	355
17103105	Cisplatin	Marelli L	Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.	Cardiovascular and interventional radiology	2007	137
17222355	Cisplatin	Hebert C	High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma.	Molecular cancer	2007	122
17227995	Cisplatin	Lewis IJ	Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.	Journal of the National Cancer Institute	2007	64
17446929	Cisplatin	Leong CO	The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers.	The Journal of clinical investigation	2007	101
17602080	Cisplatin	Cobo M	Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.	Journal of clinical oncology 	2007	96
17616691	Cisplatin	Liu LZ	AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.	Cancer research	2007	67
17634556	Cisplatin	Mabuchi S	RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.	Clinical cancer research 	2007	62
17646646	Cisplatin	Huang PH	Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.	Proceedings of the National Academy of Sciences of the United States of America	2007	149
17671123	Cisplatin	Als AB	Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer.	Clinical cancer research 	2007	55
17911266	Cisplatin	Lo AK	Modulation of LMP1 protein expression by EBV-encoded microRNAs.	Proceedings of the National Academy of Sciences of the United States of America	2007	127
17918180	Cisplatin	Fraser M	Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.	International journal of cancer	2008	51
18206965	Cisplatin	Lim ST	Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation.	Molecular cell	2008	151
18282805	Cisplatin	Koizumi W	S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.	The Lancet. Oncology	2008	325
18316592	Cisplatin	Ohta T	Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth.	Cancer research	2008	174
18362892	Cisplatin	Tajeddine N	Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death.	Oncogene	2008	54
18413725	Cisplatin	Swisher EM	Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.	Cancer research	2008	117
18426979	Cisplatin	Zeidan YH	Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway.	The Journal of cell biology	2008	52
18451214	Cisplatin	Lee JW	Altered MicroRNA expression in cervical carcinomas.	Clinical cancer research 	2008	93
18495226	Cisplatin	Gotlieb WH	In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.	Gynecologic oncology	2008	67
18519691	Cisplatin	Zhang S	Identification and characterization of ovarian cancer-initiating cells from primary human tumors.	Cancer research	2008	391
18612434	Cisplatin	Chen YC	Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells.	PloS one	2008	141
18649131	Cisplatin	Byrski T	Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.	Breast cancer research and treatment	2009	76
18686947	Cisplatin	Rieter WJ	Nanoscale coordination polymers for platinum-based anticancer drug delivery.	Journal of the American Chemical Society	2008	58
18728788	Cisplatin	Levina V	Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties.	PloS one	2008	140
18754698	Cisplatin	Chou AJ	Therapy for osteosarcoma: where do we go from here?	Paediatric drugs	2008	67
18823650	Cisplatin	Sorrentino A	Role of microRNAs in drug-resistant ovarian cancer cells.	Gynecologic oncology	2008	112
19074899	Cisplatin	Yang N	MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.	Cancer research	2008	113
19318572	Cisplatin	Eckstein N	Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.	Cancer research	2009	50
19417020	Cisplatin	Homma S	Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer.	Clinical cancer research 	2009	96
19654294	Cisplatin	Sakai W	Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.	Cancer research	2009	75
19706487	Cisplatin	Sayan AE	SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer.	Proceedings of the National Academy of Sciences of the United States of America	2009	48
19770374	Cisplatin	Allum WH	Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.	Journal of clinical oncology 	2009	131
19783996	Cisplatin	Gonfloni S	Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death.	Nature medicine	2009	79
19802016	Cisplatin	Abedini MR	Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.	Oncogene	2010	42
19805294	Cisplatin	Bertolini G	Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.	Proceedings of the National Academy of Sciences of the United States of America	2009	248
19957335	Cisplatin	Su HY	Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway.	International journal of cancer	2010	45
20028869	Cisplatin	Levina V	Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop.	Cancer research	2010	40
20041317	Cisplatin	Liu D	Inhibition of autophagy by 3-MA potentiates cisplatin-induced apoptosis in esophageal squamous cell carcinoma cells.	Medical oncology	2011	52
20068070	Cisplatin	Kwok JM	FOXM1 confers acquired cisplatin resistance in breast cancer cells.	Molecular cancer research 	2010	72
20074550	Cisplatin	Teng Y	Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells.	Biochemical and biophysical research communications	2010	67
20099276	Cisplatin	Pogribny IP	Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin.	International journal of cancer	2010	94
20100965	Cisplatin	Silver DP	Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.	Journal of clinical oncology 	2010	231
20145120	Cisplatin	Holland SJ	R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.	Cancer research	2010	121
20159816	Cisplatin	Ajani JA	Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.	Journal of clinical oncology 	2010	101
20162574	Cisplatin	Zhu W	miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines.	International journal of cancer	2010	83
20170547	Cisplatin	Arrieta O	Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study.	BMC cancer	2010	42
20196784	Cisplatin	Harhaji-Trajkovic L	AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells.	Journal of cellular and molecular medicine	2009	58
20215556	Cisplatin	Sikora AG	Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy.	Clinical cancer research 	2010	43
20236757	Cisplatin	Wang Y	Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.	Cancer letters	2010	54
20371173	Cisplatin	Guo L	Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis.	European journal of cancer	2010	48
20418188	Cisplatin	Arora S	Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.	DNA repair	2010	41
20454597	Cisplatin	Gupta A	Human copper transporters: mechanism, role in human diseases and therapeutic potential.	Future medicinal chemistry	2009	49
20530669	Cisplatin	Jiang T	High levels of Nrf2 determine chemoresistance in type II endometrial cancer.	Cancer research	2010	80
20564628	Cisplatin	Annunziata CM	Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer.	Cancer	2010	45
20581869	Cisplatin	Cooke SL	Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.	Oncogene	2010	52
20670951	Cisplatin	Harrington KJ	Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.	Clinical cancer research 	2010	60
20696752	Cisplatin	Ceppi P	Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer.	Molecular cancer research 	2010	92
20728210	Cisplatin	Bang YJ	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.	Lancet	2010	1076
20943624	Cisplatin	Vermorken JB	Optimal treatment for recurrent/metastatic head and neck cancer.	Annals of oncology 	2010	58
20943634	Cisplatin	Chan AT	Nasopharyngeal carcinoma.	Annals of oncology 	2010	48
20947521	Cisplatin	Hall CA	Hippo pathway effector Yap is an ovarian cancer oncogene.	Cancer research	2010	71
20956982	Cisplatin	Narod SA	BRCA mutations in the management of breast cancer: the state of the art.	Nature reviews. Clinical oncology	2010	41
21034966	Cisplatin	Smith J	The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.	Advances in cancer research	2010	268
21124918	Cisplatin	Leung EL	Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties.	PloS one	2010	115
21224400	Cisplatin	Ye G	MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance.	Journal of cell science	2011	40
21225626	Cisplatin	Sun S	Head neck squamous cell carcinoma c-Met⁺ cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis.	International journal of cancer	2011	37
21248297	Cisplatin	Hamano R	Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway.	Clinical cancer research 	2011	56
21258880	Cisplatin	Zhu W	miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2.	Medical oncology	2012	56
21266349	Cisplatin	Liccardi G	EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.	Cancer research	2011	73
21274007	Cisplatin	Huang Y	Phospho-ΔNp63α is a key regulator of the cisplatin-induced microRNAome in cancer cells.	Cell death and differentiation	2011	40
21325880	Cisplatin	O'Donovan TR	Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics.	Autophagy	2011	78
21327457	Cisplatin	Yang Z	Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation.	Annals of surgical oncology	2011	221
21329503	Cisplatin	Bian HB	Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549).	Journal of experimental & clinical cancer research 	2011	47
21342274	Cisplatin	Tsai LL	Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma.	Journal of oral pathology & medicine 	2011	50
21353530	Cisplatin	Otvos L Jr	Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer.	European journal of cancer	2011	38
21364678	Cisplatin	Flourakis M	Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells.	Cell death & disease	2010	47
21371883	Cisplatin	Yu H	p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins.	European journal of cancer	2011	37
21442631	Cisplatin	Schrader J	Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells.	Hepatology	2011	81
21472714	Cisplatin	Alhazzazi TY	Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer.	Cancer	2011	53
21532889	Cisplatin	Rattan R	Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo.	Neoplasia	2011	85
21550168	Cisplatin	Noguchi S	MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells.	Cancer letters	2011	38
21571862	Cisplatin	Stronach EA	HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.	Cancer research	2011	45
21702042	Cisplatin	Vinall RL	MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status.	International journal of cancer	2012	31
21725369	Cisplatin	Sun L	MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1.	Oncogene	2012	79
21726833	Cisplatin	Lee TK	CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation.	Cell stem cell	2011	148
21765211	Cisplatin	Lesterhuis WJ	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.	The Journal of clinical investigation	2011	41
21775533	Cisplatin	Tan XL	Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy.	Clinical cancer research 	2011	43
21903745	Cisplatin	Curran WJ Jr	Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.	Journal of the National Cancer Institute	2011	174
21909139	Cisplatin	Yue P	Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.	Oncogene	2012	43
21947824	Cisplatin	Thieblemont C	The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.	Journal of clinical oncology 	2011	44
22104727	Cisplatin	Huang S	Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells.	Cancer letters	2012	31
22112324	Cisplatin	Kim CH	miRNA signature associated with outcome of gastric cancer patients following chemotherapy.	BMC medical genomics	2011	39
22131882	Cisplatin	Stronach EA	DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.	Neoplasia	2011	41
22142828	Cisplatin	Steg AD	Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.	Clinical cancer research 	2012	92
22178121	Cisplatin	Lee NY	Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.	The Lancet. Oncology	2012	61
22193543	Cisplatin	Donzelli S	MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function.	Cell death and differentiation	2012	43
22222640	Cisplatin	Rüschoff J	HER2 testing in gastric cancer: a practical approach.	Modern pathology 	2012	90
22356768	Cisplatin	Huang Y	Phospho-ΔNp63α-dependent regulation of autophagic signaling through transcription and micro-RNA modulation.	Cell cycle	2012	40
22429801	Cisplatin	Haslehurst AM	EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.	BMC cancer	2012	64
22440905	Cisplatin	Zager RA	Plasma and urinary heme oxygenase-1 in AKI.	Journal of the American Society of Nephrology 	2012	33
22465665	Cisplatin	Fu X	Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells.	FEBS letters	2012	50
22467215	Cisplatin	Thiel KW	Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.	Nucleic acids research	2012	63
22473169	Cisplatin	Rossi A	Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.	Journal of clinical oncology 	2012	46
22562073	Cisplatin	Kaminskyy VO	Suppression of basal autophagy reduces lung cancer cell proliferation and enhances caspase-dependent and -independent apoptosis by stimulating ROS formation.	Autophagy	2012	38
22564997	Cisplatin	Ferrari S	Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.	Journal of clinical oncology 	2012	31
22576213	Cisplatin	Birkbak NJ	Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.	Cancer discovery	2012	50
22576688	Cisplatin	Wang Y	Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer.	International journal of oncology	2012	46
22614869	Cisplatin	Yang L	Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.	Oncology reports	2012	31
22647982	Cisplatin	Zhou C	Monitoring autophagic flux by an improved tandem fluorescent-tagged LC3 (mTagRFP-mWasabi-LC3) reveals that high-dose rapamycin impairs autophagic flux in cancer cells.	Autophagy	2012	43
22665540	Cisplatin	Ebb D	Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.	Journal of clinical oncology 	2012	46
22689061	Cisplatin	Huang JM	YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14.	Oncogene	2013	47
22696230	Cisplatin	Chung LY	Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2.	Clinical cancer research 	2012	37
22710713	Cisplatin	Guo ST	MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer.	Oncogene	2013	72
22713463	Cisplatin	Xu N	Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell.	Biochemical and biophysical research communications	2012	37
22761336	Cisplatin	Wang Y	MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition.	Cancer research	2012	35
22797058	Cisplatin	Chau WK	c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.	Oncogene	2013	53
22817698	Cisplatin	Byrski T	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.	Breast cancer research 	2012	41
22846564	Cisplatin	Xu N	Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell.	Biochemical and biophysical research communications	2012	33
22847005	Cisplatin	Bourguignon LY	Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.	The Journal of biological chemistry	2012	64
22847808	Cisplatin	Sugimura K	Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma.	Clinical cancer research 	2012	39
22854025	Cisplatin	Galluzzi L	Prognostic impact of vitamin B6 metabolism in lung cancer.	Cell reports	2012	38
22892391	Cisplatin	Ryan J	MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome.	British journal of cancer	2012	33
22893596	Cisplatin	Khorana AA	Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States.	Cancer	2013	37
22927417	Cisplatin	Zoppoli G	Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.	Proceedings of the National Academy of Sciences of the United States of America	2012	42
22928012	Cisplatin	Lohberger B	Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma.	PloS one	2012	31
22955317	Cisplatin	Feng PH	CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.	American journal of respiratory and critical care medicine	2012	31
22987153	Cisplatin	Karanja KK	DNA2 and EXO1 in replication-coupled, homology-directed repair and in the interplay between HDR and the FA/BRCA network.	Cell cycle	2012	33
23019585	Cisplatin	McAuliffe SM	Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy.	Proceedings of the National Academy of Sciences of the United States of America	2012	87
23045278	Cisplatin	van Jaarsveld MT	miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.	Oncogene	2013	59
23050965	Cisplatin	Ali AY	Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum.	Annals of the New York Academy of Sciences	2012	32
23071587	Cisplatin	Gout S	Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma.	PloS one	2012	33
23135908	Cisplatin	Liu YP	Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling.	Cancer research	2013	44
23251001	Cisplatin	Kimple RJ	Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts.	Clinical cancer research 	2013	31
23337879	Cisplatin	Wang F	MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells.	FEBS letters	2013	35
23349823	Cisplatin	Barr MP	Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.	PloS one	2013	52
23382914	Cisplatin	Pan Y	Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma.	PloS one	2013	30
23436796	Cisplatin	Dijkgraaf EM	Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment.	Cancer research	2013	40
23449973	Cisplatin	Fortier AM	Keratin 8 and 18 loss in epithelial cancer cells increases collective cell migration and cisplatin sensitivity through claudin1 up-regulation.	The Journal of biological chemistry	2013	41
23460709	Cisplatin	Martins RG	Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.	Journal of clinical oncology 	2013	34
23462296	Cisplatin	Januchowski R	Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2013	27
23483142	Cisplatin	Xu Y	miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells.	Oncology reports	2013	39
23514287	Cisplatin	Friboulet L	ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.	The New England journal of medicine	2013	89
23524583	Cisplatin	Zhang S	Generation of cancer stem-like cells through the formation of polyploid giant cancer cells.	Oncogene	2014	58
23542177	Cisplatin	Mao B	SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma.	Oncogene	2014	30
23554447	Cisplatin	Michels J	Cisplatin resistance associated with PARP hyperactivation.	Cancer research	2013	35
23610451	Cisplatin	Listerman I	The major reverse transcriptase-incompetent splice variant of the human telomerase protein inhibits telomerase activity but protects from apoptosis.	Cancer research	2013	32
23733761	Cisplatin	Baselga J	Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.	Journal of clinical oncology 	2013	80
23741487	Cisplatin	Yang Y	The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell.	PloS one	2013	77
23746666	Cisplatin	Vermorken JB	Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.	The Lancet. Oncology	2013	69
23845449	Cisplatin	Vélayoudom-Céphise FL	Are G3 ENETS neuroendocrine neoplasms heterogeneous?	Endocrine-related cancer	2013	31
23945651	Cisplatin	Maskey D	ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy.	Nature communications	2013	45
23950211	Cisplatin	Zhang L	miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance.	Cancer research	2013	39
23967051	Cisplatin	Yasuda K	Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population.	PloS one	2013	29
24068565	Cisplatin	Cao W	miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway.	Tumour biology 	2014	21
24099915	Cisplatin	Dong Z	MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9.	Cancer letters	2014	24
24115572	Cisplatin	Pereira L	Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK.	EMBO molecular medicine	2013	28
24155936	Cisplatin	Liu Z	The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression.	PloS one	2013	78
24165223	Cisplatin	Sun XP	Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.	The FEBS journal	2014	20
24240701	Cisplatin	Shin DH	SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin.	Cancer research	2014	20
24318570	Cisplatin	Liu SY	High aldehyde dehydrogenase activity identifies cancer stem cells in human cervical cancer.	Oncotarget	2013	29
24333218	Cisplatin	Wang H	Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway.	European journal of pharmacology	2014	29
24401670	Cisplatin	Riaz N	Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck.	American journal of clinical oncology	2016	10
24407244	Cisplatin	Zhang P	Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.	Cell death & disease	2014	24
24468065	Cisplatin	Zhou Y	miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.	Journal of experimental & clinical cancer research 	2014	45
24472409	Cisplatin	Chan JK	The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer.	Gynecologic oncology	2014	25
24473399	Cisplatin	Kurokawa Y	Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1).	British journal of cancer	2014	26
24495014	Cisplatin	Fan Y	Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling.	The FEBS journal	2014	79
24495516	Cisplatin	Xia JT	MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-κB signaling.	Journal of translational medicine	2014	23
24516043	Cisplatin	Drayton RM	Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.	Clinical cancer research 	2014	33
24525232	Cisplatin	Choi W	Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.	Cancer cell	2014	181
24531842	Cisplatin	Liang Q	A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses.	Nature chemical biology	2014	42
24552320	Cisplatin	Tewari KS	Improved survival with bevacizumab in advanced cervical cancer.	The New England journal of medicine	2014	164
24554720	Cisplatin	Joshi PM	Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.	The Journal of biological chemistry	2014	24
24560445	Cisplatin	Topp MD	Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts.	Molecular oncology	2014	30
24571667	Cisplatin	Ma J	NF-kappaB-dependent microRNA-425 upregulation promotes gastric cancer cell growth by targeting PTEN upon IL-1β induction.	Molecular cancer	2014	21
24587643	Cisplatin	Orditura M	Treatment of gastric cancer.	World journal of gastroenterology	2014	84
24659709	Cisplatin	Liu MX	Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.	Oncotarget	2014	25
24668391	Cisplatin	Tsuburaya A	Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.	The British journal of surgery	2014	23
24669930	Cisplatin	He C	Nanoscale metal-organic frameworks for the co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells.	Journal of the American Chemical Society	2014	31
24709421	Cisplatin	Nör C	Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer.	Neoplasia	2014	37
24788099	Cisplatin	Watanabe R	SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability.	Cancer research	2014	33
24794870	Cisplatin	Wang J	Role of autophagy in cisplatin resistance in ovarian cancer cells.	The Journal of biological chemistry	2014	34
24821881	Cisplatin	Plimack ER	Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.	Journal of clinical oncology 	2014	23
24821883	Cisplatin	Choueiri TK	Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.	Journal of clinical oncology 	2014	21
24848258	Cisplatin	Shapiro IM	Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.	Science translational medicine	2014	44
24858042	Cisplatin	Miow QH	Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer.	Oncogene	2015	26
24952704	Cisplatin	Qian W	Novel combination of mitochondrial division inhibitor 1 (mdivi-1) and platinum agents produces synergistic pro-apoptotic effect in drug resistant tumor cells.	Oncotarget	2014	23
24960601	Cisplatin	Choi W	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.	Nature reviews. Urology	2014	40
24965569	Cisplatin	Iveson T	Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.	The Lancet. Oncology	2014	76
24989332	Cisplatin	Hassan R	Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.	Cancer	2014	41
25010037	Cisplatin	Hall AB	Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.	Oncotarget	2014	27
25026298	Cisplatin	Ha K	Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.	Oncotarget	2014	25
25069034	Cisplatin	Sullivan I	Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.	Cancer letters	2014	22
25096233	Cisplatin	Van Allen EM	Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.	Cancer discovery	2014	65
25114235	Cisplatin	Xue W	Small RNA combination therapy for lung cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	56
25128483	Cisplatin	Li J	miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells.	Molecular cancer	2014	31
25129345	Cisplatin	Byrski T	Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.	Breast cancer research and treatment	2014	39
25154822	Cisplatin	Ang KK	Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.	Journal of clinical oncology 	2014	120
25165721	Cisplatin	Ozkok A	Pathophysiology of cisplatin-induced acute kidney injury.	BioMed research international	2014	54
25228385	Cisplatin	Tan X	miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.	Breast cancer research 	2014	30
25231400	Cisplatin	Hassan R	Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.	Clinical cancer research 	2014	31
25234467	Cisplatin	Guo J	MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer.	Molecules and cells	2014	20
25315138	Cisplatin	He C	Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer.	Biomaterials	2015	16
25366680	Cisplatin	Nguyen-Tan PF	Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.	Journal of clinical oncology 	2014	34
25377507	Cisplatin	Doebele RC	Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.	Cancer	2015	17
25385148	Cisplatin	Dai T	Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma cell aggressiveness by activating the NF-κB pathway.	The Journal of pathology	2015	19
25426560	Cisplatin	Pan B	Mir-24-3p downregulation contributes to VP16-DDP resistance in small-cell lung cancer by targeting ATG4A.	Oncotarget	2015	16
25537512	Cisplatin	Chiu WT	FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.	Oncotarget	2015	35
25579119	Cisplatin	Pink RC	The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.	Gynecologic oncology	2015	29
25596659	Cisplatin	Giralt J	Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.	The Lancet. Oncology	2015	25
25596660	Cisplatin	Mesía R	Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.	The Lancet. Oncology	2015	20
25609015	Cisplatin	Litchfield K	Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours.	Nature communications	2015	18
25650716	Cisplatin	He J	Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.	Autophagy	2015	22
25658419	Cisplatin	Xu J	β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells.	PloS one	2015	18
25682441	Cisplatin	Fuse N	Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.	Gastric cancer 	2016	21
25701171	Cisplatin	Paz-Ares L	Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.	The Lancet. Oncology	2015	31
25721211	Cisplatin	Zhao Z	miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells.	Cancer gene therapy	2015	15
25737278	Cisplatin	Guillemette S	Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4.	Genes & development	2015	17
25831546	Cisplatin	Srivastava AK	Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells.	Proceedings of the National Academy of Sciences of the United States of America	2015	30
25847936	Cisplatin	Isakoff SJ	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.	Journal of clinical oncology 	2015	54
25867064	Cisplatin	Zhu X	miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin.	Oncogene	2016	28
25871967	Cisplatin	Li X	MicroRNA-449a inhibits proliferation and induces apoptosis by directly repressing E2F3 in gastric cancer.	Cellular physiology and biochemistry 	2015	16
25888377	Cisplatin	Zhou X	MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7.	Journal of experimental & clinical cancer research 	2015	21
25956062	Cisplatin	Zhang XW	Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance.	Biochemical and biophysical research communications	2015	32
25965342	Cisplatin	Mohni KN	A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.	PloS one	2015	17
25967360	Cisplatin	Wang F	Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells.	Neoplasma	2015	18
25972604	Cisplatin	Challagundla KB	Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy.	Journal of the National Cancer Institute	2015	50
25992654	Cisplatin	Liu J	The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma.	PloS one	2015	36
25995442	Cisplatin	Liu G	Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.	Journal of the National Cancer Institute	2015	24
26020117	Cisplatin	Cioffi M	Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer.	Scientific reports	2015	22
26026166	Cisplatin	Tanaka K	miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.	Carcinogenesis	2015	20
26033801	Cisplatin	Bielack SS	Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.	Journal of clinical oncology 	2015	46
26036632	Cisplatin	García-Cano J	Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance.	Oncotarget	2015	19
26043084	Cisplatin	Li N	MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.	PloS one	2015	19
26045340	Cisplatin	Thatcher N	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.	The Lancet. Oncology	2015	69
26061330	Cisplatin	Du F	S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial.	Medicine	2015	18
26066081	Cisplatin	Tomas A	WASH and Tsg101/ALIX-dependent diversion of stress-internalized EGFR from the canonical endocytic pathway.	Nature communications	2015	16
26119935	Cisplatin	Ciamporcero E	YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage.	Oncogene	2016	19
26178914	Cisplatin	Balermpas P	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG).	International journal of cancer	2016	27
26201611	Cisplatin	Wu HM	Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells.	Scientific reports	2015	18
26201895	Cisplatin	Han LP	MicroRNA-138 negatively regulates non-small cell lung cancer cells through the interaction with cyclin D3.	Tumour biology 	2016	10
26234674	Cisplatin	Phatak P	Overexpression of miR-214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly and indirectly through CUG-BP1.	Oncogene	2016	15
26238431	Cisplatin	Plimack ER	Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.	European urology	2015	37
26282001	Cisplatin	Xie J	MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2.	Tumour biology 	2016	10
26325371	Cisplatin	Liu M	RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.	Oncotarget	2015	15
26341496	Cisplatin	Li J	Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/β-catenin pathway in human ovarian cancer.	Tumour biology 	2016	17
26376998	Cisplatin	Li JH	Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.	Tumour biology 	2016	11
26386726	Cisplatin	Samuel P	Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.	Tumour biology 	2016	14
26462739	Cisplatin	Pariente R	Melatonin sensitizes human cervical cancer HeLa cells to cisplatin-induced cytotoxicity and apoptosis: effects on oxidative stress and DNA fragmentation.	Journal of pineal research	2016	17
26530471	Cisplatin	Planells-Cases R	Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs.	The EMBO journal	2015	19
26595461	Cisplatin	Wanzel M	CRISPR-Cas9-based target validation for p53-reactivating model compounds.	Nature chemical biology	2016	12
26598537	Cisplatin	Cierna Z	Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.	Annals of oncology 	2016	16
26654944	Cisplatin	Choi EJ	FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.	Oncotarget	2016	12
26716514	Cisplatin	Cheng H	Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells.	Oncotarget	2016	17
26719230	Cisplatin	Zalcman G	Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.	Lancet	2016	63
26756568	Cisplatin	Zhou XL	High expression of long non-coding RNA AFAP1-AS1 predicts chemoradioresistance and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.	Molecular carcinogenesis	2016	16
26799420	Cisplatin	Su X	Overexpression of TRIM14 promotes tongue squamous cell carcinoma aggressiveness by activating the NF-κB signaling pathway.	Oncotarget	2016	12
26801672	Cisplatin	Liu S	NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.	Tumour biology 	2016	10
26801746	Cisplatin	Ai Z	Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.	Cancer letters	2016	11
26822397	Cisplatin	Fujitani K	Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.	The Lancet. Oncology	2016	32
26859293	Cisplatin	Su YC	Galectin-1-Induced Autophagy Facilitates Cisplatin Resistance of Hepatocellular Carcinoma.	PloS one	2016	11
26894974	Cisplatin	Syu JP	Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia.	Oncotarget	2016	11
26909612	Cisplatin	Zhu X	miR-194 inhibits the proliferation, invasion, migration, and enhances the chemosensitivity of non-small cell lung cancer cells by targeting forkhead box A1 protein.	Oncotarget	2016	14
26982250	Cisplatin	Czapar AE	Tobacco Mosaic Virus Delivery of Phenanthriplatin for Cancer therapy.	ACS nano	2016	14
27013395	Cisplatin	Morrow CJ	Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study.	Annals of oncology 	2016	14
27014910	Cisplatin	Chen QY	miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.	Oncotarget	2016	18
27019355	Cisplatin	Zhu Z	MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells.	PloS one	2016	13
27055401	Cisplatin	Sakallı Çetin E	Selenium potentiates the anticancer effect of cisplatin against oxidative stress and calcium ion signaling-induced intracellular toxicity in MCF-7 breast cancer cells: involvement of the TRPV1 channel.	Journal of receptor and signal transduction research	2017	5
27071093	Cisplatin	Menghi F	The tandem duplicator phenotype as a distinct genomic configuration in cancer.	Proceedings of the National Academy of Sciences of the United States of America	2016	10
27088857	Cisplatin	Lien EC	Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer.	Nature cell biology	2016	16
27166999	Cisplatin	Báez-Vega PM	Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.	Oncotarget	2016	13
27193186	Cisplatin	Zheng ZG	The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer.	Scientific reports	2016	15
27199349	Cisplatin	Langsch S	miR-29b Mediates NF-κB Signaling in KRAS-Induced Non-Small Cell Lung Cancers.	Cancer research	2016	14
27270317	Cisplatin	Jiang P	NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.	Oncotarget	2016	16
27287412	Cisplatin	Shintani Y	IL-6 Secreted from Cancer-Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial-Mesenchymal Transition Signaling.	Journal of thoracic oncology 	2016	17
27372520	Cisplatin	Malapelle U	USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.	Lung cancer	2017	5
27381626	Cisplatin	Ter Brugge P	Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.	Journal of the National Cancer Institute	2016	11
27569212	Cisplatin	Beyranvand Nejad E	Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells.	Cancer research	2016	10
27609068	Cisplatin	Wang Y	Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis.	Cancer letters	2016	18
27803105	Cisplatin	Yokoyama Y	BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.	Cancer research	2016	13
27875524	Cisplatin	Li X	microRNA-137 promotes apoptosis in ovarian cancer cells via the regulation of XIAP.	British journal of cancer	2017	8
27900563	Cisplatin	Yan J	LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes.	Tumour biology 	2016	13
27903674	Cisplatin	Inman BA	Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.	Clinical cancer research 	2017	8
27911863	Cisplatin	Wang Q	Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma.	Oncotarget	2017	8
27939400	Cisplatin	Balar AV	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.	Lancet	2017	62
28027578	Cisplatin	Li D	Long noncoding RNA HULC modulates the phosphorylation of YB-1 through serving as a scaffold of extracellular signal-regulated kinase and YB-1 to enhance hepatocarcinogenesis.	Hepatology	2017	17
28163000	Cisplatin	Cunningham D	Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.	The Lancet. Oncology	2017	7
28192397	Cisplatin	Shi ZM	Downregulation of miR-218 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling.	Oncogene	2017	10
28196596	Cisplatin	Gardner EE	Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.	Cancer cell	2017	14
28214651	Cisplatin	Bellmunt J	A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.	Cancer treatment reviews	2017	14
28240761	Cisplatin	Elia G	Hepatocellular carcinoma and CXCR3 chemokines: a narrative review.	La Clinica terapeutica	2017	6
28285905	Cisplatin	Chen D	Targeting BMI1+ Cancer Stem Cells Overcomes Chemoresistance and Inhibits Metastases in Squamous Cell Carcinoma.	Cell stem cell	2017	10
28406482	Cisplatin	Wang L	Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.	Cell death & disease	2017	6
28407783	Cisplatin	Zheng P	Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells.	Journal of experimental & clinical cancer research 	2017	15
28612710	Cisplatin	Lee MR	YC-1 induces G0/G1 phase arrest and mitochondria-dependent apoptosis in cisplatin-resistant human oral cancer CAR cells.	BioMedicine	2017	7
8090225	Platinum	O'Donovan A	XPG endonuclease makes the 3' incision in human DNA nucleotide excision repair.	Nature	1994	128
11870167	Platinum	Bristow RE	Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.	Journal of clinical oncology 	2002	270
12529460	Platinum	Zhang L	Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.	The New England journal of medicine	2003	704
12712470	Platinum	Cass I	Improved survival in women with BRCA-associated ovarian carcinoma.	Cancer	2003	117
15173214	Platinum	Gurubhagavatula S	XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.	Journal of clinical oncology 	2004	76
15310767	Platinum	Pérez-Soler R	Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.	Journal of clinical oncology 	2004	157
16014882	Platinum	Shepherd FA	Erlotinib in previously treated non-small-cell lung cancer.	The New England journal of medicine	2005	1077
17290060	Platinum	Dressman HK	An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.	Journal of clinical oncology 	2007	95
17538161	Platinum	Vermorken JB	Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.	Journal of clinical oncology 	2007	169
18024863	Platinum	Burger RA	Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.	Journal of clinical oncology 	2007	198
18094425	Platinum	Quinn JE	BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy.	Clinical cancer research 	2007	57
18836486	Platinum	Baba T	Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.	Oncogene	2009	126
18955455	Platinum	Tan DS	"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.	Journal of clinical oncology 	2008	106
19193619	Platinum	Etemadmoghadam D	Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.	Clinical cancer research 	2009	74
19380441	Platinum	Yuan X	Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy.	Journal of clinical oncology 	2009	59
19549709	Platinum	Soria JC	Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.	Annals of oncology 	2009	45
19667264	Platinum	Shaw AT	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.	Journal of clinical oncology 	2009	422
19914732	Platinum	Dempke WC	Targeted therapies for non-small cell lung cancer.	Lung cancer	2010	49
20060649	Platinum	Bosch A	Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.	Cancer treatment reviews	2010	62
20164691	Platinum	Isakoff SJ	Triple-negative breast cancer: role of specific chemotherapy agents.	Cancer journal	2010	55
20336784	Platinum	Nakayama N	Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.	Cancer	2010	48
20406929	Platinum	Fong PC	Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.	Journal of clinical oncology 	2010	223
20493771	Platinum	Cappuzzo F	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.	The Lancet. Oncology	2010	301
20534738	Platinum	Solis LM	Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.	Clinical cancer research 	2010	105
20547991	Platinum	Konstantinopoulos PA	Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.	Journal of clinical oncology 	2010	112
20551945	Platinum	Janku F	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?	Nature reviews. Clinical oncology	2010	63
20888993	Platinum	Rustin GJ	Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.	Lancet	2010	77
20889728	Platinum	Landen CN Jr	Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.	Molecular cancer therapeutics	2010	114
21216927	Platinum	Rizzo S	Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.	Molecular cancer therapeutics	2011	65
21377930	Platinum	Machiels JP	Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial.	The Lancet. Oncology	2011	39
21468130	Platinum	Forster MD	Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.	Nature reviews. Clinical oncology	2011	42
21521830	Platinum	Jelovac D	Recent progress in the diagnosis and treatment of ovarian cancer.	CA	2011	119
21627863	Platinum	Wei J	Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer.	Chinese journal of cancer	2011	50
21709188	Platinum	Norquist B	Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.	Journal of clinical oncology 	2011	102
21795409	Platinum	Coward J	Interleukin-6 as a therapeutic target in human ovarian cancer.	Clinical cancer research 	2011	103
21934105	Platinum	Lowery MA	An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.	The oncologist	2011	43
21969500	Platinum	Brugger W	Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	71
21990299	Platinum	Yang D	Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.	JAMA	2011	113
22101352	Platinum	Katagiri A	Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.	Modern pathology 	2012	42
22237007	Platinum	Gao W	MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer.	Cancer biology & therapy	2012	33
22330607	Platinum	Kim A	Therapeutic strategies in epithelial ovarian cancer.	Journal of experimental & clinical cancer research 	2012	67
22593197	Platinum	Berns EM	The changing view of high-grade serous ovarian cancer.	Cancer research	2012	43
22897840	Platinum	Marchini S	Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer.	European journal of cancer	2013	43
22941649	Platinum	McNeil EM	DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.	Nucleic acids research	2012	35
22986452	Platinum	Yao Y	Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.	Cancer immunology, immunotherapy 	2013	47
22996961	Platinum	Castellarin M	Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease.	The Journal of pathology	2013	27
23012302	Platinum	André F	Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.	Annals of oncology 	2012	66
23017820	Platinum	Obermayr E	Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium.	Gynecologic oncology	2013	26
23047548	Platinum	Abkevich V	Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.	British journal of cancer	2012	64
23129122	Platinum	Wu YL	Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).	Annals of oncology 	2013	46
23401448	Platinum	Mok T	Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?	Journal of clinical oncology 	2013	30
23649003	Platinum	Aparicio AM	Platinum-based chemotherapy for variant castrate-resistant prostate cancer.	Clinical cancer research 	2013	42
23649446	Platinum	Socinski MA	Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.	Chest	2013	28
23833300	Platinum	Cardarella S	Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.	Clinical cancer research 	2013	46
24035405	Platinum	Calabrò L	Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.	The Lancet. Oncology	2013	48
24094768	Platinum	Fuchs CS	Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.	Lancet	2014	314
24218601	Platinum	Etemadmoghadam D	Synthetic lethality between CCNE1 amplification and loss of BRCA1.	Proceedings of the National Academy of Sciences of the United States of America	2013	34
24240112	Platinum	Pennington KP	Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.	Clinical cancer research 	2014	94
24366937	Platinum	Vergote IB	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.	Journal of clinical oncology 	2014	26
24439931	Platinum	Rajan A	Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2014	25
24531034	Platinum	Wu C	Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer.	The Tohoku journal of experimental medicine	2014	28
24727321	Platinum	Beltran H	Aggressive variants of castration-resistant prostate cancer.	Clinical cancer research 	2014	59
24868098	Platinum	Khozin S	U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.	The oncologist	2014	26
24929208	Platinum	Thayanithy V	Tumor-stromal cross talk: direct cell-to-cell transfer of oncogenic microRNAs via tunneling nanotubes.	Translational research 	2014	30
24958820	Platinum	Fakhry C	Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.	Journal of clinical oncology 	2014	44
25015375	Platinum	Kuhlmann JD	ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.	Clinical chemistry	2014	20
25072261	Platinum	Golan T	Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.	British journal of cancer	2014	31
25091798	Platinum	Masterson L	De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials.	European journal of cancer	2014	39
25093514	Platinum	Watkins JA	Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.	Breast cancer research 	2014	32
25216266	Platinum	Meng E	ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling.	PloS one	2014	28
25349291	Platinum	Iyengar P	Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.	Journal of clinical oncology 	2014	35
25395283	Platinum	Scagliotti GV	Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer.	Annals of oncology 	2015	17
25398436	Platinum	Galanis E	Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.	Cancer research	2015	44
25537514	Platinum	Gu Y	The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.	Oncotarget	2015	17
25552556	Platinum	Jenkins PM	Giant ankyrin-G: a critical innovation in vertebrate evolution of fast and integrated neuronal signaling.	Proceedings of the National Academy of Sciences of the United States of America	2015	25
25597412	Platinum	Fujita Y	The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer.	Molecular therapy 	2015	28
25636205	Platinum	Groenendijk FH	ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.	European urology	2016	19
25707631	Platinum	Nick AM	A framework for a personalized surgical approach to ovarian cancer.	Nature reviews. Clinical oncology	2015	28
25708226	Platinum	Tangutoori S	PARP inhibitors: A new era of targeted therapy.	Maturitas	2015	29
25710373	Platinum	Schwarz RF	Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.	PLoS medicine	2015	61
25719666	Platinum	Waddell N	Whole genomes redefine the mutational landscape of pancreatic cancer.	Nature	2015	297
25770156	Platinum	Watkins J	Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.	Cancer discovery	2015	17
25779564	Platinum	Scott CL	Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.	Journal of clinical oncology 	2015	58
25819643	Platinum	Calabrò L	Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.	The Lancet. Respiratory medicine	2015	19
25823737	Platinum	Stevanović S	Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.	Journal of clinical oncology 	2015	61
25890361	Platinum	Koneru M	A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.	Journal of translational medicine	2015	31
26017449	Platinum	Patch AM	Whole-genome characterization of chemoresistant ovarian cancer.	Nature	2015	158
26181256	Platinum	Beltran H	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.	JAMA oncology	2015	52
26279307	Platinum	He J	Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.	Scientific reports	2015	48
26351349	Platinum	Hamanishi J	Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.	Journal of clinical oncology 	2015	96
26463832	Platinum	Konstantinopoulos PA	Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.	Cancer discovery	2015	39
26511885	Platinum	Alexandrov LB	A mutational signature in gastric cancer suggests therapeutic strategies.	Nature communications	2015	20
26724258	Platinum	Cheng HH	Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.	European urology	2016	11
26729200	Platinum	Gong WJ	Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response.	Tumour biology 	2016	24
27026676	Platinum	Sul J	FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.	The oncologist	2016	24
27041570	Platinum	Özeş AR	NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer.	Oncogene	2016	19
27074572	Platinum	Zhou M	Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer.	Oncotarget	2016	49
27558151	Platinum	Matulonis UA	Ovarian cancer.	Nature reviews. Disease primers	2016	14
27590317	Platinum	Mateo J	DNA Repair in Prostate Cancer: Biology and Clinical Implications.	European urology	2017	7
27718847	Platinum	Reck M	Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.	The New England journal of medicine	2016	369
27733243	Platinum	Sharma P	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.	The Lancet. Oncology	2016	42
27736844	Platinum	Konecny GE	PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.	British journal of cancer	2016	21
27932068	Platinum	Rudin CM	Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.	The Lancet. Oncology	2017	23
27937096	Platinum	Spigel DR	Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.	Journal of clinical oncology 	2017	13
27959700	Platinum	Mok TS	Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.	The New England journal of medicine	2017	125
28104537	Platinum	Rangachari D	Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.	Journal of thoracic oncology 	2017	10
28131785	Platinum	Sharma P	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.	The Lancet. Oncology	2017	58
28291584	Platinum	Alley EW	Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.	The Lancet. Oncology	2017	22
28328302	Platinum	Bauml J	Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.	Journal of clinical oncology 	2017	19
28373005	Platinum	Gulley JL	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.	The Lancet. Oncology	2017	23
28424325	Platinum	Ning YM	FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.	The oncologist	2017	11
1313909	Etoposide	Cai W	Herpes simplex virus type 1 ICP0 regulates expression of immediate-early, early, and late genes in productively infected cells.	Journal of virology	1992	131
8253089	Etoposide	Oberhammer F	Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation.	The EMBO journal	1993	127
9216996	Etoposide	Lee J	Gli1 is a target of Sonic hedgehog that induces ventral neural tube development.	Development	1997	156
9733516	Etoposide	Wang CY	NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.	Science	1998	515
9850056	Etoposide	Tamm I	IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs.	Cancer research	1998	242
10487762	Etoposide	Allard S	NuA4, an essential transcription adaptor/histone H4 acetyltransferase complex containing Esa1p and the ATM-related cofactor Tra1p.	The EMBO journal	1999	170
10567338	Etoposide	Masumoto J	ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells.	The Journal of biological chemistry	1999	117
11146650	Etoposide	Tsukamoto T	Visualization of gene activity in living cells.	Nature cell biology	2000	96
12717439	Etoposide	Stevens C	Chk2 activates E2F-1 in response to DNA damage.	Nature cell biology	2003	132
12773551	Etoposide	Zhu WG	Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter.	Molecular and cellular biology	2003	77
16892051	Etoposide	Wang C	Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage.	Nature cell biology	2006	131
17533374	Etoposide	Maxwell PJ	HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells.	Oncogene	2007	67
18059169	Etoposide	Azad MB	Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3.	Autophagy	2008	93
18381439	Etoposide	Hann CL	Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.	Cancer research	2008	69
18559509	Etoposide	Wang L	Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells.	Cancer research	2008	61
18663354	Etoposide	Tagscherer KE	Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.	Oncogene	2008	63
19004856	Etoposide	Ota M	Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling.	Development	2008	109
19118018	Etoposide	Ara T	Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells.	Cancer research	2009	56
19920819	Etoposide	Reardon DA	Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.	British journal of cancer	2009	47
20625515	Etoposide	Song J	Characterization of side populations in HNSCC: highly invasive, chemoresistant and abnormal Wnt signaling.	PloS one	2010	45
20922763	Etoposide	Kang MH	National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.	Pediatric blood & cancer	2011	41
21171979	Etoposide	Hué S	Disease-associated XMRV sequences are consistent with laboratory contamination.	Retrovirology	2010	85
21217779	Etoposide	Ogiwara H	Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors.	Oncogene	2011	93
21333317	Etoposide	Marquitz AR	The Epstein-Barr Virus BART microRNAs target the pro-apoptotic protein Bim.	Virology	2011	62
21565980	Etoposide	Audrito V	Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network.	Cancer research	2011	39
21737329	Etoposide	Tenev T	The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs.	Molecular cell	2011	226
21778401	Etoposide	Wu CC	Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.	Science	2011	79
22328513	Etoposide	Singh R	Downregulation of BCL2 by miRNAs augments drug-induced apoptosis--a combined computational and experimental approach.	Journal of cell science	2012	33
22508727	Etoposide	Do PM	Mutant p53 cooperates with ETS2 to promote etoposide resistance.	Genes & development	2012	53
22615413	Etoposide	Cowell IG	Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity.	Proceedings of the National Academy of Sciences of the United States of America	2012	37
23437304	Etoposide	Wu CW	MicroRNA-18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer.	PloS one	2013	29
23851503	Etoposide	Huang CK	Autocrine/paracrine mechanism of interleukin-17B receptor promotes breast tumorigenesis through NF-κB-mediated antiapoptotic pathway.	Oncogene	2014	22
24559410	Etoposide	Kendrick S	The dynamic character of the BCL2 promoter i-motif provides a mechanism for modulation of gene expression by compounds that bind selectively to the alternative DNA hairpin structure.	Journal of the American Chemical Society	2014	26
25605014	Etoposide	Kirk JS	Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.	Oncotarget	2015	16
25629630	Etoposide	Fillmore CM	EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.	Nature	2015	59
25639871	Etoposide	Seviour EG	Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer.	Oncogene	2016	14
26253167	Etoposide	Genin M	M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide.	BMC cancer	2015	29
27247353	Etoposide	Polley E	Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.	Journal of the National Cancer Institute	2016	15
11156391	irinotecan	Ando Y	Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.	Cancer research	2000	93
11325813	irinotecan	Cusack JC Jr	Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.	Cancer research	2001	87
11489791	irinotecan	Mathijssen RH	Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).	Clinical cancer research 	2001	97
11990381	irinotecan	Iyer L	UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.	The pharmacogenomics journal	2002	111
14993230	irinotecan	Saltz LB	Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.	Journal of clinical oncology 	2004	294
15175435	irinotecan	Hurwitz H	Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.	The New England journal of medicine	2004	1926
15269313	irinotecan	Cunningham D	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.	The New England journal of medicine	2004	932
15677699	irinotecan	Chung KY	Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.	Journal of clinical oncology 	2005	204
15998951	irinotecan	Ince WL	Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.	Journal of the National Cancer Institute	2005	70
16365183	irinotecan	Jubb AM	Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.	Journal of clinical oncology 	2006	106
16723399	irinotecan	Agrelo R	Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer.	Proceedings of the National Academy of Sciences of the United States of America	2006	74
16809730	irinotecan	Toffoli G	The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2006	67
17728214	irinotecan	Hoskins JM	UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.	Journal of the National Cancer Institute	2007	109
17947719	irinotecan	Vredenburgh JJ	Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.	Journal of clinical oncology 	2007	340
17998284	irinotecan	De Roock W	KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.	Annals of oncology 	2008	211
18182667	irinotecan	Sathornsumetee S	Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.	Journal of clinical oncology 	2008	79
18560594	irinotecan	Dylla SJ	Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy.	PloS one	2008	174
18842611	irinotecan	Scartozzi M	Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.	Annals of oncology 	2009	79
19144677	irinotecan	Hurwitz HI	The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.	The oncologist	2009	50
19164213	irinotecan	Bibeau F	Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.	Journal of clinical oncology 	2009	129
19273709	irinotecan	Bertagnolli MM	Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.	Journal of clinical oncology 	2009	106
19332770	irinotecan	Quant EC	Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.	Neuro-oncology	2009	51
19349540	irinotecan	Innocenti F	Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.	Journal of clinical oncology 	2009	60
19349543	irinotecan	Lara PN Jr	Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.	Journal of clinical oncology 	2009	89
19366826	irinotecan	Prenen H	PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.	Clinical cancer research 	2009	86
19398573	irinotecan	Loupakis F	PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.	Journal of clinical oncology 	2009	126
19470791	irinotecan	Piazza GA	A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity.	Cancer prevention research	2009	45
19603018	irinotecan	Loupakis F	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.	British journal of cancer	2009	139
19664991	irinotecan	Hoey T	DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.	Cell stem cell	2009	110
19738126	irinotecan	Jacobs B	Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.	Journal of clinical oncology 	2009	87
19818685	irinotecan	Boku N	Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.	The Lancet. Oncology	2009	122
19934290	irinotecan	Ogino S	KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.	Clinical cancer research 	2009	66
20008624	irinotecan	Kopetz S	Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.	Journal of clinical oncology 	2010	120
20142816	irinotecan	Vilar E	Microsatellite instability in colorectal cancer-the stable evidence.	Nature reviews. Clinical oncology	2010	120
20167811	irinotecan	de Groot JF	Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.	Neuro-oncology	2010	166
20177422	irinotecan	Graziano F	Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.	The pharmacogenomics journal	2010	41
20238327	irinotecan	Wagner AD	Chemotherapy for advanced gastric cancer.	The Cochrane database of systematic reviews	2010	148
20332776	irinotecan	Fang DD	Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery.	British journal of cancer	2010	41
20585341	irinotecan	Boni V	Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan.	The pharmacogenomics journal	2011	37
21119032	irinotecan	Moehler M	Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.	Annals of oncology 	2011	36
21948564	irinotecan	Bitarte N	MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells.	Stem cells	2011	70
22147942	irinotecan	Ogino S	Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.	Clinical cancer research 	2012	87
22180495	irinotecan	Yang H	Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.	Cancer research	2012	58
22203733	irinotecan	Montano R	Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.	Molecular cancer therapeutics	2012	53
22228631	irinotecan	Spindler KL	Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.	Clinical cancer research 	2012	52
22446188	irinotecan	Ma CX	Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.	The Journal of clinical investigation	2012	63
23081779	irinotecan	Kobayashi S	LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution.	Stem cells	2012	38
23089672	irinotecan	Sim SC	Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.	The pharmacogenomics journal	2013	38
23242585	irinotecan	Ma CX	A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.	Breast cancer research and treatment	2013	29
23358684	irinotecan	Swindall AF	ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines.	Cancer research	2013	36
23649448	irinotecan	Jett JR	Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.	Chest	2013	45
23725851	irinotecan	Seymour MT	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.	The Lancet. Oncology	2013	74
24138831	irinotecan	Loupakis F	FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.	European journal of cancer	2014	22
24277455	irinotecan	Grohar PJ	Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.	Clinical cancer research 	2014	21
24523596	irinotecan	Noguchi K	Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.	Pharmacogenomics and personalized medicine	2014	31
24859205	irinotecan	Shiovitz S	CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.	Gastroenterology	2014	31
24934408	irinotecan	Al-Ahmadie H	Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.	Cancer discovery	2014	32
24958824	irinotecan	Innocenti F	Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.	Journal of clinical oncology 	2014	22
25110412	irinotecan	Grossi V	p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance.	World journal of gastroenterology	2014	30
25185971	irinotecan	Satoh T	Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer.	Gastric cancer 	2015	23
25577133	irinotecan	Chang TC	Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.	Cancer chemotherapy and pharmacology	2015	16
26101915	irinotecan	Goldenberg DM	Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).	Oncotarget	2015	17
26294215	irinotecan	Zhang S	Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.	Cancer research	2015	20
26615328	irinotecan	Wang-Gillam A	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.	Lancet	2016	66
26989027	irinotecan	Hsu HC	Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.	Oncotarget	2016	19
27729313	irinotecan	Hong DS	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.	Cancer discovery	2016	18
28414297	irinotecan	Liu X	Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer.	The Journal of clinical investigation	2017	6
11156248	vinorelbine	Sirotnak FM	Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.	Clinical cancer research 	2000	98
12409326	vinorelbine	Scagliotti GV	Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2002	123
14559807	vinorelbine	Quinn JE	BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.	Cancer research	2003	99
16495393	vinorelbine	Joensuu H	Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.	The New England journal of medicine	2006	236
17317830	vinorelbine	Harris LN	Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.	Clinical cancer research 	2007	59
17947225	vinorelbine	Rosell R	Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.	Annals of oncology 	2008	61
18024870	vinorelbine	Tsao MS	Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.	Journal of clinical oncology 	2007	72
18237851	vinorelbine	Sève P	Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?	The Lancet. Oncology	2008	88
18594319	vinorelbine	Ramlau R	A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.	Journal of thoracic oncology 	2008	52
18927285	vinorelbine	Fichtner I	Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.	Clinical cancer research 	2008	93
19410716	vinorelbine	Pirker R	Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.	Lancet	2009	310
19491198	vinorelbine	Walker SR	Reciprocal effects of STAT5 and STAT3 in breast cancer.	Molecular cancer research 	2009	53
19884557	vinorelbine	Joensuu H	Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.	Journal of clinical oncology 	2009	90
21149659	vinorelbine	Andersson M	Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.	Journal of clinical oncology 	2011	51
21782507	vinorelbine	O'Byrne KJ	Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.	The Lancet. Oncology	2011	58
21990397	vinorelbine	Brufsky AM	RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.	Journal of clinical oncology 	2011	90
22590557	vinorelbine	Wilkerson MD	Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.	PloS one	2012	50
22967996	vinorelbine	Awada A	Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.	Annals of oncology 	2013	27
23666744	vinorelbine	Tan TZ	Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer.	EMBO molecular medicine	2013	37
24002511	vinorelbine	von Minckwitz G	Response-guided neoadjuvant chemotherapy for breast cancer.	Journal of clinical oncology 	2013	38
24742739	vinorelbine	André F	Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.	The Lancet. Oncology	2014	87
26822398	vinorelbine	Harbeck N	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.	The Lancet. Oncology	2016	12
27058664	vinorelbine	Vecchione L	A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.	Cell	2016	12
27265743	vinorelbine	Planchard D	A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.	Clinical lung cancer	2016	21
10567572	Paclitaxel	Yamamoto K	BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M.	Molecular and cellular biology	1999	194
10861441	Paclitaxel	Wang TH	Paclitaxel-induced cell death: where the cell cycle and apoptosis come together.	Cancer	2000	93
11426640	Paclitaxel	Mendelsohn J	The EGF receptor family as targets for cancer therapy.	Oncogene	2000	210
12559175	Paclitaxel	Anand S	AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.	Cancer cell	2003	164
14527951	Paclitaxel	Sunters A	FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines.	The Journal of biological chemistry	2003	148
15082135	Paclitaxel	Dougherty PM	Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients.	Pain	2004	97
15671559	Paclitaxel	Mozzetti S	Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.	Clinical cancer research 	2005	91
15766661	Paclitaxel	Tan TT	Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.	Cancer cell	2005	81
15958559	Paclitaxel	Kwok WK	Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target.	Cancer research	2005	139
16322248	Paclitaxel	Isakoff SJ	Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.	Cancer research	2005	174
16397234	Paclitaxel	Sunters A	Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt.	Cancer research	2006	79
16585214	Paclitaxel	Kelly MG	TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer.	Cancer research	2006	135
17276342	Paclitaxel	Zachos G	Chk1 is required for spindle checkpoint function.	Developmental cell	2007	80
17332325	Paclitaxel	Cheng GZ	Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel.	Cancer research	2007	170
17440056	Paclitaxel	Alexandre J	Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species.	Cancer research	2007	82
17538177	Paclitaxel	Gerstner ER	Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm.	Journal of clinical oncology 	2007	58
17560332	Paclitaxel	Swanton C	Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.	Cancer cell	2007	116
17611683	Paclitaxel	Kajiyama H	Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.	International journal of oncology	2007	127
18068629	Paclitaxel	Ahmed AA	The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel.	Cancer cell	2007	73
18160686	Paclitaxel	Miller K	Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.	The New England journal of medicine	2007	666
18375893	Paclitaxel	Seidman AD	Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.	Journal of clinical oncology 	2008	121
18451153	Paclitaxel	Shi J	Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5.	Cancer research	2008	81
18713866	Paclitaxel	Dubikovskaya EA	Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters.	Proceedings of the National Academy of Sciences of the United States of America	2008	56
18824714	Paclitaxel	Schneider BP	Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.	Journal of clinical oncology 	2008	171
19458043	Paclitaxel	Swanton C	Chromosomal instability determines taxane response.	Proceedings of the National Academy of Sciences of the United States of America	2009	80
19544473	Paclitaxel	Kurrey NK	Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells.	Stem cells	2009	191
19665763	Paclitaxel	Inaba T	Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.	Gynecologic oncology	2009	47
19720913	Paclitaxel	Gray R	Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.	Journal of clinical oncology 	2009	56
19748175	Paclitaxel	Zhang Q	A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy.	Cancer letters	2010	56
19806209	Paclitaxel	Gong Y	High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507).	PloS one	2009	58
19826413	Paclitaxel	Szajnik M	TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.	Oncogene	2009	55
19855003	Paclitaxel	Janssen A	Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	95
20113523	Paclitaxel	Ren Y	MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol.	BMC cancer	2010	47
20144215	Paclitaxel	Zhou M	Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol.	Molecular cancer	2010	67
20332234	Paclitaxel	To K	Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance.	Cancer research	2010	49
20460378	Paclitaxel	Zhou M	MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.	The Journal of biological chemistry	2010	149
20530690	Paclitaxel	Carr JR	FoxM1 mediates resistance to herceptin and paclitaxel.	Cancer research	2010	71
20624637	Paclitaxel	Li Z	MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.	Gynecologic oncology	2010	46
20687223	Paclitaxel	Kojima K	MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.	The Prostate	2010	53
20709389	Paclitaxel	Loessner D	Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells.	Biomaterials	2010	102
20975068	Paclitaxel	Andre F	Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.	Journal of clinical oncology 	2010	50
21051560	Paclitaxel	Leskelä S	The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.	Endocrine-related cancer	2011	63
21059829	Paclitaxel	Corcoran C	Intracellular and extracellular microRNAs in breast cancer.	Clinical chemistry	2011	62
21270667	Paclitaxel	Zhang JG	MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.	Journal of thoracic oncology 	2011	54
21349946	Paclitaxel	Lai D	Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF.	Cancer research	2011	107
21354697	Paclitaxel	Li J	miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression.	Cancer letters	2011	36
21511395	Paclitaxel	Xi G	Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells.	Cancer letters	2011	45
21791703	Paclitaxel	Quintavalle M	A cell-based high-content screening assay reveals activators and inhibitors of cancer cell invasion.	Science signaling	2011	36
22184370	Paclitaxel	Karlan BY	Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.	Journal of clinical oncology 	2012	61
22278287	Paclitaxel	Ajabnoor GM	Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells.	Cell death & disease	2012	33
22335738	Paclitaxel	Stone RL	Paraneoplastic thrombocytosis in ovarian cancer.	The New England journal of medicine	2012	130
22608923	Paclitaxel	Min SH	Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase.	Molecular cell	2012	51
22768203	Paclitaxel	Singh S	Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.	PloS one	2012	35
22843789	Paclitaxel	Baldwin RM	A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.	Clinical cancer research 	2012	47
23074172	Paclitaxel	Cittelly DM	Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.	Molecular cancer therapeutics	2012	39
23296900	Paclitaxel	Wang YQ	MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas.	Journal of cellular biochemistry	2013	34
23359505	Paclitaxel	Sevko A	Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.	Journal of immunology	2013	31
23552883	Paclitaxel	Mitamura T	Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET.	Oncogenesis	2013	34
23720768	Paclitaxel	Rajput S	TLR4 is a novel determinant of the response to paclitaxel in breast cancer.	Molecular cancer therapeutics	2013	28
23750239	Paclitaxel	Gao J	MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1.	PloS one	2013	34
23871962	Paclitaxel	Swaminathan SK	CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer.	Journal of controlled release 	2013	27
23943797	Paclitaxel	Cieply B	Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2.	Cancer research	2013	39
24063698	Paclitaxel	Dent RA	Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.	Breast cancer research 	2013	34
24170767	Paclitaxel	Liu N	BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.	Molecular cancer therapeutics	2013	32
24510775	Paclitaxel	Zhu X	miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.	International journal of cancer	2014	23
24591819	Paclitaxel	Kim YW	Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.	Drug design, development and therapy	2014	25
24599932	Paclitaxel	Abraham JE	Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.	Clinical cancer research 	2014	22
24755562	Paclitaxel	Chatterjee A	miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression.	PloS one	2014	29
24812269	Paclitaxel	Zhao Y	YAP-induced resistance of cancer cells to antitubulin drugs is modulated by a Hippo-independent pathway.	Cancer research	2014	23
24950985	Paclitaxel	Monk BJ	Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.	The Lancet. Oncology	2014	57
25023699	Paclitaxel	Saqcena M	Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs.	Oncogene	2015	15
25153722	Paclitaxel	Konno Y	MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells.	Oncotarget	2014	53
25154499	Paclitaxel	Wu T	Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy?	Molecular carcinogenesis	2015	20
25240821	Paclitaxel	Wilke H	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.	The Lancet. Oncology	2014	246
25258543	Paclitaxel	Ding J	Expression and clinical significance of the long non-coding RNA PVT1 in human gastric cancer.	OncoTargets and therapy	2014	28
25274031	Paclitaxel	Volk-Draper L	Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner.	Cancer research	2014	30
25435430	Paclitaxel	Chatterjee A	MiR-16 targets Bcl-2 in paclitaxel-resistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis.	Cellular signalling	2015	17
25446896	Paclitaxel	Ruffell B	Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.	Cancer cell	2014	85
25547504	Paclitaxel	Dang C	Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.	Journal of clinical oncology 	2015	18
25564897	Paclitaxel	Tolaney SM	Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.	The New England journal of medicine	2015	67
25605244	Paclitaxel	Yang Q	MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.	Oncotarget	2015	27
25684390	Paclitaxel	Weiner-Gorzel K	Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells.	Cancer medicine	2015	19
25759021	Paclitaxel	Jeon YJ	Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies.	Cancer cell	2015	28
25900794	Paclitaxel	Hu Y	miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.	Breast cancer research and treatment	2015	20
25961928	Paclitaxel	Khongkow P	Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.	Oncogene	2016	22
26071354	Paclitaxel	Chen MB	MicroRNA-101 down-regulates sphingosine kinase 1 in colorectal cancer cells.	Biochemical and biophysical research communications	2015	28
26092818	Paclitaxel	Hurvitz SA	Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.	The Lancet. Oncology	2015	47
26175417	Paclitaxel	Topham C	MYC Is a Major Determinant of Mitotic Cell Fate.	Cancer cell	2015	19
26282658	Paclitaxel	Bang YJ	Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.	Journal of clinical oncology 	2015	45
26421710	Paclitaxel	Farnie G	High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant.	Oncotarget	2015	30
26424893	Paclitaxel	Li Y	The Cancer Chemotherapeutic Paclitaxel Increases Human and Rodent Sensory Neuron Responses to TRPV1 by Activation of TLR4.	The Journal of neuroscience 	2015	33
26855150	Paclitaxel	Noll EM	CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.	Nature medicine	2016	15
26921339	Paclitaxel	Jiang YZ	Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value.	Cancer research	2016	16
26995633	Paclitaxel	Yang SX	New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.	Cancer treatment reviews	2016	25
27021436	Paclitaxel	Au Yeung CL	Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1.	Nature communications	2016	58
27556950	Paclitaxel	Jordan NV	HER2 expression identifies dynamic functional states within circulating breast cancer cells.	Nature	2016	23
27817944	Paclitaxel	Miles D	Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.	European journal of cancer	2017	10
27887917	Paclitaxel	Jeong JY	MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.	Cancer letters	2017	9
28209618	Paclitaxel	Chen MW	The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer.	Cancer research	2017	7
2644532	Tamoxifen	Fisher B	A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.	The New England journal of medicine	1989	154
9501191	Tamoxifen	Lavinsky RM	Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.	Proceedings of the National Academy of Sciences of the United States of America	1998	112
9605801	Tamoxifen	-	Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.	Lancet	1998	512
9747868	Tamoxifen	Fisher B	Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.	Journal of the National Cancer Institute	1998	717
10411913	Tamoxifen	Vasioukhin V	The magical touch: genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin.	Proceedings of the National Academy of Sciences of the United States of America	1999	237
11136970	Tamoxifen	Shang Y	Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription.	Cell	2000	515
11595837	Tamoxifen	Mandlekar S	Mechanisms of tamoxifen-induced apoptosis.	Apoptosis 	2001	89
11710890	Tamoxifen	King MC	Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.	JAMA	2001	93
11870534	Tamoxifen	Pérez-Tenorio G	Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients.	British journal of cancer	2002	92
12618500	Tamoxifen	Osborne CK	Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.	Journal of the National Cancer Institute	2003	187
12796359	Tamoxifen	Jensen EV	The estrogen receptor: a model for molecular medicine.	Clinical cancer research 	2003	83
14555514	Tamoxifen	Girault I	Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas.	Clinical cancer research 	2003	80
14970205	Tamoxifen	Scarlatti F	Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1.	The Journal of biological chemistry	2004	122
15172987	Tamoxifen	Widschwendter M	Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen.	Cancer research	2004	96
15193263	Tamoxifen	Ma XJ	A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.	Cancer cell	2004	241
15197194	Tamoxifen	Metcalfe K	Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2004	113
15310774	Tamoxifen	Fink AK	Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer.	Journal of clinical oncology 	2004	78
15342805	Tamoxifen	Hughes KS	Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.	The New England journal of medicine	2004	106
15591335	Tamoxifen	Paik S	A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.	The New England journal of medicine	2004	1319
15613444	Tamoxifen	Ring A	Mechanisms of tamoxifen resistance.	Endocrine-related cancer	2004	142
15632378	Tamoxifen	Jin Y	CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.	Journal of the National Cancer Institute	2005	181
15753463	Tamoxifen	Gutierrez MC	Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.	Journal of clinical oncology 	2005	129
15952058	Tamoxifen	Nowell SA	Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.	Breast cancer research and treatment	2005	80
16000569	Tamoxifen	De Laurentiis M	A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.	Clinical cancer research 	2005	76
16080193	Tamoxifen	Hiscox S	Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation.	International journal of cancer	2006	77
16088978	Tamoxifen	Kirkegaard T	AKT activation predicts outcome in breast cancer patients treated with tamoxifen.	The Journal of pathology	2005	76
16113104	Tamoxifen	Gee JM	Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.	Endocrine-related cancer	2005	66
16145046	Tamoxifen	Arpino G	Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.	Journal of the National Cancer Institute	2005	104
16288118	Tamoxifen	Fisher B	Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.	Journal of the National Cancer Institute	2005	240
16355216	Tamoxifen	Wu H	Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis.	Nature	2005	68
16361630	Tamoxifen	Goetz MP	Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.	Journal of clinical oncology 	2005	166
16397211	Tamoxifen	Fiegl H	Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer.	Cancer research	2006	65
16609087	Tamoxifen	Berry DA	Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.	JAMA	2006	145
16705121	Tamoxifen	Holm C	Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.	Journal of the National Cancer Institute	2006	68
16737553	Tamoxifen	Habel LA	A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.	Breast cancer research 	2006	115
16815318	Tamoxifen	Borges S	Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.	Clinical pharmacology and therapeutics	2006	117
16888645	Tamoxifen	Obexer P	FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells.	Cell death and differentiation	2007	62
17115111	Tamoxifen	Goetz MP	The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.	Breast cancer research and treatment	2007	115
17244352	Tamoxifen	Wegman P	Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.	Breast cancer research 	2007	65
17254967	Tamoxifen	Chu I	p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2.	Cell	2007	125
17280616	Tamoxifen	Lin ML	Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.	Breast cancer research 	2007	55
17312304	Tamoxifen	Cuzick J	Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.	Journal of the National Cancer Institute	2007	96
17312305	Tamoxifen	Powles TJ	Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.	Journal of the National Cancer Institute	2007	83
17401012	Tamoxifen	Loi S	Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.	Journal of clinical oncology 	2007	271
17407600	Tamoxifen	Zhou Y	Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.	BMC cancer	2007	58
17475399	Tamoxifen	Riggins RB	Pathways to tamoxifen resistance.	Cancer letters	2007	79
17512856	Tamoxifen	LHRH-agonists in Early Breast Cancer Overview group.	Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.	Lancet	2007	61
17721435	Tamoxifen	Green KA	Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state.	Nature reviews. Cancer	2007	78
18001838	Tamoxifen	Ingelman-Sundberg M	Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.	Pharmacology & therapeutics	2007	161
18024866	Tamoxifen	Schroth W	Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.	Journal of clinical oncology 	2007	97
18071188	Tamoxifen	Owusu C	Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.	Journal of clinical oncology 	2008	77
18172760	Tamoxifen	Qadir MA	Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization.	Breast cancer research and treatment	2008	70
18193062	Tamoxifen	Kouzine F	The functional response of upstream DNA to dynamic supercoiling in vivo.	Nature structural & molecular biology	2008	121
18196574	Tamoxifen	Metcalfe KA	International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.	International journal of cancer	2008	52
18386815	Tamoxifen	Davies MP	Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.	International journal of cancer	2008	53
18458534	Tamoxifen	Mercier I	Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy.	Cancer biology & therapy	2008	53
18498629	Tamoxifen	Loi S	Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.	BMC genomics	2008	136
18669459	Tamoxifen	Honma N	Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.	Journal of clinical oncology 	2008	58
18708351	Tamoxifen	Miller TE	MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.	The Journal of biological chemistry	2008	258
18765548	Tamoxifen	Helleman J	Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response.	Clinical cancer research 	2008	58
18790736	Tamoxifen	Zhao JJ	MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer.	The Journal of biological chemistry	2008	195
19005469	Tamoxifen	Hurtado A	Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.	Nature	2008	102
19221464	Tamoxifen	Schoenlein PV	Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance.	Autophagy	2009	54
19411448	Tamoxifen	Witkiewicz AK	An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers.	The American journal of pathology	2009	116
19470930	Tamoxifen	Visvanathan K	American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.	Journal of clinical oncology 	2009	73
19487384	Tamoxifen	Shi L	Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.	Journal of clinical oncology 	2009	52
19629072	Tamoxifen	Hoskins JM	CYP2D6 and tamoxifen: DNA matters in breast cancer.	Nature reviews. Cancer	2009	70
19685490	Tamoxifen	López-Knowles E	PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.	International journal of cancer	2010	66
19809024	Tamoxifen	Schroth W	Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.	JAMA	2009	118
19949017	Tamoxifen	Dowsett M	Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.	Journal of clinical oncology 	2010	178
20065188	Tamoxifen	Mamounas EP	Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.	Journal of clinical oncology 	2010	78
20124171	Tamoxifen	Kiyotani K	Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.	Journal of clinical oncology 	2010	49
20142325	Tamoxifen	Kelly CM	Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.	BMJ	2010	73
20224296	Tamoxifen	Dalby KN	Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer.	Autophagy	2010	135
20385997	Tamoxifen	Dezentjé VO	Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.	Journal of clinical oncology 	2010	45
20479250	Tamoxifen	Loi S	PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	114
20490652	Tamoxifen	Rodríguez-González FG	MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer.	Breast cancer research and treatment	2011	38
20495363	Tamoxifen	Bonuccelli G	The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts.	Cell cycle	2010	73
20625130	Tamoxifen	Burstein HJ	American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.	Journal of clinical oncology 	2010	194
20697068	Tamoxifen	Symmans WF	Genomic index of sensitivity to endocrine therapy for breast cancer.	Journal of clinical oncology 	2010	88
20805453	Tamoxifen	Bianchini G	Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.	Journal of clinical oncology 	2010	64
20837693	Tamoxifen	Nielsen TO	A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.	Clinical cancer research 	2010	187
20876285	Tamoxifen	Cittelly DM	Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.	Carcinogenesis	2010	57
21151129	Tamoxifen	Hurtado A	FOXA1 is a key determinant of estrogen receptor function and endocrine response.	Nature genetics	2011	242
21172025	Tamoxifen	Cittelly DM	Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.	Molecular cancer	2010	69
21393507	Tamoxifen	Shi W	MicroRNA-301 mediates proliferation and invasion in human breast cancer.	Cancer research	2011	72
21451508	Tamoxifen	Mürdter TE	Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.	Clinical pharmacology and therapeutics	2011	67
21482774	Tamoxifen	Mendes-Pereira AM	Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen.	Proceedings of the National Academy of Sciences of the United States of America	2012	48
21559019	Tamoxifen	Jerevall PL	Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.	British journal of cancer	2011	38
21572428	Tamoxifen	Pan X	Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer.	Nature medicine	2011	39
21666713	Tamoxifen	Bergamaschi A	Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance.	Oncogene	2012	62
21738599	Tamoxifen	Rothé F	Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer.	PloS one	2011	71
21768775	Tamoxifen	Martinez-Outschoorn UE	Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells.	Cell cycle	2011	42
21802721	Tamoxifen	Early Breast Cancer Trialists' Collaborative Group (EBCTCG).	Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.	Lancet	2011	412
21922245	Tamoxifen	Livaudais JC	Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.	Breast cancer research and treatment	2012	30
21935603	Tamoxifen	Pontiggia O	The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin.	Breast cancer research and treatment	2012	34
22116397	Tamoxifen	Shirabe K	Role of tumor-associated macrophages in the progression of hepatocellular carcinoma.	Surgery today	2012	38
22417809	Tamoxifen	Zhou C	Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration.	Breast cancer research 	2012	31
22508479	Tamoxifen	Ward A	Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer.	Oncogene	2013	73
22532584	Tamoxifen	Prat A	Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.	Annals of oncology 	2012	32
22565002	Tamoxifen	Bachelot T	Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.	Journal of clinical oncology 	2012	132
22573715	Tamoxifen	Fagan DH	Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.	Cancer research	2012	45
22689091	Tamoxifen	Murphy CC	Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.	Breast cancer research and treatment	2012	83
22711706	Tamoxifen	Chia SK	A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.	Clinical cancer research 	2012	55
23091108	Tamoxifen	Brauch H	Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.	Journal of clinical oncology 	2013	28
23143302	Tamoxifen	Nishio M	Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice.	The Journal of clinical investigation	2012	37
23292282	Tamoxifen	Muscat GE	Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer.	Molecular endocrinology	2013	27
23589310	Tamoxifen	Khurana SS	The hyaluronic acid receptor CD44 coordinates normal and metaplastic gastric epithelial progenitor cell proliferation.	The Journal of biological chemistry	2013	32
23690420	Tamoxifen	Hughes KS	Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.	Journal of clinical oncology 	2013	77
23835710	Tamoxifen	Visvanathan K	Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.	Journal of clinical oncology 	2013	81
23836010	Tamoxifen	Mihály Z	A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer.	Breast cancer research and treatment	2013	53
23918944	Tamoxifen	Phillips KA	Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2013	28
23968733	Tamoxifen	Hoppe R	Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment.	European journal of cancer	2013	31
24060820	Tamoxifen	Province MA	CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.	Clinical pharmacology and therapeutics	2014	37
24178749	Tamoxifen	Piva M	Sox2 promotes tamoxifen resistance in breast cancer cells.	EMBO molecular medicine	2014	54
24186067	Tamoxifen	Lemke G	Biology of the TAM receptors.	Cold Spring Harbor perspectives in biology	2013	70
24217577	Tamoxifen	Merenbakh-Lamin K	D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.	Cancer research	2013	70
24746818	Tamoxifen	Luo X	Isolation and molecular characterization of circulating melanoma cells.	Cell reports	2014	32
24868023	Tamoxifen	Burstein HJ	Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.	Journal of clinical oncology 	2014	119
24924200	Tamoxifen	Gan R	Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3.	Cancer gene therapy	2014	25
25007959	Tamoxifen	Wei Y	Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells.	Breast cancer research and treatment	2014	39
25091503	Tamoxifen	Saladores P	Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.	The pharmacogenomics journal	2015	20
25213081	Tamoxifen	Bergamaschi A	The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.	Breast cancer research 	2014	22
25361980	Tamoxifen	Treilleux I	Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.	Annals of oncology 	2015	18
25510853	Tamoxifen	Evans DG	The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services.	Breast cancer research 	2014	43
25580734	Tamoxifen	Zhou W	Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth.	Nature cell biology	2015	88
25663687	Tamoxifen	Nyante SJ	Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer.	Journal of the National Cancer Institute	2015	16
25879485	Tamoxifen	Lai A	Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.	Journal of medicinal chemistry	2015	29
25939896	Tamoxifen	Coates AS	Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.	Annals of oncology 	2015	194
25990368	Tamoxifen	Yuan J	Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.	Breast cancer research 	2015	16
26092816	Tamoxifen	Bernhard J	Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.	The Lancet. Oncology	2015	21
26122181	Tamoxifen	Jeselsohn R	ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.	Nature reviews. Clinical oncology	2015	45
26156960	Tamoxifen	Di Caro G	Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy.	Gut	2016	16
26211827	Tamoxifen	Early Breast Cancer Trialists' Collaborative Group (EBCTCG).	Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.	Lancet	2015	65
26243145	Tamoxifen	Sousa S	Human breast cancer cells educate macrophages toward the M2 activation status.	Breast cancer research 	2015	30
26416449	Tamoxifen	Lin L	CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer.	Oncotarget	2015	19
26538583	Tamoxifen	Tran KA	Endothelial β-Catenin Signaling Is Required for Maintaining Adult Blood-Brain Barrier Integrity and Central Nervous System Homeostasis.	Circulation	2016	11
26884586	Tamoxifen	Burstein HJ	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.	Journal of clinical oncology 	2016	17
27210762	Tamoxifen	Georgoudaki AM	Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis.	Cell reports	2016	21
27521269	Tamoxifen	Schietinger A	Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.	Immunity	2016	20
27548161	Tamoxifen	Rondón-Lagos M	Tamoxifen Resistance: Emerging Molecular Targets.	International journal of molecular sciences	2016	10
27593106	Tamoxifen	Raggi C	Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages.	Journal of hepatology	2017	16
27977766	Tamoxifen	Liu H	Knockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt/β-Catenin Pathway.	PloS one	2016	12
27986463	Tamoxifen	Muluhngwi P	Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.	Cancer letters	2017	6
28063065	Tamoxifen	Zhang HY	Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205.	Cancer chemotherapy and pharmacology	2017	8
28063929	Tamoxifen	Chen MJ	MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM.	Biochemical and biophysical research communications	2017	6
28184013	Tamoxifen	Kasikara C	Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression.	Molecular cancer research 	2017	7
28258690	Tamoxifen	Akalu YT	TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.	Immunological reviews	2017	5
28355176	Tamoxifen	Shimokawa M	Visualization and targeting of LGR5+ human colon cancer stem cells.	Nature	2017	23
28514441	Tamoxifen	Gordon SR	PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.	Nature	2017	43
15169807	Carboplatin	Johnson DH	Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.	Journal of clinical oncology 	2004	314
16043828	Carboplatin	Eberhard DA	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.	Journal of clinical oncology 	2005	363
16043829	Carboplatin	Herbst RS	TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2005	284
16782917	Carboplatin	Robert N	Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.	Journal of clinical oncology 	2006	97
17167137	Carboplatin	Sandler A	Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.	The New England journal of medicine	2006	1259
18165641	Carboplatin	Ramalingam SS	Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.	Journal of clinical oncology 	2008	61
18264088	Carboplatin	Edwards SL	Resistance to therapy caused by intragenic deletion in BRCA2.	Nature	2008	233
18316562	Carboplatin	Dowlati A	Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.	Clinical cancer research 	2008	82
18612151	Carboplatin	Hirsch FR	Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.	Journal of clinical oncology 	2008	70
19917840	Carboplatin	Kies MS	Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.	Journal of clinical oncology 	2010	40
20085937	Carboplatin	Dahlberg SE	Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.	Journal of clinical oncology 	2010	54
20100958	Carboplatin	Khambata-Ford S	Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	65
20159815	Carboplatin	Soria JC	Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer.	Journal of clinical oncology 	2010	47
20671266	Carboplatin	Park JT	Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin.	The American journal of pathology	2010	44
21555682	Carboplatin	Blumenschein GR Jr	Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.	Journal of clinical oncology 	2011	46
21676886	Carboplatin	Konstantinopoulos PA	Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.	Cancer research	2011	61
22010015	Carboplatin	Soria JC	Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	62
22048815	Carboplatin	Weigman VJ	Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival.	Breast cancer research and treatment	2012	43
22124101	Carboplatin	Kim KB	BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.	Journal of clinical oncology 	2012	52
22204724	Carboplatin	Burger RA	Incorporation of bevacizumab in the primary treatment of ovarian cancer.	The New England journal of medicine	2011	349
22204725	Carboplatin	Perren TJ	A phase 3 trial of bevacizumab in ovarian cancer.	The New England journal of medicine	2011	329
22547605	Carboplatin	Jänne PA	Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.	Journal of clinical oncology 	2012	82
22665533	Carboplatin	Carey LA	TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.	Journal of clinical oncology 	2012	122
22753922	Carboplatin	Scagliotti GV	International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.	Journal of clinical oncology 	2012	51
22858559	Carboplatin	Reck M	Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.	Annals of oncology 	2013	101
23002282	Carboplatin	Kaye SB	A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer.	Annals of oncology 	2013	26
23483678	Carboplatin	Vonderheide RH	Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.	Oncoimmunology	2013	34
24336327	Carboplatin	Li A	SALL4 is a new target in endometrial cancer.	Oncogene	2015	19
24794243	Carboplatin	von Minckwitz G	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.	The Lancet. Oncology	2014	100
24842883	Carboplatin	Lee JM	Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.	Journal of the National Cancer Institute	2014	45
24888810	Carboplatin	Langer CJ	Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2014	45
25481791	Carboplatin	Oza AM	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.	The Lancet. Oncology	2015	87
25534375	Carboplatin	Denkert C	Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.	Journal of clinical oncology 	2015	123
25795410	Carboplatin	Weber JS	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.	The Lancet. Oncology	2015	332
25867061	Carboplatin	Xue J	MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.	Oncogene	2016	16
25893298	Carboplatin	He Y	Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.	Oncogene	2016	11
26014294	Carboplatin	Zhou C	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2015	37
26025631	Carboplatin	Brozovic A	The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.	Molecular oncology	2015	15
26497652	Carboplatin	Teschendorff AE	HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer.	Genome medicine	2015	26
26928463	Carboplatin	Kumar A	Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.	Nature medicine	2016	55
27039845	Carboplatin	Noonan AM	Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.	Molecular therapy 	2016	13
27569215	Carboplatin	Bliss SA	Mesenchymal Stem Cell-Derived Exosomes Stimulate Cycling Quiescence and Early Breast Cancer Dormancy in Bone Marrow.	Cancer research	2016	20
27745820	Carboplatin	Langer CJ	Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.	The Lancet. Oncology	2016	97
28438473	Carboplatin	Coleman RL	Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.	The Lancet. Oncology	2017	9
9064324	Oligonucleotides, Antisense	O'Connell J	The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.	The Journal of experimental medicine	1996	134
11740489	Oligonucleotides, Antisense	Hofmann TG	Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2.	Nature cell biology	2002	156
12070027	Oligonucleotides, Antisense	Derenne S	Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.	Blood	2002	97
12676582	Oligonucleotides, Antisense	Tetsu O	Proliferation of cancer cells despite CDK2 inhibition.	Cancer cell	2003	100
15324695	Oligonucleotides, Antisense	Nagata Y	PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.	Cancer cell	2004	448
15895073	Oligonucleotides, Antisense	Chiarle R	Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target.	Nature medicine	2005	134
16289418	Oligonucleotides, Antisense	Sieghart W	Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy.	Journal of hepatology	2006	62
16322751	Oligonucleotides, Antisense	Schimmer AD	Targeting XIAP for the treatment of malignancy.	Cell death and differentiation	2006	70
16554823	Oligonucleotides, Antisense	Shamovsky I	RNA-mediated response to heat shock in mammalian cells.	Nature	2006	106
17363372	Oligonucleotides, Antisense	Zhu S	MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1).	The Journal of biological chemistry	2007	321
17384677	Oligonucleotides, Antisense	Matsubara H	Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92.	Oncogene	2007	109
18429962	Oligonucleotides, Antisense	Takakura S	Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells.	Cancer science	2008	72
18431520	Oligonucleotides, Antisense	Ernst M	STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice.	The Journal of clinical investigation	2008	93
18632605	Oligonucleotides, Antisense	Taguchi A	Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster.	Cancer research	2008	104
19383915	Oligonucleotides, Antisense	Graff JR	eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival.	Cancer research	2009	49
19509158	Oligonucleotides, Antisense	Li J	MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor.	Clinical cancer research 	2009	102
19546886	Oligonucleotides, Antisense	Liu M	Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma.	Cell research	2009	49
20048743	Oligonucleotides, Antisense	Zhou X	Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status.	Laboratory investigation; a journal of technical methods and pathology	2010	100
20195546	Oligonucleotides, Antisense	Qin W	miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells.	PloS one	2010	80
21718111	Oligonucleotides, Antisense	Hawinkels LJ	Exploring anti-TGF-β therapies in cancer and fibrosis.	Growth factors	2011	60
22006329	Oligonucleotides, Antisense	Zammarchi F	Antitumorigenic potential of STAT3 alternative splicing modulation.	Proceedings of the National Academy of Sciences of the United States of America	2011	48
23243023	Oligonucleotides, Antisense	Gutschner T	The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells.	Cancer research	2013	330
24170860	Oligonucleotides, Antisense	Lagier-Tourenne C	Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2013	126
25223704	Oligonucleotides, Antisense	Yin Y	Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth.	Cell research	2014	30
25766528	Oligonucleotides, Antisense	Song B	MiR-940 inhibited pancreatic ductal adenocarcinoma growth by targeting MyD88.	Cellular physiology and biochemistry 	2015	17
25970242	Oligonucleotides, Antisense	Koh CM	MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis.	Nature	2015	46
26282675	Oligonucleotides, Antisense	Wu H	MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway.	Gut	2016	17
26338776	Oligonucleotides, Antisense	Kamola PJ	In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization.	Nucleic acids research	2015	16
26538029	Oligonucleotides, Antisense	Morciano G	Mcl-1 involvement in mitochondrial dynamics is associated with apoptotic cell death.	Molecular biology of the cell	2016	16
26582900	Oligonucleotides, Antisense	Hong D	AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.	Science translational medicine	2015	33
26595814	Oligonucleotides, Antisense	Dewaele M	Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.	The Journal of clinical investigation	2016	16
27281208	Oligonucleotides, Antisense	Fox RG	Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma.	Nature	2016	16
7513258	Phosphatidylinositols	Ponzetto C	A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family.	Cell	1994	208
7792600	Phosphatidylinositols	Savitsky K	A single ataxia telangiectasia gene with a product similar to PI-3 kinase.	Science	1995	485
7929439	Phosphatidylinositols	Waltenberger J	Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor.	The Journal of biological chemistry	1994	264
9330874	Phosphatidylinositols	Frisch SM	Integrins and anoikis.	Current opinion in cell biology	1997	229
9508771	Phosphatidylinositols	Honda K	Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion.	The Journal of cell biology	1998	102
9843217	Phosphatidylinositols	Khanna KK	ATM associates with and phosphorylates p53: mapping the region of interaction.	Nature genetics	1998	125
10200246	Phosphatidylinositols	Cantley LC	New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.	Proceedings of the National Academy of Sciences of the United States of America	1999	450
10203785	Phosphatidylinositols	Maehama T	PTEN: a tumour suppressor that functions as a phospholipid phosphatase.	Trends in cell biology	1999	123
10209156	Phosphatidylinositols	Leevers SJ	Signalling through phosphoinositide 3-kinases: the lipids take centre stage.	Current opinion in cell biology	1999	129
10555148	Phosphatidylinositols	Lee JO	Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.	Cell	1999	280
10611246	Phosphatidylinositols	Lee RJ	Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway.	Molecular and cellular biology	2000	96
10839544	Phosphatidylinositols	Zhao S	Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products.	Nature	2000	109
11035810	Phosphatidylinositols	Fang X	Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A.	Proceedings of the National Academy of Sciences of the United States of America	2000	195
11156523	Phosphatidylinositols	Harari D	Molecular mechanisms underlying ErbB2/HER2 action in breast cancer.	Oncogene	2000	122
11278548	Phosphatidylinositols	Sheng H	Prostaglandin E2 increases growth and motility of colorectal carcinoma cells.	The Journal of biological chemistry	2001	151
11313365	Phosphatidylinositols	Persad S	Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343.	The Journal of biological chemistry	2001	122
11431323	Phosphatidylinositols	Sonoda Y	Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.	Cancer research	2001	90
11477064	Phosphatidylinositols	Arico S	The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway.	The Journal of biological chemistry	2001	140
11477091	Phosphatidylinositols	Re F	Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells.	The Journal of biological chemistry	2001	140
11479209	Phosphatidylinositols	Bachelder RE	Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells.	Cancer research	2001	106
11507052	Phosphatidylinositols	Zhang X	Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia.	Cancer research	2001	107
11544179	Phosphatidylinositols	Yamashita A	Human SMG-1, a novel phosphatidylinositol 3-kinase-related protein kinase, associates with components of the mRNA surveillance complex and is involved in the regulation of nonsense-mediated mRNA decay.	Genes & development	2001	120
11606375	Phosphatidylinositols	Philp AJ	The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.	Cancer research	2001	134
11778052	Phosphatidylinositols	Maeshima Y	Tumstatin, an endothelial cell-specific inhibitor of protein synthesis.	Science	2002	87
11994454	Phosphatidylinositols	Stahl M	The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2.	Journal of immunology	2002	195
12094235	Phosphatidylinositols	Vivanco I	The phosphatidylinositol 3-Kinase AKT pathway in human cancer.	Nature reviews. Cancer	2002	1428
12124177	Phosphatidylinositols	Sattler M	Critical role for Gab2 in transformation by BCR/ABL.	Cancer cell	2002	93
12149254	Phosphatidylinositols	Fukuda R	Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells.	The Journal of biological chemistry	2002	169
12351634	Phosphatidylinositols	Modur V	FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer.	The Journal of biological chemistry	2002	113
12391153	Phosphatidylinositols	Schmidt M	Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D.	Molecular and cellular biology	2002	139
12531180	Phosphatidylinositols	West KA	Activation of the PI3K/Akt pathway and chemotherapeutic resistance.	Drug resistance updates 	2002	132
12566441	Phosphatidylinositols	Fujino H	Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases.	The Journal of biological chemistry	2003	77
12764143	Phosphatidylinositols	Mottet D	Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells.	The Journal of biological chemistry	2003	87
12781366	Phosphatidylinositols	Zhao JJ	Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase.	Cancer cell	2003	101
12782577	Phosphatidylinositols	Choe G	Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.	Cancer research	2003	109
12824187	Phosphatidylinositols	Buchanan FG	Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor.	The Journal of biological chemistry	2003	106
12853564	Phosphatidylinositols	Holbro T	The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.	Proceedings of the National Academy of Sciences of the United States of America	2003	299
14607241	Phosphatidylinositols	Regan JW	EP2 and EP4 prostanoid receptor signaling.	Life sciences	2003	121
14663478	Phosphatidylinositols	Cox AD	The dark side of Ras: regulation of apoptosis.	Oncogene	2003	117
14769856	Phosphatidylinositols	Liu H	Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells.	The Journal of cell biology	2004	96
15143086	Phosphatidylinositols	Chakravarti A	The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.	Journal of clinical oncology 	2004	91
15193142	Phosphatidylinositols	Leslie NR	PTEN function: how normal cells control it and tumour cells lose it.	The Biochemical journal	2004	110
15254419	Phosphatidylinositols	Bachman KE	The PIK3CA gene is mutated with high frequency in human breast cancers.	Cancer biology & therapy	2004	183
15465916	Phosphatidylinositols	Ono A	Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane.	Proceedings of the National Academy of Sciences of the United States of America	2004	225
15467468	Phosphatidylinositols	Samuels Y	Oncogenic mutations of PIK3CA in human cancers.	Cell cycle	2004	131
15467756	Phosphatidylinositols	Asano T	The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells.	Oncogene	2004	91
15494427	Phosphatidylinositols	Yu JL	Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.	Blood	2005	118
15613447	Phosphatidylinositols	Kwabi-Addo B	The role of fibroblast growth factors and their receptors in prostate cancer.	Endocrine-related cancer	2004	81
15641016	Phosphatidylinositols	Foulstone E	Insulin-like growth factor ligands, receptors, and binding proteins in cancer.	The Journal of pathology	2005	67
15647370	Phosphatidylinositols	Kang S	Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.	Proceedings of the National Academy of Sciences of the United States of America	2005	218
15755954	Phosphatidylinositols	Inoki K	Signaling by target of rapamycin proteins in cell growth control.	Microbiology and molecular biology reviews 	2005	110
15766664	Phosphatidylinositols	Kim RH	DJ-1, a novel regulator of the tumor suppressor PTEN.	Cancer cell	2005	133
15864272	Phosphatidylinositols	Platanias LC	Mechanisms of type-I- and type-II-interferon-mediated signalling.	Nature reviews. Immunology	2005	718
15930273	Phosphatidylinositols	Ikenoue T	Functional analysis of PIK3CA gene mutations in human colorectal cancer.	Cancer research	2005	97
15942189	Phosphatidylinositols	Nawshad A	Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis.	Cells, tissues, organs	2005	95
15994075	Phosphatidylinositols	Velho S	The prevalence of PIK3CA mutations in gastric and colon cancer.	European journal of cancer	2005	97
16095999	Phosphatidylinositols	Bellacosa A	Activation of AKT kinases in cancer: implications for therapeutic targeting.	Advances in cancer research	2005	215
16261406	Phosphatidylinositols	Lo HW	EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization.	Breast cancer research and treatment	2006	67
16288007	Phosphatidylinositols	García-Rostán G	Mutation of the PIK3CA gene in anaplastic thyroid cancer.	Cancer research	2005	84
16288292	Phosphatidylinositols	Altomare DA	Perturbations of the AKT signaling pathway in human cancer.	Oncogene	2005	342
16299534	Phosphatidylinositols	Arroyo JD	Involvement of PP2A in viral and cellular transformation.	Oncogene	2005	83
16322209	Phosphatidylinositols	Oda K	High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.	Cancer research	2005	116
16324768	Phosphatidylinositols	Tang JM	Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.	Lung cancer	2006	87
16339315	Phosphatidylinositols	Zhao JJ	The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.	Proceedings of the National Academy of Sciences of the United States of America	2005	128
16341064	Phosphatidylinositols	Hennessy BT	Exploiting the PI3K/AKT pathway for cancer drug discovery.	Nature reviews. Drug discovery	2005	541
16341083	Phosphatidylinositols	Bader AG	Oncogenic PI3K deregulates transcription and translation.	Nature reviews. Cancer	2005	200
16446424	Phosphatidylinositols	Furuya F	Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.	Proceedings of the National Academy of Sciences of the United States of America	2006	65
16449998	Phosphatidylinositols	Karakas B	Mutation of the PIK3CA oncogene in human cancers.	British journal of cancer	2006	110
16453012	Phosphatidylinositols	Cully M	Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.	Nature reviews. Cancer	2006	341
16456542	Phosphatidylinositols	Takahashi Y	PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling.	The EMBO journal	2006	76
16478915	Phosphatidylinositols	Kakinuma T	Chemokines, chemokine receptors, and cancer metastasis.	Journal of leukocyte biology	2006	85
16489002	Phosphatidylinositols	Klos KS	ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.	Cancer research	2006	61
16543232	Phosphatidylinositols	Misra UK	Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78.	The Journal of biological chemistry	2006	73
16585185	Phosphatidylinositols	Orth JD	A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalization.	Cancer research	2006	85
16618748	Phosphatidylinositols	Nakamura K	Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells.	Cancer research	2006	67
16683005	Phosphatidylinositols	Nahta R	Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.	Nature clinical practice. Oncology	2006	233
16740687	Phosphatidylinositols	Song L	Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.	Cancer research	2006	79
16847462	Phosphatidylinositols	Engelman JA	The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.	Nature reviews. Genetics	2006	829
16880536	Phosphatidylinositols	Kasper M	Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes.	Molecular and cellular biology	2006	71
16912192	Phosphatidylinositols	Chesler L	Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.	Cancer research	2006	62
17060635	Phosphatidylinositols	Zhao JJ	The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation.	Proceedings of the National Academy of Sciences of the United States of America	2006	80
17068222	Phosphatidylinositols	Ferretti C	Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts.	Human reproduction update	2007	98
17159987	Phosphatidylinositols	Parsa AT	Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.	Nature medicine	2007	325
17206155	Phosphatidylinositols	Sergina NV	Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.	Nature	2007	299
17210696	Phosphatidylinositols	Maroulakou IG	Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.	Cancer research	2007	108
17308108	Phosphatidylinositols	Sawada K	c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.	Cancer research	2007	92
17322919	Phosphatidylinositols	Dillon RL	The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer.	Oncogene	2007	87
17332339	Phosphatidylinositols	Campbell PM	K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.	Cancer research	2007	79
17363567	Phosphatidylinositols	Saxena NK	Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells.	Cancer research	2007	118
17363738	Phosphatidylinositols	Chan SM	Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia.	Blood	2007	89
17372210	Phosphatidylinositols	Mehrian-Shai R	Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	62
17409416	Phosphatidylinositols	Kang HG	E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase.	Cancer research	2007	62
17452630	Phosphatidylinositols	Saal LH	Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.	Proceedings of the National Academy of Sciences of the United States of America	2007	184
17457303	Phosphatidylinositols	Marinkovich MP	Tumour microenvironment: laminin 332 in squamous-cell carcinoma.	Nature reviews. Cancer	2007	83
17546049	Phosphatidylinositols	Bauer S	KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.	Oncogene	2007	60
17574021	Phosphatidylinositols	Boehm JS	Integrative genomic approaches identify IKBKE as a breast cancer oncogene.	Cell	2007	238
17647198	Phosphatidylinositols	Chong ZZ	The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury.	Histology and histopathology	2007	80
17692802	Phosphatidylinositols	Brugge J	A new mutational AKTivation in the PI3K pathway.	Cancer cell	2007	92
17872411	Phosphatidylinositols	Stommel JM	Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.	Science	2007	349
17909010	Phosphatidylinositols	Lo HW	Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression.	Cancer research	2007	189
17964232	Phosphatidylinositols	Jiang BH	PI3K/PTEN signaling in tumorigenesis and angiogenesis.	Biochimica et biophysica acta	2008	73
18079394	Phosphatidylinositols	Huang CH	The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.	Science	2007	152
18177721	Phosphatidylinositols	DeBerardinis RJ	The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.	Cell metabolism	2008	950
18224685	Phosphatidylinositols	Barault L	Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.	International journal of cancer	2008	87
18245460	Phosphatidylinositols	Graff JR	Targeting the eukaryotic translation initiation factor 4E for cancer therapy.	Cancer research	2008	110
18296647	Phosphatidylinositols	Schmid T	Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion.	Cancer research	2008	53
18299320	Phosphatidylinositols	Havasi A	Hsp27 inhibits Bax activation and apoptosis via a phosphatidylinositol 3-kinase-dependent mechanism.	The Journal of biological chemistry	2008	53
18308254	Phosphatidylinositols	Bussink J	Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer.	The Lancet. Oncology	2008	84
18349857	Phosphatidylinositols	Turley EA	Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression?	Nature clinical practice. Oncology	2008	93
18449193	Phosphatidylinositols	Graupera M	Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration.	Nature	2008	131
18492751	Phosphatidylinositols	Liu Z	Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.	The Journal of clinical endocrinology and metabolism	2008	109
18625725	Phosphatidylinositols	Wang SE	Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.	Molecular and cellular biology	2008	65
18644989	Phosphatidylinositols	Toulany M	Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair.	Molecular cancer therapeutics	2008	52
18663744	Phosphatidylinositols	Guo C	The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers.	Genes, chromosomes & cancer	2008	124
18757405	Phosphatidylinositols	Yamamoto H	PIK3CA mutations and copy number gains in human lung cancers.	Cancer research	2008	145
18829572	Phosphatidylinositols	Oda K	PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.	Cancer research	2008	59
19002158	Phosphatidylinositols	Guo X	Signaling cross-talk between TGF-beta/BMP and other pathways.	Cell research	2009	232
19050071	Phosphatidylinositols	Sun Q	Identification of Barkor as a mammalian autophagy-specific factor for Beclin 1 and class III phosphatidylinositol 3-kinase.	Proceedings of the National Academy of Sciences of the United States of America	2008	187
19055754	Phosphatidylinositols	Marty B	Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.	Breast cancer research 	2008	63
19147560	Phosphatidylinositols	Wang SE	Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton.	Cancer research	2009	50
19147570	Phosphatidylinositols	Mirzoeva OK	Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.	Cancer research	2009	116
19176381	Phosphatidylinositols	Almog N	Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype.	Cancer research	2009	73
19176518	Phosphatidylinositols	Fan QW	EGFR signals to mTOR through PKC and independently of Akt in glioma.	Science signaling	2009	66
19214224	Phosphatidylinositols	Read RD	A drosophila model for EGFR-Ras and PI3K-dependent human glioma.	PLoS genetics	2009	54
19223473	Phosphatidylinositols	Yuan HT	Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium.	Molecular and cellular biology	2009	92
19272022	Phosphatidylinositols	Ooms LM	The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease.	The Biochemical journal	2009	72
19318560	Phosphatidylinositols	Szczepanski MJ	Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack.	Cancer research	2009	64
19412429	Phosphatidylinositols	Pillay V	The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.	Neoplasia	2009	50
19491896	Phosphatidylinositols	Shoji K	The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.	British journal of cancer	2009	52
19493313	Phosphatidylinositols	Madhunapantula SV	The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.	Pigment cell & melanoma research	2009	51
19567590	Phosphatidylinositols	Hoeflich KP	In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.	Clinical cancer research 	2009	172
19567914	Phosphatidylinositols	Schoeberl B	Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.	Science signaling	2009	114
19573809	Phosphatidylinositols	Vasudevan KM	AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.	Cancer cell	2009	187
19595306	Phosphatidylinositols	Jiang BH	PI3K/PTEN signaling in angiogenesis and tumorigenesis.	Advances in cancer research	2009	123
19602587	Phosphatidylinositols	Huang J	Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.	Cancer research	2009	46
19638457	Phosphatidylinositols	Sarker D	Targeting the PI3K/AKT pathway for the treatment of prostate cancer.	Clinical cancer research 	2009	93
19671852	Phosphatidylinositols	Kalinsky K	PIK3CA mutation associates with improved outcome in breast cancer.	Clinical cancer research 	2009	109
19789314	Phosphatidylinositols	Platt FM	Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.	Clinical cancer research 	2009	71
19797076	Phosphatidylinositols	Simonsen A	Coordination of membrane events during autophagy by multiple class III PI3-kinase complexes.	The Journal of cell biology	2009	159
19797085	Phosphatidylinositols	Li X	beta-TrCP-mediated ubiquitination and degradation of PHLPP1 are negatively regulated by Akt.	Molecular and cellular biology	2009	46
19850932	Phosphatidylinositols	Ng SS	Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade.	The Journal of biological chemistry	2009	52
19903888	Phosphatidylinositols	Xie D	DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis.	Proceedings of the National Academy of Sciences of the United States of America	2009	56
19962665	Phosphatidylinositols	Jaiswal BS	Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.	Cancer cell	2009	109
20081861	Phosphatidylinositols	Houghton AM	Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth.	Nature medicine	2010	120
20085938	Phosphatidylinositols	Courtney KD	The PI3K pathway as drug target in human cancer.	Journal of clinical oncology 	2010	325
20101214	Phosphatidylinositols	Gustafson WC	Myc proteins as therapeutic targets.	Oncogene	2010	59
20117946	Phosphatidylinositols	Krycer JR	The Akt-SREBP nexus: cell signaling meets lipid metabolism.	Trends in endocrinology and metabolism	2010	58
20145208	Phosphatidylinositols	Sehat B	SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor.	Science signaling	2010	72
20233997	Phosphatidylinositols	Zhang J	Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.	Journal of the National Cancer Institute	2010	74
20308550	Phosphatidylinositols	Vivanco I	The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation.	Proceedings of the National Academy of Sciences of the United States of America	2010	40
20379207	Phosphatidylinositols	Vanhaesebroeck B	The emerging mechanisms of isoform-specific PI3K signalling.	Nature reviews. Molecular cell biology	2010	362
20388916	Phosphatidylinositols	Poliseno L	Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation.	Science signaling	2010	166
20399811	Phosphatidylinositols	Martelli AM	The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis.	Biochimica et biophysica acta	2010	41
20406975	Phosphatidylinositols	Greshock J	Molecular target class is predictive of in vitro response profile.	Cancer research	2010	48
20421047	Phosphatidylinositols	Johnson SM	Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer.	Journal of the American College of Surgeons	2010	44
20471940	Phosphatidylinositols	Chin YR	The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration.	Molecular cell	2010	55
20535651	Phosphatidylinositols	Samuels Y	Oncogenic mutations of PIK3CA in human cancers.	Current topics in microbiology and immunology	2010	43
20578891	Phosphatidylinositols	Xing M	Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.	Thyroid 	2010	73
20643123	Phosphatidylinositols	Thoresen SB	A phosphatidylinositol 3-kinase class III sub-complex containing VPS15, VPS34, Beclin 1, UVRAG and BIF-1 regulates cytokinesis and degradative endocytic traffic.	Experimental cell research	2010	62
20686178	Phosphatidylinositols	Andersen JN	Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.	Science translational medicine	2010	57
20807812	Phosphatidylinositols	Hill R	PTEN loss accelerates KrasG12D-induced pancreatic cancer development.	Cancer research	2010	60
20826764	Phosphatidylinositols	Jones S	Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.	Science	2010	351
20864032	Phosphatidylinositols	Horejsí Z	CK2 phospho-dependent binding of R2TP complex to TEL2 is essential for mTOR and SMG1 stability.	Molecular cell	2010	58
20922461	Phosphatidylinositols	Castaneda CA	The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer.	Cancer metastasis reviews	2010	45
21045158	Phosphatidylinositols	Shultz JC	Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a.	Cancer research	2010	46
21216931	Phosphatidylinositols	Vilar E	Pushing the envelope in the mTOR pathway: the second generation of inhibitors.	Molecular cancer therapeutics	2011	37
21258406	Phosphatidylinositols	Ip CK	p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells.	Oncogene	2011	35
21278786	Phosphatidylinositols	Serra V	PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.	Oncogene	2011	174
21320503	Phosphatidylinositols	Ke AW	CD151 amplifies signaling by integrin α6β1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells.	Gastroenterology	2011	43
21324922	Phosphatidylinositols	Adams JR	Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation.	Cancer research	2011	38
21406469	Phosphatidylinositols	Hernandez-Aya LF	Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.	The oncologist	2011	42
21478295	Phosphatidylinositols	Urick ME	PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.	Cancer research	2011	61
21494257	Phosphatidylinositols	Steelman LS	Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.	Leukemia	2011	59
21628414	Phosphatidylinositols	Kuchenbauer F	Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells.	Blood	2011	38
21707707	Phosphatidylinositols	Sun CH	Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.	Histopathology	2011	38
21779497	Phosphatidylinositols	Castellano E	RAS Interaction with PI3K: More Than Just Another Effector Pathway.	Genes & cancer	2011	123
21807103	Phosphatidylinositols	Chaumeil MM	Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma.	NeuroImage	2012	34
21818118	Phosphatidylinositols	Qiang L	HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway.	Cell death and differentiation	2012	59
21822287	Phosphatidylinositols	Liu P	Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.	Nature medicine	2011	93
21906675	Phosphatidylinositols	Wang H	Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway.	Cellular signalling	2012	37
21909130	Phosphatidylinositols	Astle MV	AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.	Oncogene	2012	47
21936852	Phosphatidylinositols	Platta HW	Nedd4-dependent lysine-11-linked polyubiquitination of the tumour suppressor Beclin 1.	The Biochemical journal	2012	34
21984976	Phosphatidylinositols	Cheung LW	High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.	Cancer discovery	2011	129
22002674	Phosphatidylinositols	Florey O	Autophagy machinery mediates macroendocytic processing and entotic cell death by targeting single membranes.	Nature cell biology	2011	112
22133722	Phosphatidylinositols	Roychowdhury S	Personalized oncology through integrative high-throughput sequencing: a pilot study.	Science translational medicine	2011	190
22247021	Phosphatidylinositols	Ihle NT	Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.	Journal of the National Cancer Institute	2012	98
22248929	Phosphatidylinositols	Garrett JT	Will PI3K pathway inhibitors be effective as single agents in patients with cancer?	Oncotarget	2011	35
22264730	Phosphatidylinositols	Thapa N	Phosphoinositide signaling regulates the exocyst complex and polarized integrin trafficking in directionally migrating cells.	Developmental cell	2012	44
22271473	Phosphatidylinositols	Janku F	PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.	Journal of clinical oncology 	2012	153
22286105	Phosphatidylinositols	Smrcka AV	Role of phospholipase Cε in physiological phosphoinositide signaling networks.	Cellular signalling	2012	37
22416079	Phosphatidylinositols	Romero I	Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.	Endocrinology	2012	76
22453015	Phosphatidylinositols	Davies MA	The role of the PI3K-AKT pathway in melanoma.	Cancer journal	2012	42
22471665	Phosphatidylinositols	Sheppard K	Targeting PI3 kinase/AKT/mTOR signaling in cancer.	Critical reviews in oncogenesis	2012	70
22473959	Phosphatidylinositols	Lee K	Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia.	The Journal of experimental medicine	2012	43
22494966	Phosphatidylinositols	Torsvik A	Mesenchymal stem cell signaling in cancer progression.	Cancer treatment reviews	2013	27
22578719	Phosphatidylinositols	Hnia K	Myotubularin phosphoinositide phosphatases: cellular functions and disease pathophysiology.	Trends in molecular medicine	2012	34
22619466	Phosphatidylinositols	Wen PY	Current clinical development of PI3K pathway inhibitors in glioblastoma.	Neuro-oncology	2012	40
22624718	Phosphatidylinositols	Lapalombella R	Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.	Cancer cell	2012	31
23112296	Phosphatidylinositols	Wang RC	Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation.	Science	2012	167
23297823	Phosphatidylinositols	Cheung M	Diverse mechanisms of AKT pathway activation in human malignancy.	Current cancer drug targets	2013	42
23318419	Phosphatidylinositols	Brouxhon SM	Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling.	Oncogene	2014	22
23348690	Phosphatidylinositols	Ha GH	TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways.	Cancer letters	2013	28
23456430	Phosphatidylinositols	Bitting RL	Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.	Endocrine-related cancer	2013	63
23529353	Phosphatidylinositols	English DP	HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.	Molecular diagnosis & therapy	2013	31
23554977	Phosphatidylinositols	Lau MT	Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells.	PloS one	2013	26
23624914	Phosphatidylinositols	Ye Q	ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer.	Oncogene	2014	47
23643389	Phosphatidylinositols	Hao Y	Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.	Cancer cell	2013	25
23643661	Phosphatidylinositols	Saini KS	Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.	Cancer treatment reviews	2013	78
23658859	Phosphatidylinositols	Martini M	Targeting PI3K in Cancer: Any Good News?	Frontiers in oncology	2013	36
23671130	Phosphatidylinositols	Sun J	Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors.	Carcinogenesis	2013	25
23770288	Phosphatidylinositols	Kamato D	Transforming growth factor-β signalling: role and consequences of Smad linker region phosphorylation.	Cellular signalling	2013	47
24037752	Phosphatidylinositols	Wright AA	Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.	Cancer	2013	43
24056303	Phosphatidylinositols	He S	PtdIns(3)P-bound UVRAG coordinates Golgi-ER retrograde and Atg9 transport by differential interactions with the ER tether and the beclin 1 complex.	Nature cell biology	2013	29
24065147	Phosphatidylinositols	Niederst MJ	Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.	Science signaling	2013	61
24076665	Phosphatidylinositols	Filbin MG	Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.	Nature medicine	2013	41
24261963	Phosphatidylinositols	Akinleye A	Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.	Journal of hematology & oncology	2013	60
24387334	Phosphatidylinositols	Dillon LM	Therapeutic targeting of cancers with loss of PTEN function.	Current drug targets	2014	29
24393708	Phosphatidylinositols	Francipane MG	mTOR pathway in colorectal cancer: an update.	Oncotarget	2014	31
24440701	Phosphatidylinositols	Wang Y	MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA.	Biochemical and biophysical research communications	2014	24
24440717	Phosphatidylinositols	Janku F	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.	Cell reports	2014	59
24533074	Phosphatidylinositols	Wang L	PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.	PloS one	2014	28
24607406	Phosphatidylinositols	Todaro M	CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.	Cell stem cell	2014	116
24762440	Phosphatidylinositols	Yang Y	ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.	The Journal of clinical investigation	2014	40
24777052	Phosphatidylinositols	Ocana A	Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis.	PloS one	2014	36
24867100	Phosphatidylinositols	Wang F	MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma.	Tumour biology 	2014	22
24981249	Phosphatidylinositols	Liu G	MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer.	Tumour biology 	2014	20
25001183	Phosphatidylinositols	Hu J	microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C.	European journal of cancer	2014	33
25037117	Phosphatidylinositols	Beck JT	Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.	Cancer treatment reviews	2014	23
25086744	Phosphatidylinositols	Li H	PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.	Archives of gynecology and obstetrics	2014	23
25115638	Phosphatidylinositols	Manfredi GI	PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.	Endocrine	2015	22
25183785	Phosphatidylinositols	Rubashkin MG	Force engages vinculin and promotes tumor progression by enhancing PI3K activation of phosphatidylinositol (3,4,5)-triphosphate.	Cancer research	2014	41
25475121	Phosphatidylinositols	Huang XP	MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1.	The FEBS journal	2015	20
25503676	Phosphatidylinositols	Wei JX	Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cells.	Hepatology	2015	25
25512523	Phosphatidylinositols	Perry JA	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.	Proceedings of the National Academy of Sciences of the United States of America	2014	62
25534823	Phosphatidylinositols	Kaul A	Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.	Neuro-oncology	2015	17
25556614	Phosphatidylinositols	Cheaib B	The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.	Chinese journal of cancer	2015	25
25573003	Phosphatidylinositols	Burke JE	Synergy in activating class I PI3Ks.	Trends in biochemical sciences	2015	20
25583473	Phosphatidylinositols	Hart JR	The butterfly effect in cancer: a single base mutation can remodel the cell.	Proceedings of the National Academy of Sciences of the United States of America	2015	15
25650317	Phosphatidylinositols	Ghosh JC	Adaptive mitochondrial reprogramming and resistance to PI3K therapy.	Journal of the National Cancer Institute	2015	27
25677064	Phosphatidylinositols	Mabuchi S	The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.	Gynecologic oncology	2015	43
25682869	Phosphatidylinositols	Zhu M	Hepatitis B virus X protein induces expression of alpha-fetoprotein and activates PI3K/mTOR signaling pathway in liver cells.	Oncotarget	2015	20
25877892	Phosphatidylinositols	McGranahan N	Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.	Science translational medicine	2015	78
25925379	Phosphatidylinositols	Nakakido M	Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN.	Neoplasia	2015	16
26117819	Phosphatidylinositols	Yap TA	Drugging PI3K in cancer: refining targets and therapeutic strategies.	Current opinion in pharmacology	2015	40
26124089	Phosphatidylinositols	Caino MC	PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion.	Proceedings of the National Academy of Sciences of the United States of America	2015	32
26233890	Phosphatidylinositols	Guo H	The PI3K/AKT Pathway and Renal Cell Carcinoma.	Journal of genetics and genomics = Yi chuan xue bao	2015	17
26253360	Phosphatidylinositols	Chang L	Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.	Critical reviews in oncology/hematology	2015	18
26404259	Phosphatidylinositols	Faes S	PI3K and AKT: Unfaithful Partners in Cancer.	International journal of molecular sciences	2015	29
26926684	Phosphatidylinositols	Desmedt C	Genomic Characterization of Primary Invasive Lobular Breast Cancer.	Journal of clinical oncology 	2016	18
27199435	Phosphatidylinositols	Quail DF	The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.	Science	2016	42
27481709	Phosphatidylinositols	Heldin CH	Signaling Receptors for TGF-β Family Members.	Cold Spring Harbor perspectives in biology	2016	14
27613818	Phosphatidylinositols	Li T	Role of the PI3K-Akt Signaling Pathway in the Pathogenesis of Polycystic Ovary Syndrome.	Reproductive sciences	2017	6
27844272	Phosphatidylinositols	Duran I	Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.	Targeted oncology	2017	7
28123856	Phosphatidylinositols	Liu J	MicroRNA-363-3p inhibits papillary thyroid carcinoma progression by targeting PIK3CA.	American journal of cancer research	2017	5
28518139	Phosphatidylinositols	Li N	MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer.	Cell death & disease	2017	10
7822316	Sirolimus	Sabers CJ	Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.	The Journal of biological chemistry	1995	184
11359907	Sirolimus	Laughner E	HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.	Molecular and cellular biology	2001	265
11691836	Sirolimus	Gingras AC	Hierarchical phosphorylation of the translation inhibitor 4E-BP1.	Genes & development	2001	256
12039858	Sirolimus	Humar R	Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling.	FASEB journal 	2002	89
12045200	Sirolimus	Goncharova EA	Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM).	The Journal of biological chemistry	2002	125
12563289	Sirolimus	Jacinto E	Tor signalling in bugs, brain and brawn.	Nature reviews. Molecular cell biology	2003	151
12842888	Sirolimus	Castro AF	Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner.	The Journal of biological chemistry	2003	109
12878853	Sirolimus	Huang S	Rapamycins: mechanism of action and cellular resistance.	Cancer biology & therapy	2003	80
14561707	Sirolimus	Zhang H	Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.	The Journal of clinical investigation	2003	206
14607085	Sirolimus	Manning BD	Rheb fills a GAP between TSC and TOR.	Trends in biochemical sciences	2003	134
14729632	Sirolimus	Boulay A	Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.	Cancer research	2004	80
14871980	Sirolimus	Noh WC	Determinants of rapamycin sensitivity in breast cancer cells.	Clinical cancer research 	2004	86
15004009	Sirolimus	Mayer C	mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability.	Genes & development	2004	133
15071500	Sirolimus	Raught B	Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases.	The EMBO journal	2004	129
15094765	Sirolimus	Fingar DC	Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.	Oncogene	2004	333
15156201	Sirolimus	Majumder PK	mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.	Nature medicine	2004	282
15325584	Sirolimus	Meijer AJ	Regulation and role of autophagy in mammalian cells.	The international journal of biochemistry & cell biology	2004	150
15501954	Sirolimus	Zhou X	Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.	Clinical cancer research 	2004	90
15501983	Sirolimus	Mondesire WH	Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells.	Clinical cancer research 	2004	91
15533996	Sirolimus	Manning BD	Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis.	The Journal of cell biology	2004	174
15550488	Sirolimus	Récher C	Antileukemic activity of rapamycin in acute myeloid leukemia.	Blood	2005	67
15623621	Sirolimus	Sahin F	mTOR and P70 S6 kinase expression in primary liver neoplasms.	Clinical cancer research 	2004	78
15624019	Sirolimus	Inoki K	Dysregulation of the TSC-mTOR pathway in human disease.	Nature genetics	2005	293
15659337	Sirolimus	Tee AR	mTOR, translational control and human disease.	Seminars in cell & developmental biology	2005	88
15718470	Sirolimus	Sarbassov DD	Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.	Science	2005	2058
15728109	Sirolimus	Vignot S	mTOR-targeted therapy of cancer with rapamycin derivatives.	Annals of oncology 	2005	126
15800227	Sirolimus	Stallone G	Sirolimus for Kaposi's sarcoma in renal-transplant recipients.	The New England journal of medicine	2005	146
15805275	Sirolimus	Dasgupta B	Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.	Cancer research	2005	81
15899889	Sirolimus	Chiang GG	Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase.	The Journal of biological chemistry	2005	163
15937108	Sirolimus	Johannessen CM	The NF1 tumor suppressor critically regulates TSC2 and mTOR.	Proceedings of the National Academy of Sciences of the United States of America	2005	158
16002336	Sirolimus	Guertin DA	An expanding role for mTOR in cancer.	Trends in molecular medicine	2005	119
16096426	Sirolimus	Morgensztern D	PI3K/Akt/mTOR pathway as a target for cancer therapy.	Anti-cancer drugs	2005	90
16267020	Sirolimus	Amornphimoltham P	Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.	Cancer research	2005	78
16397245	Sirolimus	Han S	Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.	Cancer research	2006	63
16432179	Sirolimus	Bader AG	Cancer-specific mutations in PIK3CA are oncogenic in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2006	122
16452206	Sirolimus	O'Reilly KE	mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.	Cancer research	2006	806
16469695	Sirolimus	Wullschleger S	TOR signaling in growth and metabolism.	Cell	2006	1712
16585191	Sirolimus	Wang L	Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus.	Cancer research	2006	66
16636147	Sirolimus	Cai SL	Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning.	The Journal of cell biology	2006	122
16651424	Sirolimus	Mungamuri SK	Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.	Cancer research	2006	69
16715125	Sirolimus	Wang X	Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation.	Oncogene	2006	77
16763566	Sirolimus	Shahbazian D	The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity.	The EMBO journal	2006	127
16799564	Sirolimus	Androutsellis-Theotokis A	Notch signalling regulates stem cell numbers in vitro and in vivo.	Nature	2006	271
16849518	Sirolimus	Koumenis C	"Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways.	Molecular cancer research 	2006	71
16904612	Sirolimus	Sodhi A	The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.	Cancer cell	2006	65
16904613	Sirolimus	Phung TL	Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.	Cancer cell	2006	152
16912159	Sirolimus	Wang MY	Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.	Cancer research	2006	100
16915281	Sirolimus	Bernardi R	PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR.	Nature	2006	132
16915295	Sirolimus	Sabatini DM	mTOR and cancer: insights into a complex relationship.	Nature reviews. Cancer	2006	453
16951235	Sirolimus	Yee KW	Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.	Clinical cancer research 	2006	70
16959574	Sirolimus	Inoki K	TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth.	Cell	2006	372
16968213	Sirolimus	Lee CH	mTOR pathway as a target in tissue hypertrophy.	Annual review of pharmacology and toxicology	2007	74
17010674	Sirolimus	Wei G	Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.	Cancer cell	2006	149
17041628	Sirolimus	Easton JB	mTOR and cancer therapy.	Oncogene	2006	128
17047067	Sirolimus	Cao C	Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells.	Cancer research	2006	97
17047074	Sirolimus	Morgillo F	Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.	Cancer research	2006	104
17072337	Sirolimus	Vaira V	Regulation of survivin expression by IGF-1/mTOR signaling.	Oncogene	2007	58
17082322	Sirolimus	Sin SH	Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling.	Blood	2007	67
17121914	Sirolimus	Buck E	Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.	Molecular cancer therapeutics	2006	69
17253963	Sirolimus	Findlay GM	A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling.	The Biochemical journal	2007	100
17275731	Sirolimus	Tsang CK	Targeting mammalian target of rapamycin (mTOR) for health and diseases.	Drug discovery today	2007	109
17277121	Sirolimus	Zheng Y	A role for mammalian target of rapamycin in regulating T cell activation versus anergy.	Journal of immunology	2007	88
17361185	Sirolimus	Wilker EW	14-3-3sigma controls mitotic translation to facilitate cytokinesis.	Nature	2007	80
17363557	Sirolimus	Mabuchi S	RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.	Cancer research	2007	59
17376031	Sirolimus	Proud CG	Signalling to translation: how signal transduction pathways control the protein synthetic machinery.	The Biochemical journal	2007	157
17419990	Sirolimus	Bhaskar PT	The two TORCs and Akt.	Developmental cell	2007	302
17452018	Sirolimus	Dann SG	mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer.	Trends in molecular medicine	2007	170
17502379	Sirolimus	Land SC	Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif.	The Journal of biological chemistry	2007	123
17595159	Sirolimus	Chan EY	siRNA screening of the kinome identifies ULK1 as a multidomain modulator of autophagy.	The Journal of biological chemistry	2007	147
17613433	Sirolimus	Guertin DA	Defining the role of mTOR in cancer.	Cancer cell	2007	929
17635004	Sirolimus	Houghton PJ	Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.	Pediatric blood & cancer	2008	51
17646396	Sirolimus	Lamouille S	Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway.	The Journal of cell biology	2007	177
17671177	Sirolimus	Ma L	Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.	Cancer research	2007	58
17680028	Sirolimus	Yang Q	Expanding mTOR signaling.	Cell research	2007	164
17699757	Sirolimus	Armengol G	4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications.	Cancer research	2007	87
17785546	Sirolimus	Molinolo AA	Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative.	Clinical cancer research 	2007	73
17878402	Sirolimus	Tamburini J	Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.	Blood	2008	74
17905659	Sirolimus	Chiang GG	Targeting the mTOR signaling network in cancer.	Trends in molecular medicine	2007	91
18080139	Sirolimus	Martignoni G	PEComas: the past, the present and the future.	Virchows Archiv 	2008	93
18089801	Sirolimus	Masri J	mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor.	Cancer research	2007	92
18184959	Sirolimus	Bissler JJ	Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.	The New England journal of medicine	2008	296
18198340	Sirolimus	DeYoung MP	Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling.	Genes & development	2008	222
18215105	Sirolimus	Cloughesy TF	Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.	PLoS medicine	2008	205
18332467	Sirolimus	Tanaka C	Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.	Journal of clinical oncology 	2008	57
18332469	Sirolimus	Tabernero J	Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.	Journal of clinical oncology 	2008	152
18332470	Sirolimus	O'Donnell A	Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.	Journal of clinical oncology 	2008	120
18367868	Sirolimus	Mammucari C	Downstream of Akt: FoxO3 and mTOR in the regulation of autophagy in skeletal muscle.	Autophagy	2008	76
18424697	Sirolimus	Basu S	Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin.	Journal of immunology	2008	57
18519641	Sirolimus	Dan HC	Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK.	Genes & development	2008	150
18566586	Sirolimus	Facchinetti V	The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C.	The EMBO journal	2008	202
18611860	Sirolimus	Roca H	CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation.	The Journal of biological chemistry	2008	55
18653228	Sirolimus	Motzer RJ	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.	Lancet	2008	689
18664580	Sirolimus	Mills JR	mTORC1 promotes survival through translational control of Mcl-1.	Proceedings of the National Academy of Sciences of the United States of America	2008	112
18679422	Sirolimus	Zhuang D	C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.	Oncogene	2008	56
18684977	Sirolimus	Golovina TN	CD28 costimulation is essential for human T regulatory expansion and function.	Journal of immunology	2008	55
18721898	Sirolimus	Yap TA	Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.	Current opinion in pharmacology	2008	146
18722871	Sirolimus	Curatolo P	Tuberous sclerosis.	Lancet	2008	171
18725988	Sirolimus	Carracedo A	Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.	The Journal of clinical investigation	2008	507
18725993	Sirolimus	Grant S	Cotargeting survival signaling pathways in cancer.	The Journal of clinical investigation	2008	60
18768809	Sirolimus	Fujishita T	Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.	Proceedings of the National Academy of Sciences of the United States of America	2008	57
18787170	Sirolimus	Mao JH	FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.	Science	2008	138
18794129	Sirolimus	Wang X	Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.	Cancer research	2008	59
18848473	Sirolimus	Weichhart T	The TSC-mTOR signaling pathway regulates the innate inflammatory response.	Immunity	2008	197
18922904	Sirolimus	Buck E	Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.	Cancer research	2008	82
19164214	Sirolimus	Hildebrandt MA	Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.	Journal of clinical oncology 	2009	60
19166929	Sirolimus	Dunlop EA	Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms.	Cellular signalling	2009	92
19185849	Sirolimus	Guertin DA	mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice.	Cancer cell	2009	149
19197153	Sirolimus	Choo AY	Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy.	Cell cycle	2009	87
19223493	Sirolimus	Yu G	Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer.	Clinical cancer research 	2009	51
19244117	Sirolimus	Copp J	TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2.	Cancer research	2009	132
19245654	Sirolimus	Shaw RJ	LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.	Acta physiologica	2009	147
19261747	Sirolimus	Puzio-Kuter AM	Inactivation of p53 and Pten promotes invasive bladder cancer.	Genes & development	2009	98
19276368	Sirolimus	Chen RQ	CDC25B mediates rapamycin-induced oncogenic responses in cancer cells.	Cancer research	2009	46
19279323	Sirolimus	Young AR	Autophagy mediates the mitotic senescence transition.	Genes & development	2009	274
19282848	Sirolimus	Dankort D	Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.	Nature genetics	2009	324
19303758	Sirolimus	Bozulic L	PIKKing on PKB: regulation of PKB activity by phosphorylation.	Current opinion in cell biology	2009	68
19306412	Sirolimus	Amato RJ	A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.	Cancer	2009	45
19332717	Sirolimus	Meric-Bernstam F	Targeting the mTOR signaling network for cancer therapy.	Journal of clinical oncology 	2009	194
19362054	Sirolimus	Weichhart T	The multiple facets of mTOR in immunity.	Trends in immunology	2009	74
19401449	Sirolimus	Wee S	PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.	Cancer research	2009	123
19410195	Sirolimus	Brems H	Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1.	The Lancet. Oncology	2009	70
19420259	Sirolimus	Di Nardo A	Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.	The Journal of neuroscience 	2009	63
19451225	Sirolimus	James MF	NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.	Molecular and cellular biology	2009	69
19451229	Sirolimus	López-Lago MA	Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling.	Molecular and cellular biology	2009	47
19458359	Sirolimus	Tamburini J	Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.	Blood	2009	54
19535919	Sirolimus	Zhu H	Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells.	Autophagy	2009	113
19543393	Sirolimus	Strauss L	Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin.	PloS one	2009	59
19553991	Sirolimus	Scott KL	GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer.	Nature	2009	106
19562254	Sirolimus	Reardon DA	Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.	Journal of neuro-oncology	2010	65
19644473	Sirolimus	Liu P	Targeting the phosphoinositide 3-kinase pathway in cancer.	Nature reviews. Drug discovery	2009	563
19687332	Sirolimus	Ellard SL	Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.	Journal of clinical oncology 	2009	60
19773376	Sirolimus	Kim KW	Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.	Clinical cancer research 	2009	47
19789339	Sirolimus	Kurmasheva RT	The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.	Cancer research	2009	60
19796751	Sirolimus	Rini BI	Resistance to targeted therapy in renal-cell carcinoma.	The Lancet. Oncology	2009	134
19817806	Sirolimus	Wong M	Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.	Epilepsia	2010	59
19834494	Sirolimus	Kang R	The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival.	Cell death and differentiation	2010	95
19838173	Sirolimus	Lee JS	FLIP-mediated autophagy regulation in cell death control.	Nature cell biology	2009	143
19875810	Sirolimus	Lieberthal W	The role of the mammalian target of rapamycin (mTOR) in renal disease.	Journal of the American Society of Nephrology 	2009	81
19901542	Sirolimus	Shor B	Targeting mTOR globally in cancer: thinking beyond rapamycin.	Cell cycle	2009	63
19934294	Sirolimus	Gulhati P	Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer.	Clinical cancer research 	2009	56
19945836	Sirolimus	Efeyan A	mTOR and cancer: many loops in one pathway.	Current opinion in cell biology	2010	138
19951971	Sirolimus	Park S	Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.	Haematologica	2010	58
19956179	Sirolimus	Menon S	Common corruption of the mTOR signaling network in human tumors.	Oncogene	2008	98
19963098	Sirolimus	Gibbons JJ	Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.	Seminars in oncology	2009	81
19995915	Sirolimus	Julien LA	mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.	Molecular and cellular biology	2010	141
20005306	Sirolimus	Dowling RJ	Dissecting the role of mTOR: lessons from mTOR inhibitors.	Biochimica et biophysica acta	2010	118
20008787	Sirolimus	Kharas MG	Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.	Blood	2010	90
20008935	Sirolimus	Olive V	miR-19 is a key oncogenic component of mir-17-92.	Genes & development	2009	235
20018914	Sirolimus	Ghosh AK	Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression.	Blood	2010	64
20022946	Sirolimus	Soliman GA	mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.	The Journal of biological chemistry	2010	81
20038814	Sirolimus	Ma J	Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade.	The Journal of clinical investigation	2010	76
20038818	Sirolimus	Tsang CK	mTOR binds to the promoters of RNA polymerase I- and III-transcribed genes.	Cell cycle	2010	47
20042677	Sirolimus	Deng L	A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis.	The American journal of pathology	2010	57
20048174	Sirolimus	Wagner AJ	Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.	Journal of clinical oncology 	2010	66
20072130	Sirolimus	Janes MR	Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.	Nature medicine	2010	137
20080688	Sirolimus	Hung KE	Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment.	Proceedings of the National Academy of Sciences of the United States of America	2010	80
20081105	Sirolimus	Nagaraja AK	A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.	Molecular endocrinology	2010	77
20139716	Sirolimus	Blagosklonny MV	Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans).	Cell cycle	2010	85
20146692	Sirolimus	Orlova KA	The tuberous sclerosis complex.	Annals of the New York Academy of Sciences	2010	102
20175032	Sirolimus	Hoshida Y	Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.	Seminars in liver disease	2010	94
20187107	Sirolimus	Toso C	Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.	Hepatology	2010	59
20227039	Sirolimus	Hsieh AC	Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E.	Cancer cell	2010	158
20231677	Sirolimus	Doi T	Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.	Journal of clinical oncology 	2010	56
20234352	Sirolimus	Dancey J	mTOR signaling and drug development in cancer.	Nature reviews. Clinical oncology	2010	110
20360610	Sirolimus	Faoro L	EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.	The Journal of biological chemistry	2010	43
20363920	Sirolimus	Anisimov VN	Rapamycin extends maximal lifespan in cancer-prone mice.	The American journal of pathology	2010	107
20371474	Sirolimus	Amin DN	Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.	Science translational medicine	2010	69
20484036	Sirolimus	Doghman M	Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors.	Cancer research	2010	66
20491627	Sirolimus	Zhou H	The complexes of mammalian target of rapamycin.	Current protein & peptide science	2010	42
20498714	Sirolimus	Squarize CH	Accelerated wound healing by mTOR activation in genetically defined mouse models.	PloS one	2010	40
20563248	Sirolimus	Molina JR	Invasive glioblastoma cells acquire stemness and increased Akt activation.	Neoplasia	2010	62
20616057	Sirolimus	Carayol N	Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.	Proceedings of the National Academy of Sciences of the United States of America	2010	70
20616807	Sirolimus	Kang YJ	The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis.	Cell death and differentiation	2011	42
20639871	Sirolimus	Gao C	Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation.	Nature cell biology	2010	118
20664172	Sirolimus	Di Nicolantonio F	Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.	The Journal of clinical investigation	2010	117
20670887	Sirolimus	Düvel K	Activation of a metabolic gene regulatory network downstream of mTOR complex 1.	Molecular cell	2010	446
20671809	Sirolimus	Martelli AM	The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.	Oncotarget	2010	76
20681032	Sirolimus	Slomovitz BM	A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.	Cancer	2010	45
20686120	Sirolimus	Hoang B	Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.	Blood	2010	42
20805416	Sirolimus	Haidinger M	A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation.	Journal of immunology	2010	63
20810185	Sirolimus	Rautou PE	Autophagy in liver diseases.	Journal of hepatology	2010	99
20956938	Sirolimus	Dunn EF	Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.	Oncogene	2011	40
20978191	Sirolimus	Zhang F	mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis.	Cancer research	2010	49
21047224	Sirolimus	Krueger DA	Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.	The New England journal of medicine	2010	226
21115397	Sirolimus	Ehninger D	Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders.	Trends in molecular medicine	2011	59
21135857	Sirolimus	Witzig TE	A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.	Leukemia	2011	65
21145500	Sirolimus	Liu L	mTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion.	Developmental cell	2010	78
21147110	Sirolimus	Calvisi DF	Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.	Gastroenterology	2011	98
21157483	Sirolimus	Zoncu R	mTOR: from growth signal integration to cancer, diabetes and ageing.	Nature reviews. Molecular cell biology	2011	1286
21179025	Sirolimus	Caron E	A comprehensive map of the mTOR signaling network.	Molecular systems biology	2010	67
21190521	Sirolimus	Zhou H	Role of mTOR signaling in tumor cell motility, invasion and metastasis.	Current protein & peptide science	2011	53
21252315	Sirolimus	Jiao Y	DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.	Science	2011	363
21253593	Sirolimus	Golovina TN	Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells.	PloS one	2011	48
21278436	Sirolimus	Baselga J	Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.	The oncologist	2011	83
21289308	Sirolimus	Yoshimi A	Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.	Blood	2011	35
21306238	Sirolimus	Yao JC	Everolimus for advanced pancreatic neuroendocrine tumors.	The New England journal of medicine	2011	472
21331075	Sirolimus	Evangelisti C	Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.	Leukemia	2011	37
21346035	Sirolimus	Finley DS	Tumor biology and prognostic factors in renal cell carcinoma.	The oncologist	2011	39
21358673	Sirolimus	Weigelt B	PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.	Oncogene	2011	69
21383697	Sirolimus	Oneyama C	MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.	Oncogene	2011	44
21410393	Sirolimus	McCormack FX	Efficacy and safety of sirolimus in lymphangioleiomyomatosis.	The New England journal of medicine	2011	194
21413931	Sirolimus	Pearce LR	Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney.	The Biochemical journal	2011	53
21415215	Sirolimus	Altman JK	Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.	Clinical cancer research 	2011	37
21436840	Sirolimus	Martelli AM	Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.	Leukemia	2011	52
21440577	Sirolimus	Hay N	Interplay between FOXO, TOR, and Akt.	Biochimica et biophysica acta	2011	67
21460630	Sirolimus	Dunlop EA	ULK1 inhibits mTORC1 signaling, promotes multisite Raptor phosphorylation and hinders substrate binding.	Autophagy	2011	44
21460795	Sirolimus	Galan-Moya EM	Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway.	EMBO reports	2011	44
21490404	Sirolimus	Wander SA	Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.	The Journal of clinical investigation	2011	138
21525172	Sirolimus	Davies DM	Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.	Clinical cancer research 	2011	63
21538343	Sirolimus	Zhu AX	Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.	Cancer	2011	55
21547705	Sirolimus	Carew JS	Mechanisms of mTOR inhibitor resistance in cancer therapy.	Targeted oncology	2011	37
21548787	Sirolimus	Kim J	Amino acid signaling in TOR activation.	Annual review of biochemistry	2011	75
21564534	Sirolimus	Hippen KL	Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease.	American journal of transplantation 	2011	88
21613408	Sirolimus	Lovly CM	Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.	Cancer research	2011	51
21690594	Sirolimus	Taveira-DaSilva AM	Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.	Annals of internal medicine	2011	46
21730275	Sirolimus	Morrow PK	Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.	Journal of clinical oncology 	2011	65
21779436	Sirolimus	Foster DA	Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s).	Genes & cancer	2010	57
21795477	Sirolimus	Uesugi A	The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer.	Cancer research	2011	74
21841310	Sirolimus	Shuda M	Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator.	The Journal of clinical investigation	2011	100
21859846	Sirolimus	Schatz JH	Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.	The Journal of experimental medicine	2011	50
21878679	Sirolimus	Chan JC	AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer.	Science signaling	2011	41
21907282	Sirolimus	Carson RP	Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin.	Neurobiology of disease	2012	57
21915260	Sirolimus	Dabora SL	Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease.	PloS one	2011	48
21930774	Sirolimus	Liu L	Review series: TOR kinase complexes and cell migration.	The Journal of cell biology	2011	36
21963299	Sirolimus	Dazert E	mTOR signaling in disease.	Current opinion in cell biology	2011	140
21975930	Sirolimus	Patel V	Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer.	Cancer research	2011	52
21993994	Sirolimus	Ho C	AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways.	Hepatology	2012	55
22025691	Sirolimus	Goto J	Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex.	Proceedings of the National Academy of Sciences of the United States of America	2011	61
22037041	Sirolimus	Benjamin D	Rapamycin passes the torch: a new generation of mTOR inhibitors.	Nature reviews. Drug discovery	2011	220
22065737	Sirolimus	Shin S	Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation.	Proceedings of the National Academy of Sciences of the United States of America	2011	40
22071574	Sirolimus	Yellen P	High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.	Cell cycle	2011	39
22140653	Sirolimus	Rodrik-Outmezguine VS	mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.	Cancer discovery	2011	152
22154278	Sirolimus	Reungwetwattana T	Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).	Clinical lung cancer	2012	30
22156391	Sirolimus	Leontieva OV	Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression.	Aging	2011	69
22186785	Sirolimus	Criollo A	Autophagy is required for the activation of NFκB.	Cell cycle	2012	31
22234835	Sirolimus	Fang Y	MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma.	Hepatology	2012	103
22239433	Sirolimus	Bartholomeusz C	Targeting the PI3K signaling pathway in cancer therapy.	Expert opinion on therapeutic targets	2012	55
22248718	Sirolimus	Korkmaz G	miR-376b controls starvation and mTOR inhibition-related autophagy by targeting ATG4C and BECN1.	Autophagy	2012	58
22261336	Sirolimus	Zaytseva YY	mTOR inhibitors in cancer therapy.	Cancer letters	2012	68
22287548	Sirolimus	Chen W	Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway.	Cancer research	2012	37
22310280	Sirolimus	Serrano I	Role of the integrin-linked kinase (ILK)/Rictor complex in TGFβ-1-induced epithelial-mesenchymal transition (EMT).	Oncogene	2013	36
22350330	Sirolimus	Willems L	PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.	Current oncology reports	2012	61
22354785	Sirolimus	Wiza C	Role of PRAS40 in Akt and mTOR signaling in health and disease.	American journal of physiology. Endocrinology and metabolism	2012	39
22391571	Sirolimus	Kalvik TV	Protein N-terminal acetyltransferases in cancer.	Oncogene	2013	34
22394614	Sirolimus	Blagosklonny MV	Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging.	Aging	2012	130
22397650	Sirolimus	Gerlinger M	Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.	The New England journal of medicine	2012	1714
22402744	Sirolimus	Weeraratne SD	Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma.	Acta neuropathologica	2012	57
22409888	Sirolimus	Molinolo AA	mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.	Clinical cancer research 	2012	38
22422409	Sirolimus	Meric-Bernstam F	PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.	Clinical cancer research 	2012	67
22425712	Sirolimus	Chen Z	Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma.	Oral oncology	2012	44
22431589	Sirolimus	Suh SS	MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme.	Proceedings of the National Academy of Sciences of the United States of America	2012	41
22443084	Sirolimus	De Luca A	The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.	Expert opinion on therapeutic targets	2012	128
22449814	Sirolimus	Bakan I	Connecting mTORC1 signaling to SREBP-1 activation.	Current opinion in lipidology	2012	39
22457330	Sirolimus	Menon S	Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice.	Science signaling	2012	51
22473468	Sirolimus	Song MS	The functions and regulation of the PTEN tumour suppressor.	Nature reviews. Molecular cell biology	2012	494
22473592	Sirolimus	Seront E	Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.	Annals of oncology 	2012	33
22500797	Sirolimus	Laplante M	mTOR signaling in growth control and disease.	Cell	2012	2019
22504094	Sirolimus	Chang Y	miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions.	Gastroenterology	2012	53
22585904	Sirolimus	Baird TD	Eukaryotic initiation factor 2 phosphorylation and translational control in metabolism.	Advances in nutrition	2012	119
22641689	Sirolimus	Liu EY	Autophagy and cancer--issues we need to digest.	Journal of cell science	2012	51
22698676	Sirolimus	Mercier I	Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug.	The American journal of pathology	2012	68
22826565	Sirolimus	Zeng Z	Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.	Blood	2012	38
22859719	Sirolimus	Sun ZJ	Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.	Clinical cancer research 	2012	41
22889214	Sirolimus	Waickman AT	mTOR, metabolism, and the regulation of T-cell differentiation and function.	Immunological reviews	2012	77
22907434	Sirolimus	Du W	ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer.	Oncogene	2013	27
22923433	Sirolimus	Iyer G	Genome sequencing identifies a basis for everolimus sensitivity.	Science	2012	174
22924465	Sirolimus	Maiese K	Targeting disease through novel pathways of apoptosis and autophagy.	Expert opinion on therapeutic targets	2012	48
22958932	Sirolimus	Iglesias-Bartolome R	mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis.	Cell stem cell	2012	91
22980037	Sirolimus	Chong ZZ	Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin.	Progress in neurobiology	2012	49
22983984	Sirolimus	Iwaya T	Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway.	Carcinogenesis	2012	50
22990118	Sirolimus	Woods NT	Charting the landscape of tandem BRCT domain-mediated protein interactions.	Science signaling	2012	36
23012305	Sirolimus	Crown J	Emerging targeted therapies in triple-negative breast cancer.	Annals of oncology 	2012	55
23085539	Sirolimus	McCubrey JA	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.	Oncotarget	2012	105
23123587	Sirolimus	Reith RM	Loss of Tsc2 in Purkinje cells is associated with autistic-like behavior in a mouse model of tuberous sclerosis complex.	Neurobiology of disease	2013	42
23124837	Sirolimus	Hung CM	mTOR-dependent cell survival mechanisms.	Cold Spring Harbor perspectives in biology	2012	34
23151465	Sirolimus	Blagosklonny MV	Rapalogs in cancer prevention: anti-aging or anticancer?	Cancer biology & therapy	2012	46
23152448	Sirolimus	Kaul A	Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner.	Genes & development	2012	33
23158522	Sirolimus	Franz DN	Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.	Lancet	2013	129
23173671	Sirolimus	Cui L	MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma.	BMC cancer	2012	31
23246968	Sirolimus	Beauchamp EM	The evolution of the TOR pathway and its role in cancer.	Oncogene	2013	42
23265840	Sirolimus	Maiese K	mTOR: on target for novel therapeutic strategies in the nervous system.	Trends in molecular medicine	2013	61
23312829	Sirolimus	Bissler JJ	Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.	Lancet	2013	136
23317514	Sirolimus	Cornu M	mTOR in aging, metabolism, and cancer.	Current opinion in genetics & development	2013	151
23322078	Sirolimus	Tekirdag KA	MIR181A regulates starvation- and rapamycin-induced autophagy through targeting of ATG5.	Autophagy	2013	39
23431193	Sirolimus	Posch C	Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2013	70
23454761	Sirolimus	Lamming DW	Rapalogs and mTOR inhibitors as anti-aging therapeutics.	The Journal of clinical investigation	2013	122
23460185	Sirolimus	Alayev A	mTOR signaling for biological control and cancer.	Journal of cellular physiology	2013	36
23532336	Sirolimus	Casado P	Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells.	Science signaling	2013	41
23582881	Sirolimus	Templeton AJ	Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).	European urology	2013	27
23601105	Sirolimus	Chang HH	A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity.	Cell host & microbe	2013	32
23635776	Sirolimus	Serra V	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.	The Journal of clinical investigation	2013	28
23641065	Sirolimus	Laplante M	Regulation of mTORC1 and its impact on gene expression at a glance.	Journal of cell science	2013	147
23642907	Sirolimus	Khan KH	Targeting the PI3K-AKT-mTOR signaling network in cancer.	Chinese journal of cancer	2013	31
23644232	Sirolimus	Wong M	Mammalian target of rapamycin (mTOR) pathways in neurological diseases.	Biomedical journal	2013	32
23644661	Sirolimus	Loreni F	Translation factors and ribosomal proteins control tumor onset and progression: how?	Oncogene	2014	25
23663782	Sirolimus	Csibi A	The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4.	Cell	2013	122
23666471	Sirolimus	Yang J	New molecular insights into osteosarcoma targeted therapy.	Current opinion in oncology	2013	78
23677068	Sirolimus	Sekido Y	Molecular pathogenesis of malignant mesothelioma.	Carcinogenesis	2013	39
23778311	Sirolimus	McCubrey JA	Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.	Leukemia	2014	41
23792225	Sirolimus	Sun SY	mTOR kinase inhibitors as potential cancer therapeutic drugs.	Cancer letters	2013	46
23803853	Sirolimus	Pourdehnad M	Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers.	Proceedings of the National Academy of Sciences of the United States of America	2013	64
23818547	Sirolimus	Lu J	Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation.	Blood	2013	36
23818640	Sirolimus	Meckes DG Jr	Modulation of B-cell exosome proteins by gamma herpesvirus infection.	Proceedings of the National Academy of Sciences of the United States of America	2013	57
23856247	Sirolimus	Cai J	miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer.	Cancer research	2013	44
23863154	Sirolimus	Howell JJ	A growing role for mTOR in promoting anabolic metabolism.	Biochemical Society transactions	2013	55
23897969	Sirolimus	Iyer G	Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.	Journal of clinical oncology 	2013	64
23902785	Sirolimus	Op den Kamp CM	Nuclear transcription factor κ B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia.	The American journal of clinical nutrition	2013	27
23903756	Sirolimus	Elkabets M	mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.	Science translational medicine	2013	76
23953116	Sirolimus	Thedieck K	Inhibition of mTORC1 by astrin and stress granules prevents apoptosis in cancer cells.	Cell	2013	52
23973332	Sirolimus	Lamming DW	A Central role for mTOR in lipid homeostasis.	Cell metabolism	2013	72
24011086	Sirolimus	Tsubaki M	Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines.	Journal of experimental & clinical cancer research 	2013	27
24014241	Sirolimus	Willems L	Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.	Blood	2013	56
24027431	Sirolimus	Kim JK	TBK1 regulates prostate cancer dormancy through mTOR inhibition.	Neoplasia	2013	26
24043745	Sirolimus	Ohtsu A	Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.	Journal of clinical oncology 	2013	92
24052624	Sirolimus	Wang Q	Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development.	Journal of the National Cancer Institute	2013	31
24120665	Sirolimus	Stumpf CR	The translational landscape of the mammalian cell cycle.	Molecular cell	2013	61
24159565	Sirolimus	Young L	Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.	The Lancet. Respiratory medicine	2013	26
24161930	Sirolimus	Liu P	Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis.	Nature cell biology	2013	72
24165795	Sirolimus	Lucas CL	Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency.	Nature immunology	2014	100
24185040	Sirolimus	Francipane MG	Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.	Oncotarget	2013	29
24231729	Sirolimus	Matsubara S	mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions.	Scientific reports	2013	28
24270418	Sirolimus	Liu SC	Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance.	The Journal of clinical investigation	2013	29
24308993	Sirolimus	Matter MS	Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends.	Journal of hepatology	2014	41
24311635	Sirolimus	Kahn J	The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.	Neuro-oncology	2014	23
24336084	Sirolimus	Blagosklonny MV	TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists.	Cell death & disease	2013	35
24401568	Sirolimus	Liu B	Hepatitis B virus X protein inhibits autophagic degradation by impairing lysosomal maturation.	Autophagy	2014	29
24403067	Sirolimus	Neill T	Decorin induces mitophagy in breast carcinoma cells via peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) and mitostatin.	The Journal of biological chemistry	2014	23
24445654	Sirolimus	Chang L	Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.	Cancer metastasis reviews	2014	21
24469052	Sirolimus	Akeno N	p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.	Oncogene	2015	15
24470531	Sirolimus	Farid M	Malignant peripheral nerve sheath tumors.	The oncologist	2014	23
24508508	Sirolimus	Li J	Rapamycin: one drug, many effects.	Cell metabolism	2014	87
24532714	Sirolimus	Tcherkezian J	Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5'TOP mRNA translation.	Genes & development	2014	52
24556063	Sirolimus	Husseinzadeh N	mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review.	Gynecologic oncology	2014	25
24590173	Sirolimus	Puustinen P	CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation.	The Journal of cell biology	2014	24
24603303	Sirolimus	Shimizu K	ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer.	British journal of cancer	2014	25
24615500	Sirolimus	Rugo HS	Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.	Annals of oncology 	2014	24
24631838	Sirolimus	Grabiner BC	A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.	Cancer discovery	2014	83
24698685	Sirolimus	Bar-Peled L	Regulation of mTORC1 by amino acids.	Trends in cell biology	2014	170
24717934	Sirolimus	Morran DC	Targeting mTOR dependency in pancreatic cancer.	Gut	2014	25
24718867	Sirolimus	Patwardhan PP	Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs.	Clinical cancer research 	2014	20
24780124	Sirolimus	Moschetta M	Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations.	British journal of pharmacology	2014	25
24818748	Sirolimus	Xu Y	Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence.	Trends in biochemical sciences	2014	34
24841777	Sirolimus	Albiges L	A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.	European urology	2015	30
24863259	Sirolimus	Fumarola C	Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.	Biochemical pharmacology	2014	48
24889617	Sirolimus	Leontieva OV	Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program.	Proceedings of the National Academy of Sciences of the United States of America	2014	44
24897931	Sirolimus	Martini M	PI3K/AKT signaling pathway and cancer: an updated review.	Annals of medicine	2014	98
24910242	Sirolimus	Umemura A	Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition.	Cell metabolism	2014	27
24931163	Sirolimus	Dodd KM	mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3.	Oncogene	2015	24
24943720	Sirolimus	Cholongitas E	Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.	Transplant international 	2014	22
24948110	Sirolimus	Burotto M	The MAPK pathway across different malignancies: a new perspective.	Cancer	2014	56
24954509	Sirolimus	Chou SD	HSF1 regulation of β-catenin in mammary cancer cells through control of HuR/elavL1 expression.	Oncogene	2015	21
24973821	Sirolimus	Marçais A	The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells.	Nature immunology	2014	73
24990947	Sirolimus	Dan HC	Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IκB kinase α (IKKα).	The Journal of biological chemistry	2014	22
25082895	Sirolimus	Cornu M	Hepatic mTORC1 controls locomotor activity, body temperature, and lipid metabolism through FGF21.	Proceedings of the National Academy of Sciences of the United States of America	2014	34
25158238	Sirolimus	Dunlop EA	mTOR and autophagy: a dynamic relationship governed by nutrients and energy.	Seminars in cell & developmental biology	2014	67
25175012	Sirolimus	Zhu L	TSC1 controls macrophage polarization to prevent inflammatory disease.	Nature communications	2014	40
25202833	Sirolimus	Hsueh AJ	Intraovarian control of early folliculogenesis.	Endocrine reviews	2015	25
25220053	Sirolimus	Csibi A	The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation.	Current biology 	2014	38
25263562	Sirolimus	Chantranupong L	The Sestrins interact with GATOR2 to negatively regulate the amino-acid-sensing pathway upstream of mTORC1.	Cell reports	2014	83
25295501	Sirolimus	Wagle N	Response and acquired resistance to everolimus in anaplastic thyroid cancer.	The New England journal of medicine	2014	76
25307878	Sirolimus	Lee DH	Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.	International journal of cancer	2015	23
25444920	Sirolimus	Zheng B	Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma.	Cancer letters	2015	21
25450580	Sirolimus	Xu K	mTOR signaling in tumorigenesis.	Biochimica et biophysica acta	2014	34
25464856	Sirolimus	Staron MM	The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection.	Immunity	2014	66
25477072	Sirolimus	Gao B	Translational control by oncogenic signaling pathways.	Biochimica et biophysica acta	2015	15
25497227	Sirolimus	Chiarini F	Current treatment strategies for inhibiting mTOR in cancer.	Trends in pharmacological sciences	2015	54
25522665	Sirolimus	Pollizzi KN	Regulation of T cells by mTOR: the known knowns and the known unknowns.	Trends in immunology	2015	31
25524627	Sirolimus	Li J	Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells.	Proceedings of the National Academy of Sciences of the United States of America	2015	17
25531317	Sirolimus	Siu MK	Transforming growth factor-β promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway.	Oncogene	2015	19
25532816	Sirolimus	Simpson DR	Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck.	Oral oncology	2015	21
25557953	Sirolimus	Cornella H	Unique genomic profile of fibrolamellar hepatocellular carcinoma.	Gastroenterology	2015	20
25561726	Sirolimus	Marchand B	Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells.	The Journal of biological chemistry	2015	22
25590164	Sirolimus	Morita M	mTOR coordinates protein synthesis, mitochondrial activity and proliferation.	Cell cycle	2015	42
25591831	Sirolimus	Curatolo P	Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.	Pediatric neurology	2015	16
25601637	Sirolimus	Kong B	A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.	Gut	2016	14
25652038	Sirolimus	Schreiber KH	Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins.	Aging cell	2015	25
25657110	Sirolimus	Cao Y	Fibronectin promotes cell proliferation and invasion through mTOR signaling pathway activation in gallbladder cancer.	Cancer letters	2015	19
25688110	Sirolimus	Cargnello M	The expanding role of mTOR in cancer cell growth and proliferation.	Mutagenesis	2015	23
25749036	Sirolimus	Yang H	FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells.	Oncotarget	2015	21
25752815	Sirolimus	Chen J	Signaling pathways in HPV-associated cancers and therapeutic implications.	Reviews in medical virology	2015	18
25813405	Sirolimus	Wang Y	CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling.	Cancer letters	2015	45
25844603	Sirolimus	Blagosklonny MV	Rejuvenating immunity: "anti-aging drug today" eight years later.	Oncotarget	2015	17
25883264	Sirolimus	Shuda M	CDK1 substitutes for mTOR kinase to activate mitotic cap-dependent protein translation.	Proceedings of the National Academy of Sciences of the United States of America	2015	19
25907074	Sirolimus	Perl A	mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging.	Annals of the New York Academy of Sciences	2015	26
25940091	Sirolimus	Fonseca BD	La-related Protein 1 (LARP1) Represses Terminal Oligopyrimidine (TOP) mRNA Translation Downstream of mTOR Complex 1 (mTORC1).	The Journal of biological chemistry	2015	26
25961916	Sirolimus	Shi Y	Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress.	Oncogene	2016	14
26028026	Sirolimus	Ricoult SJ	Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP.	Oncogene	2016	24
26067126	Sirolimus	Curatolo P	Neurological and neuropsychiatric aspects of tuberous sclerosis complex.	The Lancet. Neurology	2015	37
26118643	Sirolimus	Egan DF	Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates.	Molecular cell	2015	63
26147250	Sirolimus	Laberge RM	MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.	Nature cell biology	2015	103
26156073	Sirolimus	Bissler JJ	Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.	Nephrology, dialysis, transplantation 	2016	28
26177051	Sirolimus	Leontieva OV	Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).	Oncotarget	2015	25
26277543	Sirolimus	Hsieh AL	MYC and metabolism on the path to cancer.	Seminars in cell & developmental biology	2015	31
26280535	Sirolimus	Herranz N	mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype.	Nature cell biology	2015	48
26315673	Sirolimus	Hurez V	Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice.	Aging cell	2015	17
26364551	Sirolimus	Powles T	A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.	European urology	2016	13
26476289	Sirolimus	Li L	Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans.	Journal of hepatology	2016	12
26517881	Sirolimus	Siddiqui N	Signalling to eIF4E in cancer.	Biochemical Society transactions	2015	27
26540343	Sirolimus	Ji J	LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway.	Oncotarget	2015	33
26563133	Sirolimus	Brunstein CG	Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.	Blood	2016	46
26565512	Sirolimus	Qiang L	Autophagy positively regulates DNA damage recognition by nucleotide excision repair.	Autophagy	2016	12
26584640	Sirolimus	Yin Y	mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR.	Cell research	2016	12
26735353	Sirolimus	Bournet B	Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.	European journal of cancer	2016	19
26779371	Sirolimus	Lee JJ	PI3K/Akt/mTOR inhibitors in breast cancer.	Cancer biology & medicine	2015	29
26826241	Sirolimus	Goh CC	Hepatitis C Virus-Induced Myeloid-Derived Suppressor Cells Suppress NK Cell IFN-γ Production by Altering Cellular Metabolism via Arginase-1.	Journal of immunology	2016	13
26884601	Sirolimus	Viel S	TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway.	Science signaling	2016	24
26917778	Sirolimus	Yun S	4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.	Blood	2016	12
26927950	Sirolimus	Curatolo P	The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.	Drugs	2016	11
26929424	Sirolimus	Kempf E	KRAS oncogene in lung cancer: focus on molecularly driven clinical trials.	European respiratory review 	2016	12
27161823	Sirolimus	Gaubitz C	TORC2 Structure and Function.	Trends in biochemical sciences	2016	29
27226234	Sirolimus	Henske EP	Tuberous sclerosis complex.	Nature reviews. Disease primers	2016	22
27232329	Sirolimus	Welsh SJ	Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?	European journal of cancer	2016	18
27465917	Sirolimus	Mao Y	IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.	Blood	2016	16
27578176	Sirolimus	Yu JS	Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination.	Development	2016	21
27621407	Sirolimus	LoRusso PM	Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.	Journal of clinical oncology 	2016	12
27628078	Sirolimus	McCormack FX	Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.	American journal of respiratory and critical care medicine	2016	13
27663511	Sirolimus	Riedl A	Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses.	Journal of cell science	2017	8
27668290	Sirolimus	Ilagan E	Emerging role of mTOR in the response to cancer therapeutics.	Trends in cancer	2016	19
27671674	Sirolimus	Clark CA	Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.	Cancer research	2016	18
27748764	Sirolimus	Kim LC	mTORC1 and mTORC2 in cancer and the tumor microenvironment.	Oncogene	2017	23
28027327	Sirolimus	Lefebvre C	Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.	PLoS medicine	2016	20
28146265	Sirolimus	Calimeri T	m-TOR inhibitors and their potential role in haematological malignancies.	British journal of haematology	2017	7
28162974	Sirolimus	Vila IK	A UBE2O-AMPKα2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy.	Cancer cell	2017	7
28283069	Sirolimus	Saxton RA	mTOR Signaling in Growth, Metabolism, and Disease.	Cell	2017	128
28292440	Sirolimus	Fan Q	A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.	Cancer cell	2017	7
7641693	afimoxifene	Cavaillès V	Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor.	The EMBO journal	1995	168
11369200	afimoxifene	Arnold I	c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny.	Current biology 	2001	103
14652237	afimoxifene	Stearns V	Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.	Journal of the National Cancer Institute	2003	171
14701735	afimoxifene	Zeisig BB	Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.	Molecular and cellular biology	2004	120
15685451	afimoxifene	Lim YC	Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.	Cancer chemotherapy and pharmacology	2005	74
17897439	afimoxifene	Schlange T	Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation.	Breast cancer research 	2007	75
19244106	afimoxifene	Wu X	The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.	Cancer research	2009	51
19264808	afimoxifene	Wickramasinghe NS	Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells.	Nucleic acids research	2009	109
20018866	afimoxifene	Fan Y	Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition.	The Journal of biological chemistry	2010	43
20179196	afimoxifene	Turner N	FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.	Cancer research	2010	139
21915098	afimoxifene	Frankel LB	microRNA-101 is a potent inhibitor of autophagy.	The EMBO journal	2011	96
23436997	afimoxifene	Skalska L	Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines.	PLoS pathogens	2013	32
26836308	afimoxifene	Fanning SW	Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation.	eLife	2016	29
12114432	gemcitabine	Lord RV	Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.	Clinical cancer research 	2002	112
12761494	gemcitabine	Arlt A	Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.	Oncogene	2003	124
12941837	gemcitabine	Maloney EK	An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.	Cancer research	2003	81
14747554	gemcitabine	Feng WH	Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.	Journal of virology	2004	84
14977831	gemcitabine	Rosell R	Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.	Clinical cancer research 	2004	79
15051286	gemcitabine	Li D	Pancreatic cancer.	Lancet	2004	470
15172981	gemcitabine	Davidson JD	An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.	Cancer research	2004	83
15226328	gemcitabine	Xiong HQ	Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.	Journal of clinical oncology 	2004	93
15317748	gemcitabine	Taron M	BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.	Human molecular genetics	2004	70
15501974	gemcitabine	Spratlin J	The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.	Clinical cancer research 	2004	82
15897578	gemcitabine	Berberat PO	Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment.	Clinical cancer research 	2005	67
16034041	gemcitabine	von der Maase H	Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.	Journal of clinical oncology 	2005	228
16239320	gemcitabine	Haraguchi N	Characterization of a side population of cancer cells from human gastrointestinal system.	Stem cells	2006	170
16258101	gemcitabine	Kindler HL	Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.	Journal of clinical oncology 	2005	107
16585222	gemcitabine	Giovannetti E	Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.	Cancer research	2006	89
16601104	gemcitabine	Dasgupta P	Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin.	Proceedings of the National Academy of Sciences of the United States of America	2006	84
16762633	gemcitabine	Meng F	Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines.	Gastroenterology	2006	296
16807468	gemcitabine	Mini E	Cellular pharmacology of gemcitabine.	Annals of oncology 	2006	117
16918309	gemcitabine	Shao J	Ribonucleotide reductase inhibitors and future drug design.	Current cancer drug targets	2006	83
16966686	gemcitabine	Bepler G	RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.	Journal of clinical oncology 	2006	81
16980606	gemcitabine	Ceppi P	ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.	Annals of oncology 	2006	67
17131328	gemcitabine	Nakahira S	Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.	International journal of cancer	2007	59
17224927	gemcitabine	Nakano Y	Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.	British journal of cancer	2007	72
17229776	gemcitabine	Bellmunt J	Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.	Annals of oncology 	2007	69
17308067	gemcitabine	Senkal CE	Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas.	Molecular cancer therapeutics	2007	59
17332336	gemcitabine	Hayes GM	Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas.	Cancer research	2007	56
17332349	gemcitabine	Feldmann G	Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.	Cancer research	2007	242
17404099	gemcitabine	Nomi T	Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.	Clinical cancer research 	2007	211
17406032	gemcitabine	Ewald B	H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation.	Molecular cancer therapeutics	2007	62
17452677	gemcitabine	Moore MJ	Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.	Journal of clinical oncology 	2007	876
17606725	gemcitabine	Wacker B	Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.	Clinical cancer research 	2007	88
17615536	gemcitabine	Rocha-Lima CM	EGFR targeting of solid tumors.	Cancer control 	2007	58
17671218	gemcitabine	Ko HJ	A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.	Cancer research	2007	62
17894887	gemcitabine	Cho WC	OncomiRs: the discovery and progress of microRNAs in cancers.	Molecular cancer	2007	210
17909916	gemcitabine	Shah AN	Development and characterization of gemcitabine-resistant pancreatic tumor cells.	Annals of surgical oncology	2007	152
18089802	gemcitabine	Olmeda D	SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells.	Cancer research	2007	61
18245495	gemcitabine	Hwang RF	Cancer-associated stromal fibroblasts promote pancreatic tumor progression.	Cancer research	2008	289
18263769	gemcitabine	Ramalingam S	Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.	The oncologist	2008	80
18281656	gemcitabine	Edelman MJ	Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.	Journal of clinical oncology 	2008	70
18339879	gemcitabine	Patra CR	Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.	Cancer research	2008	79
18413796	gemcitabine	Melisi D	LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.	Molecular cancer therapeutics	2008	93
18509182	gemcitabine	Brunner TB	Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.	Journal of clinical oncology 	2008	51
18698032	gemcitabine	Morgan MA	The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.	Clinical cancer research 	2008	56
18723486	gemcitabine	Blasina A	Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.	Molecular cancer therapeutics	2008	70
18757419	gemcitabine	Li L	Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression.	Cancer research	2008	82
18829536	gemcitabine	Ramachandran V	Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival.	Cancer research	2008	51
18992248	gemcitabine	Farrell JJ	Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.	Gastroenterology	2009	103
19047305	gemcitabine	Wolpin BM	Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.	Journal of clinical oncology 	2009	78
19139112	gemcitabine	Parsels LA	Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.	Molecular cancer therapeutics	2009	51
19174553	gemcitabine	Jimeno A	A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.	Molecular cancer therapeutics	2009	104
19188680	gemcitabine	Reck M	Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.	Journal of clinical oncology 	2009	322
19237188	gemcitabine	Boren T	MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.	Gynecologic oncology	2009	50
19276344	gemcitabine	Wang Z	Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.	Cancer research	2009	195
19318496	gemcitabine	Maréchal R	Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.	Clinical cancer research 	2009	48
19366899	gemcitabine	Beltran PJ	AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells.	Molecular cancer therapeutics	2009	52
19435867	gemcitabine	Moriyama T	MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance.	Molecular cancer therapeutics	2009	118
19487279	gemcitabine	Costantino CL	The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.	Cancer research	2009	51
19501590	gemcitabine	Mueller MT	Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.	Gastroenterology	2009	81
19571674	gemcitabine	Hochwald SN	A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.	Cell cycle	2009	61
19584296	gemcitabine	Arumugam T	Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.	Cancer research	2009	241
19598259	gemcitabine	Hong SP	CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.	International journal of cancer	2009	80
19654003	gemcitabine	Crawford M	MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer.	Biochemical and biophysical research communications	2009	60
19730150	gemcitabine	Park JK	Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma.	Pancreas	2009	87
19884554	gemcitabine	Reynolds C	Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.	Journal of clinical oncology 	2009	54
19898621	gemcitabine	Li L	Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers.	PloS one	2009	47
19901115	gemcitabine	Makhija S	Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.	Journal of clinical oncology 	2010	46
19908231	gemcitabine	Harikumar KB	Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.	International journal of cancer	2010	52
19948396	gemcitabine	Hummel R	MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types.	European journal of cancer	2010	109
20047843	gemcitabine	Stewart DJ	Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.	Critical reviews in oncology/hematology	2010	65
20072652	gemcitabine	Lin L	A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.	Neoplasia	2010	54
20150572	gemcitabine	Reck M	Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).	Annals of oncology 	2010	138
20388782	gemcitabine	Ali S	Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.	Cancer research	2010	130
20460539	gemcitabine	Giovannetti E	MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.	Cancer research	2010	122
20501833	gemcitabine	Morgan MA	Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.	Cancer research	2010	100
20606093	gemcitabine	Philip PA	Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.	Journal of clinical oncology 	2010	167
20798217	gemcitabine	Hastak K	Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.	Cancer research	2010	47
20803052	gemcitabine	Kindler HL	Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.	Investigational new drugs	2012	31
20824720	gemcitabine	da Cunha Santos G	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.	Cancer	2010	44
20927319	gemcitabine	Fujita H	Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.	Neoplasia	2010	46
21045835	gemcitabine	Singh S	CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.	British journal of cancer	2010	59
21078544	gemcitabine	Arlt A	Targeting apoptosis pathways in pancreatic cancer.	Cancer letters	2013	27
21081113	gemcitabine	Kikuta K	Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells.	Biochemical and biophysical research communications	2010	54
21106054	gemcitabine	Zhang XJ	Dysregulation of miR-15a and miR-214 in human pancreatic cancer.	Journal of hematology & oncology	2010	57
21135251	gemcitabine	Villarroel MC	Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.	Molecular cancer therapeutics	2011	71
21148071	gemcitabine	Dangi-Garimella S	Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.	Cancer research	2011	37
21163702	gemcitabine	Jordheim LP	The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.	The Lancet. Oncology	2011	36
21177151	gemcitabine	Bensouda Y	Treatment for metastatic nasopharyngeal carcinoma.	European annals of otorhinolaryngology, head and neck diseases	2011	46
21208101	gemcitabine	O'Shaughnessy J	Iniparib plus chemotherapy in metastatic triple-negative breast cancer.	The New England journal of medicine	2011	196
21216939	gemcitabine	Carrasco RA	Antisense inhibition of survivin expression as a cancer therapeutic.	Molecular cancer therapeutics	2011	37
21306953	gemcitabine	Kindler HL	Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.	The Lancet. Oncology	2011	101
21376256	gemcitabine	Dong J	Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells.	Archives of medical research	2011	35
21389100	gemcitabine	Rajeshkumar NV	MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.	Clinical cancer research 	2011	71
21408027	gemcitabine	Bao B	Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer.	PloS one	2011	73
21436454	gemcitabine	Beatty GL	CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.	Science	2011	405
21489257	gemcitabine	Lister A	Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.	Molecular cancer	2011	52
21525939	gemcitabine	Donadelli M	Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism.	Cell death & disease	2011	45
21594619	gemcitabine	Bodoky G	A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 ARRY-142886) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.	Investigational new drugs	2012	51
21742805	gemcitabine	Garrido-Laguna I	Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.	Clinical cancer research 	2011	58
21783417	gemcitabine	Zhou C	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.	The Lancet. Oncology	2011	839
21792083	gemcitabine	Kimura Y	Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.	Pancreas	2012	30
21885862	gemcitabine	Taeger J	Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.	Molecular cancer therapeutics	2011	35
21969517	gemcitabine	Von Hoff DD	Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.	Journal of clinical oncology 	2011	260
22019520	gemcitabine	Quoix E	Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.	The Lancet. Oncology	2011	73
22056140	gemcitabine	Lonardo E	Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy.	Cell stem cell	2011	102
22086681	gemcitabine	Bao B	Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.	Cancer prevention research	2012	101
22276821	gemcitabine	Bear HD	Bevacizumab added to neoadjuvant chemotherapy for breast cancer.	The New England journal of medicine	2012	104
22285168	gemcitabine	Rosell R	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.	The Lancet. Oncology	2012	1030
22330686	gemcitabine	Postel-Vinay S	The potential of exploiting DNA-repair defects for optimizing lung cancer treatment.	Nature reviews. Clinical oncology	2012	31
22363658	gemcitabine	Zhang G	DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.	PloS one	2012	39
22371451	gemcitabine	Rajan A	A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.	Clinical cancer research 	2012	35
22458527	gemcitabine	Troiani T	Targeting EGFR in pancreatic cancer treatment.	Current drug targets	2012	33
22510406	gemcitabine	Hamada S	Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells.	Biochemical and biophysical research communications	2012	46
22580602	gemcitabine	Skrypek N	The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.	Oncogene	2013	29
22589274	gemcitabine	Kelber JA	KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer.	Cancer research	2012	33
22608783	gemcitabine	Lambrechts D	VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.	The Lancet. Oncology	2012	46
22665541	gemcitabine	Kindler HL	Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.	Journal of clinical oncology 	2012	43
22700995	gemcitabine	Kindler HL	A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.	Annals of oncology 	2012	55
22705007	gemcitabine	Maréchal R	Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.	Gastroenterology	2012	60
22778317	gemcitabine	Gridelli C	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.	Journal of clinical oncology 	2012	64
22797067	gemcitabine	Adesso L	Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.	Oncogene	2013	30
22825331	gemcitabine	Prevo R	The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.	Cancer biology & therapy	2012	57
23177026	gemcitabine	Wang P	The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL.	Molecular oncology	2013	38
23222511	gemcitabine	Fokas E	Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.	Cell death & disease	2012	57
23318457	gemcitabine	Sia D	Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.	Oncogene	2013	49
23341531	gemcitabine	Herman JM	Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.	Journal of clinical oncology 	2013	36
23402593	gemcitabine	Lee GY	Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer.	ACS nano	2013	47
23402814	gemcitabine	Yabuuchi S	Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.	Cancer letters	2013	41
23437065	gemcitabine	Proctor E	Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma.	PloS one	2013	32
23520471	gemcitabine	Kreahling JM	Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas.	PloS one	2013	26
23547081	gemcitabine	Ueno H	Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.	Journal of clinical oncology 	2013	89
23548269	gemcitabine	Huntoon CJ	ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.	Cancer research	2013	38
23591198	gemcitabine	Mitsunaga S	Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer.	British journal of cancer	2013	28
23593991	gemcitabine	Thompson R	The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design.	British journal of clinical pharmacology	2013	35
23661005	gemcitabine	Hage C	The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.	Cell death & disease	2013	39
23690416	gemcitabine	Bepler G	Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2013	40
23740244	gemcitabine	Arora S	An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4.	The Journal of biological chemistry	2013	44
23774063	gemcitabine	Nath S	MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes.	Oncogenesis	2013	35
23782814	gemcitabine	Wu YL	Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.	The Lancet. Oncology	2013	75
23849556	gemcitabine	Heinemann V	Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.	Cancer treatment reviews	2014	30
23983255	gemcitabine	Beatty GL	A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.	Clinical cancer research 	2013	80
23995783	gemcitabine	Weizman N	Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase.	Oncogene	2014	45
24075276	gemcitabine	Yamada S	Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer.	Surgery	2013	31
24097873	gemcitabine	Nixon AB	Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).	Clinical cancer research 	2013	33
24114124	gemcitabine	King C	Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.	Investigational new drugs	2014	22
24143858	gemcitabine	Meng H	Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice.	ACS nano	2013	27
24147037	gemcitabine	Okamoto K	miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.	PloS one	2013	28
24178759	gemcitabine	Maftouh M	Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia.	British journal of cancer	2014	23
24216611	gemcitabine	Hamada S	MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX.	Cellular signalling	2014	25
24220555	gemcitabine	Poplin E	Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.	Journal of clinical oncology 	2013	39
24282274	gemcitabine	Fitzgerald JB	MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.	Molecular cancer therapeutics	2014	26
24301456	gemcitabine	Greenhalf W	Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.	Journal of the National Cancer Institute	2014	52
24351397	gemcitabine	Valle JW	Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.	Annals of oncology 	2014	52
24360787	gemcitabine	Earl HM	Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.	The Lancet. Oncology	2014	23
24439929	gemcitabine	Wu YL	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	282
24448638	gemcitabine	Sausville E	Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.	Cancer chemotherapy and pharmacology	2014	31
24562449	gemcitabine	Sinn M	SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.	Annals of oncology 	2014	24
24607283	gemcitabine	Liu JF	PARP inhibitors in ovarian cancer: current status and future promise.	Gynecologic oncology	2014	23
24614108	gemcitabine	Koay EJ	Transport properties of pancreatic cancer describe gemcitabine delivery and response.	The Journal of clinical investigation	2014	43
24683721	gemcitabine	Thota R	Treatment of metastatic pancreatic adenocarcinoma: a review.	Oncology	2014	37
24859161	gemcitabine	Li L	Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.	Gastroenterology	2014	29
24867695	gemcitabine	Cheng G	Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.	British journal of cancer	2014	23
24915778	gemcitabine	Infante JR	A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.	European journal of cancer	2014	46
24919854	gemcitabine	Gelbert LM	Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.	Investigational new drugs	2014	57
24928772	gemcitabine	Brana I	Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.	Targeted oncology	2015	17
24929024	gemcitabine	Houédé N	Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers.	Pharmacology & therapeutics	2015	19
24954781	gemcitabine	Middleton G	Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.	The Lancet. Oncology	2014	52
25034785	gemcitabine	Zeuner A	Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer.	Cell death and differentiation	2014	27
25041791	gemcitabine	Philip PA	Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).	Cancer	2014	27
25056373	gemcitabine	Koido S	Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.	Clinical cancer research 	2014	26
25104095	gemcitabine	Bryant C	Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.	BMC cancer	2014	23
25117811	gemcitabine	Hasegawa S	MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer.	British journal of cancer	2014	27
25149530	gemcitabine	Xu J	MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.	Oncotarget	2014	24
25156567	gemcitabine	Franco J	CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.	Oncotarget	2014	31
25249556	gemcitabine	Yu G	Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression.	Molecular cancer therapeutics	2014	44
25277192	gemcitabine	Khan S	MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer.	Oncotarget	2014	33
25278454	gemcitabine	Kim EJ	Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.	Clinical cancer research 	2014	36
25311384	gemcitabine	Fiorini C	Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.	Biochimica et biophysica acta	2015	21
25331547	gemcitabine	Guo Y	Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis.	Journal of cellular and molecular medicine	2015	16
25366685	gemcitabine	Kaufman B	Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.	Journal of clinical oncology 	2015	192
25402324	gemcitabine	Hiroshima Y	Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cell line mouse models.	Oncotarget	2014	53
25453096	gemcitabine	Samanta D	Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.	Proceedings of the National Academy of Sciences of the United States of America	2014	69
25473894	gemcitabine	Suzuki S	JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells.	Oncotarget	2015	18
25498218	gemcitabine	Sternberg CN	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.	The Lancet. Oncology	2015	32
25589191	gemcitabine	Yang JC	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.	The Lancet. Oncology	2015	226
25605849	gemcitabine	Daud AI	Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.	Journal of clinical oncology 	2015	33
25609246	gemcitabine	Fuchs CS	A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.	Annals of oncology 	2015	25
25638153	gemcitabine	Ma J	Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.	Oncotarget	2015	29
25717063	gemcitabine	Cioffi M	Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms.	Clinical cancer research 	2015	20
25829397	gemcitabine	Mok T	Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.	Clinical cancer research 	2015	66
25832687	gemcitabine	Tan T	Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma.	International journal of radiation oncology, biology, physics	2015	35
25834145	gemcitabine	Duluc C	Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance.	EMBO molecular medicine	2015	20
25840985	gemcitabine	Khan S	Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer.	Cancer research	2015	19
25847929	gemcitabine	Telli ML	Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.	Journal of clinical oncology 	2015	35
25887381	gemcitabine	Cioffi M	The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.	Gut	2015	24
25889214	gemcitabine	Li Z	The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.	Journal of translational medicine	2015	45
25934888	gemcitabine	Yen WC	Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.	Clinical cancer research 	2015	42
26036346	gemcitabine	Tréhoux S	Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells.	Biochimica et biophysica acta	2015	20
26077591	gemcitabine	Miller BW	Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.	EMBO molecular medicine	2015	33
26105600	gemcitabine	Wu YL	First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.	Annals of oncology 	2015	54
26141208	gemcitabine	Zhou C	Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).	Annals of oncology 	2015	50
26169969	gemcitabine	Hidalgo M	SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.	Clinical cancer research 	2015	30
26179201	gemcitabine	Valle JW	Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.	The Lancet. Oncology	2015	23
26234680	gemcitabine	Calabretta S	Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.	Oncogene	2016	18
26255562	gemcitabine	Nagathihalli NS	Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.	Gastroenterology	2015	16
26351344	gemcitabine	Hurwitz HI	Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.	Journal of clinical oncology 	2015	35
26410730	gemcitabine	Oing C	Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.	The Journal of urology	2016	10
26458814	gemcitabine	Yang MC	Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine.	Molecular cancer	2015	25
26517239	gemcitabine	Vendetti FP	The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.	Oncotarget	2015	26
26527777	gemcitabine	Catenacci DV	Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.	Journal of clinical oncology 	2015	30
26546043	gemcitabine	Tyagi N	p-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes in pancreatic cancer cells through activation of STAT3 signaling.	Cancer letters	2016	13
26666820	gemcitabine	Wu ZH	MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer.	Tumour biology 	2016	14
26725968	gemcitabine	Tjensvoll K	Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer.	Molecular oncology	2016	20
26817584	gemcitabine	Liu Y	MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells.	Journal of experimental & clinical cancer research 	2016	11
26828016	gemcitabine	Fan P	MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.	Cancer letters	2016	10
26862857	gemcitabine	Khan K	miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.	Oncotarget	2016	11
26939701	gemcitabine	Gifford JB	Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.	Molecular cancer therapeutics	2016	11
26957554	gemcitabine	Telli ML	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.	Clinical cancer research 	2016	33
27003603	gemcitabine	Wörmann SM	Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.	Gastroenterology	2016	17
27007129	gemcitabine	Ciccolini J	Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective.	Cancer chemotherapy and pharmacology	2016	14
27102149	gemcitabine	Chong DQ	The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.	Oncotarget	2016	15
27216178	gemcitabine	Schultz MJ	The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype.	Cancer research	2016	12
27265347	gemcitabine	Uesaka K	Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).	Lancet	2016	23
27502726	gemcitabine	Olaussen KA	Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.	Annals of oncology 	2016	12
27576197	gemcitabine	Zhang Z	Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.	Cancer letters	2016	18
27591936	gemcitabine	Pan J	Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.	Cancer letters	2016	20
27634334	gemcitabine	Kanu N	DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer.	Genome biology	2016	18
27669441	gemcitabine	Richards KE	Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells.	Oncogene	2017	28
27742686	gemcitabine	Ireland L	Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors.	Cancer research	2016	16
28034748	gemcitabine	Zhang Y	MiR-216a decreases MALAT1 expression, induces G2/M arrest and apoptosis in pancreatic cancer cells.	Biochemical and biophysical research communications	2017	6
28108630	gemcitabine	Cullis J	Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.	Cancer immunology research	2017	7
28152544	gemcitabine	Patel GK	Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK.	British journal of cancer	2017	8
8811177	O-(6)-methylguanine	Wood RD	DNA repair in eukaryotes.	Annual review of biochemistry	1996	133
9892187	O-(6)-methylguanine	Esteller M	Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.	Cancer research	1999	138
10029064	O-(6)-methylguanine	Esteller M	Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.	Cancer research	1999	225
11085511	O-(6)-methylguanine	Palmisano WA	Predicting lung cancer by detecting aberrant promoter methylation in sputum.	Cancer research	2000	143
11196170	O-(6)-methylguanine	Zöchbauer-Müller S	Aberrant promoter methylation of multiple genes in non-small cell lung cancers.	Cancer research	2001	110
11956099	O-(6)-methylguanine	Belinsky SA	Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers.	Cancer research	2002	106
15685439	O-(6)-methylguanine	Ohgaki H	Epidemiology and etiology of gliomas.	Acta neuropathologica	2005	228
16118624	O-(6)-methylguanine	Ogino S	Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component.	Modern pathology 	2006	78
18483356	O-(6)-methylguanine	Sarkaria JN	Mechanisms of chemoresistance to alkylating agents in malignant glioma.	Clinical cancer research 	2008	83
18556773	O-(6)-methylguanine	Vlassenbroeck I	Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.	The Journal of molecular diagnostics 	2008	54
18757334	O-(6)-methylguanine	Hegi ME	Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.	Journal of clinical oncology 	2008	179
19088037	O-(6)-methylguanine	Pallini R	Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.	Clinical cancer research 	2008	95
19107440	O-(6)-methylguanine	Ohgaki H	Epidemiology of brain tumors.	Methods in molecular biology	2009	92
19516334	O-(6)-methylguanine	Tubbs JL	Flipping of alkylated DNA damage bridges base and nucleotide excision repair.	Nature	2009	54
19676044	O-(6)-methylguanine	Salnikov AV	CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.	International journal of cancer	2010	54
19805672	O-(6)-methylguanine	Weller M	Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.	Journal of clinical oncology 	2009	142
19841865	O-(6)-methylguanine	Karayan-Tapon L	Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods.	Journal of neuro-oncology	2010	49
19997073	O-(6)-methylguanine	Weller M	MGMT promoter methylation in malignant gliomas: ready for personalized medicine?	Nature reviews. Neurology	2010	143
20150378	O-(6)-methylguanine	Rivera AL	MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.	Neuro-oncology	2010	60
20309962	O-(6)-methylguanine	Pistollato F	Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma.	Stem cells	2010	66
20714900	O-(6)-methylguanine	Riemenschneider MJ	Molecular diagnostics of gliomas: state of the art.	Acta neuropathologica	2010	47
20880848	O-(6)-methylguanine	Zhang WB	Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition.	The Journal of biological chemistry	2010	43
21175304	O-(6)-methylguanine	Bredel M	NFKBIA deletion in glioblastomas.	The New England journal of medicine	2011	78
21292686	O-(6)-methylguanine	Kunz M	Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas.	Neuro-oncology	2011	37
21895872	O-(6)-methylguanine	Lakomy R	MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients.	Cancer science	2011	46
22122467	O-(6)-methylguanine	Zhang J	Temozolomide: mechanisms of action, repair and resistance.	Current molecular pharmacology	2012	84
22139906	O-(6)-methylguanine	Reifenberger G	Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.	International journal of cancer	2012	52
22244911	O-(6)-methylguanine	Silber JR	O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems.	Biochimica et biophysica acta	2012	30
22261329	O-(6)-methylguanine	Roos WP	DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis.	Cancer letters	2013	153
22294349	O-(6)-methylguanine	Quillien V	Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients.	Cancer	2012	42
22810491	O-(6)-methylguanine	Bady P	MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.	Acta neuropathologica	2012	51
23095825	O-(6)-methylguanine	Weller M	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.	Neuro-oncology	2012	31
23348904	O-(6)-methylguanine	Rosty C	Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.	Modern pathology 	2013	53
23383259	O-(6)-methylguanine	Knizhnik AV	Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage.	PloS one	2013	39
23726844	O-(6)-methylguanine	Zhang XQ	A long non-coding RNA signature in glioblastoma multiforme predicts survival.	Neurobiology of disease	2013	53
23785428	O-(6)-methylguanine	Rosty C	PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.	PloS one	2013	39
23904111	O-(6)-methylguanine	Wiestler B	ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.	Acta neuropathologica	2013	51
24068788	O-(6)-methylguanine	Wick W	Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.	Neurology	2013	37
24367102	O-(6)-methylguanine	Weiler M	mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.	Proceedings of the National Academy of Sciences of the United States of America	2014	39
24469053	O-(6)-methylguanine	Zhang LH	TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway.	Oncogene	2015	16
24510240	O-(6)-methylguanine	Molenaar RJ	The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.	Neuro-oncology	2014	26
24912512	O-(6)-methylguanine	Wick W	MGMT testing--the challenges for biomarker-based glioma treatment.	Nature reviews. Neurology	2014	59
25140036	O-(6)-methylguanine	Simon M	TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.	Neuro-oncology	2015	28
25178641	O-(6)-methylguanine	Millis SZ	Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.	Clinical genitourinary cancer	2015	15
25355681	O-(6)-methylguanine	Berghoff AS	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.	Neuro-oncology	2015	83
25537990	O-(6)-methylguanine	Jansen NL	Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma.	Journal of nuclear medicine 	2015	16
26948350	O-(6)-methylguanine	Masui K	Molecular classification of gliomas.	Handbook of clinical neurology	2016	14
10759556	Reactive Oxygen Species	Kuraoka I	Removal of oxygen free-radical-induced 5',8-purine cyclodeoxynucleosides from DNA by the nucleotide excision-repair pathway in human cells.	Proceedings of the National Academy of Sciences of the United States of America	2000	92
14744246	Reactive Oxygen Species	Klaunig JE	The role of oxidative stress in carcinogenesis.	Annual review of pharmacology and toxicology	2004	257
15297389	Reactive Oxygen Species	De Larco JE	The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8.	Clinical cancer research 	2004	72
15537542	Reactive Oxygen Species	Pham CG	Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species.	Cell	2004	148
15544038	Reactive Oxygen Species	Ushio-Fukai M	Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase.	Molecular and cellular biochemistry	2004	106
15647368	Reactive Oxygen Species	Petros JA	mtDNA mutations increase tumorigenicity in prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2005	249
15811878	Reactive Oxygen Species	Komarova EA	p53 is a suppressor of inflammatory response in mice.	FASEB journal 	2005	70
16163384	Reactive Oxygen Species	Achanta G	Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma.	The EMBO journal	2005	99
16290020	Reactive Oxygen Species	Kang SW	2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications.	Trends in molecular medicine	2005	77
16294028	Reactive Oxygen Species	Desouki MM	Cross talk between mitochondria and superoxide generating NADPH oxidase in breast and ovarian tumors.	Cancer biology & therapy	2005	66
16456579	Reactive Oxygen Species	Papa S	The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease.	Cell death and differentiation	2006	70
16839880	Reactive Oxygen Species	Bensaad K	TIGAR, a p53-inducible regulator of glycolysis and apoptosis.	Cell	2006	533
16857678	Reactive Oxygen Species	Djavaheri-Mergny M	NF-kappaB activation represses tumor necrosis factor-alpha-induced autophagy.	The Journal of biological chemistry	2006	139
17072325	Reactive Oxygen Species	Bubici C	Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance.	Oncogene	2006	113
17160708	Reactive Oxygen Species	Wu WS	The signaling mechanism of ROS in tumor progression.	Cancer metastasis reviews	2006	175
17179479	Reactive Oxygen Species	Phillips TM	The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation.	Journal of the National Cancer Institute	2006	416
17289868	Reactive Oxygen Species	Fruehauf JP	Reactive oxygen species: a breath of life or death?	Clinical cancer research 	2007	207
17292829	Reactive Oxygen Species	Dolado I	p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis.	Cancer cell	2007	115
17456604	Reactive Oxygen Species	Zhou S	Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck.	Proceedings of the National Academy of Sciences of the United States of America	2007	56
17704323	Reactive Oxygen Species	Zhao W	Oxidative damage pathways in relation to normal tissue injury.	The British journal of radiology	2007	56
17726019	Reactive Oxygen Species	Leclerc E	S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains.	The Journal of biological chemistry	2007	56
17967865	Reactive Oxygen Species	Guzy RD	Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis.	Molecular and cellular biology	2008	113
18192505	Reactive Oxygen Species	Sallmyr A	Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML.	Blood	2008	79
18193822	Reactive Oxygen Species	Hoye AT	Targeting mitochondria.	Accounts of chemical research	2008	91
18339858	Reactive Oxygen Species	Kumar B	Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype.	Cancer research	2008	157
18372916	Reactive Oxygen Species	Frohlich DA	The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis.	Oncogene	2008	58
18394557	Reactive Oxygen Species	Duran A	The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis.	Cancer cell	2008	181
18406051	Reactive Oxygen Species	Ushio-Fukai M	Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy.	Cancer letters	2008	133
18413749	Reactive Oxygen Species	Derdak Z	The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells.	Cancer research	2008	56
18463161	Reactive Oxygen Species	Gianni D	The involvement of the tyrosine kinase c-Src in the regulation of reactive oxygen species generation mediated by NADPH oxidase-1.	Molecular biology of the cell	2008	53
18791199	Reactive Oxygen Species	Cannito S	Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells.	Carcinogenesis	2008	91
18795165	Reactive Oxygen Species	Pacurari M	Raw single-wall carbon nanotubes induce oxidative stress and activate MAPKs, AP-1, NF-kappaB, and Akt in normal and malignant human mesothelial cells.	Environmental health perspectives	2008	57
18801366	Reactive Oxygen Species	Lim SO	Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter.	Gastroenterology	2008	80
18979503	Reactive Oxygen Species	Tonissen KF	Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.	Molecular nutrition & food research	2009	48
19047340	Reactive Oxygen Species	Hori M	Oxidative stress and left ventricular remodelling after myocardial infarction.	Cardiovascular research	2009	95
19114105	Reactive Oxygen Species	Semenza GL	Regulation of cancer cell metabolism by hypoxia-inducible factor 1.	Seminars in cancer biology	2009	132
19118006	Reactive Oxygen Species	Cano CE	Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function.	Cancer research	2009	46
19190247	Reactive Oxygen Species	Lucas DM	The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.	Blood	2009	55
19208652	Reactive Oxygen Species	Park JS	A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis.	Human molecular genetics	2009	60
19236887	Reactive Oxygen Species	Liu J	Role of oxidative stress in cadmium toxicity and carcinogenesis.	Toxicology and applied pharmacology	2009	71
19249331	Reactive Oxygen Species	Fang J	Therapeutic strategies by modulating oxygen stress in cancer and inflammation.	Advanced drug delivery reviews	2009	71
19276362	Reactive Oxygen Species	Pelicano H	Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism.	Cancer research	2009	48
19413947	Reactive Oxygen Species	Lebedeva MA	Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis.	Biochimica et biophysica acta	2009	62
19493276	Reactive Oxygen Species	Kamata T	Roles of Nox1 and other Nox isoforms in cancer development.	Cancer science	2009	49
19696738	Reactive Oxygen Species	Park HJ	FoxM1, a critical regulator of oxidative stress during oncogenesis.	The EMBO journal	2009	72
19706526	Reactive Oxygen Species	Bertout JA	HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses.	Proceedings of the National Academy of Sciences of the United States of America	2009	59
19713938	Reactive Oxygen Species	Bensaad K	Modulation of intracellular ROS levels by TIGAR controls autophagy.	The EMBO journal	2009	101
19718051	Reactive Oxygen Species	Gruhne B	Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints.	Oncogene	2009	49
19755709	Reactive Oxygen Species	Diaz B	Tks5-dependent, nox-mediated generation of reactive oxygen species is necessary for invadopodia formation.	Science signaling	2009	80
19762091	Reactive Oxygen Species	Hall MD	Is resistance useless? Multidrug resistance and collateral sensitivity.	Trends in pharmacological sciences	2009	46
19889935	Reactive Oxygen Species	Burdette D	Activation of transcription factor Nrf2 by hepatitis C virus induces the cell-survival pathway.	The Journal of general virology	2010	46
19956681	Reactive Oxygen Species	Aghajanian A	Direct activation of RhoA by reactive oxygen species requires a redox-sensitive motif.	PloS one	2009	68
20019356	Reactive Oxygen Species	Klaunig JE	Oxidative stress and oxidative damage in carcinogenesis.	Toxicologic pathology	2010	171
20354226	Reactive Oxygen Species	Vandenabeele P	The role of the kinases RIP1 and RIP3 in TNF-induced necrosis.	Science signaling	2010	148
20453876	Reactive Oxygen Species	Bobrovnikova-Marjon E	PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage.	Oncogene	2010	78
20488920	Reactive Oxygen Species	Jutooru I	Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a.	Molecular pharmacology	2010	44
20498629	Reactive Oxygen Species	Chen Z	Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression.	Oncogene	2010	101
20523116	Reactive Oxygen Species	Graham KA	NADPH oxidase 4 is an oncoprotein localized to mitochondria.	Cancer biology & therapy	2010	64
20532218	Reactive Oxygen Species	Soucy-Faulkner A	Requirement of NOX2 and reactive oxygen species for efficient RIG-I-mediated antiviral response through regulation of MAVS expression.	PLoS pathogens	2010	43
20535745	Reactive Oxygen Species	Toullec A	Oxidative stress promotes myofibroblast differentiation and tumour spreading.	EMBO molecular medicine	2010	74
20574517	Reactive Oxygen Species	Venkataraman S	MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence.	PloS one	2010	55
20583212	Reactive Oxygen Species	Senturk S	Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth.	Hepatology	2010	53
20618067	Reactive Oxygen Species	Storz P	Forkhead homeobox type O transcription factors in the responses to oxidative stress.	Antioxidants & redox signaling	2011	74
20712410	Reactive Oxygen Species	Budanov AV	Stress-responsive sestrins link p53 with redox regulation and mammalian target of rapamycin signaling.	Antioxidants & redox signaling	2011	35
20715845	Reactive Oxygen Species	Gianni D	A novel and specific NADPH oxidase-1 (Nox1) small-molecule inhibitor blocks the formation of functional invadopodia in human colon cancer cells.	ACS chemical biology	2010	51
20819950	Reactive Oxygen Species	de Cavanagh EM	Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria?	Cardiovascular research	2011	37
20861671	Reactive Oxygen Species	Lisanti MP	Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment.	Cancer biology & therapy	2010	66
20923773	Reactive Oxygen Species	Luanpitpong S	Regulation of lung cancer cell migration and invasion by reactive oxygen species and caveolin-1.	The Journal of biological chemistry	2010	41
20965425	Reactive Oxygen Species	Wellen KE	Cellular metabolic stress: considering how cells respond to nutrient excess.	Molecular cell	2010	99
21071633	Reactive Oxygen Species	Indran IR	hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells.	Cancer research	2011	49
21072054	Reactive Oxygen Species	Lee JJ	PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation.	Cell death and differentiation	2011	41
21157431	Reactive Oxygen Species	Cosentino C	ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair.	The EMBO journal	2011	108
21235356	Reactive Oxygen Species	Giannoni E	Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness.	Antioxidants & redox signaling	2011	50
21273445	Reactive Oxygen Species	Sampson N	ROS signaling by NOX4 drives fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma.	Molecular endocrinology	2011	38
21300795	Reactive Oxygen Species	Kim MJ	Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation.	The Journal of biological chemistry	2011	76
21386137	Reactive Oxygen Species	Ozden O	Acetylation of MnSOD directs enzymatic activity responding to cellular nutrient status or oxidative stress.	Aging	2011	55
21397863	Reactive Oxygen Species	Finley LW	SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization.	Cancer cell	2011	221
21486948	Reactive Oxygen Species	Papa L	Estrogen receptor mediates a distinct mitochondrial unfolded protein response.	Journal of cell science	2011	42
21555567	Reactive Oxygen Species	Shaw AT	Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress.	Proceedings of the National Academy of Sciences of the United States of America	2011	56
21567162	Reactive Oxygen Species	Shao L	Reactive oxygen species and hematopoietic stem cell senescence.	International journal of hematology	2011	39
21853114	Reactive Oxygen Species	Hahm ER	Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species.	PloS one	2011	52
21878644	Reactive Oxygen Species	Achuthan S	Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species.	The Journal of biological chemistry	2011	47
21931870	Reactive Oxygen Species	Ivanov AV	Hepatitis C virus proteins activate NRF2/ARE pathway by distinct ROS-dependent and independent mechanisms in HUH7 cells.	PloS one	2011	42
21951851	Reactive Oxygen Species	Li ZY	Mitochondrial ROS generation for regulation of autophagic pathways in cancer.	Biochemical and biophysical research communications	2011	58
22064655	Reactive Oxygen Species	Huang WC	Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells.	Molecular cancer research 	2012	51
22079466	Reactive Oxygen Species	Piao LS	CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma.	Cancer letters	2012	53
22090360	Reactive Oxygen Species	Skinner HD	TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.	Clinical cancer research 	2012	70
22139133	Reactive Oxygen Species	Ferber EC	FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression.	Cell death and differentiation	2012	65
22286106	Reactive Oxygen Species	Ray PD	Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling.	Cellular signalling	2012	451
22331464	Reactive Oxygen Species	Ma J	PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function.	Molecular and cellular biology	2012	37
22341444	Reactive Oxygen Species	Raimundo N	Mitochondrial stress engages E2F1 apoptotic signaling to cause deafness.	Cell	2012	58
22342343	Reactive Oxygen Species	Formentini L	The mitochondrial ATPase inhibitory factor 1 triggers a ROS-mediated retrograde prosurvival and proliferative response.	Molecular cell	2012	48
22411871	Reactive Oxygen Species	Nieborowska-Skorska M	Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.	Blood	2012	32
22421439	Reactive Oxygen Species	Zhao J	Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis.	Proceedings of the National Academy of Sciences of the United States of America	2012	162
22423966	Reactive Oxygen Species	Yang CS	Autophagy protein Rubicon mediates phagocytic NADPH oxidase activation in response to microbial infection or TLR stimulation.	Cell host & microbe	2012	34
22522114	Reactive Oxygen Species	Kotsakis A	Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.	Journal of immunological methods	2012	51
22607099	Reactive Oxygen Species	Lee S	Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance.	Antioxidants & redox signaling	2013	51
22705852	Reactive Oxygen Species	Verfaillie T	PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress.	Cell death and differentiation	2012	115
22728268	Reactive Oxygen Species	Boudreau HE	Nox4 involvement in TGF-beta and SMAD3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells.	Free radical biology & medicine	2012	49
22836756	Reactive Oxygen Species	Zhang X	MicroRNA-21 modulates the levels of reactive oxygen species by targeting SOD3 and TNFα.	Cancer research	2012	42
22871044	Reactive Oxygen Species	Vernon PJ	Eat-me: autophagy, phagocytosis, and reactive oxygen species signaling.	Antioxidants & redox signaling	2013	33
22887998	Reactive Oxygen Species	Wanka C	Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis.	The Journal of biological chemistry	2012	41
22897481	Reactive Oxygen Species	Sheng SL	Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma.	The FEBS journal	2012	42
22917578	Reactive Oxygen Species	Frank M	Mitophagy is triggered by mild oxidative stress in a mitochondrial fission dependent manner.	Biochimica et biophysica acta	2012	90
22978471	Reactive Oxygen Species	Wu CC	Regulation of the intrinsic apoptosis pathway by reactive oxygen species.	Antioxidants & redox signaling	2013	47
22986741	Reactive Oxygen Species	Jerby L	Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer.	Cancer research	2012	31
23063463	Reactive Oxygen Species	Samarakoon R	TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities.	Cellular signalling	2013	80
23092325	Reactive Oxygen Species	Tibullo D	Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells.	Current pharmaceutical design	2013	27
23108410	Reactive Oxygen Species	Higgs MR	Hepatitis C virus-induced activation of β-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events.	Oncogene	2013	27
23146905	Reactive Oxygen Species	Hagenbuchner J	BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery.	Oncogene	2013	36
23185017	Reactive Oxygen Species	Cheung EC	Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death.	Proceedings of the National Academy of Sciences of the United States of America	2012	48
23277535	Reactive Oxygen Species	Austin S	PGC1α and mitochondrial metabolism--emerging concepts and relevance in ageing and neurodegenerative disorders.	Journal of cell science	2012	99
23333149	Reactive Oxygen Species	Lagadinou ED	BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.	Cell stem cell	2013	142
23334333	Reactive Oxygen Species	Nagano O	Redox regulation in stem-like cancer cells by CD44 variant isoforms.	Oncogene	2013	62
23347351	Reactive Oxygen Species	Liu G	Molecular basis of asbestos-induced lung disease.	Annual review of pathology	2013	32
23378588	Reactive Oxygen Species	Gasparre G	Relevance of mitochondrial genetics and metabolism in cancer development.	Cold Spring Harbor perspectives in biology	2013	30
23392169	Reactive Oxygen Species	Luo H	PTEN-regulated AKT/FoxO3a/Bim signaling contributes to reactive oxygen species-mediated apoptosis in selenite-treated colorectal cancer cells.	Cell death & disease	2013	35
23416000	Reactive Oxygen Species	Vazquez F	PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress.	Cancer cell	2013	133
23535601	Reactive Oxygen Species	Son J	Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.	Nature	2013	342
23546867	Reactive Oxygen Species	Kwon JE	Ionizing radiation-inducible microRNA miR-193a-3p induces apoptosis by directly targeting Mcl-1.	Apoptosis 	2013	29
23685237	Reactive Oxygen Species	Deng X	PM2.5-induced oxidative stress triggers autophagy in human lung epithelial A549 cells.	Toxicology in vitro 	2013	25
23688501	Reactive Oxygen Species	Sid B	Role of AMPK activation in oxidative cell damage: Implications for alcohol-induced liver disease.	Biochemical pharmacology	2013	31
23703322	Reactive Oxygen Species	Montero J	p53 regulates a non-apoptotic death induced by ROS.	Cell death and differentiation	2013	38
23828498	Reactive Oxygen Species	Markowitz J	Myeloid-derived suppressor cells in breast cancer.	Breast cancer research and treatment	2013	32
23936814	Reactive Oxygen Species	Gurunathan S	Cytotoxicity of biologically synthesized silver nanoparticles in MDA-MB-231 human breast cancer cells.	BioMed research international	2013	30
23941831	Reactive Oxygen Species	Rogler G	Chronic ulcerative colitis and colorectal cancer.	Cancer letters	2014	39
23955302	Reactive Oxygen Species	Zhang J	A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS.	Nature cell biology	2013	58
23994495	Reactive Oxygen Species	Lawlor KE	Ambiguities in NLRP3 inflammasome regulation: is there a role for mitochondria?	Biochimica et biophysica acta	2014	29
24080946	Reactive Oxygen Species	Stankov MV	Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy.	Leukemia	2014	21
24095676	Reactive Oxygen Species	Rouault-Pierre K	HIF-2α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress.	Cell stem cell	2013	32
24121277	Reactive Oxygen Species	Venere M	Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells.	Cell death and differentiation	2014	37
24185179	Reactive Oxygen Species	Sato A	Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells.	Stem cell research	2014	26
24293652	Reactive Oxygen Species	Lan L	Novel method for site-specific induction of oxidative DNA damage reveals differences in recruitment of repair proteins to heterochromatin and euchromatin.	Nucleic acids research	2014	25
24324009	Reactive Oxygen Species	Papa L	SirT3 regulates the mitochondrial unfolded protein response.	Molecular and cellular biology	2014	42
24325753	Reactive Oxygen Species	Bocca C	Expression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasiveness.	Expert opinion on therapeutic targets	2014	26
24381719	Reactive Oxygen Species	Popa-Wagner A	ROS and brain diseases: the good, the bad, and the ugly.	Oxidative medicine and cellular longevity	2013	29
24413150	Reactive Oxygen Species	Shi Y	ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis.	Cell death and differentiation	2014	39
24418575	Reactive Oxygen Species	Mehla K	MUC1: a novel metabolic master regulator.	Biochimica et biophysica acta	2014	21
24469051	Reactive Oxygen Species	Yin M	Selective killing of lung cancer cells by miRNA-506 molecule through inhibiting NF-κB p65 to evoke reactive oxygen species generation and p53 activation.	Oncogene	2015	20
24509161	Reactive Oxygen Species	Crosas-Molist E	The NADPH oxidase NOX4 inhibits hepatocyte proliferation and liver cancer progression.	Free radical biology & medicine	2014	20
24574456	Reactive Oxygen Species	Ishaq M	Atmospheric gas plasma-induced ROS production activates TNF-ASK1 pathway for the induction of melanoma cancer cell apoptosis.	Molecular biology of the cell	2014	30
24583638	Reactive Oxygen Species	Ogrunc M	Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation.	Cell death and differentiation	2014	46
24692350	Reactive Oxygen Species	Bhattacharyya A	Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases.	Physiological reviews	2014	99
24692674	Reactive Oxygen Species	Bauer G	Targeting extracellular ROS signaling of tumor cells.	Anticancer research	2014	20
24759730	Reactive Oxygen Species	Ma Y	Non-thermal atmospheric pressure plasma preferentially induces apoptosis in p53-mutated cancer cells by activating ROS stress-response pathways.	PloS one	2014	33
24787293	Reactive Oxygen Species	Martinez-Outschoorn U	Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function.	Seminars in oncology	2014	40
24791940	Reactive Oxygen Species	Cortez MA	Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.	Molecular therapy 	2014	38
24832602	Reactive Oxygen Species	Park EJ	β-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells.	Cell death & disease	2014	26
24836575	Reactive Oxygen Species	Schwab L	Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage.	Nature medicine	2014	30
24875536	Reactive Oxygen Species	Zhang L	Inhibition of cathepsin S induces autophagy and apoptosis in human glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K and JNK signaling pathways.	Toxicology letters	2014	28
24939850	Reactive Oxygen Species	Guo H	HIV-1 infection induces interleukin-1β production via TLR8 protein-dependent and NLRP3 inflammasome mechanisms in human monocytes.	The Journal of biological chemistry	2014	29
25043301	Reactive Oxygen Species	Lin L	MACC1 supports human gastric cancer growth under metabolic stress by enhancing the Warburg effect.	Oncogene	2015	21
25186948	Reactive Oxygen Species	Ye J	Serine catabolism regulates mitochondrial redox control during hypoxia.	Cancer discovery	2014	58
25341036	Reactive Oxygen Species	Huang H	Mcl-1 promotes lung cancer cell migration by directly interacting with VDAC to increase mitochondrial Ca2+ uptake and reactive oxygen species generation.	Cell death & disease	2014	23
25497091	Reactive Oxygen Species	Baek G	MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies.	Cell reports	2014	25
25521078	Reactive Oxygen Species	Olagnier D	Cellular oxidative stress response controls the antiviral and apoptotic programs in dengue virus-infected dendritic cells.	PLoS pathogens	2014	36
25541259	Reactive Oxygen Species	Mizuno T	Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species.	Gynecologic oncology	2015	24
25559363	Reactive Oxygen Species	Höll M	ROS signaling by NADPH oxidase 5 modulates the proliferation and survival of prostate carcinoma cells.	Molecular carcinogenesis	2016	13
25585126	Reactive Oxygen Species	Wu Q	ROS-mediated DNA methylation pattern alterations in carcinogenesis.	Current drug targets	2015	29
25592377	Reactive Oxygen Species	Liu X	NADPH oxidase 1-dependent ROS is crucial for TLR4 signaling to promote tumor metastasis of non-small cell lung cancer.	Tumour biology 	2015	16
25617478	Reactive Oxygen Species	Cashman CR	Mechanisms of distal axonal degeneration in peripheral neuropathies.	Neuroscience letters	2015	28
25651975	Reactive Oxygen Species	Hart PC	MnSOD upregulation sustains the Warburg effect via mitochondrial ROS and AMPK-dependent signalling in cancer.	Nature communications	2015	36
25818486	Reactive Oxygen Species	Roy K	NADPH oxidases and cancer.	Clinical science	2015	28
25867066	Reactive Oxygen Species	Schenk B	Reactive oxygen species regulate Smac mimetic/TNFα-induced necroptotic signaling and cell death.	Oncogene	2015	26
25912260	Reactive Oxygen Species	Zuo L	Biological and physiological role of reactive oxygen species--the good, the bad and the ugly.	Acta physiologica	2015	28
25982278	Reactive Oxygen Species	Hubackova S	IFNγ induces oxidative stress, DNA damage and tumor cell senescence via TGFβ/SMAD signaling-dependent induction of Nox4 and suppression of ANT2.	Oncogene	2016	12
26078812	Reactive Oxygen Species	Krstić J	Transforming Growth Factor-Beta and Oxidative Stress Interplay: Implications in Tumorigenesis and Cancer Progression.	Oxidative medicine and cellular longevity	2015	22
26080835	Reactive Oxygen Species	Cottini F	Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma.	Cancer discovery	2015	22
26099526	Reactive Oxygen Species	Xu MJ	Fat-Specific Protein 27/CIDEC Promotes Development of Alcoholic Steatohepatitis in Mice and Humans.	Gastroenterology	2015	23
26184557	Reactive Oxygen Species	Klotz LO	Redox regulation of FoxO transcription factors.	Redox biology	2015	45
26219228	Reactive Oxygen Species	Zhang X	Isoliensinine induces apoptosis in triple-negative human breast cancer cells through ROS generation and p38 MAPK/JNK activation.	Scientific reports	2015	16
26319899	Reactive Oxygen Species	Xu X	Aldehyde dehydrogenases and cancer stem cells.	Cancer letters	2015	19
26341399	Reactive Oxygen Species	Bronner DN	Endoplasmic Reticulum Stress Activates the Inflammasome via NLRP3- and Caspase-2-Driven Mitochondrial Damage.	Immunity	2015	36
26344566	Reactive Oxygen Species	Zhang J	ATM functions at the peroxisome to induce pexophagy in response to ROS.	Nature cell biology	2015	45
26373319	Reactive Oxygen Species	Li HJ	Long non-coding RNA UCA1 promotes glutamine metabolism by targeting miR-16 in human bladder cancer.	Japanese journal of clinical oncology	2015	18
26414765	Reactive Oxygen Species	Geng J	Kinases Mst1 and Mst2 positively regulate phagocytic induction of reactive oxygen species and bactericidal activity.	Nature immunology	2015	21
26621844	Reactive Oxygen Species	Um HD	Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species.	Oncotarget	2016	22
26631723	Reactive Oxygen Species	Yu W	Loss of SIRT3 Provides Growth Advantage for B Cell Malignancies.	The Journal of biological chemistry	2016	12
26675351	Reactive Oxygen Species	Vinchi F	Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease.	Blood	2016	27
26682001	Reactive Oxygen Species	Ryoo IG	Redox Modulating NRF2: A Potential Mediator of Cancer Stem Cell Resistance.	Oxidative medicine and cellular longevity	2016	12
26734996	Reactive Oxygen Species	Capello M	Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest.	Oncotarget	2016	11
26791157	Reactive Oxygen Species	Blaser H	TNF and ROS Crosstalk in Inflammation.	Trends in cell biology	2016	32
26804906	Reactive Oxygen Species	Franco J	Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities.	Cell reports	2016	11
26876430	Reactive Oxygen Species	García-Bermúdez J	The ATPase Inhibitory Factor 1 (IF1): A master regulator of energy metabolism and of cell survival.	Biochimica et biophysica acta	2016	12
26934227	Reactive Oxygen Species	Ma C	NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.	Nature	2016	37
26947075	Reactive Oxygen Species	Liou GY	Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions.	Cell reports	2016	17
27667751	Reactive Oxygen Species	Bagheri F	Reactive oxygen species-mediated cardiac-reperfusion injury: Mechanisms and therapies.	Life sciences	2016	11
1484317	Formaldehyde	Cattoretti G	Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.	The Journal of pathology	1992	164
2453289	Formaldehyde	Almoguera C	Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.	Cell	1988	427
10029066	Formaldehyde	Bubendorf L	Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.	Cancer research	1999	112
10873094	Formaldehyde	Cance WG	Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes.	Clinical cancer research 	2000	119
11135226	Formaldehyde	Soslow RA	COX-2 is expressed in human pulmonary, colonic, and mammary tumors.	Cancer	2000	127
11159180	Formaldehyde	Specht K	Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue.	The American journal of pathology	2001	96
12414534	Formaldehyde	Rosivatz E	Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer.	The American journal of pathology	2002	137
14576474	Formaldehyde	Ordóñez NG	Application of mesothelin immunostaining in tumor diagnosis.	The American journal of surgical pathology	2003	82
15305371	Formaldehyde	Santin AD	Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.	International journal of cancer	2004	87
16416732	Formaldehyde	Hassan R	Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.	American journal of clinical pathology	2005	73
16912200	Formaldehyde	Chung CH	Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma.	Cancer research	2006	77
16955506	Formaldehyde	Ceppi P	Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase.	Cancer	2006	75
17680565	Formaldehyde	Smeets SJ	A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen.	International journal of cancer	2007	125
18058265	Formaldehyde	Tetzlaff MT	Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues.	Endocrine pathology	2007	60
18307259	Formaldehyde	Varnholt H	MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma.	Hepatology	2008	132
18375788	Formaldehyde	Peltier HJ	Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues.	RNA	2008	239
18422971	Formaldehyde	Hofmann M	Assessment of a HER2 scoring system for gastric cancer: results from a validation study.	Histopathology	2008	211
18495026	Formaldehyde	Do H	High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.	BMC cancer	2008	55
18592007	Formaldehyde	Hoffmann AC	High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF.	Neoplasia	2008	52
18669866	Formaldehyde	Perrone F	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.	Annals of oncology 	2009	114
19056857	Formaldehyde	Santini D	High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.	The oncologist	2008	60
19147574	Formaldehyde	Wieczorek G	Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue.	Cancer research	2009	99
19204209	Formaldehyde	Sauter G	Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.	Journal of clinical oncology 	2009	107
19290006	Formaldehyde	Hui AB	Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues.	Laboratory investigation; a journal of technical methods and pathology	2009	82
19430420	Formaldehyde	Zuo Z	Application of COLD-PCR for improved detection of KRAS mutations in clinical samples.	Modern pathology 	2009	49
19528371	Formaldehyde	Jensen TO	Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma.	Journal of clinical oncology 	2009	64
19657699	Formaldehyde	Saigusa S	Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.	Annals of surgical oncology	2009	81
19917869	Formaldehyde	Denkert C	Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.	Journal of clinical oncology 	2010	286
20008640	Formaldehyde	Roth AD	Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.	Journal of clinical oncology 	2010	300
20028859	Formaldehyde	Patnaik SK	Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.	Cancer research	2010	99
20145181	Formaldehyde	Hui AB	Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas.	Clinical cancer research 	2010	126
20150367	Formaldehyde	Colman H	A multigene predictor of outcome in glioblastoma.	Neuro-oncology	2010	124
20228222	Formaldehyde	Neumeister V	In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis.	The American journal of pathology	2010	47
20233430	Formaldehyde	Sboner A	Molecular sampling of prostate cancer: a dilemma for predicting disease progression.	BMC medical genomics	2010	79
20233444	Formaldehyde	Fumagalli D	A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.	BMC cancer	2010	52
20413299	Formaldehyde	Tol J	Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.	European journal of cancer	2010	61
20413677	Formaldehyde	Earle JS	Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma.	The Journal of molecular diagnostics 	2010	56
20431034	Formaldehyde	Tsiatis AC	Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.	The Journal of molecular diagnostics 	2010	116
20519626	Formaldehyde	Badalian-Very G	Recurrent BRAF mutations in Langerhans cell histiocytosis.	Blood	2010	127
20579395	Formaldehyde	Yu J	MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation.	Molecular cancer	2010	67
20619739	Formaldehyde	De Roock W	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.	The Lancet. Oncology	2010	510
20664024	Formaldehyde	Sperinde J	Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.	Clinical cancer research 	2010	41
20710042	Formaldehyde	Aleksic T	Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells.	Cancer research	2010	60
20823417	Formaldehyde	Northcott PA	Medulloblastoma comprises four distinct molecular variants.	Journal of clinical oncology 	2011	312
20920193	Formaldehyde	Pinhel IF	Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer.	Breast cancer research 	2010	42
20921458	Formaldehyde	Ellison DW	Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.	Journal of clinical oncology 	2011	66
20925915	Formaldehyde	Ellison G	A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples.	Journal of experimental & clinical cancer research 	2010	43
20940279	Formaldehyde	Dupont Jensen J	PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer.	Clinical cancer research 	2011	59
21045789	Formaldehyde	White NM	Metastamirs: a stepping stone towards improved cancer management.	Nature reviews. Clinical oncology	2011	64
21138945	Formaldehyde	Barrow J	Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas.	Neuro-oncology	2011	42
21145831	Formaldehyde	Gao P	Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis.	Journal of hepatology	2011	43
21220479	Formaldehyde	Mortezavi A	KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy.	Clinical cancer research 	2011	35
21267586	Formaldehyde	Ellison DW	Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.	Acta neuropathologica	2011	108
21278610	Formaldehyde	Yi ES	Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.	Journal of thoracic oncology 	2011	62
21303542	Formaldehyde	Deshpande V	Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.	BMC cancer	2011	36
21310658	Formaldehyde	Cuzick J	Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.	The Lancet. Oncology	2011	141
21345667	Formaldehyde	Faber C	Overexpression of Dicer predicts poor survival in colorectal cancer.	European journal of cancer	2011	45
21572406	Formaldehyde	Brill LB 2nd	Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms.	Modern pathology 	2011	43
21594665	Formaldehyde	Razis E	Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.	Breast cancer research and treatment	2011	69
21621406	Formaldehyde	Belt EJ	Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence.	European journal of cancer	2011	35
21631526	Formaldehyde	Gillis AJ	Expression and interdependencies of pluripotency factors LIN28, OCT3/4, NANOG and SOX2 in human testicular germ cells and tumours of the testis.	International journal of andrology	2011	41
21638088	Formaldehyde	Capper D	Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.	Acta neuropathologica	2011	79
21878536	Formaldehyde	Lotan TL	PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.	Clinical cancer research 	2011	81
22018284	Formaldehyde	Nakata K	MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis.	Surgery	2011	47
22025255	Formaldehyde	Jubb AM	Neuropilin-1 expression in cancer and development.	The Journal of pathology	2012	43
22033280	Formaldehyde	Kolb T	Lamin A and lamin C form homodimers and coexist in higher complex forms both in the nucleoplasmic fraction and in the lamina of cultured human cells.	Nucleus	2011	38
22086503	Formaldehyde	Valsecchi ME	Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma.	Cancer	2012	30
22173549	Formaldehyde	Vermaat JS	Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment.	Clinical cancer research 	2012	45
22223089	Formaldehyde	Xu Y	Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors.	British journal of cancer	2012	50
22257486	Formaldehyde	de Kruijf EM	NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study.	BMC cancer	2012	34
22261801	Formaldehyde	Walter K	DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer.	Clinical cancer research 	2012	31
22331473	Formaldehyde	Lu Y	MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer.	Carcinogenesis	2012	51
22418702	Formaldehyde	Tchou J	Mesothelin, a novel immunotherapy target for triple negative breast cancer.	Breast cancer research and treatment	2012	35
22421194	Formaldehyde	Higgins MJ	Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.	Clinical cancer research 	2012	65
22426079	Formaldehyde	Didelot A	Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples.	Experimental and molecular pathology	2012	34
22437443	Formaldehyde	Visco C	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.	Leukemia	2012	72
22438992	Formaldehyde	Huang L	Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix.	PloS one	2012	36
22515559	Formaldehyde	Rizzardi AE	Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring.	Diagnostic pathology	2012	57
22536370	Formaldehyde	Lovly CM	Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.	PloS one	2012	55
22573352	Formaldehyde	Jang JS	Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers.	Clinical cancer research 	2012	34
22643842	Formaldehyde	Do H	Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase.	Oncotarget	2012	49
22665543	Formaldehyde	Vakiani E	Comparative genomic analysis of primary versus metastatic colorectal carcinomas.	Journal of clinical oncology 	2012	74
22718308	Formaldehyde	Vargas AC	Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.	Breast cancer research and treatment	2012	34
22752992	Formaldehyde	Tjalma WA	Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe.	International journal of cancer	2013	36
22782226	Formaldehyde	Lewis JS Jr	p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma.	Head and neck pathology	2012	38
22805332	Formaldehyde	Hall JS	Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation.	British journal of cancer	2012	32
22851141	Formaldehyde	Schultz NA	Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer--five microRNAs in a prognostic index.	World journal of surgery	2012	32
22878649	Formaldehyde	Schultz NA	MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma.	Modern pathology 	2012	46
22908099	Formaldehyde	Soda M	A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer.	Clinical cancer research 	2012	30
22948049	Formaldehyde	Tan KL	Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial.	Blood	2012	40
22949073	Formaldehyde	Rietbergen MM	Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm.	International journal of cancer	2013	30
22981675	Formaldehyde	Beltran H	Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.	European urology	2013	94
22996433	Formaldehyde	Kim BH	Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma.	Journal of surgical oncology	2013	36
23026937	Formaldehyde	Long GV	Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.	The American journal of surgical pathology	2013	48
23091298	Formaldehyde	Giulino-Roth L	Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes.	Blood	2012	32
23133536	Formaldehyde	Chisholm KM	Detection of long non-coding RNA in archival tissue: correlation with polycomb protein expression in primary and metastatic breast carcinoma.	PloS one	2012	46
23139264	Formaldehyde	Warneke VS	Her2/neu testing in gastric cancer: evaluating the risk of sampling errors.	Annals of oncology 	2013	27
23144797	Formaldehyde	Perkins G	Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers.	PloS one	2012	34
23154548	Formaldehyde	Heist RS	FGFR1 amplification in squamous cell carcinoma of the lung.	Journal of thoracic oncology 	2012	41
23184647	Formaldehyde	Larne O	miQ--a novel microRNA based diagnostic and prognostic tool for prostate cancer.	International journal of cancer	2013	26
23236232	Formaldehyde	Sukawa Y	Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.	World journal of gastroenterology	2012	32
23295441	Formaldehyde	Sia D	Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.	Gastroenterology	2013	66
23320393	Formaldehyde	Rong M	Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro.	BMC cancer	2013	44
23362162	Formaldehyde	Tuononen K	Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.	Genes, chromosomes & cancer	2013	35
23372687	Formaldehyde	Chen L	Role of deregulated microRNAs in breast cancer progression using FFPE tissue.	PloS one	2013	31
23374602	Formaldehyde	Pentheroudakis G	Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.	BMC cancer	2013	34
23426935	Formaldehyde	Kato H	Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma.	International journal of oncology	2013	26
23441132	Formaldehyde	Paterson EL	Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression.	Neoplasia	2013	39
23459718	Formaldehyde	Hui AB	Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma.	Clinical cancer research 	2013	33
23592755	Formaldehyde	Cao J	DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer.	Cancer research	2013	27
23649127	Formaldehyde	Do H	Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates.	Clinical chemistry	2013	37
23674495	Formaldehyde	Chen BJ	PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.	Clinical cancer research 	2013	121
23818604	Formaldehyde	Gerdes MJ	Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue.	Proceedings of the National Academy of Sciences of the United States of America	2013	73
23887298	Formaldehyde	Ross JS	Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.	Modern pathology 	2014	41
23973117	Formaldehyde	Endris V	Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing.	The Journal of molecular diagnostics 	2013	28
23979959	Formaldehyde	Nikiforova MN	Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.	The Journal of clinical endocrinology and metabolism	2013	58
24039846	Formaldehyde	Nouraee N	Expression, tissue distribution and function of miR-21 in esophageal squamous cell carcinoma.	PloS one	2013	29
24122631	Formaldehyde	Oue N	High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer.	International journal of cancer	2014	31
24132943	Formaldehyde	Markou A	Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up.	Clinical chemistry	2014	23
24189654	Formaldehyde	Pritchard CC	Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.	The Journal of molecular diagnostics 	2014	66
24192927	Formaldehyde	Ross JS	A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.	Clinical cancer research 	2014	26
24242678	Formaldehyde	Heinzelmann J	MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases.	Annals of surgical oncology	2014	21
24285342	Formaldehyde	He X	The long non-coding RNA HOTAIR is upregulated in endometrial carcinoma and correlates with poor prognosis.	International journal of molecular medicine	2014	29
24323898	Formaldehyde	Tan HL	Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.	Clinical cancer research 	2014	56
24412053	Formaldehyde	Visani M	Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III.	Molecular oncology	2014	23
24493713	Formaldehyde	Shih DJ	Cytogenetic prognostication within medulloblastoma subgroups.	Journal of clinical oncology 	2014	44
24520097	Formaldehyde	Filipits M	The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.	Clinical cancer research 	2014	26
24563076	Formaldehyde	Ross JS	New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.	The oncologist	2014	61
24563616	Formaldehyde	Blattner M	SPOP mutations in prostate cancer across demographically diverse patient cohorts.	Neoplasia	2014	33
24608573	Formaldehyde	Meric-Bernstam F	Concordance of genomic alterations between primary and recurrent breast cancer.	Molecular cancer therapeutics	2014	26
24625003	Formaldehyde	Nielsen T	Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens.	BMC cancer	2014	45
24771647	Formaldehyde	Manceau G	Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.	Clinical cancer research 	2014	23
24810926	Formaldehyde	Calvano Filho CM	Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p.	Tumour biology 	2014	23
24817381	Formaldehyde	Alemany L	Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide.	International journal of cancer	2015	50
24838331	Formaldehyde	Lin MT	Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing.	American journal of clinical pathology	2014	33
24839133	Formaldehyde	Rödel F	Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy.	International journal of cancer	2015	19
24842267	Formaldehyde	Muenst S	Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.	Breast cancer research and treatment	2014	100
24885028	Formaldehyde	Wong SQ	Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing.	BMC medical genomics	2014	41
25314059	Formaldehyde	Singh RR	Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours.	British journal of cancer	2014	22
25345567	Formaldehyde	Hagemann IS	Clinical next-generation sequencing in patients with non-small cell lung cancer.	Cancer	2015	40
25502898	Formaldehyde	Warrick JI	Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma.	Virchows Archiv 	2015	16
25514803	Formaldehyde	Lo Iacono M	Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.	Journal of thoracic oncology 	2015	27
25593300	Formaldehyde	Cani AK	Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.	Molecular cancer research 	2015	27
25641231	Formaldehyde	Stirzaker C	Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value.	Nature communications	2015	28
25712460	Formaldehyde	Chung CH	Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.	Annals of oncology 	2015	19
25749524	Formaldehyde	Ono S	A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients.	Oncotarget	2015	15
25752754	Formaldehyde	Korshunov A	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers.	Acta neuropathologica	2015	27
25823925	Formaldehyde	Han K	MicroRNA profiling identifies MiR-195 suppresses osteosarcoma cell metastasis by targeting CCND1.	Oncotarget	2015	33
25944800	Formaldehyde	Taube JM	Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.	Clinical cancer research 	2015	42
25990136	Formaldehyde	Zheng YC	A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.	Medicinal research reviews	2015	23
26004934	Formaldehyde	Paydas S	Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.	Annals of hematology	2015	15
26150155	Formaldehyde	Schläfli AM	Reliable LC3 and p62 autophagy marker detection in formalin fixed paraffin embedded human tissue by immunohistochemistry.	European journal of histochemistry 	2015	18
26164662	Formaldehyde	Peck BC	MicroRNAs Classify Different Disease Behavior Phenotypes of Crohn's Disease and May Have Prognostic Utility.	Inflammatory bowel diseases	2015	16
26172027	Formaldehyde	Talhouk A	A clinically applicable molecular-based classification for endometrial cancers.	British journal of cancer	2015	25
26181193	Formaldehyde	McDaniel AS	Next-Generation Sequencing of Tubal Intraepithelial Carcinomas.	JAMA oncology	2015	20
26182302	Formaldehyde	Ross JS	Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.	JAMA oncology	2015	24
26253700	Formaldehyde	Cieslik M	The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing.	Genome research	2015	16
26311741	Formaldehyde	Kim HS	Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer.	Oncotarget	2015	21
26317305	Formaldehyde	Phillips T	Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.	Applied immunohistochemistry & molecular morphology 	2015	32
26358176	Formaldehyde	Dietel M	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.	Cancer gene therapy	2015	28
26422389	Formaldehyde	Nuciforo P	High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.	Molecular oncology	2016	13
26546452	Formaldehyde	Mahoney KM	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.	Cancer immunology research	2015	22
26605532	Formaldehyde	Jin W	Genome-wide detection of DNase I hypersensitive sites in single cells and FFPE tissue samples.	Nature	2015	43
26724257	Formaldehyde	Mehra R	Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer.	European urology	2016	18
26913631	Formaldehyde	Howitt BE	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.	JAMA oncology	2016	10
26976201	Formaldehyde	Thompson EM	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.	The Lancet. Oncology	2016	13
27208205	Formaldehyde	Park JY	Complementation of hypersensitivity to DNA interstrand crosslinking agents demonstrates that XRCC2 is a Fanconi anaemia gene.	Journal of medical genetics	2016	25
27333219	Formaldehyde	Roach C	Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.	Applied immunohistochemistry & molecular morphology 	2016	16
27342566	Formaldehyde	Song Z	Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.	Journal of translational medicine	2016	12
27459899	Formaldehyde	Trinh A	Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry.	Clinical cancer research 	2017	9
27717372	Formaldehyde	Rebelatto MC	Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.	Diagnostic pathology	2016	12
28073897	Formaldehyde	Reguart N	Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.	Clinical chemistry	2017	7
28463396	Formaldehyde	Pollack SM	T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.	Cancer	2017	6
9108479	geldanamycin	Stebbins CE	Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent.	Cell	1997	265
9744771	geldanamycin	Schulte TW	The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.	Cancer chemotherapy and pharmacology	1998	106
11071886	geldanamycin	Xu W	Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90.	The Journal of biological chemistry	2001	115
12239347	geldanamycin	Xu W	Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu.	Proceedings of the National Academy of Sciences of the United States of America	2002	152
12890756	geldanamycin	Field N	KSHV vFLIP binds to IKK-gamma to activate IKK.	Journal of cell science	2003	96
15385631	geldanamycin	Austin CD	Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.	Molecular biology of the cell	2004	120
16288044	geldanamycin	Mahajan NP	Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox.	Cancer research	2005	76
17299090	geldanamycin	Spisek R	Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.	Blood	2007	84
17513464	geldanamycin	Workman P	Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.	Annals of the New York Academy of Sciences	2007	163
18559533	geldanamycin	Montagut C	Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.	Cancer research	2008	156
20159553	geldanamycin	Mollapour M	Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function.	Molecular cell	2010	57
22215907	geldanamycin	Neckers L	Hsp90 molecular chaperone inhibitors: are we there yet?	Clinical cancer research 	2012	247
22920906	geldanamycin	Miyata Y	The therapeutic target Hsp90 and cancer hallmarks.	Current pharmaceutical design	2013	54
23356585	geldanamycin	Barrott JJ	Hsp90, an unlikely ally in the war on cancer.	The FEBS journal	2013	43
24669860	geldanamycin	Jhaveri K	Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.	Expert opinion on investigational drugs	2014	36
9766667	wortmannin	Sarkaria JN	Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin.	Cancer research	1998	151
10572077	wortmannin	Burger JA	Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.	Blood	1999	113
10625637	wortmannin	Petiot A	Distinct classes of phosphatidylinositol 3'-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells.	The Journal of biological chemistry	2000	324
10910062	wortmannin	Sekulić A	A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.	Cancer research	2000	168
11331310	wortmannin	Rappold I	Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways.	The Journal of cell biology	2001	142
11457733	wortmannin	Jiang BH	Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1.	Cell growth & differentiation 	2001	110
11532940	wortmannin	Mäkinen T	Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3.	The EMBO journal	2001	161
12517798	wortmannin	Arboleda MJ	Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.	Cancer research	2003	118
15132991	wortmannin	Chung TW	Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential.	FASEB journal 	2004	72
15184909	wortmannin	Wang H	Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas.	Laboratory investigation; a journal of technical methods and pathology	2004	75
15602573	wortmannin	Proikas-Cezanne T	WIPI-1alpha (WIPI49), a member of the novel 7-bladed WIPI protein family, is aberrantly expressed in human cancer and is linked to starvation-induced autophagy.	Oncogene	2004	100
15840712	wortmannin	Ramanathan A	Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements.	Proceedings of the National Academy of Sciences of the United States of America	2005	111
15905173	wortmannin	Holz MK	Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase.	The Journal of biological chemistry	2005	105
16239258	wortmannin	Vivacqua A	The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.	Molecular endocrinology	2006	104
16732316	wortmannin	Cheng JC	Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway.	Oncogene	2006	64
17317726	wortmannin	Thamilselvan V	FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway.	FASEB journal 	2007	60
17353198	wortmannin	Ji Z	Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.	The Journal of biological chemistry	2007	101
18980614	wortmannin	Gastaldelli M	Infectious adenovirus type 2 transport through early but not late endosomes.	Traffic	2008	51
19805105	wortmannin	Mandelker D	A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.	Proceedings of the National Academy of Sciences of the United States of America	2009	96
20104024	wortmannin	Huang S	Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells.	Autophagy	2010	43
21179458	wortmannin	Chen Q	Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells.	PloS one	2010	48
9916800	trichostatin A	Cameron EE	Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.	Nature genetics	1999	412
10200307	trichostatin A	Saito A	A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.	Proceedings of the National Academy of Sciences of the United States of America	1999	111
10490031	trichostatin A	Finnin MS	Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.	Nature	1999	302
10521394	trichostatin A	Murphy M	Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a.	Genes & development	1999	140
11146623	trichostatin A	Mazumdar A	Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor.	Nature cell biology	2001	111
11564889	trichostatin A	Ashburner BP	The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression.	Molecular and cellular biology	2001	208
11585728	trichostatin A	Yang X	Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.	Cancer research	2001	107
12391164	trichostatin A	Westendorf JJ	Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter.	Molecular and cellular biology	2002	94
12482974	trichostatin A	Kondo Y	Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer.	Molecular and cellular biology	2003	79
12498717	trichostatin A	Yamashita K	Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma.	Cancer cell	2002	86
12589032	trichostatin A	Glaser KB	Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines.	Molecular cancer therapeutics	2003	142
12697826	trichostatin A	Mihaylova VT	Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells.	Molecular and cellular biology	2003	80
12839967	trichostatin A	Sato N	Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays.	Cancer research	2003	99
14612526	trichostatin A	Kim MS	Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.	Cancer research	2003	108
15899813	trichostatin A	Lodygin D	Functional epigenomics identifies genes frequently silenced in prostate cancer.	Cancer research	2005	89
16186112	trichostatin A	Chen CS	Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes.	The Journal of biological chemistry	2005	77
16699007	trichostatin A	Lu F	Acetylation of the latency-associated nuclear antigen regulates repression of Kaposi's sarcoma-associated herpesvirus lytic transcription.	Journal of virology	2006	78
16847267	trichostatin A	Monte M	MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents.	Proceedings of the National Academy of Sciences of the United States of America	2006	65
18286529	trichostatin A	Feng W	Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.	Cancer	2008	64
18430739	trichostatin A	Fujii S	Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.	The Journal of biological chemistry	2008	67
18664505	trichostatin A	Peng DF	DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma.	Gut	2009	54
19407485	trichostatin A	Lee KH	Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer.	Pancreatology 	2009	65
20028768	trichostatin A	Yagi K	Three DNA methylation epigenotypes in human colorectal cancer.	Clinical cancer research 	2010	81
20073067	trichostatin A	Rauhala HE	miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer.	International journal of cancer	2010	41
20482749	trichostatin A	Lee J	The anti-aging gene KLOTHO is a novel target for epigenetic silencing in human cervical carcinoma.	Molecular cancer	2010	43
20842113	trichostatin A	Zhang J	microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity.	British journal of cancer	2010	77
20946668	trichostatin A	Li Y	Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells.	Molecular cancer	2010	42
20962589	trichostatin A	McKenzie L	p53-dependent repression of polo-like kinase-1 (PLK1).	Cell cycle	2010	49
20975101	trichostatin A	Costa VL	Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples.	Clinical cancer research 	2010	51
21051724	trichostatin A	Chen X	Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma.	Investigative ophthalmology & visual science	2011	37
21383005	trichostatin A	Fan T	EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression.	Molecular cancer research 	2011	53
21491416	trichostatin A	Chen MY	Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.	Cancer	2011	38
21960261	trichostatin A	Tsai KW	Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer.	International journal of cancer	2011	59
22038994	trichostatin A	Landreville S	Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.	Clinical cancer research 	2012	66
22114073	trichostatin A	Thakur VS	Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases.	Carcinogenesis	2012	31
22282464	trichostatin A	Heller G	Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers.	Clinical cancer research 	2012	57
22308110	trichostatin A	Humphreys KJ	Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.	Molecular carcinogenesis	2013	26
22325485	trichostatin A	Hanada N	Methylation of the KEAP1 gene promoter region in human colorectal cancer.	BMC cancer	2012	46
22419664	trichostatin A	Coulouarn C	Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma.	Cancer research	2012	46
22641068	trichostatin A	Buurman R	Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.	Gastroenterology	2012	52
22699621	trichostatin A	Pérez-Mancera PA	The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.	Nature	2012	101
23085757	trichostatin A	Su SF	miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer.	Oncogene	2013	42
23379261	trichostatin A	Li Y	Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.	Molecular cancer	2013	37
23626803	trichostatin A	Manavalan TT	Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.	PloS one	2013	27
23979134	trichostatin A	Yang Z	MicroRNA-433 inhibits liver cancer cell migration by repressing the protein expression and function of cAMP response element-binding protein.	The Journal of biological chemistry	2013	29
24481854	trichostatin A	Li Z	DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer.	Gastric cancer 	2015	59
26356327	trichostatin A	Karnezis AN	Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.	The Journal of pathology	2016	16
14695887	Histone Deacetylase Inhibitors	Mitsiades CS	Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.	Proceedings of the National Academy of Sciences of the United States of America	2004	153
15619633	Histone Deacetylase Inhibitors	Nebbioso A	Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells.	Nature medicine	2005	107
16322264	Histone Deacetylase Inhibitors	Skov S	Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.	Cancer research	2005	67
16533812	Histone Deacetylase Inhibitors	Wilson AJ	Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.	The Journal of biological chemistry	2006	163
16980585	Histone Deacetylase Inhibitors	Li Y	A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity.	Genes & development	2006	62
17242198	Histone Deacetylase Inhibitors	Ye X	Definition of pRB- and p53-dependent and -independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci.	Molecular and cellular biology	2007	60
17412634	Histone Deacetylase Inhibitors	Ocker M	Histone deacetylase inhibitors: signalling towards p21cip1/waf1.	The international journal of biochemistry & cell biology	2007	93
17461739	Histone Deacetylase Inhibitors	Rasheed WK	Histone deacetylase inhibitors in cancer therapy.	Expert opinion on investigational drugs	2007	60
17545612	Histone Deacetylase Inhibitors	Chen CS	Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation.	Cancer research	2007	70
17643369	Histone Deacetylase Inhibitors	Ye X	Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells.	Molecular cell	2007	67
18171934	Histone Deacetylase Inhibitors	Langley B	Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection.	The Journal of neuroscience 	2008	67
18326939	Histone Deacetylase Inhibitors	Mariadason JM	HDACs and HDAC inhibitors in colon cancer.	Epigenetics	2008	58
18347167	Histone Deacetylase Inhibitors	Weichert W	Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.	Clinical cancer research 	2008	98
18593903	Histone Deacetylase Inhibitors	Datta J	Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis.	Cancer research	2008	160
19111391	Histone Deacetylase Inhibitors	Ellis L	Targeting tumor angiogenesis with histone deacetylase inhibitors.	Cancer letters	2009	54
19176386	Histone Deacetylase Inhibitors	Welsbie DS	Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer.	Cancer research	2009	54
19345475	Histone Deacetylase Inhibitors	Batty N	Histone deacetylase inhibitors as anti-neoplastic agents.	Cancer letters	2009	50
19383284	Histone Deacetylase Inhibitors	Ropero S	The role of histone deacetylases (HDACs) in human cancer.	Molecular oncology	2007	159
19410544	Histone Deacetylase Inhibitors	Foltz DR	Centromere-specific assembly of CENP-a nucleosomes is mediated by HJURP.	Cell	2009	200
19521961	Histone Deacetylase Inhibitors	Bandres E	Epigenetic regulation of microRNA expression in colorectal cancer.	International journal of cancer	2009	136
19689470	Histone Deacetylase Inhibitors	Lee S	Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells.	Cell proliferation	2009	46
19826124	Histone Deacetylase Inhibitors	Lane AA	Histone deacetylase inhibitors in cancer therapy.	Journal of clinical oncology 	2009	247
19836388	Histone Deacetylase Inhibitors	Kristensen LS	Epigenetics and cancer treatment.	European journal of pharmacology	2009	57
19855427	Histone Deacetylase Inhibitors	Wang L	Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells.	Nature reviews. Drug discovery	2009	63
20962572	Histone Deacetylase Inhibitors	Liu YL	Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma.	Autophagy	2010	52
21084276	Histone Deacetylase Inhibitors	Lopez G	Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.	Cancer research	2011	35
21336312	Histone Deacetylase Inhibitors	Di Micco R	Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer.	Nature cell biology	2011	103
21452019	Histone Deacetylase Inhibitors	Huang Y	Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells.	Breast cancer research and treatment	2012	40
22096249	Histone Deacetylase Inhibitors	Sampath D	Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia.	Blood	2012	60
22147512	Histone Deacetylase Inhibitors	Aghdassi A	Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer.	Gut	2012	48
22210864	Histone Deacetylase Inhibitors	Hudson RS	MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer.	Nucleic acids research	2012	63
22391568	Histone Deacetylase Inhibitors	Yan W	Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8.	Oncogene	2013	33
22422937	Histone Deacetylase Inhibitors	Pazolli E	Chromatin remodeling underlies the senescence-associated secretory phenotype of tumor stromal fibroblasts that supports cancer progression.	Cancer research	2012	35
22605338	Histone Deacetylase Inhibitors	Wang Y	Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity.	The Journal of biological chemistry	2012	49
23141799	Histone Deacetylase Inhibitors	New M	HDAC inhibitor-based therapies: can we interpret the code?	Molecular oncology	2012	71
23801635	Histone Deacetylase Inhibitors	Fiegler N	Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.	Blood	2013	30
23913134	Histone Deacetylase Inhibitors	Minami J	Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.	Leukemia	2014	24
24769080	Histone Deacetylase Inhibitors	Bose P	Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.	Pharmacology & therapeutics	2014	40
25115382	Histone Deacetylase Inhibitors	Kroesen M	HDAC inhibitors and immunotherapy; a double edged sword?	Oncotarget	2014	24
25313724	Histone Deacetylase Inhibitors	Lakshmaiah KC	Epigenetic therapy of cancer with histone deacetylase inhibitors.	Journal of cancer research and therapeutics	2014	35
25704812	Histone Deacetylase Inhibitors	Tomazou EM	Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1.	Cell reports	2015	27
25957812	Histone Deacetylase Inhibitors	Woan KV	Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.	Molecular oncology	2015	16
26032687	Histone Deacetylase Inhibitors	Liffers K	Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.	Targeted oncology	2016	11
26297712	Histone Deacetylase Inhibitors	Woods DM	HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.	Cancer immunology research	2015	23
26751469	Histone Deacetylase Inhibitors	Marchini A	Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.	Viruses	2016	14
26831668	Histone Deacetylase Inhibitors	Zhijun H	Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.	Tumour biology 	2016	11
26977882	Histone Deacetylase Inhibitors	Pei Y	HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.	Cancer cell	2016	19
9558396	fludarabine	Kitada S	Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.	Blood	1998	118
9780338	fludarabine	Aversa F	Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.	The New England journal of medicine	1998	127
10477712	fludarabine	Damle RN	Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.	Blood	1999	382
12000866	fludarabine	Dudley ME	A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.	Journal of immunotherapy	2002	91
12662126	fludarabine	Plosker GL	Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.	Drugs	2003	78
12791654	fludarabine	Maris MB	HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.	Blood	2003	79
15632206	fludarabine	Miller JS	Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.	Blood	2005	373
15753458	fludarabine	Aversa F	Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.	Journal of clinical oncology 	2005	123
15767648	fludarabine	Keating MJ	Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.	Journal of clinical oncology 	2005	181
15800326	fludarabine	Dudley ME	Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.	Journal of clinical oncology 	2005	465
15905192	fludarabine	Burger M	Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.	Blood	2005	76
15914560	fludarabine	Beyer M	Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.	Blood	2005	108
16543464	fludarabine	Kojima K	Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.	Blood	2006	71
17283363	fludarabine	Grever MR	Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.	Journal of clinical oncology 	2007	76
17296974	fludarabine	O'Brien S	Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.	Journal of clinical oncology 	2007	56
18000167	fludarabine	Lange BJ	Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.	Blood	2008	77
18411418	fludarabine	Tam CS	Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.	Blood	2008	162
18411419	fludarabine	Khouri IF	Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.	Blood	2008	92
18574029	fludarabine	Trachootham D	Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.	Blood	2008	57
18599795	fludarabine	Pepper C	Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.	Blood	2008	71
18809613	fludarabine	Dudley ME	Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.	Journal of clinical oncology 	2008	417
18836097	fludarabine	Balakrishnan K	AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.	Blood	2009	60
18941118	fludarabine	Zenz T	miR-34a as part of the resistance network in chronic lymphocytic leukemia.	Blood	2009	63
18950462	fludarabine	Shi J	Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.	British journal of haematology	2008	52
19549911	fludarabine	Buchner M	Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.	Cancer research	2009	62
19643983	fludarabine	Zenz T	Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.	Blood	2009	62
19706886	fludarabine	Verneris MR	Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units.	Blood	2009	77
19762485	fludarabine	Kurtova AV	Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.	Blood	2009	89
20085940	fludarabine	Rubnitz JE	NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.	Journal of clinical oncology 	2010	129
20194844	fludarabine	Robak T	Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.	Journal of clinical oncology 	2010	75
20194866	fludarabine	Wierda WG	Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.	Journal of clinical oncology 	2010	129
20335218	fludarabine	Buchner M	Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.	Blood	2010	62
20439626	fludarabine	Gyurkocza B	Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.	Journal of clinical oncology 	2010	46
20680271	fludarabine	Bachanova V	Allogeneic natural killer cells for refractory lymphoma.	Cancer immunology, immunotherapy 	2010	54
20697090	fludarabine	Zenz T	TP53 mutation and survival in chronic lymphocytic leukemia.	Journal of clinical oncology 	2010	99
20697368	fludarabine	Cutler C	Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.	Bone marrow transplantation	2011	39
20719934	fludarabine	Hong JJ	Successful treatment of melanoma brain metastases with adoptive cell therapy.	Clinical cancer research 	2010	47
20849361	fludarabine	Geller MA	A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.	Cytotherapy	2011	94
20888994	fludarabine	Hallek M	Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.	Lancet	2010	353
21402714	fludarabine	Amrein PC	Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.	Clinical cancer research 	2011	41
21483000	fludarabine	Gonzalez D	Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.	Journal of clinical oncology 	2011	52
21791425	fludarabine	Curti A	Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.	Blood	2011	81
21844497	fludarabine	Fischer K	Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.	Journal of clinical oncology 	2011	75
21856867	fludarabine	Wierda WG	Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.	Blood	2011	40
22039264	fludarabine	Rossi D	Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.	Blood	2011	85
22045765	fludarabine	Sorror ML	Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.	JAMA	2011	48
22128299	fludarabine	Tromp JM	Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.	Clinical cancer research 	2012	35
22308293	fludarabine	Rossi D	Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.	Blood	2012	64
22610076	fludarabine	Zhu DX	miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.	Carcinogenesis	2012	52
22740450	fludarabine	Mahoney E	ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.	Blood	2012	32
22796535	fludarabine	Ciurea SO	Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.	Biology of blood and marrow transplantation 	2012	36
22873532	fludarabine	Kluin-Nelemans HC	Treatment of older patients with mantle-cell lymphoma.	The New England journal of medicine	2012	58
23086750	fludarabine	Oscier DG	The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.	Blood	2013	52
23091097	fludarabine	Skowronska A	Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.	Journal of clinical oncology 	2012	33
23530110	fludarabine	Federico M	R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.	Journal of clinical oncology 	2013	31
23720127	fludarabine	Hallek M	Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.	American journal of hematology	2013	38
24005245	fludarabine	Ruggeri A	Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT.	Leukemia	2014	20
24719405	fludarabine	Bachanova V	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.	Blood	2014	71
25049322	fludarabine	Byrd JC	Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.	Journal of clinical oncology 	2014	39
25154820	fludarabine	Kochenderfer JN	Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.	Journal of clinical oncology 	2015	237
25319501	fludarabine	Lee DW	T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.	Lancet	2015	367
25415285	fludarabine	Szmania S	Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.	Journal of immunotherapy	2015	31
25456364	fludarabine	Kennedy GA	Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.	The Lancet. Oncology	2014	35
25908509	fludarabine	Hallek M	Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.	American journal of hematology	2015	50
25940712	fludarabine	Ninomiya S	Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.	Blood	2015	32
26002963	fludarabine	Treon SP	How I treat Waldenström macroglobulinemia.	Blood	2015	15
26276669	fludarabine	Rossi D	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.	Blood	2015	22
26486789	fludarabine	Fischer K	Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.	Blood	2016	38
26492934	fludarabine	Thompson PA	Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.	Blood	2016	29
26639348	fludarabine	Roberts AW	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.	The New England journal of medicine	2016	143
26675346	fludarabine	Ljungström V	Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.	Blood	2016	17
26762740	fludarabine	Ikeda S	PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.	Journal of thoracic oncology 	2016	16
26764356	fludarabine	Mielcarek M	Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.	Blood	2016	11
27111235	fludarabine	Turtle CJ	CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.	The Journal of clinical investigation	2016	120
28291388	fludarabine	Kochenderfer JN	Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.	Journal of clinical oncology 	2017	13
28395880	fludarabine	Chandran SS	Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.	The Lancet. Oncology	2017	8
28408462	fludarabine	Gardner RA	Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.	Blood	2017	11
28715249	fludarabine	Turtle CJ	Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.	Journal of clinical oncology 	2017	10
12506171	Leucovorin	Kabbinavar F	Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2003	255
15867200	Leucovorin	Kabbinavar FF	Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.	Journal of clinical oncology 	2005	110
15908660	Leucovorin	Hurwitz HI	Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.	Journal of clinical oncology 	2005	117
16009958	Leucovorin	Bosset JF	Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921.	Journal of clinical oncology 	2005	75
18024868	Leucovorin	Tabernero J	Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.	Journal of clinical oncology 	2007	64
18299612	Leucovorin	Schwab M	Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.	Journal of clinical oncology 	2008	63
19114683	Leucovorin	Bokemeyer C	Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.	Journal of clinical oncology 	2009	387
19339720	Leucovorin	Van Cutsem E	Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.	The New England journal of medicine	2009	841
19364970	Leucovorin	Cecchin E	Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.	Journal of clinical oncology 	2009	55
19942479	Leucovorin	Folprecht G	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.	The Lancet. Oncology	2010	140
20921462	Leucovorin	Peeters M	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2010	193
20921465	Leucovorin	Douillard JY	Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.	Journal of clinical oncology 	2010	370
21383284	Leucovorin	Hutchins G	Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.	Journal of clinical oncology 	2011	148
21502544	Leucovorin	Van Cutsem E	Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.	Journal of clinical oncology 	2011	383
23569301	Leucovorin	Ye LC	Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.	Journal of clinical oncology 	2013	55
24019539	Leucovorin	Sinicrope FA	Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.	Journal of clinical oncology 	2013	43
24024839	Leucovorin	Douillard JY	Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.	The New England journal of medicine	2013	432
24687833	Leucovorin	Schwartzberg LS	PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.	Journal of clinical oncology 	2014	117
24928083	Leucovorin	Taieb J	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	28
25088940	Leucovorin	Heinemann V	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2014	225
25337750	Leucovorin	Loupakis F	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.	The New England journal of medicine	2014	110
25361982	Leucovorin	Klingbiel D	Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.	Annals of oncology 	2015	20
25543664	Leucovorin	Sun Z	Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.	World journal of surgical oncology	2014	22
25579803	Leucovorin	Gustavsson B	A review of the evolution of systemic chemotherapy in the management of colorectal cancer.	Clinical colorectal cancer	2015	40
25605843	Leucovorin	Van Cutsem E	Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.	Journal of clinical oncology 	2015	88
25937522	Leucovorin	Bokemeyer C	FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.	European journal of cancer	2015	31
26527776	Leucovorin	André T	Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.	Journal of clinical oncology 	2015	32
27575024	Leucovorin	Stintzing S	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.	The Lancet. Oncology	2016	19
9500606	Cancer Vaccines	Rosenberg SA	Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.	Nature medicine	1998	279
10866317	Cancer Vaccines	Mach N	Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.	Cancer research	2000	120
11134207	Cancer Vaccines	Jaffee EM	Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.	Journal of clinical oncology 	2001	121
12445278	Cancer Vaccines	Scanlan MJ	Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.	Immunological reviews	2002	189
12682289	Cancer Vaccines	Hodi FS	Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.	Proceedings of the National Academy of Sciences of the United States of America	2003	194
14533809	Cancer Vaccines	Hakomori S	Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines.	Advances in experimental medicine and biology	2001	103
15867235	Cancer Vaccines	Gulley JL	Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.	Clinical cancer research 	2005	117
16467102	Cancer Vaccines	Antonia SJ	Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.	Clinical cancer research 	2006	101
16824130	Cancer Vaccines	Klebanoff CA	CD8+ T-cell memory in tumor immunology and immunotherapy.	Immunological reviews	2006	150
17517626	Cancer Vaccines	Valmori D	Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.	Proceedings of the National Academy of Sciences of the United States of America	2007	85
17988798	Cancer Vaccines	Tarp MA	Mucin-type O-glycosylation and its potential use in drug and vaccine development.	Biochimica et biophysica acta	2008	72
18519811	Cancer Vaccines	Morse MA	Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.	Blood	2008	101
18632651	Cancer Vaccines	Wheeler CJ	Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients.	Cancer research	2008	94
19719775	Cancer Vaccines	Caballero OL	Cancer/testis (CT) antigens: potential targets for immunotherapy.	Cancer science	2009	157
20488726	Cancer Vaccines	Dubensky TW Jr	Adjuvants for cancer vaccines.	Seminars in immunology	2010	51
20706612	Cancer Vaccines	Vergati M	Strategies for cancer vaccine development.	Journal of biomedicine & biotechnology	2010	40
21030562	Cancer Vaccines	Rosenblatt J	Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.	Blood	2011	51
21074057	Cancer Vaccines	Weber J	Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.	Seminars in oncology	2010	77
21217520	Cancer Vaccines	Lutz E	A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.	Annals of surgery	2011	106
21471425	Cancer Vaccines	Cheever MA	PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.	Clinical cancer research 	2011	98
21908423	Cancer Vaccines	Pere H	A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens.	Blood	2011	48
22068657	Cancer Vaccines	Li Y	Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy.	Clinical cancer research 	2011	40
22201909	Cancer Vaccines	Munn DH	Blocking IDO activity to enhance anti-tumor immunity.	Frontiers in bioscience	2012	43
22326924	Cancer Vaccines	Madan RA	Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.	The Lancet. Oncology	2012	101
22593175	Cancer Vaccines	Rech AJ	CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients.	Science translational medicine	2012	70
22959433	Cancer Vaccines	Ugel S	Immune tolerance to tumor antigens occurs in a specialized environment of the spleen.	Cell reports	2012	58
23248097	Cancer Vaccines	Kimura T	MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.	Cancer prevention research	2013	54
23271806	Cancer Vaccines	Predina J	Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery.	Proceedings of the National Academy of Sciences of the United States of America	2013	31
23408053	Cancer Vaccines	Sandoval F	Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors.	Science translational medicine	2013	57
23460531	Cancer Vaccines	Melero I	Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination.	Clinical cancer research 	2013	49
23589106	Cancer Vaccines	Iclozan C	Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.	Cancer immunology, immunotherapy 	2013	76
23657083	Cancer Vaccines	Morse MA	A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.	Annals of surgery	2013	32
23924790	Cancer Vaccines	Le DT	Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.	Journal of immunotherapy	2013	110
24513968	Cancer Vaccines	Radford KJ	Dendritic cells and cancer immunotherapy.	Current opinion in immunology	2014	26
24691994	Cancer Vaccines	Le Mercier I	VISTA Regulates the Development of Protective Antitumor Immunity.	Cancer research	2014	40
25391695	Cancer Vaccines	Yoshitake Y	Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.	Clinical cancer research 	2015	28
25904595	Cancer Vaccines	Butterfield LH	Cancer vaccines.	BMJ	2015	33
25979549	Cancer Vaccines	Cimino-Mathews A	Immune targeting in breast cancer.	Oncology	2015	20
26130065	Cancer Vaccines	Heery CR	Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.	Cancer immunology research	2015	16
26214521	Cancer Vaccines	Melief CJ	Therapeutic cancer vaccines.	The Journal of clinical investigation	2015	47
27151159	Cancer Vaccines	Farkona S	Cancer immunotherapy: the beginning of the end of cancer?	BMC medicine	2016	68
10023669	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Chelbi-Alix MK	Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins.	Oncogene	1999	151
11588023	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Guzman ML	Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells.	Blood	2001	178
12451177	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Guzman ML	Preferential induction of apoptosis for primary human leukemic stem cells.	Proceedings of the National Academy of Sciences of the United States of America	2002	98
15173011	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Nahta R	P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.	Cancer research	2004	81
16109713	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Rahmani M	Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation.	The Journal of biological chemistry	2005	99
17671210	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Jacquemont C	Proteasome function is required for DNA damage response and fanconi anemia pathway activation.	Cancer research	2007	73
18565852	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Oerlemans R	Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.	Blood	2008	126
19769945	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Yu Y	Withaferin A targets heat shock protein 90 in pancreatic cancer cells.	Biochemical pharmacology	2010	63
21693764	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Tatham MH	Comparative proteomic analysis identifies a role for SUMO in protein quality control.	Science signaling	2011	66
28098164	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Lamoliatte F	Uncovering the SUMOylation and ubiquitylation crosstalk in human cells using sequential peptide immunopurification.	Nature communications	2017	10
9129041	arsenic trioxide	Chen GQ	Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.	Blood	1997	132
9801394	arsenic trioxide	Soignet SL	Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.	The New England journal of medicine	1998	164
12727826	arsenic trioxide	Kanzawa T	Induction of autophagic cell death in malignant glioma cells by arsenic trioxide.	Cancer research	2003	120
15592527	arsenic trioxide	Kanzawa T	Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3.	Oncogene	2005	95
17640917	arsenic trioxide	Lu J	Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.	Proceedings of the National Academy of Sciences of the United States of America	2007	94
18299451	arsenic trioxide	Wang ZY	Acute promyelocytic leukemia: from highly fatal to highly curable.	Blood	2008	218
18716620	arsenic trioxide	Song MS	The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network.	Nature	2008	144
18922898	arsenic trioxide	Sun Y	The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents.	Cancer research	2008	55
19225113	arsenic trioxide	Hu J	Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2009	79
19468269	arsenic trioxide	Petrie K	Differentiation therapy of acute myeloid leukemia: past, present and future.	Current opinion in hematology	2009	56
20378816	arsenic trioxide	Zhang XW	Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.	Science	2010	164
20508647	arsenic trioxide	Smith DM	Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells.	Cell death and differentiation	2010	50
20574048	arsenic trioxide	Isakson P	Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.	Blood	2010	69
20599449	arsenic trioxide	Essers MA	Targeting leukemic stem cells by breaking their dormancy.	Molecular oncology	2010	51
20624968	arsenic trioxide	Kim J	Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector.	Proceedings of the National Academy of Sciences of the United States of America	2010	80
20644086	arsenic trioxide	Mathews V	Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.	Journal of clinical oncology 	2010	41
20966922	arsenic trioxide	de Thé H	Acute promyelocytic leukaemia: novel insights into the mechanisms of cure.	Nature reviews. Cancer	2010	115
21183792	arsenic trioxide	Beauchamp EM	Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway.	The Journal of clinical investigation	2011	74
22041887	arsenic trioxide	Martinez-Outschoorn UE	Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.	Cancer biology & therapy	2011	49
22056243	arsenic trioxide	Lallemand-Breitenbach V	Curing APL through PML/RARA degradation by As2O3.	Trends in molecular medicine	2012	41
22406621	arsenic trioxide	Rabellino A	The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.	Cancer research	2012	35
22715121	arsenic trioxide	Iland HJ	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).	Blood	2012	42
23670176	arsenic trioxide	Tomita A	Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.	International journal of hematology	2013	29
24344243	arsenic trioxide	Dos Santos GA	Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.	The Journal of experimental medicine	2013	26
24859340	arsenic trioxide	Sweeney RT	Identification of recurrent SMO and BRAF mutations in ameloblastomas.	Nature genetics	2014	26
24887205	arsenic trioxide	Kumar S	Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells.	Journal of experimental & clinical cancer research 	2014	27
25795919	arsenic trioxide	Martelli MP	Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.	Blood	2015	15
26772155	arsenic trioxide	Gu S	ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction underlie apoptosis induced by resveratrol and arsenic trioxide in A549 cells.	Chemico-biological interactions	2016	15
28109402	arsenic trioxide	Tamamyan G	Frontline treatment of acute myeloid leukemia in adults.	Critical reviews in oncology/hematology	2017	5
11786564	Fluorodeoxyglucose F18	Bos R	Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography.	Journal of clinical oncology 	2002	92
15319715	Fluorodeoxyglucose F18	Fernandez FG	Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).	Annals of surgery	2004	81
16644760	Fluorodeoxyglucose F18	Delbeke D	Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0.	Journal of nuclear medicine 	2006	83
17033037	Fluorodeoxyglucose F18	Khatcheressian JL	American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting.	Journal of clinical oncology 	2006	122
17538171	Fluorodeoxyglucose F18	Timmers HJ	Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.	Journal of clinical oncology 	2007	61
19289430	Fluorodeoxyglucose F18	Martinez-Möller A	Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data.	Journal of nuclear medicine 	2009	92
19443657	Fluorodeoxyglucose F18	Bartel TB	F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.	Blood	2009	68
20484419	Fluorodeoxyglucose F18	Baum RP	Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.	Journal of nuclear medicine 	2010	61
20831489	Fluorodeoxyglucose F18	Galavis PE	Variability of textural features in FDG PET images due to different acquisition modes and reconstruction parameters.	Acta oncologica	2010	51
20947515	Fluorodeoxyglucose F18	Herbst RS	A first-in-human study of conatumumab in adult patients with advanced solid tumors.	Clinical cancer research 	2010	42
21057787	Fluorodeoxyglucose F18	Groheux D	Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.	European journal of nuclear medicine and molecular imaging	2011	41
21422426	Fluorodeoxyglucose F18	Zander T	Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using (18)Ffluorodeoxyglucose and (18)Ffluorothymidine positron emission tomography.	Journal of clinical oncology 	2011	41
22331945	Fluorodeoxyglucose F18	Stacchiotti S	Phase II study of imatinib in advanced chordoma.	Journal of clinical oncology 	2012	35
22517990	Fluorodeoxyglucose F18	Timmers HJ	Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.	Journal of the National Cancer Institute	2012	38
23129741	Fluorodeoxyglucose F18	Khatcheressian JL	Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.	Journal of clinical oncology 	2013	92
24029656	Fluorodeoxyglucose F18	Tamura K	64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.	Journal of nuclear medicine 	2013	37
24322510	Fluorodeoxyglucose F18	Michielsen K	Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.	European radiology	2014	22
24337604	Fluorodeoxyglucose F18	Mortimer JE	Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.	Journal of nuclear medicine 	2014	32
25736399	Fluorodeoxyglucose F18	Philipp-Abbrederis K	In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.	EMBO molecular medicine	2015	31
25897473	Fluorodeoxyglucose F18	Cook GJ	Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis.	Radiology	2015	20
26449753	Fluorodeoxyglucose F18	Naik HB	Severity of Psoriasis Associates With Aortic Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational Study.	Arteriosclerosis, thrombosis, and vascular biology	2015	21
26564323	Fluorodeoxyglucose F18	Herrmann K	First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease.	Journal of nuclear medicine 	2016	21
26598545	Fluorodeoxyglucose F18	Gebhart G	Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.	Annals of oncology 	2016	28
26769866	Fluorodeoxyglucose F18	Vag T	First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers.	Journal of nuclear medicine 	2016	18
26834099	Fluorodeoxyglucose F18	Avril S	¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.	Journal of nuclear medicine 	2016	13
27688480	Fluorodeoxyglucose F18	Yip SS	Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.	Journal of nuclear medicine 	2017	9
28335509	Fluorodeoxyglucose F18	Chang JC	Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma.	International journal of molecular sciences	2017	6
28432222	Fluorodeoxyglucose F18	Rasche L	Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.	Blood	2017	6
11896092	docetaxel	Smith IC	Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.	Journal of clinical oncology 	2002	112
11919237	docetaxel	Esteva FJ	Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.	Journal of clinical oncology 	2002	99
15470213	docetaxel	Tannock IF	Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.	The New England journal of medicine	2004	993
15470214	docetaxel	Petrylak DP	Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.	The New England journal of medicine	2004	692
15547181	docetaxel	Vasey PA	Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.	Journal of the National Cancer Institute	2004	89
15735684	docetaxel	He B	Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations.	Oncogene	2005	73
15911866	docetaxel	Marty M	Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.	Journal of clinical oncology 	2005	271
15930421	docetaxel	Martin M	Adjuvant docetaxel for node-positive breast cancer.	The New England journal of medicine	2005	141
16061678	docetaxel	Li Y	Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells.	Cancer research	2005	95
16391297	docetaxel	Wedam SB	Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.	Journal of clinical oncology 	2006	131
16397019	docetaxel	Diaz N	Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression.	Clinical cancer research 	2006	81
16404427	docetaxel	Arnould L	Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?	British journal of cancer	2006	120
16606824	docetaxel	Farokhzad OC	Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2006	334
16847054	docetaxel	Peng XH	Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression.	The Journal of biological chemistry	2006	72
17308271	docetaxel	Beer TM	Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.	Journal of clinical oncology 	2007	60
17325667	docetaxel	Mahadevan D	A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.	Oncogene	2007	77
17606733	docetaxel	Marangoni E	A new model of patient tumor-derived breast cancer xenografts for preclinical assays.	Clinical cancer research 	2007	119
17878479	docetaxel	Heymach JV	Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.	Journal of clinical oncology 	2007	65
17909051	docetaxel	Loberg RD	Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.	Cancer research	2007	91
17909199	docetaxel	Herbst RS	Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.	Journal of clinical oncology 	2007	94
17920184	docetaxel	Heidenreich A	EAU guidelines on prostate cancer.	European urology	2008	142
18024211	docetaxel	Bonnefoi H	Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.	The Lancet. Oncology	2007	62
18182665	docetaxel	Berthold DR	Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.	Journal of clinical oncology 	2008	194
18258986	docetaxel	Rastogi P	Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.	Journal of clinical oncology 	2008	259
18314475	docetaxel	Merritt WM	Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.	Journal of the National Cancer Institute	2008	89
18420499	docetaxel	Sparano JA	Weekly paclitaxel in the adjuvant treatment of breast cancer.	The New England journal of medicine	2008	136
18645028	docetaxel	Meng Y	Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.	Molecular cancer therapeutics	2008	60
19027483	docetaxel	Kim ES	Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.	Lancet	2008	278
19147587	docetaxel	Kim RH	Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.	Cancer research	2009	73
19150933	docetaxel	Corkery B	Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.	Annals of oncology 	2009	74
19204201	docetaxel	Jones S	Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.	Journal of clinical oncology 	2009	82
19204205	docetaxel	Hugh J	Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.	Journal of clinical oncology 	2009	111
19275762	docetaxel	Morgan TM	Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.	Current cancer drug targets	2009	77
19380452	docetaxel	Penault-Llorca F	Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.	Journal of clinical oncology 	2009	50
19509167	docetaxel	Yao E	Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.	Clinical cancer research 	2009	48
19666588	docetaxel	Creighton CJ	Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.	Proceedings of the National Academy of Sciences of the United States of America	2009	438
19826044	docetaxel	Gan L	Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.	Cancer research	2009	52
19901561	docetaxel	Bayet-Robert M	Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.	Cancer biology & therapy	2010	52
19917839	docetaxel	Spielmann M	Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.	Journal of clinical oncology 	2009	59
20008645	docetaxel	Byrski T	Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.	Journal of clinical oncology 	2010	116
20022809	docetaxel	Mitsudomi T	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.	The Lancet. Oncology	2010	870
20038723	docetaxel	Douillard JY	Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.	Journal of clinical oncology 	2010	142
20100966	docetaxel	Lynch TJ	Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.	Journal of clinical oncology 	2010	108
20159814	docetaxel	Danila DC	Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.	Journal of clinical oncology 	2010	113
20159823	docetaxel	Reid AH	Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.	Journal of clinical oncology 	2010	127
20308670	docetaxel	Untch M	Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.	Journal of clinical oncology 	2010	97
20406831	docetaxel	Riethdorf S	Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.	Clinical cancer research 	2010	111
20498403	docetaxel	Miles DW	Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.	Journal of clinical oncology 	2010	205
20519679	docetaxel	Swain SM	Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.	The New England journal of medicine	2010	59
20570559	docetaxel	Herbst RS	Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.	The Lancet. Oncology	2010	106
20697801	docetaxel	Huober J	Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.	Breast cancer research and treatment	2010	52
20733135	docetaxel	Chi KN	Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.	Journal of clinical oncology 	2010	55
20807808	docetaxel	Zhu ML	Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.	Cancer research	2010	87
20842666	docetaxel	Zhang HL	Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.	The Prostate	2011	89
20859283	docetaxel	Seruga B	Drug resistance in metastatic castration-resistant prostate cancer.	Nature reviews. Clinical oncology	2011	74
20921363	docetaxel	Kolishetti N	Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy.	Proceedings of the National Academy of Sciences of the United States of America	2010	100
21115860	docetaxel	Valero V	Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.	Journal of clinical oncology 	2011	52
21121833	docetaxel	Martín M	Adjuvant docetaxel for high-risk, node-negative breast cancer.	The New England journal of medicine	2010	46
21135276	docetaxel	Dave B	Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.	Journal of clinical oncology 	2011	82
21149267	docetaxel	Jeyapalan Z	Expression of CD44 3'-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis.	Nucleic acids research	2011	62
21177763	docetaxel	Litzenburger BC	High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.	Clinical cancer research 	2011	40
21197560	docetaxel	Xu B	miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS.	Molecular and cellular biochemistry	2011	53
21233014	docetaxel	Lorch JH	Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.	The Lancet. Oncology	2011	61
21315502	docetaxel	Mottet N	EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.	European urology	2011	107
21325072	docetaxel	Song L	Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer.	Clinical cancer research 	2011	50
21373875	docetaxel	Glück S	TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.	Breast cancer research and treatment	2012	62
21383283	docetaxel	Robert NJ	RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.	Journal of clinical oncology 	2011	235
21399894	docetaxel	Kastl L	miRNA-34a is associated with docetaxel resistance in human breast cancer cells.	Breast cancer research and treatment	2012	44
21559013	docetaxel	Lee HE	An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.	British journal of cancer	2011	50
21680543	docetaxel	Massard C	Targeting continued androgen receptor signaling in prostate cancer.	Clinical cancer research 	2011	40
21826082	docetaxel	Yap TA	The changing therapeutic landscape of castration-resistant prostate cancer.	Nature reviews. Clinical oncology	2011	52
21837479	docetaxel	Loibl S	Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.	Breast cancer research and treatment	2011	39
21917920	docetaxel	Geng H	HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia.	The Journal of biological chemistry	2011	44
21918169	docetaxel	Brunsvig PF	Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.	Clinical cancer research 	2011	40
21976132	docetaxel	Araujo JC	Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.	Cancer	2012	54
21991949	docetaxel	Slamon D	Adjuvant trastuzumab in HER2-positive breast cancer.	The New England journal of medicine	2011	395
22139708	docetaxel	Feng B	MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3.	Cancer	2012	38
22149875	docetaxel	Baselga J	Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.	The New England journal of medicine	2012	444
22153890	docetaxel	Gianni L	Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2012	275
22264790	docetaxel	Van der Veldt AA	Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.	Cancer cell	2012	95
22331954	docetaxel	Bergh J	First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.	Journal of clinical oncology 	2012	58
22377126	docetaxel	Pierga JY	Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.	The Lancet. Oncology	2012	31
22387005	docetaxel	Shien K	Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy.	Lung cancer	2012	33
22425996	docetaxel	Chen Z	A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.	Nature	2012	141
22454414	docetaxel	Kelly WK	Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.	Journal of clinical oncology 	2012	143
22491949	docetaxel	Hrkach J	Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.	Science translational medicine	2012	221
22674438	docetaxel	Antonarakis ES	An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.	Cancer	2012	33
22683778	docetaxel	Balko JM	Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.	Nature medicine	2012	53
22771826	docetaxel	Mezynski J	Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?	Annals of oncology 	2012	53
22907596	docetaxel	Pienta KJ	Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.	Investigational new drugs	2013	46
22952424	docetaxel	Domanska UM	CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.	Neoplasia	2012	39
22965962	docetaxel	Ramlau R	Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.	Journal of clinical oncology 	2012	38
22972611	docetaxel	Sehdev V	The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.	Cancer	2013	26
22975379	docetaxel	Domingo-Domenech J	Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.	Cancer cell	2012	120
22996738	docetaxel	Liu C	Functional p53 determines docetaxel sensitivity in prostate cancer cells.	The Prostate	2013	30
23032615	docetaxel	Mamounas EP	Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.	Journal of clinical oncology 	2012	45
23041061	docetaxel	Puhr M	Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.	The American journal of pathology	2012	68
23041621	docetaxel	Qiu M	Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells.	Cancer letters	2013	26
23200175	docetaxel	Jänne PA	Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.	The Lancet. Oncology	2013	181
23246022	docetaxel	Mackey JR	Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.	The Lancet. Oncology	2013	44
23251413	docetaxel	Corcoran C	Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.	PloS one	2012	72
23306100	docetaxel	Gravis G	Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2013	46
23340294	docetaxel	Schott AF	Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.	Clinical cancer research 	2013	44
23341518	docetaxel	Loi S	Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.	Journal of clinical oncology 	2013	227
23364915	docetaxel	Hodge JW	Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.	International journal of cancer	2013	50
23368632	docetaxel	Chen J	Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures.	BMC cell biology	2013	26
23382472	docetaxel	Hurvitz SA	Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.	Journal of clinical oncology 	2013	80
23422754	docetaxel	Miles DW	Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.	British journal of cancer	2013	38
23474348	docetaxel	Armstrong DK	Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.	Gynecologic oncology	2013	36
23475636	docetaxel	Swain SM	Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.	The oncologist	2013	34
23569308	docetaxel	Fizazi K	Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.	Journal of clinical oncology 	2013	43
23569311	docetaxel	Gianni L	AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.	Journal of clinical oncology 	2013	53
23576708	docetaxel	Loriot Y	Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).	Annals of oncology 	2013	72
23602601	docetaxel	Swain SM	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.	The Lancet. Oncology	2013	161
23704196	docetaxel	Schneeweiss A	Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).	Annals of oncology 	2013	94
23724913	docetaxel	Shaw AT	Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.	The New England journal of medicine	2013	697
23742877	docetaxel	Tannock IF	Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.	The Lancet. Oncology	2013	57
23849416	docetaxel	Schrader AJ	Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.	European urology	2014	62
23883922	docetaxel	Garassino MC	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.	The Lancet. Oncology	2013	127
23957948	docetaxel	Sridhar SS	Castration-resistant prostate cancer: from new pathophysiology to new treatment.	European urology	2014	29
24008666	docetaxel	Liu P	Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells.	British journal of cancer	2013	26
24074764	docetaxel	Bianchini D	Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.	European journal of cancer	2014	34
24149323	docetaxel	Yan W	Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer.	Epigenetics	2013	30
24200698	docetaxel	van Soest RJ	Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.	European journal of cancer	2013	38
24309006	docetaxel	Stewart DJ	Wnt signaling pathway in non-small cell lung cancer.	Journal of the National Cancer Institute	2014	94
24321502	docetaxel	Heidenreich A	EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.	European urology	2014	203
24366758	docetaxel	Koizumi W	Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).	Journal of cancer research and clinical oncology	2014	27
24382803	docetaxel	Badrising S	Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.	Cancer	2014	28
24387695	docetaxel	Molife LR	Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.	Journal of hematology & oncology	2014	34
24411639	docetaxel	Reck M	Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.	The Lancet. Oncology	2014	129
24556717	docetaxel	Thadani-Mulero M	Androgen receptor splice variants determine taxane sensitivity in prostate cancer.	Cancer research	2014	55
24577057	docetaxel	Liu Y	Lack of correlation of stem cell markers in breast cancer stem cells.	British journal of cancer	2014	24
24616308	docetaxel	Goldkorn A	Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.	Journal of clinical oncology 	2014	50
24659820	docetaxel	Marín-Aguilera M	Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.	Molecular cancer therapeutics	2014	27
24685829	docetaxel	Swain SM	Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.	Annals of oncology 	2014	22
24714754	docetaxel	Lin HM	Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.	British journal of cancer	2014	29
24740322	docetaxel	Liu C	Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.	Clinical cancer research 	2014	61
24740415	docetaxel	Chen WX	Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs.	PloS one	2014	62
24799465	docetaxel	Giordano SH	Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.	Journal of clinical oncology 	2014	52
24806399	docetaxel	Sonpavde G	Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.	Clinical genitourinary cancer	2014	22
24815864	docetaxel	Palena C	Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis.	Journal of the National Cancer Institute	2014	25
24831979	docetaxel	Gregorc V	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.	The Lancet. Oncology	2014	44
24837187	docetaxel	Al Nakouzi N	Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.	European urology	2015	20
24841974	docetaxel	Kawaguchi T	Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).	Journal of clinical oncology 	2014	60
24933332	docetaxel	Garon EB	Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.	Lancet	2014	158
24985346	docetaxel	Ono M	Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells.	Science signaling	2014	105
24996221	docetaxel	Pan B	HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma.	Molecular cancer	2014	24
25002723	docetaxel	Harari PM	Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.	Journal of clinical oncology 	2014	22
25018038	docetaxel	Azad AA	Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.	European urology	2015	26
25053345	docetaxel	Corcoran C	miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.	The Prostate	2014	39
25077924	docetaxel	Lv MM	Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein.	Tumour biology 	2014	29
25108579	docetaxel	Brasso K	Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.	European urology	2015	17
25170012	docetaxel	Kazandjian D	FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.	The oncologist	2014	28
25185099	docetaxel	Mackey JR	Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.	Journal of clinical oncology 	2015	22
25263564	docetaxel	Toso A	Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.	Cell reports	2014	38
25273343	docetaxel	Gligorov J	Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2014	20
25301760	docetaxel	James ND	Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).	European urology	2015	36
25310895	docetaxel	Chen D	MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc.	European journal of cancer	2014	22
25327557	docetaxel	Soliman HH	A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors.	Oncotarget	2014	31
25332247	docetaxel	Baselga J	Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.	Journal of clinical oncology 	2014	56
25341040	docetaxel	Zhang Q	Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31.	Cell death & disease	2014	24
25359780	docetaxel	Bhardwaj A	CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1.	Oncotarget	2014	20
25439694	docetaxel	Hoskin P	Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.	The Lancet. Oncology	2014	36
25454616	docetaxel	Ferraldeschi R	PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.	European urology	2015	24
25484141	docetaxel	van Soest RJ	Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.	European urology	2015	22
25576381	docetaxel	Yang L	C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study.	Experimental cell research	2015	18
25624429	docetaxel	Fizazi K	Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.	Journal of clinical oncology 	2015	25
25691773	docetaxel	de Leeuw R	Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.	Clinical cancer research 	2015	22
25693012	docetaxel	Swain SM	Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.	The New England journal of medicine	2015	175
25722381	docetaxel	Blumenschein GR Jr	A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.	Annals of oncology 	2015	34
25771365	docetaxel	Vallabhajosula S	Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.	Current radiopharmaceuticals	2016	15
25787766	docetaxel	Leverson JD	Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.	Science translational medicine	2015	71
25975632	docetaxel	Earl HM	Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.	The Lancet. Oncology	2015	25
25997818	docetaxel	Ramalingam S	A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).	Annals of oncology 	2015	18
26028407	docetaxel	Brahmer J	Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.	The New England journal of medicine	2015	837
26074382	docetaxel	Attard G	Prostate cancer.	Lancet	2016	92
26077235	docetaxel	Sparano JA	Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.	Journal of clinical oncology 	2015	16
26117829	docetaxel	Nakazawa M	Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.	Annals of oncology 	2015	40
26125448	docetaxel	Jänne PA	Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.	British journal of cancer	2015	18
26160840	docetaxel	Zhang G	Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.	Oncotarget	2015	20
26181238	docetaxel	Antonarakis ES	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.	JAMA oncology	2015	87
26196735	docetaxel	Crawford ED	Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.	The Journal of urology	2015	24
26244877	docetaxel	Sweeney CJ	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.	The New England journal of medicine	2015	132
26253814	docetaxel	Prat A	Clinical implications of the intrinsic molecular subtypes of breast cancer.	Breast	2015	49
26324367	docetaxel	Masters GA	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.	Journal of clinical oncology 	2015	74
26351332	docetaxel	Durkee BY	Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.	Journal of clinical oncology 	2016	15
26412456	docetaxel	Borghaei H	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.	The New England journal of medicine	2015	776
26578067	docetaxel	Mendes D	The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review.	Breast cancer research 	2015	20
26617202	docetaxel	Takashima T	Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.	The Lancet. Oncology	2016	11
26847057	docetaxel	Von Hoff DD	Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.	Clinical cancer research 	2016	15
26859684	docetaxel	Black M	Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.	Oncotarget	2016	19
26884577	docetaxel	Melosky B	Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.	Journal of clinical oncology 	2016	11
26969107	docetaxel	Abdel-Rahman O	Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis.	Critical reviews in oncology/hematology	2016	13
26970723	docetaxel	Fehrenbacher L	Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.	Lancet	2016	231
26984449	docetaxel	Kazandjian D	FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.	The oncologist	2016	36
27179402	docetaxel	Gianni L	5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.	The Lancet. Oncology	2016	21
27506431	docetaxel	Yadav MP	177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment.	European journal of nuclear medicine and molecular imaging	2017	9
27566568	docetaxel	Chen J	Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells.	Oncotarget	2016	10
27591931	docetaxel	Cornford P	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.	European urology	2017	44
27765535	docetaxel	Lee CK	Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.	Journal of thoracic oncology 	2017	33
27776843	docetaxel	Al-Batran SE	Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.	The Lancet. Oncology	2016	17
27964843	docetaxel	Luen SJ	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.	The Lancet. Oncology	2017	14
27979383	docetaxel	Rittmeyer A	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.	Lancet	2017	162
28212060	docetaxel	Bellmunt J	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.	The New England journal of medicine	2017	70
28398846	docetaxel	Blum JL	Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).	Journal of clinical oncology 	2017	5
28407528	docetaxel	Giroux Leprieur E	Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.	European journal of cancer	2017	7
10757806	Camptothecin	Ashcroft M	Stress signals utilize multiple pathways to stabilize p53.	Molecular and cellular biology	2000	113
12154035	Camptothecin	Rapisarda A	Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.	Cancer research	2002	102
12660252	Camptothecin	Furuta T	Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes.	The Journal of biological chemistry	2003	127
12676925	Camptothecin	Xiao Z	Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents.	The Journal of biological chemistry	2003	81
12761490	Camptothecin	Knuefermann C	HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.	Oncogene	2003	109
14500729	Camptothecin	Fusaro G	Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling.	The Journal of biological chemistry	2003	90
15665856	Camptothecin	Sørensen CS	The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair.	Nature cell biology	2005	215
15920477	Camptothecin	Interthal H	SCAN1 mutant Tdp1 accumulates the enzyme--DNA intermediate and causes camptothecin hypersensitivity.	The EMBO journal	2005	70
17928296	Camptothecin	Anantha RW	Sequential and synergistic modification of human RPA stimulates chromosomal DNA repair.	The Journal of biological chemistry	2007	76
18834855	Camptothecin	Fujita Y	Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells.	Biochemical and biophysical research communications	2008	92
19423727	Camptothecin	Singh TR	Impaired FANCD2 monoubiquitination and hypersensitivity to camptothecin uniquely characterize Fanconi anemia complementation group M.	Blood	2009	62
19557000	Camptothecin	Sordet O	Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks.	EMBO reports	2009	67
19716789	Camptothecin	Zhang YW	The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress.	Molecular cell	2009	67
20086100	Camptothecin	Shahbazian D	Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B.	Molecular and cellular biology	2010	46
20145154	Camptothecin	Kaneda H	FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth.	Cancer research	2010	53
20347429	Camptothecin	Singh TR	MHF1-MHF2, a histone-fold-containing protein complex, participates in the Fanconi anemia pathway via FANCM.	Molecular cell	2010	94
20400963	Camptothecin	Vaz F	Mutation of the RAD51C gene in a Fanconi anemia-like disorder.	Nature genetics	2010	157
21052091	Camptothecin	Eid W	DNA end resection by CtIP and exonuclease 1 prevents genomic instability.	EMBO reports	2010	49
21693595	Camptothecin	Wang Y	MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression.	Molecular cancer research 	2011	46
22123861	Camptothecin	Regairaz M	Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes.	The Journal of cell biology	2011	46
22388737	Camptothecin	Ray Chaudhuri A	Topoisomerase I poisoning results in PARP-mediated replication fork reversal.	Nature structural & molecular biology	2012	125
22410779	Camptothecin	Wang Z	SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells.	Oncogene	2013	32
22983061	Camptothecin	Oplustilova L	Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.	Cell cycle	2012	46
23512991	Camptothecin	Batey MA	Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer.	Molecular cancer therapeutics	2013	32
25333260	Camptothecin	Eichelser C	Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients.	Oncotarget	2014	40
27239795	Camptothecin	Densham RM	Human BRCA1-BARD1 ubiquitin ligase activity counteracts chromatin barriers to DNA resection.	Nature structural & molecular biology	2016	21
27325647	Camptothecin	Pham E	Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.	Cancer research	2016	11
11043579	fulvestrant	Filardo EJ	Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF.	Molecular endocrinology	2000	343
14736707	fulvestrant	Chen JQ	Mitochondrial localization of ERalpha and ERbeta in human MCF7 cells.	American journal of physiology. Endocrinology and metabolism	2004	74
15193262	fulvestrant	Michalides R	Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer.	Cancer cell	2004	73
15735034	fulvestrant	Stabile LP	Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.	Cancer research	2005	86
16333030	fulvestrant	Lewis JS	Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.	Journal of the National Cancer Institute	2005	78
16849584	fulvestrant	Frasor J	Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.	Cancer research	2006	73
17178894	fulvestrant	Fan M	Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.	Cancer research	2006	93
18000219	fulvestrant	Hosey AM	Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.	Journal of the National Cancer Institute	2007	61
18182067	fulvestrant	Pan Q	Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids.	Journal of cellular and molecular medicine	2008	51
18794137	fulvestrant	Creighton CJ	Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.	Cancer research	2008	50
19435893	fulvestrant	Miller TW	Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.	Cancer research	2009	57
20665103	fulvestrant	Kabos P	Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers.	Breast cancer research and treatment	2011	45
21057537	fulvestrant	Rao X	MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.	Oncogene	2011	109
21123450	fulvestrant	Rhodes LV	Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.	Cancer research	2011	59
21362200	fulvestrant	Sanchez CG	Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.	Breast cancer research 	2011	49
21595894	fulvestrant	Zhang Y	Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.	Breast cancer research 	2011	47
21908557	fulvestrant	Fox EM	A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.	Cancer research	2011	58
22370325	fulvestrant	Bergh J	FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.	Journal of clinical oncology 	2012	40
22853014	fulvestrant	Mehta RS	Combination anastrozole and fulvestrant in metastatic breast cancer.	The New England journal of medicine	2012	63
24874954	fulvestrant	Feng Q	An epigenomic approach to therapy for tamoxifen-resistant breast cancer.	Cell research	2014	45
25380844	fulvestrant	van Kruchten M	Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.	Cancer discovery	2015	18
25991817	fulvestrant	Wardell SE	Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.	Clinical cancer research 	2015	19
26030518	fulvestrant	Turner NC	Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.	The New England journal of medicine	2015	177
26358751	fulvestrant	Guichard SM	AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.	Molecular cancer therapeutics	2015	15
26563128	fulvestrant	Ma CX	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.	Clinical cancer research 	2016	17
26947331	fulvestrant	Cristofanilli M	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.	The Lancet. Oncology	2016	72
27155741	fulvestrant	Krop IE	Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.	The Lancet. Oncology	2016	19
27368881	fulvestrant	Verma S	Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).	The oncologist	2016	14
27879270	fulvestrant	Shibata T	Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 Expression.	Cancer research	2017	5
27908454	fulvestrant	Robertson JFR	Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.	Lancet	2016	16
28147342	fulvestrant	McDermott MS	Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer.	Oncotarget	2017	5
7585152	decitabine	Merlo A	5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.	Nature medicine	1995	286
7585573	decitabine	Graff JR	E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas.	Cancer research	1995	167
7937876	decitabine	Herman JG	Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.	Proceedings of the National Academy of Sciences of the United States of America	1994	241
9560261	decitabine	Whang YE	Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.	Proceedings of the National Academy of Sciences of the United States of America	1998	141
9618505	decitabine	Herman JG	Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma.	Proceedings of the National Academy of Sciences of the United States of America	1998	372
10523621	decitabine	De Smet C	DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter.	Molecular and cellular biology	1999	136
10811911	decitabine	Ferguson AT	High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2000	111
11085525	decitabine	Plumb JA	Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.	Cancer research	2000	96
11196646	decitabine	Soengas MS	Inactivation of the apoptosis effector Apaf-1 in malignant melanoma.	Nature	2001	164
11593392	decitabine	Fulda S	Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer.	Oncogene	2001	88
12006535	decitabine	Soria JC	Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.	Clinical cancer research 	2002	90
12438235	decitabine	Nguyen CT	Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine.	Cancer research	2002	105
12496760	decitabine	Robert MF	DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells.	Nature genetics	2003	147
12873976	decitabine	Vanaja DK	Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression.	Cancer research	2003	113
14604977	decitabine	Issa JP	Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.	Blood	2004	164
15256437	decitabine	Mazieres J	Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer.	Cancer research	2004	74
15824739	decitabine	Schulmann K	Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.	Oncogene	2005	69
15899874	decitabine	Ghoshal K	5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal.	Molecular and cellular biology	2005	144
16007195	decitabine	Niwa Y	Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma.	Oncogene	2005	93
16140943	decitabine	Vatolin S	Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.	Cancer research	2005	70
16247458	decitabine	Ying J	Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation.	Oncogene	2006	69
16367923	decitabine	Yamashita S	Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray.	Cancer science	2006	69
16449975	decitabine	Veeck J	Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis.	Oncogene	2006	81
16491118	decitabine	Aguilera O	Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer.	Oncogene	2006	93
16585178	decitabine	McGarvey KM	Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state.	Cancer research	2006	114
16645171	decitabine	Zorn E	IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo.	Blood	2006	189
16707479	decitabine	Yang AS	DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.	Cancer research	2006	79
16766263	decitabine	Saito Y	Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells.	Cancer cell	2006	392
16799634	decitabine	Wozniak RJ	5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation.	Oncogene	2007	59
16882708	decitabine	Kantarjian H	Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.	Blood	2007	163
16882711	decitabine	Garcia-Manero G	Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.	Blood	2006	139
17079474	decitabine	Wehbe H	Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression.	Cancer research	2006	60
17145863	decitabine	Muthusamy V	Epigenetic silencing of novel tumor suppressors in malignant melanoma.	Cancer research	2006	64
17241887	decitabine	Isomoto H	Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing.	Gastroenterology	2007	66
17297461	decitabine	Nojima M	Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer.	Oncogene	2007	62
17417771	decitabine	Kumagai T	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.	International journal of cancer	2007	59
17621267	decitabine	Meng F	Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes.	Oncogene	2008	85
17660710	decitabine	Han L	DNA methylation regulates MicroRNA expression.	Cancer biology & therapy	2007	101
17679729	decitabine	Blum W	Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.	Journal of clinical oncology 	2007	93
17875710	decitabine	Iorio MV	MicroRNA signatures in human ovarian cancer.	Cancer research	2007	470
17925555	decitabine	Appleton K	Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.	Journal of clinical oncology 	2007	61
17948228	decitabine	Lehmann U	Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer.	The Journal of pathology	2008	136
17991895	decitabine	Palii SS	DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.	Molecular and cellular biology	2008	99
18179966	decitabine	Griffiths EA	DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.	Seminars in hematology	2008	56
18221536	decitabine	Roll JD	DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines.	Molecular cancer	2008	54
18381414	decitabine	Kozaki K	Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer.	Cancer research	2008	204
18519671	decitabine	Toyota M	Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer.	Cancer research	2008	178
18555005	decitabine	Wang R	Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues.	Biochemical and biophysical research communications	2008	65
18577749	decitabine	Fujita T	CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas.	Journal of the National Cancer Institute	2008	62
18931345	decitabine	Qin T	Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines.	Blood	2009	53
19221000	decitabine	Majid S	BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer.	Carcinogenesis	2009	60
19308264	decitabine	Garzia L	MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma.	PloS one	2009	79
19503096	decitabine	Saito Y	Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells.	Oncogene	2009	54
19843643	decitabine	Furuta M	miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma.	Carcinogenesis	2010	176
19897574	decitabine	Kanduri M	Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia.	Blood	2010	46
20084174	decitabine	Vrba L	Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells.	PloS one	2010	108
20103663	decitabine	Di Tomaso T	Immunobiological characterization of cancer stem cells isolated from glioblastoma patients.	Clinical cancer research 	2010	63
20124447	decitabine	Zhang P	Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth.	Molecular cancer therapeutics	2010	112
20126405	decitabine	Hollenbach PW	A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.	PloS one	2010	75
20368434	decitabine	Blum W	Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.	Proceedings of the National Academy of Sciences of the United States of America	2010	120
20427703	decitabine	Leshchenko VV	Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.	Blood	2010	51
20564122	decitabine	Fang F	A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.	Cancer	2010	46
20924086	decitabine	Suzuki H	Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect.	Carcinogenesis	2010	61
20980350	decitabine	Chik F	Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors.	Carcinogenesis	2011	37
21349819	decitabine	Suh SO	MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer.	Carcinogenesis	2011	64
21368160	decitabine	Sproul D	Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2011	57
21368878	decitabine	Bhatnagar N	Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells.	Cell death & disease	2010	63
21483003	decitabine	Lübbert M	Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.	Journal of clinical oncology 	2011	86
21547903	decitabine	Chen X	CpG island methylation status of miRNAs in esophageal squamous cell carcinoma.	International journal of cancer	2012	32
21625215	decitabine	Braconi C	microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer.	Oncogene	2011	175
21703189	decitabine	Alpini G	Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer.	Journal of hepatology	2011	41
21747116	decitabine	Stefanska B	Definition of the landscape of promoter DNA hypomethylation in liver cancer.	Cancer research	2011	57
21772049	decitabine	Kalac M	HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.	Blood	2011	37
21828134	decitabine	Braun T	Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.	Blood	2011	37
21965114	decitabine	Foulks JM	Epigenetic drug discovery: targeting DNA methyltransferases.	Journal of biomolecular screening	2012	36
22002305	decitabine	Ramachandran I	Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo.	Oncogene	2012	35
22124213	decitabine	Metzeler KH	DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.	Leukemia	2012	50
22237753	decitabine	Sun CY	Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation.	Kidney international	2012	35
22249249	decitabine	Zeller C	Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.	Oncogene	2012	61
22461695	decitabine	Yang D	Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo.	Journal of immunology	2012	30
22549947	decitabine	Matei D	Epigenetic resensitization to platinum in ovarian cancer.	Cancer research	2012	89
22566605	decitabine	Blum W	Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.	Blood	2012	47
22689435	decitabine	Neumann O	Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors.	Hepatology	2012	42
22786882	decitabine	Yan P	Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.	Blood	2012	33
22821729	decitabine	Wang F	SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer.	The Journal of pathology	2013	38
22876840	decitabine	Liu XH	MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5.	BMC cancer	2012	51
22890324	decitabine	Aprelikova O	Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility.	Oncogene	2013	38
22900969	decitabine	Zhang X	The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia.	Molecular cancer	2012	33
23071272	decitabine	Quintás-Cardama A	Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.	Blood	2012	33
23079745	decitabine	Kim JK	Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b.	Hepatology	2013	68
23144859	decitabine	Kresse SH	Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.	PloS one	2012	34
23297133	decitabine	Klco JM	Genomic impact of transient low-dose decitabine treatment on primary AML cells.	Blood	2013	51
23318422	decitabine	Xiang Y	MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.	Oncogene	2014	49
23365201	decitabine	Dar AA	The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression.	Journal of the National Cancer Institute	2013	30
23369223	decitabine	Karahoca M	Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.	Clinical epigenetics	2013	56
23408834	decitabine	Heuck CJ	Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis.	Journal of immunology	2013	25
23408854	decitabine	Pandiyan K	Functional DNA demethylation is accompanied by chromatin accessibility.	Nucleic acids research	2013	26
23526416	decitabine	Estey EH	Acute myeloid leukemia: 2013 update on risk-stratification and management.	American journal of hematology	2013	70
23667495	decitabine	Hashimoto Y	Multiple-to-multiple relationships between microRNAs and target genes in gastric cancer.	PloS one	2013	38
23703729	decitabine	Song K	Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells.	Hepatology	2013	40
23856509	decitabine	Koukos G	MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis.	Gastroenterology	2013	51
23902433	decitabine	Xu X	Parallel comparison of Illumina RNA-Seq and Affymetrix microarray platforms on transcriptomic profiles generated from 5-aza-deoxy-cytidine treated HT-29 colon cancer cells and simulated datasets.	BMC bioinformatics	2013	32
23971832	decitabine	Borges S	Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.	Breast cancer research 	2013	28
24030154	decitabine	Steinhart L	Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis.	Cell death & disease	2013	25
24045501	decitabine	Traina F	Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.	Leukemia	2014	58
24077826	decitabine	Turcan S	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.	Oncotarget	2013	49
24270737	decitabine	Yang H	Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.	Leukemia	2014	67
24283360	decitabine	Naito Y	MicroRNA-143 regulates collagen type III expression in stromal fibroblasts of scirrhous type gastric cancer.	Cancer science	2014	20
24484870	decitabine	Ufkin ML	miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia.	Leukemia research	2014	22
24495951	decitabine	Cho Y	Colon cancer cell apoptosis is induced by combined exposure to the n-3 fatty acid docosahexaenoic acid and butyrate through promoter methylation.	Experimental biology and medicine	2014	20
24535937	decitabine	Odunsi K	Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.	Cancer immunology research	2014	31
24622842	decitabine	Roy DM	Driver mutations of cancer epigenomes.	Protein & cell	2014	28
24699305	decitabine	Im AP	DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.	Leukemia	2014	42
25106087	decitabine	Marcato P	Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling.	Molecular oncology	2015	19
25210796	decitabine	Yan F	Restoration of miR-101 suppresses lung tumorigenesis through inhibition of DNMT3a-dependent DNA methylation.	Cell death & disease	2014	23
25224413	decitabine	Bejar R	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.	Blood	2014	76
25336333	decitabine	Issa JP	Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.	Cancer	2015	24
25502084	decitabine	Zhou X	The downregulation of miR-200c/141 promotes ZEB1/2 expression and gastric cancer progression.	Medical oncology	2015	20
25822018	decitabine	Meldi K	Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.	The Journal of clinical investigation	2015	25
26296954	decitabine	Issa JJ	Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.	The Lancet. Oncology	2015	36
26676363	decitabine	Li J	Epigenetic repression of long non-coding RNA MEG3 mediated by DNMT1 represses the p53 pathway in gliomas.	International journal of oncology	2016	17
26859457	decitabine	Grandin M	Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers.	Cancer cell	2016	13
26934121	decitabine	Dong P	Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression.	Oncotarget	2016	11
26967246	decitabine	Gao D	The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.	Oncotarget	2016	16
26968357	decitabine	Garcia-Manero G	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.	The Lancet. Oncology	2016	12
27259275	decitabine	Tagde A	MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia.	Oncotarget	2016	12
27489122	decitabine	Wu Y	Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer.	Scientific reports	2016	13
27623509	decitabine	Lucarini V	Combining Type I Interferons and 5-Aza-2'-Deoxycitidine to Improve Anti-Tumor Response against Melanoma.	The Journal of investigative dermatology	2017	7
27624549	decitabine	Blum W	Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).	Leukemia	2017	5
27959731	decitabine	Welch JS	TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.	The New England journal of medicine	2016	45
28359286	decitabine	Wolff F	The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.	Cell communication and signaling 	2017	8
9916799	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Shayesteh L	PIK3CA is implicated as an oncogene in ovarian cancer.	Nature genetics	1999	205
10749120	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Zhong H	Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.	Cancer research	2000	317
11139588	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Campbell RA	Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.	The Journal of biological chemistry	2001	191
11358816	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Brognard J	Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.	Cancer research	2001	209
11406568	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Cuello M	Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.	Cancer research	2001	88
11593406	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Hideshima T	Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.	Oncogene	2001	94
11861387	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Hu L	Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.	Cancer research	2002	85
12124352	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Yakes FM	Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.	Cancer research	2002	165
12446712	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Dawson CW	Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling.	The Journal of biological chemistry	2003	94
12479367	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Clark AS	Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.	Molecular cancer therapeutics	2002	139
14645548	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Li L	Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A.	Molecular and cellular biology	2003	93
15028555	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Gao N	G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.	American journal of physiology. Cell physiology	2004	77
15059890	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Stiff T	ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation.	Cancer research	2004	300
15208673	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Altomare DA	AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth.	Oncogene	2004	113
15339911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Hu P	Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death.	The Journal of biological chemistry	2004	87
15950905	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Samuels Y	Mutant PIK3CA promotes cell growth and invasion of human cancer cells.	Cancer cell	2005	297
16103051	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Sun SY	Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.	Cancer research	2005	277
16168105	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Wu G	Somatic mutation and gain of copy number of PIK3CA in human breast cancer.	Breast cancer research 	2005	66
16622124	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Yaguchi S	Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.	Journal of the National Cancer Institute	2006	70
16731745	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Smalley KS	Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.	Molecular cancer therapeutics	2006	150
16849522	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Pore N	Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway.	Molecular cancer research 	2006	62
17234779	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Tabe Y	Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells.	Cancer research	2007	61
17234785	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Opel D	Activation of Akt predicts poor outcome in neuroblastoma.	Cancer research	2007	68
17302559	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Gharbi SI	Exploring the specificity of the PI3K family inhibitor LY294002.	The Biochemical journal	2007	107
17310986	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Lue H	Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity.	Oncogene	2007	89
17334390	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Han EK	Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition.	Oncogene	2007	56
17409395	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Wang H	PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.	Cancer research	2007	78
17513297	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Kao GD	Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation.	The Journal of biological chemistry	2007	60
17551921	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Shukla S	Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.	International journal of cancer	2007	77
18676830	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Stemke-Hale K	An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.	Cancer research	2008	316
19190323	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Song S	Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity.	Cancer research	2009	52
19435898	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Mukherjee B	EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.	Cancer research	2009	74
19568240	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Meng XN	Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion.	British journal of cancer	2009	56
19633047	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Kataoka Y	Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.	Annals of oncology 	2010	61
20145128	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Ward CS	Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy.	Cancer research	2010	66
20547836	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Petersen SL	Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression.	Proceedings of the National Academy of Sciences of the United States of America	2010	43
21339740	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Kim EK	Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis.	Oncogene	2011	41
21544242	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Liu LZ	MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression.	PloS one	2011	112
21713404	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Chen XF	Transforming growth factor-β1 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways.	Molecular biology reports	2012	32
21862872	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Liu B	Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.	Cell cycle	2011	41
21996732	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Shih MC	TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.	Oncogene	2012	46
22156546	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Venkatesh HS	Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.	Neuro-oncology	2012	38
22285928	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Yang C	Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells.	Gene	2012	60
22610073	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Li XJ	As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma through induction of epithelial-mesenchymal transition and activation of AKT signaling.	Carcinogenesis	2012	38
22761812	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Han M	Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN.	PloS one	2012	68
23123500	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Liu J	PI3K/Akt-dependent phosphorylation of GSK3β and activation of RhoA regulate Wnt5a-induced gastric cancer cell migration.	Cellular signalling	2013	31
23301033	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Zhou F	HIV-1 Tat promotes Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6-induced angiogenesis and tumorigenesis by regulating PI3K/PTEN/AKT/GSK-3β signaling pathway.	PloS one	2013	27
23372675	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Zhao G	MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma.	PloS one	2013	66
23466500	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Yang SM	miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN.	Toxicology	2013	45
23604117	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Zhu X	Synergy between Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6 and HIV-1 Nef protein in promotion of angiogenesis and oncogenesis: role of the AKT signaling pathway.	Oncogene	2014	21
23869765	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Luo X	Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway.	Cell proliferation	2013	26
24194905	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Chai ZT	MicroRNA-26a inhibits angiogenesis by down-regulating VEGFA through the PIK3C2α/Akt/HIF-1α pathway in hepatocellular carcinoma.	PloS one	2013	29
24700142	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Yang N	SOX2 promotes the migration and invasion of laryngeal cancer cells by induction of MMP-2 via the PI3K/Akt/mTOR pathway.	Oncology reports	2014	20
24892425	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Forget MA	Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer.	PloS one	2014	23
26568302	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Yang CF	EB-virus latent membrane protein 1 potentiates the stemness of nasopharyngeal carcinoma via preferential activation of PI3K/AKT pathway by a positive feedback loop.	Oncogene	2016	13
27323826	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Jang HJ	Simvastatin induces heme oxygenase-1 via NF-E2-related factor 2 (Nrf2) activation through ERK and PI3K/Akt pathway in colon cancer.	Oncotarget	2016	10
27919028	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Fu X	PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.	Bioscience reports	2014	20
10914698	temozolomide	Friedman HS	Temozolomide and treatment of malignant glioma.	Clinical cancer research 	2000	128
14709739	temozolomide	Calabrese CR	Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.	Journal of the National Cancer Institute	2004	108
15041700	temozolomide	Hegi ME	Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.	Clinical cancer research 	2004	146
15758010	temozolomide	Hegi ME	MGMT gene silencing and benefit from temozolomide in glioblastoma.	The New England journal of medicine	2005	1193
15956649	temozolomide	Haas-Kogan DA	Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.	Journal of the National Cancer Institute	2005	137
16024643	temozolomide	Trivedi RN	The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death.	Cancer research	2005	78
16405512	temozolomide	Hermisson M	O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.	Journal of neurochemistry	2006	70
16421420	temozolomide	Kulke MH	Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.	Journal of clinical oncology 	2006	84
16618716	temozolomide	Hunter C	A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.	Cancer research	2006	90
16946731	temozolomide	Katayama M	DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells.	Cell death and differentiation	2007	99
17140455	temozolomide	Liu G	Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.	Molecular cancer	2006	509
17196391	temozolomide	Clement V	HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity.	Current biology 	2007	303
17363489	temozolomide	Thomas HD	Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.	Molecular cancer therapeutics	2007	64
17404084	temozolomide	Cahill DP	Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.	Clinical cancer research 	2007	91
17505000	temozolomide	Ekeblad S	Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.	Clinical cancer research 	2007	70
17522861	temozolomide	Jordan JT	Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.	Cancer immunology, immunotherapy 	2008	77
17620423	temozolomide	Omuro AM	Lessons learned in the development of targeted therapy for malignant gliomas.	Molecular cancer therapeutics	2007	61
17827463	temozolomide	Stupp R	Chemoradiotherapy in malignant glioma: standard of care and future directions.	Journal of clinical oncology 	2007	118
18082451	temozolomide	Gorlia T	Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.	The Lancet. Oncology	2008	95
18165616	temozolomide	Lefranc F	Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas.	The oncologist	2007	66
18281670	temozolomide	Testori A	Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.	Journal of clinical oncology 	2008	71
18445844	temozolomide	Brandes AA	MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.	Journal of clinical oncology 	2008	146
18565887	temozolomide	Murat A	Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.	Journal of clinical oncology 	2008	233
18632623	temozolomide	Beier D	Temozolomide preferentially depletes cancer stem cells in glioblastoma.	Cancer research	2008	83
18952979	temozolomide	Kitange GJ	Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.	Neuro-oncology	2009	47
18955445	temozolomide	Brown PD	Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.	Journal of clinical oncology 	2008	67
19047122	temozolomide	Plummer R	Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.	Clinical cancer research 	2008	101
19075262	temozolomide	Prados MD	Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.	Journal of clinical oncology 	2009	97
19118063	temozolomide	Kulke MH	O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.	Clinical cancer research 	2009	53
19188675	temozolomide	Brandes AA	Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.	Journal of clinical oncology 	2009	52
19204207	temozolomide	van den Bent MJ	Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.	Journal of clinical oncology 	2009	123
19221744	temozolomide	Banissi C	Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.	Cancer immunology, immunotherapy 	2009	57
19265662	temozolomide	Bleau AM	PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.	Cell stem cell	2009	239
19269895	temozolomide	Stupp R	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.	The Lancet. Oncology	2009	1345
19536096	temozolomide	Dunn J	Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy.	British journal of cancer	2009	67
19584161	temozolomide	Yip S	MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.	Clinical cancer research 	2009	83
19884534	temozolomide	Senzer NN	Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.	Journal of clinical oncology 	2009	162
19901110	temozolomide	Wick W	NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.	Journal of clinical oncology 	2009	140
19934293	temozolomide	Palma JP	ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.	Clinical cancer research 	2009	46
19960228	temozolomide	Peereboom DM	Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.	Journal of neuro-oncology	2010	59
20051134	temozolomide	Banáth JP	Residual gammaH2AX foci as an indication of lethal DNA lesions.	BMC cancer	2010	51
20146084	temozolomide	Ardon H	Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.	Journal of neuro-oncology	2010	44
20167819	temozolomide	De Witt Hamer PC	Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies.	Neuro-oncology	2010	42
20388803	temozolomide	Hattermann K	The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects.	Cancer research	2010	81
20423999	temozolomide	Keating AK	Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.	Molecular cancer therapeutics	2010	56
20439646	temozolomide	Stupp R	Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.	Journal of clinical oncology 	2010	99
20444541	temozolomide	Ujifuku K	miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.	Cancer letters	2010	55
20530668	temozolomide	McEllin B	PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.	Cancer research	2010	81
20587533	temozolomide	Voss V	The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma.	Molecular cancer research 	2010	49
20633539	temozolomide	Shi L	MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.	Brain research	2010	67
20855119	temozolomide	Minniti G	Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.	Radiotherapy and oncology 	2010	40
20921459	temozolomide	Sampson JH	Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.	Journal of clinical oncology 	2010	205
20935218	temozolomide	Gaspar N	MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature.	Cancer research	2010	44
20957337	temozolomide	Ulasov IV	Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy.	Molecular medicine	2011	46
20975057	temozolomide	Houillier C	IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.	Neurology	2010	92
21116835	temozolomide	Zhu X	Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.	Journal of neuro-oncology	2011	39
21135282	temozolomide	Lai A	Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.	Journal of clinical oncology 	2011	140
21149254	temozolomide	Sampson JH	Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.	Neuro-oncology	2011	92
21156036	temozolomide	Etcheverry A	DNA methylation in glioblastoma: impact on gene expression and clinical outcome.	BMC genomics	2010	58
21242296	temozolomide	Wolf A	Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme.	The Journal of experimental medicine	2011	162
21317208	temozolomide	Prasad G	Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.	Neuro-oncology	2011	48
21325076	temozolomide	Ma XH	Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.	Clinical cancer research 	2011	67
21339192	temozolomide	Cohen KJ	Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.	Neuro-oncology	2011	55
21425258	temozolomide	Felsberg J	Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.	International journal of cancer	2011	49
21499132	temozolomide	Fadul CE	Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.	Journal of immunotherapy	2011	54
21606416	temozolomide	de Groot JF	Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.	Journal of clinical oncology 	2011	47
21636705	temozolomide	Wick W	Pathway inhibition: emerging molecular targets for treating glioblastoma.	Neuro-oncology	2011	49
21709196	temozolomide	Gállego Pérez-Larraya J	Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.	Journal of clinical oncology 	2011	44
21730979	temozolomide	Peasland A	Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.	British journal of cancer	2011	46
21737504	temozolomide	Grossman SA	Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.	Clinical cancer research 	2011	84
21768296	temozolomide	Mitchell DA	Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.	Blood	2011	45
21988793	temozolomide	Beier D	Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.	Molecular cancer	2011	80
22034964	temozolomide	SongTao Q	IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.	Cancer science	2012	39
22035272	temozolomide	Narayana A	A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.	Journal of neurosurgery	2012	39
22045118	temozolomide	Johnson DR	Glioblastoma survival in the United States before and during the temozolomide era.	Journal of neuro-oncology	2012	152
22048237	temozolomide	Kirkwood JM	Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.	Clinical cancer research 	2012	77
22128301	temozolomide	Liu X	Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.	Clinical cancer research 	2012	41
22156195	temozolomide	Agnihotri S	Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.	The Journal of clinical investigation	2012	32
22197930	temozolomide	Stark MS	Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.	Nature genetics	2011	74
22383993	temozolomide	Sampson JH	A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.	PloS one	2012	33
22469979	temozolomide	Wagner L	Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner.	Oncogene	2013	28
22532597	temozolomide	Kohsaka S	STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.	Molecular cancer therapeutics	2012	31
22570426	temozolomide	Zhang W	miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression.	Neuro-oncology	2012	44
22578793	temozolomide	Wick W	Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.	The Lancet. Oncology	2012	136
22593187	temozolomide	Janouskova H	Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.	Cancer research	2012	32
22778320	temozolomide	Chan JA	Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.	Journal of clinical oncology 	2012	37
22877848	temozolomide	Malmström A	Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.	The Lancet. Oncology	2012	134
22984531	temozolomide	Safdie F	Fasting enhances the response of glioma to chemo- and radiotherapy.	PloS one	2012	33
22990979	temozolomide	Zhang W	Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme.	Cancer	2013	35
23047041	temozolomide	Triscott J	Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.	Oncotarget	2012	33
23115158	temozolomide	Li S	Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.	Neuro-oncology	2013	38
23183822	temozolomide	Asuthkar S	Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity.	Oncotarget	2012	49
23258846	temozolomide	Miranda-Gonçalves V	Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets.	Neuro-oncology	2013	52
23370117	temozolomide	Curtin NJ	Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.	Molecular aspects of medicine	2013	75
23423489	temozolomide	Plummer R	A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.	Cancer chemotherapy and pharmacology	2013	32
23569323	temozolomide	Rubenstein JL	Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).	Journal of clinical oncology 	2013	49
23792642	temozolomide	Comincini S	microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells.	Cancer biology & therapy	2013	32
23818228	temozolomide	Siebzehnrubl FA	The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance.	EMBO molecular medicine	2013	76
24101040	temozolomide	Gilbert MR	Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.	Journal of clinical oncology 	2013	119
24147153	temozolomide	Quintavalle C	MiR-221/222 target the DNA methyltransferase MGMT in glioma cells.	PloS one	2013	27
24249672	temozolomide	Bagatell R	Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.	Pediatric blood & cancer	2014	26
24336570	temozolomide	Johnson BE	Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.	Science	2014	244
24552317	temozolomide	Gilbert MR	A randomized trial of bevacizumab for newly diagnosed glioblastoma.	The New England journal of medicine	2014	381
24552318	temozolomide	Chinot OL	Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.	The New England journal of medicine	2014	358
24608791	temozolomide	Auffinger B	Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy.	Cell death and differentiation	2014	58
24650937	temozolomide	Murai J	Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.	The Journal of pharmacology and experimental therapeutics	2014	37
24675463	temozolomide	Munoz JL	Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43.	Cell death & disease	2014	25
24821329	temozolomide	Di Ieva A	Aggressive pituitary adenomas--diagnosis and emerging treatments.	Nature reviews. Endocrinology	2014	24
24861879	temozolomide	Shi Z	MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.	Neuro-oncology	2014	36
24938562	temozolomide	Carvajal RD	Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.	JAMA	2014	69
24980823	temozolomide	Wang L	MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.	Oncotarget	2014	43
24991839	temozolomide	Rangwala R	Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.	Autophagy	2014	73
25093489	temozolomide	Han S	Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway.	British journal of cancer	2014	26
25105369	temozolomide	Adair JE	Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.	The Journal of clinical investigation	2014	20
25135958	temozolomide	Bao ZS	RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.	Genome research	2014	41
25163906	temozolomide	Stupp R	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.	The Lancet. Oncology	2014	126
25283382	temozolomide	Shi J	Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.	Tumour biology 	2015	22
25364264	temozolomide	Lee JK	Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling.	OncoTargets and therapy	2014	23
25468223	temozolomide	Cohen AL	Glioma biology and molecular markers.	Cancer treatment and research	2015	30
25500058	temozolomide	Smith MA	Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.	Clinical cancer research 	2015	20
25526733	temozolomide	Ma DJ	A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.	Neuro-oncology	2015	18
25542083	temozolomide	Zanotto-Filho A	Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas.	Cancer letters	2015	23
25586468	temozolomide	Schuster J	A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.	Neuro-oncology	2015	66
25595896	temozolomide	Munoz JL	Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.	Oncotarget	2015	17
25605243	temozolomide	Wang Z	Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.	Oncotarget	2015	18
25609063	temozolomide	Pokorny JL	The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.	Clinical cancer research 	2015	16
25609769	temozolomide	Suchorska B	Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.	Neurology	2015	17
25646366	temozolomide	Caplin ME	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.	Annals of oncology 	2015	35
25655102	temozolomide	Weller M	MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.	Clinical cancer research 	2015	23
25724300	temozolomide	van Thuijl HF	Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.	Acta neuropathologica	2015	19
25762461	temozolomide	Nabors LB	Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.	Neuro-oncology	2015	30
25867026	temozolomide	Sesen J	Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.	PloS one	2015	25
25959588	temozolomide	Shao H	Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma.	Nature communications	2015	43
26115796	temozolomide	Ribas A	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.	The Lancet. Oncology	2015	208
26124478	temozolomide	Sandmann T	Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.	Journal of clinical oncology 	2015	48
26188279	temozolomide	Yu Z	NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.	Cancer letters	2015	19
26260013	temozolomide	Stepanenko AA	Pitfalls of the MTT assay: Direct and off-target effects of inhibitors can result in over/underestimation of cell viability.	Gene	2015	15
26373279	temozolomide	Kim J	Spatiotemporal Evolution of the Primary Glioblastoma Genome.	Cancer cell	2015	32
26431379	temozolomide	Yu Z	Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.	Oncotarget	2015	22
26542214	temozolomide	Murphy SF	Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.	Cancer research	2016	12
26846818	temozolomide	Phillips AC	ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.	Molecular cancer therapeutics	2016	15
26878385	temozolomide	Garros-Regulez L	mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.	Expert opinion on therapeutic targets	2016	14
26976423	temozolomide	Herrlinger U	Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.	Journal of clinical oncology 	2016	12
27370396	temozolomide	Wick W	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.	Neuro-oncology	2016	11
27440269	temozolomide	Lok BH	PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.	Clinical cancer research 	2017	13
27503138	temozolomide	Arita H	A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.	Acta neuropathologica communications	2016	12
27503200	temozolomide	Gojo I	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.	Clinical cancer research 	2017	7
27686946	temozolomide	Baumert BG	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.	The Lancet. Oncology	2016	15
27690220	temozolomide	Kawaguchi K	Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.	Oncotarget	2016	26
28106277	temozolomide	Kawaguchi K	Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.	Journal of cellular biochemistry	2017	15
28121023	temozolomide	Liao Y	LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway.	Journal of cellular biochemistry	2017	9
28187000	temozolomide	Chen W	MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.	Oncotarget	2017	8
28202508	temozolomide	Lu Y	Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.	Cancer research	2017	11
28233083	temozolomide	Ludwig K	Molecular markers in glioma.	Journal of neuro-oncology	2017	9
28296618	temozolomide	Perry JR	Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.	The New England journal of medicine	2017	20
28622068	temozolomide	Kawaguchi K	Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide.	Cell cycle	2017	8
28668966	temozolomide	Li H	Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.	Cellular physiology and biochemistry 	2017	7
28844499	temozolomide	Weller M	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.	The Lancet. Oncology	2017	11
9391166	resveratrol	Gehm BD	Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor.	Proceedings of the National Academy of Sciences of the United States of America	1997	105
10843709	resveratrol	Manna SK	Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation.	Journal of immunology	2000	133
11506818	resveratrol	Surh YJ	Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation.	Mutation research	2001	191
11895924	resveratrol	Joe AK	Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines.	Clinical cancer research 	2002	88
14744787	resveratrol	Opipari AW Jr	Resveratrol-induced autophagocytosis in ovarian cancer cells.	Cancer research	2004	79
15517885	resveratrol	Aggarwal BB	Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies.	Anticancer research	2004	204
15832402	resveratrol	de la Lastra CA	Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications.	Molecular nutrition & food research	2005	98
16043028	resveratrol	Signorelli P	Resveratrol as an anticancer nutrient: molecular basis, open questions and promises.	The Journal of nutritional biochemistry	2005	75
16356836	resveratrol	Garvin S	Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo.	Cancer letters	2006	67
17164350	resveratrol	Bhardwaj A	Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.	Blood	2007	93
17897053	resveratrol	Das S	Anti-inflammatory responses of resveratrol.	Inflammation & allergy drug targets	2007	64
18421301	resveratrol	Scarlatti F	Role of non-canonical Beclin 1-independent autophagy in cell death induced by resveratrol in human breast cancer cells.	Cell death and differentiation	2008	125
18835033	resveratrol	Wang RH	Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice.	Cancer cell	2008	260
18851829	resveratrol	Wang RH	Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis.	Molecular cell	2008	116
19047049	resveratrol	Bourguignon LY	Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells.	The Journal of biological chemistry	2009	51
19326431	resveratrol	Narayanan NK	Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice.	International journal of cancer	2009	60
19897059	resveratrol	Baur JA	Biochemical effects of SIRT1 activators.	Biochimica et biophysica acta	2010	40
20103647	resveratrol	Puissant A	Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation.	Cancer research	2010	93
20157535	resveratrol	Armour SM	Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy.	Aging	2009	65
20504360	resveratrol	Vanamala J	Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways.	BMC cancer	2010	51
20622002	resveratrol	Tili E	Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD.	Carcinogenesis	2010	61
20637737	resveratrol	Tili E	Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFβ signaling pathway in SW480 cells.	Biochemical pharmacology	2010	51
20716633	resveratrol	Chow HH	Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study.	Cancer prevention research	2010	46
20935227	resveratrol	Brown VA	Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis.	Cancer research	2010	96
21261654	resveratrol	Gupta SC	Chemosensitization of tumors by resveratrol.	Annals of the New York Academy of Sciences	2011	60
21304978	resveratrol	Shankar S	Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition.	PloS one	2011	79
21695150	resveratrol	Filippi-Chiela EC	Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells.	PloS one	2011	44
21980390	resveratrol	Roy SK	Resveratrol inhibits growth of orthotopic pancreatic tumors through activation of FOXO transcription factors.	PloS one	2011	40
22052357	resveratrol	Menendez JA	mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging.	Cell cycle	2011	58
22166724	resveratrol	Blagosklonny MV	Hormesis does not make sense except in the light of TOR-driven aging.	Aging	2011	38
22382311	resveratrol	Nakata R	Recent advances in the study on resveratrol.	Biological & pharmaceutical bulletin	2012	34
22410781	resveratrol	Yu YH	MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol.	Oncogene	2013	33
22495929	resveratrol	Sachdeva M	Negative regulation of miR-145 by C/EBP-β through the Akt pathway in cancer cells.	Nucleic acids research	2012	31
22547799	resveratrol	Lee H	Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation.	Proceedings of the National Academy of Sciences of the United States of America	2012	54
22730114	resveratrol	Villalba JM	Sirtuin activators and inhibitors.	BioFactors	2012	55
22885100	resveratrol	Chung JH	Resveratrol as a calorie restriction mimetic: therapeutic implications.	Trends in cell biology	2012	44
23104101	resveratrol	Morris BJ	Seven sirtuins for seven deadly diseases of aging.	Free radical biology & medicine	2013	72
23272133	resveratrol	Sheth S	Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway.	PloS one	2012	53
23359184	resveratrol	Liu P	Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR-21 regulation of BCL-2 expression.	Clinical & translational oncology 	2013	26
23533664	resveratrol	Luo H	Resveratrol induces premature senescence in lung cancer cells via ROS-mediated DNA damage.	PloS one	2013	33
23992306	resveratrol	Li W	Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway.	Current medicinal chemistry	2013	26
24023672	resveratrol	Venturelli S	Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone corrected proteins in human-derived hepatoblastoma cells.	PloS one	2013	28
24160699	resveratrol	Sinclair DA	Small-molecule allosteric activators of sirtuins.	Annual review of pharmacology and toxicology	2014	54
24244343	resveratrol	Ji Q	Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/β-catenin signal pathway.	PloS one	2013	60
24439680	resveratrol	Hubbard BP	Small molecule SIRT1 activators for the treatment of aging and age-related diseases.	Trends in pharmacological sciences	2014	89
24606795	resveratrol	Valero T	Mitochondrial biogenesis: pharmacological approaches.	Current pharmaceutical design	2014	29
24771768	resveratrol	Nwachukwu JC	Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network.	eLife	2014	29
24819981	resveratrol	Semba RD	Resveratrol levels and all-cause mortality in older community-dwelling adults.	JAMA internal medicine	2014	23
25315298	resveratrol	Kulkarni SS	The molecular targets of resveratrol.	Biochimica et biophysica acta	2015	43
25375374	resveratrol	Hasima N	Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer.	Cell death & disease	2014	41
25447541	resveratrol	Dhar S	Resveratrol regulates PTEN/Akt pathway through inhibition of MTA1/HDAC unit of the NuRD complex in prostate cancer.	Biochimica et biophysica acta	2015	19
25533949	resveratrol	Sajish M	A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol.	Nature	2015	22
25605016	resveratrol	Yang SF	Upregulation of miR-328 and inhibition of CREB-DNA-binding activity are critical for resveratrol-mediated suppression of matrix metalloproteinase-2 and subsequent metastatic ability in human osteosarcomas.	Oncotarget	2015	16
25869442	resveratrol	Ferguson LR	Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition.	Seminars in cancer biology	2015	27
25884904	resveratrol	Ji Q	Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.	BMC cancer	2015	28
25917875	resveratrol	Selvaraj S	Resveratrol activates autophagic cell death in prostate cancer cells via downregulation of STIM1 and the mTOR pathway.	Molecular carcinogenesis	2016	19
25938543	resveratrol	Dai W	By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice.	Oncotarget	2015	24
26223300	resveratrol	Cai H	Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice.	Science translational medicine	2015	23
26310874	resveratrol	Buhrmann C	Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, Epithelial-to-mesenchymal transition and apoptosis in colorectal cancer.	Biochemical pharmacology	2015	17
26318586	resveratrol	Dhar S	Resveratrol and pterostilbene epigenetically restore PTEN expression by targeting oncomiRs of the miR-17 family in prostate cancer.	Oncotarget	2015	24
26704305	resveratrol	Gwak H	Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells.	Cancer letters	2016	11
26759241	resveratrol	Li CW	AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation.	Cancer research	2016	13
26902888	resveratrol	Park D	Resveratrol induces autophagy by directly inhibiting mTOR through ATP competition.	Scientific reports	2016	21
26911335	resveratrol	Kim C	Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.	BMC nephrology	2016	11
26959057	resveratrol	Buhrmann C	Sirt1 Is Required for Resveratrol-Mediated Chemopreventive Effects in Colorectal Cancer Cells.	Nutrients	2016	13
28075467	resveratrol	Gao F	Resveratrol suppresses human hepatocellular carcinoma via targeting HGF-c-Met signaling pathway.	Oncology reports	2017	6
28197628	resveratrol	Chang CH	Resveratrol-induced autophagy and apoptosis in cisplatin-resistant human oral cancer CAR cells: A key role of AMPK and Akt/mTOR signaling.	International journal of oncology	2017	6
28611316	resveratrol	McCubrey JA	Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs.	Aging	2017	6
8790415	Paraffin	Herman JG	Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.	Proceedings of the National Academy of Sciences of the United States of America	1996	1074
10485474	Paraffin	McMenamin ME	Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.	Cancer research	1999	141
10595928	Paraffin	De Marzo AM	Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis.	The American journal of pathology	1999	167
10766191	Paraffin	Wilentz RE	Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression.	Cancer research	2000	136
11948129	Paraffin	Malik SN	Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.	Clinical cancer research 	2002	87
12466114	Paraffin	van de Rijn M	Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome.	The American journal of pathology	2002	121
12576453	Paraffin	Bui MH	Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.	Clinical cancer research 	2003	104
12727799	Paraffin	Brink M	K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study.	Carcinogenesis	2003	79
15709183	Paraffin	Abraham BK	Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.	Clinical cancer research 	2005	138
15897568	Paraffin	Atkins M	Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.	Clinical cancer research 	2005	71
15942643	Paraffin	Rao CG	Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors.	International journal of oncology	2005	92
16049314	Paraffin	Ogino S	Sensitive sequencing method for KRAS mutation detection by Pyrosequencing.	The Journal of molecular diagnostics 	2005	197
17047046	Paraffin	Jenkins RB	A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.	Cancer research	2006	109
17099880	Paraffin	Petersen RP	Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.	Cancer	2006	84
17200343	Paraffin	Savage K	Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis.	Clinical cancer research 	2007	55
17255298	Paraffin	Thompson RH	Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy.	Clinical cancer research 	2007	60
17360651	Paraffin	Hamanishi J	Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	331
17363526	Paraffin	Henry LR	Clinical implications of fibroblast activation protein in patients with colon cancer.	Clinical cancer research 	2007	74
17487835	Paraffin	Lawrie CH	MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma.	International journal of cancer	2007	120
18343725	Paraffin	Vergis R	Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.	The Lancet. Oncology	2008	69
18544678	Paraffin	Rimsza LM	Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.	Blood	2008	52
18973197	Paraffin	Kong DS	Prognostic significance of c-Met expression in glioblastomas.	Cancer	2009	57
19273703	Paraffin	Lebanony D	Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.	Journal of clinical oncology 	2009	120
19304953	Paraffin	Yu C	Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis.	Carcinogenesis	2009	52
19318487	Paraffin	Bandres E	microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells.	Clinical cancer research 	2009	110
19342367	Paraffin	Maru DM	MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.	The American journal of pathology	2009	51
19474676	Paraffin	Zou C	Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome.	Annals of surgery	2009	56
19765725	Paraffin	Kurahara H	Significance of M2-polarized tumor-associated macrophage in pancreatic cancer.	The Journal of surgical research	2011	135
20022135	Paraffin	Chen X	Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients.	Lung cancer	2010	49
20338029	Paraffin	Ma J	The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time.	BMC cancer	2010	96
20570930	Paraffin	Bax DA	A distinct spectrum of copy number aberrations in pediatric high-grade gliomas.	Clinical cancer research 	2010	49
20631605	Paraffin	Sholl LM	Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma.	The American journal of surgical pathology	2010	49
20842526	Paraffin	Campbell MJ	Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome.	Breast cancer research and treatment	2011	66
21225432	Paraffin	Vogt M	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.	Virchows Archiv 	2011	83
21479927	Paraffin	Ascierto ML	A signature of immune function genes associated with recurrence-free survival in breast cancer patients.	Breast cancer research and treatment	2012	46
21523733	Paraffin	Gadiot J	Overall survival and PD-L1 expression in metastasized malignant melanoma.	Cancer	2011	48
21752896	Paraffin	Korpershoek E	SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas.	The Journal of clinical endocrinology and metabolism	2011	49
21953023	Paraffin	Jensen TO	Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma.	Cancer	2012	46
22088988	Paraffin	Schmidt LH	The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth.	Journal of thoracic oncology 	2011	131
22184391	Paraffin	van Gaal JC	Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.	Journal of clinical oncology 	2012	35
22240789	Paraffin	Matsumoto K	FGFR2 gene amplification and clinicopathological features in gastric cancer.	British journal of cancer	2012	35
22389665	Paraffin	Puget S	Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas.	PloS one	2012	67
22675169	Paraffin	Zeng Z	Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor.	Clinical cancer research 	2012	37
22977193	Paraffin	Terashima M	Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.	Clinical cancer research 	2012	63
23281836	Paraffin	Nie Y	Long non-coding RNA HOTAIR is an independent prognostic marker for nasopharyngeal carcinoma progression and survival.	Cancer science	2013	79
23391413	Paraffin	Voss JS	Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.	Human pathology	2013	41
23762387	Paraffin	Wang L	Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells.	PloS one	2013	64
23825651	Paraffin	Kluk MJ	Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.	PloS one	2013	32
23901018	Paraffin	Engstrøm MJ	Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients.	Breast cancer research and treatment	2013	38
24124529	Paraffin	Shi SJ	B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells.	PloS one	2013	37
24177760	Paraffin	Walline HM	High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods.	JAMA otolaryngology-- head & neck surgery	2013	31
24209998	Paraffin	Dey N	Wnt signaling in triple negative breast cancer is associated with metastasis.	BMC cancer	2013	43
24239208	Paraffin	Zhang JX	Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.	The Lancet. Oncology	2013	91
24548766	Paraffin	Yang CY	Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.	European journal of cancer	2014	79
24821878	Paraffin	Serup-Hansen E	Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal.	Journal of clinical oncology 	2014	30
25895031	Paraffin	Tang Y	The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.	Oncotarget	2015	45
26056355	Paraffin	Matamala N	Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection.	Clinical chemistry	2015	25
26489445	Paraffin	Kuboki Y	Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer.	Annals of oncology 	2016	12
26745875	Paraffin	Mafficini A	BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.	Oncotarget	2016	11
26823521	Paraffin	Castellsagué X	HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients.	Journal of the National Cancer Institute	2016	46
9660876	sphingosine 1-phosphate	Van Brocklyn JR	Dual actions of sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival.	The Journal of cell biology	1998	106
10880336	sphingosine 1-phosphate	Pyne S	Sphingosine 1-phosphate signalling in mammalian cells.	The Biochemical journal	2000	135
12531554	sphingosine 1-phosphate	Maceyka M	Sphingosine kinase, sphingosine-1-phosphate, and apoptosis.	Biochimica et biophysica acta	2002	115
12947396	sphingosine 1-phosphate	Kolesnick R	Radiation and ceramide-induced apoptosis.	Oncogene	2003	105
14522923	sphingosine 1-phosphate	French KJ	Discovery and evaluation of inhibitors of human sphingosine kinase.	Cancer research	2003	180
15013522	sphingosine 1-phosphate	Reynolds CP	Ceramide synthesis and metabolism as a target for cancer therapy.	Cancer letters	2004	84
15623571	sphingosine 1-phosphate	Pitson SM	Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling.	The Journal of experimental medicine	2005	85
16106218	sphingosine 1-phosphate	Van Brocklyn JR	Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines.	Journal of neuropathology and experimental neurology	2005	108
16194537	sphingosine 1-phosphate	Sarkar S	Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells.	FEBS letters	2005	73
16219683	sphingosine 1-phosphate	Chalfant CE	Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling.	Journal of cell science	2005	93
16319132	sphingosine 1-phosphate	Kawamori T	Sphingosine kinase 1 is up-regulated in colon carcinogenesis.	FASEB journal 	2006	75
17090686	sphingosine 1-phosphate	Oskouian B	Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is down-regulated in colon cancer.	Proceedings of the National Academy of Sciences of the United States of America	2006	76
17303574	sphingosine 1-phosphate	Baran Y	Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells.	The Journal of biological chemistry	2007	58
18058224	sphingosine 1-phosphate	Ruckhäberle E	Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer.	Breast cancer research and treatment	2008	95
18245172	sphingosine 1-phosphate	Tan W	An essential role for Rac1 in endothelial cell function and vascular development.	FASEB journal 	2008	77
18691013	sphingosine 1-phosphate	Shida D	Targeting SphK1 as a new strategy against cancer.	Current drug targets	2008	92
18713968	sphingosine 1-phosphate	Fabre S	FOXO1 regulates L-Selectin and a network of human T cell homing molecules downstream of phosphatidylinositol 3-kinase.	Journal of immunology	2008	84
18824518	sphingosine 1-phosphate	Kawamori T	Role for sphingosine kinase 1 in colon carcinogenesis.	FASEB journal 	2009	86
19729656	sphingosine 1-phosphate	Hait NC	Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate.	Science	2009	283
20110355	sphingosine 1-phosphate	Takabe K	Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2.	The Journal of biological chemistry	2010	85
20502000	sphingosine 1-phosphate	Kornhuber J	Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications.	Cellular physiology and biochemistry 	2010	42
20555359	sphingosine 1-phosphate	Pyne NJ	Sphingosine 1-phosphate and cancer.	Nature reviews. Cancer	2010	257
20577214	sphingosine 1-phosphate	Alvarez SE	Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2.	Nature	2010	228
21062159	sphingosine 1-phosphate	Ponnusamy S	Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance.	Future oncology	2010	62
21464128	sphingosine 1-phosphate	Lim KG	FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells.	The Journal of biological chemistry	2011	35
21546914	sphingosine 1-phosphate	Spiegel S	The outs and the ins of sphingosine-1-phosphate in immunity.	Nature reviews. Immunology	2011	192
22001186	sphingosine 1-phosphate	Maceyka M	Sphingosine-1-phosphate signaling and its role in disease.	Trends in cell biology	2012	208
22098666	sphingosine 1-phosphate	Bao M	Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma.	Liver international 	2012	32
22298596	sphingosine 1-phosphate	Nagahashi M	Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis.	Cancer research	2012	90
22397330	sphingosine 1-phosphate	Schnute ME	Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1.	The Biochemical journal	2012	65
23143305	sphingosine 1-phosphate	Çuburu N	Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.	The Journal of clinical investigation	2012	44
23290781	sphingosine 1-phosphate	Heffernan-Stroud LA	Sphingosine kinase 1 in cancer.	Advances in cancer research	2013	29
23615526	sphingosine 1-phosphate	Schneider G	Bioactive lipids S1P and C1P are prometastatic factors in human rhabdomyosarcoma, and their tissue levels increase in response to radio/chemotherapy.	Molecular cancer research 	2013	25
23638983	sphingosine 1-phosphate	Neubauer HA	Roles, regulation and inhibitors of sphingosine kinase 2.	The FEBS journal	2013	40
23861887	sphingosine 1-phosphate	Rex K	Sphingosine kinase activity is not required for tumor cell viability.	PloS one	2013	26
24140934	sphingosine 1-phosphate	Qin Z	Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.	Molecular cancer therapeutics	2014	22
24210073	sphingosine 1-phosphate	Nagahashi M	Sphingosine-1-phosphate in chronic intestinal inflammation and cancer.	Advances in biological regulation	2014	23
24587339	sphingosine 1-phosphate	Zhang Y	Sphingosine kinase 1 and cancer: a systematic review and meta-analysis.	PloS one	2014	26
24798342	sphingosine 1-phosphate	Heo MJ	microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression.	Oncotarget	2014	23
25347472	sphingosine 1-phosphate	Degagné E	Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs.	The Journal of clinical investigation	2014	34
26053034	sphingosine 1-phosphate	Hait NC	The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer.	Oncogenesis	2015	23
26082434	sphingosine 1-phosphate	Panneer Selvam S	Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation.	Science signaling	2015	20
26400757	sphingosine 1-phosphate	Ratajczak MZ	Emerging Strategies to Enhance Homing and Engraftment of Hematopoietic Stem Cells.	Stem cell reviews	2016	11
26540633	sphingosine 1-phosphate	Lu Z	Long non-coding RNA HULC promotes tumor angiogenesis in liver cancer by up-regulating sphingosine kinase 1 (SPHK1).	Oncotarget	2016	30
26970273	sphingosine 1-phosphate	Pyne S	Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances.	Progress in lipid research	2016	15
27771292	sphingosine 1-phosphate	Coant N	Ceramidases, roles in sphingolipid metabolism and in health and disease.	Advances in biological regulation	2017	6
27956387	sphingosine 1-phosphate	Powell JA	Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.	Blood	2017	5
28052056	sphingosine 1-phosphate	van der Weyden L	Genome-wide in vivo screen identifies novel host regulators of metastatic colonization.	Nature	2017	19
28108260	sphingosine 1-phosphate	Maiti A	Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.	Cellular signalling	2017	11
28420720	sphingosine 1-phosphate	Britten CD	A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.	Clinical cancer research 	2017	8
10815932	oxaliplatin	Ciardiello F	Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.	Clinical cancer research 	2000	110
11731512	oxaliplatin	Shirota Y	ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.	Journal of clinical oncology 	2001	112
14998849	oxaliplatin	Rubbia-Brandt L	Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.	Annals of oncology 	2004	141
15607931	oxaliplatin	Chaney SG	Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.	Critical reviews in oncology/hematology	2005	69
16622265	oxaliplatin	Zhu AX	Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.	Journal of clinical oncology 	2006	75
16857785	oxaliplatin	Yang AD	Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.	Clinical cancer research 	2006	139
17050875	oxaliplatin	Lenz HJ	Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.	Journal of clinical oncology 	2006	92
17060484	oxaliplatin	Rubbia-Brandt L	Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.	Annals of oncology 	2007	62
17401013	oxaliplatin	Ruzzo A	Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.	Journal of clinical oncology 	2007	71
17918158	oxaliplatin	Patel BB	Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R.	International journal of cancer	2008	51
18003960	oxaliplatin	Jonker DJ	Cetuximab for the treatment of colorectal cancer.	The New England journal of medicine	2007	391
18272912	oxaliplatin	Tol J	A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.	Annals of oncology 	2008	57
18316546	oxaliplatin	Martin LP	Platinum resistance: the role of DNA repair pathways.	Clinical cancer research 	2008	161
18390971	oxaliplatin	Sobrero AF	EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2008	175
18509181	oxaliplatin	Braun MS	Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.	Journal of clinical oncology 	2008	82
18718806	oxaliplatin	Sabbah M	Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.	Drug resistance updates 	2008	99
19114685	oxaliplatin	Hecht JR	A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.	Journal of clinical oncology 	2009	189
19147571	oxaliplatin	Meng RD	gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity.	Cancer research	2009	81
19196673	oxaliplatin	Tol J	Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.	The New England journal of medicine	2009	301
19217207	oxaliplatin	Costantino E	TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells.	Cancer letters	2009	47
19230702	oxaliplatin	Catalano V	Gastric cancer.	Critical reviews in oncology/hematology	2009	100
19383922	oxaliplatin	Kopetz S	Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.	Cancer research	2009	48
19786657	oxaliplatin	Chibaudel B	Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.	Journal of clinical oncology 	2009	58
19881547	oxaliplatin	Tesniere A	Immunogenic death of colon cancer cells treated with oxaliplatin.	Oncogene	2010	142
19884549	oxaliplatin	Richman SD	KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.	Journal of clinical oncology 	2009	152
20068564	oxaliplatin	Trarbach T	Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer.	British journal of cancer	2010	47
20068568	oxaliplatin	Lordick F	Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).	British journal of cancer	2010	41
20159940	oxaliplatin	Howell SB	Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs.	Molecular pharmacology	2010	71
20194850	oxaliplatin	Gérard JP	Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.	Journal of clinical oncology 	2010	120
20386463	oxaliplatin	Correale P	Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.	Journal of immunotherapy	2010	61
20421432	oxaliplatin	Zitvogel L	Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway.	Clinical cancer research 	2010	85
20498386	oxaliplatin	Chung KY	Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.	Journal of clinical oncology 	2010	52
20530282	oxaliplatin	McLeod HL	Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.	Journal of clinical oncology 	2010	50
20648559	oxaliplatin	Ning Y	Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models.	International journal of cancer	2011	87
21151176	oxaliplatin	Martins I	Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress.	Oncogene	2011	67
21228335	oxaliplatin	Bokemeyer C	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.	Annals of oncology 	2011	181
21430067	oxaliplatin	Gulhati P	mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.	Cancer research	2011	165
21555371	oxaliplatin	Asiedu MK	TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype.	Cancer research	2011	76
21606427	oxaliplatin	Aschele C	Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.	Journal of clinical oncology 	2011	133
21641636	oxaliplatin	Maughan TS	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.	Lancet	2011	219
21670084	oxaliplatin	Montero JC	Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.	Clinical cancer research 	2011	73
21684283	oxaliplatin	Tan IB	Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy.	Gastroenterology	2011	73
21709185	oxaliplatin	Crane CH	Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.	Journal of clinical oncology 	2011	68
21743023	oxaliplatin	Melisi D	Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.	Journal of the National Cancer Institute	2011	41
21825039	oxaliplatin	Ding ZB	Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation.	Clinical cancer research 	2011	38
22172905	oxaliplatin	Della Vittoria Scarpati G	A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.	International journal of radiation oncology, biology, physics	2012	43
22216841	oxaliplatin	Ebert MP	TFAP2E-DKK4 and chemoresistance in colorectal cancer.	The New England journal of medicine	2012	34
22226241	oxaliplatin	Heinemann V	Systemic treatment of advanced pancreatic cancer.	Cancer treatment reviews	2012	37
22391039	oxaliplatin	Ning Y	The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.	Molecular cancer therapeutics	2012	31
22473155	oxaliplatin	Tveit KM	Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.	Journal of clinical oncology 	2012	111
22473163	oxaliplatin	Dewdney A	Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).	Journal of clinical oncology 	2012	61
22474202	oxaliplatin	Alberts SR	Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.	JAMA	2012	99
22627104	oxaliplatin	Rödel C	Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.	The Lancet. Oncology	2012	100
22698403	oxaliplatin	O'Brien CA	ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21.	Cancer cell	2012	62
22811078	oxaliplatin	Wang L	First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.	Cancer	2013	36
22825584	oxaliplatin	Julien S	Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.	Clinical cancer research 	2012	77
22949147	oxaliplatin	Van Cutsem E	Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.	Journal of clinical oncology 	2012	212
23017669	oxaliplatin	Foxtrot Collaborative Group	Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.	The Lancet. Oncology	2012	42
23045248	oxaliplatin	Gavin PG	Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.	Clinical cancer research 	2012	60
23056401	oxaliplatin	Takahashi M	The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer.	PloS one	2012	46
23102520	oxaliplatin	Cervantes A	Current questions for the treatment of advanced gastric cancer.	Cancer treatment reviews	2013	35
23152059	oxaliplatin	Sacconi A	miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer.	Cell death & disease	2012	54
23168366	oxaliplatin	Bennouna J	Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.	The Lancet. Oncology	2013	205
23182985	oxaliplatin	Peeters M	Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.	Journal of clinical oncology 	2013	67
23510984	oxaliplatin	Cohn AL	A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.	Annals of oncology 	2013	30
23574723	oxaliplatin	Qian X	MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers.	Cell cycle	2013	41
23723074	oxaliplatin	Dong Y	Tumor suppressor functions of miR-133a in colorectal cancer.	Molecular cancer research 	2013	31
23788041	oxaliplatin	Bullock MD	Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression.	Cell death & disease	2013	31
23811849	oxaliplatin	Yamazaki T	Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists.	Cell death and differentiation	2014	40
23881988	oxaliplatin	Hurwitz HI	Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.	The oncologist	2013	31
24048758	oxaliplatin	Lordick F	Optimal chemotherapy for advanced gastric cancer: is there a global consensus?	Gastric cancer 	2014	23
24119443	oxaliplatin	Kjersem JB	Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.	Molecular oncology	2014	33
24122958	oxaliplatin	Huang D	miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer.	Journal of cellular biochemistry	2014	26
24145123	oxaliplatin	Zhou Y	miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.	Molecular oncology	2014	40
24152956	oxaliplatin	Mahaseth H	Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.	Pancreas	2013	35
24225157	oxaliplatin	Yamada Y	Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.	The Lancet. Oncology	2013	37
24277452	oxaliplatin	Zeng ZL	Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer.	Clinical cancer research 	2014	23
24356622	oxaliplatin	Peeters M	Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.	Annals of oncology 	2014	23
24440715	oxaliplatin	Minett MS	Pain without nociceptors? Nav1.7-independent pain mechanisms.	Cell reports	2014	32
24448818	oxaliplatin	Cristóbal I	PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.	Molecular cancer therapeutics	2014	25
24465408	oxaliplatin	Nangia-Makker P	Metformin: a potential therapeutic agent for recurrent colon cancer.	PloS one	2014	30
24585723	oxaliplatin	Goldstein J	Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).	Annals of oncology 	2014	32
24717919	oxaliplatin	Primrose J	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.	The Lancet. Oncology	2014	46
25316259	oxaliplatin	Yamada Y	Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.	Annals of oncology 	2015	37
25446103	oxaliplatin	Wan LY	miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1.	Biochemical and biophysical research communications	2015	16
25616665	oxaliplatin	Zhang Y	MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer.	The Journal of biological chemistry	2015	22
25632066	oxaliplatin	Chen JS	A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.	Annals of oncology 	2015	21
25778491	oxaliplatin	Liu W	HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway.	Cancer biology & therapy	2015	16
25862517	oxaliplatin	Simkens LH	Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.	Lancet	2015	49
25877855	oxaliplatin	Tabernero J	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.	The Lancet. Oncology	2015	92
25918279	oxaliplatin	Heestand GM	Approach to patients with pancreatic cancer without detectable metastases.	Journal of clinical oncology 	2015	16
25918287	oxaliplatin	Dienstmann R	Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients.	Journal of clinical oncology 	2015	38
25924065	oxaliplatin	Shalapour S	Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.	Nature	2015	50
25943534	oxaliplatin	Stewart R	Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.	Cancer immunology research	2015	20
25979230	oxaliplatin	James MI	Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy.	Cancer letters	2015	16
26189067	oxaliplatin	Rödel C	Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.	The Lancet. Oncology	2015	41
26338525	oxaliplatin	Cremolini C	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.	The Lancet. Oncology	2015	55
26387536	oxaliplatin	Blanco FF	The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.	Oncogene	2016	19
26540314	oxaliplatin	Leone F	Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).	Cancer	2016	11
26541320	oxaliplatin	Goldstein DA	Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.	Clinical colorectal cancer	2016	11
26626800	oxaliplatin	Shitara K	Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.	Gastric cancer 	2017	7
26628478	oxaliplatin	Hecht JR	Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.	Journal of clinical oncology 	2016	77
26719345	oxaliplatin	Santoro V	Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer.	Journal of the National Cancer Institute	2016	11
26830752	oxaliplatin	Kamisawa T	Pancreatic cancer.	Lancet	2016	93
26872698	oxaliplatin	Pfirschke C	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.	Immunity	2016	49
27055731	oxaliplatin	Nywening TM	Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.	The Lancet. Oncology	2016	40
27633443	oxaliplatin	Yue B	Linc00152 Functions as a Competing Endogenous RNA to Confer Oxaliplatin Resistance and Holds Prognostic Values in Colon Cancer.	Molecular therapy 	2016	22
27729273	oxaliplatin	Yin X	Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells.	Gene	2017	7
27856123	oxaliplatin	Sunakawa Y	Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.	Clinical colorectal cancer	2017	5
28069878	oxaliplatin	Li P	MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2.	Molecular cancer therapeutics	2017	20
28094194	oxaliplatin	Hickish T	MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.	The Lancet. Oncology	2017	6
28270698	oxaliplatin	Alexander JL	Gut microbiota modulation of chemotherapy efficacy and toxicity.	Nature reviews. Gastroenterology & hepatology	2017	9
11474661	Immunotoxins	Kreitman RJ	Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.	The New England journal of medicine	2001	96
15217923	Immunotoxins	Hassan R	Mesothelin: a new target for immunotherapy.	Clinical cancer research 	2004	126
16061911	Immunotoxins	Kreitman RJ	Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.	Journal of clinical oncology 	2005	80
17025272	Immunotoxins	Kreitman RJ	Immunotoxins for targeted cancer therapy.	The AAPS journal	2006	79
17785569	Immunotoxins	Hassan R	Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.	Clinical cancer research 	2007	144
17878392	Immunotoxins	Powell DJ Jr	Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.	Journal of immunology	2007	56
18403491	Immunotoxins	Sampson JH	Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.	Neuro-oncology	2008	55
20215554	Immunotoxins	Wayne AS	Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.	Clinical cancer research 	2010	57
21034418	Immunotoxins	Seon BK	Endoglin-targeted cancer therapy.	Current drug delivery	2011	47
22351743	Immunotoxins	Kelly RJ	Mesothelin-targeted agents in clinical trials and in preclinical development.	Molecular cancer therapeutics	2012	42
22474489	Immunotoxins	Ahmad ZA	scFv antibody: principles and clinical application.	Clinical & developmental immunology	2012	75
24824231	Immunotoxins	Pastan I	Discovery of mesothelin and exploiting it as a target for immunotherapy.	Cancer research	2014	55
25239937	Immunotoxins	Alewine C	Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.	Molecular cancer therapeutics	2014	28
26864110	Immunotoxins	Mazor R	Immunogenicity of therapeutic recombinant immunotoxins.	Immunological reviews	2016	19
11278274	epigallocatechin gallate	Nam S	Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo.	The Journal of biological chemistry	2001	113
14633667	epigallocatechin gallate	Fang MZ	Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines.	Cancer research	2003	217
15585581	epigallocatechin gallate	Palmer AE	Bcl-2-mediated alterations in endoplasmic reticulum Ca2+ analyzed with an improved genetically encoded fluorescent sensor.	Proceedings of the National Academy of Sciences of the United States of America	2004	211
15814656	epigallocatechin gallate	Shimizu M	(-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells.	Clinical cancer research 	2005	69
17570133	epigallocatechin gallate	Berletch JB	Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG.	Journal of cellular biochemistry	2008	64
17942911	epigallocatechin gallate	Pyrko P	The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.	Cancer research	2007	125
17998943	epigallocatechin gallate	Siddiqui IA	Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.	Oncogene	2008	56
19147572	epigallocatechin gallate	Choi KC	Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation.	Cancer research	2009	73
19269153	epigallocatechin gallate	Tsang WP	Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells.	The Journal of nutritional biochemistry	2010	81
20015867	epigallocatechin gallate	Balasubramanian S	The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival.	Carcinogenesis	2010	42
20423306	epigallocatechin gallate	Li Y	Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components.	Current medicinal chemistry	2010	52
21177307	epigallocatechin gallate	Siddiqui IA	Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer.	FASEB journal 	2011	40
21209038	epigallocatechin gallate	Nandakumar V	(-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells.	Carcinogenesis	2011	69
21499987	epigallocatechin gallate	Scapagnini G	Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders.	Molecular neurobiology	2011	57
21796625	epigallocatechin gallate	Tang SN	Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics.	International journal of cancer	2012	50
21798853	epigallocatechin gallate	Choudhury SR	(-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells.	Carcinogenesis	2011	41
21827739	epigallocatechin gallate	Singh BN	Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications.	Biochemical pharmacology	2011	171
21965273	epigallocatechin gallate	Wang H	Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1α.	Carcinogenesis	2011	45
23201840	epigallocatechin gallate	Du GJ	Epigallocatechin Gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea.	Nutrients	2012	33
24481780	epigallocatechin gallate	Deb G	Epigenetic induction of tissue inhibitor of matrix metalloproteinase-3 by green tea polyphenols in breast cancer cells.	Molecular carcinogenesis	2015	16
24518414	epigallocatechin gallate	Saldanha SN	Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate.	Experimental cell research	2014	22
25550533	epigallocatechin gallate	Chung SS	Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling.	Anticancer research	2015	24
26499783	epigallocatechin gallate	Zhu K	Green tea polyphenol EGCG suppresses osteosarcoma cell growth through upregulating miR-1.	Tumour biology 	2016	10
26930714	epigallocatechin gallate	Toden S	Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer.	Oncotarget	2016	14
26933999	epigallocatechin gallate	Yu CC	Suppression of miR-204 enables oral squamous cell carcinomas to promote cancer stemness, EMT traits, and lymph node metastasis.	Oncotarget	2016	15
27200496	epigallocatechin gallate	Yuan CH	Epigallocatechin gallate sensitizes cisplatin-resistant oral cancer CAR cell apoptosis and autophagy through stimulating AKT/STAT3 pathway and suppressing multidrug resistance 1 signaling.	Environmental toxicology	2017	10
7559628	Curcumin	Singh S	Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) corrected.	The Journal of biological chemistry	1995	214
11448902	Curcumin	Sharma RA	Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer.	Clinical cancer research 	2001	133
11815407	Curcumin	Ireson CR	Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine.	Cancer epidemiology, biomarkers & prevention 	2002	86
12393461	Curcumin	Bharti AC	Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis.	Blood	2003	132
12466962	Curcumin	Jaiswal AS	Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells.	Oncogene	2002	91
12680238	Curcumin	Aggarwal BB	Anticancer potential of curcumin: preclinical and clinical studies.	Anticancer research	2003	283
15070700	Curcumin	Bharti AC	Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis.	Blood	2004	82
15476283	Curcumin	Li L	Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis.	Cancer	2004	76
15668484	Curcumin	Garcea G	Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences.	Cancer epidemiology, biomarkers & prevention 	2005	83
15879598	Curcumin	Fang J	Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity.	The Journal of biological chemistry	2005	70
16023083	Curcumin	Shishodia S	Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma.	Biochemical pharmacology	2005	84
16092118	Curcumin	Li L	Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis.	Cancer	2005	99
16219905	Curcumin	Aggarwal S	Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation.	Molecular pharmacology	2006	104
16243823	Curcumin	Aggarwal BB	Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.	Clinical cancer research 	2005	105
16628653	Curcumin	Wang Z	Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells.	Cancer	2006	82
16757216	Curcumin	Cruz-Correa M	Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis.	Clinical gastroenterology and hepatology 	2006	72
17211725	Curcumin	Jagetia GC	"Spicing up" of the immune system by curcumin.	Journal of clinical immunology	2007	88
17332326	Curcumin	Li M	Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.	Cancer research	2007	70
17395690	Curcumin	Aoki H	Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways.	Molecular pharmacology	2007	130
17439648	Curcumin	Bisht S	Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy.	Journal of nanobiotechnology	2007	146
17786026	Curcumin	Shinojima N	Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy.	Autophagy	2007	84
17900536	Curcumin	Goel A	Curcumin as "Curecumin": from kitchen to clinic.	Biochemical pharmacology	2008	265
18347134	Curcumin	Sun M	Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells.	Molecular cancer therapeutics	2008	110
18370854	Curcumin	Strimpakos AS	Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials.	Antioxidants & redox signaling	2008	84
18462866	Curcumin	Anand P	Curcumin and cancer: an "old-age" disease with an "age-old" solution.	Cancer letters	2008	158
18577686	Curcumin	Kasinski AL	Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin.	Molecular pharmacology	2008	57
18628464	Curcumin	Dhillon N	Phase II trial of curcumin in patients with advanced pancreatic cancer.	Clinical cancer research 	2008	216
18834508	Curcumin	Sa G	Anti cancer effects of curcumin: cycle of life and death.	Cell division	2008	51
19110321	Curcumin	Aggarwal BB	Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets.	Trends in pharmacological sciences	2009	156
19112019	Curcumin	Liu Z	Curcumin is a potent DNA hypomethylation agent.	Bioorganic & medicinal chemistry letters	2009	53
19278222	Curcumin	Ganta S	Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells.	Molecular pharmaceutics	2009	66
19516890	Curcumin	Gupta V	Fabrication and characterization of silk fibroin-derived curcumin nanoparticles for cancer therapy.	International journal of nanomedicine	2009	46
19590964	Curcumin	Ravindran J	Curcumin and cancer cells: how many ways can curry kill tumor cells selectively?	The AAPS journal	2009	125
19908170	Curcumin	Yang J	Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells.	Medical oncology	2010	46
20420526	Curcumin	Aggarwal BB	Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals.	Annual review of nutrition	2010	66
20726007	Curcumin	Shehzad A	Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials.	Archiv der Pharmazie	2010	82
20815812	Curcumin	Mudduluru G	Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer.	Bioscience reports	2011	60
20924967	Curcumin	Goel A	Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs.	Nutrition and cancer	2010	83
21193839	Curcumin	Lim KJ	A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors.	Cancer biology & therapy	2011	41
21299897	Curcumin	Wilken R	Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.	Molecular cancer	2011	111
21836020	Curcumin	Saini S	Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer.	Cancer prevention research	2011	43
21938566	Curcumin	Shu L	Epigenetic CpG demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells.	The AAPS journal	2011	37
22030090	Curcumin	Tu SP	Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth.	Cancer prevention research	2012	40
22108826	Curcumin	Bao B	Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression.	Cancer research	2012	95
22637745	Curcumin	Soubani O	Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer.	Carcinogenesis	2012	30
22662257	Curcumin	Yang CL	Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway.	PloS one	2012	40
22782502	Curcumin	Haussler MR	Molecular mechanisms of vitamin D action.	Calcified tissue international	2013	118
22952749	Curcumin	Bao B	Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF.	PloS one	2012	43
22992310	Curcumin	Roy S	Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF.	Journal of hematology & oncology	2012	44
22996381	Curcumin	Shishodia S	Molecular mechanisms of curcumin action: gene expression.	BioFactors	2013	28
23076367	Curcumin	Huang T	Curcumin inhibits LPS-induced EMT through downregulation of NF-κB-Snail signaling in breast cancer cells.	Oncology reports	2013	26
23143785	Curcumin	Gupta SC	Therapeutic roles of curcumin: lessons learned from clinical trials.	The AAPS journal	2013	154
23303697	Curcumin	Shehzad A	Molecular mechanisms of curcumin action: signal transduction.	BioFactors	2013	47
23303705	Curcumin	Shehzad A	Curcumin in various cancers.	BioFactors	2013	37
23425071	Curcumin	Aggarwal BB	Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers.	British journal of pharmacology	2013	42
23451189	Curcumin	Shakibaei M	Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and Src protein kinase signaling pathways.	PloS one	2013	30
23457487	Curcumin	Yu J	Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia.	PloS one	2013	31
23548270	Curcumin	Yu CC	miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer.	Cancer research	2013	40
23894315	Curcumin	Roy S	Difluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21.	PloS one	2013	27
24368738	Curcumin	Heger M	The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer.	Pharmacological reviews	2014	32
24371229	Curcumin	Charpentier MS	Curcumin targets breast cancer stem-like cells with microtentacles that persist in mammospheres and promote reattachment.	Cancer research	2014	27
24626093	Curcumin	Kantara C	Curcumin promotes autophagic survival of a subset of colon cancer stem cells, which are ablated by DCLK1-siRNA.	Cancer research	2014	26
25256401	Curcumin	Ma J	Curcumin inhibits cell growth and invasion through up-regulation of miR-7 in pancreatic cancer cells.	Toxicology letters	2014	26
25444916	Curcumin	Ye M	Curcumin promotes apoptosis by activating the p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer.	Cancer letters	2015	33
25653233	Curcumin	Toden S	Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer.	Carcinogenesis	2015	21
25667441	Curcumin	Vallianou NG	Potential anticancer properties and mechanisms of action of curcumin.	Anticancer research	2015	21
25714022	Curcumin	Zou P	ROS generation mediates the anti-cancer effects of WZ35 via activating JNK and ER stress apoptotic pathways in gastric cancer.	Oncotarget	2015	20
25980682	Curcumin	Kim B	Curcumin induces ER stress-mediated apoptosis through selective generation of reactive oxygen species in cervical cancer cells.	Molecular carcinogenesis	2016	13
26046466	Curcumin	Wang L	Curcumin suppresses cell growth and invasion and induces apoptosis by down-regulation of Skp2 pathway in glioma cells.	Oncotarget	2015	21
26116834	Curcumin	Taverna S	Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21.	Oncotarget	2015	15
26166196	Curcumin	Zhao Z	Curcumin induces apoptosis in pancreatic cancer cells through the induction of forkhead box O1 and inhibition of the PI3K/Akt pathway.	Molecular medicine reports	2015	17
26351877	Curcumin	Jin H	Curcumin inhibits cell proliferation and induces apoptosis of human non-small cell lung cancer cells through the upregulation of miR-192-5p and suppression of PI3K/Akt signaling pathway.	Oncology reports	2015	20
26703799	Curcumin	Suresh R	The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.	Advances in experimental medicine and biology	2016	14
26752181	Curcumin	Guan F	Curcumin Suppresses Proliferation and Migration of MDA-MB-231 Breast Cancer Cells through Autophagy-Dependent Akt Degradation.	PloS one	2016	10
27866850	Curcumin	Lim SO	Deubiquitination and Stabilization of PD-L1 by CSN5.	Cancer cell	2016	18
28236692	Curcumin	Gawde KA	Synthesis and characterization of folate decorated albumin bio-conjugate nanoparticles loaded with a synthetic curcumin difluorinated analogue.	Journal of colloid and interface science	2017	7
7522959	bicalutamide	Culig Z	Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.	Cancer research	1994	162
10363963	bicalutamide	Taplin ME	Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.	Cancer research	1999	118
15833816	bicalutamide	Bohl CE	Structural basis for antagonism and resistance of bicalutamide in prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2005	76
17566103	bicalutamide	Nickols NG	Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide.	Proceedings of the National Academy of Sciences of the United States of America	2007	71
19359544	bicalutamide	Tran C	Development of a second-generation antiandrogen for treatment of advanced prostate cancer.	Science	2009	469
19366804	bicalutamide	Steinkamp MP	Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.	Cancer research	2009	64
21633166	bicalutamide	Lehmann BD	Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.	The Journal of clinical investigation	2011	890
22266222	bicalutamide	Clegg NJ	ARN-509: a novel antiandrogen for prostate cancer treatment.	Cancer research	2012	107
22355276	bicalutamide	Yamashita S	ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.	Neoplasia	2012	44
22411952	bicalutamide	Richards J	Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.	Cancer research	2012	57
23687298	bicalutamide	Lin TH	Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.	The Journal of biological chemistry	2013	33
23928703	bicalutamide	Lin TH	Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.	Cell death & disease	2013	38
23965901	bicalutamide	Gucalp A	Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.	Clinical cancer research 	2013	104
23966621	bicalutamide	Thomas C	Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.	Molecular cancer therapeutics	2013	36
24451109	bicalutamide	Cochrane DR	Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.	Breast cancer research 	2014	60
24874833	bicalutamide	Yu Z	Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.	Clinical cancer research 	2014	23
24888812	bicalutamide	Arce-Salinas C	Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature.	Journal of clinical oncology 	2016	15
25103565	bicalutamide	Lehmann BD	PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.	Breast cancer research 	2014	38
26774508	bicalutamide	Shore ND	Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.	The Lancet. Oncology	2016	20
26811535	bicalutamide	Penson DF	Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.	Journal of clinical oncology 	2016	22
27503005	bicalutamide	Statz CM	mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review.	Targeted oncology	2017	7
28146658	bicalutamide	Shipley WU	Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.	The New England journal of medicine	2017	15
10455009	Poly Adenosine Diphosphate Ribose	D'Amours D	Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions.	The Biochemical journal	1999	444
10811897	Poly Adenosine Diphosphate Ribose	Cahir-McFarland ED	NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells.	Proceedings of the National Academy of Sciences of the United States of America	2000	97
11350913	Poly Adenosine Diphosphate Ribose	Sunwoo JB	Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.	Clinical cancer research 	2001	99
12052432	Poly Adenosine Diphosphate Ribose	Bernstein C	DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis.	Mutation research	2002	92
12748298	Poly Adenosine Diphosphate Ribose	Okano S	Spatial and temporal cellular responses to single-strand breaks in human cells.	Molecular and cellular biology	2003	113
15077142	Poly Adenosine Diphosphate Ribose	Cregan SP	Role of AIF in caspase-dependent and caspase-independent cell death.	Oncogene	2004	120
15118763	Poly Adenosine Diphosphate Ribose	Chawla-Sarkar M	Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis.	Cell death and differentiation	2004	92
15833866	Poly Adenosine Diphosphate Ribose	Chinnaiyan P	Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).	Cancer research	2005	89
16314846	Poly Adenosine Diphosphate Ribose	Gordon S	Transcription factor YY1: structure, function, and therapeutic implications in cancer biology.	Oncogene	2006	202
17431114	Poly Adenosine Diphosphate Ribose	Liu TJ	Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.	Molecular cancer therapeutics	2007	59
17825467	Poly Adenosine Diphosphate Ribose	Hsiao SJ	Tankyrase function at telomeres, spindle poles, and beyond.	Biochimie	2008	65
17891139	Poly Adenosine Diphosphate Ribose	Kanai M	Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation.	Nature cell biology	2007	59
18172500	Poly Adenosine Diphosphate Ribose	Ahel I	Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins.	Nature	2008	142
18343102	Poly Adenosine Diphosphate Ribose	Martin SA	DNA repair deficiency as a therapeutic target in cancer.	Current opinion in genetics & development	2008	59
18413764	Poly Adenosine Diphosphate Ribose	Huang S	BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.	Cancer research	2008	55
18575892	Poly Adenosine Diphosphate Ribose	Campeau PM	Hereditary breast cancer: new genetic developments, new therapeutic avenues.	Human genetics	2008	66
18644251	Poly Adenosine Diphosphate Ribose	Lord CJ	Targeted therapy for cancer using PARP inhibitors.	Current opinion in pharmacology	2008	82
18759128	Poly Adenosine Diphosphate Ribose	Berger W	Vaults and the major vault protein: novel roles in signal pathway regulation and immunity.	Cellular and molecular life sciences 	2009	52
19661379	Poly Adenosine Diphosphate Ribose	Ahel D	Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1.	Science	2009	189
19808869	Poly Adenosine Diphosphate Ribose	Bolderson E	Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair.	Clinical cancer research 	2009	66
20049735	Poly Adenosine Diphosphate Ribose	Mendes-Pereira AM	Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.	EMBO molecular medicine	2009	183
20133863	Poly Adenosine Diphosphate Ribose	Hegan DC	Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130.	Proceedings of the National Academy of Sciences of the United States of America	2010	50
20142589	Poly Adenosine Diphosphate Ribose	Zarghooni M	Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets.	Journal of clinical oncology 	2010	94
20609467	Poly Adenosine Diphosphate Ribose	Tutt A	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.	Lancet	2010	435
20609468	Poly Adenosine Diphosphate Ribose	Audeh MW	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.	Lancet	2010	336
20679605	Poly Adenosine Diphosphate Ribose	Veeck J	BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors.	Journal of clinical oncology 	2010	40
20693977	Poly Adenosine Diphosphate Ribose	Polo SE	Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4.	The EMBO journal	2010	124
20823146	Poly Adenosine Diphosphate Ribose	Redon CE	Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.	Clinical cancer research 	2010	84
20858840	Poly Adenosine Diphosphate Ribose	Anders CK	Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.	Clinical cancer research 	2010	51
20877296	Poly Adenosine Diphosphate Ribose	Carey L	Triple-negative breast cancer: disease entity or title of convenience?	Nature reviews. Clinical oncology	2010	197
20944090	Poly Adenosine Diphosphate Ribose	Dedes KJ	PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.	Science translational medicine	2010	66
21050424	Poly Adenosine Diphosphate Ribose	Chacón RD	Triple-negative breast cancer.	Breast cancer research 	2010	63
21102435	Poly Adenosine Diphosphate Ribose	Hayakawa S	ZAPS is a potent stimulator of signaling mediated by the RNA helicase RIG-I during antiviral responses.	Nature immunology	2011	47
21205831	Poly Adenosine Diphosphate Ribose	Yap TA	Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.	CA	2011	54
21458083	Poly Adenosine Diphosphate Ribose	Garrett MD	Anticancer therapy with checkpoint inhibitors: what, where and when?	Trends in pharmacological sciences	2011	63
21478859	Poly Adenosine Diphosphate Ribose	Zhang Y	RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling.	Nature cell biology	2011	103
21555554	Poly Adenosine Diphosphate Ribose	Krawczyk PM	Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.	Proceedings of the National Academy of Sciences of the United States of America	2011	49
21646373	Poly Adenosine Diphosphate Ribose	Ohanna M	Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS).	Genes & development	2011	57
21706030	Poly Adenosine Diphosphate Ribose	Johnson N	Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.	Nature medicine	2011	69
21821475	Poly Adenosine Diphosphate Ribose	Helleday T	The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.	Molecular oncology	2011	141
21963855	Poly Adenosine Diphosphate Ribose	Medema RH	Checkpoint control and cancer.	Oncogene	2012	46
22344029	Poly Adenosine Diphosphate Ribose	Adamson B	A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response.	Nature cell biology	2012	123
22401667	Poly Adenosine Diphosphate Ribose	Kummar S	Advances in using PARP inhibitors to treat cancer.	BMC medicine	2012	39
22416035	Poly Adenosine Diphosphate Ribose	Williamson CT	Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.	EMBO molecular medicine	2012	41
22460902	Poly Adenosine Diphosphate Ribose	Garnett MJ	Systematic identification of genomic markers of drug sensitivity in cancer cells.	Nature	2012	620
22464251	Poly Adenosine Diphosphate Ribose	Park DJ	Rare mutations in XRCC2 increase the risk of breast cancer.	American journal of human genetics	2012	57
22472897	Poly Adenosine Diphosphate Ribose	Galia A	PARP-1 protein expression in glioblastoma multiforme.	European journal of histochemistry 	2012	32
22496617	Poly Adenosine Diphosphate Ribose	Reiner T	Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents.	Neoplasia	2012	39
22582261	Poly Adenosine Diphosphate Ribose	Langelier MF	Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1.	Science	2012	100
22641215	Poly Adenosine Diphosphate Ribose	Tobin LA	Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.	Oncogene	2013	30
22669911	Poly Adenosine Diphosphate Ribose	Gagné JP	Quantitative proteomics profiling of the poly(ADP-ribose)-related response to genotoxic stress.	Nucleic acids research	2012	46
22711857	Poly Adenosine Diphosphate Ribose	Alsop K	BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.	Journal of clinical oncology 	2012	170
22869595	Poly Adenosine Diphosphate Ribose	Daniel JA	Loss of ATM kinase activity leads to embryonic lethality in mice.	The Journal of cell biology	2012	41
22941645	Poly Adenosine Diphosphate Ribose	Krietsch J	PARP activation regulates the RNA-binding protein NONO in the DNA damage response to DNA double-strand breaks.	Nucleic acids research	2012	47
22993403	Poly Adenosine Diphosphate Ribose	Schiewer MJ	Dual roles of PARP-1 promote cancer growth and progression.	Cancer discovery	2012	74
23071261	Poly Adenosine Diphosphate Ribose	Lok BH	Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement.	Clinical cancer research 	2012	34
23197039	Poly Adenosine Diphosphate Ribose	Riffell JL	Tankyrase-targeted therapeutics: expanding opportunities in the PARP family.	Nature reviews. Drug discovery	2012	55
23333033	Poly Adenosine Diphosphate Ribose	Langelier MF	PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis.	Current opinion in structural biology	2013	44
23337117	Poly Adenosine Diphosphate Ribose	Grotsky DA	BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells.	The Journal of cell biology	2013	26
23481255	Poly Adenosine Diphosphate Ribose	Sharifi R	Deficiency of terminal ADP-ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease.	The EMBO journal	2013	66
23634208	Poly Adenosine Diphosphate Ribose	Pettitt SJ	A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity.	PloS one	2013	35
23656790	Poly Adenosine Diphosphate Ribose	Bisso A	Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer.	Cell cycle	2013	33
23680151	Poly Adenosine Diphosphate Ribose	Li M	Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation.	Cancer cell	2013	69
23744078	Poly Adenosine Diphosphate Ribose	Young LC	Kdm4b histone demethylase is a DNA damage response protein and confers a survival advantage following γ-irradiation.	The Journal of biological chemistry	2013	39
23917125	Poly Adenosine Diphosphate Ribose	Vyas S	A systematic analysis of the PARP protein family identifies new functions critical for cell physiology.	Nature communications	2013	40
24202391	Poly Adenosine Diphosphate Ribose	Lord CJ	Mechanisms of resistance to therapies targeting BRCA-mutant cancers.	Nature medicine	2013	94
24225019	Poly Adenosine Diphosphate Ribose	Lee JM	PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.	Annals of oncology 	2014	65
24418846	Poly Adenosine Diphosphate Ribose	Liu K	MIR34A regulates autophagy and apoptosis by targeting HMGB1 in the retinoblastoma cell.	Autophagy	2014	23
24450632	Poly Adenosine Diphosphate Ribose	Curtin N	PARP inhibitors for anticancer therapy.	Biochemical Society transactions	2014	20
24598253	Poly Adenosine Diphosphate Ribose	Beck C	PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways.	Nucleic acids research	2014	22
24726141	Poly Adenosine Diphosphate Ribose	Piao L	The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells.	Neoplasia	2014	28
24778210	Poly Adenosine Diphosphate Ribose	Li X	Histone demethylase KDM5B is a key regulator of genome stability.	Proceedings of the National Academy of Sciences of the United States of America	2014	25
24928857	Poly Adenosine Diphosphate Ribose	Langelier MF	PARP-2 and PARP-3 are selectively activated by 5' phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1.	Nucleic acids research	2014	32
25017100	Poly Adenosine Diphosphate Ribose	Beck C	Poly(ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3.	Experimental cell research	2014	54
25030905	Poly Adenosine Diphosphate Ribose	Britton S	DNA damage triggers SAF-A and RNA biogenesis factors exclusion from chromatin coupled to R-loops removal.	Nucleic acids research	2014	34
25131201	Poly Adenosine Diphosphate Ribose	Khurana S	A macrohistone variant links dynamic chromatin compaction to BRCA1-dependent genome maintenance.	Cell reports	2014	52
25220415	Poly Adenosine Diphosphate Ribose	Li M	The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy.	Oncogene	2015	24
25252691	Poly Adenosine Diphosphate Ribose	Hu Y	PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.	Cancer discovery	2014	24
25286972	Poly Adenosine Diphosphate Ribose	Sonnenblick A	An update on PARP inhibitors--moving to the adjuvant setting.	Nature reviews. Clinical oncology	2015	70
25422887	Poly Adenosine Diphosphate Ribose	Gong Z	LOC401317, a p53-regulated long non-coding RNA, inhibits cell proliferation and induces apoptosis in the nasopharyngeal carcinoma cell line HNE2.	PloS one	2014	33
25456381	Poly Adenosine Diphosphate Ribose	Brewster AM	Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.	The Lancet. Oncology	2014	23
25547115	Poly Adenosine Diphosphate Ribose	Li N	Poly-ADP ribosylation of PTEN by tankyrases promotes PTEN degradation and tumor growth.	Genes & development	2015	16
25725131	Poly Adenosine Diphosphate Ribose	Walsh CS	Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.	Gynecologic oncology	2015	22
25733714	Poly Adenosine Diphosphate Ribose	Zellweger R	Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells.	The Journal of cell biology	2015	91
25758918	Poly Adenosine Diphosphate Ribose	Shen Y	Trapping Poly(ADP-Ribose) Polymerase.	The Journal of pharmacology and experimental therapeutics	2015	20
26091341	Poly Adenosine Diphosphate Ribose	Feng FY	Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function.	Molecular cell	2015	32
26100884	Poly Adenosine Diphosphate Ribose	Henneman L	Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2015	15
26268938	Poly Adenosine Diphosphate Ribose	Livraghi L	PARP inhibitors in the management of breast cancer: current data and future prospects.	BMC medicine	2015	41
26373281	Poly Adenosine Diphosphate Ribose	Ramamoorthy M	Loss of ATRX Suppresses Resolution of Telomere Cohesion to Control Recombination in ALT Cancer Cells.	Cancer cell	2015	17
26590714	Poly Adenosine Diphosphate Ribose	O'Connor MJ	Targeting the DNA Damage Response in Cancer.	Molecular cell	2015	87
26594843	Poly Adenosine Diphosphate Ribose	Esposito MT	Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.	Nature medicine	2015	17
26626479	Poly Adenosine Diphosphate Ribose	Eustermann S	Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1.	Molecular cell	2015	21
26677438	Poly Adenosine Diphosphate Ribose	Yadav BS	Biomarkers in triple negative breast cancer: A review.	World journal of clinical oncology	2015	15
26759228	Poly Adenosine Diphosphate Ribose	Park KJ	Prospero homeobox 1 mediates the progression of gastric cancer by inducing tumor cell proliferation and lymphangiogenesis.	Gastric cancer 	2017	5
26779812	Poly Adenosine Diphosphate Ribose	Du Y	Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.	Nature medicine	2016	22
26811421	Poly Adenosine Diphosphate Ribose	Moudry P	TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity.	The Journal of cell biology	2016	12
27240471	Poly Adenosine Diphosphate Ribose	Wei H	Functions of PARylation in DNA Damage Repair Pathways.	Genomics, proteomics & bioinformatics	2016	14
27678458	Poly Adenosine Diphosphate Ribose	Stover EH	Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.	Clinical cancer research 	2016	13
28003236	Poly Adenosine Diphosphate Ribose	Brown JS	Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.	Cancer discovery	2017	20
28186131	Poly Adenosine Diphosphate Ribose	Viziteu E	RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.	Leukemia	2017	5
28241136	Poly Adenosine Diphosphate Ribose	Drané P	TIRR regulates 53BP1 by masking its histone methyl-lysine binding function.	Nature	2017	7
28288110	Poly Adenosine Diphosphate Ribose	Davies H	HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.	Nature medicine	2017	10
28302823	Poly Adenosine Diphosphate Ribose	Lord CJ	PARP inhibitors: Synthetic lethality in the clinic.	Science	2017	35
28676700	Poly Adenosine Diphosphate Ribose	Ray Chaudhuri A	The multifaceted roles of PARP1 in DNA repair and chromatin remodelling.	Nature reviews. Molecular cell biology	2017	11
10051603	phosphatidylinositol 3,4,5-triphosphate	Ramaswamy S	Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway.	Proceedings of the National Academy of Sciences of the United States of America	1999	179
10400993	phosphatidylinositol 3,4,5-triphosphate	Marsh DJ	PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.	Human molecular genetics	1999	98
11559746	phosphatidylinositol 3,4,5-triphosphate	Yamada KM	Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis.	Journal of cell science	2001	108
11707428	phosphatidylinositol 3,4,5-triphosphate	Vazquez F	Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex.	The Journal of biological chemistry	2001	115
11726926	phosphatidylinositol 3,4,5-triphosphate	Backman SA	Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease.	Nature genetics	2001	139
11882383	phosphatidylinositol 3,4,5-triphosphate	Nicholson KM	The protein kinase B/Akt signalling pathway in human malignancy.	Cellular signalling	2002	313
12040186	phosphatidylinositol 3,4,5-triphosphate	Cantley LC	The phosphoinositide 3-kinase pathway.	Science	2002	1285
12743604	phosphatidylinositol 3,4,5-triphosphate	Bianco R	Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.	Oncogene	2003	92
12946627	phosphatidylinositol 3,4,5-triphosphate	Sulis ML	PTEN: from pathology to biology.	Trends in cell biology	2003	97
14976311	phosphatidylinositol 3,4,5-triphosphate	Raftopoulou M	Regulation of cell migration by the C2 domain of the tumor suppressor PTEN.	Science	2004	108
15023437	phosphatidylinositol 3,4,5-triphosphate	Fresno Vara JA	PI3K/Akt signalling pathway and cancer.	Cancer treatment reviews	2004	316
15209375	phosphatidylinositol 3,4,5-triphosphate	Mora A	PDK1, the master regulator of AGC kinase signal transduction.	Seminars in cell & developmental biology	2004	227
15505410	phosphatidylinositol 3,4,5-triphosphate	Osaki M	PI3K-Akt pathway: its functions and alterations in human cancer.	Apoptosis 	2004	220
15653324	phosphatidylinositol 3,4,5-triphosphate	Harrington LS	Restraining PI3K: mTOR signalling goes back to the membrane.	Trends in biochemical sciences	2005	127
15805248	phosphatidylinositol 3,4,5-triphosphate	Saal LH	PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.	Cancer research	2005	258
16697955	phosphatidylinositol 3,4,5-triphosphate	Fan QW	A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.	Cancer cell	2006	181
17060456	phosphatidylinositol 3,4,5-triphosphate	Kim JS	Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.	Molecular and cellular biology	2007	61
17341655	phosphatidylinositol 3,4,5-triphosphate	Blanco-Aparicio C	PTEN, more than the AKT pathway.	Carcinogenesis	2007	120
18473732	phosphatidylinositol 3,4,5-triphosphate	Carnero A	The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.	Current cancer drug targets	2008	154
19602588	phosphatidylinositol 3,4,5-triphosphate	Maurer M	3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.	Cancer research	2009	46
19729658	phosphatidylinositol 3,4,5-triphosphate	Fine B	Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a.	Science	2009	81
20214616	phosphatidylinositol 3,4,5-triphosphate	Carnero A	The PKB/AKT pathway in cancer.	Current pharmaceutical design	2010	72
20414202	phosphatidylinositol 3,4,5-triphosphate	Bunney TD	Phosphoinositide signalling in cancer: beyond PI3K and PTEN.	Nature reviews. Cancer	2010	120
20622047	phosphatidylinositol 3,4,5-triphosphate	Zhang S	PI(3)king apart PTEN's role in cancer.	Clinical cancer research 	2010	77
21041639	phosphatidylinositol 3,4,5-triphosphate	Miao B	Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains.	Proceedings of the National Academy of Sciences of the United States of America	2010	43
21042280	phosphatidylinositol 3,4,5-triphosphate	Montero JC	P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer.	Oncogene	2011	38
21385900	phosphatidylinositol 3,4,5-triphosphate	Gu T	CREB is a novel nuclear target of PTEN phosphatase.	Cancer research	2011	35
21828076	phosphatidylinositol 3,4,5-triphosphate	Rodríguez-Escudero I	A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.	Human molecular genetics	2011	46
22622578	phosphatidylinositol 3,4,5-triphosphate	Berger MF	Melanoma genome sequencing reveals frequent PREX2 mutations.	Nature	2012	232
22713753	phosphatidylinositol 3,4,5-triphosphate	Huang J	SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane.	Nature communications	2012	50
22729222	phosphatidylinositol 3,4,5-triphosphate	Lindhurst MJ	Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA.	Nature genetics	2012	46
24037532	phosphatidylinositol 3,4,5-triphosphate	Cook DR	Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease.	Oncogene	2014	69
24392697	phosphatidylinositol 3,4,5-triphosphate	Newton AC	Turning off AKT: PHLPP as a drug target.	Annual review of pharmacology and toxicology	2014	31
25284585	phosphatidylinositol 3,4,5-triphosphate	Dillon LM	P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.	Oncogene	2015	19
26293922	phosphatidylinositol 3,4,5-triphosphate	Liu P	PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex.	Cancer discovery	2015	47
28100394	phosphatidylinositol 3,4,5-triphosphate	Horrigan SK	Replication Study: Melanoma genome sequencing reveals frequent PREX2 mutations.	eLife	2017	6
28119806	phosphatidylinositol 3,4,5-triphosphate	Zhao W	Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.	Acta pharmaceutica Sinica. B	2017	6
28157504	phosphatidylinositol 3,4,5-triphosphate	Ebner M	PI(3,4,5)P3 Engagement Restricts Akt Activity to Cellular Membranes.	Molecular cell	2017	8
28343126	phosphatidylinositol 3,4,5-triphosphate	Lien EC	PI3K signaling in cancer: beyond AKT.	Current opinion in cell biology	2017	13
10766168	hydrogen sulfite	Ueki T	Hypermethylation of multiple genes in pancreatic adenocarcinoma.	Cancer research	2000	90
11984524	hydrogen sulfite	Hawkins N	CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability.	Gastroenterology	2002	97
15822191	hydrogen sulfite	Esteller M	Aberrant DNA methylation as a cancer-inducing mechanism.	Annual review of pharmacology and toxicology	2005	101
16174854	hydrogen sulfite	Shen L	MGMT promoter methylation and field defect in sporadic colorectal cancer.	Journal of the National Cancer Institute	2005	157
16645207	hydrogen sulfite	Ogino S	Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis.	The Journal of molecular diagnostics 	2006	156
16951683	hydrogen sulfite	Chan TL	Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer.	Nature genetics	2006	68
17210699	hydrogen sulfite	Zinn RL	hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site.	Cancer research	2007	66
17408664	hydrogen sulfite	Park IY	Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein.	Gastroenterology	2007	73
17476321	hydrogen sulfite	Estécio MR	LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability.	PloS one	2007	107
17591937	hydrogen sulfite	Mikeska T	Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis.	The Journal of molecular diagnostics 	2007	56
17875690	hydrogen sulfite	Taylor KH	Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing.	Cancer research	2007	77
17947473	hydrogen sulfite	Shen L	Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy.	Clinical cancer research 	2007	58
17967063	hydrogen sulfite	Shen L	Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters.	PLoS genetics	2007	134
18045775	hydrogen sulfite	Al-Mahdawi S	The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues.	Human molecular genetics	2008	90
19084528	hydrogen sulfite	Yu J	Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer.	Gastroenterology	2009	53
19232136	hydrogen sulfite	Tan Y	Transcriptional inhibiton of Hoxd4 expression by miRNA-10a in human breast cancer cells.	BMC molecular biology	2009	61
19406918	hydrogen sulfite	deVos T	Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer.	Clinical chemistry	2009	106
19491193	hydrogen sulfite	Koga Y	Genome-wide screen of promoter methylation identifies novel markers in melanoma.	Genome research	2009	73
19535783	hydrogen sulfite	Melotte V	N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.	Journal of the National Cancer Institute	2009	50
19906696	hydrogen sulfite	Serre D	MBD-isolated Genome Sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome.	Nucleic acids research	2010	136
21317930	hydrogen sulfite	Mudduluru G	Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer.	Oncogene	2011	75
21350001	hydrogen sulfite	Li D	Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer.	Clinical cancer research 	2011	94
21788354	hydrogen sulfite	Reinert T	Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers.	Clinical cancer research 	2011	49
21969817	hydrogen sulfite	He Y	Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-mir-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma.	Neoplasia	2011	37
22083596	hydrogen sulfite	Kisiel JB	Stool DNA testing for the detection of pancreatic cancer: assessment of methylation marker candidates.	Cancer	2012	35
22233696	hydrogen sulfite	Kimura T	A novel pit pattern identifies the precursor of colorectal cancer derived from sessile serrated adenoma.	The American journal of gastroenterology	2012	32
22289355	hydrogen sulfite	Augoff K	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	Molecular cancer	2012	81
22374981	hydrogen sulfite	Brennan K	Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk.	Cancer research	2012	49
22392079	hydrogen sulfite	Hoyo C	Association of cord blood methylation fractions at imprinted insulin-like growth factor 2 (IGF2), plasma IGF2, and birth weight.	Cancer causes & control 	2012	36
22534504	hydrogen sulfite	Pei L	Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia.	Epigenetics	2012	35
22589488	hydrogen sulfite	Mahapatra S	Global methylation profiling for risk prediction of prostate cancer.	Clinical cancer research 	2012	39
23064414	hydrogen sulfite	Kulis M	Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia.	Nature genetics	2012	148
23325432	hydrogen sulfite	Varley KE	Dynamic DNA methylation across diverse human cell lines and tissues.	Genome research	2013	214
23388414	hydrogen sulfite	Soubry A	Paternal obesity is associated with IGF2 hypomethylation in newborns: results from a Newborn Epigenetics Study (NEST) cohort.	BMC medicine	2013	52
23418553	hydrogen sulfite	Nye MD	Associations between methylation of paternally expressed gene 3 (PEG3), cervical intraepithelial neoplasia and invasive cervical cancer.	PloS one	2013	32
23474808	hydrogen sulfite	Shim J	Detection and quantification of methylation in DNA using solid-state nanopores.	Scientific reports	2013	34
23593011	hydrogen sulfite	Garding A	Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB.	PLoS genetics	2013	31
23916847	hydrogen sulfite	Murphy SK	Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease.	Gastroenterology	2013	52
23918943	hydrogen sulfite	Haldrup C	DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer.	Journal of clinical oncology 	2013	39
24059801	hydrogen sulfite	Ehrlich M	DNA methylation and differentiation: silencing, upregulation and modulation of gene expression.	Epigenomics	2013	28
24098911	hydrogen sulfite	Lu KH	Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression.	BMC cancer	2013	80
24158121	hydrogen sulfite	Soubry A	Newborns of obese parents have altered DNA methylation patterns at imprinted genes.	International journal of obesity	2015	49
24183680	hydrogen sulfite	Bender S	Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas.	Cancer cell	2013	114
24270890	hydrogen sulfite	Cruickshanks HA	Senescent cells harbour features of the cancer epigenome.	Nature cell biology	2013	64
24485021	hydrogen sulfite	Mitchell SM	A panel of genes methylated with high frequency in colorectal cancer.	BMC cancer	2014	36
24500968	hydrogen sulfite	Nones K	Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling.	International journal of cancer	2014	29
24504172	hydrogen sulfite	Kim HC	Collagen triple helix repeat containing 1 (CTHRC1) acts via ERK-dependent induction of MMP9 to promote invasion of colorectal cancer cells.	Oncotarget	2014	26
24859990	hydrogen sulfite	Haller F	Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad.	Endocrine-related cancer	2014	25
25608619	hydrogen sulfite	Zhang Z	microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma.	Molecular cancer	2015	20
25613496	hydrogen sulfite	Hu L	Up-regulation of long noncoding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma.	Journal of experimental & clinical cancer research 	2015	52
25641194	hydrogen sulfite	Zhuo H	The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma.	Molecular carcinogenesis	2016	33
25663388	hydrogen sulfite	Steponaitiene R	Epigenetic silencing of miR-137 is a frequent event in gastric carcinogenesis.	Molecular carcinogenesis	2016	16
26062908	hydrogen sulfite	Silver MJ	Independent genomewide screens identify the tumor suppressor VTRNA2-1 as a human epiallele responsive to periconceptional environment.	Genome biology	2015	28
26206665	hydrogen sulfite	Wang K	MDGA2 is a novel tumour suppressor cooperating with DMAP1 in gastric cancer and is associated with disease outcome.	Gut	2016	10
26437030	hydrogen sulfite	Kretzmer H	DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control.	Nature genetics	2015	29
26707824	hydrogen sulfite	Fang S	Long noncoding RNA-HOTAIR affects chemoresistance by regulating HOXA1 methylation in small cell lung cancer cells.	Laboratory investigation; a journal of technical methods and pathology	2016	13
26923874	hydrogen sulfite	Johann PD	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes.	Cancer cell	2016	31
26977886	hydrogen sulfite	Chun HE	Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways.	Cancer cell	2016	14
27582487	hydrogen sulfite	Min HY	Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors.	Clinical cancer research 	2017	5
28215704	hydrogen sulfite	Spencer DH	CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.	Cell	2017	12
10688871	Angiogenesis Inhibitors	Kerbel RS	Tumor angiogenesis: past, present and the near future.	Carcinogenesis	2000	122
15516832	Angiogenesis Inhibitors	Mohan R	Withaferin A is a potent inhibitor of angiogenesis.	Angiogenesis	2004	79
16406676	Angiogenesis Inhibitors	Ren B	Regulation of tumor angiogenesis by thrombospondin-1.	Biochimica et biophysica acta	2006	68
17098419	Angiogenesis Inhibitors	Eskens FA	The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.	European journal of cancer	2006	74
17212999	Angiogenesis Inhibitors	Shih T	Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.	Clinical therapeutics	2006	88
17363594	Angiogenesis Inhibitors	Jain RK	Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.	Cancer research	2007	142
17602710	Angiogenesis Inhibitors	Mundel TM	Type IV collagen-derived angiogenesis inhibitors.	Microvascular research	2007	55
18539962	Angiogenesis Inhibitors	Eyler CE	Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis.	Journal of clinical oncology 	2008	179
19017914	Angiogenesis Inhibitors	Nalluri SR	Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.	JAMA	2008	151
19029957	Angiogenesis Inhibitors	Fischer C	FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?	Nature reviews. Cancer	2008	164
19074844	Angiogenesis Inhibitors	Ma J	Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.	Molecular cancer therapeutics	2008	85
19249675	Angiogenesis Inhibitors	Loges S	Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.	Cancer cell	2009	118
19305413	Angiogenesis Inhibitors	Reynolds AR	Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.	Nature medicine	2009	117
19483739	Angiogenesis Inhibitors	Jain RK	Biomarkers of response and resistance to antiangiogenic therapy.	Nature reviews. Clinical oncology	2009	169
19671869	Angiogenesis Inhibitors	Ebos JM	Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.	Clinical cancer research 	2009	73
19826401	Angiogenesis Inhibitors	Norden AD	Antiangiogenic therapies for high-grade glioma.	Nature reviews. Neurology	2009	70
19949018	Angiogenesis Inhibitors	Lockhart AC	Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.	Journal of clinical oncology 	2010	69
20156114	Angiogenesis Inhibitors	Ranpura V	Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.	Acta oncologica	2010	46
20194633	Angiogenesis Inhibitors	Helfrich I	Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.	The Journal of experimental medicine	2010	50
20236818	Angiogenesis Inhibitors	Azam F	Mechanisms of resistance to antiangiogenesis therapy.	European journal of cancer	2010	40
20368560	Angiogenesis Inhibitors	Hainsworth JD	Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.	Journal of clinical oncology 	2010	49
20554717	Angiogenesis Inhibitors	Cook KM	Angiogenesis inhibitors: current strategies and future prospects.	CA	2010	87
20940405	Angiogenesis Inhibitors	Dews M	The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors.	Cancer research	2010	90
21386818	Angiogenesis Inhibitors	Zhu AX	HCC and angiogenesis: possible targets and future directions.	Nature reviews. Clinical oncology	2011	94
21436589	Angiogenesis Inhibitors	Cascone T	Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.	The Journal of clinical investigation	2011	45
21593862	Angiogenesis Inhibitors	Carmeliet P	Molecular mechanisms and clinical applications of angiogenesis.	Nature	2011	923
22525710	Angiogenesis Inhibitors	Rapisarda A	Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia.	Nature reviews. Clinical oncology	2012	48
22551559	Angiogenesis Inhibitors	Griffiths CL	Triple negative breast cancer: a brief review of its characteristics and treatment options.	Journal of pharmacy practice	2012	31
23001349	Angiogenesis Inhibitors	Sennino B	Controlling escape from angiogenesis inhibitors.	Nature reviews. Cancer	2012	71
23045683	Angiogenesis Inhibitors	Huang Y	Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.	Proceedings of the National Academy of Sciences of the United States of America	2012	133
23208836	Angiogenesis Inhibitors	Al-Husein B	Antiangiogenic therapy for cancer: an update.	Pharmacotherapy	2012	35
23401453	Angiogenesis Inhibitors	Lambrechts D	Markers of response for the antiangiogenic agent bevacizumab.	Journal of clinical oncology 	2013	90
23440426	Angiogenesis Inhibitors	Huang Y	Vascular normalization as an emerging strategy to enhance cancer immunotherapy.	Cancer research	2013	91
23512266	Angiogenesis Inhibitors	Soda Y	Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme.	Journal of molecular medicine	2013	40
23750318	Angiogenesis Inhibitors	Lu KV	Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma.	CNS oncology	2013	27
23908119	Angiogenesis Inhibitors	Welti J	Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.	The Journal of clinical investigation	2013	120
23913124	Angiogenesis Inhibitors	Chung AS	An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy.	Nature medicine	2013	104
23989717	Angiogenesis Inhibitors	Ky B	Emerging paradigms in cardiomyopathies associated with cancer therapies.	Circulation research	2013	35
24029605	Angiogenesis Inhibitors	Middleton K	Interleukin-6: an angiogenic target in solid tumours.	Critical reviews in oncology/hematology	2014	26
24964992	Angiogenesis Inhibitors	Xu L	COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models.	Science translational medicine	2014	28
25117977	Angiogenesis Inhibitors	Baker GJ	Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.	Neoplasia	2014	30
25713439	Angiogenesis Inhibitors	Lu-Emerson C	Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.	Journal of clinical oncology 	2015	33
26001391	Angiogenesis Inhibitors	Zhao Y	Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.	The oncologist	2015	55
26694831	Angiogenesis Inhibitors	Hurvitz S	Triple-negative breast cancer: advancements in characterization and treatment approach.	Current opinion in obstetrics & gynecology	2016	13
26908627	Angiogenesis Inhibitors	Bid HK	The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.	Molecular cancer therapeutics	2016	11
28104567	Angiogenesis Inhibitors	Abdel-Qadir H	Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis.	Cancer treatment reviews	2017	8
18985363	isocitric acid	Balss J	Analysis of the IDH1 codon 132 mutation in brain tumors.	Acta neuropathologica	2008	234
19117336	isocitric acid	Bleeker FE	IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.	Human mutation	2009	117
19246647	isocitric acid	Watanabe T	IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.	The American journal of pathology	2009	202
19554337	isocitric acid	Hartmann C	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.	Acta neuropathologica	2009	240
19636000	isocitric acid	Sanson M	Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.	Journal of clinical oncology 	2009	197
19737147	isocitric acid	Ohgaki H	Genetic alterations and signaling pathways in the evolution of gliomas.	Cancer science	2009	106
19903171	isocitric acid	Capper D	Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.	Brain pathology	2010	89
20097881	isocitric acid	Chou WC	Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.	Blood	2010	58
20368543	isocitric acid	Marcucci G	IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.	Journal of clinical oncology 	2010	189
20410924	isocitric acid	Pardanani A	IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.	Leukemia	2010	43
20427748	isocitric acid	Labussière M	All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.	Neurology	2010	63
20428194	isocitric acid	Tefferi A	Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.	Leukemia	2010	125
20508616	isocitric acid	Tefferi A	IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.	Leukemia	2010	76
20567020	isocitric acid	Paschka P	IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.	Journal of clinical oncology 	2010	167
20625116	isocitric acid	Boissel N	Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.	Journal of clinical oncology 	2010	46
20805365	isocitric acid	Schnittger S	IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.	Blood	2010	43
20972461	isocitric acid	Yen KE	Cancer-associated IDH mutations: biomarker and therapeutic opportunities.	Oncogene	2010	66
21163902	isocitric acid	Christensen BC	DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.	Journal of the National Cancer Institute	2011	92
21446051	isocitric acid	Huse JT	Molecular subclassification of diffuse gliomas: seeing order in the chaos.	Glia	2011	77
21596855	isocitric acid	Green CL	The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.	Blood	2011	50
21912393	isocitric acid	Tefferi A	IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.	Leukemia	2012	33
22270850	isocitric acid	Bleeker FE	Recent advances in the molecular understanding of glioblastoma.	Journal of neuro-oncology	2012	44
22289988	isocitric acid	Renneville A	Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.	Leukemia	2012	30
22343889	isocitric acid	Turcan S	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.	Nature	2012	444
22360810	isocitric acid	Filipp FV	Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells.	Pigment cell & melanoma research	2012	52
22430270	isocitric acid	Gaidzik VI	TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.	Journal of clinical oncology 	2012	49
22898539	isocitric acid	Shih AH	The role of mutations in epigenetic regulators in myeloid malignancies.	Nature reviews. Cancer	2012	204
23071355	isocitric acid	Teicher BA	Targeting cancer metabolism.	Clinical cancer research 	2012	34
23104868	isocitric acid	Kannan K	Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.	Oncotarget	2012	60
23550148	isocitric acid	Killian JK	Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor.	Cancer discovery	2013	78
23604282	isocitric acid	Hu J	Heterogeneity of tumor-induced gene expression changes in the human metabolic network.	Nature biotechnology	2013	85
23801749	isocitric acid	Hughes LA	The CpG island methylator phenotype: what's in a name?	Cancer research	2013	45
24440599	isocitric acid	Kats LM	Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.	Cell stem cell	2014	44
24755473	isocitric acid	Grassian AR	IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism.	Cancer research	2014	49
24842956	isocitric acid	Ostrom QT	The epidemiology of glioma in adults: a "state of the science" review.	Neuro-oncology	2014	127
24880135	isocitric acid	Molenaar RJ	The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.	Biochimica et biophysica acta	2014	33
25081751	isocitric acid	Chan AK	TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.	Modern pathology 	2015	21
25225364	isocitric acid	Chen R	Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.	Proceedings of the National Academy of Sciences of the United States of America	2014	25
25701198	isocitric acid	Olar A	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.	Acta neuropathologica	2015	21
25783747	isocitric acid	Weller M	Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.	Acta neuropathologica	2015	28
25852056	isocitric acid	Thol F	How I treat refractory and early relapsed acute myeloid leukemia.	Blood	2015	22
25956465	isocitric acid	Parker SJ	Metabolic consequences of oncogenic IDH mutations.	Pharmacology & therapeutics	2015	19
26188014	isocitric acid	Waitkus MS	Isocitrate dehydrogenase mutations in gliomas.	Neuro-oncology	2016	25
26945349	isocitric acid	Chen JR	Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.	Medicine	2016	13
27049945	isocitric acid	Jiang L	Reductive carboxylation supports redox homeostasis during anchorage-independent growth.	Nature	2016	56
27245312	isocitric acid	Birendra KC	Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.	Clinical lymphoma, myeloma & leukemia	2016	10
27353503	isocitric acid	Zhang B	Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.	Neuro-oncology	2017	8
27370400	isocitric acid	Garber ST	Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.	Neuro-oncology	2016	11
27820599	isocitric acid	Miroshnikova YA	Tissue mechanics promote IDH1-dependent HIF1α-tenascin C feedback to regulate glioblastoma aggression.	Nature cell biology	2016	12
28043904	isocitric acid	Sia D	Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.	Gastroenterology	2017	17
28124097	isocitric acid	Pusch S	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.	Acta neuropathologica	2017	7
28193778	isocitric acid	Yen K	AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.	Cancer discovery	2017	14
28360267	isocitric acid	Venteicher AS	Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.	Science	2017	29
28389139	isocitric acid	Rizvi S	Emerging molecular therapeutic targets for cholangiocarcinoma.	Journal of hepatology	2017	7
28420416	isocitric acid	Saygin C	Emerging therapies for acute myeloid leukemia.	Journal of hematology & oncology	2017	12
3409223	thiazolyl blue	Scudiero DA	Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.	Cancer research	1988	257
15930289	thiazolyl blue	Jiang JG	Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors.	Cancer research	2005	65
17804744	thiazolyl blue	Wang Z	Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells.	Cancer research	2007	99
18182619	thiazolyl blue	Gray MJ	Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver.	Journal of the National Cancer Institute	2008	55
18318443	thiazolyl blue	Fransvea E	Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.	Hepatology	2008	56
19363643	thiazolyl blue	Du Y	Down-regulation of miR-141 in gastric cancer and its involvement in cell growth.	Journal of gastroenterology	2009	53
21822301	thiazolyl blue	Xu Y	MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1.	Oncogene	2012	56
21993663	thiazolyl blue	Zhu W	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.	Cancer chemotherapy and pharmacology	2012	58
22270966	thiazolyl blue	Li J	MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4.	Journal of cancer research and clinical oncology	2012	43
22498306	thiazolyl blue	Cheng W	MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.	The FEBS journal	2012	64
23342249	thiazolyl blue	Fan F	Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells.	Cancer medicine	2012	58
24338509	thiazolyl blue	Hadad SM	Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle.	Clinical & translational oncology 	2014	23
24650096	thiazolyl blue	Song Y	Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma.	Molecular cancer	2014	37
26490983	thiazolyl blue	Cui D	Long non-coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung cancer.	Tumour biology 	2016	20
26758762	thiazolyl blue	Zhou T	Increased expression of LncRNA BANCR and its prognostic significance in human hepatocellular carcinoma.	World journal of surgical oncology	2016	16
26832883	thiazolyl blue	Mukai S	Overexpression of Transmembrane Protein BST2 is Associated with Poor Survival of Patients with Esophageal, Gastric, or Colorectal Cancer.	Annals of surgical oncology	2017	10
27347113	thiazolyl blue	Zhou N	Long non-coding RNA CCAT2 functions as an oncogene in hepatocellular carcinoma, regulating cellular proliferation, migration and apoptosis.	Oncology letters	2016	11
28451917	thiazolyl blue	Guo JQ	Long Noncoding RNA AFAP1-AS1 Promotes Cell Proliferation and Apoptosis of Gastric Cancer Cells via PTEN/p-AKT Pathway.	Digestive diseases and sciences	2017	8
8290962	SERPIN-B5	Zou Z	Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells.	Science	1994	183
10655109	SERPIN-B5	Zhang M	Maspin is an angiogenesis inhibitor.	Nature medicine	2000	98
12021783	SERPIN-B5	Futscher BW	Role for DNA methylation in the control of cell type specific maspin expression.	Nature genetics	2002	101
17377533	SERPIN-B5	Luo JL	Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin.	Nature	2007	139
18270520	SERPIN-B5	Zhu S	MicroRNA-21 targets tumor suppressor genes in invasion and metastasis.	Cell research	2008	318
19047126	SERPIN-B5	Heath EI	A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.	Clinical cancer research 	2008	50
20406978	SERPIN-B5	Feng XP	Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics.	Cancer research	2010	45
22419067	SERPIN-B5	Rivenbark AG	Epigenetic reprogramming of cancer cells via targeted DNA methylation.	Epigenetics	2012	68
23770133	SERPIN-B5	Yuan K	Decreased levels of miR-224 and the passenger strand of miR-221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice.	Gastroenterology	2013	30
10728709	sulforafan	Gamet-Payrastre L	Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells.	Cancer research	2000	105
14514658	sulforafan	Singh AV	Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo.	Carcinogenesis	2004	94
15073169	sulforafan	Singh SV	Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C.	The Journal of biological chemistry	2004	71
15313918	sulforafan	Myzak MC	A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.	Cancer research	2004	138
15572695	sulforafan	Zhang DD	Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex.	Molecular and cellular biology	2004	342
15764812	sulforafan	Singh SV	Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species.	The Journal of biological chemistry	2005	94
15856023	sulforafan	Xu C	Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells.	Oncogene	2005	80
16006525	sulforafan	Eggler AL	Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2.	Proceedings of the National Academy of Sciences of the United States of America	2005	121
16280330	sulforafan	Myzak MC	Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells.	Carcinogenesis	2006	86
16332662	sulforafan	Gasper AV	Glutathione S-transferase M1 polymorphism and metabolism of sulforaphane from standard and high-glucosinolate broccoli.	The American journal of clinical nutrition	2005	67
16359182	sulforafan	Hong F	Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane.	Chemical research in toxicology	2005	98
16407454	sulforafan	Myzak MC	Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice.	FASEB journal 	2006	98
16740722	sulforafan	Herman-Antosiewicz A	Sulforaphane causes autophagy to inhibit release of cytochrome C and apoptosis in human prostate cancer cells.	Cancer research	2006	93
16951197	sulforafan	Keum YS	Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma HepG2 cells.	Cancer research	2006	62
17259330	sulforafan	Myzak MC	Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects.	Experimental biology and medicine	2007	101
17339367	sulforafan	Pledgie-Tracy A	Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines.	Molecular cancer therapeutics	2007	72
17347138	sulforafan	Cornblatt BS	Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast.	Carcinogenesis	2007	82
17396224	sulforafan	Juge N	Molecular basis for chemoprevention by sulforaphane: a comprehensive review.	Cellular and molecular life sciences 	2007	138
17555985	sulforafan	Dashwood RH	Dietary histone deacetylase inhibitors: from cells to mice to man.	Seminars in cancer biology	2007	90
19812222	sulforafan	Ho E	Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention.	The Journal of nutrition	2009	50
20013083	sulforafan	Cheung KL	Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention.	The AAPS journal	2010	111
20625516	sulforafan	Meeran SM	Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines.	PloS one	2010	89
21258631	sulforafan	Meeran SM	Epigenetic targets of bioactive dietary components for cancer prevention and therapy.	Clinical epigenetics	2010	58
21374800	sulforafan	Clarke JD	Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells.	Molecular nutrition & food research	2011	49
21495793	sulforafan	Higgins LG	Mechanisms of induction of cytosolic and microsomal glutathione transferase (GST) genes by xenobiotics and pro-inflammatory agents.	Drug metabolism reviews	2011	37
21597922	sulforafan	Agyeman AS	Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles.	Breast cancer research and treatment	2012	40
21624135	sulforafan	Rajendran P	Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly.	Molecular cancer	2011	38
22558124	sulforafan	Li Y	Mechanism of chemical activation of Nrf2.	PloS one	2012	32
22578879	sulforafan	Dinkova-Kostova AT	Glucosinolates and isothiocyanates in health and disease.	Trends in molecular medicine	2012	53
22662208	sulforafan	Meeran SM	Bioactive dietary supplements reactivate ER expression in ER-negative breast cancer cells by active chromatin modifications.	PloS one	2012	30
22752583	sulforafan	Kensler TW	Keap1-nrf2 signaling: a target for cancer prevention by sulforaphane.	Topics in current chemistry	2013	59
22955508	sulforafan	Gerhauser C	Cancer chemoprevention and nutriepigenetics: state of the art and future challenges.	Topics in current chemistry	2013	38
23029396	sulforafan	Rodova M	Sonic hedgehog signaling inhibition provides opportunities for targeted therapy by sulforaphane in regulating pancreatic cancer stem cell self-renewal.	PloS one	2012	30
23129257	sulforafan	Li SH	Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway.	Molecular and cellular biochemistry	2013	30
23589329	sulforafan	Lau A	Arsenic inhibits autophagic flux, activating the Nrf2-Keap1 pathway in a p62-dependent manner.	Molecular and cellular biology	2013	36
23752191	sulforafan	Li Q	Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer.	Oncogene	2014	53
23770684	sulforafan	Rajendran P	HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates.	Epigenetics	2013	30
24147970	sulforafan	Houghton CA	Sulforaphane: translational research from laboratory bench to clinic.	Nutrition reviews	2013	28
24297178	sulforafan	Li Q	Characterization of a stem-like subpopulation in basal-like ductal carcinoma in situ (DCIS) lesions.	The Journal of biological chemistry	2014	29
24637114	sulforafan	Pekovic-Vaughan V	The circadian clock regulates rhythmic activation of the NRF2/glutathione-mediated antioxidant defense pathway to modulate pulmonary fibrosis.	Genes & development	2014	44
24913818	sulforafan	Egner PA	Rapid and sustainable detoxication of airborne pollutants by broccoli sprout beverage: results of a randomized clinical trial in China.	Cancer prevention research	2014	32
25017900	sulforafan	Appari M	Sulforaphane, quercetin and catechins complement each other in elimination of advanced pancreatic cancer by miR-let-7 induction and K-ras inhibition.	International journal of oncology	2014	20
25159108	sulforafan	Yager JD	Mechanisms of estrogen carcinogenesis: The role of E2/E1-quinone metabolites suggests new approaches to preventive intervention--A review.	Steroids	2015	22
25975984	sulforafan	Dinkova-Kostova AT	The emerging role of Nrf2 in mitochondrial function.	Free radical biology & medicine	2015	55
26970133	sulforafan	Yang L	Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane.	Seminars in oncology	2016	11
28061797	sulforafan	Angulo P	Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy.	Journal of hematology & oncology	2017	7
10954755	vorinostat	Richon VM	Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.	Proceedings of the National Academy of Sciences of the United States of America	2000	251
11016644	vorinostat	Butler LM	Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.	Cancer research	2000	143
11535817	vorinostat	Ruefli AA	The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species.	Proceedings of the National Academy of Sciences of the United States of America	2001	113
12189205	vorinostat	Butler LM	The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.	Proceedings of the National Academy of Sciences of the United States of America	2002	128
14734806	vorinostat	Gui CY	Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1.	Proceedings of the National Academy of Sciences of the United States of America	2004	159
15173093	vorinostat	Pei XY	Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.	Clinical cancer research 	2004	102
15596714	vorinostat	Shao Y	Apoptotic and autophagic cell death induced by histone deacetylase inhibitors.	Proceedings of the National Academy of Sciences of the United States of America	2004	169
15738394	vorinostat	Peart MJ	Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.	Proceedings of the National Academy of Sciences of the United States of America	2005	151
15964800	vorinostat	Dai Y	Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.	Molecular and cellular biology	2005	70
16960145	vorinostat	Duvic M	Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).	Blood	2007	228
17363733	vorinostat	Carew JS	Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance.	Blood	2007	183
17594194	vorinostat	Duvic M	Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.	Expert opinion on investigational drugs	2007	78
17962618	vorinostat	Mann BS	FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.	The oncologist	2007	260
18413790	vorinostat	Fournel M	MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.	Molecular cancer therapeutics	2008	75
18541724	vorinostat	Buglio D	Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines.	Blood	2008	59
18981013	vorinostat	Luu TH	A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study.	Clinical cancer research 	2008	64
19307505	vorinostat	Galanis E	Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.	Journal of clinical oncology 	2009	89
19583815	vorinostat	Carew JS	Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.	Journal of cellular and molecular medicine	2010	72
19671864	vorinostat	Badros A	Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.	Clinical cancer research 	2009	69
19738609	vorinostat	Munster PN	Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.	British journal of cancer	2009	46
19789319	vorinostat	Palmieri D	Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks.	Clinical cancer research 	2009	47
20028765	vorinostat	Mahalingam D	Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.	Clinical cancer research 	2010	40
20378407	vorinostat	Ree AH	Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.	The Lancet. Oncology	2010	40
20460513	vorinostat	Conti C	Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage.	Cancer research	2010	58
20631069	vorinostat	Park MA	Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.	Cancer research	2010	41
20647567	vorinostat	Bachmann PS	Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.	Blood	2010	44
20679231	vorinostat	Lee JH	Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.	Proceedings of the National Academy of Sciences of the United States of America	2010	99
21559012	vorinostat	Munster PN	A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.	British journal of cancer	2011	81
21637290	vorinostat	Li D	SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.	Cell death and differentiation	2011	77
21653597	vorinostat	Singh MM	Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.	Neuro-oncology	2011	38
21660961	vorinostat	Bruzzese F	HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.	Journal of cellular physiology	2011	43
21909380	vorinostat	Nalls D	Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.	PloS one	2011	67
21926171	vorinostat	Eades G	miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells.	The Journal of biological chemistry	2011	62
22002311	vorinostat	Zhang X	Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.	Oncogene	2012	46
22585696	vorinostat	Garcia-Manero G	Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.	Journal of clinical oncology 	2012	39
23382048	vorinostat	Nakagawa T	EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.	Cancer research	2013	44
24055414	vorinostat	Dimopoulos M	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.	The Lancet. Oncology	2013	49
24319254	vorinostat	Tian Z	A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.	Blood	2014	65
24371063	vorinostat	Shulak L	Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy.	Journal of virology	2014	21
24620025	vorinostat	Archin NM	HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.	The Journal of infectious diseases	2014	89
24636848	vorinostat	Reguart N	Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.	Lung cancer	2014	21
24706775	vorinostat	Cillo AR	Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.	Proceedings of the National Academy of Sciences of the United States of America	2014	86
24991835	vorinostat	Mahalingam D	Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.	Autophagy	2014	68
25393367	vorinostat	Yang H	Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma.	British journal of cancer	2015	26
25428224	vorinostat	Choi SW	Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans.	Blood	2015	17
27363832	vorinostat	Naymagon L	Novel agents in the treatment of multiple myeloma: a review about the future.	Journal of hematology & oncology	2016	13
28486043	vorinostat	Sekeres MA	Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.	Journal of clinical oncology 	2017	11
7697716	JM 3100	Aboussekhra A	Mammalian DNA nucleotide excision repair reconstituted with purified protein components.	Cell	1995	203
11581376	JM 3100	Gorry PR	Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity.	Journal of virology	2001	124
12220670	JM 3100	Hatse S	Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.	FEBS letters	2002	111
12384559	JM 3100	Scotton CJ	Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.	Cancer research	2002	118
14595012	JM 3100	Rubin JB	A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.	Proceedings of the National Academy of Sciences of the United States of America	2003	172
15020611	JM 3100	Devine SM	Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma.	Journal of clinical oncology 	2004	89
15087398	JM 3100	Tavor S	CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.	Cancer research	2004	78
15548713	JM 3100	Marchesi F	Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4.	Cancer research	2004	91
15574767	JM 3100	Smith MC	CXCR4 regulates growth of both primary and metastatic breast cancer.	Cancer research	2004	213
16143102	JM 3100	Zhang Y	Reconstitution of 5'-directed human mismatch repair in a purified system.	Cell	2005	152
16327781	JM 3100	Jazayeri A	ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks.	Nature cell biology	2006	394
16489019	JM 3100	Yasumoto K	Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer.	Cancer research	2006	62
16523492	JM 3100	Zou Y	Functions of human replication protein A (RPA): from DNA replication to DNA damage and stress responses.	Journal of cellular physiology	2006	112
17119115	JM 3100	Alsayed Y	Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.	Blood	2007	116
17538175	JM 3100	Pelloski CE	Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.	Journal of clinical oncology 	2007	85
17893878	JM 3100	Kajiyama H	Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.	International journal of cancer	2008	79
17965729	JM 3100	Sartori AA	Human CtIP promotes DNA end resection.	Nature	2007	506
18043246	JM 3100	Broxmeyer HE	Chemokines in hematopoiesis.	Current opinion in hematology	2008	52
18426988	JM 3100	Devine SM	Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.	Blood	2008	74
18987663	JM 3100	Burger JA	CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers.	Leukemia	2009	116
19119139	JM 3100	Casteel DE	A DNA polymerase-{alpha}{middle dot}primase cofactor with homology to replication protein A-32 regulates DNA replication in mammalian cells.	The Journal of biological chemistry	2009	64
19139079	JM 3100	Azab AK	CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.	Blood	2009	144
19161986	JM 3100	De Clercq E	The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).	Biochemical pharmacology	2009	58
19363221	JM 3100	DiPersio JF	Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.	Blood	2009	114
19588204	JM 3100	Matsusue R	Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis.	Annals of surgical oncology	2009	45
19720922	JM 3100	DiPersio JF	Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.	Journal of clinical oncology 	2009	102
19837984	JM 3100	Kofuku Y	Structural basis of the interaction between chemokine stromal cell-derived factor-1/CXCL12 and its G-protein-coupled receptor CXCR4.	The Journal of biological chemistry	2009	49
20154705	JM 3100	Lee DH	A PP4 phosphatase complex dephosphorylates RPA2 to facilitate DNA repair via homologous recombination.	Nature structural & molecular biology	2010	41
20460522	JM 3100	Nimmagadda S	Molecular imaging of CXCR4 receptor expression in human cancer xenografts with 64CuAMD3100 positron emission tomography.	Cancer research	2010	45
20631066	JM 3100	Kozin SV	Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation.	Cancer research	2010	82
20670894	JM 3100	Huang M	The FANCM/FAAP24 complex is required for the DNA interstrand crosslink-induced checkpoint response.	Molecular cell	2010	49
20705237	JM 3100	Dou H	Regulation of DNA repair through deSUMOylation and SUMOylation of replication protein A complex.	Molecular cell	2010	56
21349998	JM 3100	Duda DG	CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?	Clinical cancer research 	2011	124
21618540	JM 3100	Ping YF	The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling.	The Journal of pathology	2011	52
21699506	JM 3100	Scholten DJ	Pharmacological modulation of chemokine receptor function.	British journal of pharmacology	2012	51
21742774	JM 3100	Righi E	CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.	Cancer research	2011	51
21777809	JM 3100	Liu S	ATR autophosphorylation as a molecular switch for checkpoint activation.	Molecular cell	2011	84
22308295	JM 3100	Uy GL	A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.	Blood	2012	96
22370645	JM 3100	Jung MJ	Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells.	Oncogene	2013	54
22648473	JM 3100	Zhang Q	A microfluidic-based device for study of transendothelial invasion of tumor aggregates in realtime.	Lab on a chip	2012	31
22661229	JM 3100	Galanty Y	RNF4, a SUMO-targeted ubiquitin E3 ligase, promotes DNA double-strand break repair.	Genes & development	2012	113
22661230	JM 3100	Yin Y	SUMO-targeted ubiquitin E3 ligase RNF4 is required for the response of human cells to DNA damage.	Genes & development	2012	91
22871210	JM 3100	Zhang SS	CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients.	BMC medicine	2012	46
23630186	JM 3100	Gassenmaier M	CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis.	Stem cells	2013	27
24157575	JM 3100	Gatti M	Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity.	Toxicology	2013	27
24277834	JM 3100	Feig C	Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	169
24523241	JM 3100	McDermott DH	A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.	Blood	2014	22
25444927	JM 3100	Guan G	The HIF-1α/CXCR4 pathway supports hypoxia-induced metastasis of human osteosarcoma cells.	Cancer letters	2015	16
26199389	JM 3100	Scala S	Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.	Clinical cancer research 	2015	19
26414794	JM 3100	Izumi D	CXCL12/CXCR4 activation by cancer-associated fibroblasts promotes integrin β1 clustering and invasiveness in gastric cancer.	International journal of cancer	2016	11
26517945	JM 3100	Fontanella R	A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion.	Cancer letters	2016	10
26851944	JM 3100	Teng F	Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis.	Journal of hematology & oncology	2016	14
11559718	letrozole	Ellis MJ	Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.	Journal of clinical oncology 	2001	104
16033851	letrozole	Boulay A	Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.	Clinical cancer research 	2005	77
16382061	letrozole	Breast International Group (BIG) 1-98 Collaborative Group.	A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.	The New England journal of medicine	2005	307
17200148	letrozole	Coates AS	Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.	Journal of clinical oncology 	2007	182
17679725	letrozole	Viale G	Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.	Journal of clinical oncology 	2007	80
18509175	letrozole	Azim AA	Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.	Journal of clinical oncology 	2008	79
19380449	letrozole	Baselga J	Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.	Journal of clinical oncology 	2009	148
19692688	letrozole	BIG 1-98 Collaborative Group.	Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.	The New England journal of medicine	2009	106
19786658	letrozole	Johnston S	Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.	Journal of clinical oncology 	2009	201
19996028	letrozole	Oktay K	Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.	Journal of clinical oncology 	2010	66
21862331	letrozole	Huober J	Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.	Breast	2012	35
21916582	letrozole	Cook KL	Autophagy and endocrine resistance in breast cancer.	Expert review of anticancer therapy	2011	38
21987386	letrozole	Brufsky AM	Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.	Cancer	2012	39
22018631	letrozole	Regan MM	Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.	The Lancet. Oncology	2011	73
22395644	letrozole	Regan MM	CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.	Journal of the National Cancer Institute	2012	76
23233719	letrozole	Wolff AC	Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.	Journal of clinical oncology 	2013	61
23569315	letrozole	Rimawi MF	Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.	Journal of clinical oncology 	2013	45
24663045	letrozole	Mayer IA	Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.	Journal of clinical oncology 	2014	49
25524798	letrozole	Finn RS	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.	The Lancet. Oncology	2015	236
25624430	letrozole	Slomovitz BM	Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.	Journal of clinical oncology 	2015	21
25633049	letrozole	Vilquin P	MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.	Breast cancer research 	2015	17
25691671	letrozole	Martín M	Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.	Journal of clinical oncology 	2015	22
25792301	letrozole	Dhillon S	Palbociclib: first global approval.	Drugs	2015	18
26324739	letrozole	Beaver JA	FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.	Clinical cancer research 	2015	33
26342236	letrozole	Le Tourneau C	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.	The Lancet. Oncology	2015	94
26795347	letrozole	Bacci M	miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.	Cancer research	2016	11
27126994	letrozole	Mayer IA	A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.	Clinical cancer research 	2017	22
27264120	letrozole	Goss PE	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.	The New England journal of medicine	2016	38
27349747	letrozole	Finn RS	Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.	Breast cancer research 	2016	15
27717303	letrozole	Hortobagyi GN	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.	The New England journal of medicine	2016	63
27959613	letrozole	Finn RS	Palbociclib and Letrozole in Advanced Breast Cancer.	The New England journal of medicine	2016	71
28113032	letrozole	Smith I	Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial.	Journal of clinical oncology 	2017	7
19935646	alpha-hydroxyglutarate	Dang L	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.	Nature	2009	751
20142433	alpha-hydroxyglutarate	Gross S	Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.	The Journal of experimental medicine	2010	200
20171147	alpha-hydroxyglutarate	Ward PS	The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.	Cancer cell	2010	461
20513808	alpha-hydroxyglutarate	Reitman ZJ	Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.	Journal of the National Cancer Institute	2010	110
20559394	alpha-hydroxyglutarate	Dang L	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.	Nature	2010	95
20615753	alpha-hydroxyglutarate	Kloosterhof NK	Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?	The Lancet. Oncology	2011	47
20692206	alpha-hydroxyglutarate	Dang L	IDH mutations in glioma and acute myeloid leukemia.	Trends in molecular medicine	2010	94
20847235	alpha-hydroxyglutarate	Kranendijk M	IDH2 mutations in patients with D-2-hydroxyglutaric aciduria.	Science	2010	48
21045145	alpha-hydroxyglutarate	Seltzer MJ	Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.	Cancer research	2010	148
21130701	alpha-hydroxyglutarate	Figueroa ME	Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.	Cancer cell	2010	641
21251613	alpha-hydroxyglutarate	Xu W	Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.	Cancer cell	2011	589
21289278	alpha-hydroxyglutarate	Reitman ZJ	Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.	Proceedings of the National Academy of Sciences of the United States of America	2011	164
21326614	alpha-hydroxyglutarate	Jin G	2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.	PloS one	2011	49
21460794	alpha-hydroxyglutarate	Chowdhury R	The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.	EMBO reports	2011	239
21598255	alpha-hydroxyglutarate	Amary MF	IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.	The Journal of pathology	2011	176
21913188	alpha-hydroxyglutarate	Capper D	2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size.	International journal of cancer	2012	36
21996744	alpha-hydroxyglutarate	Ward PS	Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.	Oncogene	2012	59
22015945	alpha-hydroxyglutarate	Pope WB	Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.	Journal of neuro-oncology	2012	62
22166263	alpha-hydroxyglutarate	Luchman HA	An in vivo patient-derived model of endogenous IDH1-mutant glioma.	Neuro-oncology	2012	47
22180306	alpha-hydroxyglutarate	Borger DR	Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.	The oncologist	2012	142
22238332	alpha-hydroxyglutarate	Andronesi OC	Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.	Science translational medicine	2012	85
22238333	alpha-hydroxyglutarate	Elkhaled A	Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.	Science translational medicine	2012	53
22281806	alpha-hydroxyglutarate	Choi C	2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.	Nature medicine	2012	150
22343896	alpha-hydroxyglutarate	Koivunen P	Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.	Nature	2012	198
22343901	alpha-hydroxyglutarate	Lu C	IDH mutation impairs histone demethylation and results in a block to cell differentiation.	Nature	2012	439
23071358	alpha-hydroxyglutarate	Yang H	IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.	Clinical cancer research 	2012	55
23204232	alpha-hydroxyglutarate	Jin G	Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.	Cancer research	2013	35
23264629	alpha-hydroxyglutarate	Ward PS	The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.	The Journal of biological chemistry	2013	40
23393090	alpha-hydroxyglutarate	Losman JA	(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.	Science	2013	174
23532369	alpha-hydroxyglutarate	Cohen AL	IDH1 and IDH2 mutations in gliomas.	Current neurology and neuroscience reports	2013	54
23558169	alpha-hydroxyglutarate	Rohle D	An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.	Science	2013	275
23558173	alpha-hydroxyglutarate	Wang F	Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.	Science	2013	176
23630074	alpha-hydroxyglutarate	Losman JA	What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.	Genes & development	2013	123
23641016	alpha-hydroxyglutarate	DiNardo CD	Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.	Blood	2013	38
23863747	alpha-hydroxyglutarate	Guilhamon P	Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.	Nature communications	2013	41
23877318	alpha-hydroxyglutarate	Zhang C	IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.	Neuro-oncology	2013	29
23954893	alpha-hydroxyglutarate	Chaturvedi A	Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.	Blood	2013	51
23999439	alpha-hydroxyglutarate	Andronesi OC	Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.	The Journal of clinical investigation	2013	32
24019001	alpha-hydroxyglutarate	Chaumeil MM	Non-invasive in vivo assessment of IDH1 mutational status in glioma.	Nature communications	2013	38
24065766	alpha-hydroxyglutarate	Lu C	Induction of sarcomas by mutant IDH2.	Genes & development	2013	40
24077805	alpha-hydroxyglutarate	Borodovsky A	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.	Oncotarget	2013	37
24333121	alpha-hydroxyglutarate	Emadi A	Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.	Experimental hematology	2014	37
24344214	alpha-hydroxyglutarate	Janin M	Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.	Journal of clinical oncology 	2014	25
24366912	alpha-hydroxyglutarate	Chesnelong C	Lactate dehydrogenase A silencing in IDH mutant gliomas.	Neuro-oncology	2014	32
24478380	alpha-hydroxyglutarate	Borger DR	Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.	Clinical cancer research 	2014	24
24590270	alpha-hydroxyglutarate	Ohka F	Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.	Tumour biology 	2014	25
24986863	alpha-hydroxyglutarate	Reitman ZJ	Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia.	The Journal of biological chemistry	2014	23
25043045	alpha-hydroxyglutarate	Saha SK	Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.	Nature	2014	66
25182153	alpha-hydroxyglutarate	Shim EH	L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.	Cancer discovery	2014	45
25398940	alpha-hydroxyglutarate	Kernytsky A	IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition.	Blood	2015	33
25599133	alpha-hydroxyglutarate	Chan SM	Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.	Nature medicine	2015	55
25706986	alpha-hydroxyglutarate	Izquierdo-Garcia JL	Metabolic reprogramming in mutant IDH1 glioma cells.	PloS one	2015	18
25864878	alpha-hydroxyglutarate	Nowicki S	Oncometabolites: tailoring our genes.	The FEBS journal	2015	21
26045167	alpha-hydroxyglutarate	Izquierdo-Garcia JL	IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.	Cancer research	2015	22
26190651	alpha-hydroxyglutarate	Fu X	2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling.	Cell metabolism	2015	21
26212717	alpha-hydroxyglutarate	Intlekofer AM	Hypoxia Induces Production of L-2-Hydroxyglutarate.	Cell metabolism	2015	53
26534967	alpha-hydroxyglutarate	Andronesi OC	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.	Clinical cancer research 	2016	14
26669865	alpha-hydroxyglutarate	Emir UE	Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.	Cancer research	2016	19
26678339	alpha-hydroxyglutarate	Tateishi K	Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.	Cancer cell	2015	40
26691210	alpha-hydroxyglutarate	de la Fuente MI	Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.	Neuro-oncology	2016	22
26700815	alpha-hydroxyglutarate	Flavahan WA	Insulator dysfunction and oncogene activation in IDH mutant gliomas.	Nature	2016	130
27005468	alpha-hydroxyglutarate	Dang L	IDH mutations in cancer and progress toward development of targeted therapeutics.	Annals of oncology 	2016	26
27355333	alpha-hydroxyglutarate	Fujii T	Targeting isocitrate dehydrogenase (IDH) in cancer.	Discovery medicine	2016	13
27721426	alpha-hydroxyglutarate	Medeiros BC	Isocitrate dehydrogenase mutations in myeloid malignancies.	Leukemia	2017	11
28148839	alpha-hydroxyglutarate	Sulkowski PL	2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.	Science translational medicine	2017	18
28263965	alpha-hydroxyglutarate	Intlekofer AM	L-2-Hydroxyglutarate production arises from noncanonical enzyme function at acidic pH.	Nature chemical biology	2017	12
28588019	alpha-hydroxyglutarate	Amatangelo MD	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.	Blood	2017	10
28588020	alpha-hydroxyglutarate	Stein EM	Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.	Blood	2017	20
10851053	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Hirano T	Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors.	Oncogene	2000	254
12687404	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Kamimura D	IL-6 signal transduction and its physiological roles: the signal orchestration model.	Reviews of physiology, biochemistry and pharmacology	2003	143
16640655	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Scheller J	Interleukin-6 trans-signalling in chronic inflammation and cancer.	Scandinavian journal of immunology	2006	67
16707558	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Rose-John S	Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.	Journal of leukocyte biology	2006	159
16931107	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Nicolini A	Cytokines in breast cancer.	Cytokine & growth factor reviews	2006	64
17465721	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Rose-John S	The IL-6/sIL-6R complex as a novel target for therapeutic approaches.	Expert opinion on therapeutic targets	2007	77
17531096	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Berishaj M	Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer.	Breast cancer research 	2007	93
18060032	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Gao SP	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.	The Journal of clinical investigation	2007	209
18620071	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Regis G	Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling.	Seminars in cell & developmental biology	2008	62
19020503	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Rebouissou S	Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.	Nature	2009	108
19155309	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Shain KH	Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation.	Cancer research	2009	55
19851315	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Yu H	STATs in cancer inflammation and immunity: a leading role for STAT3.	Nature reviews. Cancer	2009	982
20478049	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Jarnicki A	Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?	Cell division	2010	67
20713517	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Inda MM	Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.	Genes & development	2010	172
20953899	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Seike T	Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis.	Clinical & experimental metastasis	2011	38
21377916	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Neurath MF	IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer.	Cytokine & growth factor reviews	2011	111
21690253	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Pilati C	Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas.	The Journal of experimental medicine	2011	64
22652781	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Camporeale A	IL-6, IL-17 and STAT3: a holy trinity in auto-immunity?	Frontiers in bioscience	2012	31
22891351	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Couto JP	STAT3 negatively regulates thyroid tumorigenesis.	Proceedings of the National Academy of Sciences of the United States of America	2012	43
23136552	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Rose-John S	IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.	International journal of biological sciences	2012	106
23136553	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Waldner MJ	Interleukin-6--a key regulator of colorectal cancer development.	International journal of biological sciences	2012	60
23948300	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Putoczki TL	Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically.	Cancer cell	2013	63
24082147	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Wang Y	STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor.	Proceedings of the National Academy of Sciences of the United States of America	2013	38
24325804	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Scheller J	Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities.	Seminars in immunology	2014	53
24735922	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Pilati C	Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.	Cancer cell	2014	36
24804649	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Judd LM	Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo.	PloS one	2014	20
25136784	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Calabrese LH	IL-6 biology: implications for clinical targeting in rheumatic disease.	Nature reviews. Rheumatology	2014	37
25731159	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Taniguchi K	A gp130-Src-YAP module links inflammation to epithelial regeneration.	Nature	2015	84
25966666	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Hossain A	Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway.	Stem cells	2015	24
26750536	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Zhao G	IL-6 mediates the signal pathway of JAK-STAT3-VEGF-C promoting growth, invasion and lymphangiogenesis in gastric cancer.	Oncology reports	2016	14
26867490	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Schmidt-Arras D	IL-6 pathway in the liver: From physiopathology to therapy.	Journal of hepatology	2016	22
26945971	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Bharti R	Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement.	Cancer letters	2016	29
27096320	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Zhang C	CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer.	Immunity	2016	13
27737952	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Sereti I	Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection.	Clinical infectious diseases 	2017	15
27893707	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Miller A	Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.	Oncogene	2017	6
15014181	exemestane	Coombes RC	A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.	The New England journal of medicine	2004	271
20427689	exemestane	Barone I	Estrogen receptor mutations and changes in downstream gene expression and signaling.	Clinical cancer research 	2010	44
20479064	exemestane	Vonderheide RH	Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.	Clinical cancer research 	2010	50
20876420	exemestane	Ingle JN	Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.	Journal of clinical oncology 	2010	75
21555689	exemestane	Ellis MJ	Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.	Journal of clinical oncology 	2011	96
22149876	exemestane	Baselga J	Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.	The New England journal of medicine	2012	561
22318280	exemestane	van de Water W	Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.	JAMA	2012	32
22331951	exemestane	Henry NL	Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.	Journal of clinical oncology 	2012	63
23358971	exemestane	Goss PE	Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.	Journal of clinical oncology 	2013	49
23414585	exemestane	Robertson JF	Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.	The Lancet. Oncology	2013	36
23744866	exemestane	Lauring J	The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.	Journal of the National Comprehensive Cancer Network 	2013	27
23902874	exemestane	Johnston SR	Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.	The Lancet. Oncology	2013	34
24069582	exemestane	den Hollander P	Targeted therapy for breast cancer prevention.	Frontiers in oncology	2013	33
24881463	exemestane	Pagani O	Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.	The New England journal of medicine	2014	93
25071141	exemestane	Sabine VS	Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.	Journal of clinical oncology 	2014	23
25231953	exemestane	Piccart M	Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.	Annals of oncology 	2014	72
25495490	exemestane	Francis PA	Adjuvant ovarian suppression in premenopausal breast cancer.	The New England journal of medicine	2015	79
26251289	exemestane	Johnston SR	Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.	Journal of the National Cancer Institute	2015	20
27059645	exemestane	Steelman LS	The therapeutic potential of mTOR inhibitors in breast cancer.	British journal of clinical pharmacology	2016	13
27217461	exemestane	Rugo HS	Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.	Journal of clinical oncology 	2016	21
27269946	exemestane	Fribbens C	Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.	Journal of clinical oncology 	2016	45
27532364	exemestane	Chandarlapaty S	Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.	JAMA oncology	2016	30
28045625	exemestane	Ellis MJ	Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).	Journal of clinical oncology 	2017	11
11772336	tanespimycin	Maloney A	HSP90 as a new therapeutic target for cancer therapy: the story unfolds.	Expert opinion on biological therapy	2002	91
11927289	tanespimycin	Neckers L	Hsp90 inhibitors as novel cancer chemotherapeutic agents.	Trends in molecular medicine	2002	136
14508491	tanespimycin	Kamal A	A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.	Nature	2003	352
14624223	tanespimycin	Neckers L	Heat shock protein 90.	Current opinion in oncology	2003	98
15168026	tanespimycin	Zhang H	Targeting multiple signal transduction pathways through inhibition of Hsp90.	Journal of molecular medicine	2004	97
15514006	tanespimycin	George P	Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.	Blood	2005	77
15718306	tanespimycin	Goetz MP	Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.	Journal of clinical oncology 	2005	86
15961763	tanespimycin	Banerji U	Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.	Journal of clinical oncology 	2005	124
16234364	tanespimycin	Mitsiades CS	Antimyeloma activity of heat shock protein-90 inhibition.	Blood	2006	80
16288046	tanespimycin	Guo F	Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.	Cancer research	2005	69
16322212	tanespimycin	da Rocha Dias S	Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.	Cancer research	2005	72
16371460	tanespimycin	Grbovic OM	V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors.	Proceedings of the National Academy of Sciences of the United States of America	2006	94
16860662	tanespimycin	Sharp S	Inhibitors of the HSP90 molecular chaperone: current status.	Advances in cancer research	2006	84
17259553	tanespimycin	Powers MV	Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.	Endocrine-related cancer	2006	81
17363532	tanespimycin	Solit DB	Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.	Clinical cancer research 	2007	55
17645779	tanespimycin	Tsutsumi S	Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis.	Cancer science	2007	79
18048823	tanespimycin	Modi S	Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.	Journal of clinical oncology 	2007	94
18591380	tanespimycin	Rao R	HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.	Blood	2008	52
18644253	tanespimycin	Taldone T	Targeting Hsp90: small-molecule inhibitors and their clinical development.	Current opinion in pharmacology	2008	90
19088048	tanespimycin	Solit DB	Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.	Clinical cancer research 	2008	70
19860730	tanespimycin	Kim YS	Update on Hsp90 inhibitors in clinical trial.	Current topics in medicinal chemistry	2009	96
19884552	tanespimycin	Spector NL	Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2009	115
20683637	tanespimycin	Pacey S	A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.	Investigational new drugs	2012	38
20940188	tanespimycin	Sequist LV	Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.	Journal of clinical oncology 	2010	101
21030459	tanespimycin	Sasaki T	The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.	Cancer research	2010	106
21219297	tanespimycin	Richardson PG	Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.	British journal of haematology	2011	36
21258415	tanespimycin	Normant E	The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.	Oncogene	2011	47
21478269	tanespimycin	Li D	Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.	Molecular cancer research 	2011	68
21502504	tanespimycin	Katayama R	Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.	Proceedings of the National Academy of Sciences of the United States of America	2011	157
21558407	tanespimycin	Modi S	HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.	Clinical cancer research 	2011	106
22144665	tanespimycin	Ying W	Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.	Molecular cancer therapeutics	2012	64
22209713	tanespimycin	Siegel D	NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.	Biochemical pharmacology	2012	41
22439642	tanespimycin	Vinci M	Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation.	BMC biology	2012	138
22538852	tanespimycin	Mimura N	Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.	Blood	2012	94
23312026	tanespimycin	Sidera K	HSP90 inhibitors: current development and potential in cancer therapy.	Recent patents on anti-cancer drug discovery	2014	52
26639656	tanespimycin	Gower A	EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer.	Molecular oncology	2016	10
7600583	lysophosphatidic acid	Hill CS	The Rho family GTPases RhoA, Rac1, and CDC42Hs regulate transcriptional activation by SRF.	Cell	1995	341
14744855	lysophosphatidic acid	Hama K	Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1.	The Journal of biological chemistry	2004	76
15271293	lysophosphatidic acid	Aoki J	Mechanisms of lysophosphatidic acid production.	Seminars in cell & developmental biology	2004	71
15599396	lysophosphatidic acid	Boucharaba A	Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.	The Journal of clinical investigation	2004	103
16211229	lysophosphatidic acid	Li S	Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression.	International journal of oncology	2005	73
17459484	lysophosphatidic acid	van Meeteren LA	Regulation and biological activities of the autotaxin-LPA axis.	Progress in lipid research	2007	102
18327261	lysophosphatidic acid	Kanda H	Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs.	Nature immunology	2008	69
19001604	lysophosphatidic acid	Yu S	Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells.	Journal of the National Cancer Institute	2008	62
19011242	lysophosphatidic acid	Chen M	Integrin alpha6beta4 controls the expression of genes associated with cell motility, invasion, and metastasis, including S100A4/metastasin.	The Journal of biological chemistry	2009	56
19238201	lysophosphatidic acid	Kam Y	Cadherin-bound beta-catenin feeds into the Wnt pathway upon adherens junctions dissociation: evidence for an intersection between beta-catenin pools.	PloS one	2009	50
19386608	lysophosphatidic acid	Yanagida K	Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6.	The Journal of biological chemistry	2009	61
19509223	lysophosphatidic acid	Zhang H	Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo.	Cancer research	2009	45
19609003	lysophosphatidic acid	Li TT	Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells.	Molecular cancer research 	2009	52
20055701	lysophosphatidic acid	Choi JW	LPA receptors: subtypes and biological actions.	Annual review of pharmacology and toxicology	2010	222
20392816	lysophosphatidic acid	Gierse J	A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.	The Journal of pharmacology and experimental therapeutics	2010	48
21041624	lysophosphatidic acid	Su F	Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	56
21240271	lysophosphatidic acid	Hausmann J	Structural basis of substrate discrimination and integrin binding by autotaxin.	Nature structural & molecular biology	2011	60
21978933	lysophosphatidic acid	Ward Y	LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells.	Cancer research	2011	36
22863277	lysophosphatidic acid	Yu FX	Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling.	Cell	2012	321
23611148	lysophosphatidic acid	Willier S	Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays.	Biology of the cell	2013	35
23618389	lysophosphatidic acid	Cai H	The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells.	Cell communication and signaling 	2013	32
24443508	lysophosphatidic acid	Knowlden S	The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation.	Journal of immunology	2014	31
25024203	lysophosphatidic acid	Xiong S	Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.	Proceedings of the National Academy of Sciences of the United States of America	2014	24
25460336	lysophosphatidic acid	Leblanc R	New insights into the autotaxin/LPA axis in cancer development and metastasis.	Experimental cell research	2015	16
25499971	lysophosphatidic acid	Kihara Y	Lysophospholipid receptors in drug discovery.	Experimental cell research	2015	28
25904553	lysophosphatidic acid	Yu OM	G Protein-Coupled Receptor and RhoA-Stimulated Transcriptional Responses: Links to Inflammation, Differentiation, and Cell Proliferation.	Molecular pharmacology	2015	19
26740622	lysophosphatidic acid	Kedziora KM	Rapid Remodeling of Invadosomes by Gi-coupled Receptors: DISSECTING THE ROLE OF Rho GTPases.	The Journal of biological chemistry	2016	12
26947063	lysophosphatidic acid	Qin H	YAP Induces Human Naive Pluripotency.	Cell reports	2016	14
27059127	lysophosphatidic acid	Velasco M	Lysophosphatidic acid receptors (LPARs): Potential targets for the treatment of neuropathic pain.	Neuropharmacology	2017	6
27981605	lysophosphatidic acid	Kaffe E	Hepatocyte autotaxin expression promotes liver fibrosis and cancer.	Hepatology	2017	8
11426655	temsirolimus	Hidalgo M	The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.	Oncogene	2000	113
11504908	temsirolimus	Neshat MS	Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.	Proceedings of the National Academy of Sciences of the United States of America	2001	217
12901945	temsirolimus	Huang S	Targeting mTOR signaling for cancer therapy.	Current opinion in pharmacology	2003	80
15136596	temsirolimus	Raymond E	Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.	Journal of clinical oncology 	2004	88
15585641	temsirolimus	deGraffenried LA	Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.	Clinical cancer research 	2004	82
15890640	temsirolimus	Ghobrial IM	Targeting apoptosis pathways in cancer therapy.	CA	2005	187
15955899	temsirolimus	Chan S	Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.	Journal of clinical oncology 	2005	105
15983389	temsirolimus	Witzig TE	Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.	Journal of clinical oncology 	2005	117
15998902	temsirolimus	Galanis E	Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.	Journal of clinical oncology 	2005	155
16012795	temsirolimus	Chang SM	Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.	Investigational new drugs	2005	94
16227402	temsirolimus	Shi Y	Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.	Molecular cancer therapeutics	2005	126
16341243	temsirolimus	Thomas GV	Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.	Nature medicine	2006	169
16740688	temsirolimus	Del Bufalo D	Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.	Cancer research	2006	63
17031397	temsirolimus	Duran I	A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.	British journal of cancer	2006	76
17158546	temsirolimus	Motzer RJ	Targeted therapy for metastatic renal cell carcinoma.	Journal of clinical oncology 	2006	67
17179228	temsirolimus	Zeng Z	Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.	Blood	2007	119
17409454	temsirolimus	Petricoin EF 3rd	Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival.	Cancer research	2007	71
18440854	temsirolimus	Jiang BH	Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.	Drug resistance updates 	2008	73
19229667	temsirolimus	Dutcher JP	Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.	Medical oncology	2009	57
20028853	temsirolimus	Baryawno N	Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.	Cancer research	2010	44
20068177	temsirolimus	Yu K	Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.	Cancer research	2010	58
20630061	temsirolimus	Javle MM	Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.	BMC cancer	2010	41
20940415	temsirolimus	Pérez-Galán P	Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.	Blood	2011	89
21289267	temsirolimus	Liu R	The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.	The Journal of clinical endocrinology and metabolism	2011	36
21346036	temsirolimus	Hutson TE	Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.	The oncologist	2011	48
21664867	temsirolimus	Négrier S	Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.	The Lancet. Oncology	2011	38
21690471	temsirolimus	Spunt SL	Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.	Journal of clinical oncology 	2011	36
21750201	temsirolimus	Naing A	Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.	Clinical cancer research 	2011	44
21752435	temsirolimus	Behbakht K	Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.	Gynecologic oncology	2011	41
21788564	temsirolimus	Oza AM	Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.	Journal of clinical oncology 	2011	59
21952069	temsirolimus	Coppin C	Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.	BJU international	2011	55
22378068	temsirolimus	Shi WY	Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.	Cell death & disease	2012	56
22408430	temsirolimus	Pópulo H	The mTOR signalling pathway in human cancer.	International journal of molecular sciences	2012	128
22465830	temsirolimus	Naing A	Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.	Clinical cancer research 	2012	60
22891270	temsirolimus	Armstrong AJ	Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.	Journal of clinical oncology 	2012	39
23375551	temsirolimus	Martelli M	Diffuse large B-cell lymphoma.	Critical reviews in oncology/hematology	2013	50
23477833	temsirolimus	Schwartz GK	Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2013	46
23633458	temsirolimus	von Roemeling CA	Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.	Clinical cancer research 	2013	49
23892718	temsirolimus	Neri LM	Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.	Leukemia	2014	23
24216225	temsirolimus	Cohen RB	Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).	Cancer treatment reviews	2014	24
24297945	temsirolimus	Rini BI	Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.	Journal of clinical oncology 	2014	34
24323026	temsirolimus	Gandhi L	Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.	Journal of clinical oncology 	2014	42
24333502	temsirolimus	Polivka J Jr	Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.	Pharmacology & therapeutics	2014	89
24422672	temsirolimus	Subbiah V	Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.	Journal of hematology & oncology	2014	21
24470557	temsirolimus	Wen PY	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.	Neuro-oncology	2014	30
24480319	temsirolimus	Santoni M	Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma.	Biochimica et biophysica acta	2014	21
24708766	temsirolimus	Zhang H	Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.	Breast cancer research 	2014	23
24748656	temsirolimus	Dienstmann R	Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.	Molecular cancer therapeutics	2014	66
24991838	temsirolimus	Rangwala R	Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.	Autophagy	2014	91
25446280	temsirolimus	Wagner LM	Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.	Pediatric blood & cancer	2015	18
25488966	temsirolimus	Hobday TJ	Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.	Journal of clinical oncology 	2015	19
25724518	temsirolimus	McKay RR	Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.	Clinical cancer research 	2015	16
25867072	temsirolimus	He K	mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation.	Oncogene	2016	20
26463117	temsirolimus	Arriola Apelo SI	Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system.	Aging cell	2016	21
27277600	temsirolimus	Bedke J	Systemic therapy in metastatic renal cell carcinoma.	World journal of urology	2017	9
16024630	Proteasome Inhibitors	Qin JZ	Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.	Cancer research	2005	90
16024631	Proteasome Inhibitors	Fernández Y	Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.	Cancer research	2005	69
16166592	Proteasome Inhibitors	Pérez-Galán P	The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.	Blood	2006	134
16507771	Proteasome Inhibitors	Obeng EA	Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.	Blood	2006	284
17093135	Proteasome Inhibitors	Yang H	The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry".	Molecular pharmacology	2007	57
17308121	Proteasome Inhibitors	Meister S	Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.	Cancer research	2007	96
17475769	Proteasome Inhibitors	Mazroui R	Inhibition of the ubiquitin-proteasome system induces stress granule formation.	Molecular biology of the cell	2007	65
17525289	Proteasome Inhibitors	Davenport EL	Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells.	Blood	2007	80
17620365	Proteasome Inhibitors	Ding WX	Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability.	The American journal of pathology	2007	235
18042711	Proteasome Inhibitors	Nikiforov MA	Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.	Proceedings of the National Academy of Sciences of the United States of America	2007	74
18641120	Proteasome Inhibitors	MacInnes AW	Loss of p53 synthesis in zebrafish tumors with ribosomal protein gene mutations.	Proceedings of the National Academy of Sciences of the United States of America	2008	56
18818117	Proteasome Inhibitors	McConkey DJ	Mechanisms of proteasome inhibitor action and resistance in cancer.	Drug resistance updates 	2008	83
19509147	Proteasome Inhibitors	Soucy TA	Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.	Clinical cancer research 	2009	71
19881538	Proteasome Inhibitors	Zhu K	Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells.	Oncogene	2010	97
21247388	Proteasome Inhibitors	Chen D	Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.	Current cancer drug targets	2011	151
21626033	Proteasome Inhibitors	Sayers TJ	Targeting the extrinsic apoptosis signaling pathway for cancer therapy.	Cancer immunology, immunotherapy 	2011	40
21993678	Proteasome Inhibitors	Ling SC	Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.	Haematologica	2012	32
22037302	Proteasome Inhibitors	Frankland-Searby S	The 26S proteasome complex: an attractive target for cancer therapy.	Biochimica et biophysica acta	2012	46
22057347	Proteasome Inhibitors	D'Arcy P	Inhibition of proteasome deubiquitinating activity as a new cancer therapy.	Nature medicine	2011	108
22204764	Proteasome Inhibitors	Mujtaba T	Advances in the understanding of mechanisms and therapeutic use of bortezomib.	Discovery medicine	2011	39
22537901	Proteasome Inhibitors	Tseng LM	CIP2A is a target of bortezomib in human triple negative breast cancer cells.	Breast cancer research 	2012	33
23151137	Proteasome Inhibitors	Zhao Y	Cullin-RING Ligases as attractive anti-cancer targets.	Current pharmaceutical design	2013	50
23316025	Proteasome Inhibitors	Chou TF	Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase.	ChemMedChem	2013	32
23729400	Proteasome Inhibitors	Vincenz L	Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma.	Molecular cancer therapeutics	2013	25
24029229	Proteasome Inhibitors	Leung-Hagesteijn C	Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.	Cancer cell	2013	82
24912524	Proteasome Inhibitors	Liu N	A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.	Scientific reports	2014	24
25385277	Proteasome Inhibitors	Deshaies RJ	Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.	BMC biology	2014	56
25670156	Proteasome Inhibitors	Niewerth D	Molecular basis of resistance to proteasome inhibitors in hematological malignancies.	Drug resistance updates 	2015	25
26286850	Proteasome Inhibitors	Larrue C	Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.	Blood	2016	14
28244987	Proteasome Inhibitors	Li J	Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11.	Nature chemical biology	2017	10
11350918	gefitinib	Ciardiello F	Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.	Clinical cancer research 	2001	85
11585753	gefitinib	Moasser MM	The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.	Cancer research	2001	91
11595683	gefitinib	Ciardiello F	A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.	Clinical cancer research 	2001	140
11751413	gefitinib	Moulder SL	Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.	Cancer research	2001	99
12202786	gefitinib	Arteaga CL	Epidermal growth factor receptor dependence in human tumors: more than just expression?	The oncologist	2002	89
12384534	gefitinib	Wakeling AE	ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.	Cancer research	2002	135
12409327	gefitinib	Baselga J	Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.	Journal of clinical oncology 	2002	108
12743152	gefitinib	Cohen EE	Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.	Journal of clinical oncology 	2003	99
14570950	gefitinib	Kris MG	Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.	JAMA	2003	406
14638850	gefitinib	Rich JN	Phase II trial of gefitinib in recurrent glioblastoma.	Journal of clinical oncology 	2004	134
15078990	gefitinib	Ono M	Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.	Molecular cancer therapeutics	2004	70
15118073	gefitinib	Lynch TJ	Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.	The New England journal of medicine	2004	2399
15118125	gefitinib	Paez JG	EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.	Science	2004	2101
15158434	gefitinib	Roskoski R Jr	The ErbB/HER receptor protein-tyrosine kinases and cancer.	Biochemical and biophysical research communications	2004	71
15199112	gefitinib	Shou J	Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.	Journal of the National Cancer Institute	2004	288
15284455	gefitinib	Sordella R	Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.	Science	2004	355
15289342	gefitinib	Huang S	Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.	Cancer research	2004	74
15329413	gefitinib	Pao W	EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.	Proceedings of the National Academy of Sciences of the United States of America	2004	1046
15492241	gefitinib	Tracy S	Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.	Cancer research	2004	90
15623594	gefitinib	Huang SF	High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.	Clinical cancer research 	2004	83
15665299	gefitinib	Amann J	Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.	Cancer research	2005	103
15696205	gefitinib	Pao W	KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.	PLoS medicine	2005	415
15709185	gefitinib	Tokumo M	The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.	Clinical cancer research 	2005	100
15710947	gefitinib	Han SW	Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.	Journal of clinical oncology 	2005	141
15728811	gefitinib	Kobayashi S	EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.	The New England journal of medicine	2005	914
15731348	gefitinib	Engelman JA	ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.	Proceedings of the National Academy of Sciences of the United States of America	2005	156
15737014	gefitinib	Pao W	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.	PLoS medicine	2005	933
15738541	gefitinib	Mitsudomi T	Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.	Journal of clinical oncology 	2005	182
15767641	gefitinib	Pao W	Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.	Journal of clinical oncology 	2005	104
15870435	gefitinib	Cappuzzo F	Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.	Journal of the National Cancer Institute	2005	322
15886310	gefitinib	Jänne PA	Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.	Journal of clinical oncology 	2005	88
15897464	gefitinib	Kwak EL	Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.	Proceedings of the National Academy of Sciences of the United States of America	2005	220
15922853	gefitinib	Christensen JG	c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.	Cancer letters	2005	120
15939921	gefitinib	Baselga J	Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.	Journal of clinical oncology 	2005	83
15998906	gefitinib	Hirsch FR	Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.	Journal of clinical oncology 	2005	101
15998907	gefitinib	Takano T	Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.	Journal of clinical oncology 	2005	142
16012181	gefitinib	Segaert S	Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.	Annals of oncology 	2005	66
16049312	gefitinib	Pan Q	Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.	The Journal of molecular diagnostics 	2005	76
16051952	gefitinib	Cappuzzo F	Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.	Journal of clinical oncology 	2005	71
16051966	gefitinib	Peréz-Soler R	Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?	Journal of clinical oncology 	2005	73
16061871	gefitinib	Schilder RJ	Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.	Clinical cancer research 	2005	67
16105816	gefitinib	Nagai Y	Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.	Cancer research	2005	102
16106023	gefitinib	Mukohara T	Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.	Journal of the National Cancer Institute	2005	90
16204011	gefitinib	Bell DW	Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.	Journal of clinical oncology 	2005	123
16278407	gefitinib	Lassman AB	Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.	Clinical cancer research 	2005	68
16322287	gefitinib	Haura EB	Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.	Clinical cancer research 	2005	73
16333527	gefitinib	Hiscox S	Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.	Breast cancer research and treatment	2006	66
16424029	gefitinib	Witta SE	Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.	Cancer research	2006	145
16467097	gefitinib	Riely GJ	Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.	Clinical cancer research 	2006	181
16540667	gefitinib	Alvarez JV	Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.	Cancer research	2006	66
16540671	gefitinib	Pore N	EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms.	Cancer research	2006	67
16648858	gefitinib	Ferby I	Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation.	Nature medicine	2006	95
16705038	gefitinib	Politi K	Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.	Genes & development	2006	130
16785471	gefitinib	Inoue A	Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.	Journal of clinical oncology 	2006	119
16818686	gefitinib	Jackman DM	Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.	Clinical cancer research 	2006	129
16818687	gefitinib	Kimura H	Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.	Clinical cancer research 	2006	71
16818711	gefitinib	Erjala K	Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.	Clinical cancer research 	2006	64
16843264	gefitinib	Zhou BB	Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.	Cancer cell	2006	123
16890793	gefitinib	Mendelsohn J	Epidermal growth factor receptor targeting in cancer.	Seminars in oncology	2006	155
16906227	gefitinib	Engelman JA	Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.	The Journal of clinical investigation	2006	153
16912157	gefitinib	Inukai M	Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.	Cancer research	2006	117
17020982	gefitinib	Kosaka T	Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.	Clinical cancer research 	2006	143
17047648	gefitinib	Asahina H	A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.	British journal of cancer	2006	68
17075123	gefitinib	Hirsch FR	Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2006	148
17085664	gefitinib	Balak MN	Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.	Clinical cancer research 	2006	213
17189394	gefitinib	Riely GJ	Update on epidermal growth factor receptor mutations in non-small cell lung cancer.	Clinical cancer research 	2006	101
17189395	gefitinib	Ono M	Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs.	Clinical cancer research 	2006	81
17290066	gefitinib	Subramanian J	Lung cancer in never smokers: a review.	Journal of clinical oncology 	2007	153
17317677	gefitinib	Hirsch FR	Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.	Annals of oncology 	2007	70
17332364	gefitinib	Mulloy R	Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.	Cancer research	2007	64
17349580	gefitinib	Yun CH	Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.	Cancer cell	2007	231
17440163	gefitinib	Farnie G	Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways.	Journal of the National Cancer Institute	2007	101
17463250	gefitinib	Engelman JA	MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.	Science	2007	1311
17470737	gefitinib	Arpino G	Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.	Journal of the National Cancer Institute	2007	62
17473213	gefitinib	Morgillo F	Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.	Clinical cancer research 	2007	82
17473659	gefitinib	Wu YL	Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.	Journal of thoracic oncology 	2007	63
17551144	gefitinib	Taguchi F	Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.	Journal of the National Cancer Institute	2007	70
17699871	gefitinib	Ritter CA	Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.	Clinical cancer research 	2007	172
17785570	gefitinib	Riely GJ	Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.	Clinical cancer research 	2007	99
17827454	gefitinib	Harari PM	Biology of interactions: antiepidermal growth factor receptor agents.	Journal of clinical oncology 	2007	58
17848912	gefitinib	Kimura H	Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).	British journal of cancer	2007	57
17888036	gefitinib	Mitsudomi T	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.	Cancer science	2007	129
17973572	gefitinib	Costa DB	BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.	PLoS medicine	2007	173
17973573	gefitinib	Cragg MS	Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.	PLoS medicine	2007	118
18006847	gefitinib	Shi Z	Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.	Cancer research	2007	91
18089823	gefitinib	Engelman JA	PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.	Cancer research	2007	177
18093943	gefitinib	Bean J	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.	Proceedings of the National Academy of Sciences of the United States of America	2007	476
18211286	gefitinib	Vazquez-Martin A	Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.	Cell proliferation	2008	59
18245484	gefitinib	Massarweh S	Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.	Cancer research	2008	154
18283321	gefitinib	Tamura K	Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).	British journal of cancer	2008	58
18297114	gefitinib	Wheeler DL	Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.	Oncogene	2008	168
18304967	gefitinib	Weiss GJ	EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.	Annals of oncology 	2008	74
18325048	gefitinib	Taniguchi K	Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.	Cancer science	2008	65
18381447	gefitinib	Fuchs BC	Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.	Cancer research	2008	94
18413800	gefitinib	Godin-Heymann N	The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.	Molecular cancer therapeutics	2008	60
18458038	gefitinib	Sequist LV	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.	Journal of clinical oncology 	2008	246
18483355	gefitinib	Engelman JA	Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.	Clinical cancer research 	2008	204
18509184	gefitinib	Yang CH	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.	Journal of clinical oncology 	2008	58
18568074	gefitinib	Guix M	Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.	The Journal of clinical investigation	2008	177
18599154	gefitinib	Rho JK	Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.	Lung cancer	2009	64
18676761	gefitinib	Wu JY	Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.	Clinical cancer research 	2008	77
18829483	gefitinib	Lo HW	Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.	Clinical cancer research 	2008	68
18836087	gefitinib	Cappuzzo F	MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.	Annals of oncology 	2009	90
18981003	gefitinib	Costa DB	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.	Clinical cancer research 	2008	54
19010870	gefitinib	Bean J	Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.	Clinical cancer research 	2008	84
19010923	gefitinib	Yano S	Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.	Cancer research	2008	181
19018475	gefitinib	Kreisl TN	A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).	Journal of neuro-oncology	2009	48
19147502	gefitinib	Griffero F	Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.	The Journal of biological chemistry	2009	52
19157632	gefitinib	Kim JE	Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.	Lung cancer	2009	48
19224850	gefitinib	Inoue A	First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.	Journal of clinical oncology 	2009	93
19238210	gefitinib	Gandhi J	Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.	PloS one	2009	75
19276163	gefitinib	McGovern UB	Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer.	Molecular cancer therapeutics	2009	49
19276373	gefitinib	Iorio MV	microRNA-205 regulates HER3 in human breast cancer.	Cancer research	2009	114
19276389	gefitinib	Narayan M	Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.	Cancer research	2009	73
19289630	gefitinib	Stewart JS	Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck corrected.	Journal of clinical oncology 	2009	60
19332730	gefitinib	Natale RB	Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.	Journal of clinical oncology 	2009	55
19349489	gefitinib	Riely GJ	KRAS mutations in non-small cell lung cancer.	Proceedings of the American Thoracic Society	2009	154
19351754	gefitinib	Kuang Y	Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.	Clinical cancer research 	2009	72
19414683	gefitinib	Bai H	Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	96
19447865	gefitinib	Naumov GN	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.	Clinical cancer research 	2009	61
19632948	gefitinib	Nguyen KS	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.	Clinical lung cancer	2009	116
19671843	gefitinib	Jackman DM	Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.	Clinical cancer research 	2009	116
19680293	gefitinib	Gazdar AF	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.	Oncogene	2009	191
19680294	gefitinib	Hirsch FR	Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.	Oncogene	2009	59
19692680	gefitinib	Mok TS	Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.	The New England journal of medicine	2009	1723
19692684	gefitinib	Rosell R	Screening for epidermal growth factor receptor mutations in lung cancer.	The New England journal of medicine	2009	495
19706799	gefitinib	Desbois-Mouthon C	Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.	Clinical cancer research 	2009	59
19843665	gefitinib	Wang W	Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.	Clinical cancer research 	2009	69
19850869	gefitinib	Faber AC	Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.	Proceedings of the National Academy of Sciences of the United States of America	2009	137
19917871	gefitinib	Azzoli CG	American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	145
19922469	gefitinib	Mitsudomi T	Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.	The FEBS journal	2010	111
19934277	gefitinib	Akiyama T	Bim-targeted cancer therapy: a link between drug action and underlying molecular changes.	Molecular cancer therapeutics	2009	54
19949011	gefitinib	Jackman D	Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.	Journal of clinical oncology 	2010	178
20064507	gefitinib	Kruser TJ	Mechanisms of resistance to HER family targeting antibodies.	Experimental cell research	2010	51
20108024	gefitinib	Suda K	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.	Cancer metastasis reviews	2010	47
20118985	gefitinib	Ercan D	Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.	Oncogene	2010	65
20130423	gefitinib	Lurje G	EGFR signaling and drug discovery.	Oncology	2009	109
20146086	gefitinib	Clarke JL	High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.	Journal of neuro-oncology	2010	57
20215504	gefitinib	Schoeberl B	An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.	Cancer research	2010	94
20351699	gefitinib	Harris TJ	The molecular pathology of cancer.	Nature reviews. Clinical oncology	2010	58
20573926	gefitinib	Maemondo M	Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.	The New England journal of medicine	2010	1115
20871269	gefitinib	Pirker R	Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.	Journal of thoracic oncology 	2010	61
20959484	gefitinib	Yamamoto C	Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.	Cancer research	2010	43
21030498	gefitinib	Heon S	Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.	Clinical cancer research 	2010	50
21037017	gefitinib	Chang TH	Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.	American journal of respiratory and critical care medicine	2011	41
21062933	gefitinib	Suda K	Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.	Clinical cancer research 	2010	55
21123652	gefitinib	Tigno-Aranjuez JT	Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses.	Genes & development	2010	49
21152424	gefitinib	Ware KE	Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.	PloS one	2010	54
21220471	gefitinib	Jänne PA	Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.	Clinical cancer research 	2011	41
21220474	gefitinib	Donev IS	Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.	Clinical cancer research 	2011	38
21220480	gefitinib	Osborne CK	Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.	Clinical cancer research 	2011	53
21248303	gefitinib	Janjigian YY	Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.	Clinical cancer research 	2011	48
21252289	gefitinib	Minematsu T	Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins.	Molecular cancer therapeutics	2011	37
21471286	gefitinib	Hegi ME	Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.	Molecular cancer therapeutics	2011	42
21482987	gefitinib	D'Angelo SP	Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.	Journal of clinical oncology 	2011	64
21482992	gefitinib	Keedy VL	American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.	Journal of clinical oncology 	2011	132
21487020	gefitinib	Huang WC	Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.	The Journal of biological chemistry	2011	61
21531810	gefitinib	Wu JY	Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.	Clinical cancer research 	2011	96
21573178	gefitinib	Querings S	Benchmarking of mutation diagnostics in clinical lung cancer specimens.	PloS one	2011	37
21597390	gefitinib	Suda K	Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.	Journal of thoracic oncology 	2011	81
21655094	gefitinib	Han W	EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.	PloS one	2011	66
21670455	gefitinib	Fukuoka M	Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).	Journal of clinical oncology 	2011	326
21734175	gefitinib	Chmielecki J	Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.	Science translational medicine	2011	177
21764376	gefitinib	Yasuda H	EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.	The Lancet. Oncology	2012	93
21788562	gefitinib	Zhou Q	Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	64
21856766	gefitinib	Chaft JE	Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.	Clinical cancer research 	2011	102
21900837	gefitinib	Goto K	Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.	Journal of thoracic oncology 	2012	58
22011650	gefitinib	Thongprasert S	Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).	Journal of thoracic oncology 	2011	35
22057914	gefitinib	Cheng Y	MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis.	Molecular cancer therapeutics	2012	40
22105169	gefitinib	Fukuoka H	EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.	The Journal of clinical investigation	2011	37
22119437	gefitinib	Soria JC	EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.	Cancer treatment reviews	2012	37
22127113	gefitinib	Brand TM	The nuclear epidermal growth factor receptor signaling network and its role in cancer.	Discovery medicine	2011	63
22130229	gefitinib	Takeuchi K	Receptor tyrosine kinases and targeted cancer therapeutics.	Biological & pharmaceutical bulletin	2011	36
22157681	gefitinib	Garofalo M	EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.	Nature medicine	2011	120
22167408	gefitinib	Jamal-Hanjani M	Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.	Clinical cancer research 	2012	37
22173954	gefitinib	Xie M	Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.	Journal of cellular biochemistry	2012	45
22228822	gefitinib	Kim Y	The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.	Molecular cancer therapeutics	2012	36
22281684	gefitinib	Prahallad A	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.	Nature	2012	428
22317763	gefitinib	Wang W	Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.	Clinical cancer research 	2012	32
22414764	gefitinib	Blivet-Van Eggelpoël MJ	Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.	Journal of hepatology	2012	39
22436374	gefitinib	Chen G	Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.	BMC medicine	2012	36
22439932	gefitinib	Yamaguchi T	NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma.	Cancer cell	2012	64
22452896	gefitinib	Miller VA	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.	The Lancet. Oncology	2012	235
22541616	gefitinib	Saintigny P	Recent advances in non-small cell lung cancer biology and clinical management.	Discovery medicine	2012	35
22586683	gefitinib	Cheung HW	Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.	Cancer discovery	2011	49
22677429	gefitinib	Park SJ	Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.	Lung cancer	2012	63
22733536	gefitinib	Heon S	The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.	Clinical cancer research 	2012	36
22738915	gefitinib	Casás-Selves M	Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.	Cancer research	2012	36
22752005	gefitinib	Cao M	MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells.	International journal of oncology	2012	48
22802077	gefitinib	Reinhold WC	CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set.	Cancer research	2012	112
22806307	gefitinib	Togashi Y	Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.	Cancer chemotherapy and pharmacology	2012	42
22810899	gefitinib	Johnson ML	Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.	Cancer	2013	34
22844075	gefitinib	Nakagawa T	Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.	Molecular cancer therapeutics	2012	31
22935675	gefitinib	Huang CP	ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors.	Cancer letters	2013	28
22967997	gefitinib	Inoue A	Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).	Annals of oncology 	2013	84
23045285	gefitinib	Gusenbauer S	HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.	Oncogene	2013	37
23154553	gefitinib	D'Angelo SP	Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.	Journal of thoracic oncology 	2012	39
23172555	gefitinib	Ellison G	EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.	Journal of clinical pathology	2013	58
23307622	gefitinib	Cufí S	Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.	Oncotarget	2012	33
23332287	gefitinib	Gadgeel SM	Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.	Clinical lung cancer	2013	31
23461856	gefitinib	Ma L	Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.	The FEBS journal	2013	26
23470965	gefitinib	Yu HA	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.	Clinical cancer research 	2013	343
23542356	gefitinib	Shien K	Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.	Cancer research	2013	72
23555954	gefitinib	Chen G	miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells.	PloS one	2013	74
23563269	gefitinib	Murtaza M	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.	Nature	2013	320
23619944	gefitinib	Peled N	Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.	Cellular oncology	2013	27
23695170	gefitinib	Morgillo F	Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.	Clinical cancer research 	2013	32
23721103	gefitinib	Sakai K	Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.	Cancer science	2013	28
23768755	gefitinib	Roengvoraphoj M	Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.	Cancer treatment reviews	2013	28
23816963	gefitinib	Katakami N	LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.	Journal of clinical oncology 	2013	68
23830194	gefitinib	Brand TM	Nuclear EGFR as a molecular target in cancer.	Radiotherapy and oncology 	2013	45
23872583	gefitinib	Kanda R	Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling.	Cancer research	2013	33
23927790	gefitinib	Kim HR	Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping.	Journal of experimental & clinical cancer research 	2013	28
23948351	gefitinib	Shi Y	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.	The Lancet. Oncology	2013	82
23953842	gefitinib	Yewale C	Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.	Biomaterials	2013	60
23980091	gefitinib	Goss GD	Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.	Journal of clinical oncology 	2013	48
24021541	gefitinib	Iuchi T	Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.	Lung cancer	2013	38
24108744	gefitinib	Buonato JM	ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition.	Cancer research	2014	39
24165158	gefitinib	Rho JK	MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.	Cancer research	2014	30
24258346	gefitinib	Kitamura K	MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.	Molecular cancer therapeutics	2014	40
24263064	gefitinib	Douillard JY	First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.	British journal of cancer	2014	48
24269963	gefitinib	Roskoski R Jr	The ErbB/HER family of protein-tyrosine kinases and cancer.	Pharmacological research	2014	150
24332320	gefitinib	Shi L	Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.	Lung cancer	2014	22
24353160	gefitinib	Yasuda H	Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.	Science translational medicine	2013	60
24355409	gefitinib	Gelsomino F	Targeting the MET gene for the treatment of non-small-cell lung cancer.	Critical reviews in oncology/hematology	2014	21
24419415	gefitinib	Watanabe S	Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.	Journal of thoracic oncology 	2014	25
24486412	gefitinib	Zhao D	Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.	Cellular signalling	2014	25
24489728	gefitinib	Murakami A	Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.	PloS one	2014	28
24520092	gefitinib	Gala K	Molecular pathways: HER3 targeted therapy.	Clinical cancer research 	2014	39
24533047	gefitinib	Liang W	Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.	PloS one	2014	25
24535670	gefitinib	de Bruin EC	Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.	Cancer discovery	2014	42
24644001	gefitinib	Li L	Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.	Clinical cancer research 	2014	54
24857124	gefitinib	Gerber DE	Management and future directions in non-small cell lung cancer with known activating mutations.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting	2014	24
24911146	gefitinib	Park KS	CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.	The Journal of clinical investigation	2014	20
24919575	gefitinib	Yoshida T	Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.	Clinical cancer research 	2014	31
24928736	gefitinib	Roskoski R Jr	ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors.	Pharmacological research	2014	29
24939055	gefitinib	Qu Y	Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.	Journal of experimental & clinical cancer research 	2014	24
24983493	gefitinib	Zhou JY	MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.	Cancer letters	2014	21
25058005	gefitinib	Shen H	Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer.	PloS one	2014	22
25122430	gefitinib	Douillard JY	Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.	Journal of thoracic oncology 	2014	86
25189483	gefitinib	Kharbanda A	Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells.	Clinical cancer research 	2014	25
25294908	gefitinib	Capelletti M	Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.	Clinical cancer research 	2014	27
25349974	gefitinib	D'Incecco A	PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.	British journal of cancer	2015	102
25359280	gefitinib	Lin GN	Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.	Asia-Pacific journal of clinical oncology	2017	14
25403583	gefitinib	Won JK	Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.	Annals of oncology 	2015	19
25482516	gefitinib	Cheng N	Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer.	Oncology reports	2015	22
25563590	gefitinib	Moody TW	EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer.	Current drug targets	2016	11
25611025	gefitinib	Liao BC	Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.	Current opinion in oncology	2015	16
25668120	gefitinib	Chiu CH	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.	Journal of thoracic oncology 	2015	23
25695221	gefitinib	Ichihara E	Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.	Journal of thoracic oncology 	2015	20
25760142	gefitinib	Bae SY	Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.	Oncotarget	2015	16
25795635	gefitinib	Burotto M	Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.	The oncologist	2015	26
25925741	gefitinib	Dong S	The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.	Journal of hematology & oncology	2015	26
25928246	gefitinib	Wen W	Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.	Molecular cancer	2015	15
25961915	gefitinib	Yonesaka K	Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.	Oncogene	2016	11
25998384	gefitinib	Lin K	EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB.	Biochemical and biophysical research communications	2015	20
26159065	gefitinib	Soria JC	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.	The Lancet. Oncology	2015	69
26160838	gefitinib	Cheng N	Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.	Oncotarget	2015	28
26282169	gefitinib	Soucheray M	Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.	Cancer research	2015	19
26308162	gefitinib	Russo A	A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.	Oncotarget	2015	38
26370354	gefitinib	Tan CS	Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.	The Lancet. Oncology	2015	50
26537995	gefitinib	Minguet J	Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.	International journal of cancer	2016	31
26579470	gefitinib	Huang L	Mechanisms of resistance to EGFR tyrosine kinase inhibitors.	Acta pharmaceutica Sinica. B	2015	42
26646759	gefitinib	Schuler M	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.	Annals of oncology 	2016	22
26707383	gefitinib	Han JJ	Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer.	Clinical lung cancer	2016	13
26724471	gefitinib	Lin JJ	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.	Journal of thoracic oncology 	2016	24
26943330	gefitinib	Bai XY	Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines.	PloS one	2016	11
26980062	gefitinib	Kazandjian D	FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.	Clinical cancer research 	2016	16
27022112	gefitinib	Urata Y	Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.	Journal of clinical oncology 	2016	13
27083334	gefitinib	Park K	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.	The Lancet. Oncology	2016	78
27125283	gefitinib	Zhu X	Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer.	Medical science monitor 	2016	13
27198414	gefitinib	Gibbons DL	57O Efficacy, safety and tolerability of MEDI4736 (durvalumab D), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC.	Journal of thoracic oncology 	2016	17
27223332	gefitinib	Greenhalgh J	First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.	The Cochrane database of systematic reviews	2016	21
27323238	gefitinib	Kobayashi Y	Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.	Cancer science	2016	12
27409677	gefitinib	Pan H	Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.	Oncotarget	2016	14
27507876	gefitinib	Cheng Y	Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.	Journal of clinical oncology 	2016	17
27619632	gefitinib	Zhou Q	Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.	Journal of hematology & oncology	2016	12
27663586	gefitinib	Scarborough HA	AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.	Clinical cancer research 	2017	5
28040594	gefitinib	Ma P	Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2017	5
28096505	gefitinib	Gemmill RM	The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancer.	Science signaling	2017	6
28103612	gefitinib	Yang JJ	A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations.	British journal of cancer	2017	9
28271729	gefitinib	Ahn MJ	EGFR TKI combination with immunotherapy in non-small cell lung cancer.	Expert opinion on drug safety	2017	10
28426106	gefitinib	Paz-Ares L	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.	Annals of oncology 	2017	20
12183421	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Wedge SR	ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.	Cancer research	2002	163
12499271	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Carlomagno F	ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.	Cancer research	2002	115
14760102	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Ciardiello F	Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.	Clinical cancer research 	2004	77
18936474	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Heymach JV	Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2008	59
19949019	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Hanrahan EO	Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.	Journal of clinical oncology 	2010	54
20065189	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Wells SA Jr	Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.	Journal of clinical oncology 	2010	100
20371362	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Huynh H	Molecularly targeted therapy in hepatocellular carcinoma.	Biochemical pharmacology	2010	40
20371662	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Robinson BG	Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.	The Journal of clinical endocrinology and metabolism	2010	44
21282537	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	de Boer RH	Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.	Journal of clinical oncology 	2011	68
21282542	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Natale RB	Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	71
22025146	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Wells SA Jr	Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.	Journal of clinical oncology 	2012	212
22327624	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Kohno T	KIF5B-RET fusions in lung adenocarcinoma.	Nature medicine	2012	189
22370318	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Lee JS	Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).	Journal of clinical oncology 	2012	74
22898678	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Leboulleux S	Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.	The Lancet. Oncology	2012	62
23454747	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Chatterjee S	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.	The Journal of clinical investigation	2013	43
23584301	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Gautschi O	A patient with lung adenocarcinoma and RET fusion treated with vandetanib.	Journal of thoracic oncology 	2013	36
23991695	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Kohno T	RET fusion gene: translation to personalized lung cancer therapy.	Cancer science	2013	26
27015562	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Booth L	Pemetrexed + Sorafenib lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.	Oncotarget	2016	10
27549930	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Sobrino A	3D microtumors in vitro supported by perfused vascular networks.	Scientific reports	2016	14
27803005	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Lee SH	Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.	Annals of oncology 	2017	9
27825616	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Yoh K	Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.	The Lancet. Respiratory medicine	2017	21
28447912	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Gautschi O	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.	Journal of clinical oncology 	2017	14
9012846	BH 3	Cheng EH	A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak.	Proceedings of the National Academy of Sciences of the United States of America	1997	122
10197582	BH 3	Korsmeyer SJ	BCL-2 gene family and the regulation of programmed cell death.	Cancer research	1999	123
11572983	BH 3	Han J	Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals.	Proceedings of the National Academy of Sciences of the United States of America	2001	114
12391322	BH 3	Mitsiades N	Molecular sequelae of proteasome inhibition in human multiple myeloma cells.	Proceedings of the National Academy of Sciences of the United States of America	2002	158
12414721	BH 3	Marsden VS	Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more.	Annual review of immunology	2003	91
12719730	BH 3	Opferman JT	Apoptosis in the development and maintenance of the immune system.	Nature immunology	2003	112
12881569	BH 3	Cheng EH	VDAC2 inhibits BAK activation and mitochondrial apoptosis.	Science	2003	213
14980220	BH 3	Lin B	Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3.	Cell	2004	179
15901672	BH 3	Willis SN	Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins.	Genes & development	2005	416
16608847	BH 3	Ming L	PUMA Dissociates Bax and Bcl-X(L) to induce apoptosis in colon cancer cells.	The Journal of biological chemistry	2006	65
16778220	BH 3	Naresh A	The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.	Cancer research	2006	76
17097560	BH 3	Konopleva M	Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.	Cancer cell	2006	331
17453158	BH 3	Lalier L	Bax activation and mitochondrial insertion during apoptosis.	Apoptosis 	2007	67
17927446	BH 3	Gong Y	Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.	PLoS medicine	2007	118
18336294	BH 3	Warr MR	Unique biology of Mcl-1: therapeutic opportunities in cancer.	Current molecular medicine	2008	62
18806760	BH 3	Maiuri MC	Control of autophagy by oncogenes and tumor suppressor genes.	Cell death and differentiation	2009	125
18949058	BH 3	Cragg MS	Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.	The Journal of clinical investigation	2008	72
19043450	BH 3	Lessene G	BCL-2 family antagonists for cancer therapy.	Nature reviews. Drug discovery	2008	159
19273585	BH 3	Bellot G	Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains.	Molecular and cellular biology	2009	317
19371598	BH 3	Morselli E	Anti- and pro-tumor functions of autophagy.	Biochimica et biophysica acta	2009	93
19380879	BH 3	Gallenne T	Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members.	The Journal of cell biology	2009	60
19486339	BH 3	Li Y	Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma.	Cancer science	2009	90
19620789	BH 3	Besch R	Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells.	The Journal of clinical investigation	2009	100
19641500	BH 3	Ni Chonghaile T	Mimicking the BH3 domain to kill cancer cells.	Oncogene	2008	90
19671867	BH 3	Gramantieri L	MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality.	Clinical cancer research 	2009	89
19822411	BH 3	Brenner D	Mitochondrial cell death effectors.	Current opinion in cell biology	2009	98
20010695	BH 3	Chang NC	Antagonism of Beclin 1-dependent autophagy by BCL-2 at the endoplasmic reticulum requires NAF-1.	The EMBO journal	2010	78
20022734	BH 3	Mazure NM	Hypoxia-induced autophagy: cell death or cell survival?	Current opinion in cell biology	2010	131
20023629	BH 3	Schwickart M	Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.	Nature	2010	209
20080742	BH 3	Rasola A	Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition.	Proceedings of the National Academy of Sciences of the United States of America	2010	65
20555361	BH 3	Ri M	Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.	Leukemia	2010	55
20615979	BH 3	Ryan JA	Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes.	Proceedings of the National Academy of Sciences of the United States of America	2010	57
20639903	BH 3	Leber B	Still embedded together binding to membranes regulates Bcl-2 protein interactions.	Oncogene	2010	56
20935509	BH 3	Kang R	HMGB1: a novel Beclin 1-binding protein active in autophagy.	Autophagy	2010	44
21132008	BH 3	Zhang H	Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines.	Oncogene	2011	36
21146563	BH 3	Shamas-Din A	BH3-only proteins: Orchestrators of apoptosis.	Biochimica et biophysica acta	2011	81
21195116	BH 3	Westphal D	Molecular biology of Bax and Bak activation and action.	Biochimica et biophysica acta	2011	77
21311563	BH 3	Kang R	The Beclin 1 network regulates autophagy and apoptosis.	Cell death and differentiation	2011	451
21353614	BH 3	Elgendy M	Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival.	Molecular cell	2011	134
21628457	BH 3	Albershardt TC	Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.	The Journal of biological chemistry	2011	43
21673659	BH 3	Büttner S	A yeast BH3-only protein mediates the mitochondrial pathway of apoptosis.	The EMBO journal	2011	50
21959933	BH 3	Kaufmann T	Fas death receptor signalling: roles of Bid and XIAP.	Cell death and differentiation	2012	77
22015607	BH 3	Dewson G	Bax dimerizes via a symmetric BH3:groove interface during apoptosis.	Cell death and differentiation	2012	61
22173547	BH 3	Lucas KM	Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.	Clinical cancer research 	2012	36
22230093	BH 3	Del Gaizo Moore V	BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions.	Cancer letters	2013	38
22426421	BH 3	Ng KP	A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.	Nature medicine	2012	140
22748923	BH 3	Leboucher GP	Stress-induced phosphorylation and proteasomal degradation of mitofusin 2 facilitates mitochondrial fragmentation and apoptosis.	Molecular cell	2012	68
23063124	BH 3	Vo TT	Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.	Cell	2012	91
23173842	BH 3	Thomas S	Targeting the Bcl-2 family for cancer therapy.	Expert opinion on therapeutic targets	2013	46
23209295	BH 3	Zhu Y	Modulation of serines 17 and 24 in the LC3-interacting region of Bnip3 determines pro-survival mitophagy versus apoptosis.	The Journal of biological chemistry	2013	62
23404709	BH 3	Leshchiner ES	Direct activation of full-length proapoptotic BAK.	Proceedings of the National Academy of Sciences of the United States of America	2013	52
23420005	BH 3	Fu LL	Beclin-1: autophagic regulator and therapeutic target in cancer.	The international journal of biochemistry & cell biology	2013	42
23532334	BH 3	Bean GR	PUMA and BIM are required for oncogene inactivation-induced apoptosis.	Science signaling	2013	36
23607990	BH 3	Ryan J	BH3 profiling in whole cells by fluorimeter or FACS.	Methods	2013	42
23680104	BH 3	Cao X	The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak.	Molecular cancer	2013	25
24019208	BH 3	Abulwerdi F	A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo.	Molecular cancer therapeutics	2014	49
24074954	BH 3	Sarosiek KA	BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response.	Molecular cell	2013	59
24488097	BH 3	Fiori ME	Antitumor effect of miR-197 targeting in p53 wild-type lung cancer.	Cell death and differentiation	2014	24
24682005	BH 3	Colak S	Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells.	Cell death and differentiation	2014	22
24749893	BH 3	Abulwerdi FA	3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.	Journal of medicinal chemistry	2014	23
25048785	BH 3	Anderson MA	Targeting BCL2 for the treatment of lymphoid malignancies.	Seminars in hematology	2014	37
25299770	BH 3	Denoyelle C	miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation.	Cell death & disease	2014	24
25398535	BH 3	Kvansakul M	The Bcl-2 family: structures, interactions and targets for drug discovery.	Apoptosis 	2015	34
25684204	BH 3	Barclay LA	Inhibition of Pro-apoptotic BAX by a noncanonical interaction mechanism.	Molecular cell	2015	25
25715028	BH 3	Pedro JM	BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy.	Autophagy	2015	22
25740983	BH 3	Shinozaki-Ushiku A	Profiling of Virus-Encoded MicroRNAs in Epstein-Barr Virus-Associated Gastric Carcinoma and Their Roles in Gastric Carcinogenesis.	Journal of virology	2015	17
25761368	BH 3	Colin DJ	Cellular responses to a prolonged delay in mitosis are determined by a DNA damage response controlled by Bcl-2 family proteins.	Open biology	2015	15
25795921	BH 3	Daver N	Secondary mutations as mediators of resistance to targeted therapy in leukemia.	Blood	2015	21
25952548	BH 3	Delbridge AR	The BCL-2 protein family, BH3-mimetics and cancer therapy.	Cell death and differentiation	2015	69
25970783	BH 3	Besbes S	New dimension in therapeutic targeting of BCL-2 family proteins.	Oncotarget	2015	26
26079328	BH 3	Vela L	Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside.	Current opinion in pharmacology	2015	19
26174630	BH 3	Touzeau C	BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics.	Leukemia	2016	20
26215860	BH 3	Dummer PD	APOL1 Kidney Disease Risk Variants: An Evolving Landscape.	Seminars in nephrology	2015	18
26405162	BH 3	Sionov RV	Regulation of Bim in Health and Disease.	Oncotarget	2015	16
26822577	BH 3	Delbridge AR	Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies.	Nature reviews. Cancer	2016	53
26973249	BH 3	Vervliet T	Bcl-2 proteins and calcium signaling: complexity beneath the surface.	Oncogene	2016	19
26996748	BH 3	Sarosiek KA	Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise.	The FEBS journal	2016	12
27126996	BH 3	Karpel-Massler G	A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.	Clinical cancer research 	2016	12
27343252	BH 3	Khaw SL	Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.	Blood	2016	13
27520294	BH 3	Konopleva M	Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.	Cancer discovery	2016	34
27760111	BH 3	Kotschy A	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.	Nature	2016	63
27843137	BH 3	Carter MJ	PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis.	Leukemia	2017	6
27913204	BH 3	Vervloessem T	The selective Bcl-2 inhibitor venetoclax, a BH3 mimetic, does not dysregulate intracellular Ca2+ signaling.	Biochimica et biophysica acta	2017	7
28017613	BH 3	Sarosiek KA	Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics.	Cancer cell	2017	15
28111464	BH 3	Deng J	Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.	Leukemia	2017	8
2549426	Amino Acids	Landis CA	GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours.	Nature	1989	177
8103403	Amino Acids	Donis-Keller H	Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.	Human molecular genetics	1993	133
8107229	Amino Acids	Dorfman T	Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein.	Journal of virology	1994	138
8380895	Amino Acids	Huibregtse JM	Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53.	Molecular and cellular biology	1993	149
9296498	Amino Acids	Jost CA	p73 is a simian correction of human p53-related protein that can induce apoptosis.	Nature	1997	196
9326658	Amino Acids	Kiyono T	Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein.	Proceedings of the National Academy of Sciences of the United States of America	1997	156
9467011	Amino Acids	Marsh DJ	Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.	Human molecular genetics	1998	121
9653180	Amino Acids	Kamijo T	Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.	Proceedings of the National Academy of Sciences of the United States of America	1998	213
10769197	Amino Acids	Levrero M	The p53/p63/p73 family of transcription factors: overlapping and distinct functions.	Journal of cell science	2000	100
11087860	Amino Acids	Strack B	A role for ubiquitin ligase recruitment in retrovirus release.	Proceedings of the National Academy of Sciences of the United States of America	2000	128
11160742	Amino Acids	Adamson AL	Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies.	Journal of virology	2001	110
12271141	Amino Acids	Tee AR	Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.	Proceedings of the National Academy of Sciences of the United States of America	2002	212
12525533	Amino Acids	Balk SP	Biology of prostate-specific antigen.	Journal of clinical oncology 	2003	91
12682293	Amino Acids	Sudhakar A	Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins.	Proceedings of the National Academy of Sciences of the United States of America	2003	111
12881723	Amino Acids	Ewart-Toland A	Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human.	Nature genetics	2003	95
12906785	Amino Acids	Tee AR	Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.	Current biology 	2003	359
14761977	Amino Acids	Zhang Z	MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53.	The Journal of biological chemistry	2004	72
15014901	Amino Acids	Ponomarev V	A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging.	European journal of nuclear medicine and molecular imaging	2004	80
15054139	Amino Acids	Xu H	A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.	Proceedings of the National Academy of Sciences of the United States of America	2004	125
15269786	Amino Acids	Sawyer SL	Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G.	PLoS biology	2004	203
15689365	Amino Acids	Pauleit D	O-(2-18Ffluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas.	Brain 	2005	70
15916903	Amino Acids	Fuchs BC	Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?	Seminars in cancer biology	2005	131
16439621	Amino Acids	Rodriguez-Viciana P	Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.	Science	2006	134
16724053	Amino Acids	Shaw RJ	Ras, PI(3)K and mTOR signalling controls tumour cell growth.	Nature	2006	571
16874027	Amino Acids	Furuya N	The evolutionarily conserved domain of Beclin 1 is required for Vps34 binding, autophagy and tumor suppressor function.	Autophagy	2005	135
16940348	Amino Acids	Young AR	Starvation and ULK1-dependent cycling of mammalian Atg9 between the TGN and endosomes.	Journal of cell science	2006	219
17020408	Amino Acids	Singh A	Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.	PLoS medicine	2006	267
17028174	Amino Acids	Baba M	Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.	Proceedings of the National Academy of Sciences of the United States of America	2006	128
17052453	Amino Acids	Zhang HH	S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt.	Molecular cell	2006	103
17158233	Amino Acids	Boasso A	HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells.	Blood	2007	125
17360675	Amino Acids	Urano J	Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells.	Proceedings of the National Academy of Sciences of the United States of America	2007	67
17522216	Amino Acids	Russell RA	Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.	Journal of virology	2007	124
17646408	Amino Acids	Thompson BJ	The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia.	The Journal of experimental medicine	2007	157
18046455	Amino Acids	Li Y	Crystal structure of human XLF/Cernunnos reveals unexpected differences from XRCC4 with implications for NHEJ.	The EMBO journal	2008	50
18159944	Amino Acids	Sawyer SL	Discordant evolution of the adjacent antiretroviral genes TRIM22 and TRIM5 in mammals.	PLoS pathogens	2007	60
18234728	Amino Acids	Toro JR	BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports.	Journal of medical genetics	2008	84
18339839	Amino Acids	McDonald PC	Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival.	Cancer research	2008	76
18349828	Amino Acids	Rennel E	The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice.	British journal of cancer	2008	50
18460336	Amino Acids	Gulati P	Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34.	Cell metabolism	2008	131
18488027	Amino Acids	Gudbjartsson DF	ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma.	Nature genetics	2008	102
18559588	Amino Acids	Jeong EG	Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.	Clinical cancer research 	2008	59
18570873	Amino Acids	Hong F	mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation.	Molecular cell	2008	98
18604198	Amino Acids	Kim E	Regulation of TORC1 by Rag GTPases in nutrient response.	Nature cell biology	2008	402
18722384	Amino Acids	Tsai CJ	Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima.	Journal of molecular biology	2008	71
18794883	Amino Acids	Zhao L	Class I PI3K in oncogenic cellular transformation.	Oncogene	2008	165
19036809	Amino Acids	Russell RA	Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.	Journal of virology	2009	58
19119421	Amino Acids	Zuo J	The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation.	PLoS pathogens	2009	47
19167434	Amino Acids	Chen N	Role and regulation of autophagy in cancer.	Biochimica et biophysica acta	2009	84
19228619	Amino Acids	Yan H	IDH1 and IDH2 mutations in gliomas.	The New England journal of medicine	2009	1088
19234517	Amino Acids	Hartman TR	The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.	Oncogene	2009	62
19443489	Amino Acids	Wang JC	Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5.	Human molecular genetics	2009	87
19582903	Amino Acids	de Lartigue J	PIKfyve regulation of endosome-linked pathways.	Traffic	2009	49
19648920	Amino Acids	Wu X	Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer.	Nature genetics	2009	97
19746446	Amino Acids	Winkler GS	The mammalian anti-proliferative BTG/Tob protein family.	Journal of cellular physiology	2010	76
19935711	Amino Acids	Treins C	Rictor is a novel target of p70 S6 kinase-1.	Oncogene	2010	56
19996293	Amino Acids	Yan H	Mutant metabolic enzymes are at the origin of gliomas.	Cancer research	2009	46
20161710	Amino Acids	Aste-Amézaga M	Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.	PloS one	2010	55
20227368	Amino Acids	Yan L	PP2A T61 epsilon is an inhibitor of MAP4K3 in nutrient signaling to mTOR.	Molecular cell	2010	49
20233713	Amino Acids	Shor B	Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells.	The Journal of biological chemistry	2010	49
20415579	Amino Acids	Phang JM	Proline metabolism and microenvironmental stress.	Annual review of nutrition	2010	42
20444900	Amino Acids	Lim ES	Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses.	Journal of virology	2010	62
20570890	Amino Acids	Janakiraman M	Genomic and biological characterization of exon 4 KRAS mutations in human cancer.	Cancer research	2010	98
20608753	Amino Acids	Keizer RJ	Clinical pharmacokinetics of therapeutic monoclonal antibodies.	Clinical pharmacokinetics	2010	86
20736484	Amino Acids	Moritz A	Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases.	Science signaling	2010	105
20870173	Amino Acids	Powell JD	The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism.	Immunity	2010	152
21179087	Amino Acids	Ngo VN	Oncogenically active MYD88 mutations in human lymphoma.	Nature	2011	287
21307646	Amino Acids	Chong ZZ	Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.	Oxidative medicine and cellular longevity	2010	56
21512002	Amino Acids	Narita M	Spatial coupling of mTOR and autophagy augments secretory phenotypes.	Science	2011	129
22084578	Amino Acids	Chen Y	Kynurenine pathway metabolites in humans: disease and healthy States.	International journal of tryptophan research 	2009	87
22301135	Amino Acids	Lee K	HIV-1 capsid-targeting domain of cleavage and polyadenylation specificity factor 6.	Journal of virology	2012	31
22496159	Amino Acids	Cheng S	Metabolite profiling identifies pathways associated with metabolic risk in humans.	Circulation	2012	116
22574197	Amino Acids	Ögmundsdóttir MH	Proton-assisted amino acid transporter PAT1 complexes with Rag GTPases and activates TORC1 on late endosomal and lysosomal membranes.	PloS one	2012	48
22589270	Amino Acids	Prior IA	A comprehensive survey of Ras mutations in cancer.	Cancer research	2012	248
22687819	Amino Acids	Jansson T	The emerging role of mTORC1 signaling in placental nutrient-sensing.	Placenta	2012	33
22734070	Amino Acids	Payne EM	L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway.	Blood	2012	45
22749019	Amino Acids	Efeyan A	Amino acids and mTORC1: from lysosomes to disease.	Trends in molecular medicine	2012	126
22901812	Amino Acids	Elde NC	Poxviruses deploy genomic accordions to adapt rapidly against host antiviral defenses.	Cell	2012	72
23097438	Amino Acids	Chaipan C	APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.	Journal of virology	2013	44
23103231	Amino Acids	Auer PL	Imputation of exome sequence variants into population- based samples and blood-cell-trait-associated loci in African Americans: NHLBI GO Exome Sequencing Project.	American journal of human genetics	2012	48
23103253	Amino Acids	Elorza A	HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.	Molecular cell	2012	33
23213057	Amino Acids	Hassanein M	SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival.	Clinical cancer research 	2013	56
23333938	Amino Acids	Atkins C	Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity.	Cancer research	2013	91
23426947	Amino Acids	McIntosh J	Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.	Blood	2013	53
23540691	Amino Acids	Kadoch C	Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma.	Cell	2013	70
23694989	Amino Acids	Kim SG	Nutrient regulation of the mTOR complex 1 signaling pathway.	Molecules and cells	2013	58
23723238	Amino Acids	Bar-Peled L	A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1.	Science	2013	209
23728943	Amino Acids	Cleary SP	Identification of driver genes in hepatocellular carcinoma by exome sequencing.	Hepatology	2013	63
23787996	Amino Acids	Wickman GR	Blebs produced by actin-myosin contraction during apoptosis release damage-associated molecular pattern proteins before secondary necrosis occurs.	Cell death and differentiation	2013	29
23842546	Amino Acids	Chae YC	Landscape of the mitochondrial Hsp90 metabolome in tumours.	Nature communications	2013	39
23863160	Amino Acids	Dunlop EA	The kinase triad, AMPK, mTORC1 and ULK1, maintains energy and nutrient homoeostasis.	Biochemical Society transactions	2013	26
23911927	Amino Acids	Linares JF	K63 polyubiquitination and activation of mTOR by the p62-TRAF6 complex in nutrient-activated cells.	Molecular cell	2013	55
23933118	Amino Acids	Thakker RV	Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4).	Molecular and cellular endocrinology	2014	46
23938202	Amino Acids	Rathore A	The local dinucleotide preference of APOBEC3G can be altered from 5'-CC to 5'-TC by a single amino acid substitution.	Journal of molecular biology	2013	28
24113281	Amino Acids	Tsai YC	Sirtuin 7 plays a role in ribosome biogenesis and protein synthesis.	Molecular & cellular proteomics 	2014	28
24155668	Amino Acids	Willard SS	Glutamate, glutamate receptors, and downstream signaling pathways.	International journal of biological sciences	2013	34
24387989	Amino Acids	Mayes MD	Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis.	American journal of human genetics	2014	40
24504062	Amino Acids	Kropski JA	A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia.	Chest	2014	25
24529380	Amino Acids	Demetriades C	Regulation of TORC1 in response to amino acid starvation via lysosomal recruitment of TSC2.	Cell	2014	85
24589857	Amino Acids	Kalvari I	iLIR: A web resource for prediction of Atg8-family interacting proteins.	Autophagy	2014	31
24762957	Amino Acids	Toyoda M	Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer.	British journal of cancer	2014	22
24808134	Amino Acids	Thomson R	Evolution of the primate trypanolytic factor APOL1.	Proceedings of the National Academy of Sciences of the United States of America	2014	55
24853390	Amino Acids	Kenney JW	Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles.	Advances in biological regulation	2014	29
24911150	Amino Acids	Baple EL	Hypomorphic PCNA mutation underlies a human DNA repair disorder.	The Journal of clinical investigation	2014	22
25233904	Amino Acids	Kocak H	Hoyeraal-Hreidarsson syndrome caused by a germline mutation in the TEL patch of the telomere protein TPP1.	Genes & development	2014	29
25411133	Amino Acids	Galldiks N	Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-18Ffluoroethyl)-L-tyrosine PET.	European journal of nuclear medicine and molecular imaging	2015	26
25411794	Amino Acids	Refsland EW	Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity.	PLoS genetics	2014	27
25474014	Amino Acids	Phang JM	Proline metabolism and cancer: emerging links to glutamine and collagen.	Current opinion in clinical nutrition and metabolic care	2015	23
25581430	Amino Acids	Zhang MY	Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.	Nature genetics	2015	44
25639242	Amino Acids	Davie E	Nitrogen regulates AMPK to control TORC1 signaling.	Current biology 	2015	15
25646817	Amino Acids	Edlefsen PT	Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial.	PLoS computational biology	2015	20
25707267	Amino Acids	Collin M	Haematopoietic and immune defects associated with GATA2 mutation.	British journal of haematology	2015	24
25745166	Amino Acids	Burg JS	Structural biology. Structural basis for chemokine recognition and activation of a viral G protein-coupled receptor.	Science	2015	47
25751625	Amino Acids	Michailidou K	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer.	Nature genetics	2015	129
25855379	Amino Acids	Bhutia YD	Amino Acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs.	Cancer research	2015	42
25896326	Amino Acids	Berkovits BD	Alternative 3' UTRs act as scaffolds to regulate membrane protein localization.	Nature	2015	51
25898173	Amino Acids	Sharma S	APOBEC3A cytidine deaminase induces RNA editing in monocytes and macrophages.	Nature communications	2015	26
25956028	Amino Acids	Hiramatsu N	Multiple Mechanisms of Unfolded Protein Response-Induced Cell Death.	The American journal of pathology	2015	40
26015570	Amino Acids	Barrett CL	Systematic transcriptome analysis reveals tumor-specific isoforms for ovarian cancer diagnosis and therapy.	Proceedings of the National Academy of Sciences of the United States of America	2015	18
26092931	Amino Acids	Nabi IR	The galectin lattice at a glance.	Journal of cell science	2015	37
26168401	Amino Acids	Perera RM	Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism.	Nature	2015	84
26186743	Amino Acids	Yeung AW	Role of indoleamine 2,3-dioxygenase in health and disease.	Clinical science	2015	20
26212640	Amino Acids	Tan H	Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity.	Scientific reports	2015	17
26279575	Amino Acids	Linares JF	Amino Acid Activation of mTORC1 by a PB1-Domain-Driven Kinase Complex Cascade.	Cell reports	2015	17
26310906	Amino Acids	Wong PM	Regulation of autophagy by coordinated action of mTORC1 and protein phosphatase 2A.	Nature communications	2015	31
26334087	Amino Acids	Schmidt LS	Molecular genetics and clinical features of Birt-Hogg-Dubé syndrome.	Nature reviews. Urology	2015	21
26389641	Amino Acids	Park YY	Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma.	Hepatology	2016	14
26449471	Amino Acids	Wolfson RL	Sestrin2 is a leucine sensor for the mTORC1 pathway.	Science	2016	119
26543160	Amino Acids	Ye J	GCN2 sustains mTORC1 suppression upon amino acid deprivation by inducing Sestrin2.	Genes & development	2015	34
26553974	Amino Acids	McLaren PJ	Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load.	Proceedings of the National Academy of Sciences of the United States of America	2015	20
26586190	Amino Acids	Saxton RA	Structural basis for leucine sensing by the Sestrin2-mTORC1 pathway.	Science	2016	54
26587888	Amino Acids	Wibmer AG	Molecular Imaging of Prostate Cancer.	Radiographics 	2016	10
26603296	Amino Acids	Bott AJ	Oncogenic Myc Induces Expression of Glutamine Synthetase through Promoter Demethylation.	Cell metabolism	2015	25
26611634	Amino Acids	Hansen CG	The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1.	Cell research	2015	21
26619011	Amino Acids	Chang MT	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.	Nature biotechnology	2016	80
26691987	Amino Acids	Okosun J	Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.	Nature genetics	2016	16
26701267	Amino Acids	Wang QJ	Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.	Cancer immunology research	2016	15
26711178	Amino Acids	Lamb CA	TBC1D14 regulates autophagy via the TRAPP complex and ATG9 traffic.	The EMBO journal	2016	34
26724171	Amino Acids	Parks SK	Hypoxia optimises tumour growth by controlling nutrient import and acidic metabolite export.	Molecular aspects of medicine	2016	13
26724577	Amino Acids	Bhutia YD	Glutamine transporters in mammalian cells and their functions in physiology and cancer.	Biochimica et biophysica acta	2016	12
26742086	Amino Acids	Carroll B	Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity.	eLife	2016	22
26791262	Amino Acids	Li C	Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer.	World journal of surgical oncology	2016	10
26797105	Amino Acids	Pires DE	In silico functional dissection of saturation mutagenesis: Interpreting the relationship between phenotypes and changes in protein stability, interactions and activity.	Scientific reports	2016	16
26818443	Amino Acids	Tang WK	Role of the D1-D2 Linker of Human VCP/p97 in the Asymmetry and ATPase Activity of the D1-domain.	Scientific reports	2016	12
26868506	Amino Acids	Demetriades C	Lysosomal recruitment of TSC2 is a universal response to cellular stress.	Nature communications	2016	15
26878238	Amino Acids	Loayza-Puch F	Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.	Nature	2016	21
26972053	Amino Acids	Chantranupong L	The CASTOR Proteins Are Arginine Sensors for the mTORC1 Pathway.	Cell	2016	79
27076075	Amino Acids	Goberdhan DC	Amino Acid Sensing by mTORC1: Intracellular Transporters Mark the Spot.	Cell metabolism	2016	25
27106405	Amino Acids	Albert NL	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.	Neuro-oncology	2016	24
27109103	Amino Acids	Patil MD	Arginine dependence of tumor cells: targeting a chink in cancer's armor.	Oncogene	2016	11
27129276	Amino Acids	Bröer A	Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells.	The Journal of biological chemistry	2016	19
27240091	Amino Acids	Li B	Landscape of tumor-infiltrating T cell repertoire of human cancers.	Nature genetics	2016	26
27247400	Amino Acids	Li H	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques.	Proceedings of the National Academy of Sciences of the United States of America	2016	26
27259050	Amino Acids	Chen DH	Ataxia-Pancytopenia Syndrome Is Caused by Missense Mutations in SAMD9L.	American journal of human genetics	2016	13
27302165	Amino Acids	Cormerais Y	Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth.	Cancer research	2016	13
27434311	Amino Acids	Rademeyer C	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.	PLoS pathogens	2016	12
27597529	Amino Acids	Wolk A	Potential health hazards of eating red meat.	Journal of internal medicine	2017	7
27609895	Amino Acids	Mayers JR	Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers.	Science	2016	36
27617932	Amino Acids	Pan M	Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation.	Nature cell biology	2016	19
27749844	Amino Acids	Majithia AR	Prospective functional classification of all possible missense variants in PPARG.	Nature genetics	2016	15
27791183	Amino Acids	Cohen-Kaplan V	p62- and ubiquitin-dependent stress-induced autophagy of the mammalian 26S proteasome.	Proceedings of the National Academy of Sciences of the United States of America	2016	14
27797973	Amino Acids	Bachmayr-Heyda A	Integrative Systemic and Local Metabolomics with Impact on Survival in High-Grade Serous Ovarian Cancer.	Clinical cancer research 	2017	7
27827318	Amino Acids	Parkhurst M	Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.	Clinical cancer research 	2017	11
27898682	Amino Acids	Lotta LA	Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis.	PLoS medicine	2016	13
28026090	Amino Acids	Fitter S	The Mesenchymal Precursor Cell Marker Antibody STRO-1 Binds to Cell Surface Heat Shock Cognate 70.	Stem cells	2017	5
28148781	Amino Acids	Khayati K	The amino acid metabolite homocysteine activates mTORC1 to inhibit autophagy and form abnormal proteins in human neurons and mice.	FASEB journal 	2017	6
28249163	Amino Acids	Saunders KO	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates.	Cell reports	2017	6
28279189	Amino Acids	Yoshida GJ	Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment.	Journal of hematology & oncology	2017	11
28380384	Amino Acids	Krishnaiah SY	Clock Regulation of Metabolites Reveals Coupling between Transcription and Metabolism.	Cell metabolism	2017	9
28408430	Amino Acids	Carroll B	The lysosome: a crucial hub for AMPK and mTORC1 signalling.	The Biochemical journal	2017	7
28424515	Amino Acids	Canul-Tec JC	Structure and allosteric inhibition of excitatory amino acid transporter 1.	Nature	2017	6
12214266	lapatinib	Xia W	Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.	Oncogene	2002	162
15374980	lapatinib	Wood ER	A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.	Cancer research	2004	215
15684311	lapatinib	Spector NL	Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.	Journal of clinical oncology 	2005	87
15955900	lapatinib	Burris HA 3rd	Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.	Journal of clinical oncology 	2005	128
16452222	lapatinib	Konecny GE	Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.	Cancer research	2006	223
16682622	lapatinib	Xia W	A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2006	113
17192538	lapatinib	Geyer CE	Lapatinib plus capecitabine for HER2-positive advanced breast cancer.	The New England journal of medicine	2006	629
17308062	lapatinib	Nahta R	Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.	Molecular cancer therapeutics	2007	69
17440164	lapatinib	Scaltriti M	Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.	Journal of the National Cancer Institute	2007	179
18188694	lapatinib	Cameron D	A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.	Breast cancer research and treatment	2008	147
18375904	lapatinib	Kumar A	Structure and clinical relevance of the epidermal growth factor receptor in human cancer.	Journal of clinical oncology 	2008	61
18421051	lapatinib	Lin NU	Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2008	101
18445819	lapatinib	Li X	Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.	Journal of the National Cancer Institute	2008	530
18458039	lapatinib	Gomez HL	Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.	Journal of clinical oncology 	2008	68
18533085	lapatinib	Perez EA	Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.	Mayo Clinic proceedings	2008	51
18664652	lapatinib	Gril B	Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.	Journal of the National Cancer Institute	2008	78
18803986	lapatinib	Medina PJ	Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.	Clinical therapeutics	2008	68
18955454	lapatinib	Di Leo A	Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.	Journal of clinical oncology 	2008	92
19010894	lapatinib	Eichhorn PJ	Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.	Cancer research	2008	148
19034632	lapatinib	Jin Q	Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.	Journal of mammary gland biology and neoplasia	2008	51
19047149	lapatinib	Saxena NK	Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.	Cancer research	2008	73
19056914	lapatinib	Polli JW	An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-(3-fluorobenzyl)oxyphenyl}-6-5-({2-(methylsulfonyl)ethylamino}methyl)-2-furyl-4-quinazolinamine; GW572016).	Drug metabolism and disposition	2009	66
19060928	lapatinib	Scaltriti M	Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.	Oncogene	2009	116
19169683	lapatinib	Ramanathan RK	A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.	Cancer chemotherapy and pharmacology	2009	60
19179558	lapatinib	Blackwell KL	Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.	Annals of oncology 	2009	51
19228746	lapatinib	Lin NU	Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.	Clinical cancer research 	2009	115
19346299	lapatinib	Ross JS	The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.	The oncologist	2009	218
19499221	lapatinib	Thiessen B	A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.	Cancer chemotherapy and pharmacology	2010	43
19671800	lapatinib	Liu L	Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.	Cancer research	2009	128
19701706	lapatinib	Weigelt B	HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.	Breast cancer research and treatment	2010	104
19718025	lapatinib	Prickett TD	Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.	Nature genetics	2009	131
19934303	lapatinib	Miller TW	Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.	Clinical cancer research 	2009	53
20009104	lapatinib	Guo D	EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.	Science signaling	2009	82
20027191	lapatinib	Esteva FJ	Molecular predictors of response to trastuzumab and lapatinib in breast cancer.	Nature reviews. Clinical oncology	2010	52
20124187	lapatinib	Blackwell KL	Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.	Journal of clinical oncology 	2010	188
20179222	lapatinib	Wainberg ZA	Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.	Clinical cancer research 	2010	49
20501798	lapatinib	O'Brien NA	Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.	Molecular cancer therapeutics	2010	88
20530283	lapatinib	Alvarez RH	Emerging targeted therapies for breast cancer.	Journal of clinical oncology 	2010	46
20571069	lapatinib	Hirai H	MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.	Molecular cancer therapeutics	2010	292
20581867	lapatinib	Chakrabarty A	H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.	Oncogene	2010	44
20606083	lapatinib	Monk BJ	Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.	Journal of clinical oncology 	2010	45
20730488	lapatinib	Junttila TT	Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.	Breast cancer research and treatment	2011	71
20736298	lapatinib	Cameron D	Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.	The oncologist	2010	52
21245432	lapatinib	Spraggs CF	HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.	Journal of clinical oncology 	2011	56
21307659	lapatinib	Garrett JT	Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications.	Cancer biology & therapy	2011	55
21324925	lapatinib	Ghosh R	Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.	Cancer research	2011	55
21385943	lapatinib	Garrett JT	Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.	Proceedings of the National Academy of Sciences of the United States of America	2011	160
21465472	lapatinib	Ciravolo V	Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy.	Journal of cellular physiology	2012	64
21468131	lapatinib	Okines A	Targeting the human EGFR family in esophagogastric cancer.	Nature reviews. Clinical oncology	2011	48
21676217	lapatinib	Wang L	PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.	BMC cancer	2011	53
21699723	lapatinib	Giuliano M	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.	Breast cancer research 	2011	46
21741829	lapatinib	von Minckwitz G	Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.	European journal of cancer	2011	41
21840482	lapatinib	Wilson TR	Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.	Cancer cell	2011	51
21847123	lapatinib	Pandya K	Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.	British journal of cancer	2011	46
21860419	lapatinib	Karadedou CT	FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer.	Oncogene	2012	42
21884573	lapatinib	Huang C	β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.	Breast cancer research 	2011	58
22059152	lapatinib	Guo D	An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.	Cancer discovery	2011	70
22123186	lapatinib	Wang YC	Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.	Breast cancer research 	2011	62
22124364	lapatinib	Arteaga CL	Treatment of HER2-positive breast cancer: current status and future perspectives.	Nature reviews. Clinical oncology	2011	215
22161825	lapatinib	Eccles SA	The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology.	The International journal of developmental biology	2011	41
22178589	lapatinib	Andersen JB	Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.	Gastroenterology	2012	86
22248472	lapatinib	McDonagh CF	Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.	Molecular cancer therapeutics	2012	79
22257523	lapatinib	Untch M	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.	The Lancet. Oncology	2012	74
22257673	lapatinib	Baselga J	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.	Lancet	2012	236
22407832	lapatinib	García-García C	Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.	Clinical cancer research 	2012	54
22461506	lapatinib	Vaught DB	HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation.	Cancer research	2012	38
22461643	lapatinib	Stern HM	Improving treatment of HER2-positive cancers: opportunities and challenges.	Science translational medicine	2012	44
22471661	lapatinib	Rexer BN	Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.	Critical reviews in oncogenesis	2012	74
22493419	lapatinib	Guarneri V	Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.	Journal of clinical oncology 	2012	64
22649126	lapatinib	Krop IE	A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.	Journal of clinical oncology 	2012	63
22658319	lapatinib	Hurvitz SA	Current approaches and future directions in the treatment of HER2-positive breast cancer.	Cancer treatment reviews	2013	31
22689807	lapatinib	Blackwell KL	Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.	Journal of clinical oncology 	2012	115
22745588	lapatinib	Clark PA	Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.	Neoplasia	2012	45
22864381	lapatinib	Komurov K	The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells.	Molecular systems biology	2012	34
23020162	lapatinib	Verma S	Trastuzumab emtansine for HER2-positive advanced breast cancer.	The New England journal of medicine	2012	432
23071597	lapatinib	Nowsheen S	Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.	PloS one	2012	33
23103568	lapatinib	Renoir JM	Estrogen receptor signaling as a target for novel breast cancer therapeutics.	Biochemical pharmacology	2013	41
23122784	lapatinib	Bachelot T	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.	The Lancet. Oncology	2013	84
23149820	lapatinib	Singh JK	Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.	Clinical cancer research 	2013	51
23173552	lapatinib	Lambert JM	Drug-conjugated antibodies for the treatment of cancer.	British journal of clinical pharmacology	2013	31
23365119	lapatinib	Montero-Conde C	Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.	Cancer discovery	2013	101
23441129	lapatinib	Walters DM	Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.	Neoplasia	2013	28
23502424	lapatinib	Polier S	ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system.	Nature chemical biology	2013	39
23563986	lapatinib	Boku N	HER2-positive gastric cancer.	Gastric cancer 	2014	33
23873022	lapatinib	Kim HP	Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.	Oncogene	2014	29
23940356	lapatinib	Hanker AB	Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.	Proceedings of the National Academy of Sciences of the United States of America	2013	43
24044505	lapatinib	Xia W	An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.	Breast cancer research 	2013	34
24080156	lapatinib	Kümler I	A systematic review of dual targeting in HER2-positive breast cancer.	Cancer treatment reviews	2014	36
24092940	lapatinib	Gebhart G	18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.	Journal of nuclear medicine 	2013	27
24095300	lapatinib	Robidoux A	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2013	61
24097864	lapatinib	Phillips GD	Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.	Clinical cancer research 	2014	36
24222194	lapatinib	Welslau M	Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.	Cancer	2014	22
24360619	lapatinib	Figueroa-Magalhães MC	Treatment of HER2-positive breast cancer.	Breast	2014	29
24379439	lapatinib	Steinkamp MP	erbB3 is an active tyrosine kinase capable of homo- and heterointeractions.	Molecular and cellular biology	2014	27
24656976	lapatinib	Yan M	HER2 aberrations in cancer: implications for therapy.	Cancer treatment reviews	2014	45
24793816	lapatinib	Krop IE	Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2014	75
24868024	lapatinib	Satoh T	Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.	Journal of clinical oncology 	2014	99
24909179	lapatinib	Moody SE	PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.	Oncogene	2015	20
24919460	lapatinib	Balduzzi S	Trastuzumab-containing regimens for metastatic breast cancer.	The Cochrane database of systematic reviews	2014	27
24973425	lapatinib	Zhang Z	Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.	Clinical cancer research 	2014	24
25025958	lapatinib	Singh JC	HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development.	British journal of cancer	2014	25
25086636	lapatinib	Müller V	Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.	Breast cancer research and treatment	2014	29
25130998	lapatinib	de Azambuja E	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.	The Lancet. Oncology	2014	50
25199759	lapatinib	Loibl S	PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.	Journal of clinical oncology 	2014	47
25355722	lapatinib	Krop IE	Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.	Annals of oncology 	2015	24
25467182	lapatinib	Scaltriti M	High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.	Clinical cancer research 	2015	18
25492965	lapatinib	Haskins JW	Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.	Science signaling	2014	29
25559818	lapatinib	Majewski IJ	PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.	Journal of clinical oncology 	2015	46
25605838	lapatinib	Pivot X	CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.	Journal of clinical oncology 	2015	23
25622903	lapatinib	Zhang L	Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer.	Neoplasia	2015	17
25712686	lapatinib	DeMichele A	The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.	Clinical cancer research 	2015	18
25779558	lapatinib	Gelmon KA	Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.	Journal of clinical oncology 	2015	18
25865888	lapatinib	Stuhlmiller TJ	Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.	Cell reports	2015	59
26022204	lapatinib	Javle M	HER2/neu-directed therapy for biliary tract cancer.	Journal of hematology & oncology	2015	17
26181252	lapatinib	Salgado R	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.	JAMA oncology	2015	46
26204261	lapatinib	Moasser MM	The Evolving Landscape of HER2 Targeting in Breast Cancer.	JAMA oncology	2015	15
26527775	lapatinib	Carey LA	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.	Journal of clinical oncology 	2016	29
26598744	lapatinib	Piccart-Gebhart M	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.	Journal of clinical oncology 	2016	25
26647992	lapatinib	Wang M	N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell-like traits via ErbB signaling in prostate cancer cells.	International journal of oncology	2016	21
26920887	lapatinib	Baselga J	Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.	Clinical cancer research 	2016	19
27034004	lapatinib	Li W	Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.	Oncotarget	2016	22
27108243	lapatinib	Sartore-Bianchi A	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2016	45
28034079	lapatinib	Powles T	Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.	Journal of clinical oncology 	2017	8
28112728	lapatinib	Cancer Genome Atlas Research Network.	Integrated genomic and molecular characterization of cervical cancer.	Nature	2017	38
28238593	lapatinib	Llombart-Cussac A	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.	The Lancet. Oncology	2017	8
12384400	lenalidomide	Richardson PG	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.	Blood	2002	116
15703420	lenalidomide	List A	Efficacy of lenalidomide in myelodysplastic syndromes.	The New England journal of medicine	2005	133
18334676	lenalidomide	Ferrajoli A	Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.	Blood	2008	111
18551193	lenalidomide	Ramsay AG	Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.	The Journal of clinical investigation	2008	145
18628480	lenalidomide	Wu L	lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.	Clinical cancer research 	2008	102
18843284	lenalidomide	Podar K	Bone marrow microenvironment and the identification of new targets for myeloma therapy.	Leukemia	2009	98
19470455	lenalidomide	Wei S	A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.	Proceedings of the National Academy of Sciences of the United States of America	2009	54
19626046	lenalidomide	Dimopoulos MA	Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.	Leukemia	2009	61
20124509	lenalidomide	Nair B	Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.	Blood	2010	68
20460501	lenalidomide	Benson DM Jr	The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.	Blood	2010	143
20978269	lenalidomide	Hsu AK	The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.	Blood	2011	45
21109694	lenalidomide	van der Veer MS	Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.	Haematologica	2011	36
21189262	lenalidomide	Bjorklund CC	Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.	The Journal of biological chemistry	2011	37
21321360	lenalidomide	Jakubikova J	Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.	Blood	2011	61
21519010	lenalidomide	Jädersten M	TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.	Journal of clinical oncology 	2011	76
21707574	lenalidomide	Lopez-Girona A	Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.	British journal of haematology	2011	50
21725050	lenalidomide	Badoux XC	Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.	Blood	2011	40
21937701	lenalidomide	Fehniger TA	A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.	Blood	2011	38
22031859	lenalidomide	Benson DM Jr	IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.	Blood	2011	47
22422823	lenalidomide	Kumar S	Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.	Blood	2012	57
22547582	lenalidomide	Ramsay AG	Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.	Blood	2012	68
22677155	lenalidomide	Wang M	Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.	The Lancet. Oncology	2012	43
22698399	lenalidomide	Yang Y	Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.	Cancer cell	2012	106
22733396	lenalidomide	Luptakova K	Lenalidomide enhances anti-myeloma cellular immunity.	Cancer immunology, immunotherapy 	2013	32
22975377	lenalidomide	Chauhan D	A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.	Cancer cell	2012	100
22975686	lenalidomide	Rushworth SA	BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.	Cellular signalling	2013	33
23100308	lenalidomide	Richter J	Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.	Blood	2013	47
23217107	lenalidomide	Farge D	International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.	Journal of thrombosis and haemostasis 	2013	45
23252516	lenalidomide	Zhang LH	Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.	British journal of haematology	2013	29
23321256	lenalidomide	Görgün GT	Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.	Blood	2013	64
23545991	lenalidomide	Wang M	Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.	Leukemia	2013	26
23565715	lenalidomide	Heintel D	High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.	British journal of haematology	2013	29
23760401	lenalidomide	Bjorklund CC	Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.	Leukemia	2014	24
24253022	lenalidomide	Ocio EM	New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).	Leukemia	2014	58
24292623	lenalidomide	Lu G	The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.	Science	2014	161
24292625	lenalidomide	Krönke J	Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.	Science	2014	169
24569262	lenalidomide	Tai YT	Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.	Blood	2014	32
24625454	lenalidomide	Vaidya R	Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.	Annals of oncology 	2014	21
24831981	lenalidomide	Vitolo U	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.	The Lancet. Oncology	2014	24
25135992	lenalidomide	Nowakowski GS	Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.	Journal of clinical oncology 	2015	36
25287778	lenalidomide	Balasa B	Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.	Cancer immunology, immunotherapy 	2015	19
25398450	lenalidomide	Nijhof IS	Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.	Clinical cancer research 	2015	17
25510242	lenalidomide	Nijhof IS	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.	Haematologica	2015	17
25979485	lenalidomide	Görgün G	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.	Clinical cancer research 	2015	40
25999435	lenalidomide	Benson DM Jr	A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.	Clinical cancer research 	2015	30
26131937	lenalidomide	Krönke J	Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.	Nature	2015	52
26195701	lenalidomide	Gribben JG	Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.	Journal of clinical oncology 	2015	21
26308596	lenalidomide	Lokhorst HM	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.	The New England journal of medicine	2015	110
26631114	lenalidomide	van de Donk NW	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.	Blood	2016	30
26686406	lenalidomide	Richardson PG	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.	The Lancet. Haematology	2015	27
27127303	lenalidomide	Tai YT	APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.	Blood	2016	12
27646843	lenalidomide	Yee AJ	Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.	The Lancet. Oncology	2016	14
28295190	lenalidomide	Shah N	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.	British journal of haematology	2017	5
15035987	sorafenib	Wan PT	Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.	Cell	2004	563
15208680	sorafenib	Karasarides M	B-RAF is a therapeutic target in melanoma.	Oncogene	2004	100
15466206	sorafenib	Wilhelm SM	BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.	Cancer research	2004	844
15781657	sorafenib	Sharma A	Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.	Cancer research	2005	98
16007148	sorafenib	Yu C	The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.	Oncogene	2005	88
16446323	sorafenib	Veronese ML	Mechanisms of hypertension associated with BAY 43-9006.	Journal of clinical oncology 	2006	76
16507829	sorafenib	Carlomagno F	BAY 43-9006 inhibition of oncogenic RET mutants.	Journal of the National Cancer Institute	2006	94
16757355	sorafenib	Adnane L	Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.	Methods in enzymology	2006	86
16880785	sorafenib	Eisen T	Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.	British journal of cancer	2006	146
16908937	sorafenib	Abou-Alfa GK	Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.	Journal of clinical oncology 	2006	269
17016424	sorafenib	Wilhelm S	Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.	Nature reviews. Drug discovery	2006	298
17178882	sorafenib	Liu L	Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.	Cancer research	2006	298
17470685	sorafenib	Strumberg D	Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.	The oncologist	2007	97
17613437	sorafenib	Ricci MS	Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.	Cancer cell	2007	87
18165647	sorafenib	Choueiri TK	Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.	Journal of clinical oncology 	2008	89
18172272	sorafenib	Dahut WL	A phase II clinical trial of sorafenib in androgen-independent prostate cancer.	Clinical cancer research 	2008	56
18200035	sorafenib	Zhang W	Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.	Leukemia	2008	61
18219225	sorafenib	Flaherty KT	Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.	Cancer biology & therapy	2008	50
18230792	sorafenib	Zhang W	Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.	Journal of the National Cancer Institute	2008	109
18288997	sorafenib	Petrelli A	From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.	Current medicinal chemistry	2008	74
18300768	sorafenib	Fecher LA	The MAPK pathway in melanoma.	Current opinion in oncology	2008	67
18304676	sorafenib	Llovet JM	Novel advancements in the management of hepatocellular carcinoma in 2008.	Journal of hepatology	2008	202
18310500	sorafenib	Hipp MM	Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.	Blood	2008	71
18483389	sorafenib	Agaram NP	Molecular characterization of pediatric gastrointestinal stromal tumors.	Clinical cancer research 	2008	58
18593924	sorafenib	Ammoun S	Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.	Cancer research	2008	53
18650514	sorafenib	Llovet JM	Sorafenib in advanced hepatocellular carcinoma.	The New England journal of medicine	2008	2137
18669456	sorafenib	Azad NS	Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.	Journal of clinical oncology 	2008	82
18676833	sorafenib	Ding Q	Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer.	Cancer research	2008	53
18787411	sorafenib	Park MA	Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.	Cancer biology & therapy	2008	77
18794803	sorafenib	Smalley KS	CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.	Oncogene	2009	56
18821591	sorafenib	Llovet JM	Molecular targeted therapies in hepatocellular carcinoma.	Hepatology	2008	288
18852116	sorafenib	Wilhelm SM	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.	Molecular cancer therapeutics	2008	297
19001320	sorafenib	Di Nicolantonio F	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.	Journal of clinical oncology 	2008	425
19064974	sorafenib	Golshayan AR	Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.	Journal of clinical oncology 	2009	51
19171708	sorafenib	Escudier B	Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2009	105
19228077	sorafenib	Keating GM	Sorafenib: a review of its use in advanced hepatocellular carcinoma.	Drugs	2009	80
19255327	sorafenib	Kloos RT	Phase II trial of sorafenib in metastatic thyroid cancer.	Journal of clinical oncology 	2009	128
19389879	sorafenib	Metzelder S	Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.	Blood	2009	67
19451442	sorafenib	Escudier B	Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.	Journal of clinical oncology 	2009	222
19595305	sorafenib	Young A	Ras signaling and therapies.	Advances in cancer research	2009	86
19652055	sorafenib	Blumenschein GR Jr	Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.	Journal of clinical oncology 	2009	51
19652060	sorafenib	Rini BI	Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.	Journal of clinical oncology 	2009	82
19665249	sorafenib	Newell P	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.	Journal of hepatology	2009	52
19671763	sorafenib	Woodman SE	Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.	Molecular cancer therapeutics	2009	51
19726678	sorafenib	Bai S	MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.	The Journal of biological chemistry	2009	157
19773371	sorafenib	Hoftijzer H	Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.	European journal of endocrinology	2009	49
19826129	sorafenib	Heng DY	Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.	Journal of clinical oncology 	2009	268
19844230	sorafenib	Kumar R	Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.	British journal of cancer	2009	60
19862815	sorafenib	Jonasch E	Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.	Cancer	2010	41
19935794	sorafenib	Bengala C	Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.	British journal of cancer	2010	49
20006922	sorafenib	Izzedine H	VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.	European journal of cancer	2010	42
20059340	sorafenib	Villanueva A	Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.	Annual review of medicine	2010	66
20212254	sorafenib	Ravandi F	Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.	Journal of clinical oncology 	2010	100
20347499	sorafenib	Shimizu S	The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.	Journal of hepatology	2010	87
20351323	sorafenib	Choueiri TK	Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.	Journal of clinical oncology 	2010	67
20368568	sorafenib	Lam ET	Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.	Journal of clinical oncology 	2010	69
20371721	sorafenib	Yang F	Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3.	Molecular cancer therapeutics	2010	46
20495567	sorafenib	Sheng Z	A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.	Nature medicine	2010	53
20616044	sorafenib	Wüstehube J	Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling.	Proceedings of the National Academy of Sciences of the United States of America	2010	47
20651059	sorafenib	Peña C	Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.	Clinical cancer research 	2010	50
20696054	sorafenib	Jones SJ	Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.	Genome biology	2010	62
20799354	sorafenib	Hikita H	The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.	Hepatology	2010	50
20952518	sorafenib	Borthakur G	Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.	Haematologica	2011	47
21098323	sorafenib	Matei D	Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.	Journal of clinical oncology 	2011	41
21187475	sorafenib	Gedaly R	PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.	Anticancer research	2010	45
21205925	sorafenib	Chen KF	Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.	The Journal of pharmacology and experimental therapeutics	2011	69
21215996	sorafenib	Burger RA	Overview of anti-angiogenic agents in development for ovarian cancer.	Gynecologic oncology	2011	35
21220499	sorafenib	Nagai T	Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.	Molecular cancer therapeutics	2011	39
21334406	sorafenib	Chen X	Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations.	Journal of hepatology	2011	38
21352471	sorafenib	Meng F	Functional analysis of microRNAs in human hepatocellular cancer stem cells.	Journal of cellular and molecular medicine	2012	41
21354226	sorafenib	Tai WT	Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.	Journal of hepatology	2011	46
21368833	sorafenib	Inuzuka H	SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.	Nature	2011	195
21464158	sorafenib	Zurita AJ	A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.	Annals of oncology 	2012	36
21538283	sorafenib	Nault JC	Genetics of hepatobiliary carcinogenesis.	Seminars in liver disease	2011	50
21576636	sorafenib	Spigel DR	Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	44
21622715	sorafenib	Bareford MD	Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.	Cancer research	2011	40
21691147	sorafenib	Shi YH	Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.	Autophagy	2011	81
21748296	sorafenib	El-Khoueiry AB	SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.	Investigational new drugs	2012	39
21751200	sorafenib	von Mehren M	Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.	Cancer	2012	35
21816126	sorafenib	Sangro B	Radioembolization for hepatocellular carcinoma.	Journal of hepatology	2012	62
21858812	sorafenib	Shimizu S	Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.	International journal of cancer	2012	56
21985599	sorafenib	Marra M	Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview.	Journal of translational medicine	2011	46
22056247	sorafenib	Rini BI	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.	Lancet	2011	329
22067401	sorafenib	Oberholzer PA	RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.	Journal of clinical oncology 	2012	81
22130231	sorafenib	Takahashi S	Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.	Biological & pharmaceutical bulletin	2011	48
22146883	sorafenib	Chen HC	SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.	Annals of surgical oncology	2012	41
22180308	sorafenib	Tai WT	Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.	Molecular cancer therapeutics	2012	36
22314428	sorafenib	Burrel M	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.	Journal of hepatology	2012	78
22322234	sorafenib	Lachenmayer A	Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.	Journal of hepatology	2012	44
22368270	sorafenib	Man CH	Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.	Blood	2012	62
22374331	sorafenib	Llovet JM	Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.	Clinical cancer research 	2012	112
22412143	sorafenib	Baselga J	Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.	Journal of clinical oncology 	2012	39
22414760	sorafenib	Personeni N	Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.	Journal of hepatology	2012	40
22446485	sorafenib	Rahmani M	Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.	Blood	2012	36
22451120	sorafenib	Xie B	Sorafenib for treatment of hepatocellular carcinoma: a systematic review.	Digestive diseases and sciences	2012	36
22473773	sorafenib	Shan J	Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma.	Hepatology	2012	74
22504140	sorafenib	Metzelder SK	High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.	Leukemia	2012	40
22617245	sorafenib	Yasuda H	Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.	Journal of thoracic oncology 	2012	34
22711876	sorafenib	Shaik S	SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2.	The Journal of experimental medicine	2012	32
22811581	sorafenib	Lachenmayer A	Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.	Clinical cancer research 	2012	56
22890726	sorafenib	Arao T	FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.	Hepatology	2013	25
22962440	sorafenib	Widemann BC	A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.	Clinical cancer research 	2012	34
22994652	sorafenib	Welker MW	Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.	Transplant international 	2013	35
23073628	sorafenib	Lennartsson J	Stem cell factor receptor/c-Kit: from basic science to clinical implications.	Physiological reviews	2012	108
23103770	sorafenib	Subramaniam A	Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma.	Biochimica et biophysica acta	2013	42
23111106	sorafenib	van Malenstein H	Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth.	Cancer letters	2013	36
23113752	sorafenib	Savvides P	Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.	Thyroid 	2013	35
23316005	sorafenib	Huang XY	αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma.	Hepatology	2013	38
23388504	sorafenib	Goyal L	Targeting the HGF/c-MET pathway in hepatocellular carcinoma.	Clinical cancer research 	2013	57
23392173	sorafenib	Tai WT	Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.	Cell death & disease	2013	46
23430109	sorafenib	Smith CC	Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.	Blood	2013	31
23471579	sorafenib	Xia H	MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.	Hepatology	2013	89
23613521	sorafenib	Ravandi F	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.	Blood	2013	66
23787822	sorafenib	Reig M	Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design.	Hepatology	2013	28
23835194	sorafenib	Pez F	Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs.	Journal of hepatology	2013	56
23862748	sorafenib	Yang F	MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment.	Technology in cancer research & treatment	2014	26
23890088	sorafenib	Botton T	Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.	Pigment cell & melanoma research	2013	30
23897964	sorafenib	Serve H	Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.	Journal of clinical oncology 	2013	56
23908138	sorafenib	Tai WT	Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.	Hepatology	2014	24
23958557	sorafenib	Govaere O	Keratin 19: a key role player in the invasion of human hepatocellular carcinomas.	Gut	2014	53
23980084	sorafenib	Johnson PJ	Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.	Journal of clinical oncology 	2013	112
23980090	sorafenib	Llovet JM	Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.	Journal of clinical oncology 	2013	107
24019545	sorafenib	Motzer RJ	Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.	Journal of clinical oncology 	2013	59
24045150	sorafenib	Giordano S	Met as a therapeutic target in HCC: facts and hopes.	Journal of hepatology	2014	29
24046014	sorafenib	Zimmerman EI	Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.	Blood	2013	43
24233839	sorafenib	Lee HJ	Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma.	Carcinogenesis	2014	21
24423918	sorafenib	El-Khoueiry AB	S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.	British journal of cancer	2014	21
24510746	sorafenib	Scartozzi M	VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.	International journal of cancer	2014	22
24556040	sorafenib	Motzer RJ	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	55
24569458	sorafenib	Imielinski M	Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.	The Journal of clinical investigation	2014	31
24589894	sorafenib	Llovet JM	Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.	Clinical cancer research 	2014	78
24651044	sorafenib	Liu L	Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.	PloS one	2014	24
24687604	sorafenib	Horwitz E	Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.	Cancer discovery	2014	21
24700742	sorafenib	Xiang Q	Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.	Clinical cancer research 	2014	26
24705351	sorafenib	Zhai B	Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.	Molecular cancer therapeutics	2014	45
24768112	sorafenib	Brose MS	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.	Lancet	2014	142
24803676	sorafenib	Karajannis MA	Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.	Neuro-oncology	2014	32
24836552	sorafenib	Takeda H	Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.	Liver international 	2015	17
24844246	sorafenib	Dixon SJ	Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis.	eLife	2014	74
24918061	sorafenib	Takahashi K	Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer.	FEBS open bio	2014	72
25017943	sorafenib	Sounni NE	Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal.	Cell metabolism	2014	34
25040368	sorafenib	Vaira V	MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.	Liver international 	2015	17
25053293	sorafenib	Fernando J	A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.	International journal of cancer	2015	23
25158999	sorafenib	Fitzmorris P	Management of hepatocellular carcinoma.	Journal of cancer research and clinical oncology	2015	17
25216638	sorafenib	Rudalska R	In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.	Nature medicine	2014	43
25239228	sorafenib	Chen YB	Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.	Biology of blood and marrow transplantation 	2014	34
25422324	sorafenib	Wu Q	Decreased expression of hepatocyte nuclear factor 4α (Hnf4α)/microRNA-122 (miR-122) axis in hepatitis B virus-associated hepatocellular carcinoma enhances potential oncogenic GALNT10 protein activity.	The Journal of biological chemistry	2015	15
25498219	sorafenib	Grignani G	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.	The Lancet. Oncology	2015	34
25633810	sorafenib	Ohta K	MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.	Oncotarget	2015	34
25704960	sorafenib	Tavallai M	Nexavar/Stivarga and viagra interact to kill tumor cells.	Journal of cellular physiology	2015	20
25712526	sorafenib	Zheng B	MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.	Biochemical and biophysical research communications	2015	21
25733155	sorafenib	Makarova-Rusher OV	The yin and yang of evasion and immune activation in HCC.	Journal of hepatology	2015	21
25832714	sorafenib	Delire B	The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.	European journal of clinical investigation	2015	20
25865556	sorafenib	Han T	PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.	Journal of hepatology	2015	19
26045065	sorafenib	Liu K	miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN.	Oncology reports	2015	25
26095784	sorafenib	Zhu AX	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.	The Lancet. Oncology	2015	58
26099527	sorafenib	Zucman-Rossi J	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.	Gastroenterology	2015	66
26311740	sorafenib	He C	MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.	Oncotarget	2015	22
26314551	sorafenib	Ross JS	The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.	International journal of cancer	2016	21
26514126	sorafenib	Lou G	Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma.	Journal of hematology & oncology	2015	38
26566875	sorafenib	Diamond EL	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.	Cancer discovery	2016	28
26592953	sorafenib	Govaere O	Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche.	Journal of hepatology	2016	13
26655273	sorafenib	Xu Y	MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.	Cancer letters	2016	17
26790028	sorafenib	Firtina Karagonlar Z	Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.	Cancer science	2016	14
26809111	sorafenib	Lencioni R	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.	Journal of hepatology	2016	54
26811478	sorafenib	Xu IM	Transketolase counteracts oxidative stress to drive cancer development.	Proceedings of the National Academy of Sciences of the United States of America	2016	18
26924089	sorafenib	Zhou SL	Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.	Gastroenterology	2016	22
26969090	sorafenib	Haas NB	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.	Lancet	2016	41
27015352	sorafenib	Sun X	Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis.	Hepatology	2016	14
27100895	sorafenib	Zhang PF	Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.	Cell death & disease	2016	15
27399335	sorafenib	Tong J	FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.	Oncogene	2017	13
27484637	sorafenib	Prieto-Domínguez N	Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy.	Journal of pineal research	2016	11
27732875	sorafenib	Sauzay C	Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma.	Clinica chimica acta; international journal of clinical chemistry	2016	13
27770556	sorafenib	Parikh ND	Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.	Hepatology	2017	6
27849399	sorafenib	Woo HY	New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?	Expert opinion on pharmacotherapy	2017	5
27849562	sorafenib	Bollard J	Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.	Gut	2017	8
28056412	sorafenib	Kroeze SG	Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review.	Cancer treatment reviews	2017	7
28147363	sorafenib	Kudo M	Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.	Oncology	2017	17
28177886	sorafenib	Zhang X	Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.	Oncotarget	2017	7
28344323	sorafenib	Zhu YJ	New knowledge of the mechanisms of sorafenib resistance in liver cancer.	Acta pharmacologica Sinica	2017	12
12531805	sunitinib	O'Farrell AM	SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.	Blood	2003	170
12538485	sunitinib	Mendel DB	In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.	Clinical cancer research 	2003	393
12748309	sunitinib	Abrams TJ	SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.	Molecular cancer therapeutics	2003	147
15459012	sunitinib	Fiedler W	A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.	Blood	2005	83
16330672	sunitinib	Motzer RJ	Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2006	257
17202116	sunitinib	Rini BI	Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.	Journal of the National Cancer Institute	2007	56
17327610	sunitinib	Chow LQ	Sunitinib: from rational design to clinical efficacy.	Journal of clinical oncology 	2007	182
17367763	sunitinib	Roskoski R Jr	Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.	Biochemical and biophysical research communications	2007	73
17473195	sunitinib	Norden-Zfoni A	Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.	Clinical cancer research 	2007	63
17512858	sunitinib	Rubin BP	Gastrointestinal stromal tumour.	Lancet	2007	93
17605814	sunitinib	Deprimo SE	Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.	Journal of translational medicine	2007	91
17942672	sunitinib	Ebos JM	Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.	Proceedings of the National Academy of Sciences of the United States of America	2007	115
18235126	sunitinib	Socinski MA	Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.	Journal of clinical oncology 	2008	84
18312355	sunitinib	Lasota J	Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.	Histopathology	2008	74
18347007	sunitinib	Burstein HJ	Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.	Journal of clinical oncology 	2008	141
18612155	sunitinib	Kulke MH	Activity of sunitinib in patients with advanced neuroendocrine tumors.	Journal of clinical oncology 	2008	114
18623623	sunitinib	Liegl B	Heterogeneity of kinase inhibitor resistance mechanisms in GIST.	The Journal of pathology	2008	80
18669461	sunitinib	Rini BI	Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.	Journal of clinical oncology 	2008	113
18927310	sunitinib	Finke JH	Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.	Clinical cancer research 	2008	126
18955458	sunitinib	Heinrich MC	Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.	Journal of clinical oncology 	2008	132
18971320	sunitinib	Shukla S	Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.	Drug metabolism and disposition	2009	53
19164557	sunitinib	Gajiwala KS	KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.	Proceedings of the National Academy of Sciences of the United States of America	2009	75
19224847	sunitinib	Feldman DR	Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2009	72
19276286	sunitinib	Ko JS	Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.	Clinical cancer research 	2009	243
19470923	sunitinib	Zhu AX	Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.	Journal of clinical oncology 	2009	143
19487381	sunitinib	Motzer RJ	Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2009	449
19648052	sunitinib	Broxterman HJ	Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib.	Drug resistance updates 	2009	59
20103629	sunitinib	Huang D	Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.	Cancer research	2010	63
20103651	sunitinib	Huang D	Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.	Cancer research	2010	114
20165865	sunitinib	Liegl-Atzwanger B	Gastrointestinal stromal tumors.	Virchows Archiv 	2010	50
20339913	sunitinib	Barrios CH	Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.	Breast cancer research and treatment	2010	50
20406969	sunitinib	Ko JS	Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.	Cancer research	2010	85
20501804	sunitinib	Hammers HJ	Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.	Molecular cancer therapeutics	2010	56
20657034	sunitinib	Patil S	Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.	Annals of oncology 	2011	40
20872043	sunitinib	Neyns B	Phase II study of sunitinib malate in patients with recurrent high-grade glioma.	Journal of neuro-oncology	2011	44
20948437	sunitinib	Adotevi O	A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients.	Journal of immunotherapy	2010	42
20952508	sunitinib	Shojaei F	HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.	Cancer research	2010	83
21237299	sunitinib	Greten TF	Myeloid derived suppressor cells in human diseases.	International immunopharmacology	2011	112
21315783	sunitinib	Finke J	MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.	International immunopharmacology	2011	73
21343371	sunitinib	Anglesio MS	IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.	Clinical cancer research 	2011	61
21527770	sunitinib	Rini BI	Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.	Journal of the National Cancer Institute	2011	122
21882181	sunitinib	Kim JJ	Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.	Cancer	2012	37
21898375	sunitinib	Molina AM	Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.	Cancer	2012	35
22015057	sunitinib	Garcia-Donas J	Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.	The Lancet. Oncology	2011	64
22261812	sunitinib	Minor DR	Sunitinib therapy for melanoma patients with KIT mutations.	Clinical cancer research 	2012	37
22308314	sunitinib	Conley SJ	Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.	Proceedings of the National Academy of Sciences of the United States of America	2012	160
22564989	sunitinib	Scagliotti GV	Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.	Journal of clinical oncology 	2012	55
22573349	sunitinib	Griffioen AW	Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients.	Clinical cancer research 	2012	40
22614970	sunitinib	George S	Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.	Journal of clinical oncology 	2012	48
23108136	sunitinib	Terme M	VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.	Cancer research	2013	70
23127174	sunitinib	Ashman LK	Therapeutic targeting of c-KIT in cancer.	Expert opinion on investigational drugs	2013	31
23177515	sunitinib	Demetri GD	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.	Lancet	2013	203
23378344	sunitinib	Hollier BG	FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer.	Cancer research	2013	75
23610448	sunitinib	Guerin E	A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.	Cancer research	2013	25
23720580	sunitinib	Chintalgattu V	Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity.	Science translational medicine	2013	28
24384849	sunitinib	Corless CL	Gastrointestinal stromal tumors: what do we know now?	Modern pathology 	2014	25
24482243	sunitinib	Vasudev NS	Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.	Angiogenesis	2014	119
24925196	sunitinib	von Mehren M	Gastrointestinal stromal tumors, version 2.2014.	Journal of the National Comprehensive Cancer Network 	2014	26
25100872	sunitinib	Kaley TJ	Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.	Neuro-oncology	2015	16
25123505	sunitinib	Mikami S	Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas.	International journal of cancer	2015	22
25200065	sunitinib	Zhang D	Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer.	Molecular cancer	2014	25
25361735	sunitinib	Huang H	VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation.	FASEB journal 	2015	22
25381264	sunitinib	Ciamporcero E	Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.	Molecular cancer therapeutics	2015	19
25538263	sunitinib	Choueiri TK	Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.	Clinical cancer research 	2015	34
25583177	sunitinib	Beuselinck B	Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.	Clinical cancer research 	2015	18
25667274	sunitinib	Lopez-Chavez A	Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.	Journal of clinical oncology 	2015	44
25861727	sunitinib	Costa PM	MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.	Journal of controlled release 	2015	22
25949902	sunitinib	Draghiciu O	Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.	Oncoimmunology	2015	17
26201448	sunitinib	Khella HWZ	miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.	Molecular therapy 	2015	15
26364599	sunitinib	Zhou L	Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.	Oncogene	2016	39
26626617	sunitinib	Tannir NM	Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.	European urology	2016	26
26794930	sunitinib	Armstrong AJ	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.	The Lancet. Oncology	2016	25
27117758	sunitinib	Qu L	Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA.	Cancer cell	2016	63
27297795	sunitinib	Oppermann S	High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.	Blood	2016	11
27487138	sunitinib	Goto Y	The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma.	Oncotarget	2016	15
27595394	sunitinib	Chen W	Targeting renal cell carcinoma with a HIF-2 antagonist.	Nature	2016	39
27718781	sunitinib	Ravaud A	Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.	The New England journal of medicine	2016	32
27751729	sunitinib	Hsieh JJ	Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.	European urology	2017	13
28199818	sunitinib	Choueiri TK	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.	Journal of clinical oncology 	2017	15
28445140	sunitinib	Jitariu AA	Triple negative breast cancer: the kiss of death.	Oncotarget	2017	6
18645193	abiraterone	Attard G	Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.	Journal of clinical oncology 	2008	214
19339269	abiraterone	Attard G	Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.	Cancer research	2009	174
19470933	abiraterone	Attard G	Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.	Journal of clinical oncology 	2009	152
19509232	abiraterone	Attard G	Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.	Cancer research	2009	59
19962664	abiraterone	Attard G	Steroid hormone receptors in prostate cancer: a hard habit to break?	Cancer cell	2009	66
20159824	abiraterone	Ryan CJ	Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.	Journal of clinical oncology 	2010	104
21612468	abiraterone	de Bono JS	Abiraterone and increased survival in metastatic prostate cancer.	The New England journal of medicine	2011	837
21632851	abiraterone	Ryan CJ	Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.	Clinical cancer research 	2011	57
21712345	abiraterone	Cai C	Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.	Endocrine-related cancer	2011	40
21807635	abiraterone	Mostaghel EA	Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.	Clinical cancer research 	2011	185
21868758	abiraterone	Cai C	Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.	Cancer research	2011	124
22170708	abiraterone	Attard G	Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.	The Journal of clinical endocrinology and metabolism	2012	65
22184395	abiraterone	Efstathiou E	Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.	Journal of clinical oncology 	2012	61
22266943	abiraterone	DeVore NM	Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.	Nature	2012	61
22710436	abiraterone	Hu R	Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.	Cancer research	2012	166
23887973	abiraterone	Mitsiades N	A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.	Cancer research	2013	33
24101480	abiraterone	Nyquist MD	TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	41
24139549	abiraterone	Egan A	Castration-resistant prostate cancer: adaptive responses in the androgen axis.	Cancer treatment reviews	2014	39
24276076	abiraterone	Yin L	CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.	Nature reviews. Urology	2014	23
24449822	abiraterone	Yu Z	Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.	Clinical cancer research 	2014	60
24497570	abiraterone	Zadra G	A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis.	EMBO molecular medicine	2014	40
24798453	abiraterone	Sprenger CC	The link between androgen receptor splice variants and castration-resistant prostate cancer.	Hormones & cancer	2014	22
25048254	abiraterone	Nakazawa M	Androgen receptor splice variants in the era of enzalutamide and abiraterone.	Hormones & cancer	2014	26
25184630	abiraterone	Antonarakis ES	AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.	The New England journal of medicine	2014	322
25306226	abiraterone	Karantanos T	Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.	European urology	2015	40
25320358	abiraterone	Chen EJ	Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.	Clinical cancer research 	2015	45
25351916	abiraterone	Toren PJ	Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer.	Molecular cancer therapeutics	2015	25
25489091	abiraterone	He B	GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.	Proceedings of the National Academy of Sciences of the United States of America	2014	28
25514466	abiraterone	Tamae D	The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.	Chemico-biological interactions	2015	18
25601341	abiraterone	Ryan CJ	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.	The Lancet. Oncology	2015	109
25712683	abiraterone	Azad AA	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.	Clinical cancer research 	2015	66
25897673	abiraterone	Salvi S	Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.	British journal of cancer	2015	22
26030522	abiraterone	Li Z	Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.	Nature	2015	44
26537258	abiraterone	Romanel A	Plasma AR and abiraterone-resistant prostate cancer.	Science translational medicine	2015	48
27430478	abiraterone	Hegemann M	Liquid biopsy: ready to guide therapy in advanced prostate cancer?	BJU international	2016	11
27733296	abiraterone	Del Re M	The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.	European urology	2017	12
28384066	abiraterone	Antonarakis ES	Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.	Journal of clinical oncology 	2017	14
21321201	5-hydroxymethylcytosine	Shock LS	DNA methyltransferase 1, cytosine methylation, and cytosine hydroxymethylation in mammalian mitochondria.	Proceedings of the National Academy of Sciences of the United States of America	2011	119
21734233	5-hydroxymethylcytosine	Pronier E	Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors.	Blood	2011	51
22052461	5-hydroxymethylcytosine	Jin SG	5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations.	Cancer research	2011	121
22157888	5-hydroxymethylcytosine	Williams K	DNA methylation: TET proteins-guardians of CpG islands?	EMBO reports	2011	101
22320381	5-hydroxymethylcytosine	Kudo Y	Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation.	Cancer science	2012	75
22391558	5-hydroxymethylcytosine	Yang H	Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation.	Oncogene	2013	140
22688054	5-hydroxymethylcytosine	Müller T	Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas.	The American journal of pathology	2012	31
22824796	5-hydroxymethylcytosine	Wang P	Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.	Oncogene	2013	81
22829908	5-hydroxymethylcytosine	Orr BA	Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma.	PloS one	2012	44
22980977	5-hydroxymethylcytosine	Lian CG	Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma.	Cell	2012	195
23634848	5-hydroxymethylcytosine	Pfeifer GP	5-hydroxymethylcytosine and its potential roles in development and cancer.	Epigenetics & chromatin	2013	39
23671639	5-hydroxymethylcytosine	Liu C	Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1.	PloS one	2013	45
23704319	5-hydroxymethylcytosine	Hur K	Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis.	Gut	2014	55
23818607	5-hydroxymethylcytosine	Huang H	TET1 plays an essential oncogenic role in MLL-rearranged leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2013	56
23827711	5-hydroxymethylcytosine	Song SJ	The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation.	Cell stem cell	2013	95
23828890	5-hydroxymethylcytosine	Lister R	Global epigenomic reconfiguration during mammalian brain development.	Science	2013	449
24028770	5-hydroxymethylcytosine	de la Rica L	PU.1 target genes undergo Tet2-coupled demethylation and DNMT3b-mediated methylation in monocyte-to-osteoclast differentiation.	Genome biology	2013	40
24153300	5-hydroxymethylcytosine	Kohli RM	TET enzymes, TDG and the dynamics of DNA demethylation.	Nature	2013	261
24270360	5-hydroxymethylcytosine	Jeong M	Large conserved domains of low DNA methylation maintained by Dnmt3a.	Nature genetics	2014	88
24334767	5-hydroxymethylcytosine	Castro-Vega LJ	Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas.	Human molecular genetics	2014	41
24373966	5-hydroxymethylcytosine	Madzo J	Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis.	Cell reports	2014	30
24835990	5-hydroxymethylcytosine	Mariani CJ	TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma.	Cell reports	2014	34
24875481	5-hydroxymethylcytosine	Jin C	TET1 is a maintenance DNA demethylase that prevents methylation spreading in differentiated cells.	Nucleic acids research	2014	42
25087872	5-hydroxymethylcytosine	Arab K	Long noncoding RNA TARID directs demethylation and activation of the tumor suppressor TCF21 via GADD45A.	Molecular cell	2014	46
25132561	5-hydroxymethylcytosine	Huang Y	Connections between TET proteins and aberrant DNA modification in cancer.	Trends in genetics 	2014	48
25284789	5-hydroxymethylcytosine	Takai H	5-Hydroxymethylcytosine plays a critical role in glioblastomagenesis by recruiting the CHTOP-methylosome complex.	Cell reports	2014	22
25362856	5-hydroxymethylcytosine	Neri F	TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway.	Oncogene	2015	40
25482556	5-hydroxymethylcytosine	Rampal R	DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.	Cell reports	2014	55
25862091	5-hydroxymethylcytosine	Ichiyama K	The methylcytosine dioxygenase Tet2 promotes DNA demethylation and activation of cytokine gene expression in T cells.	Immunity	2015	31
25922306	5-hydroxymethylcytosine	Yang Q	The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development.	Reproductive sciences	2016	15
26268241	5-hydroxymethylcytosine	Wang C	IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.	Blood	2015	24
26472283	5-hydroxymethylcytosine	Hoekstra AS	Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.	Oncotarget	2015	18
26524525	5-hydroxymethylcytosine	Hu L	Structural insight into substrate preference for TET-mediated oxidation.	Nature	2015	24
26680004	5-hydroxymethylcytosine	Chen K	Loss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer.	Cell research	2016	13
27225590	5-hydroxymethylcytosine	Li L	Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers.	Scientific reports	2016	11
27573823	5-hydroxymethylcytosine	Liu M	Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine.	Proceedings of the National Academy of Sciences of the United States of America	2016	16
28823558	5-hydroxymethylcytosine	Cimmino L	Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.	Cell	2017	14
28826859	5-hydroxymethylcytosine	Cull AH	Tet2 restrains inflammatory gene expression in macrophages.	Experimental hematology	2017	6
16443686	nutlin 3	Tovar C	Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.	Proceedings of the National Academy of Sciences of the United States of America	2006	210
16540668	nutlin 3	Patton JT	Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.	Cancer research	2006	65
16905541	nutlin 3	Hu B	MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.	The Journal of biological chemistry	2006	81
17146434	nutlin 3	Ambrosini G	Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.	Oncogene	2007	55
17364023	nutlin 3	Sarek G	Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.	The Journal of clinical investigation	2007	56
17638873	nutlin 3	Singer S	Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma.	Cancer research	2007	65
17700533	nutlin 3	Lau LM	HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.	Oncogene	2008	57
18451145	nutlin 3	Kumamoto K	Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence.	Cancer research	2008	76
18834305	nutlin 3	Shangary S	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.	Annual review of pharmacology and toxicology	2009	161
19657224	nutlin 3	Choong ML	Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy.	Cell cycle	2009	53
20606252	nutlin 3	Korotchkina LG	The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway.	Aging	2010	162
21051933	nutlin 3	Leontieva OV	Weak p53 permits senescence during cell cycle arrest.	Cell cycle	2010	66
21212465	nutlin 3	Leontieva OV	DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.	Aging	2010	96
21317459	nutlin 3	Rao B	Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.	Oncotarget	2010	50
21391907	nutlin 3	Secchiero P	Recent advances in the therapeutic perspectives of Nutlin-3.	Current pharmaceutical design	2011	40
21447859	nutlin 3	Apontes P	Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture.	Oncotarget	2011	103
21643018	nutlin 3	Aziz MH	Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.	Oncogene	2011	43
21960059	nutlin 3	Nakatani F	miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy.	The Journal of pathology	2012	48
22102694	nutlin 3	Heinemann A	Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D.	Cancer research	2012	46
22170099	nutlin 3	Michaelis M	Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.	Cell death & disease	2011	58
22847439	nutlin 3	Leontieva OV	Hypoxia suppresses conversion from proliferative arrest to cellular senescence.	Proceedings of the National Academy of Sciences of the United States of America	2012	82
23015717	nutlin 3	Hagemeier SR	The cellular ataxia telangiectasia-mutated kinase promotes epstein-barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuli.	Journal of virology	2012	32
23169817	nutlin 3	Choi M	Attractor landscape analysis reveals feedback loops in the p53 network that control the cellular response to DNA damage.	Science signaling	2012	43
23775793	nutlin 3	Menendez D	Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells.	Nucleic acids research	2013	63
24154492	nutlin 3	Herce HD	Visualization and targeted disruption of protein interactions in living cells.	Nature communications	2013	30
24419302	nutlin 3	Gasparini C	NF-κB pathways in hematological malignancies.	Cellular and molecular life sciences 	2014	38
24737129	nutlin 3	Lowe JM	p53 and NF-κB coregulate proinflammatory gene responses in human macrophages.	Cancer research	2014	23
25924068	nutlin 3	Drost J	Sequential cancer mutations in cultured human intestinal stem cells.	Nature	2015	100
16597591	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	White DL	OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.	Blood	2006	88
16721371	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Weisberg E	AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.	British journal of cancer	2006	69
17213283	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Jørgensen HG	Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells.	Blood	2007	84
17496200	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	O'Hare T	Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.	Blood	2007	124
17519960	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Brendel C	Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.	Leukemia	2007	55
17715389	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Kantarjian HM	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.	Blood	2007	138
17720881	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Rix U	Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.	Blood	2007	154
17785585	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Cortes J	Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.	Blood	2007	60
17853901	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Quintás-Cardama A	Flying under the radar: the new wave of BCR-ABL inhibitors.	Nature reviews. Drug discovery	2007	71
18938156	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Day E	Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.	European journal of pharmacology	2008	61
19363292	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Bellodi C	Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.	The Journal of clinical investigation	2009	156
19427995	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Tiwari AK	Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.	Biochemical pharmacology	2009	50
19652056	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Hughes T	Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.	Journal of clinical oncology 	2009	72
19822896	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Rosti G	Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.	Blood	2009	54
19878872	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	O'Hare T	AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.	Cancer cell	2009	235
19922818	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Manley PW	Extended kinase profile and properties of the protein kinase inhibitor nilotinib.	Biochimica et biophysica acta	2010	50
20072125	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Zhang J	Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.	Nature	2010	140
20423956	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Dohse M	Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.	Drug metabolism and disposition	2010	44
20525993	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Saglio G	Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.	The New England journal of medicine	2010	288
20537386	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	An X	BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.	Leukemia research	2010	50
20585556	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Harmon B	Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step.	PLoS pathogens	2010	42
21299849	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Quentmeier H	BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.	Journal of hematology & oncology	2011	39
21856226	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Kantarjian HM	Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.	The Lancet. Oncology	2011	99
22504141	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Cross NC	Standardized definitions of molecular response in chronic myeloid leukemia.	Leukemia	2012	59
22699418	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Larson RA	Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.	Leukemia	2012	76
23090888	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Jabbour E	Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.	American journal of hematology	2012	32
23502220	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Hochhaus A	Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.	Blood	2013	29
23620574	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Jain P	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.	Blood	2013	28
24335106	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Hughes TP	Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.	Blood	2014	42
24729196	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Jabbour E	Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.	American journal of hematology	2014	40
24950332	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Fu D	Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scattering.	Nature chemistry	2014	27
24957147	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Gallipoli P	JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.	Blood	2014	24
25971713	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Jabbour E	Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.	Clinical lymphoma, myeloma & leukemia	2015	17
26437782	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Hochhaus A	Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.	Leukemia	2016	14
26799612	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Jabbour E	Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.	American journal of hematology	2016	13
27416909	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Eadie LN	The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.	Leukemia	2017	7
28329763	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	Wylie AA	The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.	Nature	2017	6
17332304	AZD 6244	Yeh TC	Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.	Clinical cancer research 	2007	172
17699718	AZD 6244	Davies BR	AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.	Molecular cancer therapeutics	2007	141
18390968	AZD 6244	Adjei AA	Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.	Journal of clinical oncology 	2008	169
19029981	AZD 6244	Engelman JA	Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.	Nature medicine	2008	484
19915144	AZD 6244	Emery CM	MEK1 mutations confer resistance to MEK and B-RAF inhibition.	Proceedings of the National Academy of Sciences of the United States of America	2009	174
20179232	AZD 6244	Banerji U	The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.	Clinical cancer research 	2010	59
20215513	AZD 6244	Dry JR	Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).	Cancer research	2010	64
20802351	AZD 6244	Hainsworth JD	A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.	Journal of thoracic oncology 	2010	48
20959481	AZD 6244	Gopal YN	Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.	Cancer research	2010	100
21098728	AZD 6244	Corcoran RB	BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.	Science signaling	2010	88
21124782	AZD 6244	Meng J	Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.	PloS one	2010	57
21215703	AZD 6244	Chang CJ	EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.	Cancer cell	2011	134
21447798	AZD 6244	Little AS	Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.	Science signaling	2011	55
21519015	AZD 6244	O'Neil BH	Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.	Journal of clinical oncology 	2011	38
21519026	AZD 6244	Bekaii-Saab T	Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.	Journal of clinical oncology 	2011	64
21946352	AZD 6244	Prickett TD	Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma.	Nature genetics	2011	63
22194965	AZD 6244	Atefi M	Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.	PloS one	2011	69
22241789	AZD 6244	Hayes DN	Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.	Clinical cancer research 	2012	39
22392911	AZD 6244	Migliardi G	Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.	Clinical cancer research 	2012	48
22395615	AZD 6244	Shi H	Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.	Nature communications	2012	179
22872574	AZD 6244	Roberts PJ	Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.	Clinical cancer research 	2012	65
22915752	AZD 6244	Ibrahim YH	PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.	Cancer discovery	2012	114
22972589	AZD 6244	Patel SP	Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.	Cancer	2013	29
23406027	AZD 6244	Ho AL	Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.	The New England journal of medicine	2013	98
23436801	AZD 6244	Liu Q	Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.	Cancer research	2013	33
23444215	AZD 6244	Catalanotti F	Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.	Clinical cancer research 	2013	40
23515407	AZD 6244	Ohashi K	Characteristics of lung cancers harboring NRAS mutations.	Clinical cancer research 	2013	33
23735514	AZD 6244	Robert C	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.	The Lancet. Oncology	2013	38
23745794	AZD 6244	Fowles JS	Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma.	Veterinary and comparative oncology	2015	16
23918606	AZD 6244	Renshaw J	Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.	Clinical cancer research 	2013	45
24178622	AZD 6244	Jain N	Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.	Clinical cancer research 	2014	31
24363449	AZD 6244	Cope CL	Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation.	Journal of cell science	2014	26
25253770	AZD 6244	Irving J	Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.	Blood	2014	46
25297634	AZD 6244	Gopal YN	Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.	Cancer research	2014	32
25348516	AZD 6244	Alagesan B	Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.	Clinical cancer research 	2015	29
25516890	AZD 6244	Tolcher AW	Antitumor activity in RAS-driven tumors by blocking AKT and MEK.	Clinical cancer research 	2015	21
25638158	AZD 6244	Weingart MF	Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target.	Oncotarget	2015	15
25870145	AZD 6244	Eberlein CA	Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.	Cancer research	2015	46
26802155	AZD 6244	Carter CA	Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.	Annals of oncology 	2016	14
28029918	AZD 6244	Dombi E	Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.	The New England journal of medicine	2016	24
18026190	afatinib	Eskens FA	A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours.	British journal of cancer	2008	58
18408761	afatinib	Li D	BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.	Oncogene	2008	282
19759520	afatinib	Regales L	Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.	The Journal of clinical investigation	2009	119
20679611	afatinib	Yap TA	Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.	Journal of clinical oncology 	2010	85
22257651	afatinib	Ou SH	Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence.	Critical reviews in oncology/hematology	2012	32
22325357	afatinib	De Grève J	Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.	Lung cancer	2012	57
22418700	afatinib	Lin NU	A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.	Breast cancer research and treatment	2012	46
22452895	afatinib	Yang JC	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.	The Lancet. Oncology	2012	84
22888144	afatinib	Solca F	Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.	The Journal of pharmacology and experimental therapeutics	2012	109
22891040	afatinib	Kim SM	Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.	Molecular cancer therapeutics	2012	38
22956644	afatinib	Takezawa K	HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.	Cancer discovery	2012	162
23610105	afatinib	Mazières J	Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.	Journal of clinical oncology 	2013	107
23816960	afatinib	Sequist LV	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	472
23816967	afatinib	Yang JC	Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	59
24199682	afatinib	Yamaguchi N	Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.	Lung cancer	2014	28
24643470	afatinib	Modjtahedi H	A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.	Naunyn-Schmiedeberg's archives of pharmacology	2014	23
24813888	afatinib	Pirazzoli V	Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.	Cell reports	2014	23
24928832	afatinib	Seiwert TY	A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.	Annals of oncology 	2014	27
25074459	afatinib	Janjigian YY	Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.	Cancer discovery	2014	89
25247337	afatinib	Hoffknecht P	Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.	Journal of thoracic oncology 	2015	42
25892145	afatinib	Machiels JP	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2015	46
25948633	afatinib	Ercan D	EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.	Clinical cancer research 	2015	50
26051236	afatinib	Yang JC	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.	The Lancet. Oncology	2015	57
26052929	afatinib	Lee Y	Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.	Molecular carcinogenesis	2016	15
26545934	afatinib	Suzawa K	Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.	Cancer science	2016	15
26716903	afatinib	Nanjo S	High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells.	Oncotarget	2016	12
26823294	afatinib	Schuler M	First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.	Journal of thoracic oncology 	2016	17
26852079	afatinib	van der Wekken AJ	Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature.	Critical reviews in oncology/hematology	2016	18
26862733	afatinib	Wu SG	The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.	Oncotarget	2016	29
27601237	afatinib	Yang JC	Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.	Annals of oncology 	2016	12
27913578	afatinib	Kobayashi Y	Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.	Molecular cancer therapeutics	2017	8
28006816	afatinib	Wu YL	EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.	British journal of cancer	2017	7
8221889	thymosin beta(1)	Scheffner M	The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53.	Cell	1993	559
9528852	thymosin beta(1)	Jensen DE	BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.	Oncogene	1998	143
10230406	thymosin beta(1)	Tan P	Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of I kappa B alpha.	Molecular cell	1999	117
10558980	thymosin beta(1)	Huang L	Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade.	Science	1999	163
10827953	thymosin beta(1)	Mailand N	Rapid destruction of human Cdc25A in response to DNA damage.	Science	2000	196
10835629	thymosin beta(1)	Bignell GR	Identification of the familial cylindromatosis tumour-suppressor gene.	Nature genetics	2000	148
11389444	thymosin beta(1)	Bonni S	TGF-beta induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation.	Nature cell biology	2001	89
11533444	thymosin beta(1)	Koepp DM	Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase.	Science	2001	251
11704856	thymosin beta(1)	Regad T	Role and fate of PML nuclear bodies in response to interferon and viral infections.	Oncogene	2001	103
11961546	thymosin beta(1)	Zheng N	Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex.	Nature	2002	481
12890688	thymosin beta(1)	Wu-Baer F	The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin.	The Journal of biological chemistry	2003	84
14672928	thymosin beta(1)	Mehle A	Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.	The Journal of biological chemistry	2004	230
15014503	thymosin beta(1)	Wei W	Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex.	Nature	2004	164
15601839	thymosin beta(1)	Furukawa M	BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase.	Molecular and cellular biology	2005	198
15710331	thymosin beta(1)	Puc J	Lack of PTEN sequesters CHK1 and initiates genetic instability.	Cancer cell	2005	100
15950904	thymosin beta(1)	Yang Y	Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.	Cancer cell	2005	90
16054087	thymosin beta(1)	Sundqvist A	Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7).	Cell metabolism	2005	132
16407162	thymosin beta(1)	Chen B	The activity of a human endoplasmic reticulum-associated degradation E3, gp78, requires its Cue domain, RING finger, and an E2-binding site.	Proceedings of the National Academy of Sciences of the United States of America	2006	95
16407242	thymosin beta(1)	Hu J	An evolutionarily conserved function of proliferating cell nuclear antigen for Cdt1 degradation by the Cul4-Ddb1 ubiquitin ligase in response to DNA damage.	The Journal of biological chemistry	2006	60
16554418	thymosin beta(1)	Haase VH	Hypoxia-inducible factors in the kidney.	American journal of physiology. Renal physiology	2006	90
16741904	thymosin beta(1)	Swaminathan G	The Cbl family proteins: ring leaders in regulation of cell signaling.	Journal of cellular physiology	2006	97
17079684	thymosin beta(1)	He YJ	DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases.	Genes & development	2006	131
17187060	thymosin beta(1)	Binné UK	Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit.	Nature cell biology	2007	78
17218260	thymosin beta(1)	Wang X	NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN.	Cell	2007	205
17236139	thymosin beta(1)	Tarpey PS	Mutations in CUL4B, which encodes a ubiquitin E3 ligase subunit, cause an X-linked mental retardation syndrome associated with aggressive outbursts, seizures, relative macrocephaly, central obesity, hypogonadism, pes cavus, and tremor.	American journal of human genetics	2007	67
17412408	thymosin beta(1)	Smogorzewska A	Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair.	Cell	2007	295
17485488	thymosin beta(1)	Di Fiore B	Emi1 is needed to couple DNA replication with mitosis but does not regulate activation of the mitotic APC/C.	The Journal of cell biology	2007	59
17575125	thymosin beta(1)	Malyukova A	The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.	Cancer research	2007	61
17909001	thymosin beta(1)	Akhoondi S	FBXW7/hCDC4 is a general tumor suppressor in human cancer.	Cancer research	2007	150
18082865	thymosin beta(1)	Okumura A	HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation.	Virology	2008	54
18316726	thymosin beta(1)	Unk I	Human HLTF functions as a ubiquitin ligase for proliferating cell nuclear antigen polyubiquitination.	Proceedings of the National Academy of Sciences of the United States of America	2008	65
18354483	thymosin beta(1)	Westbrook TF	SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation.	Nature	2008	127
18403209	thymosin beta(1)	Perry JJ	A SIM-ultaneous role for SUMO and ubiquitin.	Trends in biochemical sciences	2008	100
18536714	thymosin beta(1)	Winter M	Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR.	Nature cell biology	2008	58
18931663	thymosin beta(1)	Gyrd-Hansen M	IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis.	Nature cell biology	2008	66
18997792	thymosin beta(1)	Vallabhapurapu S	Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling.	Nature immunology	2008	214
19270695	thymosin beta(1)	Gao D	Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction.	Nature cell biology	2009	108
19622404	thymosin beta(1)	Thompson LH	Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights.	Mutation research	2009	64
19713937	thymosin beta(1)	Parsons JL	Ubiquitin ligase ARF-BP1/Mule modulates base excision repair.	The EMBO journal	2009	50
19910467	thymosin beta(1)	Xu G	Ubiquitin-specific peptidase 21 inhibits tumor necrosis factor alpha-induced nuclear factor kappaB activation via binding to and deubiquitinating receptor-interacting protein 1.	The Journal of biological chemistry	2010	42
19917254	thymosin beta(1)	Shan J	Suppression of cancer cell growth by promoting cyclin D1 degradation.	Molecular cell	2009	64
20601937	thymosin beta(1)	Maertens GN	Ubiquitin-specific proteases 7 and 11 modulate Polycomb regulation of the INK4a tumour suppressor.	The EMBO journal	2010	41
20802491	thymosin beta(1)	Virdee S	Engineered diubiquitin synthesis reveals Lys29-isopeptide specificity of an OTU deubiquitinase.	Nature chemical biology	2010	76
20935639	thymosin beta(1)	Castillo-Lluva S	SUMOylation of the GTPase Rac1 is required for optimal cell migration.	Nature cell biology	2010	44
21855803	thymosin beta(1)	Zlatanou A	The hMsh2-hMsh6 complex acts in concert with monoubiquitinated PCNA and Pol η in response to oxidative DNA damage in human cells.	Molecular cell	2011	45
22266821	thymosin beta(1)	Dou H	Structural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl.	Nature structural & molecular biology	2012	54
22692215	thymosin beta(1)	Huang W	The N-terminal phosphodegron targets TAZ/WWTR1 protein for SCFβ-TrCP-dependent degradation in response to phosphatidylinositol 3-kinase inhibition.	The Journal of biological chemistry	2012	40
22902369	thymosin beta(1)	Dou H	BIRC7-E2 ubiquitin conjugate structure reveals the mechanism of ubiquitin transfer by a RING dimer.	Nature structural & molecular biology	2012	100
23042607	thymosin beta(1)	Davis EJ	DVC1 (C1orf124) recruits the p97 protein segregase to sites of DNA damage.	Nature structural & molecular biology	2012	49
23466868	thymosin beta(1)	Bassermann F	The ubiquitin proteasome system - implications for cell cycle control and the targeted treatment of cancer.	Biochimica et biophysica acta	2014	52
23514139	thymosin beta(1)	Hay RT	Decoding the SUMO signal.	Biochemical Society transactions	2013	28
23560854	thymosin beta(1)	Tatham MH	Ube2W conjugates ubiquitin to α-amino groups of protein N-termini.	The Biochemical journal	2013	29
18451170	navitoclax	Tse C	ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.	Cancer research	2008	456
18519752	navitoclax	Shoemaker AR	Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models.	Clinical cancer research 	2008	62
18806758	navitoclax	Vogler M	Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.	Cell death and differentiation	2009	108
21094089	navitoclax	Wilson WH	Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.	The Lancet. Oncology	2010	165
21282543	navitoclax	Gandhi L	Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.	Journal of clinical oncology 	2011	148
22184378	navitoclax	Roberts AW	Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.	Journal of clinical oncology 	2012	199
22496272	navitoclax	Rudin CM	Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.	Clinical cancer research 	2012	117
22538851	navitoclax	Mérino D	Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.	Blood	2012	66
23221385	navitoclax	Mertens JC	Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma.	Cancer research	2013	34
23291630	navitoclax	Souers AJ	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.	Nature medicine	2013	457
23832116	navitoclax	Varadarajan S	Evaluation and critical assessment of putative MCL-1 inhibitors.	Cell death and differentiation	2013	33
23974697	navitoclax	Billard C	BH3 mimetics: status of the field and new developments.	Molecular cancer therapeutics	2013	77
25590800	navitoclax	Leverson JD	Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).	Cell death & disease	2015	100
25737542	navitoclax	Faber AC	Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.	Proceedings of the National Academy of Sciences of the United States of America	2015	28
25797560	navitoclax	Kipps TJ	A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.	Leukemia & lymphoma	2015	21
25942994	navitoclax	Roberts AW	Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.	British journal of haematology	2015	17
26013319	navitoclax	Xiao Y	MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor.	Molecular cancer therapeutics	2015	23
26045609	navitoclax	Pan R	Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.	Blood	2015	19
26474387	navitoclax	Karpel-Massler G	TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.	Oncotarget	2015	21
26488112	navitoclax	Larrayoz M	The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1.	Leukemia	2016	14
26565405	navitoclax	Phillips DC	Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).	Blood cancer journal	2015	17
26828195	navitoclax	Hata AN	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.	Nature medicine	2016	82
19553641	olaparib	Fong PC	Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.	The New England journal of medicine	2009	894
20124459	olaparib	Williamson CT	ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.	Molecular cancer therapeutics	2010	58
20233726	olaparib	Wiltshire TD	Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair.	The Journal of biological chemistry	2010	46
21326243	olaparib	Khan OA	A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.	British journal of cancer	2011	38
21590367	olaparib	Samol J	Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.	Investigational new drugs	2012	39
21862407	olaparib	Gelmon KA	Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.	The Lancet. Oncology	2011	246
22452356	olaparib	Ledermann J	Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.	The New England journal of medicine	2012	239
24882434	olaparib	Ledermann J	Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.	The Lancet. Oncology	2014	192
26510020	olaparib	Mateo J	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.	The New England journal of medicine	2015	185
26723501	olaparib	Domchek SM	Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.	Gynecologic oncology	2016	22
26961146	olaparib	Matulonis UA	Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.	Annals of oncology 	2016	16
27617661	olaparib	Ledermann JA	Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.	The Lancet. Oncology	2016	27
28221868	olaparib	Lheureux S	Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.	Journal of clinical oncology 	2017	8
28490518	olaparib	Sen T	CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.	Cancer research	2017	9
28754483	olaparib	Pujade-Lauraine E	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.	The Lancet. Oncology	2017	14
18606717	dactolisib	Maira SM	Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.	Molecular cancer therapeutics	2008	380
18701483	dactolisib	Schnell CR	Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.	Cancer research	2008	63
18829560	dactolisib	Serra V	NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.	Cancer research	2008	259
19116269	dactolisib	Dubrovska A	The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations.	Proceedings of the National Academy of Sciences of the United States of America	2009	155
19366795	dactolisib	Crowder RJ	PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.	Cancer research	2009	52
19372546	dactolisib	Breuleux M	Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.	Molecular cancer therapeutics	2009	75
19584292	dactolisib	McMillin DW	Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.	Cancer research	2009	46
19671762	dactolisib	Liu TJ	NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.	Molecular cancer therapeutics	2009	92
19789349	dactolisib	Konstantinidou G	Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.	Cancer research	2009	56
20007781	dactolisib	Brachmann SM	Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	107
20068094	dactolisib	Manara MC	NVP-BEZ235 as a new therapeutic option for sarcomas.	Clinical cancer research 	2010	55
20299510	dactolisib	Bhatt AP	Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.	Blood	2010	56
20569503	dactolisib	Creighton CJ	Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.	Breast cancer research 	2010	78
20606035	dactolisib	Cho DC	The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.	Clinical cancer research 	2010	78
20857497	dactolisib	Sunayama J	Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.	Stem cells	2010	61
20876803	dactolisib	Chiarini F	Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.	Cancer research	2010	56
20884625	dactolisib	Chapuis N	Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.	Clinical cancer research 	2010	56
21372221	dactolisib	Santiskulvong C	Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.	Clinical cancer research 	2011	43
21552262	dactolisib	Toledo LI	A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.	Nature structural & molecular biology	2011	154
21876152	dactolisib	Ilic N	PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.	Proceedings of the National Academy of Sciences of the United States of America	2011	86
21966435	dactolisib	Roper J	The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.	PloS one	2011	36
22108822	dactolisib	Fokas E	Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature.	Cancer research	2012	45
22452803	dactolisib	Fokas E	NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.	Radiation oncology	2012	33
22539746	dactolisib	Thomas HE	mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.	Science translational medicine	2012	32
23012248	dactolisib	Acquaviva J	Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.	Molecular cancer therapeutics	2012	36
23243017	dactolisib	Rahmani M	Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.	Cancer research	2013	43
23246963	dactolisib	Montero JC	Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.	Oncogene	2014	29
23319457	dactolisib	Figlin RA	Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.	International journal of cancer	2013	29
23619167	dactolisib	Lui VW	Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.	Cancer discovery	2013	123
24157869	dactolisib	Chang L	Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance.	Cell death & disease	2013	72
24448243	dactolisib	Lin A	FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway.	Cancer research	2014	23
25590803	dactolisib	Choudhary GS	MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.	Cell death & disease	2015	60
25598437	dactolisib	Han L	Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.	Cytometry. Part A 	2015	20
25673820	dactolisib	Soares HP	Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.	Molecular cancer therapeutics	2015	20
25707361	dactolisib	Bendell JC	A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.	Investigational new drugs	2015	20
26451606	dactolisib	Sharma N	PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth.	Oncotarget	2015	40
28321130	dactolisib	Lu X	Effective combinatorial immunotherapy for castration-resistant prostate cancer.	Nature	2017	16
20398925	MDV 3100	Scher HI	Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.	Lancet	2010	280
21606347	MDV 3100	Evans MJ	Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.	Proceedings of the National Academy of Sciences of the United States of America	2011	57
22099611	MDV 3100	Armstrong AJ	Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.	European urology	2012	44
22894553	MDV 3100	Scher HI	Increased survival with enzalutamide in prostate cancer after chemotherapy.	The New England journal of medicine	2012	708
23117885	MDV 3100	Li Y	Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.	Cancer research	2013	196
23326489	MDV 3100	Kregel S	Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.	PloS one	2013	29
23699654	MDV 3100	Nadiminty N	NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants.	Molecular cancer therapeutics	2013	61
23752182	MDV 3100	Karantanos T	Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.	Oncogene	2013	130
23779130	MDV 3100	Joseph JD	A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.	Cancer discovery	2013	119
23842682	MDV 3100	Korpal M	An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).	Cancer discovery	2013	115
24163104	MDV 3100	Svensson C	REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer.	Nucleic acids research	2014	24
24315100	MDV 3100	Arora VK	Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.	Cell	2013	164
24478320	MDV 3100	Sternberg CN	Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.	Annals of oncology 	2014	29
24662833	MDV 3100	Nguyen HG	Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.	Oncogene	2014	34
24722067	MDV 3100	Cao B	Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.	Oncotarget	2014	51
24759320	MDV 3100	Asangani IA	Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.	Nature	2014	184
24840076	MDV 3100	Wong YN	Evolution of androgen receptor targeted therapy for advanced prostate cancer.	Nature reviews. Clinical oncology	2014	31
24859991	MDV 3100	Ware KE	Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.	Endocrine-related cancer	2014	39
24881730	MDV 3100	Beer TM	Enzalutamide in metastatic prostate cancer before chemotherapy.	The New England journal of medicine	2014	297
24882673	MDV 3100	Efstathiou E	Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.	European urology	2015	41
25135278	MDV 3100	Hu S	Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling.	Molecular oncology	2015	18
25151012	MDV 3100	Toren P	Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.	European urology	2015	32
25224448	MDV 3100	Claessens F	Emerging mechanisms of enzalutamide resistance in prostate cancer.	Nature reviews. Urology	2014	22
25428917	MDV 3100	Bishop JL	PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.	Oncotarget	2015	28
25634993	MDV 3100	Yamamoto Y	Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.	Clinical cancer research 	2015	27
25649766	MDV 3100	Liu C	Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.	Cancer research	2015	33
25713333	MDV 3100	Barton VN	Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.	Molecular cancer therapeutics	2015	40
25970160	MDV 3100	Liu C	Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.	The Prostate	2015	17
26056150	MDV 3100	Nadiminty N	NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer.	Molecular cancer therapeutics	2015	15
26554309	MDV 3100	Hickey TE	Expression of androgen receptor splice variants in clinical breast cancers.	Oncotarget	2015	17
26792867	MDV 3100	Asangani IA	BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.	Molecular cancer research 	2016	20
27148695	MDV 3100	Wyatt AW	Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.	JAMA oncology	2016	21
27429197	MDV 3100	Graff JN	Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.	Oncotarget	2016	27
27489290	MDV 3100	Qu F	Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.	Clinical cancer research 	2017	10
28059768	MDV 3100	Mu P	SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.	Science	2017	37
19360080	pevonedistat	Soucy TA	An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.	Nature	2009	464
20129059	pevonedistat	Brownell JE	Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.	Molecular cell	2010	127
20203261	pevonedistat	Swords RT	Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.	Blood	2010	75
20525923	pevonedistat	Milhollen MA	MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.	Blood	2010	112
21159650	pevonedistat	Lin JJ	NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells.	Cancer research	2010	95
21487042	pevonedistat	Milhollen MA	Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover.	Cancer research	2011	64
21677879	pevonedistat	Jia L	Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression.	Neoplasia	2011	51
21779466	pevonedistat	Soucy TA	The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy.	Genes & cancer	2010	74
22072567	pevonedistat	Wei D	Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.	Cancer research	2012	52
22457814	pevonedistat	Yang D	The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme.	PloS one	2012	33
22562464	pevonedistat	Luo Z	The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth.	Cancer research	2012	68
22799561	pevonedistat	Nawrocki ST	MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.	Expert opinion on investigational drugs	2012	52
22951983	pevonedistat	Zhao Y	Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis.	Cell death & disease	2012	38
23100467	pevonedistat	Blank JL	Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.	Cancer research	2013	38
23633453	pevonedistat	Nawrocki ST	Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.	Clinical cancer research 	2013	32
24430184	pevonedistat	Li H	Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis.	The Journal of clinical investigation	2014	26
24634471	pevonedistat	Godbersen JC	The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.	Clinical cancer research 	2014	33
24713927	pevonedistat	Gu Y	MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.	Blood	2014	22
24853380	pevonedistat	Li L	Overactivated neddylation pathway as a therapeutic target in lung cancer.	Journal of the National Cancer Institute	2014	36
25733005	pevonedistat	Swords RT	Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.	British journal of haematology	2015	44
25921528	pevonedistat	Brown JS	Neddylation promotes ubiquitylation and release of Ku from DNA-damage sites.	Cell reports	2015	24
26423795	pevonedistat	Sarantopoulos J	Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.	Clinical cancer research 	2016	20
26561559	pevonedistat	Shah JJ	Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.	Clinical cancer research 	2016	22
20130243	INCB018424	Quintás-Cardama A	Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.	Blood	2010	164
20843246	INCB018424	Verstovsek S	Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.	The New England journal of medicine	2010	275
22279053	INCB018424	Tefferi A	JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths.	Blood	2012	48
22319590	INCB018424	Looyenga BD	STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma.	PloS one	2012	37
22718840	INCB018424	Verstovsek S	Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.	Blood	2012	50
22955920	INCB018424	Maude SL	Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.	Blood	2012	69
23406773	INCB018424	Quintás-Cardama A	Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.	Clinical cancer research 	2013	66
23656643	INCB018424	Maxson JE	Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.	The New England journal of medicine	2013	100
24258498	INCB018424	Verstovsek S	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.	Cancer	2014	31
24497534	INCB018424	Wang T	GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.	Blood	2014	23
24857661	INCB018424	Albrengues J	LIF mediates proinvasive activation of stromal fibroblasts in cancer.	Cell reports	2014	25
25207766	INCB018424	Roberts KG	Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.	The New England journal of medicine	2014	178
25472969	INCB018424	Geyer HL	Therapy for myeloproliferative neoplasms: when, which agent, and how?	Blood	2014	23
25572172	INCB018424	Kleppe M	JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.	Cancer discovery	2015	41
25616577	INCB018424	Verstovsek S	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.	Haematologica	2015	35
25671252	INCB018424	Ortmann CA	Effect of mutation order on myeloproliferative neoplasms.	The New England journal of medicine	2015	70
25824483	INCB018424	Parampalli Yajnanarayana S	JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.	British journal of haematology	2015	18
26124496	INCB018424	Patel KP	Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.	Blood	2015	18
26151455	INCB018424	Thomas SJ	The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours.	British journal of cancer	2015	47
26182311	INCB018424	Tefferi A	Myeloproliferative Neoplasms: A Contemporary Review.	JAMA oncology	2015	33
26228487	INCB018424	Deininger M	The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.	Blood	2015	22
27102499	INCB018424	Verstovsek S	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.	Haematologica	2016	11
27211272	INCB018424	Harrison CN	Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.	Leukemia	2016	21
27613527	INCB018424	Yu HA	A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib.	Journal of thoracic oncology 	2017	5
27677740	INCB018424	Saenz DT	BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.	Leukemia	2017	7
27777238	INCB018424	Tasian SK	Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.	Blood	2017	15
27916398	INCB018424	Passamonti F	Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.	The Lancet. Oncology	2017	12
28139313	INCB018424	Weinacht KG	Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation.	The Journal of allergy and clinical immunology	2017	6
28228106	INCB018424	Verstovsek S	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.	Journal of hematology & oncology	2017	9
18458053	vemurafenib	Sala E	BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.	Molecular cancer research 	2008	57
20149136	vemurafenib	Halaban R	PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.	Pigment cell & melanoma research	2010	122
20472680	vemurafenib	Pratilas CA	Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response.	Clinical cancer research 	2010	53
20551065	vemurafenib	Yang H	RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.	Cancer research	2010	106
20630094	vemurafenib	Rubinstein JC	Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.	Journal of translational medicine	2010	66
20818844	vemurafenib	Flaherty KT	Inhibition of mutated, activated BRAF in metastatic melanoma.	The New England journal of medicine	2010	991
20823850	vemurafenib	Bollag G	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.	Nature	2010	468
21107323	vemurafenib	Nazarian R	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.	Nature	2010	647
21169256	vemurafenib	Comin-Anduix B	The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.	Clinical cancer research 	2010	53
21383288	vemurafenib	Wagle N	Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.	Journal of clinical oncology 	2011	286
21606968	vemurafenib	Ribas A	BRAF targeted therapy changes the treatment paradigm in melanoma.	Nature reviews. Clinical oncology	2011	57
21639808	vemurafenib	Chapman PB	Improved survival with vemurafenib in melanoma with BRAF V600E mutation.	The New England journal of medicine	2011	1658
21802280	vemurafenib	Eggermont AM	New drugs in melanoma: it's a whole new world.	European journal of cancer	2011	47
21803746	vemurafenib	Shi H	Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.	Cancer research	2011	70
22037033	vemurafenib	Flaherty KT	Vemurafenib.	Nature reviews. Drug discovery	2011	38
22113612	vemurafenib	Poulikakos PI	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).	Nature	2011	385
22205714	vemurafenib	Su F	Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.	Cancer research	2012	54
22217739	vemurafenib	Nikolaou VA	Melanoma: new insights and new therapies.	The Journal of investigative dermatology	2012	50
22241959	vemurafenib	Vergani E	Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.	Neoplasia	2011	37
22256804	vemurafenib	Su F	RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.	The New England journal of medicine	2012	219
22306669	vemurafenib	Halait H	Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.	Diagnostic molecular pathology 	2012	38
22332713	vemurafenib	Anderson S	Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.	Archives of pathology & laboratory medicine	2012	40
22351686	vemurafenib	Paraiso KH	The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.	Clinical cancer research 	2012	53
22356324	vemurafenib	Sosman JA	Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.	The New England journal of medicine	2012	522
22385436	vemurafenib	Finn L	Therapy for metastatic melanoma: the past, present, and future.	BMC medicine	2012	50
22389471	vemurafenib	Greger JG	Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.	Molecular cancer therapeutics	2012	98
22448344	vemurafenib	Corcoran RB	EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.	Cancer discovery	2012	195
22454415	vemurafenib	McArthur GA	Marked, homogeneous, and early 18Ffluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.	Journal of clinical oncology 	2012	37
22554099	vemurafenib	Ascierto PA	The role of BRAF V600 mutation in melanoma.	Journal of translational medicine	2012	70
22640478	vemurafenib	Ascierto PA	Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.	Journal of translational medicine	2012	31
22693252	vemurafenib	Koya RC	BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.	Cancer research	2012	64
22730329	vemurafenib	Yadav V	Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.	The Journal of biological chemistry	2012	49
22743296	vemurafenib	Gautschi O	A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.	Journal of thoracic oncology 	2012	40
22763448	vemurafenib	Wilson TR	Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.	Nature	2012	365
22850568	vemurafenib	Khalili JS	Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.	Clinical cancer research 	2012	66
22945644	vemurafenib	Sullivan RJ	MAP kinase signaling and inhibition in melanoma.	Oncogene	2013	29
22981501	vemurafenib	Garbe C	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012.	European journal of cancer	2012	37
23060265	vemurafenib	Bollag G	Vemurafenib: the first drug approved for BRAF-mutant cancer.	Nature reviews. Drug discovery	2012	133
23134356	vemurafenib	Callahan MK	Progression of RAS-mutant leukemia during RAF inhibitor treatment.	The New England journal of medicine	2012	62
23159108	vemurafenib	Colomba E	Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.	The Journal of molecular diagnostics 	2013	39
23237741	vemurafenib	Klein O	BRAF inhibitor activity in V600R metastatic melanoma.	European journal of cancer	2013	27
23239741	vemurafenib	Held MA	Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.	Cancer discovery	2013	35
23242808	vemurafenib	Girotti MR	Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.	Cancer discovery	2013	106
23251002	vemurafenib	Mao M	Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.	Clinical cancer research 	2013	74
23273605	vemurafenib	Greaves WO	Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.	The Journal of molecular diagnostics 	2013	45
23288408	vemurafenib	Whittaker SR	A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.	Cancer discovery	2013	92
23290787	vemurafenib	Sullivan RJ	Resistance to BRAF-targeted therapy in melanoma.	European journal of cancer	2013	83
23302800	vemurafenib	Das Thakur M	Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.	Nature	2013	185
23307859	vemurafenib	Frederick DT	BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.	Clinical cancer research 	2013	177
23344460	vemurafenib	Liu F	Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas.	The Journal of investigative dermatology	2013	26
23362240	vemurafenib	Beck D	Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.	Science signaling	2013	30
23369684	vemurafenib	Jang S	Which drug, and when, for patients with BRAF-mutant melanoma?	The Lancet. Oncology	2013	47
23460532	vemurafenib	Ascierto PA	Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types.	Clinical cancer research 	2013	48
23489023	vemurafenib	Kim KB	Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.	Thyroid 	2013	50
23526263	vemurafenib	Schilling B	Vemurafenib reverses immunosuppression by myeloid derived suppressor cells.	International journal of cancer	2013	27
23569304	vemurafenib	Trunzer K	Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.	Journal of clinical oncology 	2013	92
23733758	vemurafenib	Peters S	Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.	Journal of clinical oncology 	2013	28
23764003	vemurafenib	Roesch A	Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.	Cancer cell	2013	124
23890105	vemurafenib	Fattore L	Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies.	Journal of translational medicine	2013	28
24077405	vemurafenib	Phan GQ	Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.	Cancer control 	2013	25
24080641	vemurafenib	Jang S	Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.	Clinical pharmacology and therapeutics	2014	24
24104062	vemurafenib	O'Connell MP	Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.	Cancer discovery	2013	50
24108405	vemurafenib	Hartsough E	Resistance to RAF inhibitors revisited.	The Journal of investigative dermatology	2014	24
24133630	vemurafenib	Niessner H	Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.	Cancer medicine	2013	29
24161908	vemurafenib	Corazao-Rozas P	Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor.	Oncotarget	2013	34
24265153	vemurafenib	Van Allen EM	The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.	Cancer discovery	2014	189
24291778	vemurafenib	Bucheit AD	Emerging insights into resistance to BRAF inhibitors in melanoma.	Biochemical pharmacology	2014	30
24295639	vemurafenib	Dummer R	Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.	European journal of cancer	2014	43
24325952	vemurafenib	Hertzman Johansson C	BRAF inhibitors in cancer therapy.	Pharmacology & therapeutics	2014	21
24336571	vemurafenib	Shalem O	Genome-scale CRISPR-Cas9 knockout screening in human cells.	Science	2014	744
24410877	vemurafenib	Ihle MA	Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.	BMC cancer	2014	52
24463458	vemurafenib	Rizos H	BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.	Clinical cancer research 	2014	78
24508103	vemurafenib	McArthur GA	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.	The Lancet. Oncology	2014	161
24577748	vemurafenib	Ackerman A	Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.	Cancer	2014	34
24582505	vemurafenib	Larkin J	Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.	The Lancet. Oncology	2014	33
24589925	vemurafenib	Abdel-Wahab O	Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.	Cancer discovery	2014	23
24652991	vemurafenib	Nelson DS	Somatic activating ARAF mutations in Langerhans cell histiocytosis.	Blood	2014	30
24662767	vemurafenib	South AP	NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis.	The Journal of investigative dermatology	2014	37
24664307	vemurafenib	Johnson GL	Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.	Clinical cancer research 	2014	20
24725538	vemurafenib	Robinson GW	Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.	BMC cancer	2014	29
24812408	vemurafenib	Atefi M	Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.	Clinical cancer research 	2014	70
24823863	vemurafenib	Levy JM	Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors.	Cancer discovery	2014	40
24871132	vemurafenib	Chung SS	Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.	Science translational medicine	2014	20
24879157	vemurafenib	Goodall ML	Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.	Autophagy	2014	20
24958825	vemurafenib	Hu-Lieskovan S	Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.	Journal of clinical oncology 	2014	49
25037139	vemurafenib	Ribas A	Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.	The Lancet. Oncology	2014	36
25056119	vemurafenib	Watson IR	The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.	Cancer research	2014	21
25096067	vemurafenib	Kim G	FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.	Clinical cancer research 	2014	21
25122067	vemurafenib	Yadav V	The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.	Molecular cancer therapeutics	2014	21
25127139	vemurafenib	Sos ML	Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors.	Cell reports	2014	22
25265494	vemurafenib	Larkin J	Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.	The New England journal of medicine	2014	245
25278616	vemurafenib	Savitski MM	Tracking cancer drugs in living cells by thermal profiling of the proteome.	Science	2014	57
25344914	vemurafenib	Spagnolo F	Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.	Oncotarget	2014	40
25353071	vemurafenib	Dadu R	Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.	The Journal of clinical endocrinology and metabolism	2015	21
25399551	vemurafenib	Robert C	Improved overall survival in melanoma with combined dabrafenib and trametinib.	The New England journal of medicine	2015	311
25476604	vemurafenib	Li W	MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens.	Genome biology	2014	48
25502142	vemurafenib	Müller J	Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.	Nature communications	2014	69
25520039	vemurafenib	Maverakis E	Metastatic melanoma - a review of current and future treatment options.	Acta dermato-venereologica	2015	19
25542448	vemurafenib	Miao B	EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.	Cancer discovery	2015	17
25589621	vemurafenib	Yaeger R	Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.	Clinical cancer research 	2015	47
25807485	vemurafenib	Obenauf AC	Therapy-induced tumour secretomes promote resistance and tumour progression.	Nature	2015	81
25814555	vemurafenib	Fallahi-Sichani M	Systematic analysis of BRAF(V600E) melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis.	Molecular systems biology	2015	17
25855536	vemurafenib	Witkiewicz AK	Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.	Nature communications	2015	120
25971842	vemurafenib	Salton M	Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing.	Nature communications	2015	15
25980496	vemurafenib	Stark MS	miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma.	Oncotarget	2015	19
25980594	vemurafenib	Puzanov I	Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.	European journal of cancer	2015	24
26073081	vemurafenib	Fedorenko IV	Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.	Oncogene	2016	14
26105199	vemurafenib	Kemper K	Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.	EMBO molecular medicine	2015	26
26139106	vemurafenib	Hernandez-Davies JE	Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.	Journal of translational medicine	2015	19
26287849	vemurafenib	Hyman DM	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.	The New England journal of medicine	2015	196
26343583	vemurafenib	Peng SB	Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.	Cancer cell	2015	25
26352686	vemurafenib	Tiacci E	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.	The New England journal of medicine	2015	30
26433819	vemurafenib	Grob JJ	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.	The Lancet. Oncology	2015	20
26460303	vemurafenib	Kopetz S	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.	Journal of clinical oncology 	2015	57
26466569	vemurafenib	Zhang C	RAF inhibitors that evade paradoxical MAPK pathway activation.	Nature	2015	44
26498038	vemurafenib	Zheng G	Clinical detection and categorization of uncommon and concomitant mutations involving BRAF.	BMC cancer	2015	19
26524482	vemurafenib	Gray ES	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.	Oncotarget	2015	31
26601866	vemurafenib	Wong DJ	Targeted Therapy for Melanoma.	Cancer treatment and research	2016	10
26608120	vemurafenib	Johnson DB	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.	European journal of cancer	2015	28
26668268	vemurafenib	Kim MH	Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation.	The EMBO journal	2016	16
26768236	vemurafenib	Fiskus W	B-Raf Inhibition in the Clinic: Present and Future.	Annual review of medicine	2016	13
27042933	vemurafenib	Kaur A	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.	Nature	2016	34
27181209	vemurafenib	Bianchi-Smiraglia A	Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools.	Oncogene	2017	6
27188223	vemurafenib	Schadendorf D	Melanoma.	Nature reviews. Disease primers	2015	37
27325282	vemurafenib	Pietrantonio F	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.	Cancer discovery	2016	14
27367293	vemurafenib	Garbe C	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.	European journal of cancer	2016	18
27460442	vemurafenib	Brose MS	Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2016	13
27480103	vemurafenib	Ascierto PA	Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.	The Lancet. Oncology	2016	27
27580028	vemurafenib	Luo C	A PGC1α-mediated transcriptional axis suppresses melanoma metastasis.	Nature	2016	16
28058658	vemurafenib	Simeone E	Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.	BioDrugs 	2017	6
28094001	vemurafenib	Mulcahy Levy JM	Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors.	eLife	2017	8
20009909	crizotinib	Solomon B	ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.	Journal of thoracic oncology 	2009	67
20979469	crizotinib	Kwak EL	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.	The New England journal of medicine	2010	1124
20979472	crizotinib	Butrynski JE	Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.	The New England journal of medicine	2010	154
21156280	crizotinib	Gerber DE	ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.	Cancer cell	2010	69
21288922	crizotinib	Shaw AT	Targeting anaplastic lymphoma kinase in lung cancer.	Clinical cancer research 	2011	51
21336183	crizotinib	Camidge DR	Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.	Journal of thoracic oncology 	2011	66
21623265	crizotinib	Ou SH	Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.	Journal of thoracic oncology 	2011	106
21933749	crizotinib	Shaw AT	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.	The Lancet. Oncology	2011	230
22042947	crizotinib	Lennerz JK	MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.	Journal of clinical oncology 	2011	126
22071784	crizotinib	McLeer-Florin A	Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.	Journal of thoracic oncology 	2012	47
22072639	crizotinib	Bresler SC	Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.	Science translational medicine	2011	70
22135231	crizotinib	Chaft JE	Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.	Molecular cancer therapeutics	2012	58
22162641	crizotinib	Ou SH	Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.	Drug design, development and therapy	2011	38
22215748	crizotinib	Bergethon K	ROS1 rearrangements define a unique molecular class of lung cancers.	Journal of clinical oncology 	2012	295
22235099	crizotinib	Doebele RC	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.	Clinical cancer research 	2012	242
22277784	crizotinib	Katayama R	Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.	Science translational medicine	2012	305
22323827	crizotinib	Lovly CM	Escaping ALK inhibition: mechanisms of and strategies to overcome resistance.	Science translational medicine	2012	36
22473102	crizotinib	Camidge DR	Treating ALK-positive lung cancer--early successes and future challenges.	Nature reviews. Clinical oncology	2012	58
22585002	crizotinib	Carpenter EL	Targeting ALK in neuroblastoma--preclinical and clinical advancements.	Nature reviews. Clinical oncology	2012	38
22614325	crizotinib	Mano H	ALKoma: a cancer subtype with a shared target.	Cancer discovery	2012	36
22683780	crizotinib	Kentsis A	Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.	Nature medicine	2012	53
22919003	crizotinib	Davies KD	Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.	Clinical cancer research 	2012	77
22954507	crizotinib	Camidge DR	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.	The Lancet. Oncology	2012	288
22989574	crizotinib	Ou SH	Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.	The oncologist	2012	37
23154552	crizotinib	Weickhardt AJ	Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.	Journal of thoracic oncology 	2012	97
23201355	crizotinib	Roskoski R Jr	Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.	Pharmacological research	2013	39
23344087	crizotinib	Kim S	Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.	Journal of thoracic oncology 	2013	40
23401436	crizotinib	Shaw AT	ALK in lung cancer: past, present, and future.	Journal of clinical oncology 	2013	89
23499337	crizotinib	Minca EC	ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.	The Journal of molecular diagnostics 	2013	26
23598171	crizotinib	Mossé YP	Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.	The Lancet. Oncology	2013	127
23669222	crizotinib	Pailler E	Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.	Journal of clinical oncology 	2013	67
23719267	crizotinib	Davies KD	Molecular pathways: ROS1 fusion proteins in cancer.	Clinical cancer research 	2013	54
23724914	crizotinib	Awad MM	Acquired resistance to crizotinib from a mutation in CD74-ROS1.	The New England journal of medicine	2013	64
23729361	crizotinib	Gainor JF	ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.	Clinical cancer research 	2013	97
23743928	crizotinib	Selinger CI	Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.	Modern pathology 	2013	33
23931927	crizotinib	Gridelli C	ALK inhibitors in the treatment of advanced NSCLC.	Cancer treatment reviews	2014	39
23951022	crizotinib	Wu YC	Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan.	PloS one	2013	26
23993685	crizotinib	Kim HR	Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation.	Molecular oncology	2013	29
24060861	crizotinib	Hallberg B	Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.	Nature reviews. Cancer	2013	101
24284055	crizotinib	Cañadas I	Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.	Clinical cancer research 	2014	32
24418728	crizotinib	Lira ME	A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.	The Journal of molecular diagnostics 	2014	21
24443522	crizotinib	Yang JJ	Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.	Clinical cancer research 	2014	32
24456475	crizotinib	Warth A	ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases.	Histopathology	2014	20
24478318	crizotinib	Ou SH	Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.	Annals of oncology 	2014	41
24491302	crizotinib	Gambacorti Passerini C	Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.	Journal of the National Cancer Institute	2014	46
24518086	crizotinib	Cabillic F	Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.	Journal of thoracic oncology 	2014	25
24556908	crizotinib	Ji C	Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer.	Cancer biology & therapy	2014	23
24573551	crizotinib	Malik SM	U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.	Clinical cancer research 	2014	28
24675041	crizotinib	Friboulet L	The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.	Cancer discovery	2014	158
24736079	crizotinib	Ignatius Ou SH	Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.	Journal of thoracic oncology 	2014	40
24819116	crizotinib	Johnson TW	Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo4,3-h2,5,11-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.	Journal of medicinal chemistry	2014	47
24875859	crizotinib	Lovly CM	Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.	Cancer discovery	2014	40
24887559	crizotinib	Kodama T	Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.	Cancer letters	2014	36
25153538	crizotinib	Gadgeel SM	Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.	The Lancet. Oncology	2014	126
25173427	crizotinib	Lovly CM	Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.	Nature medicine	2014	65
25228534	crizotinib	Katayama R	Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.	Clinical cancer research 	2014	56
25234288	crizotinib	Lee SE	Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.	Modern pathology 	2015	17
25264305	crizotinib	Shaw AT	Crizotinib in ROS1-rearranged non-small-cell lung cancer.	The New England journal of medicine	2014	220
25322323	crizotinib	Awad MM	ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.	Clinical advances in hematology & oncology 	2014	48
25344360	crizotinib	Ilie MI	Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.	Annals of oncology 	2015	17
25351743	crizotinib	Katayama R	Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.	Clinical cancer research 	2015	25
25470694	crizotinib	Solomon BJ	First-line crizotinib versus chemotherapy in ALK-positive lung cancer.	The New England journal of medicine	2014	413
25517749	crizotinib	Bresler SC	ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.	Cancer cell	2014	58
25526238	crizotinib	Gainor JF	Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.	Journal of thoracic oncology 	2015	30
25667280	crizotinib	Mazières J	Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.	Journal of clinical oncology 	2015	40
25721120	crizotinib	Pekar-Zlotin M	Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.	The oncologist	2015	29
25724526	crizotinib	Gainor JF	Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.	Clinical cancer research 	2015	36
25733882	crizotinib	Zou HY	PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.	Proceedings of the National Academy of Sciences of the United States of America	2015	28
25759024	crizotinib	Wilson FH	A functional landscape of resistance to ALK inhibition in lung cancer.	Cancer cell	2015	42
25846554	crizotinib	Pailler E	High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.	Annals of oncology 	2015	28
25870799	crizotinib	Yip PY	Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.	Translational lung cancer research	2015	20
25882375	crizotinib	Ali SM	Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.	The oncologist	2015	18
26215952	crizotinib	Liu X	Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.	Journal of clinical oncology 	2016	26
26464158	crizotinib	Ou SH	ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.	Lung cancer	2016	10
26544515	crizotinib	Nilsson RJ	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.	Oncotarget	2016	20
26598747	crizotinib	Ou SH	Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.	Journal of clinical oncology 	2016	97
26708155	crizotinib	Shaw AT	Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.	The Lancet. Oncology	2016	95
26719536	crizotinib	Isozaki H	Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.	Cancer research	2016	15
26729443	crizotinib	Awad MM	MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.	Journal of clinical oncology 	2016	42
26751586	crizotinib	Fujita S	Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib.	Journal of thoracic oncology 	2016	14
26993609	crizotinib	Tan CL	Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer.	Oncotarget	2016	16
27245569	crizotinib	Ali SM	Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.	The oncologist	2016	15
27354483	crizotinib	Yoshida T	Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2016	25
27393507	crizotinib	Ou SI	High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.	Lung cancer	2016	16
27432227	crizotinib	Gainor JF	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.	Cancer discovery	2016	54
27432917	crizotinib	Crinò L	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.	Journal of clinical oncology 	2016	38
27498387	crizotinib	Ito K	Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.	Journal of thoracic oncology 	2017	7
27507192	crizotinib	Zhang Z	Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study.	Journal of thoracic oncology 	2017	5
27697581	crizotinib	Ou SI	Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.	Journal of thoracic oncology 	2017	6
27863201	crizotinib	Gadgeel SM	Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2016	16
28039177	crizotinib	Woo CG	Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.	Annals of oncology 	2017	11
28461563	crizotinib	Pailler E	Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.	Cancer research	2017	8
28475456	crizotinib	Kim DW	Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.	Journal of clinical oncology 	2017	24
28520527	crizotinib	Lim SM	Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.	Journal of clinical oncology 	2017	8
20615965	PCI 32765	Honigberg LA	The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.	Proceedings of the National Academy of Sciences of the United States of America	2010	276
21422473	PCI 32765	Herman SE	Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.	Blood	2011	188
22180443	PCI 32765	Ponader S	The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.	Blood	2012	171
22279054	PCI 32765	de Rooij MF	The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.	Blood	2012	134
22689860	PCI 32765	Tai YT	Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.	Blood	2012	48
23045577	PCI 32765	Advani RH	Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.	Journal of clinical oncology 	2013	210
23782157	PCI 32765	Wang ML	Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.	The New England journal of medicine	2013	240
23782158	PCI 32765	Byrd JC	Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.	The New England journal of medicine	2013	389
23940282	PCI 32765	Chang BY	Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.	Blood	2013	46
23958373	PCI 32765	Akinleye A	Ibrutinib and novel BTK inhibitors in clinical development.	Journal of hematology & oncology	2013	51
24270740	PCI 32765	Cheng S	BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.	Leukemia	2014	45
24307721	PCI 32765	Rushworth SA	Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.	Blood	2014	26
24311722	PCI 32765	Woyach JA	Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).	Blood	2014	48
24332241	PCI 32765	O'Brien S	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.	The Lancet. Oncology	2014	104
24357428	PCI 32765	Burger JA	Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.	Current hematologic malignancy reports	2014	21
24415539	PCI 32765	Woyach JA	Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.	Blood	2014	52
24469833	PCI 32765	Mathews Griner LA	High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.	Proceedings of the National Academy of Sciences of the United States of America	2014	73
24659631	PCI 32765	Herman SE	Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.	Blood	2014	46
24699307	PCI 32765	Herman SE	Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.	Leukemia	2014	33
24811343	PCI 32765	Sehgal L	FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.	Leukemia	2014	29
24829205	PCI 32765	Wodarz D	Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.	Blood	2014	23
24869598	PCI 32765	Woyach JA	Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.	The New England journal of medicine	2014	164
24881631	PCI 32765	Byrd JC	Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.	The New England journal of medicine	2014	203
24912431	PCI 32765	Cao Y	The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.	Leukemia	2015	21
25042202	PCI 32765	Younes A	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.	The Lancet. Oncology	2014	48
25082755	PCI 32765	Chiron D	Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.	Cancer discovery	2014	41
25138588	PCI 32765	Kamel S	Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.	Leukemia	2015	31
25150798	PCI 32765	Burger JA	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.	The Lancet. Oncology	2014	66
25189416	PCI 32765	Cheng S	Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.	Leukemia	2015	24
25284608	PCI 32765	Zhao X	Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.	British journal of haematology	2015	16
25305202	PCI 32765	Levade M	Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.	Blood	2014	34
25344523	PCI 32765	Da Roit F	Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.	Haematologica	2015	32
25555420	PCI 32765	Farooqui MZ	Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.	The Lancet. Oncology	2015	62
25573991	PCI 32765	Jain P	Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.	Blood	2015	44
25582069	PCI 32765	Cao Y	The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.	British journal of haematology	2015	18
25797245	PCI 32765	Chiron D	Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.	Oncotarget	2015	19
25805587	PCI 32765	Young RM	B-cell receptor signaling in diffuse large B-cell lymphoma.	Seminars in hematology	2015	30
25829398	PCI 32765	Cervantes-Gomez F	Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.	Clinical cancer research 	2015	37
25833959	PCI 32765	Yeh YY	Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.	Blood	2015	22
25838351	PCI 32765	Hing ZA	Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.	Blood	2015	16
25853747	PCI 32765	Treon SP	Ibrutinib in previously treated Waldenström's macroglobulinemia.	The New England journal of medicine	2015	88
25972157	PCI 32765	Liu TM	Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.	Blood	2015	21
26089373	PCI 32765	Herman SE	Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.	Clinical cancer research 	2015	19
26116658	PCI 32765	Jaglowski SM	Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.	Blood	2015	21
26170206	PCI 32765	Rai KR	Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia.	Journal of hematology & oncology	2015	15
26182309	PCI 32765	Maddocks KJ	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.	JAMA oncology	2015	55
26193078	PCI 32765	Ten Hacken E	Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.	Biochimica et biophysica acta	2016	26
26193343	PCI 32765	Wilson WH	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.	Nature medicine	2015	87
26244327	PCI 32765	Treon SP	MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia.	The New England journal of medicine	2015	28
26337639	PCI 32765	Wu J	Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.	Journal of hematology & oncology	2015	31
26563132	PCI 32765	Kwok M	ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.	Blood	2016	19
26628631	PCI 32765	Wiestner A	The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.	Haematologica	2015	18
26640039	PCI 32765	Wang ML	Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.	The Lancet. Oncology	2016	14
26641137	PCI 32765	Byrd JC	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.	The New England journal of medicine	2016	58
26655421	PCI 32765	Chanan-Khan A	Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.	The Lancet. Oncology	2016	28
26717038	PCI 32765	Guo A	Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.	Oncotarget	2016	13
26813675	PCI 32765	Fraietta JA	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.	Blood	2016	23
26819453	PCI 32765	Ruella M	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.	Clinical cancer research 	2016	11
26880800	PCI 32765	Stiff A	Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.	Cancer research	2016	16
26957112	PCI 32765	Wu J	Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.	Journal of hematology & oncology	2016	15
27095788	PCI 32765	Bojarczuk K	BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.	Blood	2016	15
27127301	PCI 32765	Saba NS	Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.	Blood	2016	13
27198718	PCI 32765	Winqvist M	Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.	Haematologica	2016	11
27535981	PCI 32765	Amin NA	Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.	Clinical cancer research 	2017	6
27590878	PCI 32765	Wu J	Second-generation inhibitors of Bruton tyrosine kinase.	Journal of hematology & oncology	2016	13
27601462	PCI 32765	Mato AR	Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.	Blood	2016	10
27637985	PCI 32765	O'Brien S	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.	The Lancet. Oncology	2016	14
27677739	PCI 32765	Ruella M	Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.	Leukemia	2017	7
27904138	PCI 32765	Yu J	Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.	Leukemia	2017	7
28034907	PCI 32765	Patel V	Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.	Clinical cancer research 	2017	6
28049639	PCI 32765	Ahn IE	Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.	Blood	2017	8
28167659	PCI 32765	Noy A	Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.	Blood	2017	6
28199309	PCI 32765	Compagno M	Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.	Nature	2017	14
28418267	PCI 32765	Woyach JA	BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.	Journal of clinical oncology 	2017	9
28424162	PCI 32765	Ding W	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.	Blood	2017	8
21245089	trametinib	Gilmartin AG	GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.	Clinical cancer research 	2011	144
21523318	trametinib	Yamaguchi T	Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo.	International journal of oncology	2011	51
22663011	trametinib	Flaherty KT	Improved survival with MEK inhibition in BRAF-mutated melanoma.	The New England journal of medicine	2012	423
22733540	trametinib	Khalili JS	Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.	Clinical cancer research 	2012	40
22805291	trametinib	Infante JR	Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.	The Lancet. Oncology	2012	94
22805292	trametinib	Falchook GS	Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.	The Lancet. Oncology	2012	114
23020132	trametinib	Flaherty KT	Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.	The New England journal of medicine	2012	596
23248257	trametinib	Kim KB	Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.	Journal of clinical oncology 	2013	99
24055054	trametinib	Villanueva J	Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.	Cell reports	2013	53
24265154	trametinib	Wagle N	MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.	Cancer discovery	2014	132
24476679	trametinib	Carlino MS	Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.	Molecular oncology	2014	28
24764582	trametinib	Vella LJ	MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.	Cancer immunology research	2014	34
25265492	trametinib	Long GV	Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.	The New England journal of medicine	2014	232
25287827	trametinib	Johnson DB	Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.	Journal of clinical oncology 	2014	45
25344362	trametinib	Tolcher AW	A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.	Annals of oncology 	2015	20
25417902	trametinib	Tolcher AW	Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.	Cancer chemotherapy and pharmacology	2015	16
25452114	trametinib	Long GV	Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.	Nature communications	2014	47
25500057	trametinib	Bedard PL	A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.	Clinical cancer research 	2015	48
25589619	trametinib	Liu L	The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.	Clinical cancer research 	2015	44
25787767	trametinib	Hu-Lieskovan S	Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.	Science translational medicine	2015	72
25899310	trametinib	Nelson DS	MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.	Genes, chromosomes & cancer	2015	22
25944484	trametinib	Queirolo P	Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.	Cancer treatment reviews	2015	19
26036643	trametinib	Tricker EM	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.	Cancer discovery	2015	41
26037941	trametinib	Long GV	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.	Lancet	2015	122
26392102	trametinib	Corcoran RB	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.	Journal of clinical oncology 	2015	60
26446943	trametinib	Santiago-Walker A	Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.	Clinical cancer research 	2016	20
26498373	trametinib	Brastianos PK	Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.	Journal of the National Cancer Institute	2016	13
26644315	trametinib	Russo M	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.	Cancer discovery	2016	40
26811525	trametinib	Long GV	Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.	Journal of clinical oncology 	2016	36
27283860	trametinib	Planchard D	Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.	The Lancet. Oncology	2016	43
27338794	trametinib	Manchado E	A combinatorial strategy for treating KRAS-mutant lung cancer.	Nature	2016	39
28108460	trametinib	Zawistowski JS	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.	Cancer discovery	2017	13
28178529	trametinib	Wang B	ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition.	Cell reports	2017	6
28268064	trametinib	Schreuer M	Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.	The Lancet. Oncology	2017	13
28475671	trametinib	Long GV	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.	Annals of oncology 	2017	10
28891408	trametinib	Long GV	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.	The New England journal of medicine	2017	10
23179945	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Afshar-Oromieh A	PET imaging with a 68Gagallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.	European journal of nuclear medicine and molecular imaging	2013	94
24352789	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Afshar-Oromieh A	Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.	European journal of nuclear medicine and molecular imaging	2014	36
25411132	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Afshar-Oromieh A	The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.	European journal of nuclear medicine and molecular imaging	2015	86
25791990	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Eiber M	Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.	Journal of nuclear medicine 	2015	80
25957851	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Maurer T	Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer.	European urology	2015	23
25975367	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Ceci F	(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?	European journal of nuclear medicine and molecular imaging	2015	25
26116958	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Budäus L	Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.	European urology	2016	35
26294298	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Afshar-Oromieh A	The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.	Journal of nuclear medicine 	2015	35
26404016	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Sterzing F	(68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients.	European journal of nuclear medicine and molecular imaging	2016	19
26508290	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Freitag MT	Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer.	European journal of nuclear medicine and molecular imaging	2016	16
26682756	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Maurer T	Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.	The Journal of urology	2016	38
26683282	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	van Leeuwen PJ	(68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.	BJU international	2016	17
26769858	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Rahbar K	Correlation of Intraprostatic Tumor Extent with ⁶⁸Ga-PSMA Distribution in Patients with Prostate Cancer.	Journal of nuclear medicine 	2016	14
26795286	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Baum RP	177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.	Journal of nuclear medicine 	2016	31
26902337	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Maurer T	Current use of PSMA-PET in prostate cancer management.	Nature reviews. Urology	2016	40
27056618	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Rahbar K	Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis.	Journal of nuclear medicine 	2016	19
27587707	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Ferdinandus J	Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617.	Journal of nuclear medicine 	2017	5
27660138	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Okamoto S	Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions.	Journal of nuclear medicine 	2017	7
27889802	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Giesel FL	F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.	European journal of nuclear medicine and molecular imaging	2017	8
28283702	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))	Fendler WP	68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.	European journal of nuclear medicine and molecular imaging	2017	8
9312064	cholecystokinin C-terminal flanking peptide	Orford K	Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin.	The Journal of biological chemistry	1997	184
9381178	cholecystokinin C-terminal flanking peptide	del Peso L	Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.	Science	1997	419
9395435	cholecystokinin C-terminal flanking peptide	Sells MA	Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells.	Current biology 	1997	206
10067896	cholecystokinin C-terminal flanking peptide	Ulloa L	Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway.	Nature	1999	146
10391244	cholecystokinin C-terminal flanking peptide	Lu PJ	The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein.	Nature	1999	169
10576742	cholecystokinin C-terminal flanking peptide	Zimmermann S	Phosphorylation and regulation of Raf by Akt (protein kinase B).	Science	1999	251
10648614	cholecystokinin C-terminal flanking peptide	Zamanian-Daryoush M	NF-kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase.	Molecular and cellular biology	2000	98
11237521	cholecystokinin C-terminal flanking peptide	Simpson L	PTEN: life as a tumor suppressor.	Experimental cell research	2001	134
11257227	cholecystokinin C-terminal flanking peptide	Mowen KA	Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription.	Cell	2001	112
11259436	cholecystokinin C-terminal flanking peptide	Madrid LV	Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38.	The Journal of biological chemistry	2001	163
11333986	cholecystokinin C-terminal flanking peptide	Bulavin DV	Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase.	Nature	2001	128
11432833	cholecystokinin C-terminal flanking peptide	Wulf GM	Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1.	The EMBO journal	2001	133
11533658	cholecystokinin C-terminal flanking peptide	Ryo A	Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC.	Nature cell biology	2001	132
11780126	cholecystokinin C-terminal flanking peptide	D'Orazi G	Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis.	Nature cell biology	2002	180
11875759	cholecystokinin C-terminal flanking peptide	Waite KA	Protean PTEN: form and function.	American journal of human genetics	2002	96
11891124	cholecystokinin C-terminal flanking peptide	Melo J	A unified view of the DNA-damage checkpoint.	Current opinion in cell biology	2002	160
11978535	cholecystokinin C-terminal flanking peptide	Lu KP	Pinning down proline-directed phosphorylation signaling.	Trends in cell biology	2002	92
12000790	cholecystokinin C-terminal flanking peptide	Amit S	Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway.	Genes & development	2002	189
12004076	cholecystokinin C-terminal flanking peptide	Min JH	Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling.	Science	2002	172
12145307	cholecystokinin C-terminal flanking peptide	Zipper LM	The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm.	The Journal of biological chemistry	2002	89
12554650	cholecystokinin C-terminal flanking peptide	Dajani R	Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex.	The EMBO journal	2003	82
14663477	cholecystokinin C-terminal flanking peptide	Franke TF	PI3K/Akt and apoptosis: size matters.	Oncogene	2003	216
14734469	cholecystokinin C-terminal flanking peptide	Deng G	BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer.	Clinical cancer research 	2004	72
15109565	cholecystokinin C-terminal flanking peptide	Lampe PD	The effects of connexin phosphorylation on gap junctional communication.	The international journal of biochemistry & cell biology	2004	171
15111319	cholecystokinin C-terminal flanking peptide	Bao L	Prevalent overexpression of prolyl isomerase Pin1 in human cancers.	The American journal of pathology	2004	96
15574592	cholecystokinin C-terminal flanking peptide	Mehle A	Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.	Genes & development	2004	147
15722192	cholecystokinin C-terminal flanking peptide	Knippschild U	The casein kinase 1 family: participation in multiple cellular processes in eukaryotes.	Cellular signalling	2005	169
15800615	cholecystokinin C-terminal flanking peptide	Esashi F	CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair.	Nature	2005	142
16226704	cholecystokinin C-terminal flanking peptide	She QB	The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.	Cancer cell	2005	133
16288032	cholecystokinin C-terminal flanking peptide	Huang L	MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin.	Cancer research	2005	105
16446383	cholecystokinin C-terminal flanking peptide	Radomska HS	Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.	The Journal of experimental medicine	2006	64
16885021	cholecystokinin C-terminal flanking peptide	Mailand N	Destruction of Claspin by SCFbetaTrCP restrains Chk1 activation and facilitates recovery from genotoxic stress.	Molecular cell	2006	93
17101782	cholecystokinin C-terminal flanking peptide	Tan Y	Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes.	Molecular and cellular biology	2007	89
17188038	cholecystokinin C-terminal flanking peptide	Lochhead PA	A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation.	Molecular cell	2006	76
17434128	cholecystokinin C-terminal flanking peptide	Huang WC	Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB.	Molecular cell	2007	91
17483355	cholecystokinin C-terminal flanking peptide	Zou HY	An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.	Cancer research	2007	171
17540176	cholecystokinin C-terminal flanking peptide	Sablina AA	The tumor suppressor PP2A Abeta regulates the RalA GTPase.	Cell	2007	81
17785202	cholecystokinin C-terminal flanking peptide	Kang S	FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.	Cancer cell	2007	63
17906618	cholecystokinin C-terminal flanking peptide	Plun-Favreau H	The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1.	Nature cell biology	2007	151
18023328	cholecystokinin C-terminal flanking peptide	Takahashi-Yanaga F	GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy.	Cellular signalling	2008	82
18056989	cholecystokinin C-terminal flanking peptide	Xie Y	The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells.	The Journal of biological chemistry	2008	60
18265945	cholecystokinin C-terminal flanking peptide	Lu X	The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways.	Cancer metastasis reviews	2008	77
19091954	cholecystokinin C-terminal flanking peptide	Wilsker D	Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control.	Proceedings of the National Academy of Sciences of the United States of America	2008	55
19130886	cholecystokinin C-terminal flanking peptide	Robey RB	Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis.	Seminars in cancer biology	2009	143
19243594	cholecystokinin C-terminal flanking peptide	Eiseler T	Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion.	Breast cancer research 	2009	58
19372545	cholecystokinin C-terminal flanking peptide	Park HU	AMP-activated protein kinase promotes human prostate cancer cell growth and survival.	Molecular cancer therapeutics	2009	56
19372583	cholecystokinin C-terminal flanking peptide	Boisvert-Adamo K	Mcl-1 is required for melanoma cell resistance to anoikis.	Molecular cancer research 	2009	52
19573808	cholecystokinin C-terminal flanking peptide	Miao H	EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt.	Cancer cell	2009	121
19738052	cholecystokinin C-terminal flanking peptide	Saetrom P	A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis.	Cancer research	2009	52
19818709	cholecystokinin C-terminal flanking peptide	Kong M	Alpha4 is an essential regulator of PP2A phosphatase activity.	Molecular cell	2009	49
20023628	cholecystokinin C-terminal flanking peptide	Sibanda BL	Crystal structure of DNA-PKcs reveals a large open-ring cradle comprised of HEAT repeats.	Nature	2010	82
20137952	cholecystokinin C-terminal flanking peptide	Li A	The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion.	Current biology 	2010	94
20140016	cholecystokinin C-terminal flanking peptide	Wang J	Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma.	Oncogene	2010	46
20493860	cholecystokinin C-terminal flanking peptide	Yuan J	Focus on histone variant H2AX: to be or not to be.	FEBS letters	2010	64
20538618	cholecystokinin C-terminal flanking peptide	Whittaker S	Gatekeeper mutations mediate resistance to BRAF-targeted therapies.	Science translational medicine	2010	61
20580720	cholecystokinin C-terminal flanking peptide	Lee G	Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis.	Gastroenterology	2010	57
20694009	cholecystokinin C-terminal flanking peptide	Cardone J	Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells.	Nature immunology	2010	73
21057494	cholecystokinin C-terminal flanking peptide	Tanaka H	Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance.	Nature medicine	2010	94
21098708	cholecystokinin C-terminal flanking peptide	Ustach CV	A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer.	Cancer research	2010	41
21107320	cholecystokinin C-terminal flanking peptide	Johannessen CM	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.	Nature	2010	447
21119616	cholecystokinin C-terminal flanking peptide	Carr SM	Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein.	The EMBO journal	2011	37
21159657	cholecystokinin C-terminal flanking peptide	Sablina AA	Identification of PP2A complexes and pathways involved in cell transformation.	Cancer research	2010	56
21212414	cholecystokinin C-terminal flanking peptide	Salah Z	Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity.	Cancer research	2011	52
21248166	cholecystokinin C-terminal flanking peptide	McCormick JA	The WNKs: atypical protein kinases with pleiotropic actions.	Physiological reviews	2011	78
21382551	cholecystokinin C-terminal flanking peptide	Sun Y	Phosphorylation state of Olig2 regulates proliferation of neural progenitors.	Neuron	2011	41
21430779	cholecystokinin C-terminal flanking peptide	Ceol CJ	The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset.	Nature	2011	145
21502402	cholecystokinin C-terminal flanking peptide	Hong J	Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes Twist1 protein and promotes breast cancer cell invasiveness.	Cancer research	2011	62
21813756	cholecystokinin C-terminal flanking peptide	Tomlins SA	Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.	Science translational medicine	2011	107
21852393	cholecystokinin C-terminal flanking peptide	Ali F	Cell cycle-regulated multi-site phosphorylation of Neurogenin 2 coordinates cell cycling with differentiation during neurogenesis.	Development	2011	51
22205726	cholecystokinin C-terminal flanking peptide	White D	The ATM substrate KAP1 controls DNA repair in heterochromatin: regulation by HP1 proteins and serine 473/824 phosphorylation.	Molecular cancer research 	2012	34
22325354	cholecystokinin C-terminal flanking peptide	Yata K	Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair.	Molecular cell	2012	46
22361354	cholecystokinin C-terminal flanking peptide	Khoronenkova SV	ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage.	Molecular cell	2012	45
22565321	cholecystokinin C-terminal flanking peptide	Falck J	CDK targeting of NBS1 promotes DNA-end resection, replication restart and homologous recombination.	EMBO reports	2012	31
22605332	cholecystokinin C-terminal flanking peptide	Ranuncolo SM	Evidence of the involvement of O-GlcNAc-modified human RNA polymerase II CTD in transcription in vitro and in vivo.	The Journal of biological chemistry	2012	43
22736790	cholecystokinin C-terminal flanking peptide	Pettersson A	The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.	Cancer epidemiology, biomarkers & prevention 	2012	80
23132929	cholecystokinin C-terminal flanking peptide	Fry AM	Cell cycle regulation by the NEK family of protein kinases.	Journal of cell science	2012	75
23277200	cholecystokinin C-terminal flanking peptide	Barrett A	p130Cas: a key signalling node in health and disease.	Cellular signalling	2013	28
23306062	cholecystokinin C-terminal flanking peptide	Laine A	Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.	Cancer discovery	2013	32
11156649	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Bolondi L	Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.	Gut	2001	108
11320250	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Ruffner H	Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.	Proceedings of the National Academy of Sciences of the United States of America	2001	101
11343240	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Llovet JM	Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma.	Hepatology	2001	85
12713871	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Shuda M	Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis.	Journal of hepatology	2003	106
15042359	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Zhang BH	Randomized controlled trial of screening for hepatocellular carcinoma.	Journal of cancer research and clinical oncology	2004	213
15508073	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Daniele B	Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma.	Gastroenterology	2004	74
17000670	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Lee TK	Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition.	Clinical cancer research 	2006	98
17570225	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Ma S	Identification and characterization of tumorigenic liver cancer stem/progenitor cells.	Gastroenterology	2007	312
17681183	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Meng F	MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer.	Gastroenterology	2007	746
17891174	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Ma S	CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.	Oncogene	2008	209
18006828	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Yamashita T	Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma.	Cancer research	2007	115
18069697	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Forner A	Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.	Hepatology	2008	134
18223217	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Jiang J	Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival.	Clinical cancer research 	2008	175
18263735	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Tang Y	Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling.	Proceedings of the National Academy of Sciences of the United States of America	2008	106
18313787	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Kim M	Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells.	Journal of hepatology	2008	65
18316609	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Yamashita T	EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.	Cancer research	2008	185
18318435	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Lai JP	Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma.	Hepatology	2008	68
18980227	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Palmer DH	A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.	Hepatology	2009	53
19111019	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Mishra L	Liver stem cells and hepatocellular carcinoma.	Hepatology	2009	99
19551889	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Xu MZ	Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma.	Cancer	2009	139
19723656	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Hoshida Y	Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.	Cancer research	2009	195
19852728	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	van Zijl F	Epithelial-mesenchymal transition in hepatocellular carcinoma.	Future oncology	2009	85
20066715	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Carr BI	Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study.	Cancer	2010	46
20227042	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	He G	Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation.	Cancer cell	2010	113
20371487	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Wei W	S-nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis.	Science translational medicine	2010	46
20385424	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Zender L	Cancer gene discovery in hepatocellular carcinoma.	Journal of hepatology	2010	47
20637208	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Saxena NK	Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma.	Gastroenterology	2010	45
21076472	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Xu MZ	AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma.	Oncogene	2011	55
21184757	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Kanwal F	Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection.	Gastroenterology	2011	100
21397858	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Sawey ET	Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.	Cancer cell	2011	81
21712406	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Raychaudhuri P	FoxM1: a master regulator of tumor metastasis.	Cancer research	2011	78
21721029	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Kogure T	Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth.	Hepatology	2011	151
21822264	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Li M	Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma.	Nature genetics	2011	138
22014574	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Kim HS	SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity.	Cancer cell	2011	128
22396537	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Santhekadur PK	Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor κB and miR-221.	The Journal of biological chemistry	2012	38
22728651	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Lee CW	AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells.	Cancer research	2012	54
22807686	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Li S	GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers.	PLoS genetics	2012	52
